<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28738127</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Early-Onset Alzheimer Disease and Candidate Risk Genes Involved in Endolysosomal Transport.</ArticleTitle><Pagination><StartPage>1113</StartPage><EndPage>1122</EndPage><MedlinePgn>1113-1122</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.1518</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Mutations in APP, PSEN1, and PSEN2 lead to early-onset Alzheimer disease (EOAD) but account for&#x2009;only approximately&#x2009;11% of EOAD overall, leaving most of the genetic risk for the most severe form of Alzheimer disease unexplained. This extreme phenotype likely harbors highly penetrant risk variants, making it primed for discovery of novel risk genes and pathways for AD.</AbstractText><AbstractText Label="OBJECTIVE">To search for rare variants contributing to the risk for EOAD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In this case-control study, whole-exome sequencing (WES) was performed in 51 non-Hispanic white (NHW) patients with EOAD (age at onset &lt;65 years) and 19 Caribbean Hispanic families previously screened as negative for established APP, PSEN1, and PSEN2 causal variants. Participants were recruited from John P. Hussman Institute for Human Genomics, Case Western Reserve University, and Columbia University. Rare, deleterious, nonsynonymous, or loss-of-function variants were filtered to identify variants in known and suspected AD genes, variants in multiple unrelated NHW patients, variants present in 19 Hispanic EOAD WES families, and genes with variants in multiple unrelated NHW patients. These variants/genes were tested for association in an independent cohort of 1524 patients with EOAD, 7046 patients with late-onset AD (LOAD), and 7001 cognitively intact controls (age at examination, &gt;65 years) from the Alzheimer's Disease Genetics Consortium. The study was conducted from January 21, 2013, to October 13, 2016.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Alzheimer disease diagnosed according to standard National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association criteria. Association between Alzheimer disease and genetic variants and genes was measured using logistic regression and sequence kernel association test-optimal gene tests, respectively.</AbstractText><AbstractText Label="RESULTS">Of the 1524 NHW patients with EOAD, 765 (50.2%) were women and mean (SD) age was 60.0 (4.9) years; of the 7046 NHW patients with LOAD, 4171 (59.2%) were women and mean (SD) age was 77.4 (8.6) years; and of the 7001 NHW controls, 4215 (60.2%) were women and mean (SD) age was 77.4 (8.6) years. The gene PSD2, for which multiple unrelated NHW cases had rare missense variants, was significantly associated with EOAD (P&#x2009;=&#x2009;2.05&#x2009;&#xd7;&#x2009;10-6; Bonferroni-corrected P value [BP]&#x2009;=&#x2009;1.3&#x2009;&#xd7;&#x2009;10-3) and LOAD (P&#x2009;=&#x2009;6.22&#x2009;&#xd7;&#x2009;10-6; BP&#x2009;=&#x2009;4.1&#x2009;&#xd7;&#x2009;10-3). A missense variant in TCIRG1, present in a NHW patient and segregating in 3 cases of a Hispanic family, was more frequent in EOAD cases (odds ratio [OR], 2.13; 95% CI, 0.99-4.55; P&#x2009;=&#x2009;.06; BP&#x2009;=&#x2009;0.413), and significantly associated with LOAD (OR, 2.23; 95% CI, 1.37-3.62; P&#x2009;=&#x2009;7.2&#x2009;&#xd7;&#x2009;10-4; BP&#x2009;=&#x2009;5.0&#x2009;&#xd7;&#x2009;10-3). A missense variant in the LOAD risk gene RIN3 showed suggestive evidence of association with EOAD after Bonferroni correction (OR, 4.56; 95% CI, 1.26-16.48; P&#x2009;=&#x2009;.02, BP&#x2009;=&#x2009;0.091). In addition, a missense variant in RUFY1 identified in 2 NHW EOAD cases showed suggestive evidence of an association with EOAD as well (OR, 18.63; 95% CI, 1.62-213.45; P&#x2009;=&#x2009;.003; BP&#x2009;=&#x2009;0.129).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The genes PSD2, TCIRG1, RIN3, and RUFY1 all may be involved in endolysosomal transport-a process known to be important to development of AD. Furthermore, this study identified shared risk genes between EOAD and LOAD similar to previously reported genes, such as SORL1, PSEN2, and TREM2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kunkle</LastName><ForeName>Brian W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Gertrude H. Sergievsky Center, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naj</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitehead</LastName><ForeName>Patrice L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rolati</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slifer</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carney</LastName><ForeName>Regina M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuccaro</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>Jeffery M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Schools of Medicine and Public Health, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Schools of Medicine and Public Health, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Schools of Medicine and Public Health, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Schools of Medicine and Public Health, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Schools of Medicine and Public Health, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Gertrude H. Sergievsky Center, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Institute for Computational Biology, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Gertrude H. Sergievsky Center, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, College of Physicians and Surgeons, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020662">Guanine Nucleotide Exchange Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C487967">RIN3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C465344">RUFY1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C472421">TCIRG1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D025262">Vacuolar Proton-Translocating ATPases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017691" MajorTopicYN="N" Type="Geographic">Caribbean Region</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059472" MajorTopicYN="N">Exome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020662" MajorTopicYN="N">Guanine Nucleotide Exchange Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025262" MajorTopicYN="N">Vacuolar Proton-Translocating ATPases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28738127</ArticleId><ArticleId IdType="pmc">PMC5691589</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.1518</ArticleId><ArticleId IdType="pii">2645746</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA. Early- versus late-onset Alzheimer&#x2019;s disease: more than age alone. J Alzheimers Dis. 2010;19(4):1401-1408.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird TD. Genetic aspects of Alzheimer disease. Genet Med. 2008;10(4):231-239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690397</ArticleId><ArticleId IdType="pubmed">18414205</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey RJ, Skelton-Robinson M, Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry. 2003;74(9):1206-1209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738690</ArticleId><ArticleId IdType="pubmed">12933919</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Hannequin D, Coutant S, et al. ; PHRC GMAJ Collaborators . High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry. 2012;17(9):875-879.</Citation><ArticleIdList><ArticleId IdType="pubmed">22472873</ArticleId></ArticleIdList></Reference><Reference><Citation>Slattery CF, Beck JA, Harper L, et al. . R47H TREM2 variant increases risk of typical early-onset Alzheimer&#x2019;s disease but not of prion or frontotemporal dementia. Alzheimers Dement. 2014;10(6):602-608.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4627504</ArticleId><ArticleId IdType="pubmed">25160042</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouery E, Delague V, Bergougnoux A, Koussa S, Serre JL, M&#xe9;garban&#xe9; A. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum Mutat. 2008;29(9):E194-E204.</Citation><ArticleIdList><ArticleId IdType="pubmed">18546367</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Wallon D, Rousseau S, et al. . TREM2 R47H variant as a risk factor for early-onset Alzheimer&#x2019;s disease. J Alzheimers Dis. 2013;35(1):45-49.</Citation><ArticleIdList><ArticleId IdType="pubmed">23380991</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Bancher C. Neuropathology of Alzheimer&#x2019;s disease: a critical update. J Neural Transm Suppl. 1998;54:77-95.</Citation><ArticleIdList><ArticleId IdType="pubmed">9850917</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingo TS, Lah JJ, Levey AI, Cutler DJ. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol. 2012;69(1):59-64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3332307</ArticleId><ArticleId IdType="pubmed">21911656</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, et al. . Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168-174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen NL, Posner SF, Gatz M. Multiple-threshold models for genetic influences on age of onset for Alzheimer disease: findings in Swedish twins. Am J Med Genet. 2001;105(8):724-728.</Citation><ArticleIdList><ArticleId IdType="pubmed">11803520</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. ; APOE and Alzheimer Disease Meta Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349-1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939-944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Handsaker B, Wysoker A, et al. ; 1000 Genome Project Data Processing Subgroup . The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-2079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723002</ArticleId><ArticleId IdType="pubmed">19505943</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan A, Abecasis GR, Kang HM. Unified representation of genetic variants. Bioinformatics. 2015;31(13):2202-2204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4481842</ArticleId><ArticleId IdType="pubmed">25701572</ArticleId></ArticleIdList></Reference><Reference><Citation>Mappability or Uniqueness of Reference Genome of ENCODE. http://genome.ucsc.edu/cgi-bin/hgFileUi?db=hg19&amp;g=wgEncodeMapability. Published 2015. Accessed September 10, 2015.</Citation></Reference><Reference><Citation>Li MX, Gui HS, Kwan JS, Bao SY, Sham PC. A comprehensive framework for prioritizing variants in exome sequencing studies of Mendelian diseases. Nucleic Acids Res. 2012;40(7):e53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3326332</ArticleId><ArticleId IdType="pubmed">22241780</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher M, Witten DM, Jain P, O&#x2019;Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310-315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992975</ArticleId><ArticleId IdType="pubmed">24487276</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry DC, Lehmann M, Yokoyama JS, et al. . Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol. 2013;70(6):774-778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3743672</ArticleId><ArticleId IdType="pubmed">23609919</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M-J, Chen T-F, Cheng T-W, Chiu M-J. rs5848 variant of progranulin gene is a risk of Alzheimer&#x2019;s disease in the Taiwanese population. Neurodegener Dis. 2011;8(4):216-220.</Citation><ArticleIdList><ArticleId IdType="pubmed">21212639</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Sleegers K, Engelborghs S, et al. . Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology. 2008;71(9):656-664.</Citation><ArticleIdList><ArticleId IdType="pubmed">18565828</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenoglio C, Galimberti D, Cortini F, et al. . Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer&#x2019;s disease. J Alzheimers Dis. 2009;18(3):603-612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842455</ArticleId><ArticleId IdType="pubmed">19625741</ArticleId></ArticleIdList></Reference><Reference><Citation>Carney RM, Kohli MA, Kunkle BW, et al. . Parkinsonism and distinct dementia patterns in a family with the MAPT R406W mutation. Alzheimers Dement. 2014;10(3):360-365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3762928</ArticleId><ArticleId IdType="pubmed">23727082</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Dermaut B, Peeters K, et al. . Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe. [1]. Hum Mutat. 2003;22(5):409-411.</Citation><ArticleIdList><ArticleId IdType="pubmed">14517953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist SG, Holm IE, Schwartz M, et al. . Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation. Eur J Neurol. 2008;15(4):377-385.</Citation><ArticleIdList><ArticleId IdType="pubmed">18284428</ArticleId></ArticleIdList></Reference><Reference><Citation>Momeni P, Pittman A, Lashley T, et al. . Clinical and pathological features of an Alzheimer&#x2019;s disease patient with the MAPT Delta K280 mutation. Neurobiol Aging. 2009;30(3):388-393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666148</ArticleId><ArticleId IdType="pubmed">17723255</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. ; European Alzheimer&#x2019;s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer&#x2019;s Disease; Alzheimer&#x2019;s Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45(12):1452-1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Karch CM, Jin SC, et al. ; UK Brain Expression Consortium; Alzheimer&#x2019;s Research UK Consortium . Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer&#x2019;s disease. Nature. 2014;505(7484):550-554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050701</ArticleId><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetzel-Smith MK, Hunkapiller J, Bhangale TR, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium . A rare mutation in UNC5C predisposes to late-onset Alzheimer&#x2019;s disease and increases neuronal cell death. Nat Med. 2014;20(12):1452-1457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301587</ArticleId><ArticleId IdType="pubmed">25419706</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue MW, Schu M, Vardarajan BN, et al. ; Alzheimer Disease Genetics Consortium; Alzheimer Disease Genetics Consortium . Two rare AKAP9 variants are associated with Alzheimer&#x2019;s disease in African Americans. Alzheimers Dement. 2014;10(6):609-618.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253055</ArticleId><ArticleId IdType="pubmed">25172201</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum MJ, Lee JM, Riley GR, et al. . ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42(Database issue):D980-D985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965032</ArticleId><ArticleId IdType="pubmed">24234437</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, et al. . Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):436-441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, van der Lee SJ, Naj AC, et al. . 
Rare coding variants in PLCG2, ABI3 and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease [published online July 17, 2017]. Nat Genet. http://orca.cf.ac.uk/id/eprint/98651</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler TW, Day FR, Croteau-Chonka DC, et al. ; Genetic Investigation of Anthropometric Traits (GIANT) Consortium . Quality control and conduct of genome-wide association meta-analyses. Nat Protoc. 2014;9(5):1192-1212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4083217</ArticleId><ArticleId IdType="pubmed">24762786</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuccaro ML, Carney RM, Zhang Y, et al. . SORL1 mutations and Parkinsonian features in early and late onset Alzheimer&#x2019;s disease. Neurol Genet. 2016;2(6):e116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5082932</ArticleId><ArticleId IdType="pubmed">27822510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Jacquart S, Chakraverty S, et al. . Extreme cerebrospinal fluid amyloid &#x3b2;levels identify family with late-onset Alzheimer&#x2019;s disease presenilin 1 mutation. Ann Neurol. 2007;61(5):446-453.</Citation><ArticleIdList><ArticleId IdType="pubmed">17366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, et al. . Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393(6686):702-705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeuchi T, Imamura T, Kawase Y, et al. . Evidence for a common founder and clinical characteristics of Japanese families with the MAPT R406W mutation. Dement Geriatr Cogn Dis Extra. 2011;1(1):267-275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235940</ArticleId><ArticleId IdType="pubmed">22545037</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bakker PIW, Ferreira MAR, Jia X, Neale BM, Raychaudhuri S, Voight BF. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum Mol Genet. 2008;17(R2):R122-R128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782358</ArticleId><ArticleId IdType="pubmed">18852200</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Endosome function and dysfunction in Alzheimer&#x2019;s disease and other neurodegenerative diseases. Neurobiol Aging. 2005;26(3):373-382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000;157(1):277-286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Goate AM. Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77(1):43-51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Petanceska S, Terio NB, et al. . A&#x3b2; localization in abnormal endosomes: association with earliest A&#x3b2; elevations in AD and Down syndrome. Neurobiol Aging. 2004;25(10):1263-1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">15465622</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, et al. . The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168-177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas G, Charbonnier C, Wallon D, et al. ; CNR-MAJ collaborators . SORL1 rare variants: a major risk factor for familial early-onset Alzheimer&#x2019;s disease. Mol Psychiatry. 2016;21(6):831-836.</Citation><ArticleIdList><ArticleId IdType="pubmed">26303663</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen J, Van den Bossche T, van der Zee J, et al. . A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer&#x2019;s disease. Acta Neuropathol. 2016;132(2):213-224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947104</ArticleId><ArticleId IdType="pubmed">27026413</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, et al. . Axonopathy and transport deficits early in the pathogenesis of Alzheimer&#x2019;s disease. Science. 2005;307(5713):1282-1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Sato Y, Nixon RA. Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer&#x2019;s-like axonal dystrophy. J Neurosci. 2011;31(21):7817-7830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351137</ArticleId><ArticleId IdType="pubmed">21613495</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres M, Jimenez S, Sanchez-Varo R, et al. . Defective lysosomal proteolysis and axonal transport are early pathogenic events that worsen with age leading to increased APP metabolism and synaptic A&#x3b2; in transgenic APP/PS1 hippocampus. Mol Neurodegener. 2012;7:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575255</ArticleId><ArticleId IdType="pubmed">23173743</ArticleId></ArticleIdList></Reference><Reference><Citation>Shearer AE, Eppsteiner RW, Booth KT, et al. . Utilizing ethnic-specific differences in minor allele frequency to recategorize reported pathogenic deafness variants. Am J Hum Genet. 2014;95(4):445-453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185121</ArticleId><ArticleId IdType="pubmed">25262649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohdanowicz M, Grinstein S. Role of phospholipids in endocytosis, phagocytosis, and macropinocytosis. Physiol Rev. 2013;93(1):69-106.</Citation><ArticleIdList><ArticleId IdType="pubmed">23303906</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulshan K, Shahi P, Moye-Rowley WS. Compartment-specific synthesis of phosphatidylethanolamine is required for normal heavy metal resistance. Mol Biol Cell. 2010;21(3):443-455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2814789</ArticleId><ArticleId IdType="pubmed">20016005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg L, Rafique S, Xuereb JH, Rapoport SI, Gershfeld NL. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer&#x2019;s disease brain. Brain Res. 1995;698(1-2):223-226.</Citation><ArticleIdList><ArticleId IdType="pubmed">8581486</ArticleId></ArticleIdList></Reference><Reference><Citation>Onodera T, Futai E, Kan E, et al. . Phosphatidylethanolamine plasmalogen enhances the inhibiting effect of phosphatidylethanolamine on &#x3b3;-secretase activity. J Biochem. 2015;157(5):301-309.</Citation><ArticleIdList><ArticleId IdType="pubmed">25409699</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenfeller P, Koska M, Pietrocola F, et al. . Phosphatidylethanolamine positively regulates autophagy and longevity. Cell Death Differ. 2015;22(3):499-508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326582</ArticleId><ArticleId IdType="pubmed">25571976</ArticleId></ArticleIdList></Reference><Reference><Citation>Morel E, Chamoun Z, Lasiecka ZM, et al. . Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system. Nat Commun. 2013;4:2250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3905799</ArticleId><ArticleId IdType="pubmed">23907271</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Barnett JL, Pieroni C, Nixon RA. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer&#x2019;s disease: neuropathologic evidence for a mechanism of increased &#x3b2;-amyloidogenesis. J Neurosci. 1997;17(16):6142-6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568334</ArticleId><ArticleId IdType="pubmed">9236226</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitagishi Y, Matsuda S. RUFY, rab and rap family proteins involved in a regulation of cell polarity and membrane trafficking. Int J Mol Sci. 2013;14(3):6487-6498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3634510</ArticleId><ArticleId IdType="pubmed">23519112</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajiho H, Sakurai K, Minoda T, et al. . Characterization of RIN3 as a guanine nucleotide exchange factor for the Rab5 subfamily GTPase Rab31. J Biol Chem. 2011;286(27):24364-24373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3129215</ArticleId><ArticleId IdType="pubmed">21586568</ArticleId></ArticleIdList></Reference><Reference><Citation>Grbovic OM, Mathews PM, Jiang Y, et al. . Rab5-stimulated up-regulation of the endocytic pathway increases intracellular &#x3b2;-cleaved amyloid precursor protein carboxyl-terminal fragment levels and A&#x3b2; production. J Biol Chem. 2003;278(33):31261-31268.</Citation><ArticleIdList><ArticleId IdType="pubmed">12761223</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr ME, Oddo S. Autophagic/lysosomal dysfunction in Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2013;5(5):53-62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979020</ArticleId><ArticleId IdType="pubmed">24171818</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal EA, Makaryan V, Burt AA, et al. ; University of Washington, Center for Mendelian Genomics . Association between absolute neutrophil count and variation at TCIRG1: the NHLBI Exome Sequencing Project. Genet Epidemiol. 2016;40(6):470-474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079157</ArticleId><ArticleId IdType="pubmed">27229898</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenaro E, Pietronigro E, Della Bianca V, et al. . Neutrophils promote Alzheimer&#x2019;s disease-like pathology and cognitive decline via LFA-1 integrin. Nat Med. 2015;21(8):880-886.</Citation><ArticleIdList><ArticleId IdType="pubmed">26214837</ArticleId></ArticleIdList></Reference><Reference><Citation>Baik SH, Cha MY, Hyun YM, et al. . Migration of neutrophils targeting amyloid plaques in Alzheimer&#x2019;s disease mouse model. Neurobiol Aging. 2014;35(6):1286-1292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4248665</ArticleId><ArticleId IdType="pubmed">24485508</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Haller G, Chakraverty S, et al. ; NIA-LOAD/NCRAD Family Study Consortium . Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer&#x2019;s disease families. PLoS One. 2012;7(2):e31039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270040</ArticleId><ArticleId IdType="pubmed">22312439</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacace R, Sleegers K, Van Broeckhoven C. Molecular genetics of early-onset Alzheimer&#x2019;s disease revisited. Alzheimers Dement. 2016;12(6):733-748.</Citation><ArticleIdList><ArticleId IdType="pubmed">27016693</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28738126</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau-Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers.</ArticleTitle><Pagination><StartPage>1063</StartPage><EndPage>1072</EndPage><MedlinePgn>1063-1072</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.0655</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Annually in the United States, at least 3.5 million people seek medical attention for traumatic brain injury (TBI). The development of therapies for TBI is limited by the absence of diagnostic and prognostic biomarkers. Microtubule-associated protein tau is an axonal phosphoprotein. To date, the presence of the hypophosphorylated tau protein (P-tau) in plasma from patients with acute TBI and chronic TBI has not been investigated.</AbstractText><AbstractText Label="OBJECTIVE">To examine the associations between plasma P-tau and total-tau (T-tau) levels and injury presence, severity, type of pathoanatomic lesion (neuroimaging), and patient outcomes in acute and chronic TBI.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In the TRACK-TBI Pilot study, plasma was collected at a single time point from 196 patients with acute TBI admitted to 3 level I trauma centers (&lt;24 hours after injury) and 21 patients with TBI admitted to inpatient rehabilitation units (mean [SD], 176.4 [44.5] days after injury). Control samples were purchased from a commercial vendor. The TRACK-TBI Pilot study was conducted from April 1, 2010, to June 30, 2012. Data analysis for the current investigation was performed from August 1, 2015, to March 13, 2017.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Plasma samples were assayed for P-tau (using an antibody that specifically recognizes phosphothreonine-231) and T-tau using ultra-high sensitivity laser-based immunoassay multi-arrayed fiberoptics conjugated with rolling circle amplification.</AbstractText><AbstractText Label="RESULTS">In the 217 patients with TBI, 161 (74.2%) were men; mean (SD) age was 42.5 (18.1) years. The P-tau and T-tau levels and P-tau-T-tau ratio in patients with acute TBI were higher than those in healthy controls. Receiver operating characteristic analysis for the 3 tau indices demonstrated accuracy with area under the curve (AUC) of 1.000, 0.916, and 1.000, respectively, for discriminating mild TBI (Glasgow Coma Scale [GCS] score, 13-15, n&#x2009;=&#x2009;162) from healthy controls. The P-tau level and P-tau-T-tau ratio were higher in individuals with more severe TBI (GCS, &#x2264;12 vs 13-15). The P-tau level and P-tau-T-tau ratio outperformed the T-tau level in distinguishing cranial computed tomography-positive from -negative cases (AUC&#x2009;=&#x2009;0.921, 0.923, and 0.646, respectively). Acute P-tau levels and P-tau-T-tau ratio weakly distinguished patients with TBI who had good outcomes (Glasgow Outcome Scale-Extended GOS-E, 7-8) (AUC&#x2009;=&#x2009;0.663 and 0.658, respectively) and identified those with poor outcomes (GOS-E, &#x2264;4 vs &gt;4) (AUC&#x2009;=&#x2009;0.771 and 0.777, respectively). Plasma samples from patients with chronic TBI also showed elevated P-tau levels and a P-tau-T-tau ratio significantly higher than that of healthy controls, with both P-tau indices strongly discriminating patients with chronic TBI from healthy controls (AUC&#x2009;=&#x2009;1.000 and 0.963, respectively).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Plasma P-tau levels and P-tau-T-tau ratio outperformed T-tau level as diagnostic and prognostic biomarkers for acute TBI. Compared with T-tau levels alone, P-tau levels and P-tau-T-tau ratios show more robust and sustained elevations among patients with chronic TBI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rubenstein</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Neurodegenerative Diseases and CNS Biomarker Discovery, Departments of Neurology and Physiology/Pharmacology, State University of New York Downstate Medical Center, Brooklyn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Binggong</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory of Neurodegenerative Diseases and CNS Biomarker Discovery, Departments of Neurology and Physiology/Pharmacology, State University of New York Downstate Medical Center, Brooklyn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>John K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, San Francisco General Hospital, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Allen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Neurodegenerative Diseases and CNS Biomarker Discovery, Departments of Neurology and Physiology/Pharmacology, State University of New York Downstate Medical Center, Brooklyn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>Ethan A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, San Francisco General Hospital, San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puccio</LastName><ForeName>Ava M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuh</LastName><ForeName>Esther L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, San Francisco General Hospital, San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukherjee</LastName><ForeName>Pratik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, San Francisco General Hospital, San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valadka</LastName><ForeName>Alex B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Virginia Commonwealth University, Richmond.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Wayne A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okonkwo</LastName><ForeName>David O</ForeName><Initials>DO</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Litwin-Zucker Center for Research in Alzheimer's Disease, Feinstein Institute for Medical Research, Manhasset, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Sanjeev</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery and Rehabilitation Medicine, State University of New York Downstate Medical Center, Brooklyn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Program for Neurotrauma, Neuroproteomics, and Biomarker Research, Department of Emergency Medicine, Psychiatry and Chemistry, University of Florida, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkis</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Program for Neurotrauma, Neuroproteomics, and Biomarker Research, Department of Emergency Medicine, Psychiatry and Chemistry, University of Florida, Gainesville.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science, Alexandria University, Ibrahimia, Alexandria, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadikar</LastName><ForeName>Hamad</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Program for Neurotrauma, Neuroproteomics, and Biomarker Research, Department of Emergency Medicine, Psychiatry and Chemistry, University of Florida, Gainesville.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Kuwait University, Khadiya, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhihui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Program for Neurotrauma, Neuroproteomics, and Biomarker Research, Department of Emergency Medicine, Psychiatry and Chemistry, University of Florida, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manley</LastName><ForeName>Geoffrey T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, San Francisco General Hospital, San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kevin K W</ForeName><Initials>KKW</Initials><AffiliationInfo><Affiliation>Program for Neurotrauma, Neuroproteomics, and Biomarker Research, Department of Emergency Medicine, Psychiatry and Chemistry, University of Florida, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>the TRACK-TBI Investigators</CollectiveName></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Shelly R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Psychology, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dams-O'Connor</LastName><ForeName>Kristen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borrasso</LastName><ForeName>Allison J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Tomoo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, San Francisco General Hospital, San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maas</LastName><ForeName>Andrew I R</ForeName><Initials>AIR</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>David K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Departments of Anesthesia and Neurocritical Care, University of Cambridge, Cambridge, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnyer</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Texas, Austin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vassar</LastName><ForeName>Mary J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, San Francisco General Hospital, San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I01 RX001859</GrantID><Acronym>RX</Acronym><Agency>RRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022102</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 NS069409</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS086090</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 Sep 1;74(9):1045-1047. doi: 10.1001/jamaneurol.2017.0800.</RefSource><PMID Version="1">28738117</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="N">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015600" MajorTopicYN="Y">Glasgow Coma Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023261" MajorTopicYN="Y">Glasgow Outcome Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014193" MajorTopicYN="N">Trauma Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Wang holds stock in Banyan Biomarkers Inc. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28738126</ArticleId><ArticleId IdType="mid">NIHMS896875</ArticleId><ArticleId IdType="pmc">PMC5710183</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.0655</ArticleId><ArticleId IdType="pii">2645745</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeKosky ST, Kochanek PM, Clark RS, Ciallella JR, Dixon CE. Secondary injury after head trauma: subacute and long-term mechanisms. Semin Clin Neuropsychiatry. 1998;3(3):176-185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10085205</ArticleId></ArticleIdList></Reference><Reference><Citation>DoD Numbers for Traumatic Brain Injury. http://dvbic.dcoe.mil/dod-worldwide-numbers-tbi. Updated February 17, 2017. Accessed April 6, 2017.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) CDC grand rounds: reducing severe traumatic brain injury in the United States. MMWR Morb Mortal Wkly Rep. 2013;62(27):549-552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4604943</ArticleId><ArticleId IdType="pubmed">23842444</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivanandam TM, Thakur MK. Traumatic brain injury: a risk factor for Alzheimer&#x2019;s disease. Neurosci Biobehav Rev. 2012;36(5):1376-1381.</Citation><ArticleIdList><ArticleId IdType="pubmed">22390915</ArticleId></ArticleIdList></Reference><Reference><Citation>Omalu BI, Fitzsimmons RP, Hammers J, Bailes J. Chronic traumatic encephalopathy in a professional American wrestler. J Forensic Nurs. 2010;6(3):130-136.</Citation><ArticleIdList><ArticleId IdType="pubmed">21175533</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Stern RA, Nowinski CJ, et al. . The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136(Pt 1):43-64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624697</ArticleId><ArticleId IdType="pubmed">23208308</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nat Rev Neurol. 2013;9(4):211-221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513655</ArticleId><ArticleId IdType="pubmed">23458973</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Cairns NJ, Dickson DW, et al. ; TBI/CTE group . The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016;131(1):75-86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4698281</ArticleId><ArticleId IdType="pubmed">26667418</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M; FRS PMGS . Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609-622.</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SY, Tournell C, Sinjoanu RC, Ferreira A. Caspase-3- and calpain-mediated tau cleavage are differentially prevented by estrogen and testosterone in beta-amyloid&#x2013;treated hippocampal neurons. Neuroscience. 2007;144(1):119-127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1955430</ArticleId><ArticleId IdType="pubmed">17055174</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu MC, Kobeissy F, Zheng W, Zhang Z, Hayes RL, Wang KKW. Dual vulnerability of tau to calpains and caspase-3 proteolysis under neurotoxic and neurodegenerative conditions. ASN Neuro. 2011;3(1):e00051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040574</ArticleId><ArticleId IdType="pubmed">21359008</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW, Head E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer&#x2019;s disease brain. Neurobiol Dis. 2002;11(2):341-354.</Citation><ArticleIdList><ArticleId IdType="pubmed">12505426</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonnis S, Cappelletti G, Taverna F, et al. . Tau is endogenously nitrated in mouse brain: identification of a tyrosine residue modified in vivo by NO. Neurochem Res. 2008;33(3):518-525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17768677</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes JF, Reynolds MR, Horowitz PM, et al. . A possible link between astrocyte activation and tau nitration in Alzheimer&#x2019;s disease. Neurobiol Dis. 2008;31(2):198-208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2766349</ArticleId><ArticleId IdType="pubmed">18562203</ArticleId></ArticleIdList></Reference><Reference><Citation>Horiguchi T, Uryu K, Giasson BI, et al. . Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol. 2003;163(3):1021-1031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868254</ArticleId><ArticleId IdType="pubmed">12937143</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Chen XH, Nonaka M, et al. . Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. J Neuropathol Exp Neurol. 1999;58(9):982-992.</Citation><ArticleIdList><ArticleId IdType="pubmed">10499440</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Y, Dong S, Gu F, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer&#x2019;s disease: focusing on tau-mediated neurodegeneration. Transl Neurodegener. 2012;1(1):24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3598890</ArticleId><ArticleId IdType="pubmed">23241453</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Cantu RC, Nowinski CJ, et al. . Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol. 2009;68(7):709-735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945234</ArticleId><ArticleId IdType="pubmed">19535999</ArticleId></ArticleIdList></Reference><Reference><Citation>Omalu BI, Hamilton RL, Kamboh MI, DeKosky ST, Bailes J. Chronic traumatic encephalopathy (CTE) in a National Football League Player: case report and emerging medicolegal practice questions. J Forensic Nurs. 2010;6(1):40-46.</Citation><ArticleIdList><ArticleId IdType="pubmed">20201914</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LE, Fisher AM, Tagge CA, et al. . Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med. 2012;4(134):134ra60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739428</ArticleId><ArticleId IdType="pubmed">22593173</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Wang P, Morgan D, et al. . Temporal MRI characterization, neurobiochemical and neurobehavioral changes in a mouse repetitive concussive head injury model. Sci Rep. 2015;5:11178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4461921</ArticleId><ArticleId IdType="pubmed">26058556</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz G, Beer R, Kampfl A, et al. . Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology. 2003;60(9):1457-1461.</Citation><ArticleIdList><ArticleId IdType="pubmed">12743231</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsitsopoulos PP, Marklund N. Amyloid-&#x3b2; peptides and tau protein as biomarkers in cerebrospinal and interstitial fluid following traumatic brain injury: a review of experimental and clinical studies. Front Neurol. 2013;4:79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693096</ArticleId><ArticleId IdType="pubmed">23805125</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Nellg&#xe5;rd B. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology. 2004;62(1):159-160.</Citation><ArticleIdList><ArticleId IdType="pubmed">14718730</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahim P, Tegner Y, Wilson DH, et al. . Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol. 2014;71(6):684-692.</Citation><ArticleIdList><ArticleId IdType="pubmed">24627036</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivera A, Lejbman N, Jeromin A, et al. . Peripheral total tau in military personnel who sustain traumatic brain injuries during deployment. JAMA Neurol. 2015;72(10):1109-1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">26237304</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubenstein R, Chang B, Davies P, Wagner AK, Robertson CS, Wang KKW. A novel, ultrasensitive assay for tau: potential for assessing traumatic brain injury in tissues and biofluids. J Neurotrauma. 2015;32(5):342-352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4348038</ArticleId><ArticleId IdType="pubmed">25177776</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue JK, Vassar MJ, Lingsma HF, et al. ; TRACK-TBI Investigators . Transforming research and clinical knowledge in traumatic brain injury pilot: multicenter implementation of the common data elements for traumatic brain injury. J Neurotrauma. 2013;30(22):1831-1844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814815</ArticleId><ArticleId IdType="pubmed">23815563</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagoda AS, Bazarian JJ, Bruns JJ Jr, et al. . Clinical policy: neuroimaging and decision making in adult mild traumatic brain injury in the acute setting. J Emerg Nurs. 2009;35(2):e5-e40.</Citation><ArticleIdList><ArticleId IdType="pubmed">19285163</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang KKW, Yang Z, Yue JK, et al. . Plasma anti-glial fibrillary acidic protein autoantibody levels during the acute and chronic phases of traumatic brain injury: a Transforming Research and Clinical Knowledge in Traumatic Brain Injury pilot study. J Neurotrauma. 2016;33(13):1270-1277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4931336</ArticleId><ArticleId IdType="pubmed">26560343</ArticleId></ArticleIdList></Reference><Reference><Citation>Manley GT, Diaz-Arrastia R, Brophy M, et al. . Common data elements for traumatic brain injury: recommendations from the biospecimens and biomarkers working group. Arch Phys Med Rehabil. 2010;91(11):1667-1672.</Citation><ArticleIdList><ArticleId IdType="pubmed">21044710</ArticleId></ArticleIdList></Reference><Reference><Citation>Forslund MV, Roe C, Sigurdardottir S, Andelic N. Predicting health-related quality of life 2 years after moderate-to-severe traumatic brain injury. Acta Neurol Scand. 2013;128(4):220-227.</Citation><ArticleIdList><ArticleId IdType="pubmed">23621298</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Q, Wu X, Yu J, et al. . Effects and clinical characteristics of intracranial pressure monitoring&#x2013;targeted management for subsets of traumatic brain injury: an observational multicenter study. Crit Care Med. 2015;43(7):1405-1414.</Citation><ArticleIdList><ArticleId IdType="pubmed">25803654</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson U, Lew&#xe9;n A, Ronne-Engstr&#xf6;m E, Howells T, Enblad P. Should the neurointensive care management of traumatic brain injury patients be individualized according to autoregulation status and injury subtype? Neurocrit Care. 2014;21(2):259-265.</Citation><ArticleIdList><ArticleId IdType="pubmed">24515639</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Arrastia R, Wang KKW, Papa L, et al. ; TRACK-TBI Investigators . Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma. 2014;31(1):19-25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880090</ArticleId><ArticleId IdType="pubmed">23865516</ArticleId></ArticleIdList></Reference><Reference><Citation>Papa L, Brophy GM, Welch RD, et al. . Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury. JAMA Neurol. 2016;73(5):551-560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8805143</ArticleId><ArticleId IdType="pubmed">27018834</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch RD, Ayaz SI, Lewis LM, et al. . ability of serum glial fibrillary acidic protein, ubiquitin C-terminal hydrolase-L1, and S100B to differentiate normal and abnormal head computed tomography findings in patients with suspected mild or moderate traumatic brain injury. J Neurotrauma. 2016;33(2):203-214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4722555</ArticleId><ArticleId IdType="pubmed">26467555</ArticleId></ArticleIdList></Reference><Reference><Citation>Brophy GM, Mondello S, Papa L, et al. . Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J Neurotrauma. 2011;28(6):861-870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3113451</ArticleId><ArticleId IdType="pubmed">21309726</ArticleId></ArticleIdList></Reference><Reference><Citation>Diniz BSO, Pinto J&#xfa;nior JA, Forlenza OV. Do CSF total tau, phosphorylated tau, and &#x3b2;-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer&#x2019;s disease? a systematic review and meta-analysis of the literature. World J Biol Psychiatry. 2008;9(3):172-182.</Citation><ArticleIdList><ArticleId IdType="pubmed">17886169</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabaraud F, Leman JPJ, Milor AMA, et al. . Alzheimer CSF biomarkers in routine clinical setting. Acta Neurol Scand. 2012;125(6):416-423.</Citation><ArticleIdList><ArticleId IdType="pubmed">21954973</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Zetterberg H, van Harten AC, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Alzheimer&#x2019;s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain. 2015;138(pt 9):2701-2715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643624</ArticleId><ArticleId IdType="pubmed">26220940</ArticleId></ArticleIdList></Reference><Reference><Citation>Martland HS. Punch drunk. JAMA. 1928;91(15):1103-1107.</Citation></Reference><Reference><Citation>Critchley M. Medical aspects of boxing, particularly from a neurological standpoint. BMJ. 1957;1(5015):357-362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1974382</ArticleId><ArticleId IdType="pubmed">13396257</ArticleId></ArticleIdList></Reference><Reference><Citation>Corsellis JA, Bruton CJ, Freeman-Browne D. The aftermath of boxing. Psychol Med. 1973;3(3):270-303.</Citation><ArticleIdList><ArticleId IdType="pubmed">4729191</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern RA, Daneshvar DH, Baugh CM, et al. . Clinical presentation of chronic traumatic encephalopathy. Neurology. 2013;81(13):1122-1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795597</ArticleId><ArticleId IdType="pubmed">23966253</ArticleId></ArticleIdList></Reference><Reference><Citation>Montenigro PH, Baugh CM, Daneshvar DH, et al. . Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. Alzheimers Res Ther. 2014;6(5):68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4288217</ArticleId><ArticleId IdType="pubmed">25580160</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M, Brooks DJ, Edison P. Tau imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2016;43(6):1139-1150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4844651</ArticleId><ArticleId IdType="pubmed">26572762</ArticleId></ArticleIdList></Reference><Reference><Citation>clinicaltrials.gov. Transforming Research and Clinical Knowledge in Traumatic Brain Injury. NCT02119182. https://clinicaltrials.gov/ct2/show/NCT02119182. Accessed June 9, 2017.</Citation></Reference><Reference><Citation>Zhong C, Cockburn M, Cozen W, et al. . Evaluating the use of friend or family controls in epidemiologic case-control studies. Cancer Epidemiol. 2017;46(2):9-13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6252092</ArticleId><ArticleId IdType="pubmed">27871006</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28758999</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Necroptosis activation in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1236</StartPage><EndPage>1246</EndPage><MedlinePgn>1236-1246</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4608</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by severe neuronal loss; however, the mechanisms by which neurons die remain elusive. Necroptosis, a programmed form of necrosis, is executed by the mixed lineage kinase domain-like (MLKL) protein, which is triggered by receptor-interactive protein kinases (RIPK) 1 and 3. We found that necroptosis was activated in postmortem human AD brains, positively correlated with Braak stage, and inversely correlated with brain weight and cognitive scores. In addition, we found that the set of genes regulated by RIPK1 overlapped significantly with multiple independent AD transcriptomic signatures, indicating that RIPK1 activity could explain a substantial portion of transcriptomic changes in AD. Furthermore, we observed that lowering necroptosis activation reduced cell loss in a mouse model of AD. We anticipate that our findings will spur a new area of research in the AD field focused on developing new therapeutic strategies aimed at blocking its activation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caccamo</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Arizona State University-Banner Neurodegenerative Disease Research Center at the Biodesign Institute, Arizona State University, Tempe, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Branca</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Arizona State University-Banner Neurodegenerative Disease Research Center at the Biodesign Institute, Arizona State University, Tempe, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piras</LastName><ForeName>Ignazio S</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Translational Genomics Research Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Arizona State University-Banner Neurodegenerative Disease Research Center at the Biodesign Institute, Arizona State University, Tempe, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Translational Genomics Research Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Winnie S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Translational Genomics Research Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Readhead</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dudley</LastName><ForeName>Joel T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spangenberg</LastName><ForeName>Elizabeth E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Kim N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belfiore</LastName><ForeName>Ramona</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Arizona State University-Banner Neurodegenerative Disease Research Center at the Biodesign Institute, Arizona State University, Tempe, Arizona, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winslow</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Arizona State University-Banner Neurodegenerative Disease Research Center at the Biodesign Institute, Arizona State University, Tempe, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oddo</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7304-7430</Identifier><AffiliationInfo><Affiliation>Arizona State University-Banner Neurodegenerative Disease Research Center at the Biodesign Institute, Arizona State University, Tempe, Arizona, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Sciences, Arizona State University, Tempe, Arizona, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS083801</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG037637</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057507" MajorTopicYN="N">Mice, 129 Strain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28758999</ArticleId><ArticleId IdType="doi">10.1038/nn.4608</ArticleId><ArticleId IdType="pii">nn.4608</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mol Cell. 2014 Apr 10;54(1):133-146</Citation><ArticleIdList><ArticleId IdType="pubmed">24703947</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2017 Jun;22(6):865-873</Citation><ArticleIdList><ArticleId IdType="pubmed">27573878</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2016 Jan 4;44(D1):D574-80</Citation><ArticleIdList><ArticleId IdType="pubmed">26578574</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2015 Apr 20;43(7):e47</Citation><ArticleIdList><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Neuropharmacol. 2006 Apr;4(2):139-47</Citation><ArticleIdList><ArticleId IdType="pubmed">18615127</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Jan 28;362(4):329-44</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2011 Apr 19;76(16):1395-402</Citation><ArticleIdList><ArticleId IdType="pubmed">21490323</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Oct 1;526(7571):68-74</Citation><ArticleIdList><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm Suppl. 1997;50:141-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9120414</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4441-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18332434</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2014 May 27;111(21):7753-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24821786</ArticleId></ArticleIdList></Reference><Reference><Citation>G3 (Bethesda). 2011 Nov;1(6):457-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22384356</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2009 Jul 15;25(14):1754-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2015 Mar 05;(3):CD010783</Citation><ArticleIdList><ArticleId IdType="pubmed">25740785</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Alzheimer Res. 2006 Sep;3(4):393-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17017869</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Sep 02;8(9):e73645</Citation><ArticleIdList><ArticleId IdType="pubmed">24023894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2014 Apr 1;30(7):923-30</Citation><ArticleIdList><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2012 May;71(5):362-81</Citation><ArticleIdList><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2014 Mar 5;81(5):1001-1008</Citation><ArticleIdList><ArticleId IdType="pubmed">24508385</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1991 Apr;41(4):479-86</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2016 Jul 13;11(1):52</Citation><ArticleIdList><ArticleId IdType="pubmed">27412291</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Genomics. 2007 Feb 12;28(3):311-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17077275</ArticleId></ArticleIdList></Reference><Reference><Citation>Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189</Citation><ArticleIdList><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 May 22;157(5):1189-202</Citation><ArticleIdList><ArticleId IdType="pubmed">24813850</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Genet. 2009 May 27;10:23</Citation><ArticleIdList><ArticleId IdType="pubmed">19473544</ArticleId></ArticleIdList></Reference><Reference><Citation>Biostatistics. 2003 Apr;4(2):249-64</Citation><ArticleIdList><ArticleId IdType="pubmed">12925520</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2012 May 15;28(10):1353-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22492648</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1995 May-Jun;16(3):271-8; discussion 278-84</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2016 Jan 4;44(D1):D862-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26582918</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2013 May 1;41(10):e108</Citation><ArticleIdList><ArticleId IdType="pubmed">23558742</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Genet. 2009 Jun;5(6):e1000529</Citation><ArticleIdList><ArticleId IdType="pubmed">19543373</ArticleId></ArticleIdList></Reference><Reference><Citation>Biophys J. 2004 Jun;86(6):3993-4003</Citation><ArticleIdList><ArticleId IdType="pubmed">15189895</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2014 Oct;30(19):2811-2</Citation><ArticleIdList><ArticleId IdType="pubmed">24930139</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2009 Feb 1;25(3):415-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19106121</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2008 Dec 26;135(7):1311-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19109899</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2016 Feb 09;10:31</Citation><ArticleIdList><ArticleId IdType="pubmed">26903798</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2004 Apr;6(2):123-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15096695</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2014 May 22;7(4):971-81</Citation><ArticleIdList><ArticleId IdType="pubmed">24813885</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Dis. 2014 Feb 27;5:e1084</Citation><ArticleIdList><ArticleId IdType="pubmed">24577082</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1998 Nov 13;282(5392):1268-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9867630</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Cell Dev Biol. 2015 Mar;39:63-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25736836</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Pathol. 1996 Oct;6(4):493-506</Citation><ArticleIdList><ArticleId IdType="pubmed">8944319</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2010 Jan 1;26(1):139-40</Citation><ArticleIdList><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Bull. 2012 Feb;28(1):14-24</Citation><ArticleIdList><ArticleId IdType="pubmed">22233886</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2014 Jan 30;370(5):455-65</Citation><ArticleIdList><ArticleId IdType="pubmed">24476434</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Oct 4;26(40):10129-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Structure. 2014 Oct 7;22(10):1489-500</Citation><ArticleIdList><ArticleId IdType="pubmed">25220470</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Biol. 2014 Feb 03;15(2):R29</Citation><ArticleIdList><ArticleId IdType="pubmed">24485249</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2012 Jul 20;150(2):339-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22817896</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mutat. 2000;15(1):57-61</Citation><ArticleIdList><ArticleId IdType="pubmed">10612823</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Neurodegener. 2016 Apr 05;5:7</Citation><ArticleIdList><ArticleId IdType="pubmed">27054030</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2173-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2013 Jan 1;29(1):15-21</Citation><ArticleIdList><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2009 Jun 12;137(6):1112-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19524513</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2015 Mar;11(3):332-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25984581</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2013 Dec;9(12):677-86</Citation><ArticleIdList><ArticleId IdType="pubmed">24217510</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Med. 2009 Jan 22;1(1):13</Citation><ArticleIdList><ArticleId IdType="pubmed">19348700</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Tissue Bank. 2008 Sep;9(3):229-45</Citation><ArticleIdList><ArticleId IdType="pubmed">18347928</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cell Biol. 2004 Apr;14(4):184-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15066636</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2015;43(3):949-55</Citation><ArticleIdList><ArticleId IdType="pubmed">25125457</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2015 Mar 24;10(11):1836-49</Citation><ArticleIdList><ArticleId IdType="pubmed">25801023</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33</Citation><ArticleIdList><ArticleId IdType="pubmed">25431634</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Nov;67(11):1784-800</Citation><ArticleIdList><ArticleId IdType="pubmed">17196061</ArticleId></ArticleIdList></Reference><Reference><Citation>Database (Oxford). 2016 Jul 03;2016:</Citation><ArticleIdList><ArticleId IdType="pubmed">27374120</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Biol Ther. 2016 Sep;17(9):899-910</Citation><ArticleIdList><ArticleId IdType="pubmed">27434654</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2016 Jan;23(1):76-88</Citation><ArticleIdList><ArticleId IdType="pubmed">26024392</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2008 Jul 1;24(13):1547-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18467348</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2014 Jan;42(Database issue):D1001-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24316577</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Oncol. 2015 Apr 08;2(4):e975093</Citation><ArticleIdList><ArticleId IdType="pubmed">27308513</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2016 Aug 5;353(6299):603-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Mol Cell Biol. 2010 Oct;11(10):700-14</Citation><ArticleIdList><ArticleId IdType="pubmed">20823910</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 1998 May;57(5):456-64</Citation><ArticleIdList><ArticleId IdType="pubmed">9596416</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2004 Jan 15;13(2):159-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28768174</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1932-7420</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Cell metabolism</Title><ISOAbbreviation>Cell Metab</ISOAbbreviation></Journal><ArticleTitle>Loss of Brain Aerobic Glycolysis in Normal Human Aging.</ArticleTitle><Pagination><StartPage>353</StartPage><EndPage>360.e3</EndPage><MedlinePgn>353-360.e3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmet.2017.07.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1550-4131(17)30431-X</ELocationID><Abstract><AbstractText>The normal aging human brain experiences global decreases in metabolism, but whether this affects the topography of brain metabolism is unknown. Here we describe PET-based measurements of brain glucose uptake, oxygen utilization, and blood flow in&#xa0;cognitively normal adults from 20 to 82 years of age. Age-related decreases in brain glucose uptake exceed that of oxygen use, resulting in loss of brain aerobic glycolysis (AG). Whereas the topographies of total brain glucose uptake, oxygen utilization, and blood flow remain largely stable with age, brain AG topography changes significantly. Brain regions with high AG in young adults show the greatest change, as do regions with prolonged developmental transcriptional features (i.e., neoteny). The normal aging human brain thus undergoes characteristic metabolic changes, largely driven by global loss and topographic changes in brain AG.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Manu S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: goyalm@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlassenko</LastName><ForeName>Andrei G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blazey</LastName><ForeName>Tyler M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couture</LastName><ForeName>Lars E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durbin</LastName><ForeName>Tony J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L-S</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marcus E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS006833</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 NS057901</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 MH077967</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB009352</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS098577</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Metab</MedlineTA><NlmUniqueID>101233170</NlmUniqueID><ISSNLinking>1550-4131</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Metab. 2017 Aug 1;26(2):284-285. doi: 10.1016/j.cmet.2017.07.015.</RefSource><PMID Version="1">28768166</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006019" MajorTopicYN="Y">Glycolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aerobic glycolysis</Keyword><Keyword MajorTopicYN="N">brain aging</Keyword><Keyword MajorTopicYN="N">brain metabolism</Keyword><Keyword MajorTopicYN="N">neoteny</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28768174</ArticleId><ArticleId IdType="mid">NIHMS894293</ArticleId><ArticleId IdType="pmc">PMC5573225</ArticleId><ArticleId IdType="doi">10.1016/j.cmet.2017.07.010</ArticleId><ArticleId IdType="pii">S1550-4131(17)30431-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aanerud J, Borghammer P, Rodell A, Jonsdottir KY, Gjedde A. Sex differences of human cortical blood flow and energy metabolism. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5531342</ArticleId><ArticleId IdType="pubmed">27629099</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergersen LH, Gjedde A. Is lactate a volume transmitter of metabolic states of the brain? Frontiers in neuroenergetics. 2012;4:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307048</ArticleId><ArticleId IdType="pubmed">22457647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">12538238</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PJ, Scott JC, Krentz AJ, Nagy RJ, Comstock E, Hoffman C. Diminished brain glucose metabolism is a significant determinant for falling rates of systemic glucose utilization during sleep in normal humans. J Clin Invest. 1994;93:529&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC293874</ArticleId><ArticleId IdType="pubmed">8113391</ArticleId></ArticleIdList></Reference><Reference><Citation>Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, Haberkorn U, Doll J, Oberdorfer F, Lorenz WJ. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1997;38:1614&#x2013;1623.</Citation><ArticleIdList><ArticleId IdType="pubmed">9379202</ArticleId></ArticleIdList></Reference><Reference><Citation>Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005;120:513&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734683</ArticleId></ArticleIdList></Reference><Reference><Citation>Dastur DK. Cerebral blood flow and metabolism in normal human aging, pathological aging, and senile dementia. J Cereb Blood Flow Metab. 1985;5:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">3972914</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekaban AS. Changes in brain weights during the span of human life: relation of brain weights to body heights and body weights. Annals of neurology. 1978;4:345&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">727739</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Dienel GA. Brain lactate metabolism: the discoveries and the controversies. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2012;32:1107&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390802</ArticleId><ArticleId IdType="pubmed">22186669</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Groves AR, Tamnes CK, Westlye LT, Duff EP, Engvig A, Walhovd KB, James A, Gass A, Monsch AU, et al. A common brain network links development, aging, and vulnerability to disease. Proceedings of the National Academy of Sciences of the United States of America. 2014;111:17648&#x2013;17653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4267352</ArticleId><ArticleId IdType="pubmed">25422429</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, Busa E, Seidman LJ, Goldstein J, Kennedy D, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">14654453</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Schott JM. Imaging cerebral atrophy: normal ageing to Alzheimer&#x2019;s disease. Lancet. 2004;363:392&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">15074306</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox PT, Raichle ME, Mintun MA, Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science. 1988;241:462&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">3260686</ArticleId></ArticleIdList></Reference><Reference><Citation>Frouin V, Comtat C, Reilhac A, Gregoire MC. Correction of partial-volume effect for PET striatal imaging: fast implementation and study of robustness. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2002;43:1715&#x2013;1726.</Citation><ArticleIdList><ArticleId IdType="pubmed">12468524</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasser MF, Goyal MS, Preuss TM, Raichle ME, Van Essen DC. Trends and properties of human cerebral cortex: correlations with cortical myelin content. Neuroimage. 2014;93(Pt 2):165&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795824</ArticleId><ArticleId IdType="pubmed">23567887</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenn TC, Martin NA, Horning MA, McArthur DL, Hovda DA, Vespa P, Brooks GA. Lactate: brain fuel in human traumatic brain injury: a comparison with normal healthy control subjects. Journal of neurotrauma. 2015;32:820&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530406</ArticleId><ArticleId IdType="pubmed">25594628</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal MS, Hawrylycz M, Miller JA, Snyder AZ, Raichle ME. Aerobic glycolysis in the human brain is associated with development and neotenous gene expression. Cell metabolism. 2014;19:49&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4389678</ArticleId><ArticleId IdType="pubmed">24411938</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal MS, Raichle ME. Gene expression-based modeling of human cortical synaptic density. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:6571&#x2013;6576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631628</ArticleId><ArticleId IdType="pubmed">23576754</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham MM, Muzi M, Spence AM, O&#x2019;Sullivan F, Lewellen TK, Link JM, Krohn KA. The FDG lumped constant in normal human brain. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2002;43:1157&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">12215553</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat AJ, Trachtenberg JT, Wilbrecht L, Shepherd GM, Zhang X, Knott GW, Svoboda K. Transient and persistent dendritic spines in the neocortex in vivo. Neuron. 2005;45:279&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">15664179</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttenlocher PR. Synaptic density in human frontal cortex - developmental changes and effects of aging. Brain research. 1979;163:195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">427544</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M, Sousa AM, Pletikos M, Meyer KA, Sedmak G, et al. Spatio-temporal transcriptome of the human brain. Nature. 2011;478:483&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3566780</ArticleId><ArticleId IdType="pubmed">22031440</ArticleId></ArticleIdList></Reference><Reference><Citation>Kety SS. Human cerebral blood flow and oxygen consumption as related to aging. Journal of chronic diseases. 1956;3:478&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">13306754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kety SS, Schmidt CF. The Nitrous Oxide Method for the Quantitative Determination of Cerebral Blood Flow in Man: Theory, Procedure and Normal Values. J Clin Invest. 1948;27:476&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC439518</ArticleId><ArticleId IdType="pubmed">16695568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkwood TB, Austad SN. Why do we age? Nature. 2000;408:233&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089980</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhl DE, Metter EJ, Riege WH, Phelps ME. Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1982;2:163&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">6978885</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster JL, Glass TG, Lankipalli BR, Downs H, Mayberg H, Fox P. A modality-indepedent approach to spatial normalization of tomographic images of the human brain. Human Brain Mapping. 1995;3:209&#x2013;223.</Citation></Reference><Reference><Citation>Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends in biochemical sciences. 2016;41:211&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4783224</ArticleId><ArticleId IdType="pubmed">26778478</ArticleId></ArticleIdList></Reference><Reference><Citation>Locasale JW, Cantley LC. Metabolic flux and the regulation of mammalian cell growth. Cell metabolism. 2011;14:443&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196640</ArticleId><ArticleId IdType="pubmed">21982705</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubow JM, Pinon IG, Avogaro A, Cobelli C, Treeson DM, Mandeville KA, Toffolo G, Boyle PJ. Brain oxygen utilization is unchanged by hypoglycemia in normal humans: lactate, alanine, and leucine uptake are not sufficient to offset energy deficit. American journal of physiology Endocrinology and metabolism. 2006;290:E149&#x2013;E153.</Citation><ArticleIdList><ArticleId IdType="pubmed">16144821</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annual review of cell and developmental biology. 2011;27:441&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">21985671</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen PL, Cruz NF, Sokoloff L, Dienel GA. Cerebral oxygen/glucose ratio is low during sensory stimulation and rises above normal during recovery: excess glucose consumption during stimulation is not accounted for by lactate efflux from or accumulation in brain tissue. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1999;19:393&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197509</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen PL, Hasselbalch SG, Hagemann LP, Olsen KS, Bulow J, Holm S, Wildschiodtz G, Paulson OB, Lassen NA. Persistent resetting of the cerebral oxygen/glucose uptake ratio by brain activation: evidence obtained with the Kety-Schmidt technique. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1995;15:485&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">7714007</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistretti PJ. Imaging brain aerobic glycolysis as a marker of synaptic plasticity. Proceedings of the National Academy of Sciences of the United States of America. 2016;113:7015&#x2013;7016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4932986</ArticleId><ArticleId IdType="pubmed">27317739</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin AJ, Friston KJ, Colebatch JG, Frackowiak RS. Decreases in regional cerebral blood flow with normal aging. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1991;11:684&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">2050757</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin WR, Powers WJ, Raichle ME. Cerebral blood volume measured with inhaled C15O and positron emission tomography. J Cereb Blood Flow Metab. 1987;7:421&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">3497162</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Hansen L, DeTeresa R, Terry RD. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology. 1993;43:192&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mink JW, Blumenschine RJ, Adams DB. Ratio of central nervous system to body metabolism in vertebrates: its constancy and functional basis. The American journal of physiology. 1981;241:R203&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">7282965</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Raichle ME, Martin WR, Herscovitch P. Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1984;25:177&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610032</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Vlassenko AG, Rundle MM, Raichle ME. Increased lactate/pyruvate ratio augments blood flow in physiologically activated human brain. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:659&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC327204</ArticleId><ArticleId IdType="pubmed">14704276</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Overgaard M, Rasmussen P, Bohm AM, Seifert T, Brassard P, Zaar M, Homann P, Evans KA, Nielsen HB, Secher NH. Hypoxia and exercise provoke both lactate release and lactate oxidation by the human brain. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2012;26:3012&#x2013;3020.</Citation><ArticleIdList><ArticleId IdType="pubmed">22441982</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantano P, Baron JC, Lebrun-Grandie P, Duquesnoy N, Bousser MG, Comar D. Regional cerebral blood flow and oxygen consumption in human aging. Stroke; a journal of cerebral circulation. 1984;15:635&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">6611613</ArticleId></ArticleIdList></Reference><Reference><Citation>Petanjek Z, Judas M, Simic G, Rasin MR, Uylings HB, Rakic P, Kostovic I. Extraordinary neoteny of synaptic spines in the human prefrontal cortex. Proceedings of the National Academy of Sciences of the United States of America. 2011;108:13281&#x2013;13286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156171</ArticleId><ArticleId IdType="pubmed">21788513</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME. The restless brain: how intrinsic activity organizes brain function. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2015:370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4387513</ArticleId><ArticleId IdType="pubmed">25823869</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, Martin WR, Herscovitch P, Mintun MA, Markham J. Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1983;24:790&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">6604140</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, Posner JB, Plum F. Cerebral blood flow during and after hyperventilation. Archives of neurology. 1970;23:394&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">5471647</ArticleId></ArticleIdList></Reference><Reference><Citation>Salat DH, Buckner RL, Snyder AZ, Greve DN, Desikan RS, Busa E, Morris JC, Dale AM, Fischl B. Thinning of the cerebral cortex in aging. Cereb Cortex. 2004;14:721&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">15054051</ArticleId></ArticleIdList></Reference><Reference><Citation>Scahill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC. A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Archives of neurology. 2003;60:989&#x2013;994.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873856</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon BJ, Vaishnavi SN, Vlassenko AG, Shimony JS, Rutlin J, Raichle ME. Brain aerobic glycolysis and motor adaptation learning. Proceedings of the National Academy of Sciences of the United States of America. 2016;113:E3782&#x2013;3791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4932971</ArticleId><ArticleId IdType="pubmed">27217563</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith D, Pernet A, Hallett WA, Bingham E, Marsden PK, Amiel SA. Lactate: a preferred fuel for human brain metabolism in vivo. J Cereb Blood Flow Metab. 2003;23:658&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">12796713</ArticleId></ArticleIdList></Reference><Reference><Citation>Somel M, Franz H, Yan Z, Lorenc A, Guo S, Giger T, Kelso J, Nickel B, Dannemann M, Bahn S, et al. Transcriptional neoteny in the human brain. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:5743&#x2013;5748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659716</ArticleId><ArticleId IdType="pubmed">19307592</ArticleId></ArticleIdList></Reference><Reference><Citation>Somel M, Rohlfs R, Liu X. Transcriptomic insights into human brain evolution: acceleration, neutrality, heterochrony. Current opinion in genetics &amp; development. 2014;29:110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">25233113</ArticleId></ArticleIdList></Reference><Reference><Citation>Sowell ER, Peterson BS, Thompson PM, Welcome SE, Henkenius AL, Toga AW. Mapping cortical change across the human life span. Nature neuroscience. 2003;6:309&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">12548289</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, Bateman RJ, Cairns NJ, Aldea P, Cash L, et al. Partial volume correction in quantitative amyloid imaging. NeuroImage. 2015;107:55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, D&#x2019;Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, Blazey TM, Christensen JJ, Vora S, Morris JC, et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs. Plos One. 2013;8:e73377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3819320</ArticleId><ArticleId IdType="pubmed">24223109</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaishnavi SN, Vlassenko AG, Rundle MM, Snyder AZ, Mintun MA, Raichle ME. Regional aerobic glycolysis in the human brain. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:17757&#x2013;17762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955101</ArticleId><ArticleId IdType="pubmed">20837536</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Raichle ME. Brain aerobic glycolysis functions and Alzheimer&#x2019;s disease. Clin Transl Imaging. 2015;3:27&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4743905</ArticleId><ArticleId IdType="pubmed">26855936</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, Morris JC, Raichle ME, Mintun MA. Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:17763&#x2013;17767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955133</ArticleId><ArticleId IdType="pubmed">20837517</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Pan F, Gan WB. Stably maintained dendritic spines are associated with lifelong memories. Nature. 2009;462:920&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4724802</ArticleId><ArticleId IdType="pubmed">19946265</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Lin A, Chang P, Gan WB. Development of long-term dendritic spine stability in diverse regions of cerebral cortex. Neuron. 2005;46:181&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">15848798</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28783817</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort.</ArticleTitle><Pagination><StartPage>1246</StartPage><EndPage>1254</EndPage><MedlinePgn>1246-1254</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.1658</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Vascular risk factors have been associated with cognitive decline. Midlife exposure to these factors may be most important in conferring late-life risk of cognitive impairment.</AbstractText><AbstractText Label="OBJECTIVES">To examine Atherosclerosis Risk in Communities (ARIC) participants in midlife and to explore associations between midlife vascular risk factors and 25-year dementia incidence.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This prospective cohort investigation of the Atherosclerosis Risk in Communities (ARIC) Study was conducted from 1987-1989 through 2011-2013. The dates of this analysis were April 2015 through August 2016. The setting was ARIC field centers (Washington County, Maryland; Forsyth County, North Carolina; Jackson, Mississippi; and Minneapolis suburbs, Minnesota). The study comprised 15&#x202f;744 participants (of whom 27.1% were black and 72.9% white) who were aged 44 to 66 years at baseline.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Demographic and vascular risk factors were measured at baseline (obesity, smoking, diabetes, prehypertension, hypertension, and hypercholesterolemia) as well as presence of the APOE &#x3b5;4 genotype. After the baseline visit, participants had 4 additional in-person visits, for a total of 5 in-person visits, hospitalization surveillance, telephone calls, and repeated cognitive evaluations. Most recently, in 2011-2013, through the ARIC Neurocognitive Study (ARIC-NCS), participants underwent a detailed neurocognitive battery, informant interviews, and adjudicated review to define dementia cases. Additional cases were identified through the Telephone Interview for Cognitive Status-Modified or informant interview, for participants not attending the ARIC-NCS visit, or by an International Classification of Diseases, Ninth Revision dementia code during a hospitalization. Fully adjusted Cox proportional hazards regression was used to evaluate associations of baseline vascular and demographic risk factors with dementia.</AbstractText><AbstractText Label="RESULTS">In total, 1516 cases of dementia (57.0% female and 34.9% black, with a mean [SD] age at visit 1 of 57.4 [5.2] years) were identified among 15 744 participants. Black race (hazard ratio [HR], 1.36; 95% CI, 1.21-1.54), older age (HR, 8.06; 95% CI, 6.69-9.72 for participants aged 60-66 years), lower educational attainment (HR, 1.61; 95% CI, 1.28-2.03 for less than a high school education), and APOE &#x3b5;4 genotype (HR, 1.98; 95% CI, 1.78-2.21) were associated with increased risk of dementia, as were midlife smoking (HR, 1.41; 95% CI, 1.23-1.61), diabetes (HR, 1.77; 95% CI, 1.53-2.04), prehypertension (HR, 1.31; 95% CI, 1.14-1.51), and hypertension (HR, 1.39; 95% CI, 1.22-1.59). The HR for dementia for diabetes was almost as high as that for APOE &#x3b5;4 genotype.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Midlife vascular risk factors are associated with increased risk of dementia in black and white ARIC Study participants. Further studies are needed to evaluate the mechanism of and opportunities for prevention of the cognitive sequelae of these risk factors in midlife.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gottesman</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, The Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coker</LastName><ForeName>Laura H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coresh</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, The Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Sonia M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, The University of North Carolina at Chapel Hill.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deal</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, The Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKhann</LastName><ForeName>Guy M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharrett</LastName><ForeName>A Richey</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, The Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Andrea L C</ForeName><Initials>ALC</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windham</LastName><ForeName>B Gwen</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wruck</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL096812</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096902</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096814</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096899</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG052573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044383" MajorTopicYN="N">Black People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="Y">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014652" MajorTopicYN="N">Vascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Gottesman reported being an associate editor for <i>Neurology</i>. Dr Davis reported serving on a data and safety monitoring board for Eli Lilly. Dr Windham reported being an investigator in a clinical trial sponsored by Acadia Pharmaceuticals. Dr Knopman reported serving on a data and safety monitoring board for Lundbeck Pharmaceuticals and for the Dominantly Inherited Alzheimer Network (DIAN) study; reported being an investigator in clinical trials sponsored by Biogen, TauRx Therapeutics, and Eli Lilly; and reported receiving research support from the National Institutes of Health. No other disclosures were reported. No authors were compensated for being coauthors or helping with the adjudication process.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28783817</ArticleId><ArticleId IdType="pmc">PMC5710244</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.1658</ArticleId><ArticleId IdType="pii">2646624</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Swan GE, DeCarli C, Miller BL, et al. . Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology. 1998;51(4):986-993.</Citation><ArticleIdList><ArticleId IdType="pubmed">9781518</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function: the Honolulu-Asia Aging Study. JAMA. 1995;274(23):1846-1851.</Citation><ArticleIdList><ArticleId IdType="pubmed">7500533</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider AL, Albert M, et al. . Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities Neurocognitive Study. JAMA Neurol. 2014;71(10):1218-1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226067</ArticleId><ArticleId IdType="pubmed">25090106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawlings AM, Sharrett AR, Schneider AL, et al. . Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med. 2014;161(11):785-793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432464</ArticleId><ArticleId IdType="pubmed">25437406</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Zhou Y, et al. . Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317(14):1443-1450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5921896</ArticleId><ArticleId IdType="pubmed">28399252</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer&#x2019;s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788-794.</Citation><ArticleIdList><ArticleId IdType="pubmed">25030513</ArticleId></ArticleIdList></Reference><Reference><Citation>ARIC Investigators The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129(4):687-702.</Citation><ArticleIdList><ArticleId IdType="pubmed">2646917</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Gottesman RF, Sharrett AR, et al. . Mild cognitive impairment and dementia prevalence: the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Alzheimers Dement (Amst). 2016;2:1-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772876</ArticleId><ArticleId IdType="pubmed">26949733</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond MG, Davis CE. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1994;14(7):1098-1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">8018665</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedel J, H&#xe4;gele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 1983;29(6):1075-1080.</Citation><ArticleIdList><ArticleId IdType="pubmed">6851096</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Mosley TH Jr, Gottesman RF, Catellier D, Sharrett AR, Coresh J. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) Study. J Neurol Neurosurg Psychiatry. 2009;80(11):1194-1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783764</ArticleId><ArticleId IdType="pubmed">19692426</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider AL, Gottesman RF, Mosley T, et al. . Cognition and incident dementia hospitalization: results from the Atherosclerosis Risk in Communities Study. Neuroepidemiology. 2013;40(2):117-124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3642775</ArticleId><ArticleId IdType="pubmed">23095770</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.</Citation></Reference><Reference><Citation>Plassman BL, Langa KM, Fisher GG, et al. . Prevalence of dementia in the United States: the Aging, Demographics, and Memory Study. Neuroepidemiology. 2007;29(1-2):125-132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705925</ArticleId><ArticleId IdType="pubmed">17975326</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277-281.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Ngandu T, Fratiglioni L, et al. . Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005;62(10):1556-1560.</Citation><ArticleIdList><ArticleId IdType="pubmed">16216938</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala EL, Laakso MP, et al. . Midlife vascular risk factors and Alzheimer&#x2019;s disease in later life: longitudinal, population based study. BMJ. 2001;322(7300):1447-1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC32306</ArticleId><ArticleId IdType="pubmed">11408299</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Ross GW, Petrovitch H, et al. . Midlife blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiol Aging. 2000;21(1):49-55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794848</ArticleId></ArticleIdList></Reference><Reference><Citation>Husaini BA, Sherkat DE, Moonis M, Levine R, Holzer C, Cain VA. Racial differences in the diagnosis of dementia and in its effects on the use and costs of health care services. Psychiatr Serv. 2003;54(1):92-96.</Citation><ArticleIdList><ArticleId IdType="pubmed">12509673</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang MX, Cross P, Andrews H, et al. . Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56(1):49-56.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148235</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley KP, Snowdon DA, Desrosiers MF, Markesbery WR. Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. Neurobiol Aging. 2005;26(3):341-347.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639312</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela M, Brayne C, Sachdev P, Wilcock G, Matthews F; Medical Research Council Cognitive Function and Ageing Study . Cognitive lifestyle and long-term risk of dementia and survival after diagnosis in a multicenter population-based cohort. Am J Epidemiol. 2011;173(9):1004-1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">21378129</ArticleId></ArticleIdList></Reference><Reference><Citation>Whalley LJ, Starr JM, Athawes R, Hunter D, Pattie A, Deary IJ. Childhood mental ability and dementia. Neurology. 2000;55(10):1455-1459.</Citation><ArticleIdList><ArticleId IdType="pubmed">11094097</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Fornage M, Knopman DS, Mosley TH. Brain aging in African-Americans: the Atherosclerosis Risk in Communities (ARIC) experience. Curr Alzheimer Res. 2015;12(7):607-613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739532</ArticleId><ArticleId IdType="pubmed">26239037</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambless LE, Shahar E, Sharrett AR, et al. . Association of transient ischemic attack/stroke symptoms assessed by standardized questionnaire and algorithm with cerebrovascular risk factors and carotid artery wall thickness: the ARIC Study, 1987-1989. Am J Epidemiol. 1996;144(9):857-866.</Citation><ArticleIdList><ArticleId IdType="pubmed">8890664</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DA, Bennett DA, Wilson RS, et al. . Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 2003;60(2):185-189.</Citation><ArticleIdList><ArticleId IdType="pubmed">12580702</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang MX, Stern Y, Marder K, et al. . The APOE-&#x3b5;4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279(10):751-755.</Citation><ArticleIdList><ArticleId IdType="pubmed">9508150</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Zhou Y, et al. . The ARIC-PET amyloid imaging study: brain amyloid differences by age, race, sex, and APOE. Neurology. 2016;87(5):473-480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970663</ArticleId><ArticleId IdType="pubmed">27371485</ArticleId></ArticleIdList></Reference><Reference><Citation>Letenneur L, Gilleron V, Commenges D, Helmer C, Orgogozo JM, Dartigues JF. Are sex and educational level independent predictors of dementia and Alzheimer&#x2019;s disease? incidence data from the PAQUID project. J Neurol Neurosurg Psychiatry. 1999;66(2):177-183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736218</ArticleId><ArticleId IdType="pubmed">10071096</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Rawlings AM, Sharrett AR, et al. . Impact of differential attrition on the association of education with cognitive change over 20 years of follow-up: the ARIC Neurocognitive Study. Am J Epidemiol. 2014;179(8):956-966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3966720</ArticleId><ArticleId IdType="pubmed">24627572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott A, van Rossum CT, van Harskamp F, van de Mheen H, Hofman A, Breteler MM. Education and the incidence of dementia in a large population-based study: the Rotterdam Study. Neurology. 1999;52(3):663-666.</Citation><ArticleIdList><ArticleId IdType="pubmed">10025813</ArticleId></ArticleIdList></Reference><Reference><Citation>Moll van Charante EP, Richard E, Eurelings LS, et al. . Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016;388(10046):797-805.</Citation><ArticleIdList><ArticleId IdType="pubmed">27474376</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28802038</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>170</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>649</StartPage><EndPage>663.e13</EndPage><MedlinePgn>649-663.e13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2017.07.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(17)30830-9</ELocationID><Abstract><AbstractText>Elevated risk of developing Alzheimer's disease (AD) is associated with hypomorphic variants of TREM2, a surface receptor required for microglial responses to neurodegeneration, including proliferation, survival, clustering, and phagocytosis. How TREM2 promotes such diverse responses is unknown. Here, we find that microglia in AD patients carrying TREM2 risk variants and TREM2-deficient mice with AD-like pathology have abundant autophagic vesicles, as do TREM2-deficient macrophages under growth-factor limitation or endoplasmic reticulum (ER) stress.&#xa0;Combined metabolomics and RNA sequencing (RNA-seq) linked this anomalous autophagy to defective mammalian target of rapamycin (mTOR) signaling, which affects ATP levels and biosynthetic pathways. Metabolic derailment and autophagy were offset in&#xa0;vitro through Dectin-1, a receptor that elicits TREM2-like intracellular signals, and cyclocreatine, a creatine analog that can supply ATP. Dietary cyclocreatine tempered autophagy, restored microglial clustering around plaques, and decreased plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-&#x3b2; pathology. Thus, TREM2 enables microglial responses during AD by sustaining cellular energetic and biosynthetic metabolism.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ulland</LastName><ForeName>Tyler K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Wilbur M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Stanley Ching-Cheng</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sergushichev</LastName><ForeName>Alexey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Computer Technologies Department, ITMO University, Saint Petersburg 197101, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beatty</LastName><ForeName>Wandy L</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loboda</LastName><ForeName>Alexander A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Computer Technologies Department, ITMO University, Saint Petersburg 197101, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yingyue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kambal</LastName><ForeName>Amal</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loginicheva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilfillan</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cella</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Virgin</LastName><ForeName>Herbert W</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unanue</LastName><ForeName>Emil R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yaming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artyomov</LastName><ForeName>Maxim N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: mcolonna@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI109725</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK058177</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009547</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG059176</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI007163</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059082</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051485</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI114551</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037181">Lectins, C-Type</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C411658">dectin 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>6732XGX1RK</RegistryNumber><NameOfSubstance UI="C012260">cyclocreatine</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.31</RegistryNumber><NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055372" MajorTopicYN="N">AMP-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="Y">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037181" MajorTopicYN="N">Lectins, C-Type</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">metabolism</Keyword><Keyword MajorTopicYN="N">microglia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>8</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28802038</ArticleId><ArticleId IdType="mid">NIHMS893939</ArticleId><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2017.07.023</ArticleId><ArticleId IdType="pii">S0092-8674(17)30830-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ara G, Gravelin LM, Kaddurah-Daouk R, Teicher BA. Antitumor activity of creatine analogs produced by alterations in pancreatic hormones and glucose metabolism. In vivo. 1998;12:223&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">9627806</ArticleId></ArticleIdList></Reference><Reference><Citation>Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science. 2002;296:1323&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">11950999</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, et al. Apolipoprotein E is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) J Biochem 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CC, DeVaux LB, Farzan M. The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E. J Biochem 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646256</ArticleId><ArticleId IdType="pubmed">26374897</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho MH, Cho K, Kang HJ, Jeon EY, Kim HS, Kwon HJ, Kim HM, Kim DH, Yoon SY. Autophagy in microglia degrades extracellular beta-amyloid fibrils and regulates the NLRP3 inflammasome. Autophagy. 2014;10:1761&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4198361</ArticleId><ArticleId IdType="pubmed">25126727</ArticleId></ArticleIdList></Reference><Reference><Citation>Dambuza IM, Brown GD. C-type lectins in immunity: recent developments. Curr Opin Immunol. 2015;32:21&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4589735</ArticleId><ArticleId IdType="pubmed">25553393</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol. 2009;21:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723941</ArticleId><ArticleId IdType="pubmed">19230638</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman LC, Ting JP. The pathogenic role of the inflammasome in neurodegenerative diseases. J Neurochem. 2016;136(Suppl 1):29&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">26119245</ArticleId></ArticleIdList></Reference><Reference><Citation>Galluzzi L, Pietrocola F, Levine B, Kroemer G. Metabolic control of autophagy. Cell. 2014;159:1263&#x2013;1276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4500936</ArticleId><ArticleId IdType="pubmed">25480292</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold M, El Khoury J. beta-amyloid, microglia, and the inflammasome in Alzheimer&#x2019;s disease. Semin Immunopathol. 2015;37:607&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4618770</ArticleId><ArticleId IdType="pubmed">26251237</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Hardy J. Genetics of Alzheimer&#x2019;s disease. Neurotherapeutics. 2014;11:732&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362699</ArticleId><ArticleId IdType="pubmed">25113539</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006;441:885&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedrick SM, Matis LA, Hecht TT, Samelson LE, Longo DL, Heber-Katz E, Schwartz RH. The fine specificity of antigen and Ia determinant recognition by T cell hybridoma clones specific for pigeon cytochrome c. Cell. 1982;30:141&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">6181895</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer&#x2019;s disease. Nat Immunol. 2015;16:229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">25689443</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, et al. NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer&#x2019;s disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT, Landreth GE. Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer&#x2019;s Disease. J Neurosci. 2017;37:637&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3987946</ArticleId><ArticleId IdType="pubmed">21258367</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Autophagy. 2016;12:1&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835977</ArticleId><ArticleId IdType="pubmed">26799652</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441:880&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40:280&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3127250</ArticleId><ArticleId IdType="pubmed">20965422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuiper JW, Pluk H, Oerlemans F, van Leeuwen FN, de Lange F, Fransen J, Wieringa B. Creatine kinase-mediated ATP supply fuels actin-based events in phagocytosis. PLoS biology. 2008;6:e51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265766</ArticleId><ArticleId IdType="pubmed">18336068</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosawa Y, Degrauw TJ, Lindquist DM, Blanco VM, Pyne-Geithman GJ, Daikoku T, Chambers JB, Benoit SC, Clark JF. Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency. J Clin Invest. 2012;122:2837&#x2013;2846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3408730</ArticleId><ArticleId IdType="pubmed">22751104</ArticleId></ArticleIdList></Reference><Reference><Citation>Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331679</ArticleId><ArticleId IdType="pubmed">22500797</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucin KM, O&#x2019;Brien CE, Bieri G, Czirr E, Mosher KI, Abbey RJ, Mastroeni DF, Rogers J, Spencer B, Masliah E, et al. Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer&#x2019;s disease. Neuron. 2013;79:873&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779465</ArticleId><ArticleId IdType="pubmed">24012002</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer&#x2019;s disease. J Neurosci. 1996;16:5795&#x2013;5811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578961</ArticleId><ArticleId IdType="pubmed">8795633</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin AC, Cohn M, Kenyon GL. Specificity of creatine kinase for guanidino substrates. Kinetic and proton nuclear magnetic relaxation rate studies. J Biol Chem. 1972;247:4382&#x2013;4388.</Citation><ArticleIdList><ArticleId IdType="pubmed">5035696</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Prinz M. Myeloid cells in Alzheimer&#x2019;s disease: culprits, victims or innocent bystanders? Trends in neurosciences. 2015;38:659&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">26442698</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea-Maier RT, Plantinga TS, van de Veerdonk FL, Smit JW, Netea MG. Modulation of inflammation by autophagy: Consequences for human disease. Autophagy. 2016;12:245&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836004</ArticleId><ArticleId IdType="pubmed">26222012</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann H, Takahashi K. Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol. 2007;184:92&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">17239445</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill LA, Pearce EJ. Immunometabolism governs dendritic cell and macrophage function. J Exp Med. 2016;213:15&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4710204</ArticleId><ArticleId IdType="pubmed">26694970</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre M, Kamphuis W, Osborn LM, Jansen AH, Kooijman L, Bossers K, Hol EM. Isolation of glia from Alzheimer&#x2019;s mice reveals inflammation and dysfunction. Neurobiol Aging. 2014;35:2746&#x2013;2760.</Citation><ArticleIdList><ArticleId IdType="pubmed">25002035</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Q, Malhotra S, Torchia JA, Kerr WG, Coggeshall KM, Humphrey MB. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci Signal. 2010;3:ra38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900152</ArticleId><ArticleId IdType="pubmed">20484116</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol. 2014;10:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">24638131</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168:960&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5394987</ArticleId><ArticleId IdType="pubmed">28283069</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergushichev AA, Loboda AA, Jha AK, Vincent EE, Driggers EM, Jones RG, Pearce EJ, Artyomov MN. GAM: a web-service for integrated transcriptional and metabolic network analysis. Nucleic Acids Res. 2016;44:W194&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987878</ArticleId><ArticleId IdType="pubmed">27098040</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya Y, Chang CC, Huang LH, Bryleva EY, Chang TY. Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Abeta1-42 clearance. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2014;34:14484&#x2013;14501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205563</ArticleId><ArticleId IdType="pubmed">25339759</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow RJ, Murphy RM. Creatine and the creatine transporter: a review. Mol Cell Biochem. 2001;224:169&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11693194</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3475404</ArticleId><ArticleId IdType="pubmed">23028126</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejera D, Heneka MT. Microglia in Alzheimer&#x2019;s disease: the good, the bad and the ugly. Curr Alzheimer Res. 2016;13:370&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">26567746</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006;177:3520&#x2013;3524.</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener. 2014;9:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent EE, Sergushichev A, Griss T, Gingras MC, Samborska B, Ntimbane T, Coelho PP, Blagih J, Raissi TC, Choiniere L, et al. Mitochondrial Phosphoenolpyruvate Carboxykinase Regulates Metabolic Adaptation and Enables Glucose-Independent Tumor Growth. Mol Cell. 2015;60:195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">26474064</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker JB. Creatine: biosynthesis, regulation, and function. Adv Enzymol Relat Areas Mol Biol. 1979;50:177&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">386719</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213:667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner M, Hobeika E, Jumaa H. Role of PI3K in the generation and survival of B cells. Immunol Rev. 2010;237:55&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20727029</ArticleId></ArticleIdList></Reference><Reference><Citation>Woznicki DT, Walker JB. Formation of a supplemental long time-constant reservoir of high energy phosphate by brain in vivo and in vitro and its reversible depletion by potassium depolarization. J Neurochem. 1979;33:75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">458473</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80:1107&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pubmed">10893433</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, Schmidt SD, Wesson D, Bandyopadhyay U, Jiang Y, et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer&#x2019;s disease ameliorates amyloid pathologies and memory deficits. Brain : a journal of neurology. 2011;134:258&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3009842</ArticleId><ArticleId IdType="pubmed">21186265</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron. 2016;91:328&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron. 2016;90:724&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28735855</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>390</Volume><Issue>10113</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>16</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Dementia prevention, intervention, and care.</ArticleTitle><Pagination><StartPage>2673</StartPage><EndPage>2734</EndPage><MedlinePgn>2673-2734</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(17)31363-6</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(17)31363-6</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Livingston</LastName><ForeName>Gill</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK. Electronic address: g.livingston@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sommerlad</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orgeta</LastName><ForeName>Vasiliki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costafreda</LastName><ForeName>Sergi G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huntley</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK; Department of Old Age Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Ageing Research Institute, Parkville, VIC, Australia; Academic Unit for Psychiatry of Old Age, University of Melbourne, Kew, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical School, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Sube</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Dementia Studies, Brighton and Sussex Medical School, University of Sussex, Brighton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Dementia Studies, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen-Mansfield</LastName><ForeName>Jiska</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Health Promotion, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Heczeg Institute on Aging, Tel Aviv University, Tel Aviv, Israel; Minerva Center for Interdisciplinary Study of End of Life, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitlin</LastName><ForeName>Laura N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Center for Innovative Care in Aging, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kales</LastName><ForeName>Helen C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA; VA Center for Clinical Management Research, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Inserm, Unit 1061, Neuropsychiatry: Epidemiological and Clinical Research, La Colombi&#xe8;re Hospital, University of Montpellier, Montpellier, France; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rockwood</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for the Health Care of Elderly People, Geriatric Medicine Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampson</LastName><ForeName>Elizabeth L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Marie Curie Palliative Care Research Department, Division of Psychiatry, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samus</LastName><ForeName>Quincy</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins Bayview, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Neurology and Department of Psychiatry and the Behavioural Sciences, Keck School of Medicine, Leonard Davis School of Gerontology of the University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selb&#xe6;k</LastName><ForeName>Geir</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Norwegian National Advisory Unit on Aging and Health, Vestfold Health Trust, T&#xf8;nsberg, Norway; Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway; Centre for Old Age Psychiatric Research, Innlandet Hospital Trust, Ottestad, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teri</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department Psychosocial and Community Health, School of Nursing, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukadam</LastName><ForeName>Naaheed</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0901982</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MCCC-FCO-11-U</GrantID><Acronym>MCCC_</Acronym><Agency>Marie Curie</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2017 Sep 29;13(10):579-580. doi: 10.1038/nrneurol.2017.136.</RefSource><PMID Version="1">28960208</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2018 Apr 21;391(10130):1574-1575. doi: 10.1016/S0140-6736(18)30578-6.</RefSource><PMID Version="1">29695343</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2018 Apr 21;391(10130):1575. doi: 10.1016/S0140-6736(18)30579-8.</RefSource><PMID Version="1">29695344</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2018 Apr 21;391(10130):1575-1576. doi: 10.1016/S0140-6736(18)30570-1.</RefSource><PMID Version="1">29695345</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ir J Psychol Med. 2019 Jun;36(2):85-88. doi: 10.1017/ipm.2018.4.</RefSource><PMID Version="1">31187723</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Healthy Longev. 2022 Apr;3(4):e225-e226. doi: 10.1016/S2666-7568(22)00077-0.</RefSource><PMID Version="1">36098296</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28735855</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(17)31363-6</ArticleId><ArticleId IdType="pii">S0140-6736(17)31363-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28817800</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Aug</Month><Day>16</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics.</ArticleTitle><Pagination><StartPage>808</StartPage><EndPage>816.e9</EndPage><MedlinePgn>808-816.e9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2017.07.025</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(17)30647-5</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are age-related neurodegenerative disorders with shared genetic etiologies and overlapping clinical and pathological features. Here we studied a novel ALS/FTD family and identified the P362L mutation in the low-complexity domain (LCD) of T&#xa0;cell-restricted intracellular antigen-1 (TIA1). Subsequent genetic association analyses showed an increased burden of TIA1 LCD mutations in ALS patients compared to controls (p&#xa0;= 8.7&#xa0;&#xd7; 10<sup>-6</sup>). Postmortem neuropathology of five TIA1 mutations carriers showed a consistent pathological signature with numerous round, hyaline, TAR DNA-binding protein 43 (TDP-43)-positive inclusions. TIA1 mutations significantly increased the propensity of TIA1 protein to undergo phase transition. In live cells, TIA1 mutations delayed stress granule (SG) disassembly and promoted the accumulation of non-dynamic SGs that harbored TDP-43. Moreover, TDP-43 in SGs became less mobile and insoluble. The identification of TIA1 mutations in ALS/FTD reinforces the importance of RNA metabolism and SG dynamics in ALS/FTD pathogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Vancouver Coastal Health and the University of British Colombia, Vancouver, BC V6T 2B5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Alexandra M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Mohona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messing</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purice</LastName><ForeName>Maria D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pottier</LastName><ForeName>Cyril</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Annu</LastName><ForeName>Kavya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Matt</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perkerson</LastName><ForeName>Ralph B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurti</LastName><ForeName>Aishe</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matchett</LastName><ForeName>Billie J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mittag</LastName><ForeName>Tanja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Temirov</LastName><ForeName>Jamshid</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Division of Neurology, Vancouver Coastal Health and the University of British Columbia, Vancouver, BC V6T 2B5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krieger</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Neurology, Vancouver Coastal Health and the University of British Columbia, Vancouver, BC V6T 2B5, Canada; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fryer</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keith</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zivkovic</LastName><ForeName>Sasha A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirsch-Reinshagen</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Vancouver Coastal Health and the University of British Colombia, Vancouver, BC V6T 2B5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roos</LastName><ForeName>Raymond P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Chicago Medicine, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Z&#xfc;chner</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dr. John T. Macdonald Foundation, Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Rochester, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caselli</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Scottsdale, Phoenix, AZ 85054, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wszolek</LastName><ForeName>Zbigniew K</ForeName><Initials>ZK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON N6A 5C1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lippa</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19107, USA; Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacomis</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Neurology, Vancouver Coastal Health and the University of British Columbia, Vancouver, BC V6T 2B5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hong Joo</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON M5T 2S8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boylan</LastName><ForeName>Kevin B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>J Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Electronic address: jpaul.taylor@stjude.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA. Electronic address: rademakers.rosa@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092091</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097261</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS076471</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS072187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS072248</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS075764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076245">Heterogeneous Nuclear Ribonucleoprotein A1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034481">Heterogeneous-Nuclear Ribonucleoprotein Group A-B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039102">Poly(A)-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074019">T-Cell Intracellular Antigen-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C071558">TIA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="N">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076245" MajorTopicYN="N">Heterogeneous Nuclear Ribonucleoprotein A1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034481" MajorTopicYN="N">Heterogeneous-Nuclear Ribonucleoprotein Group A-B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039102" MajorTopicYN="N">Poly(A)-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013312" MajorTopicYN="N">Stress, Physiological</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074019" MajorTopicYN="N">T-Cell Intracellular Antigen-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">T cell-restricted intracellular antigen-1</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">liquid-liquid phase separation</Keyword><Keyword MajorTopicYN="N">low-complexity domain</Keyword><Keyword MajorTopicYN="N">membrane-less organelle</Keyword><Keyword MajorTopicYN="N">stress granules</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>8</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28817800</ArticleId><ArticleId IdType="mid">NIHMS897730</ArticleId><ArticleId IdType="pmc">PMC5576574</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.07.025</ArticleId><ArticleId IdType="pii">S0896-6273(17)30647-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aulas A, Vande Velde C. Alterations in stress granule dynamics driven by TDP-43 and FUS: a link to pathological inclusions in ALS? Front Cell Neurosci. 2015;9:423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4615823</ArticleId><ArticleId IdType="pubmed">26557057</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand P, Dyck PJ, Liu J, Berini S, Selcen D, Milone M. Distal myopathy with coexisting heterozygous TIA1 and MYH7 Variants. Neuromuscul Disord. 2016;26:511&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">27282841</ArticleId></ArticleIdList></Reference><Reference><Citation>Brangwynne CP, Mitchison TJ, Hyman AA. Active liquid-like behavior of nucleoli determines their size and shape in Xenopus laevis oocytes. Proc Natl Acad Sci U S A. 2011;108:4334&#x2013;4339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060270</ArticleId><ArticleId IdType="pubmed">21368180</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunello CA, Yan X, Huttunen HJ. Internalized Tau sensitizes cells to stress by promoting formation and stability of stress granules. Sci Rep. 2016;6:30498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962319</ArticleId><ArticleId IdType="pubmed">27460788</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, Couthouis J, Lu YF, Wang Q, Krueger BJ, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier NC, Heuser J, Levy MA, Schlesinger MJ. Ultrastructural and biochemical analysis of the stress granule in chicken embryo fibroblasts. J Cell Biol. 1988;106:1131&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2114993</ArticleId><ArticleId IdType="pubmed">3283146</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaum-Garfinkle S, Kim Y, Szczepaniak K, Chen CC, Eckmann CR, Myong S, Brangwynne CP. The disordered P granule protein LAF-1 drives phase separation into droplets with tunable viscosity and dynamics. Proc Natl Acad Sci U S A. 2015;112:7189&#x2013;7194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4466716</ArticleId><ArticleId IdType="pubmed">26015579</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, Zheng JG, Shi Y, Siddique N, Arrat H, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Archives of neurology. 2011;68:1440&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pubmed">22084127</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, Muller K, Marroquin N, Nordin F, Hubers A, Weydt P, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18:631&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilks N, Kedersha N, Ayodele M, Shen L, Stoecklin G, Dember LM, Anderson P. Stress granule assembly is mediated by prion-like aggregation of TIA-1. Mol Biol Cell. 2004;15:5383&#x2013;5398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC532018</ArticleId><ArticleId IdType="pubmed">15371533</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez M, Falk MJ, Gai X, Postrel R, Schule R, Zuchner S. Innovative genomic collaboration using the GENESIS (GEM.app) platform. Human mutation. 2015;36:950&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4682547</ArticleId><ArticleId IdType="pubmed">26173844</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackman P, Sarparanta J, Lehtinen S, Vihola A, Evila A, Jonson PH, Luque H, Kere J, Screen M, Chinnery PF, et al. Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1. Ann Neurol. 2013;73:500&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">23401021</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Rogaeva E. Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not. Exp Neurol. 2014;262(Pt B):75&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">24246281</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Spector DL. U1 and U2 small nuclear RNAs are present in nuclear speckles. Proc Natl Acad Sci U S A. 1992;89:305&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48225</ArticleId><ArticleId IdType="pubmed">1530887</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji AL, Zhang X, Chen WW, Huang WJ. Genetics insight into the amyotrophic lateral sclerosis/frontotemporal dementia spectrum. J Med Genet. 2017;54:145&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">28087719</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wuu J, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, Pliner HA, Abramzon Y, Marangi G, Winborn BJ, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci. 2014;17:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000579</ArticleId><ArticleId IdType="pubmed">24686783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, Mirzaei H, Goldsmith EJ, Longgood J, Pei J, et al. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell. 2012;149:753&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N, Cho MR, Li W, Yacono PW, Chen S, Gilks N, Golan DE, Anderson P. Dynamic shuttling of TIA-1 accompanies the recruitment of mRNA to mammalian stress granules. J Cell Biol. 2000;151:1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190599</ArticleId><ArticleId IdType="pubmed">11121440</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Klar J, Sobol M, Melberg A, Mabert K, Ameur A, Johansson AC, Feuk L, Entesarian M, Orlen H, Casar-Borota O, Dahl N. Welander distal myopathy caused by an ancient founder mutation in TIA1 associated with perturbed splicing. Hum Mutat. 2013;34:572&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">23348830</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi Y, Yang S, Nykamp K, Garcia J, Lincoln SE, Topper SE. Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation. Genome Med. 2017;9:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5295186</ArticleId><ArticleId IdType="pubmed">28166811</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KH, Zhang P, Kim HJ, Mitrea DM, Sarkar M, Freibaum BD, Cika J, Coughlin M, Messing J, Molliex A, et al. C9orf72 Dipeptide Repeats Impair the Assembly, Dynamics, and Function of Membrane-Less Organelles. Cell. 2016;167:774&#x2013;788.e717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Protter DS, Rosen MK, Parker R. Formation and Maturation of Phase-Separated Liquid Droplets by RNA-Binding Proteins. Mol Cell. 2015;60:208&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609299</ArticleId><ArticleId IdType="pubmed">26412307</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda T, Nagai T. Quantitative measurement of intracellular protein dynamics using photobleaching or photoactivation of fluorescent proteins. Microscopy (Oxf) 2014;63:403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">25268018</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A, Temirov J, Lee J, Coughlin M, Kanagaraj AP, Kim HJ, Mittag T, Taylor JP. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T, Qamar S, Lin JQ, Schierle GS, Rees E, Miyashita A, Costa AR, Dodd RB, Chan FT, Michel CH, et al. ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function. Neuron. 2015;88:678&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4660210</ArticleId><ArticleId IdType="pubmed">26526393</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, Forman MS, Troost D, Kretzschmar HA, Trojanowski JQ, Lee VM. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Truax AC, Vanmassenhove B, Kretzschmar HA, Van Deerlin VM, Clark CM, Grossman M, Miller BL, Trojanowski JQ, Lee VM. TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol. 2007;66:177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">17356379</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Panas MD, Ivanov P, Anderson P. Mechanistic insights into mammalian stress granule dynamics. J Cell Biol. 2016;215:313&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5100297</ArticleId><ArticleId IdType="pubmed">27821493</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, Lee HO, Jawerth L, Maharana S, Jahnel M, Hein MY, Stoynov S, Mahamid J, Saha S, Franzmann TM, et al. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell. 2015;162:1066&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HB, Gorlich D. Transport Selectivity of Nuclear Pores, Phase Separation, and Membraneless Organelles. Trends Biochem Sci. 2016;41:46&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">26705895</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheth U, Parker R. Decapping and decay of messenger RNA occur in cytoplasmic processing bodies. Science. 2003;300:805&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876714</ArticleId><ArticleId IdType="pubmed">12730603</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP. Multisystem proteinopathy: intersecting genetics in muscle, bone, and brain degeneration. Neurology. 2015;85:658&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">26208960</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016a;539:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor N, Elbaum-Garfinkle S, Vaidya N, Zhang H, Stone HA, Brangwynne CP. Biophysical characterization of organelle-based RNA/protein liquid phases using microfluidics. Soft Matter. 2016b;12:9142&#x2013;9150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724727</ArticleId><ArticleId IdType="pubmed">27791212</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderweyde T, Apicco DJ, Youmans-Kidder K, Ash PE, Cook C, Lummertz da Rocha E, Jansen-West K, Frame AA, Citro A, Leszyk JD, et al. Interaction of tau with the RNA-Binding Protein TIA1 Regulates tau Pathophysiology and Toxicity. Cell Rep. 2016;15:1455&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325702</ArticleId><ArticleId IdType="pubmed">27160897</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderweyde T, Yu H, Varnum M, Liu-Yesucevitz L, Citro A, Ikezu T, Duff K, Wolozin B. Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2012;32:8270&#x2013;8283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3402380</ArticleId><ArticleId IdType="pubmed">22699908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, Hochstrasser DF. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol. 1999;112:531&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027275</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CH, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, Piotrowska K, Lowe P, Koppers M, McKenna-Yasek D, Baron DM, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488:499&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet. 2011;89:82&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135811</ArticleId><ArticleId IdType="pubmed">21737059</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, Bailey R, Pickering-Brown S, Dickson D, Petrucelli L. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci. 2007;27:10530&#x2013;10534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673167</ArticleId><ArticleId IdType="pubmed">17898224</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28814675</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2379-3708</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>16</Issue><PubDate><Year>2017</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>JCI insight</Title><ISOAbbreviation>JCI Insight</ISOAbbreviation></Journal><ArticleTitle>Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e93621</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1172/jci.insight.93621</ELocationID><ELocationID EIdType="pii" ValidYN="Y">93621</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Noninvasive detection of Alzheimer's disease (AD) with high specificity and sensitivity can greatly facilitate identification of at-risk populations for earlier, more effective intervention. AD patients exhibit a myriad of retinal pathologies, including hallmark amyloid &#x3b2;-protein (A&#x3b2;) deposits.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Burden, distribution, cellular layer, and structure of retinal A&#x3b2; plaques were analyzed in flat mounts and cross sections of definite AD patients and controls (n = 37). In a proof-of-concept retinal imaging trial (n = 16), amyloid probe curcumin formulation was determined and protocol was established for retinal amyloid imaging in live patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Histological examination uncovered classical and neuritic-like A&#x3b2; deposits with increased retinal A&#x3b2;42 plaques (4.7-fold; P = 0.0063) and neuronal loss (P = 0.0023) in AD patients versus matched controls. Retinal A&#x3b2; plaque mirrored brain pathology, especially in the primary visual cortex (P = 0.0097 to P = 0.0018; Pearson's r = 0.84-0.91). Retinal deposits often associated with blood vessels and occurred in hot spot peripheral regions of the superior quadrant and innermost retinal layers. Transmission electron microscopy revealed retinal A&#x3b2; assembled into protofibrils and fibrils. Moreover, the ability to image retinal amyloid deposits with solid-lipid curcumin and a modified scanning laser ophthalmoscope was demonstrated in live patients. A fully automated calculation of the retinal amyloid index (RAI), a quantitative measure of increased curcumin fluorescence, was constructed. Analysis of RAI scores showed a 2.1-fold increase in AD patients versus controls (P = 0.0031).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The geometric distribution and increased burden of retinal amyloid pathology in AD, together with the feasibility to noninvasively detect discrete retinal amyloid deposits in living patients, may lead to a practical approach for large-scale AD diagnosis and monitoring.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">National Institute on Aging award (AG044897) and The Saban and The Marciano Family Foundations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koronyo</LastName><ForeName>Yosef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biggs</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>NeuroVision Imaging LLC, Sacramento, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barron</LastName><ForeName>Ernesto</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Doheny Eye Institute, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyer</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Retina Vitreous Associates Medical Group, Beverly Hills, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearlman</LastName><ForeName>Joel A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Retinal Consultants Medical Group, Sacramento, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Au</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Sutter Neuroscience Institute, Sacramento, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kile</LastName><ForeName>Shawn J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Sutter Neuroscience Institute, Sacramento, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanco</LastName><ForeName>Austin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NeuroVision Imaging LLC, Sacramento, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuchs</LastName><ForeName>Dieu-Trang</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashfaq</LastName><ForeName>Adeel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frautschy</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Medicine, University of California, Los Angeles, Los Angeles, California, USA; Geriatric Research Education and Clinical Center, Los Angeles, California, USA; and Veterans Greater Los Angeles Healthcare System, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Gregory M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Medicine, University of California, Los Angeles, Los Angeles, California, USA; Geriatric Research Education and Clinical Center, Los Angeles, California, USA; and Veterans Greater Los Angeles Healthcare System, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Pathology Program in Neuroscience, Keck School of Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinton</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Departments of Pathology and Ophthalmology, USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verdooner</LastName><ForeName>Steven R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>NeuroVision Imaging LLC, Sacramento, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Keith L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koronyo-Hamaoui</LastName><ForeName>Maya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056478</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R41 AG044897</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055865</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCI Insight</MedlineTA><NlmUniqueID>101676073</NlmUniqueID><ISSNLinking>2379-3708</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Neuroscience</Keyword><Keyword MajorTopicYN="N">Ophthalmology</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> Y. Koronyo, K.L. Black, S.R. Verdooner, and M. Koronyo-Hamaoui are founding members of NeuroVision Imaging. S. Frautschy and G.M. Cole are founding members of Optimized Curcumin Longvida.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>8</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28814675</ArticleId><ArticleId IdType="pmc">PMC5621887</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.93621</ArticleId><ArticleId IdType="pii">93621</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association. 2016 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2016;12(4):459&#x2013;509. doi: 10.1016/j.jalz.2016.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.03.001</ArticleId><ArticleId IdType="pubmed">27570871</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Karran E. The cellular phase of Alzheimer&#x2019;s disease. Cell. 2016;164(4):603&#x2013;615. doi: 10.1016/j.cell.2015.12.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.12.056</ArticleId><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M. Genetic dissection of Alzheimer&#x2019;s disease and related dementias: amyloid and its relationship to tau. Nat Neurosci. 1998;1(5):355&#x2013;358. doi: 10.1038/1565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/1565</ArticleId><ArticleId IdType="pubmed">10196523</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367(9):795&#x2013;804. doi: 10.1056/NEJMoa1202753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgel M, et al. Individual estimates of age at detectable amyloid onset for risk factor assessment. Alzheimers Dement. 2016;12(4):373&#x2013;379. doi: 10.1016/j.jalz.2015.08.166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.08.166</ArticleId><ArticleId IdType="pmc">PMC4841700</ArticleId><ArticleId IdType="pubmed">26588863</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer&#x2019;s disease. Nature. 2009;461(7266):916&#x2013;922. doi: 10.1038/nature08538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08538</ArticleId><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;319. doi: 10.1002/ana.20009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20009</ArticleId><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Mattsson N, Sch&#xf6;ll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer&#x2019;s disease. Trends Pharmacol Sci. 2015;36(5):297&#x2013;309. doi: 10.1016/j.tips.2015.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2015.03.002</ArticleId><ArticleId IdType="pubmed">25840462</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan TK, Alkon DL. Alzheimer&#x2019;s disease cerebrospinal fluid and neuroimaging biomarkers: diagnostic accuracy and relationship to drug efficacy. J Alzheimers Dis. 2015;46(4):817&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">26402622</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu P, Fu H, Cui M. Compounds for imaging amyloid-&#x3b2; deposits in an Alzheimer&#x2019;s brain: a patent review. Expert Opin Ther Pat. 2015;25(4):413&#x2013;423. doi: 10.1517/13543776.2015.1007953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543776.2015.1007953</ArticleId><ArticleId IdType="pubmed">25746836</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M. Ocular indicators of Alzheimer&#x2019;s: exploring disease in the retina. Acta Neuropathol. 2016;132(6):767&#x2013;787. doi: 10.1007/s00401-016-1613-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1613-6</ArticleId><ArticleId IdType="pmc">PMC5106496</ArticleId><ArticleId IdType="pubmed">27645291</ArticleId></ArticleIdList></Reference><Reference><Citation>The Retina. In: Purves D, et al, eds. Neuroscience. 2nd ed. Chapters 11 and 12. Sunderland (MA): Sinauer Associates; 2001.</Citation></Reference><Reference><Citation>Byerly MS, Blackshaw S. Vertebrate retina and hypothalamus development. Wiley Interdiscip Rev Syst Biol Med. 2009;1(3):380&#x2013;389. doi: 10.1002/wsbm.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wsbm.22</ArticleId><ArticleId IdType="pubmed">20836003</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost A, et al. Brain and Retinal Pericytes: Origin, Function and Role. Front Cell Neurosci. 2016;10:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4740376</ArticleId><ArticleId IdType="pubmed">26869887</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayhan HA, Aslan Bayhan S, Celikbilek A, Tan&#x131;k N, G&#xfc;rdal C. Evaluation of the chorioretinal thickness changes in Alzheimer&#x2019;s disease using spectral-domain optical coherence tomography. Clin Experiment Ophthalmol. 2015;43(2):145&#x2013;151. doi: 10.1111/ceo.12386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.12386</ArticleId><ArticleId IdType="pubmed">24995484</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RH. Retinal pathology in Alzheimer&#x2019;s disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging. 1996;17(3):385&#x2013;395. doi: 10.1016/0197-4580(96)00009-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(96)00009-7</ArticleId><ArticleId IdType="pubmed">8725900</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola G, et al. Optical coherence tomography in Alzheimer&#x2019;s disease: a meta-analysis. PLoS One. 2015;10(8):e0134750. doi: 10.1371/journal.pone.0134750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0134750</ArticleId><ArticleId IdType="pmc">PMC4529274</ArticleId><ArticleId IdType="pubmed">26252902</ArticleId></ArticleIdList></Reference><Reference><Citation>Curcio CA, Drucker DN. Retinal ganglion cells in Alzheimer&#x2019;s disease and aging. Ann Neurol. 1993;33(3):248&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">8498808</ArticleId></ArticleIdList></Reference><Reference><Citation>Feke GT, Hyman BT, Stern RA, Pasquale LR. Retinal blood flow in mild cognitive impairment and Alzheimer&#x2019;s disease. Alzheimers Dement (Amst) 2015;1(2):144&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4876882</ArticleId><ArticleId IdType="pubmed">27239502</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost S, et al. Retinal vascular biomarkers for early detection and monitoring of Alzheimer&#x2019;s disease. Transl Psychiatry. 2013;3:e233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3591002</ArticleId><ArticleId IdType="pubmed">23443359</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Liu Y, Li X, Bai Q, Liu P. Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer&#x2019;s disease. Arch Gerontol Geriatr. 2015;60(1):162&#x2013;167. doi: 10.1016/j.archger.2014.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2014.10.011</ArticleId><ArticleId IdType="pubmed">25459918</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Duggan J, Cordeiro MF. Alzheimer&#x2019;s disease and retinal neurodegeneration. Curr Alzheimer Res. 2010;7(1):3&#x2013;14. doi: 10.2174/156720510790274491.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720510790274491</ArticleId><ArticleId IdType="pubmed">20205667</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer&#x2019;s disease. N Engl J Med. 1986;315(8):485&#x2013;487. doi: 10.1056/NEJM198608213150804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198608213150804</ArticleId><ArticleId IdType="pubmed">3736630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirbas S, Turkyilmaz K, Anlar O, Tufekci A, Durmus M. Retinal nerve fiber layer thickness in patients with Alzheimer disease. J Neuroophthalmol. 2013;33(1):58&#x2013;61. doi: 10.1097/WNO.0b013e318267fd5f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNO.0b013e318267fd5f</ArticleId><ArticleId IdType="pubmed">22918296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kromer R, Serbecic N, Hausner L, Froelich L, Aboul-Enein F, Beutelspacher SC. Detection of retinal nerve fiber layer defects in Alzheimer&#x2019;s disease Using SD-OCT. Front Psychiatry. 2014;5:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934110</ArticleId><ArticleId IdType="pubmed">24616709</ArticleId></ArticleIdList></Reference><Reference><Citation>La Morgia C, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. 2016;79(1):90&#x2013;109. doi: 10.1002/ana.24548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24548</ArticleId><ArticleId IdType="pmc">PMC4737313</ArticleId><ArticleId IdType="pubmed">26505992</ArticleId></ArticleIdList></Reference><Reference><Citation>Marziani E, et al. Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer&#x2019;s disease using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2013;54(9):5953&#x2013;5958. doi: 10.1167/iovs.13-12046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.13-12046</ArticleId><ArticleId IdType="pubmed">23920375</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Ramos T, Benito-Le&#xf3;n J, Villarejo A, Bermejo-Pareja F. Retinal nerve fiber layer thinning in dementia associated with Parkinson&#x2019;s disease, dementia with Lewy bodies, and Alzheimer&#x2019;s disease. J Alzheimers Dis. 2013;34(3):659&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">23271313</ArticleId></ArticleIdList></Reference><Reference><Citation>Moschos MM, et al. Structural and functional impairment of the retina and optic nerve in Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2012;9(7):782&#x2013;788. doi: 10.2174/156720512802455340.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512802455340</ArticleId><ArticleId IdType="pubmed">22698074</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer&#x2019;s disease. Neurosci Lett. 2007;420(2):97&#x2013;99. doi: 10.1016/j.neulet.2007.02.090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2007.02.090</ArticleId><ArticleId IdType="pubmed">17543991</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z, et al. Greater attenuation of retinal nerve fiber layer thickness in Alzheimer&#x2019;s disease patients. J Alzheimers Dis. 2014;40(2):277&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">24413621</ArticleId></ArticleIdList></Reference><Reference><Citation>Trick GL, Barris MC, Bickler-Bluth M. Abnormal pattern electroretinograms in patients with senile dementia of the Alzheimer type. Ann Neurol. 1989;26(2):226&#x2013;231. doi: 10.1002/ana.410260208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410260208</ArticleId><ArticleId IdType="pubmed">2774510</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams MA, et al. Retinal microvascular network attenuation in Alzheimer&#x2019;s disease. Alzheimers Dement (Amst) 2015;1(2):229&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4629099</ArticleId><ArticleId IdType="pubmed">26634224</ArticleId></ArticleIdList></Reference><Reference><Citation>Patton N, Aslam T, Macgillivray T, Pattie A, Deary IJ, Dhillon B. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. J Anat. 2005;206(4):319&#x2013;348. doi: 10.1111/j.1469-7580.2005.00395.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-7580.2005.00395.x</ArticleId><ArticleId IdType="pmc">PMC1571489</ArticleId><ArticleId IdType="pubmed">15817102</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecino E, Rodriguez FD, Ruzafa N, Pereiro X, Sharma SC. Glia-neuron interactions in the mammalian retina. Prog Retin Eye Res. 2016;51:1&#x2013;40. doi: 10.1016/j.preteyeres.2015.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2015.06.003</ArticleId><ArticleId IdType="pubmed">26113209</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin PJ, et al. Amyloid precursor protein is synthesized by retinal ganglion cells, rapidly transported to the optic nerve plasma membrane and nerve terminals, and metabolized. J Neurochem. 1993;61(2):464&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">7687653</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai J, et al. &#x3b2;-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med. 2012;4(9):980&#x2013;991. doi: 10.1002/emmm.201101084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201101084</ArticleId><ArticleId IdType="pmc">PMC3491829</ArticleId><ArticleId IdType="pubmed">22903875</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, et al. BACE1 in the retina: a sensitive biomarker for monitoring early pathological changes in Alzheimer&#x2019;s disease. Neural Regen Res. 2016;11(3):447&#x2013;453. doi: 10.4103/1673-5374.179057.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.179057</ArticleId><ArticleId IdType="pmc">PMC4829010</ArticleId><ArticleId IdType="pubmed">27127484</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandrov PN, Pogue A, Bhattacharjee S, Lukiw WJ. Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer&#x2019;s disease. Neuroreport. 2011;22(12):623&#x2013;627. doi: 10.1097/WNR.0b013e3283497334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNR.0b013e3283497334</ArticleId><ArticleId IdType="pmc">PMC3719862</ArticleId><ArticleId IdType="pubmed">21734608</ArticleId></ArticleIdList></Reference><Reference><Citation>Koronyo-Hamaoui M, et al. Identification of amyloid plaques in retinas from Alzheimer&#x2019;s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. 2011;54 Suppl 1:S204&#x2013;S217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2991559</ArticleId><ArticleId IdType="pubmed">20550967</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;n C, et al. Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS ONE. 2012;7(12):e53547. doi: 10.1371/journal.pone.0053547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0053547</ArticleId><ArticleId IdType="pmc">PMC3534024</ArticleId><ArticleId IdType="pubmed">23300938</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai Y, et al. Ocular changes in TgF344-AD rat model of Alzheimer&#x2019;s disease. Invest Ophthalmol Vis Sci. 2014;55(1):523&#x2013;534. doi: 10.1167/iovs.13-12888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.13-12888</ArticleId><ArticleId IdType="pmc">PMC3907137</ArticleId><ArticleId IdType="pubmed">24398104</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho CY, Troncoso JC, Knox D, Stark W, Eberhart CG. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer&#x2019;s and Parkinson&#x2019;s disease patients. Brain Pathol. 2014;24(1):25&#x2013;32. doi: 10.1111/bpa.12070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12070</ArticleId><ArticleId IdType="pmc">PMC3976129</ArticleId><ArticleId IdType="pubmed">23714377</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YE, et al. Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013;70(5):587&#x2013;593. doi: 10.1001/jamaneurol.2013.2334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.2334</ArticleId><ArticleId IdType="pmc">PMC3676720</ArticleId><ArticleId IdType="pubmed">23479184</ArticleId></ArticleIdList></Reference><Reference><Citation>Du LY, et al. Alzheimer&#x2019;s disease-related protein expression in the retina of Octodon degus. PLoS ONE. 2015;10(8):e0135499. doi: 10.1371/journal.pone.0135499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0135499</ArticleId><ArticleId IdType="pmc">PMC4534194</ArticleId><ArticleId IdType="pubmed">26267479</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutescu RM, Li QX, Crowston J, Masters CL, Baird PN, Culvenor JG. Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer&#x2019;s disease. Graefes Arch Clin Exp Ophthalmol. 2009;247(9):1213&#x2013;1221. doi: 10.1007/s00417-009-1060-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-009-1060-3</ArticleId><ArticleId IdType="pubmed">19271231</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards MM, Rodr&#xed;guez JJ, Gutierrez-Lanza R, Yates J, Verkhratsky A, Lutty GA. Retinal macroglia changes in a triple transgenic mouse model of Alzheimer&#x2019;s disease. Exp Eye Res. 2014;127:252&#x2013;260. doi: 10.1016/j.exer.2014.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2014.08.006</ArticleId><ArticleId IdType="pmc">PMC4175519</ArticleId><ArticleId IdType="pubmed">25149907</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, et al. Neuroprotective effect of memantine on the retinal ganglion cells of APPswe/PS1&#x394;E9 mice and its immunomodulatory mechanisms. Exp Eye Res. 2015;135:47&#x2013;58. doi: 10.1016/j.exer.2015.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2015.04.013</ArticleId><ArticleId IdType="pubmed">25912193</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta VK, et al. Amyloid &#x3b2; accumulation and inner retinal degenerative changes in Alzheimer&#x2019;s disease transgenic mouse. Neurosci Lett. 2016;623:52&#x2013;56. doi: 10.1016/j.neulet.2016.04.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2016.04.059</ArticleId><ArticleId IdType="pubmed">27133194</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Zhao H, Su G. Ginsenoside Rg1 decreases neurofibrillary tangles accumulation in retina by regulating activities of neprilysin and PKA in retinal cells of AD mice model. J Mol Neurosci. 2014;52(1):101&#x2013;106. doi: 10.1007/s12031-013-0173-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-013-0173-7</ArticleId><ArticleId IdType="pubmed">24287922</ArticleId></ArticleIdList></Reference><Reference><Citation>Koronyo Y, Salumbides BC, Black KL, Koronyo-Hamaoui M. Alzheimer&#x2019;s disease in the retina: imaging retinal a&#x3b2; plaques for early diagnosis and therapy assessment. Neurodegener Dis. 2012;10(1-4):285&#x2013;293. doi: 10.1159/000335154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000335154</ArticleId><ArticleId IdType="pubmed">22343730</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, et al. Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer&#x2019;s transgenic mice. Am J Pathol. 2009;175(5):2099&#x2013;2110. doi: 10.2353/ajpath.2009.090159.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2009.090159</ArticleId><ArticleId IdType="pmc">PMC2774073</ArticleId><ArticleId IdType="pubmed">19834067</ArticleId></ArticleIdList></Reference><Reference><Citation>More SS, Vince R. Hyperspectral imaging signatures detect amyloidopathy in Alzheimer&#x2019;s mouse retina well before onset of cognitive decline. ACS Chem Neurosci. 2015;6(2):306&#x2013;315. doi: 10.1021/cn500242z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn500242z</ArticleId><ArticleId IdType="pubmed">25354367</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning A, Cui J, To E, Ashe KH, Matsubara J. Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci. 2008;49(11):5136&#x2013;5143. doi: 10.1167/iovs.08-1849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.08-1849</ArticleId><ArticleId IdType="pmc">PMC3947384</ArticleId><ArticleId IdType="pubmed">18566467</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SW, et al. Intracellular amyloid beta alters the tight junction of retinal pigment epithelium in 5XFAD mice. Neurobiol Aging. 2014;35(9):2013&#x2013;2020. doi: 10.1016/j.neurobiolaging.2014.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.03.008</ArticleId><ArticleId IdType="pubmed">24709310</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthasarathy R, et al. Reduction of amyloid-beta levels in mouse eye tissues by intra-vitreally delivered neprilysin. Exp Eye Res. 2015;138:134&#x2013;144. doi: 10.1016/j.exer.2015.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2015.06.027</ArticleId><ArticleId IdType="pmc">PMC4659645</ArticleId><ArticleId IdType="pubmed">26142956</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S. Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer&#x2019;s disease. Invest Ophthalmol Vis Sci. 2009;50(2):793&#x2013;800. doi: 10.1167/iovs.08-2384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.08-2384</ArticleId><ArticleId IdType="pmc">PMC3697019</ArticleId><ArticleId IdType="pubmed">18791173</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogue AI, Dua P, Hill JM, Lukiw WJ. Progressive inflammatory pathology in the retina of aluminum-fed 5xFAD transgenic mice. J Inorg Biochem. 2015;152:206&#x2013;209. doi: 10.1016/j.jinorgbio.2015.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinorgbio.2015.07.009</ArticleId><ArticleId IdType="pmc">PMC4681626</ArticleId><ArticleId IdType="pubmed">26213226</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams PA, et al. Retinal ganglion cell dendritic degeneration in a mouse model of Alzheimer&#x2019;s disease. Neurobiol Aging. 2013;34(7):1799&#x2013;1806. doi: 10.1016/j.neurobiolaging.2013.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.01.006</ArticleId><ArticleId IdType="pubmed">23465714</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, et al. Suppressed retinal degeneration in aged wild type and APPswe/PS1&#x394;E9 mice by bone marrow transplantation. PLoS ONE. 2013;8(6):e64246. doi: 10.1371/journal.pone.0064246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064246</ArticleId><ArticleId IdType="pmc">PMC3672108</ArticleId><ArticleId IdType="pubmed">23750207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, et al. Hyperphosphorylation of tau protein by calpain regulation in retina of Alzheimer&#x2019;s disease transgenic mouse. Neurosci Lett. 2013;551:12&#x2013;16. doi: 10.1016/j.neulet.2013.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.06.026</ArticleId><ArticleId IdType="pubmed">23810804</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S, et al. Quantitative analysis of brain perfusion SPECT in Alzheimer&#x2019;s disease using a fully automated regional cerebral blood flow quantification software, 3DSRT. J Neurol Sci. 2008;264(1-2):27&#x2013;33. doi: 10.1016/j.jns.2007.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.07.015</ArticleId><ArticleId IdType="pubmed">17764699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumaraswamy P, Sethuraman S, Krishnan UM. Mechanistic insights of curcumin interactions with the core-recognition motif of &#x3b2;-amyloid peptide. J Agric Food Chem. 2013;61(13):3278&#x2013;3285. doi: 10.1021/jf4000709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jf4000709</ArticleId><ArticleId IdType="pubmed">23480634</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda Y, et al. Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid &#x3b2;-protein fibrils. Bioorg Med Chem. 2011;19(20):5967&#x2013;5974. doi: 10.1016/j.bmc.2011.08.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2011.08.052</ArticleId><ArticleId IdType="pubmed">21924918</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutsuga M, et al. Binding of curcumin to senile plaques and cerebral amyloid angiopathy in the aged brain of various animals and to neurofibrillary tangles in Alzheimer&#x2019;s brain. J Vet Med Sci. 2012;74(1):51&#x2013;57. doi: 10.1292/jvms.11-0307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1292/jvms.11-0307</ArticleId><ArticleId IdType="pubmed">21891973</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagisawa D, et al. Relationship between the tautomeric structures of curcumin derivatives and their Abeta-binding activities in the context of therapies for Alzheimer&#x2019;s disease. Biomaterials. 2010;31(14):4179&#x2013;4185. doi: 10.1016/j.biomaterials.2010.01.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2010.01.142</ArticleId><ArticleId IdType="pubmed">20181392</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagisawa D, Taguchi H, Yamamoto A, Shirai N, Hirao K, Tooyama I. Curcuminoid binds to amyloid-&#x3b2;1-42 oligomer and fibril. J Alzheimers Dis. 2011;24 Suppl 2:33&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">21335654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu EK, Choe YS, Lee KH, Choi Y, Kim BT. Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006;49(20):6111&#x2013;6119. doi: 10.1021/jm0607193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm0607193</ArticleId><ArticleId IdType="pubmed">17004725</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Cole GM, Baird A. Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Am J Pathol. 1992;140(6):1389&#x2013;1399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886549</ArticleId><ArticleId IdType="pubmed">1376558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M, et al. Structural conversion of neurotoxic amyloid-beta (1-42) oligomers to fibrils. Nat Struct Mol Biol. 2010;17(5):561&#x2013;567. doi: 10.1038/nsmb.1799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.1799</ArticleId><ArticleId IdType="pmc">PMC2922021</ArticleId><ArticleId IdType="pubmed">20383142</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem. 1999;274(36):25945&#x2013;25952. doi: 10.1074/jbc.274.36.25945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.36.25945</ArticleId><ArticleId IdType="pubmed">10464339</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 2002;418(6895):291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12124613</ArticleId></ArticleIdList></Reference><Reference><Citation>Teplow DB. On the subject of rigor in the study of amyloid &#x3b2;-protein assembly. Alzheimers Res Ther. 2013;5(4):39. doi: 10.1186/alzrt203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt203</ArticleId><ArticleId IdType="pmc">PMC3978854</ArticleId><ArticleId IdType="pubmed">23981712</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox KH, Pipingas A, Scholey AB. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol (Oxford) 2015;29(5):642&#x2013;651. doi: 10.1177/0269881114552744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881114552744</ArticleId><ArticleId IdType="pubmed">25277322</ArticleId></ArticleIdList></Reference><Reference><Citation>DiSilvestro RA, Joseph E, Zhao S, Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J. 2012;11:79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3518252</ArticleId><ArticleId IdType="pubmed">23013352</ArticleId></ArticleIdList></Reference><Reference><Citation>Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer&#x2019;s disease. Invest Ophthalmol Vis Sci. 2007;48(5):2285&#x2013;2289. doi: 10.1167/iovs.06-1029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.06-1029</ArticleId><ArticleId IdType="pubmed">17460292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, Neudorfer M. Retinal thickness in patients with mild cognitive impairment and Alzheimer&#x2019;s disease. Clin Neurol Neurosurg. 2011;113(7):523&#x2013;526. doi: 10.1016/j.clineuro.2011.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2011.02.014</ArticleId><ArticleId IdType="pubmed">21454010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, et al. Retinal nerve fiber layer structure abnormalities in early Alzheimer&#x2019;s disease: evidence in optical coherence tomography. Neurosci Lett. 2010;480(1):69&#x2013;72. doi: 10.1016/j.neulet.2010.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2010.06.006</ArticleId><ArticleId IdType="pubmed">20609426</ArticleId></ArticleIdList></Reference><Reference><Citation>Trick GL, Trick LR, Morris P, Wolf M. Visual field loss in senile dementia of the Alzheimer&#x2019;s type. Neurology. 1995;45(1):68&#x2013;74. doi: 10.1212/WNL.45.1.68.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.45.1.68</ArticleId><ArticleId IdType="pubmed">7824139</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilmore GC, Wenk HE, Naylor LA, Koss E. Motion perception and Alzheimer&#x2019;s disease. J Gerontol. 1994;49(2):P52&#x2013;P57. doi: 10.1093/geronj/49.2.P52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronj/49.2.P52</ArticleId><ArticleId IdType="pubmed">8126359</ArticleId></ArticleIdList></Reference><Reference><Citation>Risacher SL, et al. Visual contrast sensitivity in Alzheimer&#x2019;s disease, mild cognitive impairment, and older adults with cognitive complaints. Neurobiol Aging. 2013;34(4):1133&#x2013;1144. doi: 10.1016/j.neurobiolaging.2012.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.08.007</ArticleId><ArticleId IdType="pmc">PMC3545045</ArticleId><ArticleId IdType="pubmed">23084085</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuroff L, Daley D, Black KL, Koronyo-Hamaoui M. Clearance of cerebral A&#x3b2; in Alzheimer&#x2019;s disease: reassessing the role of microglia and monocytes. Cell Mol Life Sci. 2017;74(12):2167&#x2013;2201. doi: 10.1007/s00018-017-2463-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-017-2463-7</ArticleId><ArticleId IdType="pmc">PMC5425508</ArticleId><ArticleId IdType="pubmed">28197669</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LE, et al. Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer&#x2019;s disease. Lancet. 2003;361(9365):1258&#x2013;1265. doi: 10.1016/S0140-6736(03)12981-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)12981-9</ArticleId><ArticleId IdType="pubmed">12699953</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodis-Wollner I, Kozlowski PB, Glazman S, Miri S. &#x3b1;-synuclein in the inner retina in parkinson disease. Ann Neurol. 2014;75(6):964&#x2013;966. doi: 10.1002/ana.24182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24182</ArticleId><ArticleId IdType="pubmed">24816946</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanks JC, Hinton DR, Sadun AA, Miller CA. Retinal ganglion cell degeneration in Alzheimer&#x2019;s disease. Brain Res. 1989;501(2):364&#x2013;372. doi: 10.1016/0006-8993(89)90653-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(89)90653-7</ArticleId><ArticleId IdType="pubmed">2819446</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz B, Rimmer S, Iragui V, Katzman R. Abnormal pattern electroretinogram in Alzheimer&#x2019;s disease: evidence for retinal ganglion cell degeneration? Ann Neurol. 1989;26(2):221&#x2013;225. doi: 10.1002/ana.410260207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410260207</ArticleId><ArticleId IdType="pubmed">2774509</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordeiro MF, et al. Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo. Cell Death Dis. 2010;1:e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032512</ArticleId><ArticleId IdType="pubmed">21364622</ArticleId></ArticleIdList></Reference><Reference><Citation>Meli G, et al. Conformational targeting of intracellular A&#x3b2; oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum. Nat Commun. 2014;5:3867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050278</ArticleId><ArticleId IdType="pubmed">24861166</ArticleId></ArticleIdList></Reference><Reference><Citation>Pensalfini A, et al. Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. Neurobiol Dis. 2014;71:53&#x2013;61. doi: 10.1016/j.nbd.2014.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.07.011</ArticleId><ArticleId IdType="pmc">PMC4179983</ArticleId><ArticleId IdType="pubmed">25092575</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong RA. Beta-amyloid plaques: stages in life history or independent origin? Dement Geriatr Cogn Disord. 1998;9(4):227&#x2013;238. doi: 10.1159/000017051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000017051</ArticleId><ArticleId IdType="pubmed">9681645</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18(2):311&#x2013;324. doi: 10.1161/01.STR.18.2.311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.18.2.311</ArticleId><ArticleId IdType="pubmed">3551211</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost S, Martins RN, Kanagasingam Y. Ocular biomarkers for early detection of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2010;22(1):1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">20847434</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer&#x2019;s disease. Nat Rev Neurosci. 2004;5(5):347&#x2013;360. doi: 10.1038/nrn1387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1387</ArticleId><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruitenberg A, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol. 2005;57(6):789&#x2013;794. doi: 10.1002/ana.20493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20493</ArticleId><ArticleId IdType="pubmed">15929050</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimbrough IF, Robel S, Roberson ED, Sontheimer H. Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer&#x2019;s disease. Brain. 2015;138(Pt 12):3716&#x2013;3733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006220</ArticleId><ArticleId IdType="pubmed">26598495</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280(7):5892&#x2013;5901. doi: 10.1074/jbc.M404751200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M404751200</ArticleId><ArticleId IdType="pubmed">15590663</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieschke J, Zhang Q, Powers ET, Lerner RA, Kelly JW. Oxidative metabolites accelerate Alzheimer&#x2019;s amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry. 2005;44(13):4977&#x2013;4983. doi: 10.1021/bi0501030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi0501030</ArticleId><ArticleId IdType="pubmed">15794636</ArticleId></ArticleIdList></Reference><Reference><Citation>Han M, et al. Age-related structural abnormalities in the human retina-choroid complex revealed by two-photon excited autofluorescence imaging. J Biomed Opt. 2007;12(2):024012. doi: 10.1117/1.2717522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1117/1.2717522</ArticleId><ArticleId IdType="pubmed">17477727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell SA, Staines WA, Wessendorf MW. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem. 1999;47(6):719&#x2013;730. doi: 10.1177/002215549904700601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/002215549904700601</ArticleId><ArticleId IdType="pubmed">10330448</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiti P, et al. A comparative study of dietary curcumin, nanocurcumin, and other classical amyloid-binding dyes for labeling and imaging of amyloid plaques in brain tissue of 5&#xd7;-familial Alzheimer&#x2019;s disease mice. Histochem Cell Biol. 2016;146(5):609&#x2013;625. doi: 10.1007/s00418-016-1464-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00418-016-1464-1</ArticleId><ArticleId IdType="pubmed">27406082</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao PP, Mohamed T, Teckwani K, Tin G. Curcumin binding to beta amyloid: a computational study. Chem Biol Drug Des. 2015;86(4):813&#x2013;820. doi: 10.1111/cbdd.12552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cbdd.12552</ArticleId><ArticleId IdType="pubmed">25776887</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem. 2007;102(4):1095&#x2013;1104. doi: 10.1111/j.1471-4159.2007.04613.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04613.x</ArticleId><ArticleId IdType="pubmed">17472706</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhillon N, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491&#x2013;4499. doi: 10.1158/1078-0432.CCR-08-0024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-08-0024</ArticleId><ArticleId IdType="pubmed">18628464</ArticleId></ArticleIdList></Reference><Reference><Citation>Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem. 2010;58(4):2095&#x2013;2099. doi: 10.1021/jf9024807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jf9024807</ArticleId><ArticleId IdType="pubmed">20092313</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadhaniya P, et al. Safety assessment of a solid lipid curcumin particle preparation: acute and subchronic toxicity studies. Food Chem Toxicol. 2011;49(8):1834&#x2013;1842. doi: 10.1016/j.fct.2011.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2011.05.001</ArticleId><ArticleId IdType="pubmed">21571027</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayabasi U, Sergott R, Rispoli M. Retinal examination for the diagnosis of Alzheimer&#x2019;s disease. J Ophthalmic Pathol. 2014;3(4):1&#x2013;4.</Citation></Reference><Reference><Citation>Dentchev T, Milam AH, Lee VM, Trojanowski JQ, Dunaief JL. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis. 2003;9:184&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764254</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer&#x2019;s A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA. 2002;99(18):11830&#x2013;11835. doi: 10.1073/pnas.192203399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.192203399</ArticleId><ArticleId IdType="pmc">PMC129354</ArticleId><ArticleId IdType="pubmed">12189211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratnayaka JA, Serpell LC, Lotery AJ. Dementia of the eye: the role of amyloid beta in retinal degeneration. Eye (Lond) 2015;29(8):1013&#x2013;1026. doi: 10.1038/eye.2015.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/eye.2015.100</ArticleId><ArticleId IdType="pmc">PMC4541342</ArticleId><ArticleId IdType="pubmed">26088679</ArticleId></ArticleIdList></Reference><Reference><Citation>Algvere PV, Kvanta A, Seregard S. Drusen maculopathy: a risk factor for visual deterioration. Acta Ophthalmol. 2016;94(5):427&#x2013;433. doi: 10.1111/aos.13011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aos.13011</ArticleId><ArticleId IdType="pubmed">27009526</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, et al. Brain &#x3b2;-amyloid load approaches a plateau. Neurology. 2013;80(10):890&#x2013;896. doi: 10.1212/WNL.0b013e3182840bbe.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182840bbe</ArticleId><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Begum AN, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer&#x2019;s disease. J Pharmacol Exp Ther. 2008;326(1):196&#x2013;208. doi: 10.1124/jpet.108.137455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.108.137455</ArticleId><ArticleId IdType="pmc">PMC2527621</ArticleId><ArticleId IdType="pubmed">18417733</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28827321</PMID><DateCompleted><Year>2018</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>36</Issue><PubDate><Year>2017</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Hsp90 activator Aha1 drives production of pathological tau aggregates.</ArticleTitle><Pagination><StartPage>9707</StartPage><EndPage>9712</EndPage><MedlinePgn>9707-9712</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1707039114</ELocationID><Abstract><AbstractText>The microtubule-associated protein tau (MAPT, tau) forms neurotoxic aggregates that promote cognitive deficits in tauopathies, the most common of which is Alzheimer's disease (AD). The 90-kDa heat shock protein (Hsp90) chaperone system affects the accumulation of these toxic tau species, which can be modulated with Hsp90 inhibitors. However, many Hsp90 inhibitors are not blood-brain barrier-permeable, and several present associated toxicities. Here, we find that the cochaperone, activator of Hsp90 ATPase homolog 1 (Aha1), dramatically increased the production of aggregated tau. Treatment with an Aha1 inhibitor, KU-177, dramatically reduced the accumulation of insoluble tau. Aha1 colocalized with tau pathology in human brain tissue, and this association positively correlated with AD progression. Aha1 overexpression in the rTg4510 tau transgenic mouse model promoted insoluble and oligomeric tau accumulation leading to a physiological deficit in cognitive function. Overall, these data demonstrate that Aha1 contributes to tau fibril formation and neurotoxicity through Hsp90. This suggests that therapeutics targeting Aha1 may reduce toxic tau oligomers and slow or prevent neurodegenerative disease progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>Lindsey B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Jeremy D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Dali</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Leia E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solanki</LastName><ForeName>Parth K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webster</LastName><ForeName>Jack M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Zheying</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Jonathan J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordhues</LastName><ForeName>Bryce A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koren</LastName><ForeName>John</ForeName><Initials>J</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Suman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, The University of Kansas, Lawrence, KS 66045.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blagg</LastName><ForeName>Brian S J</ForeName><Initials>BSJ</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, The University of Kansas, Lawrence, KS 66045.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Laura J</ForeName><Initials>LJ</Initials><Identifier Source="ORCID">0000-0002-4981-5564</Identifier><AffiliationInfo><Affiliation>Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613; lblair@health.usf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickey</LastName><ForeName>Chad A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I01 BX002947</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH103848</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX001637</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX002475</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073899</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515652">AHSA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C575823">Ahsa1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018841">HSP90 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558298">Mapt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018841" MajorTopicYN="N">HSP90 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aha1</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Hsp90</Keyword><Keyword MajorTopicYN="N">chaperones</Keyword><Keyword MajorTopicYN="N">tau oligomers</Keyword></KeywordList><CoiStatement>Conflict of interest statement: C.A.D., L.B.S., B.S.J.B., J.K., and L.J.B. are the coinventors for the following provisional patent application: &#x201c;The Hsp90 Activator Aha1 Drives Production of Pathological Tau Aggregates.&#x201d;</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>3</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28827321</ArticleId><ArticleId IdType="pmc">PMC5594679</ArticleId><ArticleId IdType="doi">10.1073/pnas.1707039114</ArticleId><ArticleId IdType="pii">1707039114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM-Y, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nat Rev Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">12704221</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N, et al. Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain. J Neurosci Res. 2007;85:3098&#x2013;3108.</Citation><ArticleIdList><ArticleId IdType="pubmed">17628496</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair LJ, Sabbagh JJ, Dickey CA. Targeting Hsp90 and its co-chaperones to treat Alzheimer&#x2019;s disease. Expert Opin Ther Targets. 2014;18:1219&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625388</ArticleId><ArticleId IdType="pubmed">25069659</ArticleId></ArticleIdList></Reference><Reference><Citation>Karag&#xf6;z GE, et al. Hsp90-Tau complex reveals molecular basis for specificity in chaperone action. Cell. 2014;156:963&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4263503</ArticleId><ArticleId IdType="pubmed">24581495</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP. Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharmacol Toxicol. 2015;55:353&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4372135</ArticleId><ArticleId IdType="pubmed">25292434</ArticleId></ArticleIdList></Reference><Reference><Citation>Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin Cancer Res. 2012;18:64&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3252205</ArticleId><ArticleId IdType="pubmed">22215907</ArticleId></ArticleIdList></Reference><Reference><Citation>Inda C, Bolaender A, Wang T, Gandu SR, Koren J., 3rd Stressing out Hsp90 in neurotoxic proteinopathies. Curr Top Med Chem. 2016;16:2829&#x2013;2838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995127</ArticleId><ArticleId IdType="pubmed">27072699</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler LM, Ferraldeschi R, Armstrong HK, Centenera MM, Workman P. Maximizing the therapeutic potential of HSP90 inhibitors. Mol Cancer Res. 2015;13:1445&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4645455</ArticleId><ArticleId IdType="pubmed">26219697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong DS, et al. Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions. Cancer Treat Rev. 2013;39:375&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">23199899</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaali S, et al. Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat Chem Biol. 2015;11:33&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">25436518</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolmarans A, Lee B, Spyracopoulos L, LaPointe P. The mechanism of Hsp90 ATPase stimulation by Aha1. Sci Rep. 2016;6:33179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018835</ArticleId><ArticleId IdType="pubmed">27615124</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Richter K, Reinstein J, Buchner J. Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle. Nat Struct Mol Biol. 2013;20:326&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">23396352</ArticleId></ArticleIdList></Reference><Reference><Citation>Okayama S, et al. p53 protein regulates Hsp90 ATPase activity and thereby Wnt signaling by modulating Aha1 expression. J Biol Chem. 2014;289:6513&#x2013;6525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3945316</ArticleId><ArticleId IdType="pubmed">24451373</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell. 2006;127:803&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">17110338</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair LJ, et al. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest. 2013;123:4158&#x2013;4169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3784538</ArticleId><ArticleId IdType="pubmed">23999428</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S, et al. Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90&#x3b1;/Aha1 complex in PC3-MM2 cells. ACS Chem Biol. 2015;10:577&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4340358</ArticleId><ArticleId IdType="pubmed">25402753</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Michaelis ML, Blagg BSJ. Hsp90 modulation for the treatment of Alzheimer&#x2019;s disease. Adv Pharmacol. 2012;64:1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">22840743</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R, Dobbelstein M, Moll UM. HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates. Oncoimmunology. 2012;1:1425&#x2013;1426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3518525</ArticleId><ArticleId IdType="pubmed">23243616</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang F, et al. Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties. Bioorg Med Chem. 2016;24:5431&#x2013;5439.</Citation><ArticleIdList><ArticleId IdType="pubmed">27647369</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther. 2008;7:162&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">18202019</ArticleId></ArticleIdList></Reference><Reference><Citation>Patwardhan CA, et al. Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis. J Biol Chem. 2013;288:7313&#x2013;7325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3591639</ArticleId><ArticleId IdType="pubmed">23355466</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadli A, et al. Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the Co-chaperone p23. J Biol Chem. 2010;285:4224&#x2013;4231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823561</ArticleId><ArticleId IdType="pubmed">19996313</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu M, et al. Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells. Invest New Drugs. 2014;32:68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3865103</ArticleId><ArticleId IdType="pubmed">23887853</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, et al. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol. 2010;79:542&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794909</ArticleId><ArticleId IdType="pubmed">19769945</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinadinos C, et al. Low endogenous and chemical induced heat shock protein induction in a 0N3Rtau-expressing Drosophila larval model of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2013;33:1117&#x2013;1133.</Citation><ArticleIdList><ArticleId IdType="pubmed">23114515</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerheide SD, et al. Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem. 2004;279:56053&#x2013;56060.</Citation><ArticleIdList><ArticleId IdType="pubmed">15509580</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi F, Regan L. A novel class of small molecule inhibitors of Hsp90. ACS Chem Biol. 2008;3:645&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282108</ArticleId><ArticleId IdType="pubmed">18785742</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimienta G, Herbert KM, Regan L. A compound that inhibits the HOP-Hsp90 complex formation and has unique killing effects in breast cancer cell lines. Mol Pharm. 2011;8:2252&#x2013;2261.</Citation><ArticleIdList><ArticleId IdType="pubmed">21882818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihrig V, Obermann WMJ. Identifying inhibitors of the Hsp90-Aha1 protein complex, a potential target to drug cystic fibrosis, by alpha technology. SLAS Discov. 2017;22:923&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pubmed">28346090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S, et al. Diverging novobiocin anti-cancer activity from neuroprotective activity through modification of the amide tail. ACS Med Chem Lett. 2016;7:813&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4983738</ArticleId><ArticleId IdType="pubmed">27563408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L) J Neurosci. 2005;25:10637&#x2013;10647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall JA, et al. Novobiocin analogues that inhibit the MAPK pathway. J Med Chem. 2016;59:925&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444390</ArticleId><ArticleId IdType="pubmed">26745854</ArticleId></ArticleIdList></Reference><Reference><Citation>Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc. 2006;1:1671&#x2013;1679.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487150</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey C, et al. Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. Am J Pathol. 2009;174:228&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631335</ArticleId><ArticleId IdType="pubmed">19074615</ArticleId></ArticleIdList></Reference><Reference><Citation>Abisambra JF, et al. Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J Neurosci. 2013;33:9498&#x2013;9507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3733249</ArticleId><ArticleId IdType="pubmed">23719816</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouton PR, Pakkenberg B, Gundersen HJ, Price DL. Absolute number and size of pigmented locus coeruleus neurons in young and aged individuals. J Chem Neuroanat. 1994;7:185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">7848573</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28832877</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6238</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA psychiatry</Title><ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association of Lithium in Drinking Water With the Incidence of Dementia.</ArticleTitle><Pagination><StartPage>1005</StartPage><EndPage>1010</EndPage><MedlinePgn>1005-1010</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2017.2362</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Results from animal and human studies suggest that lithium in therapeutic doses may improve learning and memory and modify the risk of developing dementia. Additional preliminary studies suggest that subtherapeutic levels, including microlevels of lithium, may influence human cognition.</AbstractText><AbstractText Label="OBJECTIVE">To investigate whether the incidence of dementia in the general population covaries with long-term exposure to microlevels of lithium in drinking water.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This Danish nationwide, population-based, nested case-control study examined longitudinal, individual geographic data on municipality of residence and data from drinking water measurements combined with time-specific data from all patients aged 50 to 90 years with a hospital contact with a diagnosis of dementia from January 1, 1970, through December 31, 2013, and 10 age- and sex-matched control individuals from the Danish population. The mean lithium exposure in drinking water since 1986 was estimated for all study individuals. Data analysis was performed from January 1, 1995, through December 31, 2013.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">A diagnosis of dementia in a hospital inpatient or outpatient contact. Diagnoses of Alzheimer disease and vascular dementia were secondary outcome measures. In primary analyses, distribution of lithium exposure was compared between patients with dementia and controls.</AbstractText><AbstractText Label="RESULTS">A total of 73&#x202f;731 patients with dementia and 733&#x202f;653 controls (median age, 80.3 years; interquartile range, 74.9-84.6 years; 44 760 female [60.7%] and 28 971 male [39.3%]) were included in the study. Lithium exposure was statistically significantly different between patients with a diagnosis of dementia (median, 11.5 &#xb5;g/L; interquartile range, 6.5-14.9 &#xb5;g/L) and controls (median, 12.2 &#xb5;g/L; interquartile range, 7.3-16.0 &#xb5;g/L; P&#x2009;&lt;&#x2009;.001). A nonlinear association was observed. Compared with individuals exposed to 2.0 to 5.0 &#xb5;g/L, the incidence rate ratio (IRR) of dementia was decreased in those exposed to more than 15.0 &#xb5;g/L (IRR, 0.83; 95% CI, 0.81-0.85; P&#x2009;&lt;&#x2009;.001) and 10.1 to 15.0 &#xb5;g/L (IRR, 0.98; 95% CI, 0.96-1.01; P&#x2009;=&#x2009;.17) and increased with 5.1 to 10.0 &#xb5;g/L (IRR, 1.22; 95% CI, 1.19-1.25; P&#x2009;&lt;&#x2009;.001). Similar patterns were found with Alzheimer disease and vascular dementia as outcomes.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Long-term increased lithium exposure in drinking water may be associated with a lower incidence of dementia in a nonlinear way; however, confounding from other factors associated with municipality of residence cannot be excluded.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>Lars Vedel</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Psychiatric Center Copenhagen, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerds</LastName><ForeName>Thomas Alexander</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knudsen</LastName><ForeName>Nikoline Nyg&#xe5;rd</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>National Institute of Public Health, University of Southern Denmark, Odense.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf8;rgensen</LastName><ForeName>Lisbeth Flindt</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Geological Survey of Denmark and Greenland, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristiansen</LastName><ForeName>S&#xf8;ren Munch</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Geoscience, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voutchkova</LastName><ForeName>Denitza</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Geological Survey of Denmark and Greenland, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geoscience, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geography, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ernstsen</LastName><ForeName>Vibeke</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Geological Survey of Denmark and Greenland, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schullehner</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Geological Survey of Denmark and Greenland, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Birgitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Geological Survey of Denmark and Greenland, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Per Kragh</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ersb&#xf8;ll</LastName><ForeName>Annette Kj&#xe6;r</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>National Institute of Public Health, University of Southern Denmark, Odense.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Psychiatry</MedlineTA><NlmUniqueID>101589550</NlmUniqueID><ISSNLinking>2168-622X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060766">Drinking Water</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Psychiatry. 2017 Oct 1;74(10):983-984. doi: 10.1001/jamapsychiatry.2017.2336.</RefSource><PMID Version="1">28832875</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Psychiatry. 2018 Mar 1;75(3):302-303. doi: 10.1001/jamapsychiatry.2017.3677.</RefSource><PMID Version="1">29322161</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Psychiatry. 2018 Mar 1;75(3):301. doi: 10.1001/jamapsychiatry.2017.4190.</RefSource><PMID Version="1">29322162</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Psychiatry. 2018 Mar 1;75(3):301-302. doi: 10.1001/jamapsychiatry.2017.4187.</RefSource><PMID Version="1">29322166</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="Y">Dementia, Vascular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060766" MajorTopicYN="N">Drinking Water</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004781" MajorTopicYN="Y">Environmental Exposure</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013995" MajorTopicYN="N">Time</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Kessing reported working as a consultant for Lundbeck, AstraZeneca, and Sunovion. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28832877</ArticleId><ArticleId IdType="pmc">PMC5710473</ArticleId><ArticleId IdType="doi">10.1001/jamapsychiatry.2017.2362</ArticleId><ArticleId IdType="pii">2649277</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sousa RM, Ferri CP, Acosta D, et al. . Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. Lancet. 2009;374(9704):1821-1830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854331</ArticleId><ArticleId IdType="pubmed">19944863</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa RM, Ferri CP, Acosta D, et al. . The contribution of chronic diseases to the prevalence of dependence among older people in Latin America, China and India: a 10/66 Dementia Research Group population-based survey. BMC Geriatr. 2010;10:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923155</ArticleId><ArticleId IdType="pubmed">20691064</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63-75.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013;368(14):1326-1334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959992</ArticleId><ArticleId IdType="pubmed">23550670</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G, Berk M. The putative use of lithium in Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2016;13(8):853-861.</Citation><ArticleIdList><ArticleId IdType="pubmed">26892287</ArticleId></ArticleIdList></Reference><Reference><Citation>Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry. 2000;48(8):740-754.</Citation><ArticleIdList><ArticleId IdType="pubmed">11063971</ArticleId></ArticleIdList></Reference><Reference><Citation>Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3&#x3b1; regulates production of Alzheimer&#x2019;s disease amyloid-&#x3b2; peptides. Nature. 2003;423(6938):435-439.</Citation><ArticleIdList><ArticleId IdType="pubmed">12761548</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Oddo S, Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not A&#x3b2; or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol. 2007;170(5):1669-1675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1854961</ArticleId><ArticleId IdType="pubmed">17456772</ArticleId></ArticleIdList></Reference><Reference><Citation>Nocjar C, Hammonds MD, Shim SS. Chronic lithium treatment magnifies learning in rats. Neuroscience. 2007;150(4):774-788.</Citation><ArticleIdList><ArticleId IdType="pubmed">17996377</ArticleId></ArticleIdList></Reference><Reference><Citation>Watase K, Gatchel JR, Sun Y, et al. . Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 2007;4(5):e182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880853</ArticleId><ArticleId IdType="pubmed">17535104</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessing LV, S&#xf8;nderg&#xe5;rd L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry. 2008;65(11):1331-1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">18981345</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord. 2010;12(1):87-94.</Citation><ArticleIdList><ArticleId IdType="pubmed">20148870</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessing LV, Gerds TA, Feldt-Rasmussen B, Andersen PK, Licht RW. Use of lithium and anticonvulsants and the rate of chronic kidney disease: a nationwide population-based study. JAMA Psychiatry. 2015;72(12):1182-1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">26535805</ArticleId></ArticleIdList></Reference><Reference><Citation>Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011;198(5):351-356.</Citation><ArticleIdList><ArticleId IdType="pubmed">21525519</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2013;10(1):104-107.</Citation><ArticleIdList><ArticleId IdType="pubmed">22746245</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7)(suppl):22-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">21775345</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistics Denmark [serial online]. 2016. 
http://www.dst.dk. Accessed July 11, 2017.</Citation></Reference><Reference><Citation>Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(7)(suppl):30-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">21775347</ArticleId></ArticleIdList></Reference><Reference><Citation>Munk-J&#xf8;rgensen P, Mortensen PB. The Danish Psychiatric Central Register. Dan Med Bull. 1997;44(1):82-84.</Citation><ArticleIdList><ArticleId IdType="pubmed">9062767</ArticleId></ArticleIdList></Reference><Reference><Citation>Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health. 2011;39(7)(suppl):26-29.</Citation><ArticleIdList><ArticleId IdType="pubmed">21775346</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen TF, Madsen M, J&#xf8;rgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263-268.</Citation><ArticleIdList><ArticleId IdType="pubmed">10421985</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation Klassifikation af sygdomme In: International Statistical Classification of Diseases and Related Health Problems. 10th rev. Munksgaard, Copenhagen: World Health Organisation ; 1993.</Citation></Reference><Reference><Citation>Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull. 1999;46(4):354-357.</Citation><ArticleIdList><ArticleId IdType="pubmed">10514943</ArticleId></ArticleIdList></Reference><Reference><Citation>Phung TK, Andersen BB, H&#xf8;gh P, Kessing LV, Mortensen PB, Waldemar G. Validity of dementia diagnoses in the Danish hospital registers. Dement Geriatr Cogn Disord. 2007;24(3):220-228.</Citation><ArticleIdList><ArticleId IdType="pubmed">17690555</ArticleId></ArticleIdList></Reference><Reference><Citation>Voutchkova DD, Schullehner J, Knudsen N, et al. . Exposure to selected geogenic trace elements (I, Li, and Sr) from drinking water in Denmark. Geosciences (Basel). 2015;5:45-66.</Citation></Reference><Reference><Citation>Knudsen NN, Schullehner J, Hansen B, et al. . Lithium in drinking water and risk of suicide: a nation-wide individual-level cohort study with 22 years of follow-up. Int J Environ Res Public Health. 2017;14(6):627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5486313</ArticleId><ArticleId IdType="pubmed">28604590</ArticleId></ArticleIdList></Reference><Reference><Citation>Voutchkova DD, Ernstsen V, Hansen B, S&#xf8;rensen BL, Zhang C, Kristiansen SM. Assessment of spatial variation in drinking water iodine and its implications for dietary intake: a new conceptual model for Denmark. Sci Total Environ. 2014;493:432-444.</Citation><ArticleIdList><ArticleId IdType="pubmed">24956076</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgan L, Goldstein B, Langholz B. Methods for the analysis of sampled cohort data in the Cox proportional hazards model. Ann Stat. 1995;23(5):1749-1778.</Citation></Reference><Reference><Citation>Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression and Survival Analysis. New York, NY: Springer; 2001.</Citation></Reference><Reference><Citation>van Os J, Pedersen CB, Mortensen PB. Confirmation of synergy between urbanicity and familial liability in the causation of psychosis. Am J Psychiatry. 2004;161(12):2312-2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">15569906</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen CB, Mortensen PB. Urbanicity during upbringing and bipolar affective disorders in Denmark. Bipolar Disord. 2006;8(3):242-247.</Citation><ArticleIdList><ArticleId IdType="pubmed">16696825</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgami H, Terao T, Shiotsuki I, Ishii N, Iwata N. Lithium levels in drinking water and risk of suicide. Br J Psychiatry. 2009;194(5):464-465.</Citation><ArticleIdList><ArticleId IdType="pubmed">19407280</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapusta ND, Mossaheb N, Etzersdorfer E, et al. . Lithium in drinking water and suicide mortality. Br J Psychiatry. 2011;198(5):346-350.</Citation><ArticleIdList><ArticleId IdType="pubmed">21525518</ArticleId></ArticleIdList></Reference><Reference><Citation>Phung TK, Waltoft BL, Kessing LV, Mortensen PB, Waldemar G. Time trend in diagnosing dementia in secondary care. Dement Geriatr Cogn Disord. 2010;29(2):146-153.</Citation><ArticleIdList><ArticleId IdType="pubmed">20150733</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratiglioni L, Launer LJ, Andersen K, et al. ; Neurologic Diseases in the Elderly Research Group . Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology. 2000;54(11)(suppl 5):S10-S15.</Citation><ArticleIdList><ArticleId IdType="pubmed">10854355</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrauzer GN. Lithium: occurrence, dietary intakes, nutritional essentiality. J Am Coll Nutr. 2002;21(1):14-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838882</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimann C, Birke M. Geochemistry of European Bottled Water. Stuttgart, Germany: Borntraeger Science Publisher; 2010.</Citation></Reference><Reference><Citation>Banks D, Reimann CBM, Flem B, Filzmoser P, Frengstad B. Inorganic chemical quality of European tap-water, 1: distribution of parameters and regulatory compliance. Appl Geochem. 2015;59:200-210.</Citation></Reference><Reference><Citation>Rondeau V, Jacqmin-Gadda H, Commenges D, Helmer C, Dartigues JF. Aluminum and silica in drinking water and the risk of Alzheimer&#x2019;s disease or cognitive decline: findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol. 2009;169(4):489-496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809081</ArticleId><ArticleId IdType="pubmed">19064650</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelo CAJ, Postma D. Geochemistry, Groundwater and Pollution. 2nd ed Leiden, the Netherlands: AA Balkema Publishers; 2005.</Citation></Reference><Reference><Citation>Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson&#x2019;s disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci. 2004;1012:306-325.</Citation><ArticleIdList><ArticleId IdType="pubmed">15105275</ArticleId></ArticleIdList></Reference><Reference><Citation>Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A feasibility and tolerability study of lithium in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2008;23(7):704-711.</Citation><ArticleIdList><ArticleId IdType="pubmed">18181229</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Ewers M, B&#xfc;rger K, et al. . Lithium trial in Alzheimer&#x2019;s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009;70(6):922-931.</Citation><ArticleIdList><ArticleId IdType="pubmed">19573486</ArticleId></ArticleIdList></Reference><Reference><Citation>De-Paula VJ, Kerr DS, Scola G, Gattaz WF, Forlenza OV. Lithium distinctly modulates the secretion of pro- and anti-inflammatory interleukins in co-cultures of neurons and glial cells at therapeutic and sub-therapeutic concentrations. Curr Alzheimer Res. 2016;13(8):848-852.</Citation><ArticleIdList><ArticleId IdType="pubmed">26892291</ArticleId></ArticleIdList></Reference><Reference><Citation>De-Paula VdeJ, Kerr DS, de Carvalho MP, et al. . Long-term lithium treatment increases cPLA2 and iPLA2 activity in cultured cortical and hippocampal neurons. Molecules. 2015;20(11):19878-19885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6332452</ArticleId><ArticleId IdType="pubmed">26556322</ArticleId></ArticleIdList></Reference><Reference><Citation>Mury FB, da Silva WC, Barbosa NR, et al. . Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimer&#x2019;s disease. Eur Arch Psychiatry Clin Neurosci. 2016;266(7):607-618.</Citation><ArticleIdList><ArticleId IdType="pubmed">26661385</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrauzer GN, de Vroey E. Effects of nutritional lithium supplementation on mood: a placebo-controlled study with former drug users. Biol Trace Elem Res. 1994;40(1):89-101.</Citation><ArticleIdList><ArticleId IdType="pubmed">7511924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajek T, Weiner MW. Neuroprotective effects of lithium in human brain? food for thought. Curr Alzheimer Res. 2016;13(8):862-872.</Citation><ArticleIdList><ArticleId IdType="pubmed">26892290</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28746864</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>The Lifespan and Turnover of Microglia in the Human Brain.</ArticleTitle><Pagination><StartPage>779</StartPage><EndPage>784</EndPage><MedlinePgn>779-784</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2017.07.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(17)30943-9</ELocationID><Abstract><AbstractText>The hematopoietic system seeds the CNS with microglial progenitor cells during the fetal period, but the subsequent cell generation dynamics and maintenance of this population have been poorly understood. We report that microglia, unlike most other hematopoietic lineages, renew slowly at a median rate of 28% per year, and some microglia last for more than two decades. Furthermore, we find no evidence for the existence of a substantial population of quiescent long-lived cells, meaning that the microglia population in the human brain is sustained by continuous slow turnover throughout adult life.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>R&#xe9;u</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden; Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khosravi</LastName><ForeName>Azadeh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernard</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut Camille Jordan, CNRS UMR 5208, University of Lyon, 69622 Villeurbanne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mold</LastName><ForeName>Jeff E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salehpour</LastName><ForeName>Mehran</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physics and Astronomy, Ion Physics, Uppsala University, 751 20 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alkass</LastName><ForeName>Kanar</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden; Department of Forensic Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perl</LastName><ForeName>Shira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NHLBI, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tisdale</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NHLBI, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Possnert</LastName><ForeName>G&#xf6;ran</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Physics and Astronomy, Ion Physics, Uppsala University, 751 20 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Druid</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Forensic Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fris&#xe9;n</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden. Electronic address: jonas.frisen@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">human</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">proliferation</Keyword><Keyword MajorTopicYN="N">renewal</Keyword><Keyword MajorTopicYN="N">turnover</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28746864</ArticleId><ArticleId IdType="pmc">PMC5540680</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2017.07.004</ArticleId><ArticleId IdType="pii">S2211-1247(17)30943-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ajami B., Bennett J.L., Krieger C., Tetzlaff W., Rossi F.M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 2007;10:1538&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026097</ArticleId></ArticleIdList></Reference><Reference><Citation>Askew K., Li K., Olmos-Alonso A., Garcia-Moreno F., Liang Y., Richardson P., Tipton T., Chapman M.A., Riecken K., Beccari S. Coupled proliferation and apoptosis maintain the rapid turnover of microglia in the adult brain. Cell Rep. 2017;18:391&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5263237</ArticleId><ArticleId IdType="pubmed">28076784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann O., Liebl J., Bernard S., Alkass K., Yeung M.S., Steier P., Kutschera W., Johnson L., Land&#xe9;n M., Druid H. The age of olfactory bulb neurons in humans. Neuron. 2012;74:634&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">22632721</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard S., Fris&#xe9;n J., Spalding K.L. A mathematical model for the interpretation of nuclear bomb test derived 14C incorporation in biological systems. Nucl. Instrum. Methods Phys. Res. B. 2010;268:1295&#x2013;1298.</Citation></Reference><Reference><Citation>Beura L.K., Hamilton S.E., Bi K., Schenkel J.M., Odumade O.A., Casey K.A., Thompson E.A., Fraser K.A., Rosato P.C., Filali-Mouhim A. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature. 2016;532:512&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4871315</ArticleId><ArticleId IdType="pubmed">27096360</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruttger J., Karram K., W&#xf6;rtge S., Regen T., Marini F., Hoppmann N., Klein M., Blank T., Yona S., Wolf Y. Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. Immunity. 2015;43:92&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">26163371</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch R., Neese R.A., Awada M., Hayes G.M., Hellerstein M.K. Measurement of cell proliferation by heavy water labeling. Nat. Protoc. 2007;2:3045&#x2013;3057.</Citation><ArticleIdList><ArticleId IdType="pubmed">18079703</ArticleId></ArticleIdList></Reference><Reference><Citation>Casano A.M., Peri F. Microglia: multitasking specialists of the brain. Dev. Cell. 2015;32:469&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">25710533</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson P.S., Perfilieva E., Bj&#xf6;rk-Eriksson T., Alborn A.M., Nordborg C., Peterson D.A., Gage F.H. Neurogenesis in the adult human hippocampus. Nat. Med. 1998;4:1313&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst A., Alkass K., Bernard S., Salehpour M., Perl S., Tisdale J., Possnert G., Druid H., Fris&#xe9;n J. Neurogenesis in the striatum of the adult human brain. Cell. 2014;156:1072&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pubmed">24561062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., Mehler M.F., Conway S.J., Ng L.G., Stanley E.R. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeffel G., Chen J., Lavin Y., Low D., Almeida F.F., See P., Beaudin A.E., Lum J., Low I., Forsberg E.C. C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity. 2015;42:665&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545768</ArticleId><ArticleId IdType="pubmed">25902481</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttner H.B., Bergmann O., Salehpour M., R&#xe1;cz A., Tatarishvili J., Lindgren E., Csonka T., Csiba L., Hortob&#xe1;gyi T., M&#xe9;hes G. The age and genomic integrity of neurons after cortical stroke in humans. Nat. Neurosci. 2014;17:801&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">24747576</ArticleId></ArticleIdList></Reference><Reference><Citation>Landsverk O.J., Snir O., Casado R.B., Richter L., Mold J.E., R&#xe9;u P., Horneland R., Paulsen V., Yaqub S., Aandahl E.M. Antibody-secreting plasma cells persist for decades in human intestine. J.&#xa0;Exp. Med. 2017;214:309&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5294861</ArticleId><ArticleId IdType="pubmed">28104812</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson L.J., Perry V.H., Gordon S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience. 1992;48:405&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">1603325</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin I., Naegler T., Kromer B., Diehl M., Francey R.J., Gomez-Pelaez A.J., Steele L.P., Wagenbach D., Weller R., Worthy D.E. Observations and modelling of the global distribution and long-term trend of atmospheric 14CO2. Tellus B Chem. Phys. Meteorol. 2010;62:26&#x2013;46.</Citation></Reference><Reference><Citation>Macallan D.C., Wallace D.L., Zhang Y., Ghattas H., Asquith B., de Lara C., Worth A., Panayiotakopoulos G., Griffin G.E., Tough D.F., Beverley P.C. B-cell kinetics in humans: rapid turnover of peripheral blood memory cells. Blood. 2005;105:3633&#x2013;3640.</Citation><ArticleIdList><ArticleId IdType="pubmed">15644412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A., Schmidt H., Nitsche M., Merkler D., Hanisch U.K., Mack M., Heikenwalder M., Br&#xfc;ck W., Priller J., Prinz M. Microglia in the&#xa0;adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci. 2007;10:1544&#x2013;1553.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026096</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC334765</ArticleId><ArticleId IdType="pubmed">3344216</ArticleId></ArticleIdList></Reference><Reference><Citation>Neese R.A., Misell L.M., Turner S., Chu A., Kim J., Cesar D., Hoh R., Antelo F., Strawford A., McCune J.M. Measurement in&#xa0;vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA. Proc. Natl. Acad. Sci. USA. 2002;99:15345&#x2013;15350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137719</ArticleId><ArticleId IdType="pubmed">12424339</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M., Raj D., Brouwer N., De Haas A.H., Eggen B.J.L., Den Dunnen W.F.A., Biber K.P.H., Boddeke H.W.G.M. An optimized protocol for the acute isolation of human microglia from autopsy brain samples. Glia. 2012;60:96&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989594</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst C.N., Yang G., Ninan I., Savas J.N., Yates J.R., 3rd, Lafaille J.J., Hempstead B.L., Littman D.R., Gan W.B. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell. 2013;155:1596&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimer P.J., Brown T.A., Reimer R.W. Discussion: reporting and calibration of post-bomb 14C data. Radiocarbon. 2004;46:1299&#x2013;1304.</Citation></Reference><Reference><Citation>Salehpour M., H&#xe5;kansson K., Possnert G. Accelerator mass spectrometry of ultra-small samples with applications in the biosciences. Nucl. Instrum. Methods Phys. Res. B. 2013;294:97&#x2013;103.</Citation></Reference><Reference><Citation>Salehpour M., H&#xe5;kansson K., Westermark P., Antoni G., Wikstr&#xf6;m G., Possnert G. Life science applications utilizing radiocarbon tracing. Radiocarbon. 2013;55:865&#x2013;873.</Citation></Reference><Reference><Citation>Salehpour M., H&#xe5;kansson K., Possnert G. Small sample accelerator mass spectrometry for biomedical applications. Nucl. Instrum. Methods Phys. Res. B. 2015;361:43&#x2013;47.</Citation></Reference><Reference><Citation>Schulz C., Gomez Perdiguero E., Chorro L., Szabo-Rogers H., Cagnard N., Kierdorf K., Prinz M., Wu B., Jacobsen S.E., Pollard J.W. A&#xa0;lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336:86&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">22442384</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankaran M., Marino M.E., Busch R., Keim C., King C., Lee J., Killion S., Awada M., Hellerstein M.K. Measurement of brain microglial proliferation rates in&#xa0;vivo in response to neuroinflammatory stimuli: application to drug discovery. J.&#xa0;Neurosci. Res. 2007;85:2374&#x2013;2384.</Citation><ArticleIdList><ArticleId IdType="pubmed">17551981</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding K.L., Bhardwaj R.D., Buchholz B.A., Druid H., Fris&#xe9;n J. Retrospective birth dating of cells in humans. Cell. 2005;122:133&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009139</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding K.L., Bergmann O., Alkass K., Bernard S., Salehpour M., Huttner H.B., Bostr&#xf6;m E., Westerlund I., Vial C., Buchholz B.A. Dynamics of hippocampal neurogenesis in adult humans. Cell. 2013;153:1219&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394608</ArticleId><ArticleId IdType="pubmed">23746839</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuiver M., Polach H.A. Discussion reporting of 14C data. Radiocarbon. 1977;19:355&#x2013;363.</Citation></Reference><Reference><Citation>Tambuyzer B.R., Ponsaerts P., Nouwen E.J. Microglia: gatekeepers of central nervous system immunology. J.&#xa0;Leukoc. Biol. 2009;85:352&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">19028958</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay T.L., Mai D., Dautzenberg J., Fern&#xe1;ndez-Klett F., Lin G., Sagar, Datta M., Drougard A., Stempfl T., Ardura-Fabregat A. A new fate mapping system reveals context-dependent random or clonal expansion of microglia. Nat. Neurosci. 2017;20:793&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">28414331</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonchev A.B., Yamashima T., Zhao L., Okano H. Differential proliferative response in the postischemic hippocampus, temporal cortex, and olfactory bulb of young adult macaque monkeys. Glia. 2003;42:209&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">12673828</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung M.S., Zdunek S., Bergmann O., Bernard S., Salehpour M., Alkass K., Perl S., Tisdale J., Possnert G., Brundin L. Dynamics of oligodendrocyte generation and myelination in the human brain. Cell. 2014;159:766&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">25417154</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28846081</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Microglia turnover with aging and in an Alzheimer's model via long-term in vivo single-cell imaging.</ArticleTitle><Pagination><StartPage>1371</StartPage><EndPage>1376</EndPage><MedlinePgn>1371-1376</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4631</ELocationID><Abstract><AbstractText>To clarify the role of microglia in brain homeostasis and disease, an understanding of their maintenance, proliferation and turnover is essential. The lifespan of brain microglia, however, remains uncertain, and reflects confounding factors in earlier assessments that were largely indirect. We genetically labeled single resident microglia in living mice and then used multiphoton microscopy to monitor these cells over time. Under homeostatic conditions, we found that neocortical resident microglia were long-lived, with a median lifetime of well over 15 months; thus, approximately half of these cells survive the entire mouse lifespan. While proliferation of resident neocortical microglia under homeostatic conditions was low, microglial proliferation in a mouse model of Alzheimer's &#x3b2;-amyloidosis was increased threefold. The persistence of individual microglia throughout the mouse lifespan provides an explanation for how microglial priming early in life can induce lasting functional changes and how microglial senescence may contribute to age-related neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>F&#xfc;ger</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE-German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hefendehl</LastName><ForeName>Jasmin K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE-German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veeraraghavalu</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wendeln</LastName><ForeName>Ann-Christin</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE-German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlosser</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberm&#xfc;ller</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE-German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wegenast-Braun</LastName><ForeName>Bettina M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE-German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neher</LastName><ForeName>Jonas J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0003-1346-8924</Identifier><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE-German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martus</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Medical Biometry, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohsaka</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurochemistry, National Institute of Neuroscience, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thunemann</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Interfaculty Institute of Biochemistry, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feil</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Interfaculty Institute of Biochemistry, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skodras</LastName><ForeName>Angelos</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE-German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE-German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG021494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036641" MajorTopicYN="N">Microscopy, Fluorescence, Multiphoton</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="Y">Single-Cell Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28846081</ArticleId><ArticleId IdType="doi">10.1038/nn.4631</ArticleId><ArticleId IdType="pii">nn.4631</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neurosci Methods. 2012 Apr 15;205(2):357-63</Citation><ArticleIdList><ArticleId IdType="pubmed">22093765</ArticleId></ArticleIdList></Reference><Reference><Citation>Org Biomol Chem. 2011 Dec 21;9(24):8356-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22051883</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2004 Jan 15;45(2):208-12</Citation><ArticleIdList><ArticleId IdType="pubmed">14730714</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Cell. 2014 Feb;13(1):60-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23953759</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Hum Neurosci. 2016 Aug 09;10:398</Citation><ArticleIdList><ArticleId IdType="pubmed">27555812</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2008 Nov;29(11):1754-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17544173</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2015 Jun;16(6):358-72</Citation><ArticleIdList><ArticleId IdType="pubmed">25991443</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2014 Sep 26;2:142</Citation><ArticleIdList><ArticleId IdType="pubmed">25257319</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2014 May;15(5):300-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24713688</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1992;48(2):405-15</Citation><ArticleIdList><ArticleId IdType="pubmed">1603325</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2005 Aug 1;81(3):357-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15948177</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2014 Apr 16;82(2):380-97</Citation><ArticleIdList><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2010 Jan;13(1):133-40</Citation><ArticleIdList><ArticleId IdType="pubmed">20023653</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2013 Apr 18;38(4):792-804</Citation><ArticleIdList><ArticleId IdType="pubmed">23601688</ArticleId></ArticleIdList></Reference><Reference><Citation>Genesis. 2007 Sep;45(9):593-605</Citation><ArticleIdList><ArticleId IdType="pubmed">17868096</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2014 Apr;10(4):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">24638131</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2000 May 5;288(5467):771</Citation><ArticleIdList><ArticleId IdType="pubmed">10809639</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cell Biol. 2017 Jan;27(1):82-92</Citation><ArticleIdList><ArticleId IdType="pubmed">27717533</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Cell Dev Biol. 2016 Oct 6;32:127-141</Citation><ArticleIdList><ArticleId IdType="pubmed">27298094</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 May 27;308(5726):1314-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2016 Aug 19;353(6301):777-83</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 Dec;10 (12 ):1538-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18026097</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 1997 Apr;85(1):1-26</Citation><ArticleIdList><ArticleId IdType="pubmed">9095338</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2010 Nov 5;330(6005):841-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO Rep. 2006 Sep;7(9):940-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2015 Aug 18;43(2):382-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26287683</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2017 Jun;20(6):793-803</Citation><ArticleIdList><ArticleId IdType="pubmed">28414331</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2012 Dec;181(6):1953-60</Citation><ArticleIdList><ArticleId IdType="pubmed">23041059</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2016 Mar 15;44(3):505-515</Citation><ArticleIdList><ArticleId IdType="pubmed">26982357</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1998 Dec 7;813(2):241-53</Citation><ArticleIdList><ArticleId IdType="pubmed">9838143</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2016 Mar;19(3):504-16</Citation><ArticleIdList><ArticleId IdType="pubmed">26780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2014 Nov;10(11):643-60</Citation><ArticleIdList><ArticleId IdType="pubmed">25311587</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2017 Jan 10;18(2):391-405</Citation><ArticleIdList><ArticleId IdType="pubmed">28076784</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Brain Res. 2002;138:3-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12432759</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2015 Jul 21;43(1):92-106</Citation><ArticleIdList><ArticleId IdType="pubmed">26163371</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2013 Feb 6;33(6):2481-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23392676</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2016 Nov;64(11):1801-40</Citation><ArticleIdList><ArticleId IdType="pubmed">27634048</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28846757</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis.</ArticleTitle><Pagination><StartPage>1178</StartPage><EndPage>1189</EndPage><MedlinePgn>1178-1189</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.2188</ELocationID><Abstract><AbstractText Label="IMPORTANCE">It is unclear whether female carriers of the apolipoprotein E (APOE) &#x3b5;4 allele are at greater risk of developing Alzheimer disease (AD) than men, and the sex-dependent association of mild cognitive impairment (MCI) and APOE has not been established.</AbstractText><AbstractText Label="OBJECTIVE">To determine how sex and APOE genotype affect the risks for developing MCI and AD.</AbstractText><AbstractText Label="DATA SOURCES">Twenty-seven independent research studies in the Global Alzheimer's Association Interactive Network with data on nearly 58&#x202f;000 participants.</AbstractText><AbstractText Label="STUDY SELECTION">Non-Hispanic white individuals with clinical diagnostic and APOE genotype data.</AbstractText><AbstractText Label="DATA EXTRACTION AND SYNTHESIS">Homogeneous data sets were pooled in case-control analyses, and logistic regression models were used to compute risks.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Age-adjusted odds ratios (ORs) and 95% confidence intervals for developing MCI and AD were calculated for men and women across APOE genotypes.</AbstractText><AbstractText Label="RESULTS">Participants were men and women between ages 55 and 85 years. Across data sets most participants were white, and for many participants, racial/ethnic information was either not collected or not known. Men (OR, 3.09; 95% CI, 2.79-3.42) and women (OR, 3.31; CI, 3.03-3.61) with the APOE &#x3b5;3/&#x3b5;4 genotype from ages 55 to 85 years did not show a difference in AD risk; however, women had an increased risk compared with men between the ages of 65 and 75 years (women, OR, 4.37; 95% CI, 3.82-5.00; men, OR, 3.14; 95% CI, 2.68-3.67; P&#x2009;=&#x2009;.002). Men with APOE &#x3b5;3/&#x3b5;4 had an increased risk of AD compared with men with APOE &#x3b5;3/&#x3b5;3. The APOE &#x3b5;2/&#x3b5;3 genotype conferred a protective effect on women (OR, 0.51; 95% CI, 0.43-0.61) decreasing their risk of AD more (P value&#x2009;=&#x2009;.01) than men (OR, 0.71; 95% CI, 0.60-0.85). There was no difference between men with APOE &#x3b5;3/&#x3b5;4 (OR, 1.55; 95% CI, 1.36-1.76) and women (OR, 1.60; 95% CI, 1.43-1.81) in their risk of developing MCI between the ages of 55 and 85 years, but women had an increased risk between 55 and 70 years (women, OR, 1.43; 95% CI, 1.19-1.73; men, OR, 1.07; 95% CI, 0.87-1.30; P&#x2009;=&#x2009;.05). There were no significant differences between men and women in their risks for converting from MCI to AD between the ages of 55 and 85 years. Individuals with APOE &#x3b5;4/&#x3b5;4 showed increased risks vs individuals with &#x3b5;3/&#x3b5;4, but no significant differences between men and women with &#x3b5;4/&#x3b5;4 were seen.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Contrary to long-standing views, men and women with the APOE &#x3b5;3/&#x3b5;4 genotype have nearly the same odds of developing AD from age 55 to 85 years, but women have an increased risk at younger ages.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Laboratory of Neuro Imaging, Stevens Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pa</LastName><ForeName>Judy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Neuro Imaging, Stevens Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Alzheimer's Coordinating Center, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beekly</LastName><ForeName>Duane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Alzheimer's Coordinating Center, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuzma</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gangadharan</LastName><ForeName>Prabhakaran</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Coalition Against Major Disease, Critical Path Institute, Tucson, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arneric</LastName><ForeName>Stephen P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Coalition Against Major Disease, Critical Path Institute, Tucson, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redolfi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCCS Fatebenefratelli, The National Centre for Alzheimer's Disease, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orlandi</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>IRCCS Fatebenefratelli, The National Centre for Alzheimer's Disease, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>IRCCS Fatebenefratelli, The National Centre for Alzheimer's Disease, Brescia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals and University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Au</LastName><ForeName>Rhoda</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Neurology and Epidemiology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Framingham Heart Study, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devine</LastName><ForeName>Sherral</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Framingham Heart Study, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auerbach</LastName><ForeName>Sanford</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Framingham Heart Study, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinosa</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic, Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boada</LastName><ForeName>Merc&#xe8;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic, Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Agust&#xed;n</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic, Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koscik</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jiun-Jie</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging and Radiological Sciences, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Wen-Chuin</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Center, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yao-Liang</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Imaging and Intervention, Keelung Branch, Chang Gung Memorial Hospital, Keelung City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Laboratory of Neuro Imaging, Stevens Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 FD005320</GrantID><Acronym>FD</Acronym><Agency>FDA HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001855</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000130</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 EB015922</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 EB020406</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016495</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG035982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG041689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG027161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC025195</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033040</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000612345">ApoE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 Oct 1;74(10):1167-1168. doi: 10.1001/jamaneurol.2017.1470.</RefSource><PMID Version="1">28846761</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2017 Oct;13(10):575. doi: 10.1038/nrneurol.2017.130.</RefSource><PMID Version="1">28884752</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28846757</ArticleId><ArticleId IdType="mid">NIHMS924470</ArticleId><ArticleId IdType="pmc">PMC5759346</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.2188</ArticleId><ArticleId IdType="pii">2649260</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. Jama. 1997 Oct 22;278(16):1349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology. 2013 Feb 1;9(2):106&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungar L, Altmann A, Greicius MD. Apolipoprotein E, gender, and Alzheimer&#x2019;s disease: An overlooked, but potent and promising interaction. Brain imaging and behavior. 2014 Jun 1;8(2):262&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282773</ArticleId><ArticleId IdType="pubmed">24293121</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. Journal of internal medicine. 2014 Mar 1;275(3):214&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3967548</ArticleId><ArticleId IdType="pubmed">24605806</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Jagust WJ, Dulberg C, Becker JT, DeKosky ST, Fitzpatrick A, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Archives of neurology. 2003 Oct 1;60(10):1394&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568809</ArticleId></ArticleIdList></Reference><Reference><Citation>Tervo S, Kivipelto M, H&#xe4;nninen T, Vanhanen M, Hallikainen M, Mannermaa A, Soininen H. Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dementia and geriatric cognitive disorders. 2004 Mar 17;17(3):196&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">14739544</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery WR. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology. 2006 Mar 28;66(6):828&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567698</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Buchman AS, Wilson RS, Kelly JF, Bennett DA. The APOE e4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology. 2009 Nov 11;34(1):43&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2857623</ArticleId><ArticleId IdType="pubmed">19907191</ArticleId></ArticleIdList></Reference><Reference><Citation>Barabash A, Marcos A, Ancin I, Vazquez-Alvarez B, de Ugarte C, Gil P, Fern&#xe1;ndez C, Encinas M, L&#xf3;pez-Ibor JJ, Cabranes JA. APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer&#x2019;s disease. Neurobiology of aging. 2009 Aug 31;30(8):1254&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">18078695</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu WL, Caracciolo B, Wang HX, Santoni G, Winblad B, Fratiglioni L. Accelerated progression from mild cognitive impairment to dementia among APOE &#x3b5;4&#x3b5;4 carriers. Journal of Alzheimer&#x2019;s Disease. 2013 Jan 1;33(2):507&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">23247007</ArticleId></ArticleIdList></Reference><Reference><Citation>Brainerd CJ, Reyna VF, Petersen RC, Smith GE, Kenney AE, Gross CJ, Taub ES, Plassman BL, Fisher GG. The apolipoprotein E genotype predicts longitudinal transitions to mild cognitive impairment but not to Alzheimer&#x2019;s dementia: findings from a nationally representative study. Neuropsychology. 2013 Jan;27(1):86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3874553</ArticleId><ArticleId IdType="pubmed">23356599</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, Kokmen E, Waring SC, Kurland LT. Apolipoprotein E status as a predictor of the development of Alzheimer&#x2019;s disease in memory-impaired individuals. Jama. 1995 Apr 26;273(16):1274&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7646655</ArticleId></ArticleIdList></Reference><Reference><Citation>Samaranch L, Cervantes S, Barabash A, Alonso A, Cabranes JA, Lamet I, Anc&#xed;n I, Lorenzo E, Mart&#xed;nez-Lage P, Marcos A, Clarim&#xf3;n J. The effect of MAPT H1 and APOE &#x3b5;4 on transition from mild cognitive impairment to dementia. Journal of Alzheimer&#x2019;s Disease. 2010 Jan 1;22(4):1065&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20930301</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Berry-Kravis E, Bennett DA. The apolipoprotein E &#x3b5;4 allele and incident Alzheimer&#x2019;s disease in persons with mild cognitive impairment. Neurocase. 2005 Feb 26;11(1):3&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15804918</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H, Jagust W. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology. 2004 Jul 27;63(2):220&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820872</ArticleId><ArticleId IdType="pubmed">15277612</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, Scarmeas N, Braun I, Stern Y, Mayeux R. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Archives of neurology. 2005 Jun 1;62(6):975&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956169</ArticleId></ArticleIdList></Reference><Reference><Citation>Suri S, Heise V, Trachtenberg AJ, Mackay CE. The forgotten APOE allele: a review of the evidence and suggested mechanisms for the protective effect of APOE &#x3b5;2. Neuroscience &amp; Biobehavioral Reviews. 2013 Dec 31;37(10):2878&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">24183852</ArticleId></ArticleIdList></Reference><Reference><Citation>Payami H, Montee KR, Kaye JA, Bird TD, Yu CE, Wijsman EM, Schellenberg GD. Alzheimer&#x2019;s disease, apolipoprotein E4, and gender. Jama. 1994 May 4;271(17):1316&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8158809</ArticleId></ArticleIdList></Reference><Reference><Citation>Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye JA, Bird TD, Yu CE, Wijsman EM, Heston LL, Litt M, Schellenberg GD. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. American journal of human genetics. 1996 Apr;58(4):803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1914663</ArticleId><ArticleId IdType="pubmed">8644745</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Adrienne Cupples L, Van Duijn CM, Kurz A, Zimmer R, M&#xfc;ller U, Green RC, Clarke V, Shoffner J, Wallace DC, Chui H. Apolipoprotein E genotype in patients with Alzheimer&#x2019;s disease: implications for the risk of dementia among relatives. Annals of neurology. 1995 Nov 1;38(5):797&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">7486872</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez M, Campion D, Brice A, Hannequin D, Dubois B, Didierjean O, Michon A, Thomas-Anterion C, Puel M, Frebourg T, Agid Y. Apolipoprotein E &#x3b5;4 allele and familial aggregation of Alzheimer disease. Archives of neurology. 1998 Jun 1;55(6):810&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9626772</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, Norton MC, Tschanz JT, Plassman BL, Meyer MR, Skoog I, Khachaturian A. APOE-&#x3b5;4 count predicts age when prevalence of AD increases, then declines The Cache County Study. Neurology. 1999 Jul 1;53(2):321&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430421</ArticleId></ArticleIdList></Reference><Reference><Citation>Molero AE, Pino-Rami&#xb4;rez G, Maestre GE. Modulation by age and gender of risk for Alzheimer&#x2019;s disease and vascular dementia associated with the apolipoprotein E-&#x3b5;4 allele in Latin Americans: findings from the Maracaibo Aging Study. Neuroscience letters. 2001 Jul 6;307(1):5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11516561</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortensen EL, H&#xf8;gh P. A gender difference in the association between APOE genotype and age-related cognitive decline. Neurology. 2001 Jul 10;57(1):89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445633</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann DJ, Refsum H, Nurk E, Warden DR, Tell GS, Vollset SE, Engedal K, Nygaard HA, Smith AD. Apolipoprotein E e4 and impaired episodic memory in community-dwelling elderly people: a marked sex difference. The Hordaland Health Study. Journal of Neurology. Neurosurgery &amp; Psychiatry. 2006 Aug 1;77(8):902&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077621</ArticleId><ArticleId IdType="pubmed">16595618</ArticleId></ArticleIdList></Reference><Reference><Citation>Bickeb&#xf6;ller H, Campion D, Brice A, Amouyel P, Hannequin D, Didierjean O, Penet C, Martin C, Perez-Tur J, Michon A, Dubois B. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. American journal of human genetics. 1997 Feb;60(2):439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1712413</ArticleId><ArticleId IdType="pubmed">9012418</ArticleId></ArticleIdList></Reference><Reference><Citation>Combarros O, Leno C, Oterino A, Berciano J, Fernandez-Luna JL, Fernandez-Viadero C, Pena N, Miro J, Delgado M. Gender effect on apolipoprotein E &#x3b5;4 allele-associated risk for sporadic Alzheimer&#x2019;s disease. Acta neurologica scandinavica. 1998 Jan 1;97(1):68&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">9482681</ArticleId></ArticleIdList></Reference><Reference><Citation>Slooter AJ, Cruts M, Kalmijn S, Hofman A, Breteler MM, Van Broeckhoven C, van Duijn CM. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Archives of neurology. 1998 Jul 1;55(7):964&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9678314</ArticleId></ArticleIdList></Reference><Reference><Citation>Beydoun MA, Boueiz A, Abougergi MS, Kitner-Triolo MH, Beydoun HA, Resnick SM, O&#x2019;Brien R, Zonderman AB. Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline. Neurobiology of aging. 2012 Apr 30;33(4):720&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2974952</ArticleId><ArticleId IdType="pubmed">20619505</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann A, Tian L, Henderson VW, Greicius MD. Sex modifies the APOE-related risk of developing Alzheimer disease. Annals of neurology. 2014 Apr 1;75(4):563&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117990</ArticleId><ArticleId IdType="pubmed">24623176</ArticleId></ArticleIdList></Reference><Reference><Citation>Neu SC, Crawford KL, Toga AW. Sharing data in the global Alzheimer&#x2019;s Association Interactive Network. Neuroimage. 2016 Jan 1;124:1168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4651771</ArticleId><ArticleId IdType="pubmed">26049147</ArticleId></ArticleIdList></Reference><Reference><Citation>Toga AW, Neu SC, Bhatt P, Crawford KL, Ashish N. The Global Alzheimer&#x2019;s Association Interactive Network. Alzheimer&#x2019;s &amp; Dementia. 2016 Jan 31;12(1):49&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4817494</ArticleId><ArticleId IdType="pubmed">26318022</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiology of aging. 2004 Jun 30;25(5):641&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172743</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarone Robert E. On heterogeneity tests based on efficient scores. Biometrika. 1985;72(1):91&#x2013;95.</Citation></Reference><Reference><Citation>McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 1992 Jan;14(2):103&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">1565019</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedel M, Thompson PM, Brinton RD. Age, APOE and sex: Triad of risk of Alzheimer&#x2019;s disease. J of Steroid Biochem and Mol Biol. 2016 Jun;160:134&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4905558</ArticleId><ArticleId IdType="pubmed">26969397</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, Verhey FR, Visser PJ. Predictive value of APOE-e4 allele for progression from MCI to AD-type dementia: a meta-analysis. Journal of Neurology, Neurosurgery &amp; Psychiatry. 2011 Oct 1;82(10):1149&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">21493755</ArticleId></ArticleIdList></Reference><Reference><Citation>Loy CT, Schofield PR, Turner AM, Kwok JB. Genetics of dementia. The Lancet. 2014 Mar 7;383(9919):828&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">23927914</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nature genetics. 2007 Jan 1;39(1):17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xea;ne G, Beiser A, Au R, Preis SR, Wolf PA, Dufouil C, Seshadri S. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimer&#x2019;s &amp; Dementia. 2015 Mar 31;11(3):310&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4092061</ArticleId><ArticleId IdType="pubmed">24418058</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelros P, Stegmayr B, Ter&#xe9;nt A. Sex differences in stroke epidemiology a systematic review. Stroke. 2009 Apr 1;40(4):1082&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">19211488</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, McCann JJ, Beckett LA, Evans DA. Is the risk of developing Alzheimer&#x2019;s disease greater for women than for men? American journal of epidemiology. 2001 Jan 15;153(2):132&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11159157</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratiglioni L, Ahlbom A, Viitanen M, Winblad B. Risk factors for late-onset Alzheimer&#x2019;s disease: A population-based, case-control study. Annals of neurology. 1993 Mar 1;33(3):258&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">8498809</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Sano M, Chen J, Tatemichi T, Stern Y. Risk of dementia in first-degree relatives of patients with Alzheimer&#x2019;s disease and related disorders. Archives of Neurology. 1991 Mar 1;48(3):269&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">2001183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lautenschlager NT, Cupples LA, Rao VS, Auerbach SA, Becker R, Burke J, Chui H, Duara R, Foley EJ, Glatt SL, Green RC. Risk of dementia among relatives of Alzheimer&#x2019;s disease patients in the MIRAGE study What is in store for the oldest old? Neurology. 1996 Mar 1;46(3):641&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618660</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton MC, Breitner J, Welsh KA, Wyse BW. Characteristics of nonresponders in a community survey of the elderly. Journal of the American Geriatrics Society. 1994 Dec 1;42(12):1252&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7983287</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang D, Kukull W, Sheppard L, Barnhart RL, Peskind E, Edland SD, Schellenberg G, Raskind M, Larson EB. Impact of sample selection on APOE&#x3b5; 4 allele frequency: A comparison of two Alzheimer&#x2019;s disease samples. Journal of the American Geriatrics Society. 1996 Jun 1;44(6):704&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8642164</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke Michelle M, Vemuri Prashanthi, Rocca Walter A. Clinical epidemiology of Alzheimer&#x2019;s disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891487</ArticleId><ArticleId IdType="pubmed">24470773</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes Deborah E, Yaffe Kristine. The projected effect of risk factor reduction on Alzheimer&#x2019;s disease prevalence. The Lancet Neurology. 2011;10(9):819&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647614</ArticleId><ArticleId IdType="pubmed">21775213</ArticleId></ArticleIdList></Reference><Reference><Citation>Boada M, T&#xe1;rraga L, Hern&#xe1;ndez I, Valero S, Alegret M, Ruiz A, Lopez OL, Becker JT, Center FA, Clinic M. Design of a comprehensive Alzheimer&#x2019;s disease clinic and research center in Spain to meet critical patient and family needs. Alzheimer&#x2019;s &amp; Dementia. 2014 May 31;10(3):409&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951687</ArticleId><ArticleId IdType="pubmed">24035148</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Aisen PS, Jack CR, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A. The Alzheimer&#x2019;s disease neuroimaging initiative: progress report and future plans. Alzheimer&#x2019;s &amp; Dementia. 2010 May 31;6(3):202&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927112</ArticleId><ArticleId IdType="pubmed">20451868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer&#x2019;s disease. International Psychogeriatrics. 2009 Aug 1;21(04):672&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">19470201</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Prestia A, Zanetti O, Galluzzi S, Romano M, Cotelli M, Gennarelli M, Binetti G, Bocchio L, Paghera B, Amicucci G, Bonetti M, Benussi L, Ghidoni R, Geroldi C. Markers of Alzheimer&#x2019;s disease in a population attending a memory clinic. Alzheimers Dement. 2009 Jul;5(4):307&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">19560101</ArticleId></ArticleIdList></Reference><Reference><Citation>Galluzzi S, Testa C, Boccardi M, Bresciani L, Benussi L, Ghidoni R, Beltramello A, Bonetti M, Bono G, Falini A, Magnani G, Minonzio G, Piovan E, Binetti G, Frisoni GB. The Italian Brain Normative Archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. Aging Clin Exp Res. 2009 Aug-Oct;21(4&#x2013;5):266&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">19959914</ArticleId></ArticleIdList></Reference><Reference><Citation>Neville J, Kopko S, Broadbent S, Avil&#xe9;s E, Stafford R, Solinsky CM, Bain LJ, Cisneroz M, Romero K, Stephenson D. Development of a unified clinical trial database for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s &amp; Dementia. 2015 Oct 31;11(10):1212&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">25676387</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, Wegrzyn M, Meindl T, Frisoni G, Bokde AL, Fellgiebel A, Filippi M, Hampel H, Kl&#xf6;ppel S, Hauenstein K, Ewers M. Anatomical MRI and DTI in the diagnosis of Alzheimer&#x2019;s disease: a European multicenter study. Journal of Alzheimer&#x2019;s Disease. 2012 Jan 1;31(s3)</Citation><ArticleIdList><ArticleId IdType="pubmed">22992380</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham Study. Annals of the New York Academy of Sciences. 1963 May 1;107(2):539&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">14025561</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA. The National Alzheimer&#x2019;s Coordinating Center (NACC) database: the uniform data set. Alzheimer Disease &amp; Associated Disorders. 2007 Jul 1;21(3):249&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">17804958</ArticleId></ArticleIdList></Reference><Reference><Citation>Partch AB, Laufer D, Valladares O, Iodice J, Greenfest-Allen E, Childress DM, Malamon J, Gangadharan P, Arnold SE, Stoeckert CJ, Schellenberg GD. Nia genetics of Alzheimer&#x2019;s disease data storage site (NIAGADS): 2015 update. Alzheimer&#x2019;s &amp; Dementia: The Journal of the Alzheimer&#x2019;s Association. 2015 Jan 7;11(7):P362.</Citation></Reference><Reference><Citation>Kamboh MI, Minster RL, Demirci FY, Ganguli M, DeKosky ST, Lopez OL, Barmada MM. Association of CLU and PICALM variants with Alzheimer&#x2019;s disease. Neurobiology of aging. 2012 Mar 31;33(3):518&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010357</ArticleId><ArticleId IdType="pubmed">20570404</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW. GAB2 alleles modify Alzheimer&#x2019;s risk in APOE ?4 carriers. Neuron. 2007 Jun 7;54(5):713&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587162</ArticleId><ArticleId IdType="pubmed">17553421</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Reiman EM, Locke DE, Hutton ML, Hentz JG, Hoffman-Snyder C, Woodruff BK, Alexander GE, Osborne D. Cognitive domain decline in healthy apolipoprotein E e4 homozygotes before the diagnosis of mild cognitive impairment. Archives of neurology. 2007 Sep 1;64(9):1306&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846270</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, Holmans P, Rohrer K, Zhao A, Marlowe L, Kaleem M, McCorquodale DS. Genetic control of human brain transcript expression in Alzheimer disease. The American Journal of Human Genetics. 2009 Apr 10;84(4):445&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J. Natural history of mild cognitive impairment in older persons. Neurology. 2002 Jul 23;59(2):198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">12136057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005 Mar 8;64(5):834&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15753419</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Mendes de Leon C, Bienias JL, Wilson RS. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology. 2005 Oct 28;25(4):163&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007 Dec 11;69(24):2197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, Williams M, Hipps Y, Graff-Radford N, Bachman D, Farrer LA. Risk of dementia among white and African American relatives of patients with Alzheimer disease. Jama. 2002 Jan 16;287(3):329&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Graff-Radford N, Foroud T, Mayeux R. Analyses of the national institute on aging late-onset alzheimer&#x2019;s disease family study: implication of additional loci. Archives of neurology. 2008 Nov 10;65(11):1518&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694670</ArticleId><ArticleId IdType="pubmed">19001172</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, van Belle G, Jolley L, Larson EB. Dementia and Alzheimer disease incidence: a prospective cohort study. Archives of neurology. 2002 Nov 1;59(11):1737&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12433261</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, Haines JL, Pericak-Vance MA. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. The American Journal of Human Genetics. 2009 Jan 9;84(1):35&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668056</ArticleId><ArticleId IdType="pubmed">19118814</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP, Younkin SG, Younkin CS, Younkin LH, Bisceglio GD, Ertekin-Taner N. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer&#x2019;s disease. Nature genetics. 2009 Feb 1;41(2):192&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873177</ArticleId><ArticleId IdType="pubmed">19136949</ArticleId></ArticleIdList></Reference><Reference><Citation>Galluzzi S, Marizzoni M, Babiloni C, Albani D, Antelmi L, Bagnoli C, Bartres-Faz D, Cordone S, Didic M, Farotti L, Fiedler U, Forloni G, Girtler N, Hensch T, Jovicich J, Leeuwis A, Marra C, Molinuevo JL, Nobili F, Pariente J, Parnetti L, Payoux P, Del Percio C, Ranjeva JP, Rolandi, Rossini PM, Sch&#xf6;nknecht P, Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB, PharmaCog Consortium Clinical and biomarker profiling of prodromal Alzheimer&#x2019;s disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a &#x2019;European ADNI study&#x2019;. J Intern Med. 2016 Jun;279(6):576&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">26940242</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer&#x2019;s disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer&#x2019;s Prevention. Journal of geriatric psychiatry and neurology. 2005 Dec 1;18(4):245&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16306248</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28855301</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Oct</Month></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant.</ArticleTitle><Pagination><StartPage>1366</StartPage><EndPage>1378</EndPage><MedlinePgn>1366-1378</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.201707673</ELocationID><Abstract><AbstractText>We have characterised the proteolytic cleavage events responsible for the shedding of triggering receptor expressed on myeloid cells 2 (TREM2) from primary cultures of human macrophages, murine microglia and TREM2-expressing human embryonic kidney (HEK293) cells. In all cell types, a soluble 17&#xa0;kDa N-terminal cleavage fragment was shed into the conditioned media in a constitutive process that is inhibited by G1254023X and metalloprotease inhibitors and siRNA targeting ADAM10. Inhibitors of serine proteases and matrix metalloproteinases 2/9, and ADAM17 siRNA did not block TREM2 shedding. Peptidomimetic protease inhibitors highlighted a possible cleavage site, and mass spectrometry confirmed that shedding occurred predominantly at the H157-S158 peptide bond for both wild-type and H157Y human TREM2 and for the wild-type murine orthologue. Crucially, we also show that the Alzheimer's disease-associated H157Y TREM2 variant was shed more rapidly than wild type from HEK293 cells, possibly by a novel, batimastat- and ADAM10-siRNA-independent, sheddase activity. These insights offer new therapeutic targets for modulating the innate immune response in Alzheimer's and other neurological diseases.</AbstractText><CopyrightInformation>&#xa9; 2017 MedImmune Ltd. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thornton</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neuroscience, Innovative Medicines and Early Development, AstraZeneca Granta Park, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sevalle</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deery</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Cambridge Centre for Proteomics, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>Graham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neuroscience, Innovative Medicines and Early Development, AstraZeneca Granta Park, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xe5;hl</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AstraZeneca Translational Sciences Centre, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franssen</LastName><ForeName>Elske H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Neuroscience, Innovative Medicines and Early Development, AstraZeneca Granta Park, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodd</LastName><ForeName>Roger B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MedImmune Limited Granta Park, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qamar</LastName><ForeName>Seema</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez Perez-Nievas</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neuroscience, Innovative Medicines and Early Development, AstraZeneca Granta Park, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicol</LastName><ForeName>Louise Sc</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>MedImmune Limited Granta Park, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eketj&#xe4;ll</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca, ICMC, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revell</LastName><ForeName>Jefferson</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MedImmune Limited Granta Park, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Clare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MedImmune Limited Granta Park, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Billinton</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience, Innovative Medicines and Early Development, AstraZeneca Granta Park, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chessell</LastName><ForeName>Iain</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neuroscience, Innovative Medicines and Early Development, AstraZeneca Granta Park, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowther</LastName><ForeName>Damian C</ForeName><Initials>DC</Initials><Identifier Source="ORCID">0000-0001-7791-1396</Identifier><AffiliationInfo><Affiliation>Neuroscience, Innovative Medicines and Early Development, AstraZeneca Granta Park, Cambridge, UK damian.crowther@azneuro.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>203249/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_G1000734</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N012453/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C445140">G1268267X</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007653">Ketocholesterols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061965">Matrix Metalloproteinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="D000072197">ADAM10 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="C491236">ADAM10 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.86</RegistryNumber><NameOfSubstance UI="D000072198">ADAM17 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.86</RegistryNumber><NameOfSubstance UI="C000606462">ADAM17 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.15252/emmm.201707672</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000072197" MajorTopicYN="N">ADAM10 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072198" MajorTopicYN="N">ADAM17 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007653" MajorTopicYN="N">Ketocholesterols</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061965" MajorTopicYN="N">Matrix Metalloproteinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="Y">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">genetic risk</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28855301</ArticleId><ArticleId IdType="pmc">PMC5623839</ArticleId><ArticleId IdType="doi">10.15252/emmm.201707673</ArticleId><ArticleId IdType="pii">emmm.201707673</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Caescu CI, Jeschke GR, Turk BE (2009) Active&#x2010;site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Biochem J 424: 79&#x2013;88</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774824</ArticleId><ArticleId IdType="pubmed">19715556</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M (2003) TREMs in the immune system and beyond. Nat Rev Immunol 3: 445&#x2013;453</Citation><ArticleIdList><ArticleId IdType="pubmed">12776204</ArticleId></ArticleIdList></Reference><Reference><Citation>Finelli D, Rollinson S, Harris J, Jones M, Richardson A, Gerhard A, Snowden J, Mann D, Pickering&#x2010;Brown S (2015) TREM2 analysis and increased risk of Alzheimer's disease. Neurobiol Aging 36: 546.e9&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pubmed">25260849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghani M, Sato C, Kakhki EG, Gibbs JR, Traynor B, St George&#x2010;Hyslop P, Rogaeva E (2016) Mutation analysis of the MS4A and TREM gene clusters in a case&#x2013;control Alzheimer's disease data set. Neurobiol Aging 42: 217.e7&#x2013;217.e13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8985522</ArticleId><ArticleId IdType="pubmed">27084067</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JSK, Younkin S et&#xa0;al (2013) TREM2 variants in Alzheimer's disease. N Engl J Med 368: 117&#x2013;127</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakola HP (1972) Neuropsychiatric and genetic aspects of a new hereditary disease characterized by progressive dementia and lipomembranous polycystic osteodysplasia. Acta Psychiatr Scand Suppl 232: 1&#x2013;173</Citation><ArticleIdList><ArticleId IdType="pubmed">4509294</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakola HP, Iivanainen M (1973) A new hereditary disease with progressive dementia and polycystic osteodysplasia: neuroradiological analysis of seven cases. Neuroradiology 6: 162&#x2013;168</Citation><ArticleIdList><ArticleId IdType="pubmed">4764488</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamerman JA, Tchao NK, Lowell CA, Lanier LL (2005) Enhanced Toll&#x2010;like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol 6: 579&#x2013;586</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1282462</ArticleId><ArticleId IdType="pubmed">15895090</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL (2006) Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)&#x2010;2 and DAP12. J Immunol 177: 2051&#x2013;2055</Citation><ArticleIdList><ArticleId IdType="pubmed">16887962</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, &#xd6;hrfelt A, Blennow K, Hardy J, Schott J et&#xa0;al (2016) Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener 11: 3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4709982</ArticleId><ArticleId IdType="pubmed">26754172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL et&#xa0;al (2015) TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 212: 287&#x2013;295</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT, Landreth GE (2017) Disease progression&#x2010;dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. J Neurosci 37: 637&#x2013;647</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T, Tan L, Chen Q, Tan M&#x2010;SS, Zhou J&#x2010;SS, Zhu X&#x2010;CC, Lu H, Wang H&#x2010;FF, Zhang Y&#x2010;DD, Yu J&#x2010;TT (2016) A rare coding variant in TREM2 increases risk for Alzheimer's disease in Han Chinese. Neurobiol Aging 42: 217.e1&#x2013;217.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">27067662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ et&#xa0;al (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368: 107&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson K (2013) TREM2 and neurodegenerative disease. N Engl J Med 369: 1568&#x2013;1569</Citation><ArticleIdList><ArticleId IdType="pubmed">24131183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawabori M, Kacimi R, Kauppinen T, Calosing C, Kim JY, Hsieh CL, Nakamura MC, Yenari MA (2015) Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke. J Neurosci 35: 3384&#x2013;3396</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339351</ArticleId><ArticleId IdType="pubmed">25716838</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren&#x2010;Shaul H, Spinrad A, Weiner A, Matcovitch&#x2010;Natan O, Dvir&#x2010;Szternfeld R, Ulland TK, David E, Baruch K, Lara&#x2010;Astaiso D, Toth B et&#xa0;al (2017) A unique microglia type associated with restricting development of Alzheimer's disease. Cell 169: 1276&#x2013;1290</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Su&#xe1;rez&#x2010;Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger&#x2010;Weinzierl A, Mazaheri F et&#xa0;al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6: 243ra86</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kl&#xfc;nemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, De Bleecker JL, Rossor MN, Marienhagen J, Klein HE et&#xa0;al (2005) The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology 64: 1502&#x2013;1507</Citation><ArticleIdList><ArticleId IdType="pubmed">15883308</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Pazgier M, Li J, Li C, Liu M, Zou G, Li Z, Chen J, Tarasov SG, Lu W&#x2010;Y et&#xa0;al (2010) Limitations of peptide retro&#x2010;inverso isomerization in molecular mimicry. J Biol Chem 285: 19572&#x2013;19581</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885236</ArticleId><ArticleId IdType="pubmed">20382735</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Kestil&#xe4; M, Wu J, Salminen A, B&#xf6;hling T, Ruotsalainen V, Hakola P, Bakker AB, Phillips JH, Pekkarinen P et&#xa0;al (2000) Loss&#x2010;of&#x2010;function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet 25: 357&#x2013;361</Citation><ArticleIdList><ArticleId IdType="pubmed">10888890</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J&#x2010;S, Ji IJ, An HJ, Kang M&#x2010;J, Kang S&#x2010;W, Kim D&#x2010;H, Yoon S&#x2010;Y (2015) Disease&#x2010;associated mutations of TREM2 alter the processing of N&#x2010;linked oligosaccharides in the golgi apparatus. Traffic 16: 510&#x2013;518</Citation><ArticleIdList><ArticleId IdType="pubmed">25615530</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Deming Y, Del&#x2010;&#xc1;guila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C (2016) Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131: 925&#x2013;933</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Slattery CF, Beck JA, Harper L, Adamson G, Abdi Z, Uphill J, Campbell T, Druyeh R, Mahoney CJ, Rohrer JD et&#xa0;al (2014) R47H TREM2 variant increases risk of typical early&#x2010;onset Alzheimer's disease but not of prion&#xa0;or frontotemporal dementia. Alzheimers Dement 10: 602&#x2013;608.e4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4627504</ArticleId><ArticleId IdType="pubmed">25160042</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez&#x2010;Calvet M, Araque Caballero M&#xc1;, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C et&#xa0;al (2016a) Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8: 369ra178</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez&#x2010;Calvet M, Kleinberger G, Araque Caballero M&#xc1;, Brendel M, Rominger A, Alcolea D, Fortea J, Lle&#xf3; A, Blesa R, Gispert JD et&#xa0;al (2016b) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early&#x2010;stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 8: 466&#x2013;476</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CDP, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells&#x2010;2. J Exp Med 201: 647&#x2013;657</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor M, Moore S, Mayes J, Parkin E, Beeg M, Canovi M, Gobbi M, Mann DM, Allsop D (2010) Development of a proteolytically stable retro&#x2010;inverso peptide inhibitor of beta&#x2010;amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry 49: 3261&#x2013;3272</Citation><ArticleIdList><ArticleId IdType="pubmed">20230062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH et&#xa0;al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160: 1061&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J (2013) Sequential proteolytic processing of the triggering receptor expressed on myeloid cells&#x2010;2 (TREM2) protein by ectodomain shedding and &#x3b3;&#x2010;secretase&#x2010;dependent intramembranous cleavage. J Biol Chem 288: 33027&#x2013;33036</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829152</ArticleId><ArticleId IdType="pubmed">24078628</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing J, Titus AR, Humphrey MB (2015) The TREM2&#x2010;DAP12 signaling pathway in Nasu&#x2010;Hakola disease: a molecular genetics perspective. Res Rep Biochem 5: 89&#x2013;100</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4605443</ArticleId><ArticleId IdType="pubmed">26478868</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J (2016) TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90: 724&#x2013;739</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28855300</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Oct</Month></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function.</ArticleTitle><Pagination><StartPage>1356</StartPage><EndPage>1365</EndPage><MedlinePgn>1356-1365</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.201707672</ELocationID><Abstract><AbstractText>Sequence variations occurring in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) support an essential function of microglia and innate immunity in the pathogenesis of Alzheimer's disease (AD) and other neurodegenerative disorders. TREM2 matures within the secretory pathway, and its ectodomain is shed on the plasma membrane. Missense mutations in the immunoglobulin (Ig)-like domain such as p.T66M and p.Y38C retain TREM2 within the endoplasmic reticulum and reduce shedding as well as TREM2-dependent phagocytosis. Using mass spectrometry, we have now determined the cleavage site of TREM2. TREM2 is shed by proteases of the ADAM (a disintegrin and metalloproteinase domain containing protein) family C-terminal to histidine 157, a position where an AD-associated coding variant has been discovered (p.H157Y) in the Han Chinese population. Opposite to the characterized mutations within the Ig-like domain, such as p.T66M and p.Y38C, the p.H157Y variant within the stalk region leads to enhanced shedding of TREM2. Elevated ectodomain shedding reduces cell surface full-length TREM2 and lowers TREM2-dependent phagocytosis. Therefore, two seemingly opposite cellular effects of TREM2 variants, namely reduced versus enhanced shedding, result in similar phenotypic outcomes by reducing cell surface TREM2.</AbstractText><CopyrightInformation>&#xa9; 2017 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schlepckow</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinberger</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5811-8226</Identifier><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukumori</LastName><ForeName>Akio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feederle</LastName><ForeName>Regina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz Center Munich, German Research Center for Environmental Health, Institute for Diabetes and Obesity, Core Facility Monoclonal Antibody Development, Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichtenthaler</LastName><ForeName>Stefan F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroproteomics, Klinikum Rechts der Isar, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Advanced Study, Technische Universit&#xe4;t M&#xfc;nchen, Garching, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Harald</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3935-0318</Identifier><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4869-1627</Identifier><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QD397987E</RegistryNumber><NameOfSubstance UI="D006639">Histidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="D000072197">ADAM10 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="C491236">ADAM10 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.86</RegistryNumber><NameOfSubstance UI="D000072198">ADAM17 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.86</RegistryNumber><NameOfSubstance UI="C000606462">ADAM17 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.15252/emmm.201707673</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000072197" MajorTopicYN="N">ADAM10 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072198" MajorTopicYN="N">ADAM17 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006639" MajorTopicYN="N">Histidine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020539" MajorTopicYN="N">Sequence Analysis, Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074084" MajorTopicYN="N">THP-1 Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">phagocytosis</Keyword><Keyword MajorTopicYN="N">regulated intramembrane proteolysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28855300</ArticleId><ArticleId IdType="pmc">PMC5623859</ArticleId><ArticleId IdType="doi">10.15252/emmm.201707672</ArticleId><ArticleId IdType="pii">emmm.201707672</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H et&#xa0;al (2015) Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem 290: 26043&#x2013;26050</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CC, DeVaux LB, Farzan M (2015) The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J Biol Chem 290: 26033&#x2013;26042</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646256</ArticleId><ArticleId IdType="pubmed">26374897</ArticleId></ArticleIdList></Reference><Reference><Citation>Black RA (2002) Tumor necrosis factor&#x2010;alpha converting enzyme. Int J Biochem Cell Biol 34: 1&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pubmed">11733179</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, Fenoglio C, Piaceri I, Archetti S, Bonvicini C et&#xa0;al (2014) Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging 35: 934 e937&#x2013;910</Citation><ArticleIdList><ArticleId IdType="pubmed">24139279</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Koval ED, Benitez BA, Zaidman C, Jockel&#x2010;Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH et&#xa0;al (2014) TREM2 variant p. R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol 71: 449&#x2013;453</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087113</ArticleId><ArticleId IdType="pubmed">24535663</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai XD, Golde TE, Younkin SG (1993) Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 259: 514&#x2013;516</Citation><ArticleIdList><ArticleId IdType="pubmed">8424174</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo&#x2010;Pelfrey C, Lieberburg I, Selkoe DJ (1992) Mutation of the beta&#x2010;amyloid precursor protein in familial Alzheimer's disease increases beta&#x2010;protein production. Nature 360: 672&#x2013;674</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M, Wang Y (2016) TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci 17: 201&#x2013;207</Citation><ArticleIdList><ArticleId IdType="pubmed">26911435</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, Engelborghs S, Vandenbulcke M, Van Dongen J, Geerts N et&#xa0;al (2014) Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging 35: 726 e711&#x2013;726 e729</Citation><ArticleIdList><ArticleId IdType="pubmed">24119542</ArticleId></ArticleIdList></Reference><Reference><Citation>Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ et&#xa0;al (2001) Functional gamma&#x2010;secretase inhibitors reduce beta&#x2010;amyloid peptide levels in brain. J Neurochem 76: 173&#x2013;181</Citation><ArticleIdList><ArticleId IdType="pubmed">11145990</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumori A, Fluhrer R, Steiner H, Haass C (2010) Three&#x2010;amino acid spacing of presenilin endoproteolysis suggests a general stepwise cleavage of gamma&#x2010;secretase&#x2010;mediated intramembrane proteolysis. J Neurosci 30: 7853&#x2013;7862</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632680</ArticleId><ArticleId IdType="pubmed">20534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Glebov K, Wunderlich P, Karaca I, Walter J (2016) Functional involvement of gamma&#x2010;secretase in signaling of the triggering receptor expressed on myeloid cells&#x2010;2 (TREM2). J Neuroinflammation 13: 17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721188</ArticleId><ArticleId IdType="pubmed">26792193</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Hardy J (2013) TREM2 and neurodegenerative disease. N Engl J Med 369: 1569&#x2013;1570</Citation><ArticleIdList><ArticleId IdType="pubmed">24143816</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S et&#xa0;al (2013) TREM2 variants in Alzheimer's disease. N Engl J Med 368: 117&#x2013;127</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Hung AY, Schlossmacher MG, Teplow DB, Selkoe DJ (1993) beta&#x2010;Amyloid peptide and a 3&#x2010;kDa fragment are derived by distinct cellular mechanisms. J Biol Chem 268: 3021&#x2013;3024</Citation><ArticleIdList><ArticleId IdType="pubmed">8428976</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Koo EH, Capell A, Teplow DB, Selkoe DJ (1995a) Polarized sorting of beta&#x2010;amyloid precursor protein and its proteolytic products in MDCK cells is regulated by two independent signals. J Cell Biol 128: 537&#x2013;547</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2199885</ArticleId><ArticleId IdType="pubmed">7860629</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ (1995b) The Swedish mutation causes early&#x2010;onset Alzheimer's disease by beta&#x2010;secretase cleavage within the secretory pathway. Nat Med 1: 1291&#x2013;1296</Citation><ArticleIdList><ArticleId IdType="pubmed">7489411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL (2006) Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)&#x2010;2 and DAP12. J Immunol 177: 2051&#x2013;2055</Citation><ArticleIdList><ArticleId IdType="pubmed">16887962</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, Ohrfelt A, Blennow K, Hardy J, Schott J et&#xa0;al (2016) Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener 11: 3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4709982</ArticleId><ArticleId IdType="pubmed">26754172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL et&#xa0;al (2015) TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 212: 287&#x2013;295</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T, Tan L, Chen Q, Tan MS, Zhou JS, Zhu XC, Lu H, Wang HF, Zhang YD, Yu JT (2016) A rare coding variant in TREM2 increases risk for Alzheimer's disease in Han Chinese. Neurobiol Aging 42: 217.e1&#x2013;217.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">27067662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson K (2013) TREM2 and neurodegenerative disease. N Engl J Med 369: 1568&#x2013;1569</Citation><ArticleIdList><ArticleId IdType="pubmed">24131183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Suarez&#x2010;Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger&#x2010;Weinzierl A, Mazaheri F et&#xa0;al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6: 243ra286</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, Xiang X, Focke C, Deussing M, Suarez&#x2010;Calvet M, Mazaheri F et&#xa0;al (2017) The FTD&#x2010;like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO J 36: 1837&#x2013;1853</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494459</ArticleId><ArticleId IdType="pubmed">28559417</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, De Bleecker JL, Rossor MN, Marienhagen J, Klein HE et&#xa0;al (2005) The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology 64: 1502&#x2013;1507</Citation><ArticleIdList><ArticleId IdType="pubmed">15883308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober DL, Alexander&#x2010;Brett JM, Karch CM, Cruchaga C, Colonna M, Holtzman MJ, Brett TJ (2016) Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss&#x2010;of&#x2010;function mechanisms. eLife 5: e20391</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173322</ArticleId><ArticleId IdType="pubmed">27995897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Haass C, Steiner H (2011) Regulated intramembrane proteolysis&#x2013;lessons from amyloid precursor protein processing. J Neurochem 117: 779&#x2013;796</Citation><ArticleIdList><ArticleId IdType="pubmed">21413990</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyman M, Lloyd DG, Ji X, Vizcaychipi MP, Ma D (2014) Neuroinflammation: the role and consequences. Neurosci Res 79: 1&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">24144733</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Zhou Y, Xu J, Liu X, Wang Y, Deng Y, Wang G, Xu W, Ren R, Liu X et&#xa0;al (2014) Association study of TREM2 polymorphism rs75932628 with late&#x2010;onset Alzheimer's disease in Chinese Han population. Neurol Res 36: 894&#x2013;896</Citation><ArticleIdList><ArticleId IdType="pubmed">24725293</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258: 304&#x2013;307</Citation><ArticleIdList><ArticleId IdType="pubmed">1411529</ArticleId></ArticleIdList></Reference><Reference><Citation>Paradowska&#x2010;Gorycka A, Jurkowska M (2013) Structure, expression pattern and biological activity of molecular complex TREM&#x2010;2/DAP12. Hum Immunol 74: 730&#x2013;737</Citation><ArticleIdList><ArticleId IdType="pubmed">23459077</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Ji IJ, An HJ, Kang MJ, Kang SW, Kim DH, Yoon SY (2015) Disease&#x2010;associated mutations of TREM2 alter the processing of N&#x2010;linked oligosaccharides in the Golgi apparatus. Traffic 16: 510&#x2013;518</Citation><ArticleIdList><ArticleId IdType="pubmed">25615530</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Deming Y, Del&#x2010;Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C (2016) Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131: 925&#x2013;933</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ, Lomen&#x2010;Hoerth C, Kertesz A, Bigio EH et&#xa0;al (2013) TREM2 in neurodegeneration: evidence for association of the p. R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener 8: 19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691612</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId></ArticleIdList></Reference><Reference><Citation>Saftig P, Lichtenthaler SF (2015) The alpha secretase ADAM10: a metalloprotease with multiple functions in the brain. Prog Neurobiol 135: 1&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pubmed">26522965</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirotani K, Tomioka M, Kremmer E, Haass C, Steiner H (2007) Pathological activity of familial Alzheimer's disease&#x2010;associated mutant presenilin can be executed by six different gamma&#x2010;secretase complexes. Neurobiol Dis 27: 102&#x2013;107</Citation><ArticleIdList><ArticleId IdType="pubmed">17560791</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Hooli B, Mullin K, Jin SC, Cella M, Ulland TK, Wang Y, Tanzi R, Colonna M (2017) Alzheimer's disease&#x2010;associated TREM2 variants exhibit either decreased or increased ligand&#x2010;dependent activation. Alzheimers Dement 13: 381&#x2013;387</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299056</ArticleId><ArticleId IdType="pubmed">27520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez&#x2010;Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C et&#xa0;al (2016a) Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8: 369ra178</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez&#x2010;Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, Fortea J, Lleo A, Blesa R, Gispert JD et&#xa0;al (2016b) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early&#x2010;stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 8: 466&#x2013;476</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS (1996) Metabolism of the &#x201c;Swedish&#x201d; amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the &#x201c;beta&#x2010;secretase&#x201d; site occurs in the golgi apparatus. J Biol Chem 271: 9390&#x2013;9397</Citation><ArticleIdList><ArticleId IdType="pubmed">8621605</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K (1980) Establishment and characterization of a human acute monocytic leukemia cell line (THP&#x2010;1). Int J Cancer 26: 171&#x2013;176</Citation><ArticleIdList><ArticleId IdType="pubmed">6970727</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Holtzman DM (2016) TREM2 function in Alzheimer's disease and neurodegeneration. ACS Chem Neurosci 7: 420&#x2013;427</Citation><ArticleIdList><ArticleId IdType="pubmed">26854967</ArticleId></ArticleIdList></Reference><Reference><Citation>Villegas&#x2010;Llerena C, Phillips A, Garcia&#x2010;Reitboeck P, Hardy J, Pocock JM (2016) Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. Curr Opin Neurobiol 36: 74&#x2013;81</Citation><ArticleIdList><ArticleId IdType="pubmed">26517285</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH et&#xa0;al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160: 1061&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S et&#xa0;al (2016) TREM2&#x2010;mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213: 667&#x2013;675</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J (2013) Sequential proteolytic processing of the triggering receptor expressed on myeloid cells&#x2010;2 (TREM2) protein by ectodomain shedding and gamma&#x2010;secretase&#x2010;dependent intramembranous cleavage. J Biol Chem 288: 33027&#x2013;33036</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829152</ArticleId><ArticleId IdType="pubmed">24078628</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel I, Kleinberger G, Haass C (2016) TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med 8: 992&#x2013;1004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009806</ArticleId><ArticleId IdType="pubmed">27402340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M (2016) TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid&#x2010;beta by microglia. Neuron 91: 328&#x2013;340</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J (2016) TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90: 724&#x2013;739</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28854169</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>549</Volume><Issue>7672</Issue><PubDate><Year>2017</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease.</ArticleTitle><Pagination><StartPage>389</StartPage><EndPage>393</EndPage><MedlinePgn>389-393</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature23672</ELocationID><Abstract><AbstractText>The pathophysiology of neurodegenerative diseases is poorly understood and there are few therapeutic options. Neurodegenerative diseases are characterized by progressive neuronal dysfunction and loss, and chronic glial activation. Whether microglial activation, which is generally viewed as a secondary process, is harmful or protective in neurodegeneration remains unclear. Late-onset neurodegenerative disease observed in patients with histiocytoses, which are clonal myeloid diseases associated with somatic mutations in the RAS-MEK-ERK pathway such as BRAF(V600E), suggests a possible role of somatic mutations in myeloid cells in neurodegeneration. Yet the expression of BRAF(V600E) in the haematopoietic stem cell lineage causes leukaemic and tumoural diseases but not neurodegenerative disease. Microglia belong to a lineage of adult tissue-resident myeloid cells that develop during organogenesis from yolk-sac erythro-myeloid progenitors (EMPs) distinct from haematopoietic stem cells. We therefore hypothesized that a somatic BRAF(V600E) mutation in the EMP lineage may cause neurodegeneration. Here we show that mosaic expression of BRAF(V600E) in mouse EMPs results in clonal expansion of tissue-resident macrophages and a severe late-onset neurodegenerative disorder. This is associated with accumulation of ERK-activated amoeboid microglia in mice, and is also observed in human patients with histiocytoses. In the mouse model, neurobehavioural signs, astrogliosis, deposition of amyloid precursor protein, synaptic loss and neuronal death were driven by ERK-activated microglia and were preventable by BRAF inhibition. These results identify the fetal precursors of tissue-resident macrophages as a potential cell-of-origin for histiocytoses and demonstrate that a somatic mutation in the EMP lineage in mice can drive late-onset neurodegeneration. Moreover, these data identify activation of the MAP kinase pathway in microglia as a cause of neurodegeneration and this offers opportunities for therapeutic intervention aimed at the prevention of neuronal death in neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mass</LastName><ForeName>Elvira</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacome-Galarza</LastName><ForeName>Christian E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blank</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, BIOSS Centre for Biological Signalling Studies, University of Freiburg, 79104 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazarov</LastName><ForeName>Tomi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durham</LastName><ForeName>Benjamin H</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozkaya</LastName><ForeName>Neval</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastore</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwabenland</LastName><ForeName>Marius</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, BIOSS Centre for Biological Signalling Studies, University of Freiburg, 79104 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Young Rock</ForeName><Initials>YR</Initials><AffiliationInfo><Affiliation>Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenblum</LastName><ForeName>Marc K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prinz</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, BIOSS Centre for Biological Signalling Studies, University of Freiburg, 79104 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel-Wahab</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geissmann</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular and Cellular Biology of Inflammation (CMCBI), King's College London, London SE1 1UL, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA201247</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI130345</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA201247-01</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL138090</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Sep 21;549(7672):340-342. doi: 10.1038/nature23547.</RefSource><PMID Version="1">28854170</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cell Stem Cell. 2017 Nov 2;21(5):566-568. doi: 10.1016/j.stem.2017.10.006.</RefSource><PMID Version="1">29100009</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002999" MajorTopicYN="N">Clone Cells</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015672" MajorTopicYN="N">Erythroid Precursor Cells</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015614" MajorTopicYN="N">Histiocytosis</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020935" MajorTopicYN="Y">MAP Kinase Signaling System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009030" MajorTopicYN="N">Mosaicism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023461" MajorTopicYN="N">Myeloid Progenitor Cells</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048493" MajorTopicYN="N">Proto-Oncogene Proteins B-raf</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28854169</ArticleId><ArticleId IdType="mid">NIHMS895894</ArticleId><ArticleId IdType="pmc">PMC6047345</ArticleId><ArticleId IdType="doi">10.1038/nature23672</ArticleId><ArticleId IdType="pii">nature23672</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777&#x2013;783. doi: 10.1126/science.aag2590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aag2590</ArticleId><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015;160:1061&#x2013;1071. doi: 10.1016/j.cell.2015.01.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712&#x2013;716. doi: 10.1126/science.aad8373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71:656&#x2013;662. doi: 10.1086/342259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/342259</ArticleId><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nature genetics. 2011;44:200&#x2013;205. doi: 10.1038/ng.1027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.1027</ArticleId><ArticleId IdType="pmc">PMC3267847</ArticleId><ArticleId IdType="pubmed">22197934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. The New England journal of medicine. 2013;368:107&#x2013;116. doi: 10.1056/NEJMoa1211103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer's disease. The New England journal of medicine. 2013;368:117&#x2013;127. doi: 10.1056/NEJMoa1211851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellwig S, Heinrich A, Biber K. The brain's best friend: microglial neurotoxicity revisited. Frontiers in cellular neuroscience. 2013;7:71. doi: 10.3389/fncel.2013.00071.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00071</ArticleId><ArticleId IdType="pmc">PMC3655268</ArticleId><ArticleId IdType="pubmed">23734099</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachenal F, et al. Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature. J Neurol. 2006;253:1267&#x2013;1277. doi: 10.1007/s00415-006-0160-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-006-0160-9</ArticleId><ArticleId IdType="pubmed">17063320</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurencikas E, et al. Incidence and pattern of radiological central nervous system Langerhans cell histiocytosis in children: a population based study. Pediatric blood &amp; cancer. 2011;56:250&#x2013;257. doi: 10.1002/pbc.22791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pbc.22791</ArticleId><ArticleId IdType="pubmed">21157893</ArticleId></ArticleIdList></Reference><Reference><Citation>Wnorowski M, et al. Pattern and course of neurodegeneration in Langerhans cell histiocytosis. The Journal of pediatrics. 2008;153:127&#x2013;132. doi: 10.1016/j.jpeds.2007.12.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2007.12.042</ArticleId><ArticleId IdType="pubmed">18571550</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigaud C, et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. British journal of haematology. 2016;174:887&#x2013;898. doi: 10.1111/bjh.14140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.14140</ArticleId><ArticleId IdType="pubmed">27273725</ArticleId></ArticleIdList></Reference><Reference><Citation>Heritier S, et al. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. J Clin Oncol. 2016;34:3023&#x2013;3030. doi: 10.1200/JCO.2015.65.9508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2015.65.9508</ArticleId><ArticleId IdType="pmc">PMC5321082</ArticleId><ArticleId IdType="pubmed">27382093</ArticleId></ArticleIdList></Reference><Reference><Citation>Badalian-Very G, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919&#x2013;1923. doi: 10.1182/blood-2010-04-279083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-04-279083</ArticleId><ArticleId IdType="pmc">PMC3173987</ArticleId><ArticleId IdType="pubmed">20519626</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T, et al. B-RAF Mutant Alleles Associated with Langerhans Cell Histiocytosis, a Granulomatous Pediatric Disease. PloS one. 2012;7:e33891. doi: 10.1371/journal.pone.0033891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0033891</ArticleId><ArticleId IdType="pmc">PMC3323620</ArticleId><ArticleId IdType="pubmed">22506009</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroche J, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120:2700&#x2013;2703. doi: 10.1182/blood-2012-05-430140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-05-430140</ArticleId><ArticleId IdType="pubmed">22879539</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond EL, et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer discovery. 2016;6:154&#x2013;165. doi: 10.1158/2159-8290.CD-15-0913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-15-0913</ArticleId><ArticleId IdType="pmc">PMC4744547</ArticleId><ArticleId IdType="pubmed">26566875</ArticleId></ArticleIdList></Reference><Reference><Citation>Berres ML, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. The Journal of experimental medicine. 2014;211:669&#x2013;683. doi: 10.1084/jem.20130977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20130977</ArticleId><ArticleId IdType="pmc">PMC3978272</ArticleId><ArticleId IdType="pubmed">24638167</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung SS, et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Science translational medicine. 2014;6:238ra271. doi: 10.1126/scitranslmed.3008004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3008004</ArticleId><ArticleId IdType="pmc">PMC4501573</ArticleId><ArticleId IdType="pubmed">24871132</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz C, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336:86&#x2013;90. doi: 10.1126/science.1219179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1219179</ArticleId><ArticleId IdType="pubmed">22442384</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci. 2013;16:273&#x2013;280. doi: 10.1038/nn.3318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3318</ArticleId><ArticleId IdType="pubmed">23334579</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Perdiguero E, et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature. 2015;518:547&#x2013;551. doi: 10.1038/nature13989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13989</ArticleId><ArticleId IdType="pmc">PMC5997177</ArticleId><ArticleId IdType="pubmed">25470051</ArticleId></ArticleIdList></Reference><Reference><Citation>Mass E, et al. Specification of tissue-resident macrophages during organogenesis. Science. 2016;353 doi: 10.1126/science.aaf4238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf4238</ArticleId><ArticleId IdType="pmc">PMC5066309</ArticleId><ArticleId IdType="pubmed">27492475</ArticleId></ArticleIdList></Reference><Reference><Citation>Behjati S, et al. Genome sequencing of normal cells reveals developmental lineages and mutational processes. Nature. 2014;513:422&#x2013;425. doi: 10.1038/nature13448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13448</ArticleId><ArticleId IdType="pmc">PMC4227286</ArticleId><ArticleId IdType="pubmed">25043003</ArticleId></ArticleIdList></Reference><Reference><Citation>Martincorena I, et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science. 2015;348:880&#x2013;886. doi: 10.1126/science.aaa6806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa6806</ArticleId><ArticleId IdType="pmc">PMC4471149</ArticleId><ArticleId IdType="pubmed">25999502</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer K, et al. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res. 2005;65:11493&#x2013;11500. doi: 10.1158/0008-5472.CAN-05-2211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-05-2211</ArticleId><ArticleId IdType="pmc">PMC2640458</ArticleId><ArticleId IdType="pubmed">16357158</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian BZ, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475:222&#x2013;225. doi: 10.1038/nature10138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10138</ArticleId><ArticleId IdType="pmc">PMC3208506</ArticleId><ArticleId IdType="pubmed">21654748</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel HC, Boutin H, Allan SM. Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Annals of the New York Academy of Sciences. 2003;992:39&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794045</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell IL, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:10061&#x2013;10065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47713</ArticleId><ArticleId IdType="pubmed">7694279</ArticleId></ArticleIdList></Reference><Reference><Citation>Waisman A, Hauptmann J, Regen T. The role of IL-17 in CNS diseases. Acta neuropathologica. 2015;129:625&#x2013;637. doi: 10.1007/s00401-015-1402-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1402-7</ArticleId><ArticleId IdType="pubmed">25716179</ArticleId></ArticleIdList></Reference><Reference><Citation>Caton ML, Smith-Raska MR, Reizis B. Notch-RBP-J signaling controls the homeostasis of CD8- dendritic cells in the spleen. The Journal of experimental medicine. 2007;204:1653&#x2013;1664. doi: 10.1084/jem.20062648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20062648</ArticleId><ArticleId IdType="pmc">PMC2118632</ArticleId><ArticleId IdType="pubmed">17591855</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng L, et al. A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. The American journal of pathology. 2010;176:952&#x2013;967. doi: 10.2353/ajpath.2010.090622.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2010.090622</ArticleId><ArticleId IdType="pmc">PMC2808099</ArticleId><ArticleId IdType="pubmed">20042677</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:3041&#x2013;3046. doi: 10.1073/pnas.0711741105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0711741105</ArticleId><ArticleId IdType="pmc">PMC2268581</ArticleId><ArticleId IdType="pubmed">18287029</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyenet SJ, et al. A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. Journal of visualized experiments : JoVE. 2010 doi: 10.3791/1787.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/1787</ArticleId><ArticleId IdType="pmc">PMC3121238</ArticleId><ArticleId IdType="pubmed">20495529</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner S, Afzali AM, Wiendl H, Meuth SG. Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. Journal of visualized experiments : JoVE. 2014 doi: 10.3791/51275.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/51275</ArticleId><ArticleId IdType="pmc">PMC4172026</ArticleId><ArticleId IdType="pubmed">24797125</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter RJ, et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1999;19:3248&#x2013;3257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782264</ArticleId><ArticleId IdType="pubmed">10191337</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15&#x2013;21. doi: 10.1093/bioinformatics/bts635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Patro R, Mount SM, Kingsford C. Sailfish enables alignment-free isoform quantification from RNA-seq reads using lightweight algorithms. Nat Biotechnol. 2014;32:462&#x2013;464. doi: 10.1038/nbt.2862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2862</ArticleId><ArticleId IdType="pmc">PMC4077321</ArticleId><ArticleId IdType="pubmed">24752080</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome biology. 2014;15:550. doi: 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284&#x2013;287. doi: 10.1089/omi.2011.0118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond EL, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124:483&#x2013;492. doi: 10.1182/blood-2014-03-561381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-03-561381</ArticleId><ArticleId IdType="pmc">PMC4110656</ArticleId><ArticleId IdType="pubmed">24850756</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28878053</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>14</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Subjective memory complaints in preclinical autosomal dominant Alzheimer disease.</ArticleTitle><Pagination><StartPage>1464</StartPage><EndPage>1470</EndPage><MedlinePgn>1464-1470</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000004533</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To cross-sectionally study subjective memory complaints (SMC) in autosomal dominant Alzheimer disease (ADAD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We examined self-reported and study partner-based SMC in 52 young, cognitively unimpaired individuals from a Colombian kindred with early-onset ADAD. Twenty-six carried the <i>PSEN-1</i> E280A mutation, averaging 7 years of age younger than the kindred's expected clinical onset. Twenty-six were age-matched noncarriers. Participants also underwent structural MRI and cognitive testing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Self-reported SMC were greater in carriers than noncarriers (<i>p</i> = 0.02). Study partner-based SMC did not differ between groups (<i>p</i> = 0.21), but in carriers increased with age (<i>r</i> = 0.66, <i>p</i> &lt; 0.001) and decreased with hippocampal volume (<i>r</i> = -0.35, <i>p</i> = 0.08).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Cognitively unimpaired <i>PSEN-1</i> carriers have elevated SMC. Self-reported SMC may be a relatively early indicator of preclinical AD, while partner- reported SMC increases later in preclinical AD, closer to clinical onset.</AbstractText><CopyrightInformation>&#xa9; 2017 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amariglio</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Protas</LastName><ForeName>Hillary</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguirre-Acevedo</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulsifer</LastName><ForeName>Brendan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castrillon</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tirado</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munoz</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langbaum</LastName><ForeName>Jessica B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopera</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Yakeel T</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA. yquiroz@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG037497</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP5 OD019833</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034556</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG044431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28878053</ArticleId><ArticleId IdType="pmc">PMC5631170</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004533</ArticleId><ArticleId IdType="pii">WNL.0000000000004533</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging&#x2013;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron 2014;84:608&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285623</ArticleId><ArticleId IdType="pubmed">25442939</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, Townsend MK, Grodstein F, Sperling RA, Rentz DM. Specific subjective memory complaints in older persons may indicate poor cognitive function. J Am Geriatr Soc 2011;59:1612&#x2013;1617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315361</ArticleId><ArticleId IdType="pubmed">21919893</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Chen K, Locke DEC, et al. . Subjective cognitive decline: self and informant comparisons. Alzheimers Dement 2014;10:93&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3732500</ArticleId><ArticleId IdType="pubmed">23562429</ArticleId></ArticleIdList></Reference><Reference><Citation>Laske C, Sohrabi HR, Jasielec MS, et al. . Diagnostic value of subjective memory complaints assessed with a single item in dominantly inherited Alzheimer's disease: results of the DIAN study. Biomed Res Int 2015;2015:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4398930</ArticleId><ArticleId IdType="pubmed">25922840</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Maruff P, Ames D, et al. . Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. Alzheimers Dement 2016;12:796&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">26852195</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerlings MI, Jonker C, Bouter LM, Ad&#xe8;r HJ, Schmand B. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiatry 1999;156:531&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10200730</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F, Amariglio RE, van Boxtel M, et al. . A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 2014;10:844&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4317324</ArticleId><ArticleId IdType="pubmed">24798886</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmand B, Jonker C, Hooijer C, Lindeboom J. Subjective memory complaints may announce dementia. Neurology 1996;46:121&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">8559359</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldorff FB, Siersma V, Vogel A, Waldemar G. Subjective memory complaints in general practice predicts future dementia: a 4-year follow-up study. Int J Geriatr Psychiatry 2012;27:1180&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">22253004</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, van Belle G, Crane PK, et al. . Subjective memory deterioration and future dementia in people aged 65 and older. J Am Geriatr Soc 2004;52:2045&#x2013;2051.</Citation><ArticleIdList><ArticleId IdType="pubmed">15571540</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, et al. . Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. . Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol 2015;72:316&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355261</ArticleId><ArticleId IdType="pubmed">25580592</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Schultz AP, Chen K, et al. . Brain imaging and blood biomarker abnormalities in children with autosomal dominant Alzheimer disease: a cross-sectional study. JAMA Neurol 2015;72:912&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625544</ArticleId><ArticleId IdType="pubmed">26121081</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopera F, Ardilla A, Mart&#xed;nez A, et al. . Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997;277:793&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052708</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B. Functional Assessment Staging (FAST). Psychopharmacol Bull 1988;24:653&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249767</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh J, Yesavage J. Recent evidence and development of a shorter version. In: Clinical Gerontology: A Guide to Assessment and Intervention. New York: The Hawthorn Press; 1986:165&#x2013;173.</Citation></Reference><Reference><Citation>Acosta-Baena N, Sepulveda-Falla D, Lopera-G&#xf3;mez CM, et al. . Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol 2011;10:213&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296022</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin LA, Smart CM, Crane PK, et al. . Subjective cognitive decline in older adults: an overview of self-report measures used across 19 International research studies. J Alzheimers Dis 2015;48(suppl 1):S63&#x2013;S86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4617342</ArticleId><ArticleId IdType="pubmed">26402085</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre-Acevedo DC, G&#xf3;mez RD, Moreno S, et al. . Validity and reliability of the CERAD-Col neuropsychological battery [in Spanish]. Rev Neurol 2007;45:655&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">18050096</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8:3&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">10347857</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre-Acevedo DC, Lopera F, Henao E, et al. . Cognitive decline in a Colombian kindred with autosomal dominant Alzheimer disease: a retrospective cohort study. JAMA Neurol 2016;73:431&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505685</ArticleId><ArticleId IdType="pubmed">26902171</ArticleId></ArticleIdList></Reference><Reference><Citation>Comijs HC, Deeg DJ, Dik MG, Twisk JW, Jonker C. Memory complaints; the association with psycho-affective and health problems and the role of personality characteristics: a 6-year follow-up study. J Affect Disord 2002;72:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">12200206</ArticleId></ArticleIdList></Reference><Reference><Citation>Minett TSC, Da Silva RV, Ortiz KZ, Bertolucci PHF. Subjective memory complaints in an elderly sample: a cross-sectional study. Int J Geriatr Psychiatry 2008;23:49&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">17520662</ArticleId></ArticleIdList></Reference><Reference><Citation>Lineweaver TT, Bondi MW, Galasko D, Salmon DP. Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry 2014;171:201&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4037144</ArticleId><ArticleId IdType="pubmed">24170170</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28882996</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>358</Volume><Issue>6359</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Fibril structure of amyloid-&#x3b2;(1-42) by cryo-electron microscopy.</ArticleTitle><Pagination><StartPage>116</StartPage><EndPage>119</EndPage><MedlinePgn>116-119</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aao2825</ELocationID><Abstract><AbstractText>Amyloids are implicated in neurodegenerative diseases. Fibrillar aggregates of the amyloid-&#x3b2; protein (A&#x3b2;) are the main component of the senile plaques found in brains of Alzheimer's disease patients. We present the structure of an A&#x3b2;(1-42) fibril composed of two intertwined protofilaments determined by cryo-electron microscopy (cryo-EM) to 4.0-angstrom resolution, complemented by solid-state nuclear magnetic resonance experiments. The backbone of all 42 residues and nearly all side chains are well resolved in the EM density map, including the entire N terminus, which is part of the cross-&#x3b2; structure resulting in an overall "LS"-shaped topology of individual subunits. The dimer interface protects the hydrophobic C termini from the solvent. The characteristic staggering of the nonplanar subunits results in markedly different fibril ends, termed "groove" and "ridge," leading to different binding pathways on both fibril ends, which has implications for fibril growth.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gremer</LastName><ForeName>Lothar</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7065-5027</Identifier><AffiliationInfo><Affiliation>Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut f&#xfc;r Physikalische Biologie, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xf6;lzel</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut f&#xfc;r Physikalische Biologie, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schenk</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinartz</LastName><ForeName>Elke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Physikalische Biologie, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labahn</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0648-8145</Identifier><AffiliationInfo><Affiliation>Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut f&#xfc;r Physikalische Biologie, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Structural Systems Biology (CSSB), Deutsches Elektronen-Synchrotron (DESY), 22607 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravelli</LastName><ForeName>Raimond B G</ForeName><Initials>RBG</Initials><Identifier Source="ORCID">0000-0001-6056-5888</Identifier><AffiliationInfo><Affiliation>The Maastricht Multimodal Molecular Imaging Institute, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tusche</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez-Iglesias</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Maastricht Multimodal Molecular Imaging Institute, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoyer</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-4301-5416</Identifier><AffiliationInfo><Affiliation>Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut f&#xfc;r Physikalische Biologie, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heise</LastName><ForeName>Henrike</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9081-3894</Identifier><AffiliationInfo><Affiliation>Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut f&#xfc;r Physikalische Biologie, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willbold</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0065-7366</Identifier><AffiliationInfo><Affiliation>Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany. gu.schroeder@fz-juelich.de d.willbold@fz-juelich.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut f&#xfc;r Physikalische Biologie, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schr&#xf6;der</LastName><ForeName>Gunnar F</ForeName><Initials>GF</Initials><Identifier Source="ORCID">0000-0003-1803-5431</Identifier><AffiliationInfo><Affiliation>Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany. gu.schroeder@fz-juelich.de d.willbold@fz-juelich.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Physics Department, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2017 Oct 6;358(6359):45-46. doi: 10.1126/science.aap8002.</RefSource><PMID Version="1">28983039</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019906" MajorTopicYN="N">Nuclear Magnetic Resonance, Biomolecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014961" MajorTopicYN="N">X-Ray Diffraction</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>8</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28882996</ArticleId><ArticleId IdType="mid">EMS78845</ArticleId><ArticleId IdType="pmc">PMC6080689</ArticleId><ArticleId IdType="doi">10.1126/science.aao2825</ArticleId><ArticleId IdType="pii">science.aao2825</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Riek R, Eisenberg DS. The activities of amyloids from a structural perspective. Nature. 2016 Nov 10;539:227.</Citation><ArticleIdList><ArticleId IdType="pubmed">27830791</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles TP, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nature reviews. Molecular cell biology. 2014 Jun;15:384.</Citation><ArticleIdList><ArticleId IdType="pubmed">24854788</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013 Sep 05;501:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016 Jun 01;8:595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xe4;ndrich M, Meinhardt J, Grigorieff N. Structural polymorphism of Alzheimer A&#x3b2; and other amyloid fibrils. Prion. 2009 Apr-Jun;3:89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2712605</ArticleId><ArticleId IdType="pubmed">19597329</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, et al. Molecular structure of &#x3b2;-amyloid fibrils in Alzheimer's disease brain tissue. Cell. 2013 Sep 12;154:1257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Leapman RD, Yau WM, Tycko R. Molecular structural basis for polymorphism in Alzheimer's &#x3b2;-amyloid fibrils. Proc Natl Acad Sci U S A. 2008 Nov 25;105:18349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587602</ArticleId><ArticleId IdType="pubmed">19015532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez del Amo JM, et al. An Asymmetric Dimer as the Basic Subunit in Alzheimer&#x2019;s Disease Amyloid &#x3b2; Fibrils. Angewandte Chemie International Edition. 2012;51:6136.</Citation><ArticleIdList><ArticleId IdType="pubmed">22565601</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, et al. Peptide dimer structure in an A&#x3b2;(1&#x2013;42) fibril visualized with cryo-EM. Proceedings of the National Academy of Sciences. 2015 Sep 22;112:11858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586870</ArticleId><ArticleId IdType="pubmed">26351699</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg DS, Sawaya MR. Structural Studies of Amyloid Proteins at the Molecular Level. Annual review of biochemistry. 2017 Jan 03;</Citation><ArticleIdList><ArticleId IdType="pubmed">28125289</ArticleId></ArticleIdList></Reference><Reference><Citation>Colvin MT, et al. Atomic Resolution Structure of Monomorphic A&#x3b2;42 Amyloid Fibrils. J Am Chem Soc. 2016 Aug 03;138:9663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389415</ArticleId><ArticleId IdType="pubmed">27355699</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;tz AK, et al. Atomic-resolution three-dimensional structure of amyloid &#x3b2; fibrils bearing the Osaka mutation. Angew Chem Int Ed Engl. 2015 Jan 02;54:331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502972</ArticleId><ArticleId IdType="pubmed">25395337</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xe4;lti MA, et al. Atomic-resolution structure of a disease-relevant A&#x3b2;(1-42) amyloid fibril. Proc Natl Acad Sci U S A. 2016 Aug 23;113:E4976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003276</ArticleId><ArticleId IdType="pubmed">27469165</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, et al. A&#x3b2;(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease. Nat Struct Mol Biol. 2015 Jun;22:499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4476499</ArticleId><ArticleId IdType="pubmed">25938662</ArticleId></ArticleIdList></Reference><Reference><Citation>Luhrs T, et al. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A. 2005 Nov 29;102:17342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1297669</ArticleId><ArticleId IdType="pubmed">16293696</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer's disease. Nature. 2017 Jul 13;547:185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang W, Yau WM, Lu JX, Collinge J, Tycko R. Structural variation in amyloid-beta fibrils from Alzheimer's disease clinical subtypes. Nature. 2017 Jan 12;541:217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233555</ArticleId><ArticleId IdType="pubmed">28052060</ArticleId></ArticleIdList></Reference><Reference><Citation>DePace AH, Weissman JS. Origins and kinetic consequences of diversity in Sup35 yeast prion fibers. Nat Struct Biol. 2002 May;9:389.</Citation><ArticleIdList><ArticleId IdType="pubmed">11938354</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue Y, Kishimoto A, Hirao J, Yoshida M, Taguchi H. Strong growth polarity of yeast prion fiber revealed by single fiber imaging. J Biol Chem. 2001 Sep 21;276:35227.</Citation><ArticleIdList><ArticleId IdType="pubmed">11473105</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, et al. Interprotofilament interactions between Alzheimer's Abeta1-42 peptides in amyloid fibrils revealed by cryoEM. Proc Natl Acad Sci U S A. 2009 Mar 24;106:4653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2660777</ArticleId><ArticleId IdType="pubmed">19264960</ArticleId></ArticleIdList></Reference><Reference><Citation>Brener O, et al. QIAD assay for quantitating a compound's efficacy in elimination of toxic A&#x3b2; oligomers. Sci Rep. 2015 Sep 23;5 13222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4585794</ArticleId><ArticleId IdType="pubmed">26394756</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohn M, et al. SPARX, a new environment for Cryo-EM image processing. Journal of structural biology. 2007 Jan;157:47.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931051</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G, et al. EMAN2: an extensible image processing suite for electron microscopy. Journal of structural biology. 2007 Jan;157:38.</Citation><ArticleIdList><ArticleId IdType="pubmed">16859925</ArticleId></ArticleIdList></Reference><Reference><Citation>Penczek PA, et al. CTER-rapid estimation of CTF parameters with error assessment. Ultramicroscopy. 2014 May;140:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016771</ArticleId><ArticleId IdType="pubmed">24562077</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta crystallographica. Section D, Biological crystallography. 2010 Apr;66:486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta crystallographica. Section D, Biological crystallography. 2010 Feb;66:213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine PV, et al. Towards automated crystallographic structure refinement with phenix.refine. Acta crystallographica. Section D, Biological crystallography. 2012 Apr;68:352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322595</ArticleId><ArticleId IdType="pubmed">22505256</ArticleId></ArticleIdList></Reference><Reference><Citation>Echols N, et al. Graphical tools for macromolecular crystallography in PHENIX. Journal of applied crystallography. 2012 Jun 01;45:581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3359726</ArticleId><ArticleId IdType="pubmed">22675231</ArticleId></ArticleIdList></Reference><Reference><Citation>Heise H, et al. Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. Proc Natl Acad Sci U S A. 2005 Nov 01;102:15871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1276071</ArticleId><ArticleId IdType="pubmed">16247008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohwy M, Rienstra CM, Jaroniec CP, Griffin RG. Fivefold symmetric homonuclear dipolar recoupling in rotating solids: Application to double quantum spectroscopy. J Chem Phys. 1999 Apr 22;110:7983.</Citation></Reference><Reference><Citation>Baldus M, Petkova AT, Herzfeld J, Griffin RG. Cross polarization in the tilted frame: assignment and spectral simplification in heteronuclear spin systems. Mol Phys. 1998 Dec 20;95:1197.</Citation></Reference><Reference><Citation>Takegoshi K, Nakamura S, Terao T. 13C-1H dipolar-assisted rotational resonance in magic-angle spinning NMR. Chemical Physics Letters. 2001;344:631.</Citation></Reference><Reference><Citation>Shi C, et al. BSH-CP based 3D solid-state NMR experiments for protein resonance assignment. J Biomol NMR. 2014 May 01;59:15. 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">24584701</ArticleId></ArticleIdList></Reference><Reference><Citation>Verel R, Ernst M, Meier BH. Adiabatic dipolar recoupling in solid-state NMR: The DREAM scheme. J Magn Reson. 2001 May;150:81.</Citation><ArticleIdList><ArticleId IdType="pubmed">11330986</ArticleId></ArticleIdList></Reference><Reference><Citation>De Paepe G, Lewandowski JR, Loquet A, Bockmann A, Griffin RG. Proton assisted recoupling and protein structure determination. J Chem Phys. 2008 Dec 28;129</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755343</ArticleId><ArticleId IdType="pubmed">19123534</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung BM, Khitrin AK, Ermolaev K. An improved broadband decoupling sequence for liquid crystals and solids. J Magn Reson. 2000 Jan;142:97.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617439</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaglio F, et al. NMRpipe - a multidimensional spectral processing system based on unix pipes. J Biomol NMR. 1995 Nov;6:277.</Citation><ArticleIdList><ArticleId IdType="pubmed">8520220</ArticleId></ArticleIdList></Reference><Reference><Citation>Skinner SP, et al. CcpNmr AnalysisAssign: a flexible platform for integrated NMR analysis. J Biomol NMR. 2016;66:111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5095159</ArticleId><ArticleId IdType="pubmed">27663422</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzinger S, Kroon GJA, Foss TR, Wright PE, Dyson HJ. Random coil chemical shifts in acidic 8 M urea: Implementation of random coil shift data in NMRView. J Biomol NMR. 2000;18:43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11061227</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SH, Hong M. Protonation, Tautomerization, and Rotameric Structure of Histidine: A Comprehensive Study by Magic-Angle-Spinning Solid-State NMR. Journal of the American Chemical Society. 2011 Feb;133:1534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4082993</ArticleId><ArticleId IdType="pubmed">21207964</ArticleId></ArticleIdList></Reference><Reference><Citation>Keim P, Vigna RA, Morrow JS, Marshall RC, Gurd FRN. C-13 Nuclear Magnetic-Resonance of Pentapeptides of Glycine Containing Central Residues of Serine, Threonine, Aspartic and Glutamic Acids, Asparagine, and Glutamine. Journal of Biological Chemistry. 1973;248:7811.</Citation><ArticleIdList><ArticleId IdType="pubmed">4750428</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris KL, Serpell LC. X-ray fibre diffraction studies of amyloid fibrils. Methods in molecular biology. 2012;849:121.</Citation><ArticleIdList><ArticleId IdType="pubmed">22528087</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammersley A. FIT2D V9.129 Reference Manual V3.1. 1998</Citation></Reference><Reference><Citation>Winn MD, et al. Overview of the CCP4 suite and current developments. Acta crystallographica. Section D, Biological crystallography. 2011 Apr;67:235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069738</ArticleId><ArticleId IdType="pubmed">21460441</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, et al. Amyloid structure exhibits polymorphism on multiple length scales in human brain tissue. Scientific reports. 2016 Sep 15;6 33079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024092</ArticleId><ArticleId IdType="pubmed">27629394</ArticleId></ArticleIdList></Reference><Reference><Citation>Perutz MF, Staden R, Moens L, De Baere I. Polar zippers. Current biology : CB. 1993 May 01;3:249.</Citation><ArticleIdList><ArticleId IdType="pubmed">15335744</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28904096</PMID><DateCompleted><Year>2018</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>41</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>RIPK1 mediates a disease-associated microglial response in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>E8788</StartPage><EndPage>E8797</EndPage><MedlinePgn>E8788-E8797</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1714175114</ELocationID><Abstract><AbstractText>Dysfunction of microglia is known to play an important role in Alzheimer's disease (AD). Here, we investigated the role of RIPK1 in microglia mediating the pathogenesis of AD. RIPK1 is highly expressed by microglial cells in human AD brains. Using the amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic mouse model, we found that inhibition of RIPK1, using both pharmacological and genetic means, reduced amyloid burden, the levels of inflammatory cytokines, and memory deficits. Furthermore, inhibition of RIPK1 promoted microglial degradation of A&#x3b2; in vitro. We characterized the transcriptional profiles of adult microglia from APP/PS1 mice and identified a role for RIPK1 in regulating the microglial expression of <i>CH25H</i> and <i>Cst7</i>, a marker for disease-associated microglia (DAM), which encodes an endosomal/lysosomal cathepsin inhibitor named Cystatin F. We present evidence that RIPK1-mediated induction of Cst7 leads to an impairment in the lysosomal pathway. These data suggest that RIPK1 may mediate a critical checkpoint in the transition to the DAM state. Together, our study highlights a non-cell death mechanism by which the activation of RIPK1 mediates the induction of a DAM phenotype, including an inflammatory response and a reduction in phagocytic activity, and connects RIPK1-mediated transcription in microglia to the etiology of AD. Our results support that RIPK1 is an important therapeutic target for the treatment of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ofengeim</LastName><ForeName>Dimitry</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzitelli</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeWitt</LastName><ForeName>Judy Park</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mifflin</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Chengyu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Sudeshna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Cambridge, MA 02139.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adiconis</LastName><ForeName>Xian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Broad Institute, Cambridge, MA 02142.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hongbo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelliher</LastName><ForeName>Michelle A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Joshua Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Broad Institute, Cambridge, MA 02142.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Junying</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115; jyuan@hms.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG047231</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI075118</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS082257</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C580804">presenilin 1, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C506249">RIPK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D053422">Receptor-Interacting Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C506251">Ripk1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):10813-10814. doi: 10.1073/pnas.1715241114.</RefSource><PMID Version="1">28973950</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053422" MajorTopicYN="N">Receptor-Interacting Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">RIP1</Keyword><Keyword MajorTopicYN="N">RIPK1</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">microglia</Keyword></KeywordList><CoiStatement>Conflict of interest statement: Denali Therapeutics has licensed the Necrostatin program (including Nec-1s) from Harvard Medical School. J.Y. is a consultant of Denali Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>4</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28904096</ArticleId><ArticleId IdType="pmc">PMC5642727</ArticleId><ArticleId IdType="doi">10.1073/pnas.1714175114</ArticleId><ArticleId IdType="pii">1714175114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mandrekar-Colucci S, Landreth GE. Microglia and inflammation in Alzheimer&#x2019;s disease. CNS Neurol Disord Drug Targets. 2010;9:156&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653290</ArticleId><ArticleId IdType="pubmed">20205644</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Goate AM. Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77:43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Abduljaleel Z, et al. Evidence of trem2 variant associated with triple risk of Alzheimer&#x2019;s disease. PLoS One. 2014;9:e92648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963925</ArticleId><ArticleId IdType="pubmed">24663666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. CHARGE consortium. EADI1 consortium Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet. 2011;43:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. European Alzheimer&#x2019;s Disease Initiative (EADI) Genetic and Environmental Risk in Alzheimer&#x2019;s Disease. Alzheimer&#x2019;s Disease Genetic Consortium. Cohorts for Heart and Aging Research in Genomic Epidemiology Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollmer MA. Cholesterol-related genes in Alzheimer&#x2019;s disease. Biochim Biophys Acta. 2010;1801:762&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">20580938</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2003;74:1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738668</ArticleId><ArticleId IdType="pubmed">12933918</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitz TM, Town T. Microglia in Alzheimer&#x2019;s disease: It&#x2019;s all about context. Int J Alzheimers Dis. 2012;2012:314185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388286</ArticleId><ArticleId IdType="pubmed">22779026</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) 2010;117:949&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653296</ArticleId><ArticleId IdType="pubmed">20552234</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho MH, et al. Autophagy in microglia degrades extracellular &#x3b2;-amyloid fibrils and regulates the NLRP3 inflammasome. Autophagy. 2014;10:1761&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4198361</ArticleId><ArticleId IdType="pubmed">25126727</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton G, Colbert JD, Schuettelkopf AW, Watts C. Cystatin F is a cathepsin C-directed protease inhibitor regulated by proteolysis. EMBO J. 2008;27:499&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2241651</ArticleId><ArticleId IdType="pubmed">18256700</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofengeim D, Yuan J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat Rev Mol Cell Biol. 2013;14:727&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">24129419</ArticleId></ArticleIdList></Reference><Reference><Citation>Polykratis A, et al. Cutting edge: RIPK1 kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo. J Immunol. 2014;193:1539&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4119562</ArticleId><ArticleId IdType="pubmed">25015821</ArticleId></ArticleIdList></Reference><Reference><Citation>Shutinoski B, et al. K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo. Cell Death Differ. 2016;23:1628&#x2013;1637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5041191</ArticleId><ArticleId IdType="pubmed">27258786</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng X, et al. Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett. 2005;15:5039&#x2013;5044.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153840</ArticleId></ArticleIdList></Reference><Reference><Citation>Degterev A, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">16408008</ArticleId></ArticleIdList></Reference><Reference><Citation>Degterev A, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4:313&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5434866</ArticleId><ArticleId IdType="pubmed">18408713</ArticleId></ArticleIdList></Reference><Reference><Citation>Christofferson DE, et al. A novel role for RIP1 kinase in mediating TNF&#x3b1; production. Cell Death Dis. 2012;3:e320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388236</ArticleId><ArticleId IdType="pubmed">22695613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353:603&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444917</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofengeim D, et al. Activation of necroptosis in multiple sclerosis. Cell Rep. 2015;10:1836&#x2013;1849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4494996</ArticleId><ArticleId IdType="pubmed">25801023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondylis V, Kumari S, Vlantis K, Pasparakis M. The interplay of IKK, NF-&#x3ba;B and RIPK1 signaling in the regulation of cell death, tissue homeostasis and inflammation. Immunol Rev. 2017;277:113&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">28462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Yuan J. Necroptosis in health and diseases. Semin Cell Dev Biol. 2014;35:14&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">25087983</ArticleId></ArticleIdList></Reference><Reference><Citation>Magister S, Kos J. Cystatins in immune system. J Cancer. 2013;4:45&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564246</ArticleId><ArticleId IdType="pubmed">23386904</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger SB, et al. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol. 2014;192:5476&#x2013;5480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4048763</ArticleId><ArticleId IdType="pubmed">24821972</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol. 1999;19:223&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471976</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillit H, et al. Elevated circulating tumor necrosis factor levels in Alzheimer&#x2019;s disease. Neurosci Lett. 1991;129:318&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">1745413</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost JL, et al. An anti-pyroglutamate-3 A&#x3b2; vaccine reduces plaques and improves cognition in APPswe/PS1&#x394;E9 mice. Neurobiol Aging. 2015;36:3187&#x2013;3199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641825</ArticleId><ArticleId IdType="pubmed">26453001</ArticleId></ArticleIdList></Reference><Reference><Citation>Audrain M, et al. Alzheimer&#x2019;s disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression. Mol Neurodegener. 2016;11:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4709894</ArticleId><ArticleId IdType="pubmed">26759118</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong H, et al. Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer&#x2019;s disease. Neurosci Bull. 2011;27:221&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5560305</ArticleId><ArticleId IdType="pubmed">21788993</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy CM, et al. Caspase-2 mediates neuronal cell death induced by beta-amyloid. J Neurosci. 2000;20:1386&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772358</ArticleId><ArticleId IdType="pubmed">10662829</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa T, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature. 2000;403:98&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">10638761</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron R, Babcock AA, Nemirovsky A, Finsen B, Monsonego A. Accelerated microglial pathology is associated with A&#x3b2; plaques in mouse models of Alzheimer&#x2019;s disease. Aging Cell. 2014;13:584&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326940</ArticleId><ArticleId IdType="pubmed">24641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, et al. Single App knock-in mouse models of Alzheimer&#x2019;s disease. Nat Neurosci. 2014;17:661&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Riederer BM, Leuba G, Vernay A, Riederer IM. The role of the ubiquitin proteasome system in Alzheimer&#x2019;s disease. Exp Biol Med (Maywood) 2011;236:268&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">21383047</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, et al. Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer&#x2019;s disease. Neurodegener Dis. 2005;2:233&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909003</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 2013;4:385&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, et al. Microglial cystatin F expression is a sensitive indicator for ongoing demyelination with concurrent remyelination. J Neurosci Res. 2011;89:639&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">21344476</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuvolone M, et al. Cystatin F is a biomarker of prion pathogenesis in mice. PLoS One. 2017;12:e0171923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5298286</ArticleId><ArticleId IdType="pubmed">28178353</ArticleId></ArticleIdList></Reference><Reference><Citation>Colbert JD, Plechanovov&#xe1; A, Watts C. Glycosylation directs targeting and activation of cystatin f from intracellular and extracellular sources. Traffic. 2009;10:425&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691902</ArticleId><ArticleId IdType="pubmed">19192250</ArticleId></ArticleIdList></Reference><Reference><Citation>Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989;24:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">2808689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak RE. Microglia in Alzheimer brain: A neuropathological perspective. Int J Alzheimers Dis. 2012;2012:165021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3359674</ArticleId><ArticleId IdType="pubmed">22655212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedgwick JD, et al. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci USA. 1991;88:7438&#x2013;7442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC52311</ArticleId><ArticleId IdType="pubmed">1651506</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J Exp Med. 2015;212:287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Fran&#xe7;ois A, et al. Involvement of interleukin-1&#x3b2; in the autophagic process of microglia: Relevance to Alzheimer&#x2019;s disease. J Neuroinflammation. 2013;10:151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3878742</ArticleId><ArticleId IdType="pubmed">24330807</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CN, et al. Mechanism mediating oligomeric A&#x3b2; clearance by na&#xef;ve primary microglia. Neurobiol Dis. 2011;42:221&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">21220023</ArticleId></ArticleIdList></Reference><Reference><Citation>Malm TM, Jay TR, Landreth GE. The evolving biology of microglia in Alzheimer&#x2019;s disease. Neurotherapeutics. 2015;12:81&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322081</ArticleId><ArticleId IdType="pubmed">25404051</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer&#x2019;s disease amyloid hypothesis: A genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>van Leeuwen FW, et al. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer&#x2019;s and Down patients. Science. 1998;279:242&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">9422699</ArticleId></ArticleIdList></Reference><Reference><Citation>McBrayer M, Nixon RA. Lysosome and calcium dysregulation in Alzheimer&#x2019;s disease: Partners in crime. Biochem Soc Trans. 2013;41:1495&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960943</ArticleId><ArticleId IdType="pubmed">24256243</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">20234358</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton K, et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science. 2014;343:1357&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pubmed">24557836</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">9150132</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspina A, Kaushik N, de Belleroche J. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J Neurochem. 2001;77:132&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279269</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanke F, et al. EBI2 is highly expressed in multiple sclerosis lesions and promotes early CNS migration of encephalitogenic CD4 T cells. Cell Rep. 2017;18:1270&#x2013;1284.</Citation><ArticleIdList><ArticleId IdType="pubmed">28147280</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold ES, et al. 25-hydroxycholesterol acts as an amplifier of inflammatory signaling. Proc Natl Acad Sci USA. 2014;111:10666&#x2013;10671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115544</ArticleId><ArticleId IdType="pubmed">24994901</ArticleId></ArticleIdList></Reference><Reference><Citation>Lathe R, Sapronova A, Kotelevtsev Y. Atherosclerosis and Alzheimer&#x2013;Diseases with a common cause? Inflammation, oxysterols, vasculature. BMC Geriatr. 2014;14:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3994432</ArticleId><ArticleId IdType="pubmed">24656052</ArticleId></ArticleIdList></Reference><Reference><Citation>Karunakaran D, et al. Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci Adv. 2016;2:e1600224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4985228</ArticleId><ArticleId IdType="pubmed">27532042</ArticleId></ArticleIdList></Reference><Reference><Citation>Magister S, et al. Regulation of cathepsins S and L by cystatin F during maturation of dendritic cells. Eur J Cell Biol. 2012;91:391&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">22365146</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher K, Konjar S, Watts C, Turk B, Kopitar-Jerala N. Cystatin F regulates proteinase activity in IL-2-activated natural killer cells. Protein Pept Lett. 2014;21:957&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">24702263</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DS, et al. Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimer disease by enhancing lysosomal proteolysis. Autophagy. 2011;7:788&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3359468</ArticleId><ArticleId IdType="pubmed">21464620</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre M, et al. Isolation of glia from Alzheimer&#x2019;s mice reveals inflammation and dysfunction. Neurobiol Aging. 2014;35:2746&#x2013;2760.</Citation><ArticleIdList><ArticleId IdType="pubmed">25002035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtman IR, et al. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: A co-expression meta-analysis. Acta Neuropathol Commun. 2015;3:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4489356</ArticleId><ArticleId IdType="pubmed">26001565</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16:1896&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28873124</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Trends in Dementia Incidence in a Birth Cohort Analysis of the Einstein Aging Study.</ArticleTitle><Pagination><StartPage>1345</StartPage><EndPage>1351</EndPage><MedlinePgn>1345-1351</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.1964</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Trends in dementia incidence rates have important implications for planning and prevention. To better understand incidence trends over time requires separation of age and cohort effects, and few prior studies have used this approach.</AbstractText><AbstractText Label="OBJECTIVES">To examine trends in dementia incidence and concomitant trends in cardiovascular comorbidities among individuals aged 70 years or older who were enrolled in the Einstein Aging Study between 1993 and 2015.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In this birth cohort analysis of all-cause dementia incidence in persons enrolled in the Einstein Aging Study from October 20, 1993, through November 17, 2015, a systematically recruited, population-based sample of 1348 participants from Bronx County, New York, who were 70 years or older without dementia at enrollment and at least one annual follow-up was studied. Poisson regression was used to model dementia incidence as a function of age, sex, educational level, race, and birth cohort, with profile likelihood used to identify the timing of significant increases or decreases in incidence.</AbstractText><AbstractText Label="EXPOSURES">Birth year and age.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Incident dementia defined by consensus case conference based on annual, standardized neuropsychological and neurologic examination findings, using criteria from the DSM-IV.</AbstractText><AbstractText Label="RESULTS">Among 1348 individuals (mean [SD] baseline age, 78.5 [5.4] years; 830 [61.6%] female; 915 [67.9%] non-Hispanic white), 150 incident dementia cases developed during 5932 person-years (mean [SD] follow-up, 4.4 [3.4] years). Dementia incidence decreased in successive birth cohorts. Incidence per 100 person-years was 5.09 in birth cohorts before 1920, 3.11 in the 1920 through 1924 birth cohorts, 1.73 in the 1925 through 1929 birth cohorts, and 0.23 in cohorts born after 1929. Change point analyses identified a significant decrease in dementia incidence among those born after July 1929 (95% CI, June 1929 to January 1930). The relative rate for birth cohorts before July 1929 vs after was 0.13 (95% CI, 0.04-0.41). Prevalence of stroke and myocardial infarction decreased across successive birth cohorts, whereas diabetes prevalence increased. Adjustment for these cardiovascular comorbidities did not explain the decreased dementia incidence rates for more recent birth cohorts.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Analyses confirm decreasing dementia incidence in this population-based sample. Whether decreasing incidence will contribute to reduced burden of dementia given the aging of the population is not known.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Derby</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Mindy J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Charles B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001073</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009519" MajorTopicYN="N">New York City</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Derby reported receiving grants from the National Institute on Aging during the conduct of the study and personal fees from the National Institutes of Health for reviewing proposals outside the submitted work. Ms Katz reported receiving grant support from Eli Lilly and Company outside the submitted work. Dr Lipton reported receiving grants from the National Institutes of Health during the conduct of the study and from the National Headache Foundation and Boston Scientific; serving on the editorial board of <i>Neurology</i> and as a senior adviser to <i>Headache</i>; reviewing for the National Institute on Aging and the National Institute of Neurological Disorders and Stroke; holding stock options in eNeura Therapeutics; serving as a consultant or advisory board member or receiving honoraria from Alder, Allergan, the American Headache Society, Amgen, Autonomic Technologies, Avanir, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, CoLucid, Dr. Reddy&#x2019;s, ElectroCore, Eli Lilly and Company, eNeura Therapeutics, Merck, Novartis, Pfizer, Teva, and Vedanta; and receiving royalties from <i>Wolff&#x2019;s Headache and Other Head Pain, 8th Edition</i> and Informa. Dr Hall reported conducting data analyses for this project and receiving grants from the National Institute on Aging during the conduct of the study, personal fees from the National Institutes of Health, personal fees from Washington University, St Louis, personal fees from University of Cincinnati, grants from the National Institute on Aging, grants and other support from the National Institute for Occupational Safety and Health, grants from the National Cancer Institute, and grants from National Center for Advancing Translational Sciences outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>11</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28873124</ArticleId><ArticleId IdType="pmc">PMC5710583</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.1964</ArticleId><ArticleId IdType="pii">2650659</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>United Nations  World population prospects: the 2010.  revision. https://esa.un.org/unpd/wpp/Publications/Files/WPP2017_KeyFindings.pdf. Updated 2016. Accessed June 1, 2017.</Citation></Reference><Reference><Citation>World Health Organization; Alzheimer&#x2019;s Disease International . Dementia: A Public Health Priority. Geneva, Switzerland: World Health Organization; 2012.</Citation></Reference><Reference><Citation>Langa KM. Is the risk of Alzheimer&#x2019;s disease and dementia declining? Alzheimers Res Ther. 2015;7(1):34. doi:10.1186/s13195-015-0118-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-015-0118-1</ArticleId><ArticleId IdType="pmc">PMC4374373</ArticleId><ArticleId IdType="pubmed">25815064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokmen E, Chandra V, Schoenberg BS. Trends in incidence of dementing illness in Rochester, Minnesota, in three quinquennial periods, 1960-1974. Neurology. 1988;38(6):975-980.</Citation><ArticleIdList><ArticleId IdType="pubmed">3368079</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokmen E, Beard CM, O&#x2019;Brien PC, Offord KP, Kurland LT. Is the incidence of dementing illness changing? a 25-year time trend study in Rochester, Minnesota (1960-1984). Neurology. 1993;43(10):1887-1892.</Citation><ArticleIdList><ArticleId IdType="pubmed">8413943</ArticleId></ArticleIdList></Reference><Reference><Citation>Rorsman B, Hagnell O, Lanke J. Prevalence and incidence of senile and multi-infarct dementia in the Lundby study: a comparison between the time periods 1947-1957 and 1957-1972. Neuropsychobiology. 1986;15(3-4):122-129.</Citation><ArticleIdList><ArticleId IdType="pubmed">3785641</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Petersen RC, Knopman DS, et al. . Trends in the incidence and prevalence of Alzheimer&#x2019;s disease, dementia, and cognitive impairment in the United States. Alzheimers Dement. 2011;7(1):80-93. doi:10.1016/j.jalz.2010.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.11.002</ArticleId><ArticleId IdType="pmc">PMC3026476</ArticleId><ArticleId IdType="pubmed">21255746</ArticleId></ArticleIdList></Reference><Reference><Citation>Satizabal CL, Beiser AS, Chouraki V, Ch&#xea;ne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med. 2016;374(6):523-532. doi:10.1056/NEJMoa1504327</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1504327</ArticleId><ArticleId IdType="pmc">PMC4943081</ArticleId><ArticleId IdType="pubmed">26863354</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining? trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012;78(19):1456-1463. doi:10.1212/WNL.0b013e3182553be6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182553be6</ArticleId><ArticleId IdType="pubmed">22551732</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulrahman GO., Jnr Alzheimer&#x2019;s disease: current trends in Wales. Oman Med J. 2014;29(4):280-284. doi:10.5001/omj.2014.73</Citation><ArticleIdList><ArticleId IdType="doi">10.5001/omj.2014.73</ArticleId><ArticleId IdType="pmc">PMC4137586</ArticleId><ArticleId IdType="pubmed">25170410</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol. 2015;12(5):267-277. doi:10.1038/nrcardio.2014.223</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2014.223</ArticleId><ArticleId IdType="pubmed">25583619</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer&#x2019;s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788-794. doi:10.1016/S1474-4422(14)70136-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70136-X</ArticleId><ArticleId IdType="pubmed">25030513</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz MJ, Lipton RB, Hall CB, et al. . Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites: a report from the Einstein Aging Study. Alzheimer Dis Assoc Disord. 2012;26(4):335-343. doi:10.1097/WAD.0b013e31823dbcfc</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e31823dbcfc</ArticleId><ArticleId IdType="pmc">PMC3334445</ArticleId><ArticleId IdType="pubmed">22156756</ArticleId></ArticleIdList></Reference><Reference><Citation>US Census Bureau  American FactFinder. http://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml?_ts=498596416732. Accessed January 1, 2011.</Citation></Reference><Reference><Citation>Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114(512):797-811.</Citation><ArticleIdList><ArticleId IdType="pubmed">5662937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS); recent evidence and development of a shorter version In: Brink TL, ed. Clinical Gerontology: A Guide to Assessment and Intervention. New York, NY: Haworth Press; 1986:165-173.</Citation></Reference><Reference><Citation>Fahn S, Elton R. Unified Parkinson&#x2019;s Disease Rating Scale In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson&#x2019;s Disease. Vol 2 Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.</Citation></Reference><Reference><Citation>Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia: a cause of mental deterioration in the elderly. Lancet . 1974;2(7874):207-210.</Citation><ArticleIdList><ArticleId IdType="pubmed">4135618</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Associaiton Diagnostic and Statistical Manual of Mental Disorders. 4th ed Washington, DC: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>Wechsler D. Memory Scale - Revised. New York, NY: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Buschke H. Cued recall in amnesia. J Clin Neuropsychol. 1984;6(4):433-440.</Citation><ArticleIdList><ArticleId IdType="pubmed">6501581</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179-186.</Citation><ArticleIdList><ArticleId IdType="pubmed">5349366</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland WS, Devlin SJ. Locally weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc. 1988;83(403):596-610.</Citation></Reference><Reference><Citation>Hastie TJ, Tibshirani RJ. Generalized Additive Models. London, England: Chapman &amp; Hall/CRC; 1990.</Citation></Reference><Reference><Citation>Hall CB, Lipton RB, Sliwinski M, Stewart WF. A change point model for estimating the onset of cognitive decline in preclinical Alzheimer&#x2019;s disease. Stat Med. 2000;19(11-12):1555-1566. doi:10.1002/(SICI)1097-0258(20000615/30)19:11/123.0.CO;2-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(20000615/30)19:11/123.0.CO;2-3</ArticleId><ArticleId IdType="pubmed">10844718</ArticleId></ArticleIdList></Reference><Reference><Citation>Koton S, Schneider AL, Rosamond WD, et al. . Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA. 2014;312(3):259-268. doi:10.1001/jama.2014.7692</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.7692</ArticleId><ArticleId IdType="pubmed">25027141</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosamond W, Flegal K, Furie K, et al. . Heart disease and stroke statistics&#x2014;2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-e146.</Citation><ArticleIdList><ArticleId IdType="pubmed">18086926</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Yan F, Li G, et al. . Is the dementia rate increasing in Beijing? prevalence and incidence of dementia 10 years later in an urban elderly population. Acta Psychiatr Scand. 2007;115(1):73-79.</Citation><ArticleIdList><ArticleId IdType="pubmed">17201869</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Bienias JL, Aggarwal NT, et al. . Change in risk of Alzheimer disease over time. Neurology. 2010;75(9):786-791. doi:10.1212/WNL.0b013e3181f0754f</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181f0754f</ArticleId><ArticleId IdType="pmc">PMC2938969</ArticleId><ArticleId IdType="pubmed">20805524</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge HH, Zhu J, Lee CW, Chang CC, Ganguli M. Cohort effects in age-associated cognitive trajectories. J Gerontol A Biol Sci Med Sci. 2014;69(6):687-694. doi:10.1093/gerona/glt181</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glt181</ArticleId><ArticleId IdType="pmc">PMC4022091</ArticleId><ArticleId IdType="pubmed">24270062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y. The recent decline in prevalence of dementia in developed countries: implications for prevention in the Republic of Korea. J Korean Med Sci. 2014;29(7):913-918. doi:10.3346/jkms.2014.29.7.913</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2014.29.7.913</ArticleId><ArticleId IdType="pmc">PMC4101778</ArticleId><ArticleId IdType="pubmed">25045222</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YT, Fratiglioni L, Matthews FE, et al. . Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol. 2016;15(1):116-124. doi:10.1016/S1474-4422(15)00092-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00092-7</ArticleId><ArticleId IdType="pubmed">26300044</ArticleId></ArticleIdList></Reference><Reference><Citation>Daviglus ML, Bell CC, Berrettini W, et al. . National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline. Ann Intern Med. 2010;153(3):176-181. doi:10.7326/0003-4819-153-3-201008030-00260</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-3-201008030-00260</ArticleId><ArticleId IdType="pubmed">20547888</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, von Strauss E, B&#xe4;ckman L, Winblad B, Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology. 2013;80(20):1888-1894. doi:10.1212/WNL.0b013e318292a2f9</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318292a2f9</ArticleId><ArticleId IdType="pubmed">23596063</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosteniuk JG, Morgan DG, O&#x2019;Connell ME, et al. . Simultaneous temporal trends in dementia incidence and prevalence, 2005-2013: a population-based retrospective cohort study in Saskatchewan, Canada. Int Psychogeriatr. 2016;28(10):1643-1658. doi:10.1017/S1041610216000818</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610216000818</ArticleId><ArticleId IdType="pubmed">27352934</ArticleId></ArticleIdList></Reference><Reference><Citation>NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513-1530. doi:10.1016/S0140-6736(16)00618-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00618-8</ArticleId><ArticleId IdType="pmc">PMC5081106</ArticleId><ArticleId IdType="pubmed">27061677</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukull WA, Higdon R, Bowen JD, et al. . Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002;59(11):1737-1746.</Citation><ArticleIdList><ArticleId IdType="pubmed">12433261</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28959956</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>549</Volume><Issue>7673</Issue><PubDate><Year>2017</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.</ArticleTitle><Pagination><StartPage>523</StartPage><EndPage>527</EndPage><MedlinePgn>523-527</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature24016</ELocationID><Abstract><AbstractText>APOE4 is the strongest genetic risk factor for late-onset Alzheimer disease. ApoE4 increases brain amyloid-&#x3b2; pathology relative to other ApoE isoforms. However, whether APOE independently influences tau pathology, the other major proteinopathy of Alzheimer disease and other tauopathies, or tau-mediated neurodegeneration, is not clear. By generating P301S tau transgenic mice on either a human ApoE knock-in (KI) or ApoE knockout (KO) background, here we show that P301S/E4 mice have significantly higher tau levels in the brain and a greater extent of somatodendritic tau redistribution by three months of age compared with P301S/E2, P301S/E3, and P301S/EKO mice. By nine months of age, P301S mice with different ApoE genotypes display distinct phosphorylated tau protein (p-tau) staining patterns. P301S/E4 mice develop markedly more brain atrophy and neuroinflammation than P301S/E2 and P301S/E3 mice, whereas P301S/EKO mice are largely protected from these changes. In vitro, E4-expressing microglia exhibit higher innate immune reactivity after lipopolysaccharide treatment. Co-culturing P301S tau-expressing neurons with E4-expressing mixed glia results in a significantly higher level of tumour-necrosis factor-&#x3b1; (TNF-&#x3b1;) secretion and markedly reduced neuronal viability compared with neuron/E2 and neuron/E3 co-cultures. Neurons co-cultured with EKO glia showed the greatest viability with the lowest level of secreted TNF-&#x3b1;. Treatment of P301S neurons with recombinant ApoE (E2, E3, E4) also leads to some neuronal damage and death compared with the absence of ApoE, with ApoE4 exacerbating the effect. In individuals with a sporadic primary tauopathy, the presence of an &#x3b5;4 allele is associated with more severe regional neurodegeneration. In individuals who are positive for amyloid-&#x3b2; pathology with symptomatic Alzheimer disease who usually have tau pathology, &#x3b5;4-carriers demonstrate greater rates of disease progression. Our results demonstrate that ApoE affects tau pathogenesis, neuroinflammation, and tau-mediated neurodegeneration independently of amyloid-&#x3b2; pathology. ApoE4 exerts a 'toxic' gain of function whereas the absence of ApoE is protective.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liddelow</LastName><ForeName>Shane Antony</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, School of Medicine, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, The University of Melbourne, Melbourne, Parkville, Victoria 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Scott T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Lingzhi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, New York, New York 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, New York, New York 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, California 94143 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, California 94143 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, California 94143 USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas</LastName><ForeName>Julio C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, California 94143 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallardo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kairuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roh</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Missouri School of Medicine, Columbia, Missouri 65212, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University Medical Center, Durham Veterans Health Administration Medical Center's Geriatric Research, Education and Clinical Center, Durham, North Carolina 27705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baufeld</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>AstraZeneca R&amp;D, Wilmington, Delaware 19850, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutphen</LastName><ForeName>Courtney</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCue</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University in St Louis, St Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University in St Louis, St Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del-Aguila</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Avenue B8134, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Avenue B8134, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Developmental Biology, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, California 94143 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, California 94143 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, California 94143 USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butovsky</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Evergrande Center for Immunologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barres</LastName><ForeName>Ben A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, School of Medicine, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Voyager Therapeutics, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG052648</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG051812</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088137</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG055688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054672</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 NS096719</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2017 Dec;13(12):706-707. doi: 10.1038/nrneurol.2017.145.</RefSource><PMID Version="1">28984314</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2017 Oct 18;18(11):641. doi: 10.1038/nrn.2017.131.</RefSource><PMID Version="1">29042688</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28959956</ArticleId><ArticleId IdType="mid">NIHMS910420</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pii">nature24016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor perspectives in medicine. 2012;2 doi: 10.1101/cshperspect.a006312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006312</ArticleId><ArticleId IdType="pmc">PMC3282491</ArticleId><ArticleId IdType="pubmed">22393530</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:1977&#x2013;1981. doi: 10.1073/pnas.90.5.1977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.5.1977</ArticleId><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, et al. &#x3b2;-Amyloid Burden Is Not Associated with Rates of Brain Atrophy. Annals of Neurology. 2008;63:204&#x2013;212. doi: 10.1002/ana.21223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21223</ArticleId><ArticleId IdType="pmc">PMC2735194</ArticleId><ArticleId IdType="pubmed">17894374</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedleywhyte ET, Hyman BT. Neurofibrillary Tangles But Not Senile Plaques Parallel Duration and Severity of Alzheimers-Disease. Neurology. 1992;42:631&#x2013;639. doi: 10.1212/WNL.42.3.631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.42.3.631</ArticleId><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson&#x2019;s syndrome. Brain. 2007;130:1566&#x2013;1576. doi: 10.1093/brain/awm104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm104</ArticleId><ArticleId IdType="pubmed">17525140</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:11183&#x2013;11186. doi: 10.1073/pnas.91.23.11183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.23.11183</ArticleId><ArticleId IdType="pmc">PMC45191</ArticleId><ArticleId IdType="pubmed">7972031</ArticleId></ArticleIdList></Reference><Reference><Citation>Brecht WJ. Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice. Journal of Neuroscience. 2004;24:2527&#x2013;2534. doi: 10.1523/JNEUROSCI.4315-03.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4315-03.2004</ArticleId><ArticleId IdType="pmc">PMC6729489</ArticleId><ArticleId IdType="pubmed">15014128</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y, et al. Genome-wide association study identifies four novel loci associated with Alzheimer&#x2019;s endophenotypes and disease modifiers. Acta Neuropathol. 2017;133:839&#x2013;856. doi: 10.1007/s00401-017-1685-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1685-y</ArticleId><ArticleId IdType="pmc">PMC5613285</ArticleId><ArticleId IdType="pubmed">28247064</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra A, et al. Gene-based association studies report genetic links for clinical subtypes of frontotemporal dementia. Brain. 2017 doi: 10.1093/brain/awx066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx066</ArticleId><ArticleId IdType="pubmed">28387812</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens M, et al. Apolipoprotein E gene and sporadic frontal lobe dementia. Neurology. 1997;48:1526&#x2013;1529.</Citation><ArticleIdList><ArticleId IdType="pubmed">9191760</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, et al. Apolipoprotein E &#x3b5;4 is associated with disease-specific effects on brain atrophy in Alzheimer&#x2019;s disease and frontotemporal dementia. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:2018&#x2013;2022. doi: 10.1073/pnas.0812697106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0812697106</ArticleId><ArticleId IdType="pmc">PMC2644156</ArticleId><ArticleId IdType="pubmed">19164761</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, et al. Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. Neurobiol Aging. 2006;27:285&#x2013;292. doi: 10.1016/j.neurobiolaging.2005.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.02.005</ArticleId><ArticleId IdType="pubmed">16399213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model. Neuron. 2007;53:337&#x2013;351. doi: 10.1016/j.neuron.2007.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonovitch S, et al. Impaired Autophagy in APOE4 Astrocytes. Journal of Alzheimer&#x2019;s Disease. 2016;51:915&#x2013;927. doi: 10.3233/JAD-151101.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-151101</ArticleId><ArticleId IdType="pubmed">26923027</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, et al. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2009;29:6771&#x2013;6779. doi: 10.1523/JNEUROSCI.0887-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0887-09.2009</ArticleId><ArticleId IdType="pmc">PMC6665579</ArticleId><ArticleId IdType="pubmed">19474305</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481&#x2013;487. doi: 10.1038/nature21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016;535:153&#x2013;158. doi: 10.1038/nature18629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18629</ArticleId><ArticleId IdType="pmc">PMC5539988</ArticleId><ArticleId IdType="pubmed">27383986</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. Neurobiology of Aging. 2009;30:1350&#x2013;1360. doi: 10.1016/j.neurobiolaging.2007.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.11.014</ArticleId><ArticleId IdType="pmc">PMC2782461</ArticleId><ArticleId IdType="pubmed">18155324</ArticleId></ArticleIdList></Reference><Reference><Citation>Gale SC, et al. APOE4 is associated with enhanced in vivo innate immune responses in human subjects. The Journal of allergy and clinical immunology. 2014;134:127&#x2013;134. doi: 10.1016/j.jaci.2014.01.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2014.01.032</ArticleId><ArticleId IdType="pmc">PMC4125509</ArticleId><ArticleId IdType="pubmed">24655576</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian JL, et al. Genomic Analysis of Reactive Astrogliosis. The Journal of Neuroscience. 2012;32:6391&#x2013;6410. doi: 10.1523/JNEUROSCI.6221-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6221-11.2012</ArticleId><ArticleId IdType="pmc">PMC3480225</ArticleId><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, et al. Allele epsilon 4 of apolipoprotein E shows a dose effect on age at onset of Pick disease. Exp Neurol. 1995;136:162&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">7498406</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, et al. Apolipoprotein E fragments present in Alzheimer&#x2019;s disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A. 2001;98:8838&#x2013;8843. doi: 10.1073/pnas.151254698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.151254698</ArticleId><ArticleId IdType="pmc">PMC37522</ArticleId><ArticleId IdType="pubmed">11447277</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, et al. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron. 2016;90:724&#x2013;739. doi: 10.1016/j.neuron.2016.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.003</ArticleId><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213:667&#x2013;675. doi: 10.1084/jem.20151948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, et al. Anti-tau antibodies that block tau aggregate seeding invitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402&#x2013;414. doi: 10.1016/j.neuron.2013.07.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.046</ArticleId><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;143. doi: 10.1038/nn.3599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3599</ArticleId><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol. 2015;77:75&#x2013;99. doi: 10.1002/ana.24304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24304</ArticleId><ArticleId IdType="pmc">PMC4432483</ArticleId><ArticleId IdType="pubmed">25381879</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinberg LT, et al. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta Neuropathol. 2013;125:581&#x2013;593. doi: 10.1007/s00401-013-1080-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1080-2</ArticleId><ArticleId IdType="pmc">PMC3692283</ArticleId><ArticleId IdType="pubmed">23371364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8:1&#x2013;13. doi: 10.1016/j.jalz.2011.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28930663</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4180</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Immunity</Title><ISOAbbreviation>Immunity</ISOAbbreviation></Journal><ArticleTitle>The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.</ArticleTitle><Pagination><StartPage>566</StartPage><EndPage>581.e9</EndPage><MedlinePgn>566-581.e9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.immuni.2017.08.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1074-7613(17)30366-7</ELocationID><Abstract><AbstractText>Microglia play a pivotal role in the maintenance of brain homeostasis but lose homeostatic function during neurodegenerative disorders. We identified a specific apolipoprotein E (APOE)-dependent molecular signature in microglia from models of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Alzheimer's disease (AD) and in microglia surrounding neuritic &#x3b2;-amyloid (A&#x3b2;)-plaques in the brains of people with AD. The APOE pathway mediated a switch from a homeostatic to a neurodegenerative microglia phenotype after phagocytosis of apoptotic neurons. TREM2 (triggering receptor expressed on myeloid cells 2) induced APOE signaling, and targeting the TREM2-APOE pathway restored the homeostatic signature of microglia in ALS and AD mouse models and prevented neuronal loss in&#xa0;an acute model of neurodegeneration. APOE-mediated neurodegenerative microglia had lost their tolerogenic function. Our work identifies the TREM2-APOE pathway as a major regulator of microglial functional phenotype in neurodegenerative diseases and serves as a novel target that could aid in the restoration of homeostatic microglia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krasemann</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madore</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cialic</LastName><ForeName>Ron</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baufeld</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calcagno</LastName><ForeName>Narghes</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Fatimy</LastName><ForeName>Rachid</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckers</LastName><ForeName>Lien</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Loughlin</LastName><ForeName>Elaine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanek</LastName><ForeName>Zain</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greco</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Scott T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tweet</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Humulock</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zrzavy</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Brain Research, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conde-Sanroman</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Icahn School of Medicine at Mount Sinai, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gacias</LastName><ForeName>Mar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Icahn School of Medicine at Mount Sinai, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Zhiping</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tjon</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazaheri</LastName><ForeName>Fargol</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madi</LastName><ForeName>Asaf</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glatzel</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Worthmann</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heeren</LastName><ForeName>Joerg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budnik</LastName><ForeName>Bogdan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Mass Spectrometry and Proteomics Resource Laboratory, Faculty of Arts and Sciences Division of Science, Harvard University, Cambridge MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemere</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikezu</LastName><ForeName>Tsuneya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics and Department of Neurology, Boston University School of Medicine, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heppner</LastName><ForeName>Frank L</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany; Cluster of Excellence, NeuroCure, Charit&#xe9;platz 1, 10117 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litvak</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lassmann</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Brain Research, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Howard L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Evergrande Center for Immunologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ochando</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Icahn School of Medicine at Mount Sinai, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany; Biomedical Center, Biochemistry, Ludwig-Maximilians-Universit&#xe4;t Munich, Munich, Germany; Munich Cluster for Systems Neurology, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butovsky</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Evergrande Center for Immunologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: obutovsky@rics.bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG054199</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040092</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043975</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088137</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054672</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AG000399</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG051812</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Immunity</MedlineTA><NlmUniqueID>9432918</NlmUniqueID><ISSNLinking>1074-7613</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Immunity. 2017 Sep 19;47(3):398-400. doi: 10.1016/j.immuni.2017.08.015.</RefSource><PMID Version="1">28930654</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004681" MajorTopicYN="N">Encephalomyelitis, Autoimmune, Experimental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018390" MajorTopicYN="N">Gene Targeting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007108" MajorTopicYN="N">Immune Tolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOE</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">transcriptional regulation</Keyword></KeywordList><CoiStatement><b>Competing financial interests:</b> CH: Roche advisor and collaborator. All other authors declare no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28930663</ArticleId><ArticleId IdType="mid">NIHMS901481</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pii">S1074-7613(17)30366-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, et al. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) J Biol Chem. 2015;290:26043&#x2013;26050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B, Song W, Ji Y, Liu X, Tian L, Wang C, Chen D, Zhang X, Zhang M. Microglia and microglia-like cell differentiated from DC inhibit CD4 T cell proliferation. PloS one. 2009;4:e7869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773419</ArticleId><ArticleId IdType="pubmed">19924241</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, Greco DJ, Wu PM, Doykan CE, Kiner O, et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Annals of neurology. 2015;77:75&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432483</ArticleId><ArticleId IdType="pubmed">25381879</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nature neuroscience. 2014;17:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, Doykan CE, Wu PM, Gali RR, Iyer LK, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012;122:3063&#x2013;3087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttgereit A, Lelios I, Yu X, Vrohlings M, Krakoski NR, Gautier EL, Nishinakamura R, Becher B, Greter M. Sall1 is a transcriptional regulator defining microglia identity and function. Nature immunology. 2016;17:1397&#x2013;1406.</Citation><ArticleIdList><ArticleId IdType="pubmed">27776109</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan G, White CC, Winn PA, Cimpean M, Replogle JM, Glick LR, Cuerdon NE, Ryan KJ, Johnson KA, Schneider JA, et al. CD33 modulates TREM2: convergence of Alzheimer loci. Nature neuroscience. 2015;18:1556&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4682915</ArticleId><ArticleId IdType="pubmed">26414614</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Morimoto ET, Goodarzi H, Liao JT, O&#x2019;Keeffe S, Phatnani HP, Muratet M, Carroll MC, Levy S, Tavazoie S, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell reports. 2013;4:385&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SH. Alzheimer&#x2019;s disease. A double-labeling immunohistochemical study of senile plaques. The American journal of pathology. 1988;132:86&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880629</ArticleId><ArticleId IdType="pubmed">2456021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, Helft J, Chow A, Elpek KG, Gordonov S, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nature immunology. 2012;13:1118&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558276</ArticleId><ArticleId IdType="pubmed">23023392</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, Spann NJ, Stender JD, Chun HB, Garner H, Geissmann F, Glass CK. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell. 2014;159:1327&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4364385</ArticleId><ArticleId IdType="pubmed">25480297</ArticleId></ArticleIdList></Reference><Reference><Citation>Grutzendler J, Helmin K, Tsai J, Gan WB. Various dendritic abnormalities are associated with fibrillar amyloid deposits in Alzheimer&#x2019;s disease. Annals of the New York Academy of Sciences. 2007;1097:30&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413007</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer&#x2019;s disease. The New England journal of medicine. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38:576&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898526</ArticleId><ArticleId IdType="pubmed">20513432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, El Khoury J. The microglial sensome revealed by direct RNA sequencing. Nature neuroscience. 2013;16:1896&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtman IR, Raj DD, Miller JA, Schaafsma W, Yin Z, Brouwer N, Wes PD, Moller T, Orre M, Kamphuis W, et al. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis. Acta neuropathologica communications. 2015;3:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4489356</ArticleId><ArticleId IdType="pubmed">26001565</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YA, Zhou B, Wernig M, Sudhof TC. ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Abeta Secretion. Cell. 2017;168:427&#x2013;441. e421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5310835</ArticleId><ArticleId IdType="pubmed">28111074</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell. 1997;88:347&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">9039261</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT, Landreth GE. Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer&#x2019;s Disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2017;37:637&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. The Journal of experimental medicine. 2015;212:287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell. 2017;169:1276&#x2013;1290. e1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. The Journal of experimental medicine. 2012;209:2149&#x2013;2156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501350</ArticleId><ArticleId IdType="pubmed">23129750</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pubmed">8068938</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostic V, Jackson-Lewis V, de Bilbao F, Dubois-Dauphin M, Przedborski S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science. 1997;277:559&#x2013; 562.</Citation><ArticleIdList><ArticleId IdType="pubmed">9228005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19:312&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">8843599</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ. The cortical neuritic dystrophy of Alzheimer&#x2019;s disease: nature, significance, and possible pathogenesis. Dementia. 1995;6:218&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">7550602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, Jung S, Amit I. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell. 2014;159:1312&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437213</ArticleId><ArticleId IdType="pubmed">25480296</ArticleId></ArticleIdList></Reference><Reference><Citation>Levesque M, Avoli M. The kainic acid model of temporal lobe epilepsy. Neurosci Biobehav Rev. 2013;37:2887&#x2013;2899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878897</ArticleId><ArticleId IdType="pubmed">24184743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu D, Nakagawa R, Lazzaro S, Staudacher P, Abreu-Goodger C, Henley T, Boiani S, Leyland R, Galloway A, Andrews S, et al. The miR-155-PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation. The Journal of experimental medicine. 2014;211:2183&#x2013;2198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4203942</ArticleId><ArticleId IdType="pubmed">25288398</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime reports. 2014;6:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944738</ArticleId><ArticleId IdType="pubmed">24669294</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, Tanaka S, Hansen LA. Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. Journal of neuropathology and experimental neurology. 1998;57:1041&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">9825941</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcovitch-Natan O, Winter DR, Giladi A, Vargas Aguilar S, Spinrad A, Sarrazin S, Ben-Yehuda H, David E, Zelada Gonzalez F, Perrin P, et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science. 2016;353:aad8670.</Citation><ArticleIdList><ArticleId IdType="pubmed">27338705</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Apoptosis in neurodegenerative disorders. Nature reviews Molecular cell biology. 2000;1:120&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">11253364</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Keller JN, Begley JG. Evidence for synaptic apoptosis. Experimental neurology. 1998;153:35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743565</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, Krasemann S, Capell A, Trumbach D, Wurst W, et al. TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofengeim D, Ito Y, Najafov A, Zhang Y, Shan B, DeWitt JP, Ye J, Zhang X, Chang A, Vakifahmetoglu-Norberg H, et al. Activation of necroptosis in multiple sclerosis. Cell reports. 2015;10:1836&#x2013;1849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4494996</ArticleId><ArticleId IdType="pubmed">25801023</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre M, Kamphuis W, Osborn LM, Melief J, Kooijman L, Huitinga I, Klooster J, Bossers K, Hol EM. Acute isolation and transcriptome characterization of cortical astrocytes and microglia from young and aged mice. Neurobiol Aging. 2014;35:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">23954174</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nature reviews Neurology. 2014;10:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">24638131</ArticleId></ArticleIdList></Reference><Reference><Citation>Picelli S, Bjorklund AK, Faridani OR, Sagasser S, Winberg G, Sandberg R. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nature methods. 2013;10:1096&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">24056875</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, Wolburg H, Gengler S, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh J, Kino Y, Asahina N, Takitani M, Miyoshi J, Ishida T, Saito Y. TMEM119 marks a subset of microglia in the human brain. Neuropathology. 2016;36:39&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">26250788</ArticleId></ArticleIdList></Reference><Reference><Citation>Seok HY, Tatsuguchi M, Callis TE, He A, Pu WT, Wang DZ. miR-155 inhibits expression of the MEF2A protein to repress skeletal muscle differentiation. J Biol Chem. 2011;286:35339&#x2013; 35346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3195620</ArticleId><ArticleId IdType="pubmed">21868385</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S, Walz KA, Archambault AS, Sim J, Bollman BP, Koenigsknecht-Talboo J, Cross AH, Holtzman DM, Wu GF. Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis. Journal of neuroimmunology. 2014;271:8&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4042395</ArticleId><ArticleId IdType="pubmed">24794230</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadelmann C, Deckwerth TL, Srinivasan A, Bancher C, Bruck W, Jellinger K, Lassmann H. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer&#x2019;s disease. Evidence for apoptotic cell death. The American journal of pathology. 1999;155:1459&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866960</ArticleId><ArticleId IdType="pubmed">10550301</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternberger NH, Sternberger LA, Ulrich J. Aberrant neurofilament phosphorylation in Alzheimer disease. Proc Natl Acad Sci U S A. 1985;82:4274&#x2013;4276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397980</ArticleId><ArticleId IdType="pubmed">3159022</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer&#x2019;s disease. Acta neuropathologica. 2009;118:475&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737117</ArticleId><ArticleId IdType="pubmed">19513731</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C Dominantly Inherited Alzheimer N. Early changes in CSF sTREM2 in dominantly inherited Alzheimer&#x2019;s disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8:369ra178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay TL, Mai D, Dautzenberg J, Fernandez-Klett F, Lin G, Sagar Datta M, Drougard A, Stempfl T, Ardura-Fabregat A, et al. A new fate mapping system reveals context-dependent random or clonal expansion of microglia. Nature neuroscience. 2017;20:793&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">28414331</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Da X, Weiner MW, Wolk DA, Xie SX, Arnold SE, Davatzikos C, Shaw LM, Trojanowski JQ Alzheimer&#x2019;s Disease Neuroimaging I. CSF Apo-E levels associate with cognitive decline and MRI changes. Acta neuropathologica. 2014;127:621&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988233</ArticleId><ArticleId IdType="pubmed">24385135</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature protocols. 2012;7:562&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334321</ArticleId><ArticleId IdType="pubmed">22383036</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006;177:3520&#x2013;3524.</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijden S, Bottelbergs A, Krysko O, Krysko DV, Beckers L, De Munter S, Van Veldhoven PP, Wyns S, Kulik W, Nave KA, et al. Peroxisomal multifunctional protein-2 deficiency causes neuroinflammation and degeneration of Purkinje cells independent of very long chain fatty acid accumulation. Neurobiol Dis. 2013;58:258&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">23777740</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner T, Bartelt A, Schlein C, Heeren J. Genetic Dissection of Tissue-Specific Apolipoprotein E Function for Hypercholesterolemia and Diet-Induced Obesity. PloS one. 2015;10:e0145102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687855</ArticleId><ArticleId IdType="pubmed">26695075</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. The Journal of experimental medicine. 2016;213:667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2006;26:4985&#x2013;4994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674234</ArticleId><ArticleId IdType="pubmed">16687490</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron. 2016;92:252&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">27710785</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28942918</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>171</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Structure of FUS Protein Fibrils and Its Relevance to Self-Assembly and Phase Separation of Low-Complexity Domains.</ArticleTitle><Pagination><StartPage>615</StartPage><EndPage>627.e16</EndPage><MedlinePgn>615-627.e16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2017.08.048</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(17)31007-3</ELocationID><Abstract><AbstractText>Polymerization and phase separation of proteins containing low-complexity (LC) domains are important factors in gene expression, mRNA processing and trafficking, and localization of translation. We have used solid-state nuclear magnetic resonance methods to characterize the molecular structure of self-assembling fibrils formed by the LC domain of the fused in sarcoma (FUS) RNA-binding protein. From the 214-residue LC domain of FUS (FUS-LC), a segment of only 57 residues forms the fibril core, while other segments remain dynamically disordered. Unlike pathogenic amyloid fibrils, FUS-LC fibrils lack hydrophobic interactions within the core and are not polymorphic at the molecular structural level. Phosphorylation of core-forming residues by DNA-dependent protein kinase blocks binding of soluble FUS-LC to FUS-LC hydrogels and dissolves phase-separated, liquid-like FUS-LC droplets. These studies offer a structural basis for understanding LC domain self-assembly, phase separation, and regulation by post-translational modification.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Dylan T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0520, USA; Postdoctoral Research Associate Program, National Institute of General Medical Sciences, National Institutes of Health, Bethesda, MD 20892-6200, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thurber</LastName><ForeName>Kent R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>National High Magnetic Field Laboratory, Florida State University, Tallahassee, FL 32310, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKnight</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA. Electronic address: steven.mcknight@utsouthwestern.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tycko</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0520, USA. Electronic address: robertty@mail.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S10 OD021684</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 GM107623</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA DK075031</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2017 Oct 19;171(3):499-500. doi: 10.1016/j.cell.2017.10.007.</RefSource><PMID Version="1">29053965</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018625" MajorTopicYN="N">Microscopy, Atomic Force</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019906" MajorTopicYN="N">Nuclear Magnetic Resonance, Biomolecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">amyloid structure</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">electron microscopy</Keyword><Keyword MajorTopicYN="N">labile cross-&#x3b2; polymer</Keyword><Keyword MajorTopicYN="N">liquid droplet</Keyword><Keyword MajorTopicYN="N">liquid-liquid phase separation</Keyword><Keyword MajorTopicYN="N">low-complexity sequence</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">solid-state nuclear magnetic resonance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28942918</ArticleId><ArticleId IdType="mid">NIHMS903965</ArticleId><ArticleId IdType="pmc">PMC5650524</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2017.08.048</ArticleId><ArticleId IdType="pii">S0092-8674(17)31007-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alberti S, Hyman AA. Are aberrant phase transitions a driver of cellular aging? Bioessays. 2016;38:959&#x2013;968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5108435</ArticleId><ArticleId IdType="pubmed">27554449</ArticleId></ArticleIdList></Reference><Reference><Citation>Banani SF, Lee HO, Hyman AA, Rosen MK. Biomolecular condensates: Organizers of cellular biochemistry. Nat Rev Mol Cell Biol. 2017;18:285&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7434221</ArticleId><ArticleId IdType="pubmed">28225081</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayro MJ, Chen B, Yau WM, Tycko R. Site-specific structural variations accompanying tubular assembly of the HIV-1 capsid protein. J Mol Biol. 2014;426:1109&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3952194</ArticleId><ArticleId IdType="pubmed">24370930</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett AE, Rienstra CM, Auger M, Lakshmi KV, Griffin RG. Heteronuclear decoupling in rotating solids. J Chem Phys. 1995;103:6951&#x2013;6958.</Citation></Reference><Reference><Citation>Bertini I, Gonnelli L, Luchinat C, Mao JF, Nesi A. A new structural model of A&#x3b2;(40) fibrils. J Am Chem Soc. 2011;133:16013&#x2013;16022.</Citation><ArticleIdList><ArticleId IdType="pubmed">21882806</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke KA, Janke AM, Rhine CL, Fawzi NL. Residue-by-residue view of in vitro FUS granules that bind the C-terminal domain of RNA polymerase II. Mol Cell. 2015;60:231&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609301</ArticleId><ArticleId IdType="pubmed">26455390</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani F, van Rossum BJ, Diehl A, Rehbein K, Oschkinat H. Determination of solid state NMR structures of proteins by means of three-dimensional 15N-13C-13C dipolar correlation spectroscopy and chemical shift analysis. Biochemistry. 2003;42:11476&#x2013;11483.</Citation><ArticleIdList><ArticleId IdType="pubmed">14516199</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Thurber KR, Shewmaker F, Wickner RB, Tycko R. Measurement of amyloid fibril mass-per-length by tilted-beam transmission electron microscopy. Proc Natl Acad Sci U S A. 2009;106:14339&#x2013;14344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732815</ArticleId><ArticleId IdType="pubmed">19706519</ArticleId></ArticleIdList></Reference><Reference><Citation>Colvin MT, Silvers R, Ni QZ, Can TV, Sergeyev I, Rosay M, Donovan KJ, Michael B, Wall J, Linse S, et al. Atomic resolution structure of monomorphic A&#x3b2;(42) amyloid fibrils. J Am Chem Soc. 2016;138:9663&#x2013;9674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389415</ArticleId><ArticleId IdType="pubmed">27355699</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot NS, Castillo V, Grana-Montes R, Zamora SV. Aggrescan: Method, application, and perspectives for drug design. In: Baron R, editor. Computational drug discovery and design. 2012. pp. 199&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">22183539</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRpipe: A multidimensional spectral processing system based on Unix pipes. J Biomol NMR. 1995;6:277&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">8520220</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng QD, Holler CJ, Taylor G, Hudson KF, Watkins W, Gearing M, Ito D, Murray ME, Dickson DW, Seyfned NT, et al. FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage. J Neurosci. 2014;34:7802&#x2013;7813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044245</ArticleId><ArticleId IdType="pubmed">24899704</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol. 2005;6:197&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15738986</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaum-Garfinkle S, Kim Y, Szczepaniak K, Chen CCH, Eckmann CR, Myong S, Brangwynne CP. The disordered P granule protein LAF-1 drives phase separation into droplets with tunable viscosity and dynamics. Proc Natl Acad Sci USA. 2015;112:7189&#x2013;7194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4466716</ArticleId><ArticleId IdType="pubmed">26015579</ArticleId></ArticleIdList></Reference><Reference><Citation>Emily M, Talvas A, Delamarche C. Metamyl: A meta-predictor for amyloid proteins. PLoS One. 2013:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834037</ArticleId><ArticleId IdType="pubmed">24260292</ArticleId></ArticleIdList></Reference><Reference><Citation>Feric M, Vaidya N, Harmon TS, Mitrea DM, Zhu L, Richardson TM, Kriwacki RW, Pappu RV, Brangwynne CP. Coexisting liquid phases underlie nucleolar subcompartments. Cell. 2016;165:1686&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127388</ArticleId><ArticleId IdType="pubmed">27212236</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzynskiy SO, Lobanov MY, Galzitskaya OV. FoldAmyloid: A method of prediction of amyloidogenic regions from protein sequence. Bioinformatics. 2010;26:326&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">20019059</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardiner M, Toth R, Vandermoere F, Morrice NA, Rouse J. Identification and characterization of FUS/TLS as a new target of ATM. Biochem J. 2008;415:297&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">18620545</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasior P, Kotulska M. Fish amyloid: A new method for finding amyloidogenic segments in proteins based on site specific co-occurence of aminoacids. BMC Bioinformatics. 2014:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941796</ArticleId><ArticleId IdType="pubmed">24564523</ArticleId></ArticleIdList></Reference><Reference><Citation>Han TNW, Kato M, Xie SH, Wu LC, Mirzaei H, Pei JM, Chen M, Xie Y, Allen I, Xiao GH, et al. Cell-free formation of RNA granules: Bound RNAs identify features and components of cellular assemblies. Cell. 2012;149:768&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pubmed">22579282</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison AF, Shorter J. RNA-binding proteins with prion-like domains in health and disease. Biochem J. 2017;474:1417&#x2013;1438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639257</ArticleId><ArticleId IdType="pubmed">28389532</ArticleId></ArticleIdList></Reference><Reference><Citation>Heise H, Hoyer W, Becker S, Andronesi OC, Riedel D, Baldus M. Molecular-level secondary structure, polymorphism, and dynamics of full-length &#x3b1;-synuclein fibrils studied by solid state NMR. Proc Natl Acad Sci U S A. 2005;102:15871&#x2013;15876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1276071</ArticleId><ArticleId IdType="pubmed">16247008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M, Jakes K. Selective and extensive 13C labeling of a membrane protein for solid state NMR investigations. J Biomol NMR. 1999;14:71&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">10382307</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu KN, Qiang W, Bermejo GA, Schwieters CD, Tycko R. Restraints on backbone conformations in solid state NMR studies of uniformly labeled proteins from quantitative amide 15N-15N and carbonyl 13C-13C dipolar recoupling data. J Magn Reson. 2012;218:115&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568759</ArticleId><ArticleId IdType="pubmed">22449573</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu KN, Qiang W, Tycko R. A general Monte carlo/simulated annealing algorithm for resonance assignment in NMR of uniformly labeled biopolymers. J Biomol NMR. 2011;50:267&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199575</ArticleId><ArticleId IdType="pubmed">21710190</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. J Mol Graph. 1996;14:33&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744570</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttlin EL, Jedrychowski MP, Elias JE, Goswami T, Rad R, Beausoleil SA, Villen J, Haas W, Sowa ME, Gygi SP. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell. 2010;143:1174&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035969</ArticleId><ArticleId IdType="pubmed">21183079</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, Han TNW, Xie SH, Shi K, Du XL, Wu LC, Mirzaei H, Goldsmith EJ, Longgood J, Pei JM, et al. Cell-free formation of RNA granules: Low complexity sequence domains form dynamic fibers within hydrogels. Cell. 2012;149:753&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiebler MA, Bassell GJ. Neuronal RNA granules: Movers and makers. Neuron. 2006;51:685&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">16982415</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, Kato M, Xiang SH, Wu L, Theodoropoulos P, Mirzaei H, Han T, Xie SH, Corden JL, McKnight SL. Phosphorylation-regulated binding of RNA polymerase II to fibrous polymers of low-complexity domains. Cell. 2013;155:1049&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010232</ArticleId><ArticleId IdType="pubmed">24267890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamond AI, Spector DL. Nuclear speckles: A model for nuclear organelles. Nat Rev Mol Cell Biol. 2003;4:605&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">12923522</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Mori E, Kato M, Xiang SH, Wu LJ, Kwon I, McKmght SL. Toxic PR poly-dipeptides encoded by the C9orf72 repeat expansion target LC domain polymers. Cell. 2016;167:789&#x2212;+.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076566</ArticleId><ArticleId IdType="pubmed">27768897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Protter DSW, Rosen MK, Parker R. Formation and maturation of phase-separated liquid droplets by RNA-binding proteins. Mol Cell. 2015;60:208&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609299</ArticleId><ArticleId IdType="pubmed">26412307</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JG, Perumal NB, Oldfield CJ, Su EW, Uversky VN, Dunker AK. Intrinsic disorder in transcription factors. Biochemistry. 2006;45:6873&#x2013;6888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2538555</ArticleId><ArticleId IdType="pubmed">16734424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R. Molecular structure of &#x3b2;-amyloid fibrils in Alzheimer's disease brain tissue. Cell. 2013;154:1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer-Stroh S, Debulpaep M, Kuemmerer N, de la Paz ML, Martins IC, Reumers J, Morris KL, Copland A, Serpell L, Serrano L, et al. Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nat Methods. 2010;7:237&#x2013;U109.</Citation><ArticleIdList><ArticleId IdType="pubmed">20154676</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris GA, Freeman R. Enhancement of nuclear magnetic resonance signals by polarization transfer. J Am Chem Soc. 1979;101:760&#x2013;762.</Citation></Reference><Reference><Citation>Murakami T, Qamar S, Lin JQ, Schierle GSK, Rees E, Miyashita A, Costa AR, Dodd RB, Chan FTS, Michel CH, et al. ALS/FTD mutation-induced phase transition of FUS liquid droplets and reversible hydrogels into irreversible hydrogels impairs RNP granule function. Neuron. 2015;88:678&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4660210</ArticleId><ArticleId IdType="pubmed">26526393</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott TJ, Petsalaki E, Farber P, Jervis D, Fussner E, Plochowietz A, Craggs TD, Bazett-Jones DP, Pawson T, Forman-Kay JD, et al. Phase transition of a disordered uage protein generates environmentally responsive membraneless organelles. Mol Cell. 2015;57:936&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352761</ArticleId><ArticleId IdType="pubmed">25747659</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen JV, Schwartz JC, Griep-Raming J, Nielsen ML, Damoc E, Denisov E, Lange O, Remes P, Taylor D, Splendore M, et al. A dual pressure linear ion trap orbitrap instrument with very high sequencing speed. Mol Cell Proteomics. 2009;8:2759&#x2013;2769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2816009</ArticleId><ArticleId IdType="pubmed">19828875</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Leapman RD, Yau WM, Tycko R. Molecular structural basis for polymorphism in Alzheimer's &#x3b2;-amyloid fibrils. Proc Natl Acad Sci USA. 2008;105:18349&#x2013;18354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587602</ArticleId><ArticleId IdType="pubmed">19015532</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, Lee HO, Jawerth L, Maharana S, Jahnel M, Hein MY, Stoynov S, Mahamid J, Saha S, Franzmann TM, et al. A liquid-to-solid phase transition of the ALS protein FUS accelerated by disease mutation. Cell. 2015;162:1066&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Perutz MF, Johnson T, Suzuki M, Finch JT. Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A. 1994;91:5355&#x2013;5358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43993</ArticleId><ArticleId IdType="pubmed">8202492</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, Schulten K. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26:1781&#x2013;1802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2486339</ArticleId><ArticleId IdType="pubmed">16222654</ArticleId></ArticleIdList></Reference><Reference><Citation>Pines A, Gibby MG, Waugh JS. Proton-enhanced NMR of dilute spins in solids. J Chem Phys. 1973;59:569&#x2013;590.</Citation></Reference><Reference><Citation>Saha S, Weber CA, Nousch M, Adame-Arana O, Hoege C, Hein MY, Osborne-Nishimura E, Mahamid J, Jahnel M, Jawerth L, et al. Polar positioning of phase-separated liquid compartments in cells regulated by an mRNA competition mechanism. Cell. 2016;166:1572&#x2013;1584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5034880</ArticleId><ArticleId IdType="pubmed">27594427</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJW, McFarlane HT, et al. Atomic structures of amyloid cross-&#x3b2; spines reveal varied steric zippers. Nature. 2007;447:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schutz AK, Vagt T, Huber M, Ovchinnikova OY, Cadalbert R, Wall J, Guntert P, Bockmann A, Glockshuber R, Meier BH. Atomic-resolution three-dimensional structure of amyloid-&#x3b2; fibrils bearing the Osaka mutation. Angew Chem-Int Edit. 2015;54:331&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502972</ArticleId><ArticleId IdType="pubmed">25395337</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwieters CD, Kuszewski JJ, Clore GM. Using Xplor-NIH for NMR molecular structure determination. Prog Nucl Magn Reson Spectrosc. 2006;48:47&#x2013;62.</Citation></Reference><Reference><Citation>Shah NH, Dann GP, Vila-Perello M, Liu ZH, Muir TW. Ultrafast protein splicing is common among cyanobacterial split inteins: Implications for protein enGlneering. J Am Chem Soc. 2012;734:11338&#x2013;11341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535263</ArticleId><ArticleId IdType="pubmed">22734434</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheffield P, Garrard S, Derewenda Z. Overcoming expression and purification problems of rhogdi using a family of "parallel" expression vectors. Protein Expr Purif. 1999;15:34&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">10024467</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Bax A. Protein backbone and sidechain torsion angles predicted from NMR chemical shifts using artificial neural networks. J Biomol NMR. 2013;56:227&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701756</ArticleId><ArticleId IdType="pubmed">23728592</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi KY, Mori E, Nizami ZF, Lin Y, Kato M, Xiang SH, Wu LC, Ding M, Yu YH, Gall JG, et al. Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proc Natl Acad Sci U S A. 2017;114:E1111&#x2013;E1117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5320981</ArticleId><ArticleId IdType="pubmed">28069952</ArticleId></ArticleIdList></Reference><Reference><Citation>Strambio-De-Castillia C, Niepel M, Rout MP. The nuclear pore complex: BridGlng nuclear transport and gene regulation. Nat Rev Mol Cell Biol. 2010;11:490&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">20571586</ArticleId></ArticleIdList></Reference><Reference><Citation>Takegoshi K, Nakamura S, Terao T. 13C-1H dipolar-assisted rotational resonance in magic-angle spinning NMR. Chem Phys Lett. 2001;344:631&#x2013;637.</Citation></Reference><Reference><Citation>Tartaglia GG, Vendruscolo M. The Zyggregator method for predicting protein aggregation propensities. Chem Soc Rev. 2008;37:1395&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pubmed">18568165</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirumalai D, Reddy G, Straub JE. Role of water in protein aggregation and amyloid polymorphism. Accounts Chem Res. 2012;45:83&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218239</ArticleId><ArticleId IdType="pubmed">21761818</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson MJ, Sievers SA, Karanicolas J, Ivanova MI, Baker D, Eisenberg D. The 3D profile method for identifying fibril-forming segments of proteins. Proc Natl Acad Sci U S A. 2006;103:4074&#x2013;4078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1449648</ArticleId><ArticleId IdType="pubmed">16537487</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuttle MD, Comellas G, Nieuwkoop AJ, Covell DJ, Berthold DA, Kloepper KD, Courtney JM, Kim JK, Barclay AM, Kendall A, et al. Solid state NMR structure of a pathogenic fibril of full-length human &#x3b1;-synuclein. Nat Struct Mol Biol. 2016;23:409&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5034296</ArticleId><ArticleId IdType="pubmed">27018801</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko R. Symmetry-based constant-time homonuclear dipolar recoupling in solid state NMR. J Chem Phys. 2007:126.</Citation><ArticleIdList><ArticleId IdType="pubmed">17313228</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Melckebeke H, Wasmer C, Lange A, Ab E, Loquet A, Bockmann A, Meier BH. Atomic-resolution three-dimensional structure of HET-s(218&#x2013;289) amyloid fibrils by solid state NMR spectroscopy. J Am Chem Soc. 2010;132:13765&#x2013;13775.</Citation><ArticleIdList><ArticleId IdType="pubmed">20828131</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh I, Seno F, Tosatto SCE, Trovato A. PASTA 2.0: An improved server for protein aggregation prediction. Nucleic Acids Res. 2014;42:W301&#x2013;W307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086119</ArticleId><ArticleId IdType="pubmed">24848016</ArticleId></ArticleIdList></Reference><Reference><Citation>Walti MA, Ravotti F, Arai H, Glabe CG, Wall JS, Bockmann A, Guntert P, Meier BH, Riek R. Atomic-resolution structure of a disease-relevant A&#x3b2;(1&#x2013;42) amyloid fibril. Proc Natl Acad Sci U S A. 2016;113:E4976&#x2013;E4984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003276</ArticleId><ArticleId IdType="pubmed">27469165</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang SH, Kato M, Wu LC, Lin Y, Ding M, Zhang YJ, Yu YH, McKnight SL. The LC domain of hnRNPA2 adopts similar conformations in hydrogel polymers, liquid-like droplets, and nuclei. Cell. 2015;163:829&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879888</ArticleId><ArticleId IdType="pubmed">26544936</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao YL, Ma BY, McElheny D, Parthasarathy S, Long F, Hoshi M, Nussinov R, Ishii Y. A&#x3b2;(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease. Nat Struct Mol Biol. 2015;22:499&#x2013;U497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4476499</ArticleId><ArticleId IdType="pubmed">25938662</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou HX. Loops, linkages, rings, catenanes, cages, and crowders: Entropy-based strategies for stabilizing proteins. Accounts Chem Res. 2004;37:123&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">14967059</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28969384</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>140</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice.</ArticleTitle><Pagination><StartPage>2706</StartPage><EndPage>2721</EndPage><MedlinePgn>2706-2721</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awx221</ELocationID><Abstract><AbstractText>Mutations in glucocerebrosidase 1 (GBA1) represent the most prevalent risk factor for Parkinson's disease. The molecular mechanisms underlying the link between GBA1 mutations and Parkinson's disease are incompletely understood. We analysed two aged (24-month-old) Gba1 mouse models, one carrying a knock-out mutation and the other a L444P knock-in mutation. A significant reduction of glucocerebrosidase activity was associated with increased total alpha-synuclein accumulation in both these models. Gba1 mutations alone did not alter the number of nigral dopaminergic neurons nor striatal dopamine levels. We then investigated the effect of overexpression of human alpha-synuclein in the substantia nigra of aged (18 to 21-month-old) L444P Gba1 mice. Following intraparenchymal injections of human alpha-synuclein carrying viral vectors, pathological accumulation of phosphorylated alpha-synuclein occurred within the transduced neurons. Stereological counts of nigral dopaminergic neurons revealed a significantly greater cell loss in Gba1-mutant than wild-type mice. These results indicate that Gba1 deficiency enhances neuronal vulnerability to neurodegenerative processes triggered by increased alpha-synuclein expression.</AbstractText><CopyrightInformation>&#xa9; The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Migdalska-Richards</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, London NW3 2PF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wegrzynowicz</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge, CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rusconi</LastName><ForeName>Raffaella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>German Centre for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Strasse 27, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deangeli</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge, CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scuola Superiore Sant'Anna, Piazza Martiri della Libert&#xe0; 33, 56127 Pisa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Pisa, Lungarno Antonio Pacinotti 43, 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Monte</LastName><ForeName>Donato A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>German Centre for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Strasse 27, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spillantini</LastName><ForeName>Maria G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge, CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schapira</LastName><ForeName>Anthony H V</ForeName><Initials>AHV</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, London NW3 2PF, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G-0701</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-1102</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M006646/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501499/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N028651/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DLQ4CIU6V</RegistryNumber><NameOfSubstance UI="D011392">Proline</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.45</RegistryNumber><NameOfSubstance UI="D005962">Glucosylceramidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.52</RegistryNumber><NameOfSubstance UI="D001619">beta-N-Acetylhexosaminidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>GMW67QNF9C</RegistryNumber><NameOfSubstance UI="D007930">Leucine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005962" MajorTopicYN="N">Glucosylceramidase</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="N">Smell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014161" MajorTopicYN="N">Transduction, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001619" MajorTopicYN="N">beta-N-Acetylhexosaminidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GBA1</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">alpha-synuclein</Keyword><Keyword MajorTopicYN="N">glucocerebrosidase</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28969384</ArticleId><ArticleId IdType="pmc">PMC5841155</ArticleId><ArticleId IdType="doi">10.1093/brain/awx221</ArticleId><ArticleId IdType="pii">4106291</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, et al.Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 2014; 71: 752&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4082726</ArticleId><ArticleId IdType="pubmed">24756352</ArticleId></ArticleIdList></Reference><Reference><Citation>Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012; 78: 417&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22282650</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 2008; 116: 277&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708176</ArticleId><ArticleId IdType="pubmed">18626651</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutler E. Gaucher disease: new molecular approaches to diagnosis and treatment. Science 1992; 256: 794&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1589760</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockmann K, Srulijes K, Hauser AK, Schulte C, Csoti I, Gasser T, et al.GBA-associated PD presents with nonmotor characteristics. Neurology 2011; 77: 276&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">21734182</ArticleId></ArticleIdList></Reference><Reference><Citation>Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, et al.The risk of Parkinson&#x2019;s disease in type 1 Gaucher disease. J Inherit Metab Dis 2010; 33: 167&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887303</ArticleId><ArticleId IdType="pubmed">20177787</ArticleId></ArticleIdList></Reference><Reference><Citation>Calo L, Wegrzynowicz M, Santiva&#xf1;ez-Perez J, Grazia Spillantini M. Synaptic failure and &#x3b1;-synuclein. Mov Disord 2016; 31: 169&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">26790375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleeter MW, Chau KY, Gluck C, Mehta A, Hughes DA, Duchen M, et al.Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int 2013; 62: 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3550523</ArticleId><ArticleId IdType="pubmed">23099359</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, et al.Acid b-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter a-synuclein processing. Ann Neurol 2011; 69: 940&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">21472771</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis MY, Trinh K, Thomas RE, Yu S, Germanos AA, Whitley BN, et al.Glucocerebrosidase deficiency in Drosophila results in &#x3b1;-synuclein-independent protein aggregation and neurodegeneration. PLoS Genet 2016; 12: e1005944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4809718</ArticleId><ArticleId IdType="pubmed">27019408</ArticleId></ArticleIdList></Reference><Reference><Citation>Decressac M, Mattsson B, Lundblad M, Weikop P, Bj&#xf6;rklund A. Progressive neurodegeneration and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis 2012; 45: 939&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">22182688</ArticleId></ArticleIdList></Reference><Reference><Citation>Enquist IB, Lo Bianco C, Ooka A, Nilsson E, M&#xe4;nsson JE, Ehinger M, et al.Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad Sci USA 2007; 104: 17483&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077282</ArticleId><ArticleId IdType="pubmed">17954912</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfel-Becker T, Vitner E, Dekel H, Leshem N, Enquist IB, Karlsson S, et al.No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum Mol Genet 2009; 18: 1482&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19193629</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishbein I, Kuo YM, Giasson BI, Nussbaum RL. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. Brain 2014; 137 (Pt 12): 3235&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240298</ArticleId><ArticleId IdType="pubmed">25351739</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. Alpha-synuclein is phosphorylated in synucleopathy lesions. Nat Cell Biol 2002; 4: 160&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, et al.Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012; 72: 455&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3638323</ArticleId><ArticleId IdType="pubmed">23034917</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc 1987; 147: 229&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">3430576</ArticleId></ArticleIdList></Reference><Reference><Citation>Helwig M, Klinkenberg M, Rusconi R, Musgrove RE, Majbour NK, El-Agnaf OM, et al.Brain propagation of transduced &#x3b1;-synuclein involves non-fibrillar protein species and is enhanced in &#x3b1;-synuclein null mice. Brain 2016; 139: 856&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">26719384</ArticleId></ArticleIdList></Reference><Reference><Citation>Houck SA, Singh S, Cyr DM. Cellular responses to misfolded proteins and protein aggregates. Methods Mol Biol 2012; 832: 455&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4445682</ArticleId><ArticleId IdType="pubmed">22350905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilpatrick IC, Jones MW, Phillipson OT. A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J Neurochem 1986; 46: 1865&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">2422325</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 2002; 22: 2780&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758323</ArticleId><ArticleId IdType="pubmed">11923443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I, Ulusoy A, Innamorato NG, Sahin G, R&#xe1;bano A, Kirik D, et al.&#x3b1;-synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Hum Mol Genet 2012; 21: 3173&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">22513881</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Suzuki K, Reed JD, Grinberg A, Westphal H, Hoffmann A, et al. Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure (SIMP). Proc Natl Acad Sci USA 1998; 95: 2503&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19391</ArticleId><ArticleId IdType="pubmed">9482915</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeb JE, Cordier WS, Harris ME, Weitzman MD, Hope TJ. Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus postrascriptional regulatory element: implication for gene therapy. Hum Gen Ther 1999; 10: 2295&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">10515449</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338: 949&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning-Bo&#x11d; AB, Sch&#xfc;le B, Langston JW. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 2009; 30: 1127&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">19576930</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell G, et al.Gaucher disease glucocerebrosidase and a-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011; 146: 37&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132082</ArticleId><ArticleId IdType="pubmed">21700325</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeill A, Duran R, Hughes DA, Mehta A, Schapira AH. A clinical and family history study of Parkinson&#x2019;s disease in heterozygous glucocerebrosidase mutation carriers. J Neurol Neurosurg Psychiatry 2012a; 83: 853&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3927562</ArticleId><ArticleId IdType="pubmed">22577228</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeill A, Duran R, Proukakis C, Bras J, Hughes D, Mehta A, et al.Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov Disord 2012b; 27: 526&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4188387</ArticleId><ArticleId IdType="pubmed">22344629</ArticleId></ArticleIdList></Reference><Reference><Citation>Migdalska-Richards A, Schapira AH. The relationship between glucocerebrosidase mutations and Parkinson disease. J Neurochem 2016; 139: 77&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111601</ArticleId><ArticleId IdType="pubmed">26860875</ArticleId></ArticleIdList></Reference><Reference><Citation>Migdalska-Richards A, Daly L, Bezard E, Schapira AH. Ambroxol effect in glucocerebrosidase and &#x3b1;-synuclein transgenic mice. Ann Neurol 2016; 80: 766&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5132106</ArticleId><ArticleId IdType="pubmed">27859541</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy KE, Halliday GM. Glucocerebrosidase deficits in sporadic Parkinson disease. Autophagy 2014; 10: 1350&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4203563</ArticleId><ArticleId IdType="pubmed">24915553</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, et al.Glucocerebrosidase mutations in clinical and pathologically proven Parkinson&#x2019;s disease. Brain 2009; 132: 1783&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702833</ArticleId><ArticleId IdType="pubmed">19286695</ArticleId></ArticleIdList></Reference><Reference><Citation>Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, et al.Mitochondria and quality control defects in a mouse model of Gaucher disease-links to Parkinson's disease. Cell Metab 2013; 17: 941&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3678026</ArticleId><ArticleId IdType="pubmed">23707074</ArticleId></ArticleIdList></Reference><Reference><Citation>Oueslati A. Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the last decade? J Parkinsons Dis 2016; 6: 39&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4927808</ArticleId><ArticleId IdType="pubmed">27003784</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates. London: Academic Press; 2001.</Citation></Reference><Reference><Citation>Rana HQ, Balwani M, Bier L, Alcalay RN. Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling. Genet Med 2013; 15: 146&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3519952</ArticleId><ArticleId IdType="pubmed">22935721</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Martinez A, Beavan M, Gegg ME, Chau KY, Whitworth AJ, Schapira AH. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Sci Rep 2016; 6: 31380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4990939</ArticleId><ArticleId IdType="pubmed">27539639</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardi SP, Clarke J, Kinnecom C, Tamsett TJ, Li L, Stanek LM, et al.CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci USA 2011; 108: 12101&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3141921</ArticleId><ArticleId IdType="pubmed">21730160</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardi SP, Clarke J, Viel C, Chan M, Tamsett TJ, Treleaven CM, et al.Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other gaucher-related synucleinopathies. Proc Natl Acad Sci USA 2013; 110: 3537&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3587272</ArticleId><ArticleId IdType="pubmed">23297226</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato H, Kato T, Arawaka S. The role of Ser129 phosphorylation of a-synuclein in neurodegeneration of Parkinson&#x2019;s disease: a review of in vivo models. Rev Neurosci 2013; 24: 115&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">23314528</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira AH. Glucocerebrosidase and Parkinson disease: recent advances. Mol Cell Neurosci 2015; 66: 37&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4471139</ArticleId><ArticleId IdType="pubmed">25802027</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira AH, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 2010; 6: 309&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">20479780</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ndorf DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B, et al. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun 2014; 5: 4028.</Citation><ArticleIdList><ArticleId IdType="pubmed">24905578</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol 2012; 11: 986&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4141416</ArticleId><ArticleId IdType="pubmed">23079555</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al.Multicenter analysis of glucocerebrosidase mutations in Parkinson&#x2019;s disease. N Engl J Med 2009; 361: 1651&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856322</ArticleId><ArticleId IdType="pubmed">19846850</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinelli KJ, Taylor JK, Osterberg VR, Churchill MJ, Pollock E, Moore C, et al. Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease. J Neurosci 2014; 34: 2037&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913861</ArticleId><ArticleId IdType="pubmed">24501346</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Sisk A, et al. Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab Invest 1998; 78: 1169&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">9759660</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EK, Tong J, Fook-Chong S, Yih Y, Wong MC, Pavanni R, et al.Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol 2007; 64: 1056&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17620502</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulusoy A, Phillips RJ, Helwig M, Klinkenberg M, Powley TL, Di Monte DA. Brain-to-stomach transfer of alpha-synuclein via vagal preganglionic projections. Acta Neurophatol 2017; 133: 381&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5326583</ArticleId><ArticleId IdType="pubmed">28012041</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulusoy A, Musgrove RE, Rusconi R, Klinkenberg M, Helwig M, Schneider A, et al.Neuron-to-neuron &#x3b1;-synuclein propagation in vivo is independent of neuronal injury. Acta Neuropathol Commun 2015; 3: 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369863</ArticleId><ArticleId IdType="pubmed">25853980</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulusoy A, Rusconi R, P&#xe9;rez-Revuelta BI, Musgrove RE, Helwig M, Winzen-Reichert B, et al.Caudo-rostral brain spreading of &#x3b1;-synuclein through vagal connections. EMBO Mol Med 2013; 5: 1119&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3721477</ArticleId><ArticleId IdType="pubmed">23703938</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener 2015; 12: 4&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4603346</ArticleId><ArticleId IdType="pubmed">26464797</ArticleId></ArticleIdList></Reference><Reference><Citation>Winder-Rhodes SE, Evans JR, Ban M, Mason SL, Williams-Gray CH, Foltynie T, et al.Glucocerebrosidase mutations influence the natural history of Parkinson&#x2019;s disease in a community-based incident cohort. Brain 2013; 136: 392&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23413260</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YH, Sun Y, Ran H, Quinn B, Witte D, Grabowski GA. Accumulation and distribution of &#x3b1;-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab 2011; 102: 436&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059359</ArticleId><ArticleId IdType="pubmed">21257328</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YH, Xu K, Sun Y, Li RH, Liou B, Quinn B, et al.Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum Mol Genet 2014; 23: 3943&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4082362</ArticleId><ArticleId IdType="pubmed">24599400</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SY, Beavan M, Chau KY, Taanman JW, Schapira AH. A human neural crest stem cell-derived dopaminergic neuronal model recapitulates biochemical abnormalities in GBA1 mutation carriers. Stem Cell Reports 2017; 8: 728&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5355624</ArticleId><ArticleId IdType="pubmed">28216145</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28892059</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci.</ArticleTitle><Pagination><StartPage>1511</StartPage><EndPage>1516</EndPage><MedlinePgn>1511-1516</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.3955</ELocationID><Abstract><AbstractText>Common variant genome-wide association studies (GWASs) have, to date, identified &gt;24 risk loci for Parkinson's disease (PD). To discover additional loci, we carried out a GWAS comparing 6,476 PD cases with 302,042 controls, followed by a meta-analysis with a recent study of over 13,000 PD cases and 95,000 controls at 9,830 overlapping variants. We then tested 35 loci (P &lt; 1 &#xd7; 10<sup>-6</sup>) in a replication cohort of 5,851 cases and 5,866 controls. We identified 17 novel risk loci (P &lt; 5 &#xd7; 10<sup>-8</sup>) in a joint analysis of 26,035 cases and 403,190 controls. We used a neurocentric strategy to assign candidate risk genes to the loci. We identified protein-altering or cis-expression quantitative trait locus (cis-eQTL) variants in linkage disequilibrium with the index variant in 29 of the 41 PD loci. These results indicate a key role for autophagy and lysosomal biology in PD risk, and suggest potential new drug targets for PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalls</LastName><ForeName>Mike A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, US National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Data Tecnica International, Glen Echo, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallgr&#xed;msd&#xf3;ttir</LastName><ForeName>Ingileif B</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>23andMe Inc., Mountain View, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunkapiller</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Brug</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>International Parkinson's Disease Genomics Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>23andMe Research Team</CollectiveName></Author><Author ValidYN="Y"><LastName>Kerchner</LastName><ForeName>Geoffrey A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayalon</LastName><ForeName>Gai</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bingol</LastName><ForeName>Baris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinds</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>23andMe Inc., Mountain View, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behrens</LastName><ForeName>Timothy W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, US National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhangale</LastName><ForeName>Tushar R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Robert R</ForeName><Initials>RR</Initials><Identifier Source="ORCID">0000-0001-7151-4277</Identifier><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G-1307</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z99 AG999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2018 Jan;33(1):74. doi: 10.1002/mds.27276.</RefSource><PMID Version="1">29266412</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>COMPETING FINANCIAL INTERESTS</b>. The authors declare competing financial interests: details are available in the online version of the paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28892059</ArticleId><ArticleId IdType="mid">NIHMS940616</ArticleId><ArticleId IdType="pmc">PMC5812477</ArticleId><ArticleId IdType="doi">10.1038/ng.3955</ArticleId><ArticleId IdType="pii">ng.3955</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson&#x2019;s disease. Physiol. Rev. 2011;91:1161&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">22013209</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet. 2015;31:140&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">25703649</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbaum RL, Ellis CE. Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease. N. Engl. J. Med. 2003;348:1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672864</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, De Jager PL, Feany MB. Parkinson&#x2019;s disease: genetics and pathogenesis. Annu. Rev. Pathol. 2011;6:193&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">21034221</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein C, Westenberger A. Genetics of Parkinson&#x2019;s disease. Cold Spring Harb. Perspect. Med. 2012;2:a008888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253033</ArticleId><ArticleId IdType="pubmed">22315721</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. Genetic analysis of pathways to Parkinson disease. Neuron. 2010;68:201&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997424</ArticleId><ArticleId IdType="pubmed">20955928</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson&#x2019;s disease: progress and therapeutic implications. Mov. Disord. 2013;28:14&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578399</ArticleId><ArticleId IdType="pubmed">23389780</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nat. Genet. 2014;46:989&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller MF, et al. Using genome-wide complex trait analysis to quantify &#x2018;missing heritability&#x2019; in Parkinson&#x2019;s disease. Hum. Mol. Genet. 2012;21:4996&#x2013;5009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3576713</ArticleId><ArticleId IdType="pubmed">22892372</ArticleId></ArticleIdList></Reference><Reference><Citation>Do CB, et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson&#x2019;s disease. PLoS Genet. 2011;7:e1002141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121750</ArticleId><ArticleId IdType="pubmed">21738487</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchsberger C, Abecasis GR, Hinds DA. minimac2: faster genotype imputation. Bioinformatics. 2015;31:782&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4341061</ArticleId><ArticleId IdType="pubmed">25338720</ArticleId></ArticleIdList></Reference><Reference><Citation>Abecasis GR, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498066</ArticleId><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliano SA, et al. Genomics implicates adaptive and innate immunity in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Ann. Clin. Transl. Neurol. 2016;3:924&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5224821</ArticleId><ArticleId IdType="pubmed">28097204</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190&#x2013;2191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Welter D, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42:D1001&#x2013;D1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965119</ArticleId><ArticleId IdType="pubmed">24316577</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickrell JK, et al. Detection and interpretation of shared genetic influences on 42 human traits. Nat. Genet. 2016;48:709&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5207801</ArticleId><ArticleId IdType="pubmed">27182965</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol. Aging. 2015;36:1605.e7&#x2013;1605.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4317375</ArticleId><ArticleId IdType="pubmed">25444595</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. Imputation of sequence variants for identification of genetic risks for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377:641&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696507</ArticleId><ArticleId IdType="pubmed">21292315</ArticleId></ArticleIdList></Reference><Reference><Citation>International Parkinson&#x2019;s Disease Genomics Consortium &amp; Wellcome Trust Case Control Consortium 2. A two-stage meta-analysis identifies several new loci for Parkinson&#x2019;s disease. PLoS Genet. 2011;7:e1002142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128098</ArticleId><ArticleId IdType="pubmed">21738488</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankratz N, et al. Meta-analysis of Parkinson&#x2019;s disease: identification of a novel locus. RIT2. Ann. Neurol. 2012;71:370&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3354734</ArticleId><ArticleId IdType="pubmed">22451204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wissemann WT, et al. Association of Parkinson disease with structural and regulatory variants in the HLA region. Am. J. Hum. Genet. 2013;93:984&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824116</ArticleId><ArticleId IdType="pubmed">24183452</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekar A, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530:177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752392</ArticleId><ArticleId IdType="pubmed">26814963</ArticleId></ArticleIdList></Reference><Reference><Citation>Kichaev G, et al. Integrating functional data to prioritize causal variants in statistical fine-mapping studies. PLoS Genet. 2014;10:e1004722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4214605</ArticleId><ArticleId IdType="pubmed">25357204</ArticleId></ArticleIdList></Reference><Reference><Citation>Maller JB, et al. Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat. Genet. 2012;44:1294&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3791416</ArticleId><ArticleId IdType="pubmed">23104008</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, et al. Fine mapping causal variants with an approximate Bayesian method using marginal test statistics. Genetics. 2015;200:719&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4512539</ArticleId><ArticleId IdType="pubmed">25948564</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada Y, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506:376&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944098</ArticleId><ArticleId IdType="pubmed">24390342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentham J, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat. Genet. 2015;47:1457&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4668589</ArticleId><ArticleId IdType="pubmed">26502338</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348:648&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4547484</ArticleId><ArticleId IdType="pubmed">25954001</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 2014;34:11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10:e1004383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson&#x2019;s disease. N. Engl. J. Med. 2009;361:1651&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856322</ArticleId><ArticleId IdType="pubmed">19846850</ArticleId></ArticleIdList></Reference><Reference><Citation>Cang C, Aranda K, Seo YJ, Gasnier B, Ren D. TMEM175 is an organelle K+ channel regulating lysosomal function. Cell. 2015;162:1101&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317472</ArticleId></ArticleIdList></Reference><Reference><Citation>Felbor U, et al. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc. Natl. Acad. Sci. USA. 2002;99:7883&#x2013;7888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122989</ArticleId><ArticleId IdType="pubmed">12048238</ArticleId></ArticleIdList></Reference><Reference><Citation>McGlinchey RP, Lee JC. Cysteine cathepsins are essential in lysosomal degradation of &#x3b1;-synuclein. Proc. Natl. Acad. Sci. USA. 2015;112:9322&#x2013;9327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522768</ArticleId><ArticleId IdType="pubmed">26170293</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale CM, et al. Identification of modulators of autophagic flux in an image-based high content siRNA screen. Autophagy. 2016;12:713&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836002</ArticleId><ArticleId IdType="pubmed">27050463</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PH, O&#x2019;Dushlaine C, Thomas B, Purcell SM. INRICH: interval-based enrichment analysis for genome-wide association studies. Bioinformatics. 2012;28:1797&#x2013;1799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381960</ArticleId><ArticleId IdType="pubmed">22513993</ArticleId></ArticleIdList></Reference><Reference><Citation>Arranz AM, et al. LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism. J. Cell Sci. 2015;128:541&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">25501810</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin D, Shin JY, McManus MT, Pt&#xe1;cek LJ, Fu YH. Dicer ablation in oligodendrocytes provokes neuronal impairment in mice. Ann. Neurol. 2009;66:843&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885004</ArticleId><ArticleId IdType="pubmed">20035504</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan NN, et al. Epigenetic downregulation of Scn3a expression by valproate: a possible role in its anticonvulsant activity. Mol. Neurobiol. 2016;54:2831&#x2013;2842.</Citation><ArticleIdList><ArticleId IdType="pubmed">27013471</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittmer S, et al. TOX3 is a neuronal survival factor that induces transcription depending on the presence of CITED1 or phosphorylated CREB in the transcriptionally active complex. J. Cell Sci. 2011;124:252&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">21172805</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo M, et al. SATB1 plays a critical role in establishment of immune tolerance. J. Immunol. 2016;196:563&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">26667169</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins AL, Groom CR. The druggable genome. Nat. Rev. Drug Discov. 2002;1:727&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">12209152</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis AG, Yel L, Cao JN, Agrawal S, Gupta S. Common variable immunodeficiency associated with microdeletion of chromosome 1q42.1&#x2013;q42.3 and inositol 1,4,5-trisphosphate kinase B (ITPKB) deficiency. Clin. Transl. Immunology. 2016;5:e59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4735063</ArticleId><ArticleId IdType="pubmed">26900472</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc. Natl. Acad. Sci. USA. 2009;106:226&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629209</ArticleId><ArticleId IdType="pubmed">19114657</ArticleId></ArticleIdList></Reference><Reference><Citation>Durand EY, Do CB, Mountain JL, Macpherson JM. Ancestry composition: a novel, efficient pipeline for ancestry deconvolution. bioRxiv. 2014 Preprint at  http://www.biorxiv.org/content/early/2014/10/18/010512.</Citation></Reference><Reference><Citation>Henn BM, et al. Cryptic distant relatives are common in both isolated and cosmopolitan genetic samples. PLoS One. 2012;7:e34267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3317976</ArticleId><ArticleId IdType="pubmed">22509285</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through prephasing. Nat. Genet. 2012;44:955&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696580</ArticleId><ArticleId IdType="pubmed">22820512</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bakker PI, et al. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum. Mol. Genet. 2008;17:R122&#x2013;R128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782358</ArticleId><ArticleId IdType="pubmed">18852200</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan BK, et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 2015;47:291&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4495769</ArticleId><ArticleId IdType="pubmed">25642630</ArticleId></ArticleIdList></Reference><Reference><Citation>Finucane HK, et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 2015;47:1228&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626285</ArticleId><ArticleId IdType="pubmed">26414678</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Yang J, Goddard ME, Visscher PM, Wray NR. Estimation of pleiotropy between complex diseases using single-nucleotide polymorphism-derived genomic relationships and restricted maximum likelihood. Bioinformatics. 2012;28:2540&#x2013;2542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463125</ArticleId><ArticleId IdType="pubmed">22843982</ArticleId></ArticleIdList></Reference><Reference><Citation>Cingolani P, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 2012;6:80&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679285</ArticleId><ArticleId IdType="pubmed">22728672</ArticleId></ArticleIdList></Reference><Reference><Citation>dos Santos G, et al. FlyBase: introduction of the Drosophila melanogaster Release 6 reference genome assembly and large-scale migration of genome annotations. Nucleic Acids Res. 2015;43:D690&#x2013;D697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383921</ArticleId><ArticleId IdType="pubmed">25398896</ArticleId></ArticleIdList></Reference><Reference><Citation>Eppig JT, Blake JA, Bult CJ, Kadin JA, Richardson JE. The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease. Nucleic Acids Res. 2015;43:D726&#x2013;D736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384027</ArticleId><ArticleId IdType="pubmed">25348401</ArticleId></ArticleIdList></Reference><Reference><Citation>McKusick VA. MENDELIAN Inheritance in Man and its online version, OMIM. Am. J. Hum. Genet. 2007;80:588&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852721</ArticleId><ArticleId IdType="pubmed">17357067</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45:D362&#x2013;D368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210637</ArticleId><ArticleId IdType="pubmed">27924014</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AC, Robinson AJ. MitoMiner v3.1, an update on the mitochondrial proteomics database. Nucleic Acids Res. 2016;44:D1258&#x2013;D1261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702766</ArticleId><ArticleId IdType="pubmed">26432830</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo SE, Clauser KR, Mootha VK. MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins. Nucleic Acids Res. 2016;44:D1251&#x2013;D1257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702768</ArticleId><ArticleId IdType="pubmed">26450961</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagliarini DJ, et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell. 2008;134:112&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778844</ArticleId><ArticleId IdType="pubmed">18614015</ArticleId></ArticleIdList></Reference><Reference><Citation>Brozzi A, Urbanelli L, Germain PL, Magini A, Emiliani C. hLGDB: a database of human lysosomal genes and their regulation. Database (Oxford) 2013;2013:bat024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625959</ArticleId><ArticleId IdType="pubmed">23584836</ArticleId></ArticleIdList></Reference><Reference><Citation>Moussay E, et al. The acquisition of resistance to TNF&#x3b1; in breast cancer cells is associated with constitutive activation of autophagy as revealed by a transcriptome analysis using a custom microarray. Autophagy. 2011;7:760&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">21490427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28:27&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102409</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ontology Consortium. Gene Ontology Consortium: going forward. Nucleic Acids Res. 2015;43:D1049&#x2013;D1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383973</ArticleId><ArticleId IdType="pubmed">25428369</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC, et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342193</ArticleId><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28973551</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>12</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global &#x3b2;-Amyloid Burden.</ArticleTitle><Pagination><StartPage>1455</StartPage><EndPage>1463</EndPage><MedlinePgn>1455-1463</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.2216</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The ability to explore associations between reports of subjective cognitive decline (SCD) and biomarkers of early Alzheimer disease (AD) pathophysiologic processes (accumulation of neocortical &#x3b2;-amyloid [A&#x3b2;] and tau) provides an important opportunity to understand the basis of SCD and AD risk.</AbstractText><AbstractText Label="OBJECTIVE">To examine associations between SCD and global A&#x3b2; and tau burdens in regions of interest in clinically healthy older adults.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This imaging substudy of the Harvard Aging Brain Study included 133 clinically healthy older participants (Clinical Dementia Rating Scale global scores of 0) participating in the Harvard Aging Brain Study who underwent cross-sectional flortaucipir F 18 (previously known as AV 1451, T807) positron emission tomography (FTP-PET) imaging for tau and Pittsburgh compound B carbon 11-labeled PET (PiB-PET) imaging for A&#x3b2;. The following 2 regions for tau burden were identified: the entorhinal cortex, which exhibits early signs of tauopathy, and the inferior temporal region, which is more closely associated with AD-related pathologic mechanisms. Data were collected from June 11, 2012, through April 7, 2016.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Subjective cognitive decline was measured using a previously published method of z-transforming subscales from the Memory Functioning Questionnaire, the Everyday Cognition battery, and a 7-item questionnaire. The A&#x3b2; level was measured according to a summary distribution volume ratio of frontal, lateral temporal and parietal, and retrosplenial PiB-PET tracer uptake. The FTP-PET measures were computed as standardized uptake value ratios. Linear regression models focused on main and interactive effects of A&#x3b2;, entorhinal cortical, and inferior temporal tau on SCD, controlling for age, sex, educational attainment, and Geriatric Depression Scale score.</AbstractText><AbstractText Label="RESULTS">Of the 133 participants, 75 (56.3%) were women and 58 (43.6%) were men; mean (SD) age was 76 (6.9) years (range, 55-90 years). Thirty-nine participants (29.3%) exhibited a high A&#x3b2; burden. Greater SCD was associated with increasing entorhinal cortical tau burden (&#x3b2;&#x2009;=&#x2009;0.35; 95% CI, 0.19-.52; P&#x2009;&lt;&#x2009;.001) and A&#x3b2; burden (&#x3b2;&#x2009;=&#x2009;0.24; 95% CI, 0.08-.40; P&#x2009;=&#x2009;.005), but not inferior temporal tau burden (&#x3b2;&#x2009;=&#x2009;0.10; 95% CI, -0.08 to 0.28; P&#x2009;=&#x2009;.27). This association between entorhinal cortical tau burden and SCD was largely unchanged after accounting for A&#x3b2; burden (&#x3b2;&#x2009;=&#x2009;0.36; 95% CI, 0.15-.58; P&#x2009;=&#x2009;.001), and no interaction influenced SCD (&#x3b2;&#x2009;=&#x2009;-0.36; 95% CI, -0.34 to 0.09; P&#x2009;=&#x2009;.25). An exploratory post hoc whole-brain analysis also indicated that SCD was predominantly associated with greater tau burden in the entorhinal cortex.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Subjective cognitive decline is indicative of accumulation of early tauopathy in the medial temporal lobe, specifically in the entorhinal cortex, and to a lesser extent, elevated global levels of A&#x3b2;. Our findings suggest multiple underlying pathways that motivate SCD that do not necessarily interact to influence SCD endorsement. As such, multiple biological factors must be considered when assessing SCD in clinically healthy older adults.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buckley</LastName><ForeName>Rachel F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Florey Institutes of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melbourne School of Psychological Science, University of Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanseeuw</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Radiology, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>now affiliated with Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of Neuroscience, Universit&#xe9; Catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vannini</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aghjayan</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Properzi</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amariglio</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG048287</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG044431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR021110</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG051718</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR023043</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046396</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 EB015896</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR023401</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010618">Phenanthrolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 Dec 1;74(12):1400-1402. doi: 10.1001/jamaneurol.2017.2224.</RefSource><PMID Version="1">28973114</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059026" MajorTopicYN="N">Diagnostic Self Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010618" MajorTopicYN="N">Phenanthrolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Schultz reports sitting on an advisory board for Biogen in April 2016. Dr Sperling reports serving as a paid consultant for Abbvie, Biogen, Bracket, Genentech, Lundbeck, Roche, and Sanofi; serving as a coinvestigator for Avid, Eli Lilly and Co, and Janssen Alzheimer Immunotherapy clinical trials; speaking at symposia sponsored by Eli Lilly and Co, Biogen, and Janssen; and receiving research support from Janssen Pharmaceuticals, and Eli Lilly and Co. Dr Johnson reports serving as a paid consultant for Bayer, GE Healthcare, Janssen Alzheimer&#x2019;s Immunotherapy, Siemens Medical Solutions, Genzyme, Novartis, Biogen, Roche, ISIS Pharma, AZ Therapy, GEHC, Lundberg, and Abbvie; serving as a site coinvestigator for Lilly/Avid, Pfizer, Janssen Immunotherapy, and Navidea; and speaking at symposia sponsored by Janssen Alzheimer&#x2019;s Immunotherapy and Pfizer. These relationships are not related to the content in the manuscript. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>1</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28973551</ArticleId><ArticleId IdType="mid">NIHMS933894</ArticleId><ArticleId IdType="pmc">PMC5774633</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.2216</ArticleId><ArticleId IdType="pii">2656323</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Luck T, Luppa M, Matschinger H, Jessen F, Angermeyer MC, Riedel-Heller SG. Incident subjective memory complaints and the risk of subsequent dementia. Acta Psychiatr Scand. 2015;131(4):290&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">25201166</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Maruff P, Ames D, et al. AIBL Study. Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer&#x2019;s disease. Alzheimers Dement. 2016;12(7):796&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">26852195</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfsgruber S, Jessen F, Koppara A, et al. Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. Neurology. 2015;84(12):1261&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">25716354</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012;50(12):2880&#x2013;2886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3473106</ArticleId><ArticleId IdType="pubmed">22940426</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F, Feyen L, Freymann K, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging. 2006;27(12):1751&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pubmed">16309795</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer&#x2019;s disease. Neurobiol Aging. 2001;22(5):747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705634</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheef L, Spottke A, Daerr M, et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology. 2012;79(13):1332&#x2013;1339.</Citation><ArticleIdList><ArticleId IdType="pubmed">22914828</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryscio RJ, Abner EL, Cooper GE, et al. Self-reported memory complaints: implications from a longitudinal cohort with autopsies. Neurology. 2014;83(15):1359&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189103</ArticleId><ArticleId IdType="pubmed">25253756</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Schneider JA, Boyle PA, Bienias JL, Bennett DA. Memory complaints are related to Alzheimer disease pathology in older persons. Neurology. 2006;67(9):1581&#x2013;1585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740723</ArticleId><ArticleId IdType="pubmed">17101887</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, Betensky RA, Schultz AN, et al. FDG metabolism associated with tau-amyloid interaction predicts memory decline. Ann Neurol. 2017;81(4):583&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404378</ArticleId><ArticleId IdType="pubmed">28253546</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48(8):314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3611032</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982&#x2013;1983&#x2013;1983;17(1):37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Memory Scale&#x2013;Revised. San Antonio, TX: Psychological Corp; 1987.</Citation></Reference><Reference><Citation>Gilewski MJ, Zelinski EM, Schaie KW. The Memory Functioning Questionnaire for assessment of memory complaints in adulthood and old age. Psychol Aging. 1990;5(4):482&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">2278670</ArticleId></ArticleIdList></Reference><Reference><Citation>Farias ST, Mungas D, Reed BR, et al. The measurement of Everyday Cognition (ECog): scale development and psychometric properties. Neuropsychology. 2008;22(4):531&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2877034</ArticleId><ArticleId IdType="pubmed">18590364</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, Townsend MK, Grodstein F, Sperling RA, Rentz DM. Specific subjective memory complaints in older persons may indicate poor cognitive function. J Am Geriatr Soc. 2011;59(9):1612&#x2013;1617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315361</ArticleId><ArticleId IdType="pubmed">21919893</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O&#x2019;Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63(2):178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoup TM, Yokell DL, Rice PA, et al. A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J Labelled Comp Radiopharm. 2013;56(14):736&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114396</ArticleId><ArticleId IdType="pubmed">24339014</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, et al. Amyloid-&#x3b2; associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Labb&#xe9; C, Koepp M, Ashburner J, et al. Quantitative FBIWPET, editor. In: Absolute PET quantification with correction for partial volume effects within cerebral structures. Carson RE, Daube Witherspoon ME, Herscovitch P, editors. Bethesda, MD: National Institutes of Health; 1998. pp. 59&#x2013;66.</Citation></Reference><Reference><Citation>Greve DN, Salat DH, Bowen SL, et al. Different partial volume correction methods lead to different conclusions: an (18)F-FDG-PET study of aging. Neuroimage. 2016;132:334&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4851886</ArticleId><ArticleId IdType="pubmed">26915497</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study. Amyloid and APOE &#x3b5;4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760&#x2013;1767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Racine J. Cross-validated local linear nonparametric regression. Stat Sin. 2004;14:485&#x2013;512.</Citation></Reference><Reference><Citation>Lindeman RH, Merenda PF, Gold RZ. Introduction to Bivariate and Multivariate Analysis. London, England: Scott Foresman; 1980.</Citation></Reference><Reference><Citation>Dormann CF, Elith J, Bacher S, et al. Collinearity: a review of methods to deal with it and a simulation study evaluating their performance. Ecography. 2013;36(1):27&#x2013;46.</Citation></Reference><Reference><Citation>Hill NL, Mogle J, Wion R, et al. Subjective cognitive impairment and affective symptoms: a systematic review. Gerontologist. 2016;56(6):e109&#x2013;e127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181393</ArticleId><ArticleId IdType="pubmed">27342440</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Sue LI, Walker DG, et al. Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer&#x2019;s disease: implications for amyloid imaging. J Alzheimers Dis. 2012;28(4):869&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3760731</ArticleId><ArticleId IdType="pubmed">22112552</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, Mormino E, Vannini P, et al. Greater subjective cognitive concerns correspond with advancing stages of preclinical AD. Alzheimers Dement. 2014;10(4):566.</Citation></Reference><Reference><Citation>Colijn MA, Grossberg GT. Amyloid and tau biomarkers in subjective cognitive impairment. J Alzheimers Dis. 2015;47(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26402749</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Braak H, Brion J-P, et al. PART is part of Alzheimer disease. Acta Neuropathol. 2015;129(5):749&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4405349</ArticleId><ArticleId IdType="pubmed">25628035</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A, David JP, Sergeant N, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer&#x2019;s disease. Neurology. 1999;52(6):1158&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">10214737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain. 2016;139(pt 5):1551&#x2013;1567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DRMD, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo M, Devous M, Joshi A, et al. Relationships between 18F-AV-1451 (aka 18F-T807) PET tau binding and amyloid burden in cognitively normal subjects and patients with cognitive impairments suspected of Alzheimer&#x2019;s disease. J Nucl Med. 2015;56(suppl 3):245.</Citation></Reference><Reference><Citation>Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138(pt 7):2020&#x2013;2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806716</ArticleId><ArticleId IdType="pubmed">25953778</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, Kaufman SK, DeVos SL, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82(6):1271&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer&#x2019;s disease. Neuron. 2014;82(4):756&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135182</ArticleId><ArticleId IdType="pubmed">24853936</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Okamura N. Tau imaging in the study of ageing, Alzheimer&#x2019;s disease, and other neurodegenerative conditions. Curr Opin Neurobiol. 2016;36:43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">26397020</ArticleId></ArticleIdList></Reference><Reference><Citation>Beharry C, Cohen LS, Di J, Ibrahim K, Briffa-Mirabella S, Alonso AdC. Tau-induced neurodegeneration: mechanisms and targets. Neurosci Bull. 2014;30(2):346&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5562659</ArticleId><ArticleId IdType="pubmed">24733656</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F, Amariglio RE, van Boxtel M, et al. Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer&#x2019;s disease. Alzheimers Dement. 2014;10(6):844&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4317324</ArticleId><ArticleId IdType="pubmed">24798886</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinuevo JL, Rabin LA, Amariglio R, et al. Subjective Cognitive Decline Initiative (SCD-I) Working Group. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017;13(3):296&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344703</ArticleId><ArticleId IdType="pubmed">27825022</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28978656</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>18</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Female sex, early-onset hypertension, and risk of dementia.</ArticleTitle><Pagination><StartPage>1886</StartPage><EndPage>1893</EndPage><MedlinePgn>1886-1893</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000004602</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the association of early-adulthood and mid-adulthood hypertension with dementia in men and women.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated 5,646 members of a diverse integrated health care delivery system who had clinical examinations and health survey data from 1964 to 1973 (mean age 32.7 years; early adulthood) and 1978-1985 (mean age 44.3 years; mid-adulthood) and were members as of January 1, 1996 (mean age 59.8 years). Hypertension categories based on measurements of blood pressure (BP) and change in hypertension categories between the 2 examinations (e.g., onset hypertension) were used to predict dementia incidence from January 1, 1996, to September 30, 2015. Cox proportional hazard models were adjusted for demographics, vascular comorbidities, and hypertension treatment; inverse probability weighting accounted for differential attrition between first BP measurement and start of follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 532 individuals (9.4%) were diagnosed with dementia. Early adulthood hypertension was not associated with dementia, though effect estimates were elevated among women. Mid-adulthood hypertension was associated with 65% (95% confidence interval [CI] 1.25-2.18) increased dementia risk among women but not men. Onset of hypertension in mid-adulthood predicted 73% higher dementia risk in women (95% CI 1.24-2.40) compared to stable normotensive. There was no evidence that hypertension or changes in hypertension increased dementia risk among men.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Though midlife hypertension was more common in men, it was only associated with dementia risk in women. Sex differences in the timing of dementia risk factors have important implications for brain health and hypertension management.</AbstractText><CopyrightInformation>&#xa9; 2017 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gilsanz</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Kaiser Permanente Division of Research (P.G., C.P.Q., A.D., R.A.W.), Oakland; Department of Epidemiology and Biostatistics (P.G., E.R.M., M.M.G., R.A.W.), University of California, San Francisco; Department of Epidemiology (E.R.M.), Fielding School of Public Health, University of California, Los Angeles; and Department of Neurology (D.M.M., C.D.), University of California Davis, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeda</LastName><ForeName>Elizabeth Rose</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>From the Kaiser Permanente Division of Research (P.G., C.P.Q., A.D., R.A.W.), Oakland; Department of Epidemiology and Biostatistics (P.G., E.R.M., M.M.G., R.A.W.), University of California, San Francisco; Department of Epidemiology (E.R.M.), Fielding School of Public Health, University of California, Los Angeles; and Department of Neurology (D.M.M., C.D.), University of California Davis, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glymour</LastName><ForeName>M Maria</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>From the Kaiser Permanente Division of Research (P.G., C.P.Q., A.D., R.A.W.), Oakland; Department of Epidemiology and Biostatistics (P.G., E.R.M., M.M.G., R.A.W.), University of California, San Francisco; Department of Epidemiology (E.R.M.), Fielding School of Public Health, University of California, Los Angeles; and Department of Neurology (D.M.M., C.D.), University of California Davis, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quesenberry</LastName><ForeName>Charles P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>From the Kaiser Permanente Division of Research (P.G., C.P.Q., A.D., R.A.W.), Oakland; Department of Epidemiology and Biostatistics (P.G., E.R.M., M.M.G., R.A.W.), University of California, San Francisco; Department of Epidemiology (E.R.M.), Fielding School of Public Health, University of California, Los Angeles; and Department of Neurology (D.M.M., C.D.), University of California Davis, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mungas</LastName><ForeName>Dan M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>From the Kaiser Permanente Division of Research (P.G., C.P.Q., A.D., R.A.W.), Oakland; Department of Epidemiology and Biostatistics (P.G., E.R.M., M.M.G., R.A.W.), University of California, San Francisco; Department of Epidemiology (E.R.M.), Fielding School of Public Health, University of California, Los Angeles; and Department of Neurology (D.M.M., C.D.), University of California Davis, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Kaiser Permanente Division of Research (P.G., C.P.Q., A.D., R.A.W.), Oakland; Department of Epidemiology and Biostatistics (P.G., E.R.M., M.M.G., R.A.W.), University of California, San Francisco; Department of Epidemiology (E.R.M.), Fielding School of Public Health, University of California, Los Angeles; and Department of Neurology (D.M.M., C.D.), University of California Davis, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dean</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Kaiser Permanente Division of Research (P.G., C.P.Q., A.D., R.A.W.), Oakland; Department of Epidemiology and Biostatistics (P.G., E.R.M., M.M.G., R.A.W.), University of California, San Francisco; Department of Epidemiology (E.R.M.), Fielding School of Public Health, University of California, Los Angeles; and Department of Neurology (D.M.M., C.D.), University of California Davis, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitmer</LastName><ForeName>Rachel A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>From the Kaiser Permanente Division of Research (P.G., C.P.Q., A.D., R.A.W.), Oakland; Department of Epidemiology and Biostatistics (P.G., E.R.M., M.M.G., R.A.W.), University of California, San Francisco; Department of Epidemiology (E.R.M.), Fielding School of Public Health, University of California, Los Angeles; and Department of Neurology (D.M.M., C.D.), University of California Davis, Sacramento. Rachel.Whitmer@kp.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K99 AG053410</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG052132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG049663</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28978656</ArticleId><ArticleId IdType="pmc">PMC5664296</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004602</ArticleId><ArticleId IdType="pii">WNL.0000000000004602</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yoon SS, Fryar CD, Carroll M. Hypertension Prevalence and Control Among Adults: United States, 2011&#x2013;2014: NCHS Data Brief, No 220. Hyattsville: NCHS; 2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">26633197</ArticleId></ArticleIdList></Reference><Reference><Citation>Palatini P, Mos L, Santonastaso M, et al. . Premenopausal women have increased risk of hypertensive target organ damage compared with men of similar age. J Womens Health 2011;20:1175&#x2013;1181.</Citation><ArticleIdList><ArticleId IdType="pubmed">21702688</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng S, Claggett B, Correia AW, et al. . Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study. Circulation 2014;130:820&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161984</ArticleId><ArticleId IdType="pubmed">25210095</ArticleId></ArticleIdList></Reference><Reference><Citation>Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol 2008;585:97&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">18395201</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668425</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Ross GW, Petrovitch H, et al. . Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000;21:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794848</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Mosley TH Jr, Gottesman RF, Catellier D, Sharrett AR, Coresh J. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry 2009;80:1194&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783764</ArticleId><ArticleId IdType="pubmed">19692426</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer's Association. 2017 Alzheimer's disease facts and figures. Alzheimers Dement 2017;13:325&#x2013;373.</Citation></Reference><Reference><Citation>Gordon NP, Kaplan GA. Some evidence refuting the HMO &#x201c;favorable selection&#x201d; hypothesis: the case of Kaiser Permanente. Adv Health Econ Health Serv Res 1991;12:19&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">10122802</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992;82:703&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1694121</ArticleId><ArticleId IdType="pubmed">1566949</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon NP. Similarity of the Kaiser Permanente Senior Member Population in Northern California to the Non-Kaiser Permanente Covered and General Population of Seniors in Northern California: Statistics from the 2009 California Health Interview Survey. Oakland: Kaiser Permanente Northern California Division of Research; 2012.</Citation></Reference><Reference><Citation>Chobanian AV, Bakris GL, Black HR, et al. . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560&#x2013;2572.</Citation><ArticleIdList><ArticleId IdType="pubmed">12748199</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement 2016;12:216&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969071</ArticleId><ArticleId IdType="pubmed">26874595</ArticleId></ArticleIdList></Reference><Reference><Citation>Exalto LG, Biessels GJ, Karter AJ, Huang ES, Quesenberry CP Jr, Whitmer RA. Severe diabetic retinal disease and dementia risk in type 2 diabetes. J Alzheimers Dis 2014;42(suppl 3):S109&#x2013;S117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4373321</ArticleId><ArticleId IdType="pubmed">24625797</ArticleId></ArticleIdList></Reference><Reference><Citation>Exalto LG, Biessels GJ, Karter AJ, et al. . Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. Lancet Diabetes Endocrinol 2013;1:183&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4429783</ArticleId><ArticleId IdType="pubmed">24622366</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeda ER, Karter AJ, Huang ES, Moffet HH, Haan MN, Whitmer RA. Racial/ethnic differences in dementia risk among older type 2 diabetic patients: the diabetes and aging study. Diabetes Care 2014;37:1009&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964496</ArticleId><ArticleId IdType="pubmed">24271192</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301:1565&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782622</ArticleId><ArticleId IdType="pubmed">19366776</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology 2008;71:1057&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">18367704</ArticleId></ArticleIdList></Reference><Reference><Citation>Katon WJ, Lin EHB, Williams LH, et al. . Comorbid depression is associated with an increased risk of dementia diagnosis in patients with diabetes: a prospective cohort study. J Gen Intern Med 2010;25:423&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855007</ArticleId><ArticleId IdType="pubmed">20108126</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Q, Schaubel DE. Evaluating bias correction in weighted proportional hazards regression. Lifetime Data Anal 2009;15:120&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367517</ArticleId><ArticleId IdType="pubmed">18958616</ArticleId></ArticleIdList></Reference><Reference><Citation>Beiser A, D'Agostino RB Sr, Seshadri S, Sullivan LM, Wolf PA. Computing estimates of incidence, including lifetime risk: Alzheimer's disease in the Framingham Study: The Practical Incidence Estimators (PIE) macro. Stat Med 2000;19:1495&#x2013;1522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10844714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala E-L, Laakso MP, et al. . Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001;322:1447&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC32306</ArticleId><ArticleId IdType="pubmed">11408299</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Kasagi F, Sasaki H, Masunari N, Mimori Y, Suzuki G. Association between dementia and midlife risk factors: the radiation effects research foundation adult health study. J Am Geriatr Soc 2003;51:410&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">12588587</ArticleId></ArticleIdList></Reference><Reference><Citation>Joas E, Backman K, Gustafson D, et al. . Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension 2012;59:796&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">22331381</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevre K, Lefrandt JD, Nordby G, et al. . Autonomic function in hypertensive and normotensive subjects: the importance of gender. Hypertension 2001;37:1351&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408376</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim JG, Shapiro EP, Vaidya D, et al. . Sex differences in left ventricular function in older persons with mild hypertension. Am Heart J 2005;150:934&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">16290968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimm H, Lee PH, Shin YJ, et al. . Mid-life and late-life vascular risk factors and dementia in Korean men and women. Arch Gerontol Geriatr 2011;52:e117&#x2013;e122.</Citation><ArticleIdList><ArticleId IdType="pubmed">20932588</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, Xue QL, Masaki K, et al. . Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension 2009;54:233&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136040</ArticleId><ArticleId IdType="pubmed">19564551</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadic M, Cuspidi C, Hering D. Hypertension and cognitive dysfunction in elderly: blood pressure management for this global burden. BMC Cardiovasc Disord 2016;16:208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5093934</ArticleId><ArticleId IdType="pubmed">27809779</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009;8:1006&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">19782001</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Hoshide S, Kario K. Hypertension and dementia. Am J Hypertens 2010;23:116&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">19927134</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28883427</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Sep</Month><Day>07</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Tau exacerbates excitotoxic brain damage in an animal model of stroke.</ArticleTitle><Pagination><StartPage>473</StartPage><MedlinePgn>473</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">473</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-017-00618-0</ELocationID><Abstract><AbstractText>Neuronal excitotoxicity induced by aberrant excitation of glutamatergic receptors contributes to brain damage in stroke. Here we show that tau-deficient (tau<sup>-/-</sup>) mice are profoundly protected from excitotoxic brain damage and neurological deficits following experimental stroke, using a middle cerebral artery occlusion with reperfusion model. Mechanistically, we show that this protection is due to site-specific inhibition of glutamate-induced and Ras/ERK-mediated toxicity by accumulation of Ras-inhibiting SynGAP1, which resides in a post-synaptic complex with tau. Accordingly, reducing SynGAP1 levels in tau<sup>-/-</sup> mice abolished the protection from pharmacologically induced excitotoxicity and middle cerebral artery occlusion-induced brain damage. Conversely, over-expression of SynGAP1 prevented excitotoxic ERK activation in wild-type neurons. Our findings suggest that tau mediates excitotoxic Ras/ERK signaling by controlling post-synaptic compartmentalization of SynGAP1.Excitotoxicity contributes to neuronal injury following stroke. Here the authors show that tau promotes excitotoxicity by a post-synaptic mechanism, involving site-specific control of ERK activation, in a mouse model of stroke.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>Mian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dementia Research Unit (DRU), School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gladbach</LastName><ForeName>Amadeus</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dementia Research Unit (DRU), School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eersel</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Dementia Research Unit (DRU), School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ittner</LastName><ForeName>Arne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dementia Research Unit (DRU), School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Przybyla</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dementia Research Unit (DRU), School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Hummel</LastName><ForeName>Annika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dementia Research Unit (DRU), School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Sook Wern</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Dementia Research Unit (DRU), School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Hoven</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Dementia Research Unit (DRU), School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wei S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Dementia Research Unit (DRU), School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Julius</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1046-2968</Identifier><AffiliationInfo><Affiliation>Division of Cancer Genetics and Therapeutics, Laboratory of Chromatin, Epigenetics &amp; Differentiation, Institute of Molecular and Cell Biology, A*STAR (Agency for Science, Technology and Research), Singapore, 138673, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parmar</LastName><ForeName>Jasneet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Translational Neuroscience Facility and Department of Physiology, School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonquieres</LastName><ForeName>Georg von</ForeName><Initials>GV</Initials><AffiliationInfo><Affiliation>Translational Neuroscience Facility and Department of Physiology, School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefen</LastName><ForeName>Holly</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuron Culture Core Facility (NCCF), The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guccione</LastName><ForeName>Ernesto</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Cancer Genetics and Therapeutics, Laboratory of Chromatin, Epigenetics &amp; Differentiation, Institute of Molecular and Cell Biology, A*STAR (Agency for Science, Technology and Research), Singapore, 138673, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117549, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fath</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neuron Culture Core Facility (NCCF), The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurodegeneration and Repair Unit (NRU), School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Housley</LastName><ForeName>Gary D</ForeName><Initials>GD</Initials><Identifier Source="ORCID">0000-0002-8413-588X</Identifier><AffiliationInfo><Affiliation>Translational Neuroscience Facility and Department of Physiology, School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klugmann</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0574-612X</Identifier><AffiliationInfo><Affiliation>Translational Neuroscience Facility and Department of Physiology, School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Yazi D</ForeName><Initials>YD</Initials><AffiliationInfo><Affiliation>Dementia Research Unit (DRU), School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ittner</LastName><ForeName>Lars M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Dementia Research Unit (DRU), School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia. l.ittner@unsw.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transgenic Animal Unit, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney, NSW, 2052, Australia. l.ittner@unsw.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Australia (NeuRA), Sydney, NSW, 2031, Australia. l.ittner@unsw.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484512">Syngap1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020703">ras GTPase-Activating Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2017 Nov;13(11):639. doi: 10.1038/nrneurol.2017.141.</RefSource><PMID Version="1">28960188</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020244" MajorTopicYN="N">Infarction, Middle Cerebral Artery</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013574" MajorTopicYN="N">Synaptosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020703" MajorTopicYN="N">ras GTPase-Activating Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28883427</ArticleId><ArticleId IdType="pmc">PMC5589746</ArticleId><ArticleId IdType="doi">10.1038/s41467-017-00618-0</ArticleId><ArticleId IdType="pii">10.1038/s41467-017-00618-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008;371:1612&#x2013;1623. doi: 10.1016/S0140-6736(08)60694-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(08)60694-7</ArticleId><ArticleId IdType="pubmed">18468545</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanderson TH, Reynolds CA, Kumar R, Przyklenk K, Huttemann M. Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. Mol. Neurobiol. 2013;47:9&#x2013;23. doi: 10.1007/s12035-012-8344-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8344-z</ArticleId><ArticleId IdType="pmc">PMC3725766</ArticleId><ArticleId IdType="pubmed">23011809</ArticleId></ArticleIdList></Reference><Reference><Citation>Hacke W, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 2008;359:1317&#x2013;1329. doi: 10.1056/NEJMoa0804656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0804656</ArticleId><ArticleId IdType="pubmed">18815396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidwell CS, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N. Engl. J. Med. 2013;368:914&#x2013;923. doi: 10.1056/NEJMoa1212793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1212793</ArticleId><ArticleId IdType="pmc">PMC3690785</ArticleId><ArticleId IdType="pubmed">23394476</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell BC, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N. Engl. J. Med. 2015;372:1009&#x2013;1018. doi: 10.1056/NEJMoa1414792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1414792</ArticleId><ArticleId IdType="pubmed">25671797</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkhemer OA, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N. Engl. J. Med. 2015;372:11&#x2013;20. doi: 10.1056/NEJMoa1411587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1411587</ArticleId><ArticleId IdType="pubmed">25517348</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt A, Minnerup J, Kleinschnitz C. Emerging neuroprotective drugs for the treatment of acute ischaemic stroke. Expert Opin. Emerg. Drugs. 2013;18:109&#x2013;120. doi: 10.1517/14728214.2013.790363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728214.2013.790363</ArticleId><ArticleId IdType="pubmed">23600899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai TW, Zhang S, Wang YT. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog. Neurobiol. 2014;115:157&#x2013;188. doi: 10.1016/j.pneurobio.2013.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2013.11.006</ArticleId><ArticleId IdType="pubmed">24361499</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon RP, Swan JH, Griffiths T, Meldrum BS. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science. 1984;226:850&#x2013;852. doi: 10.1126/science.6093256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.6093256</ArticleId><ArticleId IdType="pubmed">6093256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nat. Rev. Neurosci. 2007;8:663&#x2013;672. doi: 10.1038/nrn2194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2194</ArticleId><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Ittner A, Ittner LM. Tau-targeted treatment strategies in Alzheimer&#x2019;s disease. Br. J. Pharmacol. 2012;165:1246&#x2013;1259. doi: 10.1111/j.1476-5381.2011.01713.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2011.01713.x</ArticleId><ArticleId IdType="pmc">PMC3372713</ArticleId><ArticleId IdType="pubmed">22044248</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159&#x2013;168. doi: 10.1016/0896-6273(92)90117-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(92)90117-V</ArticleId><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke YD, et al. Lessons from tau-deficient mice. Int. J. Alzheimers Dis. 2012;2012:873270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375147</ArticleId><ArticleId IdType="pubmed">22720190</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, et al. Transient cerebral ischemia induces aberrant neuronal cell cycle re-entry and Alzheimer&#x2019;s disease-like tauopathy in female rats. J. Biol. Chem. 2004;279:22684&#x2013;22692. doi: 10.1074/jbc.M311768200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M311768200</ArticleId><ArticleId IdType="pubmed">14982935</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, Yang S, Liu R, Simpkins JW. Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein. Brain Res. 2004;1022:30&#x2013;38. doi: 10.1016/j.brainres.2004.05.106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2004.05.106</ArticleId><ArticleId IdType="pubmed">15353210</ArticleId></ArticleIdList></Reference><Reference><Citation>Morioka M, et al. Hyperphosphorylation at serine 199/202 of tau factor in the gerbil hippocampus after transient forebrain ischemia. Biochem. Biophys. Res. Commun. 2006;347:273&#x2013;278. doi: 10.1016/j.bbrc.2006.06.096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.06.096</ArticleId><ArticleId IdType="pubmed">16815303</ArticleId></ArticleIdList></Reference><Reference><Citation>Geddes JW, Schwab C, Craddock S, Wilson JL, Pettigrew LC. Alterations in tau immunostaining in the rat hippocampus following transient cerebral ischemia. J. Cereb. Blood Flow Metab. 1994;14:554&#x2013;564. doi: 10.1038/jcbfm.1994.69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.1994.69</ArticleId><ArticleId IdType="pubmed">7516935</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar D, Dawson D. Tau protein is altered by focal cerebral ischaemia in the rat: an immunohistochemical and immunoblotting study. Brain. Res. 1995;684:70&#x2013;78. doi: 10.1016/0006-8993(95)00417-O.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(95)00417-O</ArticleId><ArticleId IdType="pubmed">7583206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon-Krajcer W, Kozniewska E, Lazarewicz JW, Ksiezak-Reding H. Differential changes in phosphorylation of tau at PHF-1 and 12E8 epitopes during brain ischemia and reperfusion in gerbils. Neurochem. Res. 2007;32:729&#x2013;737. doi: 10.1007/s11064-006-9199-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-006-9199-3</ArticleId><ArticleId IdType="pubmed">17191139</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316:750&#x2013;754. doi: 10.1126/science.1141736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1141736</ArticleId><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, et al. Dendritic Function of Tau Mediates Amyloid-beta Toxicity in Alzheimer&#x2019;s Disease Mouse Models. Cell. 2010;142:387&#x2013;397. doi: 10.1016/j.cell.2010.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.06.036</ArticleId><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner A, et al. Site-specific phosphorylation of tau inhibits amyloid-beta toxicity in Alzheimer&#x2019;s mice. Science. 2016;354:904&#x2013;908. doi: 10.1126/science.aah6205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aah6205</ArticleId><ArticleId IdType="pubmed">27856911</ArticleId></ArticleIdList></Reference><Reference><Citation>Brott T, Bogousslavsky J. Treatment of acute ischemic stroke. N. Engl. J. Med. 2000;343:710&#x2013;722. doi: 10.1056/NEJM200009073431007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200009073431007</ArticleId><ArticleId IdType="pubmed">10974136</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarts M, et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science. 2002;298:846&#x2013;850. doi: 10.1126/science.1072873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072873</ArticleId><ArticleId IdType="pubmed">12399596</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur. J. Pharmacol. 2013;698:6&#x2013;18. doi: 10.1016/j.ejphar.2012.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2012.10.032</ArticleId><ArticleId IdType="pubmed">23123057</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, McCullough LD. Middle cerebral artery occlusion model in rodents: methods and potential pitfalls. J. Biomed. Biotechnol. 2011;2011:464701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035178</ArticleId><ArticleId IdType="pubmed">21331357</ArticleId></ArticleIdList></Reference><Reference><Citation>Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol. Biochem. Behav. 2007;87:179&#x2013;197. doi: 10.1016/j.pbb.2007.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbb.2007.04.015</ArticleId><ArticleId IdType="pubmed">17521716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, et al. Comparison of surgical methods of transient middle cerebral artery occlusion between rats and mice. J. Vet. Med. Sci. 2014;76:1555&#x2013;1561. doi: 10.1292/jvms.14-0258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1292/jvms.14-0258</ArticleId><ArticleId IdType="pmc">PMC4300368</ArticleId><ArticleId IdType="pubmed">25649935</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Schafer DP, McCullough LD. TTC, fluoro-Jade B and NeuN staining confirm evolving phases of infarction induced by middle cerebral artery occlusion. J. Neurosci. Methods. 2009;179:1&#x2013;8. doi: 10.1016/j.jneumeth.2008.12.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2008.12.028</ArticleId><ArticleId IdType="pmc">PMC2674851</ArticleId><ArticleId IdType="pubmed">19167427</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HB, et al. Neuroprotective effects of LBP on brain ischemic reperfusion neurodegeneration. Eur. Rev. Med. Pharmacol. Sci. 2013;17:2760&#x2013;2765.</Citation><ArticleIdList><ArticleId IdType="pubmed">24174357</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartings JA, Williams AJ, Tortella FC. Occurrence of nonconvulsive seizures, periodic epileptiform discharges, and intermittent rhythmic delta activity in rat focal ischemia. Exp. Neurol. 2003;179:139&#x2013;149. doi: 10.1016/S0014-4886(02)00013-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-4886(02)00013-4</ArticleId><ArticleId IdType="pubmed">12618120</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Jiang N, Powers C, Chopp M. Neuronal damage and plasticity identified by microtubule-associated protein 2, growth-associated protein 43, and cyclin D1 immunoreactivity after focal cerebral ischemia in rats. Stroke. 1998;29:1972&#x2013;1980. doi: 10.1161/01.STR.29.9.1972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.29.9.1972</ArticleId><ArticleId IdType="pubmed">9731626</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Vulnerability of dentate granule cells to disruption of arc expression in human amyloid precursor protein transgenic mice. J. Neurosci. 2005;25:9686&#x2013;9693. doi: 10.1523/JNEUROSCI.2829-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2829-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725729</ArticleId><ArticleId IdType="pubmed">16237173</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass P, et al. Induction of FOS and JUN proteins after focal ischemia in the rat: differential effect of the N-methyl-D-aspartate receptor antagonist MK-801. Acta Neuropathol. 1992;84:545&#x2013;553. doi: 10.1007/BF00304474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00304474</ArticleId><ArticleId IdType="pubmed">1462767</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowe SL, Tsukerman S, Gale K, Jorgensen TJ, Kondratyev AD. Phosphorylation of histone H2A.X as an early marker of neuronal endangerment following seizures in the adult rat brain. J. Neurosci. 2011;31:7648&#x2013;7656. doi: 10.1523/JNEUROSCI.0092-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0092-11.2011</ArticleId><ArticleId IdType="pmc">PMC3118469</ArticleId><ArticleId IdType="pubmed">21613478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov A, et al. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J. Physiol. 2006;572:789&#x2013;798. doi: 10.1113/jphysiol.2006.105510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2006.105510</ArticleId><ArticleId IdType="pmc">PMC1779993</ArticleId><ArticleId IdType="pubmed">16513670</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols RA, Sihra TS, Czernik AJ, Nairn AC, Greengard P. Calcium/calmodulin-dependent protein kinase II increases glutamate and noradrenaline release from synaptosomes. Nature. 1990;343:647&#x2013;651. doi: 10.1038/343647a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/343647a0</ArticleId><ArticleId IdType="pubmed">2154695</ArticleId></ArticleIdList></Reference><Reference><Citation>Corera AT, Doucet G, Fon EA. Long-term potentiation in isolated dendritic spines. PLoS ONE. 2009;4:e6021. doi: 10.1371/journal.pone.0006021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0006021</ArticleId><ArticleId IdType="pmc">PMC2695539</ArticleId><ArticleId IdType="pubmed">19547754</ArticleId></ArticleIdList></Reference><Reference><Citation>Krapivinsky G, et al. The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1. Neuron. 2003;40:775&#x2013;784. doi: 10.1016/S0896-6273(03)00645-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00645-7</ArticleId><ArticleId IdType="pubmed">14622581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondragon-Rodriguez S, et al. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. J. Biol. Chem. 2012;287:32040&#x2013;32053. doi: 10.1074/jbc.M112.401240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.401240</ArticleId><ArticleId IdType="pmc">PMC3442535</ArticleId><ArticleId IdType="pubmed">22833681</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambilla R, et al. A role for the Ras signalling pathway in synaptic transmission and long-term memory. Nature. 1997;390:281&#x2013;286. doi: 10.1038/36849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/36849</ArticleId><ArticleId IdType="pubmed">9384379</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Liao D, Lau LF, Huganir RL. SynGAP: a synaptic RasGAP that associates with the PSD-95/SAP90 protein family. Neuron. 1998;20:683&#x2013;691. doi: 10.1016/S0896-6273(00)81008-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)81008-9</ArticleId><ArticleId IdType="pubmed">9581761</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HJ, Rojas-Soto M, Oguni A, Kennedy MB. A synaptic Ras-GTPase activating protein (p135 SynGAP) inhibited by CaM kinase II. Neuron. 1998;20:895&#x2013;904. doi: 10.1016/S0896-6273(00)80471-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80471-7</ArticleId><ArticleId IdType="pubmed">9620694</ArticleId></ArticleIdList></Reference><Reference><Citation>King PD, Lubeck BA, Lapinski PE. Nonredundant functions for Ras GTPase-activating proteins in tissue homeostasis. Sci. Signal. 2013;6:re1. doi: 10.1126/scisignal.2003669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2003669</ArticleId><ArticleId IdType="pmc">PMC5483993</ArticleId><ArticleId IdType="pubmed">23443682</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell KF, et al. Calmodulin kinase IV-dependent CREB activation is required for neuroprotection via NMDA receptor-PSD95 disruption. J. Neurochem. 2013;126:274&#x2013;287. doi: 10.1111/jnc.12176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12176</ArticleId><ArticleId IdType="pubmed">23363435</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladbach A, van Eersel J, Bi M, Ke YD, Ittner LM. ERK inhibition with PD184161 mitigates brain damage in a mouse model of stroke. J. Neural Transm. 2014;121:543&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">24337667</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy K, et al. Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. Am. J. Pathol. 2012;181:1928&#x2013;1940. doi: 10.1016/j.ajpath.2012.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2012.08.012</ArticleId><ArticleId IdType="pubmed">23026200</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK, et al. Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J. Neurosci. 2013;33:1651&#x2013;1659. doi: 10.1523/JNEUROSCI.3191-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3191-12.2013</ArticleId><ArticleId IdType="pmc">PMC3711605</ArticleId><ArticleId IdType="pubmed">23345237</ArticleId></ArticleIdList></Reference><Reference><Citation>Namura S, et al. Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc. Natl Acad. Sci. USA. 2001;98:11569&#x2013;11574. doi: 10.1073/pnas.181213498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.181213498</ArticleId><ArticleId IdType="pmc">PMC58770</ArticleId><ArticleId IdType="pubmed">11504919</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterweil EK, et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron. 2013;77:243&#x2013;250. doi: 10.1016/j.neuron.2012.01.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.01.034</ArticleId><ArticleId IdType="pmc">PMC3597444</ArticleId><ArticleId IdType="pubmed">23352161</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh JS, Manzerra P, Kennedy MB. Regulation of the neuron-specific Ras GTPase-activating protein, synGAP, by Ca2+/calmodulin-dependent protein kinase II. J. Biol. Chem. 2004;279:17980&#x2013;17988. doi: 10.1074/jbc.M314109200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M314109200</ArticleId><ArticleId IdType="pubmed">14970204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MJ, Dunah AW, Wang YT, Sheng M. Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron. 2005;46:745&#x2013;760. doi: 10.1016/j.neuron.2005.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.04.031</ArticleId><ArticleId IdType="pubmed">15924861</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Tao-Cheng JH, Reese TS, Dosemeci A. SynGAP moves out of the core of the postsynaptic density upon depolarization. Neuroscience. 2011;192:132&#x2013;139. doi: 10.1016/j.neuroscience.2011.06.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2011.06.061</ArticleId><ArticleId IdType="pmc">PMC3166368</ArticleId><ArticleId IdType="pubmed">21736925</ArticleId></ArticleIdList></Reference><Reference><Citation>Walkup WGt, et al. Phosphorylation of synaptic GTPase-activating protein (synGAP) by Ca2+/calmodulin-dependent protein kinase II (CaMKII) and cyclin-dependent kinase 5 (CDK5) alters the ratio of its GAP activity toward Ras and Rap GTPases. J. Biol. Chem. 2015;290:4908&#x2013;4927. doi: 10.1074/jbc.M114.614420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.614420</ArticleId><ArticleId IdType="pmc">PMC4335230</ArticleId><ArticleId IdType="pubmed">25533468</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki Y, Zeng M, Zhang M, Huganir RL. Rapid dispersion of SynGAP from synaptic spines triggers AMPA receptor insertion and spine enlargement during LTP. Neuron. 2015;85:173&#x2013;189. doi: 10.1016/j.neuron.2014.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.12.023</ArticleId><ArticleId IdType="pmc">PMC4428669</ArticleId><ArticleId IdType="pubmed">25569349</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei L, Teves RL, Wallace MC, Gurd JW. Transient cerebral ischemia increases tyrosine phosphorylation of the synaptic RAS-GTPase activating protein, SynGAP. J. Cereb. Blood Flow Metab. 2001;21:955&#x2013;963. doi: 10.1097/00004647-200108000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004647-200108000-00008</ArticleId><ArticleId IdType="pubmed">11487731</ArticleId></ArticleIdList></Reference><Reference><Citation>Song B, Yan XB, Zhang GY. PSD-95 promotes CaMKII-catalyzed serine phosphorylation of the synaptic RAS-GTPase activating protein SynGAP after transient brain ischemia in rat hippocampus. Brain Res. 2004;1005:44&#x2013;50. doi: 10.1016/j.brainres.2004.01.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2004.01.032</ArticleId><ArticleId IdType="pubmed">15044063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamdan FF, et al. Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation. N. Engl. J. Med. 2009;360:599&#x2013;605. doi: 10.1056/NEJMoa0805392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0805392</ArticleId><ArticleId IdType="pmc">PMC2925262</ArticleId><ArticleId IdType="pubmed">19196676</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvill GL, et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat. Genet. 2013;45:825&#x2013;830. doi: 10.1038/ng.2646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2646</ArticleId><ArticleId IdType="pmc">PMC3704157</ArticleId><ArticleId IdType="pubmed">23708187</ArticleId></ArticleIdList></Reference><Reference><Citation>Berryer MH, et al. Mutations in SYNGAP1 cause intellectual disability, autism, and a specific form of epilepsy by inducing haploinsufficiency. Hum. Mutat. 2013;34:385&#x2013;394. doi: 10.1002/humu.22248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22248</ArticleId><ArticleId IdType="pubmed">23161826</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumbaugh G, Adams JP, Kim JH, Huganir RL. SynGAP regulates synaptic strength and mitogen-activated protein kinases in cultured neurons. Proc. Natl Acad. Sci. USA. 2006;103:4344&#x2013;4351. doi: 10.1073/pnas.0600084103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0600084103</ArticleId><ArticleId IdType="pmc">PMC1450173</ArticleId><ArticleId IdType="pubmed">16537406</ArticleId></ArticleIdList></Reference><Reference><Citation>Krapivinsky G, Medina I, Krapivinsky L, Gapon S, Clapham DE. SynGAP-MUPP1-CaMKII synaptic complexes regulate p38 MAP kinase activity and NMDA receptor-dependent synaptic AMPA receptor potentiation. Neuron. 2004;43:563&#x2013;574. doi: 10.1016/j.neuron.2004.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.08.003</ArticleId><ArticleId IdType="pubmed">15312654</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez LE, Chen HJ, Sokolova I, Knuesel I, Kennedy MB. SynGAP regulates spine formation. J. Neurosci. 2004;24:8862&#x2013;8872. doi: 10.1523/JNEUROSCI.3213-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3213-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729942</ArticleId><ArticleId IdType="pubmed">15470153</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhia M, Feldon J, Knuesel I, Yee BK. Appetitively motivated instrumental learning in SynGAP heterozygous knockout mice. Behav. Neurosci. 2009;123:1114&#x2013;1128. doi: 10.1037/a0017118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0017118</ArticleId><ArticleId IdType="pubmed">19824778</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhia M, Yee BK, Feldon J, Markopoulos F, Knuesel I. Disruption of hippocampus-regulated behavioural and cognitive processes by heterozygous constitutive deletion of SynGAP. Eur. J. Neurosci. 2010;31:529&#x2013;543. doi: 10.1111/j.1460-9568.2010.07079.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2010.07079.x</ArticleId><ArticleId IdType="pubmed">20105235</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement JP, et al. Pathogenic SYNGAP1 mutations impair cognitive development by disrupting maturation of dendritic spine synapses. Cell. 2012;151:709&#x2013;723. doi: 10.1016/j.cell.2012.08.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.08.045</ArticleId><ArticleId IdType="pmc">PMC3500766</ArticleId><ArticleId IdType="pubmed">23141534</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhia M, et al. Molecular and behavioral changes associated with adult hippocampus-specific SynGAP1 knockout. Learn. Mem. 2012;19:268&#x2013;281. doi: 10.1101/lm.026351.112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/lm.026351.112</ArticleId><ArticleId IdType="pubmed">22700469</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker KL, Meyer M, Barde YA. Neurotrophins are required for nerve growth during development. Nat. Neurosci. 2001;4:29&#x2013;37. doi: 10.1038/82868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/82868</ArticleId><ArticleId IdType="pubmed">11135642</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly ES, Jr, Winfree CJ, Stern DM, Solomon RA, Pinsky DJ. Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia. Neurosurgery. 1996;38:523&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">8837805</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke YD, et al. Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathol. 2015;130:661&#x2013;678. doi: 10.1007/s00401-015-1486-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1486-0</ArticleId><ArticleId IdType="pubmed">26437864</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl Acad. Sci. USA. 2008;105:15597&#x2013;16002. doi: 10.1073/pnas.0808084105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0808084105</ArticleId><ArticleId IdType="pmc">PMC2572931</ArticleId><ArticleId IdType="pubmed">18832465</ArticleId></ArticleIdList></Reference><Reference><Citation>Harasta AE, et al. Septal Glucagon-Like Peptide 1 Receptor Expression Determines Suppression of Cocaine-Induced Behavior. Neuropsychopharmacology. 2015;40:1969&#x2013;1978. doi: 10.1038/npp.2015.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2015.47</ArticleId><ArticleId IdType="pmc">PMC4839521</ArticleId><ArticleId IdType="pubmed">25669605</ArticleId></ArticleIdList></Reference><Reference><Citation>von Jonquieres G, et al. Glial promoter selectivity following AAV-delivery to the immature brain. PLoS. ONE. 2013;8:e65646. doi: 10.1371/journal.pone.0065646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0065646</ArticleId><ArticleId IdType="pmc">PMC3683058</ArticleId><ArticleId IdType="pubmed">23799030</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner AA, Gladbach A, Bertz J, Suh LS, Ittner LM. p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer inverted question marks disease. Acta Neuropathol. Commun. 2014;2:149. doi: 10.1186/s40478-014-0149-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0149-z</ArticleId><ArticleId IdType="pmc">PMC4212118</ArticleId><ArticleId IdType="pubmed">25331068</ArticleId></ArticleIdList></Reference><Reference><Citation>Fath T, Ke YD, Gunning P, Gotz J, Ittner LM. Primary support cultures of hippocampal and substantia nigra neurons. Nat. Protoc. 2009;4:78&#x2013;85. doi: 10.1038/nprot.2008.199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.199</ArticleId><ArticleId IdType="pubmed">19131959</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Hollern D, Liao J, Andrechek E, Wang H. NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis. 2013;4:e560. doi: 10.1038/cddis.2013.82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.82</ArticleId><ArticleId IdType="pmc">PMC3615746</ArticleId><ArticleId IdType="pubmed">23538441</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Koller D, Muff R, Fischer JA, Born W. The N-terminal extracellular domain 23-60 of the calcitonin receptor-like receptor in chimeras with the parathyroid hormone receptor mediates association with receptor activity-modifying protein 1. Biochemistry. 2005;44:5749&#x2013;5754. doi: 10.1021/bi048111o.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi048111o</ArticleId><ArticleId IdType="pubmed">15823033</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Gotz J. Phosphorylated Tau Interacts with c-Jun N-terminal Kinase-interacting Protein 1 (JIP1) in Alzheimer Disease. J. Biol. Chem. 2009;284:20909&#x2013;20916. doi: 10.1074/jbc.M109.014472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.014472</ArticleId><ArticleId IdType="pmc">PMC2742856</ArticleId><ArticleId IdType="pubmed">19491104</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue S, et al. Indian-ink perfusion based method for reconstructing continuous vascular networks in whole mouse brain. PLoS ONE. 2014;9:e88067. doi: 10.1371/journal.pone.0088067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0088067</ArticleId><ArticleId IdType="pmc">PMC3907580</ArticleId><ArticleId IdType="pubmed">24498247</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 2012;7:562&#x2013;578. doi: 10.1038/nprot.2012.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2012.016</ArticleId><ArticleId IdType="pmc">PMC3334321</ArticleId><ArticleId IdType="pubmed">22383036</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat. Methods. 2012;9:357&#x2013;359. doi: 10.1038/nmeth.1923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1923</ArticleId><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009;4:44&#x2013;57. doi: 10.1038/nprot.2008.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.211</ArticleId><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40:D109&#x2013;D114. doi: 10.1093/nar/gkr988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr988</ArticleId><ArticleId IdType="pmc">PMC3245020</ArticleId><ArticleId IdType="pubmed">22080510</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda R, et al. Supersensitive Ras activation in dendrites and spines revealed by two-photon fluorescence lifetime imaging. Nat. Neurosci. 2006;9:283&#x2013;291. doi: 10.1038/nn1635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1635</ArticleId><ArticleId IdType="pubmed">16429133</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28886009</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Tau-mediated iron export prevents ferroptotic damage after ischemic stroke.</ArticleTitle><Pagination><StartPage>1520</StartPage><EndPage>1530</EndPage><MedlinePgn>1520-1530</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2017.171</ELocationID><Abstract><AbstractText>Functional failure of tau contributes to age-dependent, iron-mediated neurotoxicity, and as iron accumulates in ischemic stroke tissue, we hypothesized that tau failure may exaggerate ischemia-reperfusion-related toxicity. Indeed, unilateral, transient middle cerebral artery occlusion (MCAO) suppressed hemispheric tau and increased iron levels in young (3-month-old) mice and rats. Wild-type mice were protected by iron-targeted interventions: ceruloplasmin and amyloid precursor protein ectodomain, as well as ferroptosis inhibitors. At this age, tau-knockout mice did not express elevated brain iron and were protected against hemispheric reperfusion injury following MCAO, indicating that tau suppression may prevent ferroptosis. However, the accelerated age-dependent brain iron accumulation that occurs in tau-knockout mice at 12 months of age negated the protective benefit of tau suppression against MCAO-induced focal cerebral ischemia-reperfusion injury. The protective benefit of tau knockout was revived in older mice by iron-targeting interventions. These findings introduce tau-iron interaction as a pleiotropic modulator of ferroptosis and ischemic stroke outcome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tuo</LastName><ForeName>Q-Z</ForeName><Initials>QZ</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxidation Biology Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Oxidation Biology Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackman</LastName><ForeName>K A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Oxidation Biology Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>X-L</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Department of Neurology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>X-L</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Oxidation Biology Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liuyang</LastName><ForeName>Z-Y</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roisman</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>S-T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Neurology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayton</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oxidation Biology Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Q</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crouch</LastName><ForeName>P J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganio</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Oxidation Biology Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>X-C</ForeName><Initials>XC</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pei</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adlard</LastName><ForeName>P A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Oxidation Biology Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Y-M</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cappai</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>J-Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>A I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Oxidation Biology Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558298">Mapt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2017 Nov;13(11):639. doi: 10.1038/nrneurol.2017.141.</RefSource><PMID Version="1">28960188</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020244" MajorTopicYN="N">Infarction, Middle Cerebral Artery</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015427" MajorTopicYN="N">Reperfusion Injury</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28886009</ArticleId><ArticleId IdType="doi">10.1038/mp.2017.171</ArticleId><ArticleId IdType="pii">mp2017171</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28978478</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Semagacestat Is a Pseudo-Inhibitor of &#x3b3;-Secretase.</ArticleTitle><Pagination><StartPage>259</StartPage><EndPage>273</EndPage><MedlinePgn>259-273</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2017.09.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(17)31307-4</ELocationID><Abstract><AbstractText>&#x3b3;-secretase inhibitors (GSI) are drugs developed to decrease amyloid-&#x3b2; peptide (A&#x3b2;) production by inhibiting intramembranous cleavage of &#x3b2;-amyloid protein precursor (&#x3b2;APP). However, a large phase 3 trial of semagacestat, a potential non-transition state analog (non-TSA) GSI, in patients with Alzheimer's disease (AD) was terminated due to unexpected aggravation of cognitive deficits and side effects. Here, we show that some semagacestat effects are clearly different from a phenotype caused by a loss of function of presenilins, core proteins in the &#x3b3;-secretase complex. Semagacestat increases intracellular byproduct peptides, produced along with A&#x3b2; through serial &#x3b3;-cleavage of &#x3b2;APP, as well as intracellular long A&#x3b2; species, in cell-based and in&#xa0;vivo studies of AD model mice. Other potential non-TSA GSIs, but not L685,458, a TSA GSI, have similar effects. Furthermore, semagacestat inhibits release of de novo intramembranous &#x3b3;-byproducts to the soluble space. Thus, semagacestat is a pseudo-GSI, and therefore, the semagacestat clinical trial did not truly test the A&#x3b2; hypothesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tagami</LastName><ForeName>Shinji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuropsychiatry, Department of Integrated Medicine, Division of Internal Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanagida</LastName><ForeName>Kanta</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neuropsychiatry, Department of Integrated Medicine, Division of Internal Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kodama</LastName><ForeName>Takashi S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Neuropsychiatry, Department of Integrated Medicine, Division of Internal Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takami</LastName><ForeName>Mako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Faculty of Life and Medical Sciences, Doshisha University, Kizugawa, Kyoto 619-0225, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizuta</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuropsychiatry, Department of Integrated Medicine, Division of Internal Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oyama</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuropsychiatry, Department of Integrated Medicine, Division of Internal Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan; Pain and Neurology, Shionogi &amp; Co. Ltd., Osaka, Osaka 561-0825, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishitomi</LastName><ForeName>Kouhei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neuropsychiatry, Department of Integrated Medicine, Division of Internal Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan; Pain and Neurology, Shionogi &amp; Co. Ltd., Osaka, Osaka 561-0825, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Yu-Wen</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Neuropsychiatry, Department of Integrated Medicine, Division of Internal Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Toru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Niigata 951-8520, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakaguchi</LastName><ForeName>Gaku</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pain and Neurology, Shionogi &amp; Co. Ltd., Osaka, Osaka 561-0825, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kudo</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Osaka University Health Care Center, Toyonaka, Osaka 560-0043, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuura</LastName><ForeName>Yoshiharu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukumori</LastName><ForeName>Akio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuropsychiatry, Department of Integrated Medicine, Division of Internal Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Masatoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuropsychiatry, Department of Integrated Medicine, Division of Internal Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ihara</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Faculty of Life and Medical Sciences, Doshisha University, Kizugawa, Kyoto 619-0225, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okochi</LastName><ForeName>Masayasu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuropsychiatry, Department of Integrated Medicine, Division of Internal Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan. Electronic address: mokochi@psy.med.osaka-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001381">Azepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C410009">L 685458</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484278">N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2; hypothesis</Keyword><Keyword MajorTopicYN="N">MK-0752</Keyword><Keyword MajorTopicYN="N">RO4929097</Keyword><Keyword MajorTopicYN="N">anti-cancer drugs</Keyword><Keyword MajorTopicYN="N">avagacetat</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">semagacestat</Keyword><Keyword MajorTopicYN="N">&#x3b3;-byproducts</Keyword><Keyword MajorTopicYN="N">&#x3b3;-secretase inhibitors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28978478</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2017.09.032</ArticleId><ArticleId IdType="pii">S2211-1247(17)31307-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28994390</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-084X</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2017</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>eLife</Title><ISOAbbreviation>Elife</ISOAbbreviation></Journal><ArticleTitle>Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e29595</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7554/eLife.29595</ELocationID><Abstract><AbstractText>Amyloid plaques, consisting of deposited beta-amyloid (A&#x3b2;), are a neuropathological hallmark of Alzheimer's Disease (AD). Cerebral vessels play a major role in AD, as A&#x3b2; is cleared from the brain by pathways involving the cerebrovasculature, most AD patients have cerebrovascular amyloid (cerebral amyloid angiopathy (CAA), and cardiovascular risk factors increase dementia risk. Here we present a notable advance in vascular tissue engineering by generating the first functional 3-dimensioinal model of CAA in bioengineered human vessels. We show that lipoproteins including brain (apoE) and circulating (high-density lipoprotein, HDL) synergize to facilitate A&#x3b2; transport across bioengineered human cerebral vessels. These lipoproteins facilitate A&#x3b2;42 transport more efficiently than A&#x3b2;40, consistent with A&#x3b2;40 being the primary species that accumulates in CAA. Moreover, apoE4 is less effective than apoE2 in promoting A&#x3b2; transport, also consistent with the well-established role of apoE4 in A&#x3b2; deposition in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2847-9362</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Button</LastName><ForeName>Emily B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0003-0390-0867</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuen</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilmour</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5929-1645</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahrabadi</LastName><ForeName>Arvin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1042-6075</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stukas</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wenchen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulic</LastName><ForeName>Iva</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-9093-113X</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wellington</LastName><ForeName>Cheryl L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0001-7014-039X</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>155048</GrantID><Acronym>SNSF_</Acronym><Agency>Swiss National Science Foundation</Agency><Country>Switzerland</Country></Grant><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Elife</MedlineTA><NlmUniqueID>101579614</NlmUniqueID><ISSNLinking>2050-084X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Elife. 2017 Oct 10;6:e31808. doi: 10.7554/eLife.31808.</RefSource><PMID Version="1">28994392</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057005" MajorTopicYN="N">Bioengineering</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001808" MajorTopicYN="N">Blood Vessels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008075" MajorTopicYN="N">Lipoproteins, HDL</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">cerebrovasculature</Keyword><Keyword MajorTopicYN="N">human</Keyword><Keyword MajorTopicYN="N">human biology</Keyword><Keyword MajorTopicYN="N">lipoprotein</Keyword><Keyword MajorTopicYN="N">medicine</Keyword><Keyword MajorTopicYN="N">neuroscience</Keyword><Keyword MajorTopicYN="N">tissue engineering</Keyword></KeywordList><CoiStatement>No competing interests declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28994390</ArticleId><ArticleId IdType="pmc">PMC5634784</ArticleId><ArticleId IdType="doi">10.7554/eLife.29595</ArticleId><ArticleId IdType="pii">e29595</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer's disease-lessons from pathology. BMC medicine. 2014;12:206. doi: 10.1186/s12916-014-0206-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-014-0206-2</ArticleId><ArticleId IdType="pmc">PMC4226890</ArticleId><ArticleId IdType="pubmed">25385447</ArticleId></ArticleIdList></Reference><Reference><Citation>Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine. 2007;357:1301&#x2013;1310. doi: 10.1056/NEJMoa064278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa064278</ArticleId><ArticleId IdType="pubmed">17898099</ArticleId></ArticleIdList></Reference><Reference><Citation>Bicker J, Alves G, Fortuna A, Falc&#xe3;o A. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. European Journal of Pharmaceutics and Biopharmaceutics. 2014;87:409&#x2013;432. doi: 10.1016/j.ejpb.2014.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2014.03.012</ArticleId><ArticleId IdType="pubmed">24686194</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi A, Greenberg SM. Cerebral amyloid angiopathy: a systematic review. Journal of Clinical Neurology. 2011;7:1&#x2013;9. doi: 10.3988/jcn.2011.7.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2011.7.1.1</ArticleId><ArticleId IdType="pmc">PMC3079153</ArticleId><ArticleId IdType="pubmed">21519520</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth R, Kim H. Characterization of a microfluidic in vitro model of the blood-brain barrier (&#x3bc;BBB) Lab on a Chip. 2012;12:1784&#x2013;1792. doi: 10.1039/c2lc40094d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c2lc40094d</ArticleId><ArticleId IdType="pubmed">22422217</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science. 2008;321:1221&#x2013;1224. doi: 10.1126/science.1161591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1161591</ArticleId><ArticleId IdType="pmc">PMC2577829</ArticleId><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussolari SR, Dewey CF, Gimbrone MA. Apparatus for subjecting living cells to fluid shear stress. Review of Scientific Instruments. 1982;53:1851&#x2013;1854. doi: 10.1063/1.1136909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.1136909</ArticleId><ArticleId IdType="pubmed">7156852</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. Human apoE isoforms differentially regulate brain amyloid-&#x3b2; peptide clearance. Science Translational Medicine. 2011;3:89ra57. doi: 10.1126/scitranslmed.3002156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002156</ArticleId><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Seo JH, Wong KH, Terasaki Y, Park J, Bong K, Arai K, Lo EH, Irimia D. Three-dimensional blood-brain barrier model for in vitro studies of neurovascular pathology. Scientific Reports. 2015;5:15222. doi: 10.1038/srep15222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep15222</ArticleId><ArticleId IdType="pmc">PMC4622078</ArticleId><ArticleId IdType="pubmed">26503597</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S, Wood A, Bowlby MR. Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. Current Neuropharmacology. 2007;5:19&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2435340</ArticleId><ArticleId IdType="pubmed">18615151</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucullo L, Hossain M, Rapp E, Manders T, Marchi N, Janigro D. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia. 2007;48:505&#x2013;516. doi: 10.1111/j.1528-1167.2006.00960.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1528-1167.2006.00960.x</ArticleId><ArticleId IdType="pubmed">17326793</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, Mishra VK, Epand RM, Epand RF, Lund-Katz S, Phillips MC, Segrest JP, Anantharamaiah GM. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. Journal of Lipid Research. 2001;42:1096&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441137</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. Journal of Clinical Investigation. 2008;118:4002&#x2013;4013. doi: 10.1172/JCI36663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI36663</ArticleId><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>Di L, Kerns EH, Bezar IF, Petusky SL, Huang Y. Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. Journal of Pharmaceutical Sciences. 2009;98:1980&#x2013;1991. doi: 10.1002/jps.21580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.21580</ArticleId><ArticleId IdType="pubmed">18837012</ArticleId></ArticleIdList></Reference><Reference><Citation>Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vascular Health and Risk Management. 2008;4:363&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2496986</ArticleId><ArticleId IdType="pubmed">18561512</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan J, Zareyan S, Zhao W, Shimizu Y, Pfeifer TA, Tak JH, Isman MB, Van den Hoven B, Duggan ME, Wood MW, Wellington CL, Kulic I. Identification of a chrysanthemic ester as an apolipoprotein E Inducer in astrocytes. PLoS One. 2016;11:e0162384. doi: 10.1371/journal.pone.0162384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0162384</ArticleId><ArticleId IdType="pmc">PMC5012716</ArticleId><ArticleId IdType="pubmed">27598782</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaillard PJ, Voorwinden LH, Nielsen JL, Ivanov A, Atsumi R, Engman H, Ringbom C, de Boer AG, Breimer DD. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. European Journal of Pharmaceutical Sciences. 2001;12:215&#x2013;222. doi: 10.1016/S0928-0987(00)00123-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0928-0987(00)00123-8</ArticleId><ArticleId IdType="pubmed">11113640</ArticleId></ArticleIdList></Reference><Reference><Citation>Getz GS, Reardon CA. Animal models of atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32:1104&#x2013;1115. doi: 10.1161/ATVBAHA.111.237693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.111.237693</ArticleId><ArticleId IdType="pmc">PMC3331926</ArticleId><ArticleId IdType="pubmed">22383700</ArticleId></ArticleIdList></Reference><Reference><Citation>Giri M, Zhang M, L&#xfc; Y. Genes associated with Alzheimer's disease: an overview and current status. Clinical Interventions in Aging. 2016;11:665&#x2013;681. doi: 10.2147/CIA.S105769.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S105769</ArticleId><ArticleId IdType="pmc">PMC4876682</ArticleId><ArticleId IdType="pubmed">27274215</ArticleId></ArticleIdList></Reference><Reference><Citation>Griep LM, Wolbers F, de Wagenaar B, ter Braak PM, Weksler BB, Romero IA, Couraud PO, Vermes I, van der Meer AD, van den Berg A. BBB on chip: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function. Biomedical Microdevices. 2013;15:145&#x2013;150. doi: 10.1007/s10544-012-9699-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10544-012-9699-7</ArticleId><ArticleId IdType="pubmed">22955726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatherell K, Couraud PO, Romero IA, Weksler B, Pilkington GJ. Development of a three-dimensional, all-human in vitro model of the blood-brain barrier using mono-, co-, and tri-cultivation Transwell models. Journal of Neuroscience Methods. 2011;199:223&#x2013;229. doi: 10.1016/j.jneumeth.2011.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2011.05.012</ArticleId><ArticleId IdType="pubmed">21609734</ArticleId></ArticleIdList></Reference><Reference><Citation>Herland A, van der Meer AD, FitzGerald EA, Park TE, Sleeboom JJ, Ingber DE. Distinct contributions of astrocytes and pericytes to neuroinflammation identified in a 3D human blood-brain barrier on a chip. PLoS&#xa0;One. 2016;11:e0150360. doi: 10.1371/journal.pone.0150360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0150360</ArticleId><ArticleId IdType="pmc">PMC4773137</ArticleId><ArticleId IdType="pubmed">26930059</ArticleId></ArticleIdList></Reference><Reference><Citation>Herukka SK, Rummukainen J, Ihalainen J, von Und Zu Fraunberg M, Koivisto AM, Nerg O, Puli LK, Sepp&#xe4;l&#xe4; TT, Zetterberg H, Pyykk&#xf6; OT, Helisalmi S, Tanila H, Alafuzoff I, Hiltunen M, Rinne J, Soininen H, J&#xe4;&#xe4;skel&#xe4;inen JE, Leinonen V. Amyloid-&#x3b2; and tau dynamics in human brain interstitial fluid in patients with suspected normal pressure hydrocephalus. Journal of Alzheimer's Disease. 2015;46:261&#x2013;269. doi: 10.3233/JAD-142862.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-142862</ArticleId><ArticleId IdType="pubmed">25720406</ArticleId></ArticleIdList></Reference><Reference><Citation>Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, Westman E, Simmons A, Dobson R, Sattlecker M, Lupton M, Lunnon K, Keohane A, Ward M, Pike I, Zucht HD, Pepin D, Zheng W, Tunnicliffe A, Richardson J, Gauthier S, Soininen H, K&#x142;oszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimer's &amp; Dementia. 2014;10:799&#x2013;807. doi: 10.1016/j.jalz.2014.05.1749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.05.1749</ArticleId><ArticleId IdType="pmc">PMC4240530</ArticleId><ArticleId IdType="pubmed">25012867</ArticleId></ArticleIdList></Reference><Reference><Citation>Koren E, Puchois P, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of human plasma apolipoprotein A-I by a noncompetitive enzyme-linked immunosorbent assay&#xa0;Clinica chimica acta. Clinica Chimica Acta; International Journal of Clinical Chemistry. 1985;147:85&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">3921293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane-Donovan C, Herz J. ApoE, ApoE receptors, and the synapse in Alzheimer's disease. Trends in Endocrinology &amp; Metabolism. 2017;28:273&#x2013;284. doi: 10.1016/j.tem.2016.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2016.12.001</ArticleId><ArticleId IdType="pmc">PMC5366078</ArticleId><ArticleId IdType="pubmed">28057414</ArticleId></ArticleIdList></Reference><Reference><Citation>Love S. Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy. Frontiers in Bioscience. 2009;14:4778&#x2013;4792. doi: 10.2741/3567.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/3567</ArticleId><ArticleId IdType="pubmed">19273389</ArticleId></ArticleIdList></Reference><Reference><Citation>Man S, Ubogu EE, Williams KA, Tucky B, Callahan MK, Ransohoff RM. Human brain microvascular endothelial cells and umbilical vein endothelial cells differentially facilitate leukocyte recruitment and utilize chemokines for T cell migration. Clinical and Developmental Immunology. 2008;2008:1&#x2013;8. doi: 10.1155/2008/384982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2008/384982</ArticleId><ArticleId IdType="pmc">PMC2248224</ArticleId><ArticleId IdType="pubmed">18320011</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2012;2:a006239. doi: 10.1101/cshperspect.a006239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006239</ArticleId><ArticleId IdType="pmc">PMC3405821</ArticleId><ArticleId IdType="pubmed">22908189</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, DeLucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47:191&#x2013;199. doi: 10.1016/j.neuron.2005.06.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.06.030</ArticleId><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>Merched A, Xia Y, Visvikis S, Serot JM, Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiology of Aging. 2000;21:27&#x2013;30. doi: 10.1016/S0197-4580(99)00103-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(99)00103-7</ArticleId><ArticleId IdType="pubmed">10794845</ArticleId></ArticleIdList></Reference><Reference><Citation>Navone SE, Marfia G, Invernici G, Cristini S, Nava S, Balbi S, Sangiorgi S, Ciusani E, Bosutti A, Alessandri G, Slevin M, Parati EA. Isolation and expansion of human and mouse brain microvascular endothelial cells. Nature Protocols. 2013;8:1680&#x2013;1693. doi: 10.1038/nprot.2013.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.107</ArticleId><ArticleId IdType="pubmed">23928501</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhakarpandian B, Shen MC, Nichols JB, Mills IR, Sidoryk-Wegrzynowicz M, Aschner M, Pant K. SyM-BBB: a microfluidic blood brain barrier model. Lab on a Chip. 2013;13:1093&#x2013;1101. doi: 10.1039/c2lc41208j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c2lc41208j</ArticleId><ArticleId IdType="pmc">PMC3613157</ArticleId><ArticleId IdType="pubmed">23344641</ArticleId></ArticleIdList></Reference><Reference><Citation>Qosa H, Abuasal BS, Romero IA, Weksler B, Couraud PO, Keller JN, Kaddoumi A. Differences in amyloid-&#x3b2; clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Neuropharmacology. 2014;79:668&#x2013;678. doi: 10.1016/j.neuropharm.2014.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2014.01.023</ArticleId><ArticleId IdType="pmc">PMC3965363</ArticleId><ArticleId IdType="pubmed">24467845</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. Journal of Cerebral Blood Flow &amp; Metabolism. 2016;36:172&#x2013;186. doi: 10.1038/jcbfm.2015.164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2015.164</ArticleId><ArticleId IdType="pmc">PMC4758551</ArticleId><ArticleId IdType="pubmed">26174330</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Archives of Neurology. 2010;67:1491&#x2013;1497. doi: 10.1001/archneurol.2010.297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.297</ArticleId><ArticleId IdType="pmc">PMC3065942</ArticleId><ArticleId IdType="pubmed">21149810</ArticleId></ArticleIdList></Reference><Reference><Citation>Riwanto M, Landmesser U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. Journal of Lipid Research. 2013;54:3227&#x2013;3243. doi: 10.1194/jlr.R037762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R037762</ArticleId><ArticleId IdType="pmc">PMC3826672</ArticleId><ArticleId IdType="pubmed">23873269</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert J, Button EB, Stukas S, Boyce GK, Gibbs E, Cowan CM, Gilmour M, Cheng WH, Soo SK, Yuen B, Bahrabadi A, Kang K, Kulic I, Francis G, Cashman N, Wellington CL. High-density lipoproteins suppress A&#x3b2;-induced PBMC adhesion to human endothelial cells in bioengineered vessels and in monoculture. Molecular Neurodegeneration. 2017;12:60. doi: 10.1186/s13024-017-0201-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0201-0</ArticleId><ArticleId IdType="pmc">PMC5568306</ArticleId><ArticleId IdType="pubmed">28830501</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert J, Lehner M, Frank S, Perisa D, von Eckardstein A, Rohrer L. Interleukin 6 stimulates endothelial binding and transport of high-density lipoprotein through induction of endothelial lipase. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013b;33:2699&#x2013;2706. doi: 10.1161/ATVBAHA.113.301363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.113.301363</ArticleId><ArticleId IdType="pubmed">24115033</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert J, Stukas S, Button E, Cheng WH, Lee M, Fan J, Wilkinson A, Kulic I, Wright SD, Wellington CL. Reconstituted high-density lipoproteins acutely reduce soluble brain A&#x3b2; levels in symptomatic APP/PS1 mice. Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease. 2016;1862:1027&#x2013;1036. doi: 10.1016/j.bbadis.2015.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2015.10.005</ArticleId><ArticleId IdType="pubmed">26454209</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert J, Weber B, Frese L, Emmert MY, Schmidt D, von Eckardstein A, Rohrer L, Hoerstrup SP. A three-dimensional engineered artery model for in vitro atherosclerosis research. PLoS One. 2013a;8:e79821. doi: 10.1371/journal.pone.0079821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079821</ArticleId><ArticleId IdType="pmc">PMC3828234</ArticleId><ArticleId IdType="pubmed">24244566</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacre SM, Stannard AK, Owen JS. Apolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells. FEBS Letters. 2003;540:181&#x2013;187. doi: 10.1016/S0014-5793(03)00261-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(03)00261-8</ArticleId><ArticleId IdType="pubmed">12681505</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt D, Asmis LM, Odermatt B, Kelm J, Breymann C, G&#xf6;ssi M, Genoni M, Zund G, Hoerstrup SP. Engineered living blood vessels: functional endothelia generated from human umbilical cord-derived progenitors. The Annals of Thoracic Surgery. 2006;82:1465&#x2013;1471. doi: 10.1016/j.athoracsur.2006.05.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2006.05.066</ArticleId><ArticleId IdType="pubmed">16996955</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 1992;359:325&#x2013;327. doi: 10.1038/359325a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/359325a0</ArticleId><ArticleId IdType="pubmed">1406936</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih YH, Tsai KJ, Lee CW, Shiesh SC, Chen WT, Pai MC, Kuo YM. Apolipoprotein C-III is an amyloid-beta-binding protein and an early marker for Alzheimer&#x2019;s disease. Journal of Alzheimer's Disease : JAD. 2014;41:855&#x2013;865. doi: 10.3233/JAD-140111.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-140111</ArticleId><ArticleId IdType="pubmed">24685634</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder HM. Vascular contributions to cognitive impairment and dementia including Alzheimer&#x2019;s disease. Alzheimer&#x2019;s&#xa0;&amp;&#xa0;Dementia : The Journal of the Alzheimer&#x2019;s Association. 2015;11:710&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731036</ArticleId><ArticleId IdType="pubmed">25510382</ArticleId></ArticleIdList></Reference><Reference><Citation>Stukas S, Robert J, Lee M, Kulic I, Carr M, Tourigny K, Fan J, Namjoshi D, Lemke K, DeValle N, Chan J, Wilson T, Wilkinson A, Chapanian R, Kizhakkedathu JN, Cirrito JR, Oda MN, Wellington CL. Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus. Journal of the American Heart Association. 2014a;3:e001156. doi: 10.1161/JAHA.114.001156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.114.001156</ArticleId><ArticleId IdType="pmc">PMC4338702</ArticleId><ArticleId IdType="pubmed">25392541</ArticleId></ArticleIdList></Reference><Reference><Citation>Stukas S, Robert J, Wellington CL. High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease. Cell Metabolism. 2014b;19:574&#x2013;591. doi: 10.1016/j.cmet.2014.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2014.01.003</ArticleId><ArticleId IdType="pubmed">24508505</ArticleId></ArticleIdList></Reference><Reference><Citation>Takamatsu K, Ikeda T, Haruta M, Matsumura K, Ogi Y, Nakagata N, Uchino M, Ando Y, Nishimura Y, Senju S. Degradation of amyloid beta by human induced pluripotent stem cell-derived macrophages expressing Neprilysin-2. Stem Cell Research. 2014;13:442&#x2013;453. doi: 10.1016/j.scr.2014.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2014.10.001</ArticleId><ArticleId IdType="pubmed">25460605</ArticleId></ArticleIdList></Reference><Reference><Citation>Truran S, Weissig V, Madine J, Davies HA, Guzman-Villanueva D, Franco DA, Karamanova N, Burciu C, Serrano G, Beach TG, Migrino RQ. Nanoliposomes protect against human arteriole endothelial dysfunction induced by &#x3b2;-amyloid peptide. Journal of Cerebral Blood Flow &amp; Metabolism. 2016;36:405&#x2013;412. doi: 10.1177/0271678X15610134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X15610134</ArticleId><ArticleId IdType="pmc">PMC4759678</ArticleId><ArticleId IdType="pubmed">26661197</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueno M, Chiba Y, Matsumoto K, Nakagawa T, Miyanaka H. Clearance of beta-amyloid in the brain. Current Medicinal Chemistry. 2014;21:4085&#x2013;4090.</Citation><ArticleIdList><ArticleId IdType="pubmed">25312211</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Lei Y, Luo J, Wang J, Zhang S, Yang XJ, Sun M, Nuwaysir E, Fan G, Zhao J, Lei L, Zhong Z. Prevention of &#x3b2;-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of cyclin-dependent kinases and associated cell cycle events. Stem Cell Research. 2013;10:213&#x2013;227. doi: 10.1016/j.scr.2012.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2012.11.005</ArticleId><ArticleId IdType="pubmed">23305945</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M. Cerebral amyloid angiopathy: emerging concepts. Journal of Stroke. 2015;17:17&#x2013;30. doi: 10.5853/jos.2015.17.1.17.</Citation><ArticleIdList><ArticleId IdType="doi">10.5853/jos.2015.17.1.17</ArticleId><ArticleId IdType="pmc">PMC4325636</ArticleId><ArticleId IdType="pubmed">25692104</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin W, Carballo-Jane E, McLaren DG, Mendoza VH, Gagen K, Geoghagen NS, McNamara LA, Gorski JN, Eiermann GJ, Petrov A, Wolff M, Tong X, Wilsie LC, Akiyama TE, Chen J, Thankappan A, Xue J, Ping X, Andrews G, Wickham LA, Gai CL, Trinh T, Kulick AA, Donnelly MJ, Voronin GO, Rosa R, Cumiskey AM, Bekkari K, Mitnaul LJ, Puig O, Chen F, Raubertas R, Wong PH, Hansen BC, Koblan KS, Roddy TP, Hubbard BK, Strack AM. Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. Journal of Lipid Research. 2012;53:51&#x2013;65. doi: 10.1194/jlr.M019927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M019927</ArticleId><ArticleId IdType="pmc">PMC3243481</ArticleId><ArticleId IdType="pubmed">22021650</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurology. 2013;70:440&#x2013;444. doi: 10.1001/jamaneurol.2013.2152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.2152</ArticleId><ArticleId IdType="pmc">PMC4414030</ArticleId><ArticleId IdType="pubmed">23400708</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuliani G, Cavalieri M, Galvani M, Volpato S, Cherubini A, Bandinelli S, Corsi AM, Lauretani F, Guralnik JM, Fellin R, Ferrucci L. Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2010;65:559&#x2013;564. doi: 10.1093/gerona/glq026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glq026</ArticleId><ArticleId IdType="pmc">PMC2854885</ArticleId><ArticleId IdType="pubmed">20299544</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29020624</PMID><DateCompleted><Year>2018</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution.</ArticleTitle><Pagination><StartPage>366</StartPage><EndPage>380</EndPage><MedlinePgn>366-380</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2017.09.039</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(17)31314-1</ELocationID><Abstract><AbstractText>Microglia, the tissue-resident macrophages in the brain, are damage sensors that react to nearly any perturbation, including neurodegenerative diseases such as Alzheimer's disease (AD). Here, using single-cell RNA sequencing, we determined the transcriptome of more than 1,600 individual microglia cells isolated from the hippocampus of a mouse model of severe neurodegeneration with AD-like phenotypes and of control mice at multiple time points during progression of neurodegeneration. In this neurodegeneration model, we discovered two molecularly distinct reactive microglia phenotypes that are typified by modules of co-regulated type I and type II interferon response genes, respectively. Furthermore, our work identified previously unobserved heterogeneity in the response of microglia to neurodegeneration, discovered disease stage-specific microglia cell states, revealed the trajectory of cellular reprogramming of microglia in response to neurodegeneration, and uncovered the underlying transcriptional programs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mathys</LastName><ForeName>Hansruedi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adaikkan</LastName><ForeName>Chinnakkaruppan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Jennie Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manet</LastName><ForeName>Elodie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemberg</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Genetics, Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1SA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Center for Translational and Systems Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ransohoff</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regev</LastName><ForeName>Aviv</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02140, USA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: lhtsai@mit.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG054012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG058002</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054321</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS110453</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062335</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046174</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008262" MajorTopicYN="Y">Macrophage Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">single-cell RNA sequencing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29020624</ArticleId><ArticleId IdType="mid">NIHMS907763</ArticleId><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2017.09.039</ArticleId><ArticleId IdType="pii">S2211-1247(17)31314-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;339:156&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431634</ArticleId><ArticleId IdType="pubmed">23307732</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezman NA, Kim CC, Sun JC, Min-Oo G, Hendricks DW, Kamimura Y, Best JA, Goldrath AW, Lanier LL Immunological Genome Project Consortium. Molecular definition of the identity and activation of natural killer cells. Nat Immunol. 2012;13:1000&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3572860</ArticleId><ArticleId IdType="pubmed">22902830</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouvier DS, Jones EV, Quesseveur G, Davoli MA, Ferreira AT, Quirion R, Mechawar N, Murai KK. High resolution dissection of reactive glial nets in Alzheimer&#x2019;s disease. Sci Rep. 2016;6:24544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835751</ArticleId><ArticleId IdType="pubmed">27090093</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, et al. Identification of a unique TGF-&#x3b2;-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tsai LH. A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr Opin Neurobiol. 2004;14:390&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">15194121</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron. 2003;40:471&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642273</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Kim D, Moy LY, Dobbin MM, Sun X, Bronson RT, Tsai LH. p25/cyclin-dependent kinase 5 induces production and intra-neuronal accumulation of amyloid beta in vivo. J Neurosci. 2006;26:10536&#x2013;10541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674706</ArticleId><ArticleId IdType="pubmed">17035538</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron. 2005;48:825&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337919</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourgeaud L, Trav&#xe9;s PG, Tufail Y, Leal-Bailey H, Lew ED, Burrola PG, Callaway P, Zag&#xf3;rska A, Rothlin CV, Nimmerjahn A, Lemke G. TAM receptors regulate multiple features of microglial physiology. Nature. 2016;532:240&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5358512</ArticleId><ArticleId IdType="pubmed">27049947</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatro TF, Holtman IR, Lerario AM, Vainchtein ID, Brouwer N, Sola PR, Veras MM, Pereira TF, Leite REP, M&#xf6;ller T, et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat Neurosci. 2017;20:1162&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">28671693</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaublomme JT, Yosef N, Lee Y, Gertner RS, Yang LV, Wu C, Pandolfi PP, Mak T, Satija R, Shalek AK, et al. Single-cell genomics unveils critical regulators of Th17 cell pathogenicity. Cell. 2015;163:1400&#x2013;1412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4671824</ArticleId><ArticleId IdType="pubmed">26607794</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjoneska E, Pfenning AR, Mathys H, Quon G, Kundaje A, Tsai LH, Kellis M. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer&#x2019;s disease. Nature. 2015;518:365&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530583</ArticleId><ArticleId IdType="pubmed">25693568</ArticleId></ArticleIdList></Reference><Reference><Citation>Hargis K, Blalock E. Transcriptional signatures of brain aging and Alzheimer&#x2019;s disease: What are our rodent models telling us? Behav Brain Res. 2017;322:311&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5533609</ArticleId><ArticleId IdType="pubmed">27155503</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;rtlova A, Erttmann SF, Raffi FA, Schmalz AM, Resch U, Anugula S, Lienenklaus S, Nilsson LM, Kr&#xf6;ger A, Nilsson JA, et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity. 2015;42:332&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">25692705</ArticleId></ArticleIdList></Reference><Reference><Citation>Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16:358&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">25991443</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016;540:230&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5656389</ArticleId><ArticleId IdType="pubmed">27929004</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290. e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharchenko PV, Silberstein L, Scadden DT. Bayesian approach to single-cell differential expression analysis. Nat Methods. 2014;11:740&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112276</ArticleId><ArticleId IdType="pubmed">24836921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Frank CL, Dobbin MM, Tsunemoto RK, Tu W, Peng PL, Guan JS, Lee BH, Moy LY, Giusti P, et al. Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron. 2008;60:803&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912147</ArticleId><ArticleId IdType="pubmed">19081376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiselev VY, Kirschner K, Schaub MT, Andrews T, Yiu A, Chandra T, Natarajan KN, Reik W, Barahona M, Green AR, Hemberg M, et al. SC3: consensus clustering of single-cell RNA-seq data. Nat Methods. 2016;14:483&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5410170</ArticleId><ArticleId IdType="pubmed">28346451</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, Jung S, Amit I. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell. 2014;159:1312&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437213</ArticleId><ArticleId IdType="pubmed">25480296</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, M&#xfc;nch AE, Chung WS, Peterson TC, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushima GK, Taniike M, Glimcher LH, Grusby MJ, Frelinger JA, Suzuki K, Ting JP. Absence of MHC class II molecules reduces CNS demyelination, microglial/macrophage infiltration, and twitching in murine globoid cell leukodystrophy. Cell. 1994;78:645&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">8069913</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher KI, Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer&#x2019;s disease. Biochem Pharmacol. 2014;88:594&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann H, Daly MJ. Variant TREM2 as risk factor for Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:182&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">23151315</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Keefe GM, Nguyen VT, Ping Tang LL, Benveniste EN. IFN-gamma regulation of class II transactivator promoter IV in macrophages and microglia: involvement of the suppressors of cytokine signaling-1 protein. J Immunol. 2001;166:2260&#x2013;2269.</Citation><ArticleIdList><ArticleId IdType="pubmed">11160280</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre M, Kamphuis W, Osborn LM, Jansen AH, Kooijman L, Bossers K, Hol EM. Isolation of glia from Alzheimer&#x2019;s mice reveals inflammation and dysfunction. Neurobiol Aging. 2014;35:2746&#x2013;2760.</Citation><ArticleIdList><ArticleId IdType="pubmed">25002035</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402:615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604467</ArticleId></ArticleIdList></Reference><Reference><Citation>Picelli S, Faridani OR, Bj&#xf6;rklund AK, Winberg G, Sagasser S, Sandberg R. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc. 2014;9:171&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">24385147</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci. 2014;15:300&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">24713688</ArticleId></ArticleIdList></Reference><Reference><Citation>Probert L. TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects. Neuroscience. 2015;302:2&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">26117714</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalek AK, Satija R, Shuga J, Trombetta JJ, Gennert D, Lu D, Chen P, Gertner RS, Gaublomme JT, Yosef N, et al. Single-cell RNA-seq reveals dynamic paracrine control of cellular variation. Nature. 2014;510:363&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4193940</ArticleId><ArticleId IdType="pubmed">24919153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting JP-Y, Trowsdale J. Genetic control of MHC class II expression. Cell. 2002;109(Suppl):S21&#x2013;S33.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983150</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirosh I, Venteicher AS, Hebert C, Escalante LE, Patel AP, Yizhak K, Fisher JM, Rodman C, Mount C, Filbin MG, et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature. 2016;539:309&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5465819</ArticleId><ArticleId IdType="pubmed">27806376</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Maaten L, Hinton G. Visualizing data using t-SNE. J Mach Learn Res. 2008;9:2579&#x2013;2605.</Citation></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell. 2013;153:707&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28971799</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-084X</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2017</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>eLife</Title><ISOAbbreviation>Elife</ISOAbbreviation></Journal><ArticleTitle>Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e29738</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7554/eLife.29738</ELocationID><Abstract><AbstractText>Here, we report the existence of meningeal lymphatic vessels in human and nonhuman primates (common marmoset monkeys) and the feasibility of noninvasively imaging and mapping them in vivo with high-resolution, clinical MRI. On T2-FLAIR and T1-weighted black-blood imaging, lymphatic vessels enhance with gadobutrol, a gadolinium-based contrast agent with high propensity to extravasate across a permeable capillary endothelial barrier, but not with gadofosveset, a blood-pool contrast agent. The topography of these vessels, running alongside dural venous sinuses, recapitulates the meningeal lymphatic system of rodents. In primates, meningeal lymphatics display a typical panel of lymphatic endothelial markers by immunohistochemistry. This discovery holds promise for better understanding the normal physiology of lymphatic drainage from the central nervous system and potential aberrations in neurological diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Absinta</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0276-383X</Identifier><AffiliationInfo><Affiliation>Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ha</LastName><ForeName>Seung-Kwon</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0000-0003-3671-4454</Identifier><AffiliationInfo><Affiliation>Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Govind</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3725-615X</Identifier><AffiliationInfo><Affiliation>Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sati</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luciano</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palisoc</LastName><ForeName>Maryknoll</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louveau</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia, Department of Neuroscience, School of Medicine, University of Virginia, Charlottesville, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaghloul</LastName><ForeName>Kareem A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0001-8575-3578</Identifier><AffiliationInfo><Affiliation>Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pittaluga</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipnis</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia, Department of Neuroscience, School of Medicine, University of Virginia, Charlottesville, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0002-2628-4334</Identifier><AffiliationInfo><Affiliation>Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034113</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Elife</MedlineTA><NlmUniqueID>101579614</NlmUniqueID><ISSNLinking>2050-084X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Am Osteopath Assoc. 2018 Jan 1;118(1):53. doi: 10.7556/jaoa.2018.012.</RefSource><PMID Version="1">29309097</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002144" MajorTopicYN="N">Callithrix</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042601" MajorTopicYN="N">Lymphatic Vessels</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008578" MajorTopicYN="N">Meninges</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MRI</Keyword><Keyword MajorTopicYN="N">human</Keyword><Keyword MajorTopicYN="N">human biology</Keyword><Keyword MajorTopicYN="N">lymphatics</Keyword><Keyword MajorTopicYN="N">marmoset monkey</Keyword><Keyword MajorTopicYN="N">medicine</Keyword><Keyword MajorTopicYN="N">meninges</Keyword><Keyword MajorTopicYN="N">neuroscience</Keyword></KeywordList><CoiStatement>Dr. Absinta was partially supported by a National Multiple Sclerosis Society (NMSS) fellowship award #FG 2093-A-1 and holds a Marilyn Hilton Award for Innovation in MS research from the Conrad N. Hilton Foundation. No competing interests declared. Dr. Reich received research support from collaborations with the Myelin Repair Foundation and Vertex Pharmaceuticals, unrelated to the present study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28971799</ArticleId><ArticleId IdType="pmc">PMC5626482</ArticleId><ArticleId IdType="doi">10.7554/eLife.29738</ArticleId><ArticleId IdType="pii">29738</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Absinta M, Nair G, Filippi M, Ray-Chaudhury A, Reyes-Mantilla MI, Pardo CA, Reich DS. Postmortem magnetic resonance imaging to guide the pathologic cut: individualized, 3-dimensionally printed cutting boxes for fixed brains. Journal of Neuropathology and Experimental Neurology. 2014;73:780&#x2013;788. doi: 10.1097/NEN.0000000000000096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0000000000000096</ArticleId><ArticleId IdType="pmc">PMC4144036</ArticleId><ArticleId IdType="pubmed">25007244</ArticleId></ArticleIdList></Reference><Reference><Citation>Absinta M, Vuolo L, Rao A, Nair G, Sati P, Cortese IC, Ohayon J, Fenton K, Reyes-Mantilla MI, Maric D, Calabresi PA, Butman JA, Pardo CA, Reich DS. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology. 2015;85:18&#x2013;28. doi: 10.1212/WNL.0000000000001587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001587</ArticleId><ArticleId IdType="pmc">PMC4501940</ArticleId><ArticleId IdType="pubmed">25888557</ArticleId></ArticleIdList></Reference><Reference><Citation>Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005;438:946&#x2013;953. doi: 10.1038/nature04480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04480</ArticleId><ArticleId IdType="pubmed">16355212</ArticleId></ArticleIdList></Reference><Reference><Citation>Antony J, Hacking C, Jeffree RL. Pachymeningeal enhancement-a comprehensive review of literature. Neurosurgical Review. 2015;38:649&#x2013;659. doi: 10.1007/s10143-015-0646-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10143-015-0646-y</ArticleId><ArticleId IdType="pubmed">26264063</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspelund A, Tammela T, Antila S, Nurmi H, Lepp&#xe4;nen VM, Zarkada G, Stanczuk L, Francois M, M&#xe4;kinen T, Saharinen P, Immonen I, Alitalo K. The Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel. Journal of Clinical Investigation. 2014;124:3975&#x2013;3986. doi: 10.1172/JCI75395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI75395</ArticleId><ArticleId IdType="pmc">PMC4153703</ArticleId><ArticleId IdType="pubmed">25061878</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H, Alitalo K. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. The Journal of Experimental Medicine. 2015;212:991&#x2013;999. doi: 10.1084/jem.20142290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142290</ArticleId><ArticleId IdType="pmc">PMC4493418</ArticleId><ArticleId IdType="pubmed">26077718</ArticleId></ArticleIdList></Reference><Reference><Citation>Gait&#xe1;n MI, Maggi P, Wohler J, Leibovitch E, Sati P, Calandri IL, Merkle H, Massacesi L, Silva AC, Jacobson S, Reich DS. Perivenular brain lesions in a primate multiple sclerosis model at 7-tesla magnetic resonance imaging. Multiple Sclerosis Journal. 2014;20:64&#x2013;71. doi: 10.1177/1352458513492244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458513492244</ArticleId><ArticleId IdType="pmc">PMC4745928</ArticleId><ArticleId IdType="pubmed">23773983</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy JR, Sati P, Leibovitch E, Jacobson S, Silva AC, Reich DS. Custom fit 3D-printed brain holders for comparison of histology with MRI in marmosets. Journal of Neuroscience Methods. 2016;257:55&#x2013;63. doi: 10.1016/j.jneumeth.2015.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2015.09.002</ArticleId><ArticleId IdType="pmc">PMC4662872</ArticleId><ArticleId IdType="pubmed">26365332</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#x3b2;. Science Translational Medicine. 2012;4:147ra111. doi: 10.1126/scitranslmed.3003748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003748</ArticleId><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M, Benveniste H. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. Journal of Clinical Investigation. 2013;123:1299&#x2013;1309. doi: 10.1172/JCI67677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI67677</ArticleId><ArticleId IdType="pmc">PMC3582150</ArticleId><ArticleId IdType="pubmed">23434588</ArticleId></ArticleIdList></Reference><Reference><Citation>Kida S, Pantazis A, Weller RO. CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathology and Applied Neurobiology. 1993;19:480&#x2013;488. doi: 10.1111/j.1365-2990.1993.tb00476.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1993.tb00476.x</ArticleId><ArticleId IdType="pubmed">7510047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Kataru RP, Koh GY. Regulation and implications of inflammatory lymphangiogenesis. Trends in Immunology. 2012;33:350&#x2013;356. doi: 10.1016/j.it.2012.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2012.03.006</ArticleId><ArticleId IdType="pubmed">22579522</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipnis J. Multifaceted interactions between adaptive immunity and the central nervous system. Science. 2016;353:766&#x2013;771. doi: 10.1126/science.aag2638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aag2638</ArticleId><ArticleId IdType="pmc">PMC5590839</ArticleId><ArticleId IdType="pubmed">27540163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Lutz MI, Ricken G, Str&#xf6;bel T, H&#xf6;ftberger R, Preusser M, Regelsberger G, H&#xf6;nigschnabl S, Reiner A, Fischer P, Budka H, Hainfellner JA. Dura mater is a potential source of A&#x3b2; seeds. Acta Neuropathologica. 2016;131:911&#x2013;923. doi: 10.1007/s00401-016-1565-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1565-x</ArticleId><ArticleId IdType="pmc">PMC4865536</ArticleId><ArticleId IdType="pubmed">27016065</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauffer RB, Parmelee DJ, Dunham SU, Ouellet HS, Dolan RP, Witte S, McMurry TJ, Walovitch RC. MS-325: albumin-targeted contrast agent for MR angiography. Radiology. 1998;207:529&#x2013;538. doi: 10.1148/radiology.207.2.9577506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.207.2.9577506</ArticleId><ArticleId IdType="pubmed">9577506</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A, Harris TH, Kipnis J. Revisiting the Mechanisms of CNS Immune Privilege. Trends in Immunology. 2015a;36:569&#x2013;577. doi: 10.1016/j.it.2015.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2015.08.006</ArticleId><ArticleId IdType="pmc">PMC4593064</ArticleId><ArticleId IdType="pubmed">26431936</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015b;523:337&#x2013;341. doi: 10.1038/nature14432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14432</ArticleId><ArticleId IdType="pmc">PMC4506234</ArticleId><ArticleId IdType="pubmed">26030524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe KL, Finney BA, Deppermann C, H&#xe4;gerling R, Gazit SL, Frampton J, Buckley C, Camerer E, Nieswandt B, Kiefer F, Watson SP. Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development. Blood. 2015;125:3769&#x2013;3777. doi: 10.1182/blood-2014-09-603803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-09-603803</ArticleId><ArticleId IdType="pmc">PMC4463737</ArticleId><ArticleId IdType="pubmed">25908104</ArticleId></ArticleIdList></Reference><Reference><Citation>Luciano NJ, Sati P, Nair G, Guy JR, Ha SK, Absinta M, Chiang WY, Leibovitch EC, Jacobson S, Silva AC, Reich DS. Utilizing 3D printing technology to merge mri with histology: a protocol for brain sectioning. Journal of Visualized Experiments. 2016;118 doi: 10.3791/54780.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/54780</ArticleId><ArticleId IdType="pmc">PMC5226356</ArticleId><ArticleId IdType="pubmed">28060281</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamourian AC, Hoopes PJ, Lewis LD. Visualization of intravenously administered contrast material in the CSF on fluid-attenuated inversion-recovery MR images: an in vitro and animal-model investigation. AJNR. American Journal of Neuroradiology. 2000;21:105&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7976336</ArticleId><ArticleId IdType="pubmed">10669233</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandell DM, Mossa-Basha M, Qiao Y, Hess CP, Hui F, Matouk C, Johnson MH, Daemen MJ, Vossough A, Edjlali M, Saloner D, Ansari SA, Wasserman BA, Mikulis DJ, Vessel Wall Imaging Study Group of the American Society of Neuroradiology Intracranial Vessel Wall MRI: Principles and Expert Consensus Recommendations of the American Society of Neuroradiology. American Journal of Neuroradiology. 2017;38:218&#x2013;229. doi: 10.3174/ajnr.A4893.</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A4893</ArticleId><ArticleId IdType="pmc">PMC7963837</ArticleId><ArticleId IdType="pubmed">27469212</ArticleId></ArticleIdList></Reference><Reference><Citation>Mascagni P, Bellini GB. Istoria Completa Dei Vasi Linfatici. Vol. II. Florence: Presso Eusebio Pacini e Figlio; 1816. p. 195.</Citation></Reference><Reference><Citation>Mathews VP, Caldemeyer KS, Lowe MJ, Greenspan SL, Weber DM, Ulmer JL. Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging. Radiology. 1999;211:257&#x2013;263. doi: 10.1148/radiology.211.1.r99mr25257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.211.1.r99mr25257</ArticleId><ArticleId IdType="pubmed">10189481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ny A, Koch M, Schneider M, Neven E, Tong RT, Maity S, Fischer C, Plaisance S, Lambrechts D, H&#xe9;ligon C, Terclavers S, Ciesiolka M, K&#xe4;lin R, Man WY, Senn I, Wyns S, Lupu F, Br&#xe4;ndli A, Vleminckx K, Collen D, Dewerchin M, Conway EM, Moons L, Jain RK, Carmeliet P. A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nature Medicine. 2005;11:998&#x2013;1004. doi: 10.1038/nm1285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1285</ArticleId><ArticleId IdType="pubmed">16116431</ArticleId></ArticleIdList></Reference><Reference><Citation>Raper D, Louveau A, Kipnis J. How do meningeal lymphatic vessels drain the cns? Trends in Neurosciences. 2016;39:581&#x2013;586. doi: 10.1016/j.tins.2016.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2016.07.001</ArticleId><ArticleId IdType="pmc">PMC5002390</ArticleId><ArticleId IdType="pubmed">27460561</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson OC, Bane O, Scott ML, Tanner SF, Waterton JC, Sourbron SP, Carroll TJ, Buckley DL. Gadofosveset-based biomarker of tissue albumin concentration: technical validation in vitro and feasibility in vivo. Magnetic Resonance in Medicine. 2015;73:244&#x2013;253. doi: 10.1002/mrm.25128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrm.25128</ArticleId><ArticleId IdType="pmc">PMC4296221</ArticleId><ArticleId IdType="pubmed">24515975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma R, Wendt JA, Rasmussen JC, Adams KE, Marshall MV, Sevick-Muraca EM. New horizons for imaging lymphatic function. Annals of the New York Academy of Sciences. 2008;1131:13&#x2013;36. doi: 10.1196/annals.1413.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1413.002</ArticleId><ArticleId IdType="pmc">PMC3094766</ArticleId><ArticleId IdType="pubmed">18519956</ArticleId></ArticleIdList></Reference><Reference><Citation>Smirniotopoulos JG, Murphy FM, Rushing EJ, Rees JH, Schroeder JW. Patterns of contrast enhancement in the brain and meninges. RadioGraphics. 2007;27:525&#x2013;551. doi: 10.1148/rg.272065155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/rg.272065155</ArticleId><ArticleId IdType="pubmed">17374867</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan RS, Dillard ME, Lagutin OV, Lin FJ, Tsai S, Tsai MJ, Samokhvalov IM, Oliver G. Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes &amp; Development. 2007;21:2422&#x2013;2432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1993873</ArticleId><ArticleId IdType="pubmed">17908929</ArticleId></ArticleIdList></Reference><Reference><Citation>Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nature Reviews Cancer. 2014;14:159&#x2013;172. doi: 10.1038/nrc3677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3677</ArticleId><ArticleId IdType="pubmed">24561443</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Djuanda E, Yow HY, Carare RO. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathologica. 2009;117:1&#x2013;14. doi: 10.1007/s00401-008-0457-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0457-0</ArticleId><ArticleId IdType="pubmed">19002474</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O'Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard M. Sleep drives metabolite clearance from the adult brain. Science. 2013;342:373&#x2013;377. doi: 10.1126/science.1241224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1241224</ArticleId><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaniv K, Isogai S, Castranova D, Dye L, Hitomi J, Weinstein BM. Live imaging of lymphatic development in the zebrafish. Nature Medicine. 2006;12:711&#x2013;716. doi: 10.1038/nm1427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1427</ArticleId><ArticleId IdType="pubmed">16732279</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29024660</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Amyloid Beta Peptides Block New Synapse Assembly by Nogo Receptor-Mediated Inhibition of T-Type Calcium Channels.</ArticleTitle><Pagination><StartPage>355</StartPage><EndPage>372.e6</EndPage><MedlinePgn>355-372.e6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2017.09.041</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(17)30910-8</ELocationID><Abstract><AbstractText>Compelling evidence links amyloid beta (A&#x3b2;) peptide accumulation in the brains of Alzheimer's disease (AD) patients with the emergence of learning and memory deficits, yet a clear understanding of the events that drive this synaptic pathology are lacking. We present evidence that neurons exposed to A&#x3b2; are unable to form new synapses, resulting in learning deficits in&#xa0;vivo. We demonstrate the Nogo receptor family (NgR1-3) acts as A&#x3b2; receptors mediating an inhibition of synapse assembly, plasticity, and learning. Live imaging studies reveal A&#x3b2; activates NgRs on the dendritic shaft of neurons, triggering an inhibition of calcium signaling. We define T-type calcium channels as a target of A&#x3b2;-NgR signaling, mediating A&#x3b2;'s inhibitory effects on calcium, synapse assembly, plasticity, and learning. These studies highlight deficits in new synapse assembly as a potential initiator of cognitive pathology in AD, and pinpoint calcium dysregulation mediated by NgRs and T-type channels as key components. VIDEO ABSTRACT.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yanjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sivaji</LastName><ForeName>Sivaprakash</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA; Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Haadi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zukowski</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Sareen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sklyar</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Zihan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Alexander K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kodali</LastName><ForeName>Ravindra</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Structural Biology and Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borowski</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beukema</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for the Neural Basis of Cognition, Carnegie Mellon University, Pittsburgh, PA 15213, USA; Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wills</LastName><ForeName>Zachary P</ForeName><Initials>ZP</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA; Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA. Electronic address: zpwills@pitt.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 MH107966</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020747">Calcium Channels, T-Type</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000070156">Nogo Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020747" MajorTopicYN="N">Calcium Channels, T-Type</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070156" MajorTopicYN="N">Nogo Receptors</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020318" MajorTopicYN="N">Rats, Long-Evans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FRET imaging</Keyword><Keyword MajorTopicYN="N">ICV injections</Keyword><Keyword MajorTopicYN="N">Nogo receptors</Keyword><Keyword MajorTopicYN="N">RCaMP sensor</Keyword><Keyword MajorTopicYN="N">RhoA2G sensor</Keyword><Keyword MajorTopicYN="N">T-type calcium channels</Keyword><Keyword MajorTopicYN="N">amyloid beta peptides</Keyword><Keyword MajorTopicYN="N">calcium dysfunction</Keyword><Keyword MajorTopicYN="N">new synapse assembly</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29024660</ArticleId><ArticleId IdType="mid">NIHMS911195</ArticleId><ArticleId IdType="pmc">PMC6101033</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.09.041</ArticleId><ArticleId IdType="pii">S0896-6273(17)30910-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arbel-Ornath M, Hudry E, Boivin JR, Hashimoto T, Takeda S, Kuchibhotla KV, et al. Soluble oligomeric amyloid-&#x3b2; induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. Molecular Neurodegeneration. 2017;12:27, 1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5361864</ArticleId><ArticleId IdType="pubmed">28327181</ArticleId></ArticleIdList></Reference><Reference><Citation>Akerboom J, Carreras Calderon N, Tian L, Wabnig S, Prigge M, Tolo J, Gordus A, Orger MB, Severi KE, Macklin JJ, et al. Genetically encoded calcium indicators for multi-color neural activity imaging and combination with optogenetics. Front Mol Neurosci. 2013;6:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586699</ArticleId><ArticleId IdType="pubmed">23459413</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I, Mattson M. Neuronal calcium mishandling and the pathogenesis of Alzheimer&#x2019;s disease. Trends Neurosci. 2008;31(9):454&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner R. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron. 2004;44(1):195&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450170</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Chen X, Henning HA, Reichwald J, Staufenbiel M, Sakmann B, Konnerth A. Critical role of soluble amyloid-&#x3b2; for early hippocampal hyperactivity in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2012;109(22):8740&#x2013;8745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365221</ArticleId><ArticleId IdType="pubmed">22592800</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs L, Lee J, Yang J, Satin J, Zhang Y, Daud A, Barclay J, Williamson M, Fox M, Rees M, Perez-Reyes E. Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family. Circ Res. 1998;83(1):103&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9670923</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritz RD, Letzelter M, Reimann A, Martin K, Fusco L, Ritsma L, Ponsioen B, Fluri E, et al. A versatile toolkit to produce sensitive FRET biosensors to visualize signaling in time and space. Sci Signal. 2013;6:I.</Citation><ArticleIdList><ArticleId IdType="pubmed">23882122</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu M, Yu X, Lu J, Zuo Y. Repetitive motor learning induces coordinated formation of clustered dendritic spines in vivo. Nature. 2012;482(7387):92&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292711</ArticleId><ArticleId IdType="pubmed">22343892</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Rountree S, Finn S, LaPlante B, Weber E, Oltersdorf T. Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer&#x2019;s Disease: A Randomized Phase 2 Study. J Alzheimers Dis. 2015;48(2):473&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">26402011</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomora J, Murbartian J, Arias J, Lee J, Perez-Reyes E. Cloning and expression of the human T-type channel Ca(v)3.3: insights into prepulse facilitation. Biophys J. 2002;83(1):229&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1302142</ArticleId><ArticleId IdType="pubmed">12080115</ArticleId></ArticleIdList></Reference><Reference><Citation>Engert F, Bonhoeffer T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature. 1999;399:66&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331391</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiredo C, Clarke J, Ledo J, Ribeiro F, Costa C, Melo H, Mota-Sales A, Saraiva L, et al. Memantine Rescues Transient Cognitive Impairment Caused by High-Molecular-Weight A&#x3b2; Oligomers but Not the Persistent Impairment Induced by Low-Molecular-Weight Oligomers. J Neurosci. 2013;33(23):9626&#x2013;9634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619709</ArticleId><ArticleId IdType="pubmed">23739959</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris KM, Jensen FE, Tsao B. Three-dimensional structure of dendritic spines and synapses in rat hippocampus (CA1) at postnatal day 15 and adult ages: implications for the maturation of synaptic physiology and long-term potentiation. J Neurosci. 1992;12(7):2685&#x2013;2705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575840</ArticleId><ArticleId IdType="pubmed">1613552</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi-Takagi A, Yagishita S, Nakamura M, Shirai F, Wu YI, Loshbaugh AL, et al. Labelling and optical erasure of synaptic memory traces in the motor cortex. Nature. 2015;525:333&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4634641</ArticleId><ArticleId IdType="pubmed">26352471</ArticleId></ArticleIdList></Reference><Reference><Citation>Iftinca M, Hamid J, Chen L, Varela D, Tadayonnejad R, Altier C, Turner RW, Zamponi GW. Regulation of T-type calcium channels by Rho-associated kinase. Nat Neurosci. 2007;10:854&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">17558400</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C, Knopman DS, Jagust W, Petersen R, Weiner M, Aisen P, Shaw L, Vemuri P, et al. Personal View Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology. 2013;12:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarosz-Griffiths HH, Noble E, Rushworth JV, Hooper NM. Amyloid-beta Receptors: The Good, the Bad, and the Prion Protein. J Biol Chem. 2016;291:3174&#x2013;3183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751366</ArticleId><ArticleId IdType="pubmed">26719327</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, Vidal G, Djurisic M, William C, Birnbaum M, Garcia K, Hyman B, Shatz C. Human LilrB2 is a &#x3b2;-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer&#x2019;s model. Science. 2013;341:1399&#x2013;1404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853120</ArticleId><ArticleId IdType="pubmed">24052308</ArticleId></ArticleIdList></Reference><Reference><Citation>Laur&#xe9;n J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457(7233):1128&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Koeglsperger T, Shepardson N, Shankar G, Selkoe D. Soluble A&#x3b2; Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors. J Neurosci. 2011;31:6627&#x2013;6638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohmann C, Bonhoeffer T. A role for local calcium signaling in rapid synaptic partner selection by dendritic filopodia. Neuron. 2008;59:253&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">18667153</ArticleId></ArticleIdList></Reference><Reference><Citation>Magee JC, Christofi G, Miyakawa H, Christie B, Lasser-Ross N, Johnston D. Subthreshold synaptic activation of voltage-gated Ca2+ channels mediates a localized Ca2+ influx into the dendrites of hippocampal pyramidal neurons. J Neurophys. 1995;74:1335&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pubmed">7500154</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay BE, McRory JE, Molineux ML, Hamid J, Snutch TP, Zamponi GW, Turner RW. Ca(V)3 T-type calcium channel isoforms differentially distribute to somatic and dendritic compartments in rat central neurons. The European Journal of Neuroscience. 2006;24(9):2581&#x2013;2594.</Citation><ArticleIdList><ArticleId IdType="pubmed">17100846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mironova YA, Giger RJ. Where no synapses go: gatekeepers of circuit remodeling and synaptic strength. Trends Neurosci. 2013;36:363&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3674226</ArticleId><ArticleId IdType="pubmed">23642707</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriguchi S, Shioda N, Yamamoto Y, Tagashira H, Fukunaga K. The T-type voltage-gated calcium channel as a molecular target of the novel cognitive enhancer ST101: enhancement of long-term potentiation and CaMKII autophosphorylation in rat cortical slices. J Neurochem. 2012;121:44&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">22251222</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakoshi H, Wang H, Yasuda R. Local, persistent activation of Rho GTPases during plasticity of single dendritic spines. Nature. 2011;472:100&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3105377</ArticleId><ArticleId IdType="pubmed">21423166</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi S, Fox R, Proulx C, Lin J, Tsien R, Malinow R. Engineering a memory with LTD and LTP. Nature. 2014;511:348&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4210354</ArticleId><ArticleId IdType="pubmed">24896183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, Aoki K, Matsuda M. Monitoring spatio-temporal regulation of Ras and Rho GTPase with GFP-based FRET probes. Methods. 2005;37:146&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">16288890</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll AJ, Panico S, Freir DB, Wright D, Terry C, Risse E, Herron CE, O&#x2019;Malley T, et al. Amyloid-beta nanotubes are associated with prion protein-dependent synaptotoxicity. Nat Commun. 2013;4:2416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3908552</ArticleId><ArticleId IdType="pubmed">24022506</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, et al. Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Widi GA, Gimbel DA, Harel NY, Lee DHS, Strittmatter SM. Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer&#x2019;s transgenic mice. J Neurosci. 2006b;26:13279&#x2013;13286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856604</ArticleId><ArticleId IdType="pubmed">17182778</ArticleId></ArticleIdList></Reference><Reference><Citation>Park Y, Park H, Lee C, Choi S, Jo S, Choi H, Kim Y, Shin H, Llinas R, Kim D. CaV3.1 is a tremor rhythm pacemaker in the inferior olive. Proc Natl Acad Sci. 2010;107:10731&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890811</ArticleId><ArticleId IdType="pubmed">20498062</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel TP, Gullotti DM, Hernandez P, O&#x2019;Brien WT, Capehart BP, Morrison B, et al. An open-source toolbox for automated phenotyping of mice in behavioral tasks. Frontiers in Behavioral Neuroscience. 2014;8:349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189437</ArticleId><ArticleId IdType="pubmed">25339878</ArticleId></ArticleIdList></Reference><Reference><Citation>Pertz O, Hodgson L, Klemke RL, Hahn KM. Spatiotemporal dynamics of RhoA activity in migrating cells. Nature. 2006;440:1069&#x2013;1072.</Citation><ArticleIdList><ArticleId IdType="pubmed">16547516</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Bio Chem. 1995;270(16):9564&#x2013;9570.</Citation><ArticleIdList><ArticleId IdType="pubmed">7721886</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozueta J, Lefort R, Ribe EM, Troy CM, Arancio O, Shelanski M. Caspase-2 is required for dendritic spine and behavioural alterations in J20 APP transgenic mice. Nature. 2013;4:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4398315</ArticleId><ArticleId IdType="pubmed">23748737</ArticleId></ArticleIdList></Reference><Reference><Citation>Rex C, Chen L, Sharma A, Liu J, Babayan A, Gall C, Lynch G. Different Rho GTPase&#x2013;dependent signaling pathways initiate sequential steps in the consolidation of long-term potentiation. J Cell Biol. 2009;186:85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2712993</ArticleId><ArticleId IdType="pubmed">19596849</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice RA, Berchtold NC, Cotman CW, Green KN. Age-related downregulation of the CaV3.1 T-type calcium channel as a mediator of amyloid beta production. Neurobiol Aging. 2014;35:1002&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939046</ArticleId><ArticleId IdType="pubmed">24268883</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset M, Cens T, Menard C, Bowerman M, Bellis M, Brus&#xe9;s J, et al. Regulation of neuronal high-voltage activated CaV2 Ca2+ channels by the small GTPase RhoA. Neuropharmacology. 2015;97(C):201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">26044639</ArticleId></ArticleIdList></Reference><Reference><Citation>Schram MT, Trompet S, Kamper AM, de Craen AJ, Hofman A, Euser SM, Breteler MM, Westendorp RG. Serum calcium and cognitive function in old age. J Am Geriatr Soc. 2007;55:1786&#x2013;1792.</Citation><ArticleIdList><ArticleId IdType="pubmed">17979900</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmandke A, Schmandke A, Strittmatter S. ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases. Neuroscientist. 2007;13:454&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849133</ArticleId><ArticleId IdType="pubmed">17901255</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE. The synaptic Abeta hypothesis of Alzheimer disease. Nat Neurosci. 2005;8:977&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">16047022</ArticleId></ArticleIdList></Reference><Reference><Citation>Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron. 2013;79:887&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3768018</ArticleId><ArticleId IdType="pubmed">24012003</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Welzel AT, Maggio JE, Shankar GM, Walker DE, Ostaszewski BL, Li S, et al. Secreted Amyloid &#x3b2;-Proteins in a Cell Culture Model Include N-Terminally Extended Peptides That Impair Synaptic Plasticity. Biochemistry. 2014;53(24):3908&#x2013;3921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4070750</ArticleId><ArticleId IdType="pubmed">24840308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills ZP, Mandel-Brehm C, Mardinly AR, McCord AE, Giger RJ, Greenberg ME. The nogo receptor family restricts synapse number in the developing hippocampus. Neuron. 2012;73:466&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532882</ArticleId><ArticleId IdType="pubmed">22325200</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu T, Yu X, Perlik AJ, Tobin WF, Zweig JA, Tennant K, Jones T, Zuo Y. Rapid formation and selective stabilization of synapses for enduring motor memories. Nature. 2009;462:915&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844762</ArticleId><ArticleId IdType="pubmed">19946267</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Pan F, Gan WB. Stably maintained dendritic spines are associated with lifelong memories. Nature. 2009;462:920&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4724802</ArticleId><ArticleId IdType="pubmed">19946265</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda R, Sabatini BL, Svoboda K. Plasticity of calcium channels in dendritic spines. Nat Neurosci. 2003;6:948&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">12937422</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi Y, Miyashita H, Tsunekawa H, Mouri A, Kim HC, Saito K, Matsuno T, et al. Effects of a novel cognitive enhancer, spiro[imidazo-[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446), on learning impairments induced by amyloid-beta1-40 in the rat. J Pharmacol Exp Ther. 2006;317:1079&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">16474004</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto Y, Shioda N, Han F, Moriguchi S, Fukunaga K. Novel cognitive enhancer ST101 enhances acetylcholine release in mouse dorsal hippocampus through T-type voltage-gated calcium channel stimulation. J Pharmacol Sci. 2013;121:212&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">23449490</ArticleId></ArticleIdList></Reference><Reference><Citation>Zemmar A, Weinmann O, Kellner Y, Yu X, Vicente R, Gullo M, Kasper H, Lussi K, Ristic Z, et al. Neutralization of Nogo-A enhances synaptic plasticity in the rodent motor cortex and improves motor learning in vivo. J Neurosci. 2014;34:8685&#x2013;8698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4147625</ArticleId><ArticleId IdType="pubmed">24966370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng B, Atwal J, Ho C, Case L, He XL, Garcia KC, et al. Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or promote corticospinal tract regeneration in vivo. Proc Natl Acad Sci U S A. 2005;102(4):1205&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544342</ArticleId><ArticleId IdType="pubmed">15647357</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Hu X, He W, Tang X, Shi Q, Zhang Z, Yan R. Interaction between amyloid precursor protein and Nogo receptors regulates amyloid deposition. FASEB. 2011;25(9):3146&#x2013;3156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157691</ArticleId><ArticleId IdType="pubmed">21670066</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou C, Montagna E, Shi E, Peters F, Blazquez-Llorca L, Shi S, Filser S, Dorostkar M, Herms J. Intraneuronal APP and extracellular A&#x3b2; independently cause dendritic spine pathology in transgenic mouse models of Alzheimer&#x2019;s disease. Acta Neuropathol. 2015;129:909&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4436699</ArticleId><ArticleId IdType="pubmed">25862638</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29073081</PMID><DateCompleted><Year>2018</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>43</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy.</ArticleTitle><Pagination><StartPage>11524</StartPage><EndPage>11529</EndPage><MedlinePgn>11524-11529</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1710311114</ELocationID><Abstract><AbstractText>Variants in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) were recently found to increase the risk for developing Alzheimer's disease (AD). In the brain, TREM2 is predominately expressed on microglia, and its association with AD adds to increasing evidence implicating a role for the innate immune system in AD initiation and progression. Thus far, studies have found TREM2 is protective in the response to amyloid pathology while variants leading to a loss of TREM2 function impair microglial signaling and are deleterious. However, the potential role of TREM2 in the context of tau pathology has not yet been characterized. In this study, we crossed <i>Trem2</i><sup>+/+</sup> (T2<sup>+/+</sup>) and <i>Trem2</i><sup>-/-</sup> (T2<sup>-/-</sup>) mice to the PS19 human tau transgenic line (PS) to investigate whether loss of TREM2 function affected tau pathology, the microglial response to tau pathology, or neurodegeneration. Strikingly, by 9 mo of age, T2<sup>-/-</sup>PS mice exhibited significantly less brain atrophy as quantified by ventricular enlargement and preserved cortical volume in the entorhinal and piriform regions compared with T2<sup>+/+</sup>PS mice. However, no TREM2-dependent differences were observed for phosphorylated tau staining or insoluble tau levels. Rather, T2<sup>-/-</sup>PS mice exhibited significantly reduced microgliosis in the hippocampus and piriform cortex compared with T2<sup>+/+</sup>PS mice. Gene expression analyses and immunostaining revealed microglial activation was significantly attenuated in T2<sup>-/-</sup>PS mice, and there were lower levels of inflammatory cytokines and astrogliosis. These unexpected findings suggest that impairing microglial TREM2 signaling reduces neuroinflammation and is protective against neurodegeneration in the setting of pure tauopathy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 the Author(s). Published by PNAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leyns</LastName><ForeName>Cheryl E G</ForeName><Initials>CEG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Mary B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Floy R</ForeName><Initials>FR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koscal</LastName><ForeName>Lauren J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remolina Serrano</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Grace O</ForeName><Initials>GO</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Elise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110; holtzman@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 AG053976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>Conflict of interest statement: C.E.G.L. and D.M.H. are listed as inventors on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. cofounded and is on the scientific advisory board of C2N Diagnostics, LLC. C2N Diagnostics, LLC, has licensed certain anti-tau antibodies to AbbVie for therapeutic development. D.M.H. is on the scientific advisory board of Proclara Biosciences and consults for Genentech, Eli Lilly, AbbVie, GlaxoSmithKline, and Denali. J.D.U., M.B.F., F.R.S., L.J.K., J.R.S., G.O.R., E.A., and M.C. declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29073081</ArticleId><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="doi">10.1073/pnas.1710311114</ArticleId><ArticleId IdType="pii">1710311114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer&#x2019;s disease: The challenge of the second century. Sci Transl Med. 2011;3:77sr1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989;24:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">2808689</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheffield LG, Marquis JG, Berman NE. Regional distribution of cortical microglia parallels that of neurofibrillary tangles in Alzheimer&#x2019;s disease. Neurosci Lett. 2000;285:165&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806312</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease&#x2014;a double-edged sword. Neuron. 2002;35:419&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165466</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Holtzman DM. Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener. 2017;12:50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5492997</ArticleId><ArticleId IdType="pubmed">28662669</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. Alzheimer Genetic Analysis Group TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Ulland TK, Colonna M, Holtzman DM. Elucidating the role of TREM2 in Alzheimer&#x2019;s disease. Neuron. 2017;94:237&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">28426958</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2) J Biol Chem. 2015;290:26043&#x2013;26050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CC, DeVaux LB, Farzan M. The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J Biol Chem. 2015;290:26033&#x2013;26042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646256</ArticleId><ArticleId IdType="pubmed">26374897</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober DL, et al. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. Elife. 2016;5:e20391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173322</ArticleId><ArticleId IdType="pubmed">27995897</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron. 2016;91:328&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, et al. Alzheimer&#x2019;s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement. 2017;13:381&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299056</ArticleId><ArticleId IdType="pubmed">27520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: Time, space and &#x201c;wingmen.&#x201d;. Nat Neurosci. 2015;18:800&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4445458</ArticleId><ArticleId IdType="pubmed">26007213</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, et al. Altered microglial response to A&#x3b2; plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener. 2014;9:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J Exp Med. 2015;212:287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2017;37:637&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213:667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;92:252&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">27710785</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, et al. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006;177:3520&#x2013;3524.</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack JC, Schneider A, Mandelkow E-M, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer&#x2019;s disease. Acta Neuropathol. 2002;103:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci A, Bugiani O, Ghetti B, Spillantini MG. Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener Dis. 2011;8:221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3214942</ArticleId><ArticleId IdType="pubmed">21212632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M, et al. Early abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer&#x2019;s disease. Am J Pathol. 2011;179:1373&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157187</ArticleId><ArticleId IdType="pubmed">21777559</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol. 2015;77:75&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432483</ArticleId><ArticleId IdType="pubmed">25381879</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, et al. TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep. 2017;18:1186&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566&#x2013;581.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan K, et al. Untangling the brain&#x2019;s neuroinflammatory and neurodegenerative transcriptional responses. Nat Commun. 2016;7:11295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4844685</ArticleId><ArticleId IdType="pubmed">27097852</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282491</ArticleId><ArticleId IdType="pubmed">22393530</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Saber M, Kokiko-Cochran O, Puntambekar SS, Lathia JD, Lamb BT. Triggering receptor expressed on myeloid cells 2 deficiency alters acute macrophage distribution and improves recovery after traumatic brain injury. J Neurotrauma. 2017;34:423&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">26976047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieber MW, et al. Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PLoS One. 2013;8:e52982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536811</ArticleId><ArticleId IdType="pubmed">23301011</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi M, Konishi H, Sayo A, Takai T, Kiyama H. TREM2/DAP12 signal elicits proinflammatory response in microglia and exacerbates neuropathic pain. J Neurosci. 2016;36:11138&#x2013;11150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6705657</ArticleId><ArticleId IdType="pubmed">27798193</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol. 2003;3:445&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">12776204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, et al. TREM2 maintains microglial metabolic fitness in Alzheimer&#x2019;s disease. Cell. 2017;170:649&#x2013;663.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, et al. TREM2 promotes microglial survival by activating Wnt/&#x3b2;-catenin pathway. J Neurosci. 2017;37:1772&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5320608</ArticleId><ArticleId IdType="pubmed">28077724</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero K, et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat Immunol. 2009;10:734&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004764</ArticleId><ArticleId IdType="pubmed">19503107</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Lull ME, Block ML. Microglial activation and chronic neurodegeneration. Neurotherapeutics. 2010;7:354&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951017</ArticleId><ArticleId IdType="pubmed">20880500</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W-Y, Tan M-S, Yu J-T, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer&#x2019;s disease. Ann Transl Med. 2015;3:136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486922</ArticleId><ArticleId IdType="pubmed">26207229</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, et al. Dominantly Inherited Alzheimer Network Early changes in CSF sTREM2 in dominantly inherited Alzheimer&#x2019;s disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8:369ra178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med. 2017;214:597&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5339672</ArticleId><ArticleId IdType="pubmed">28209725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ising C, et al. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. J Exp Med. 2017;214:1227&#x2013;1238, and erratum (2017) 214:2163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5413341</ArticleId><ArticleId IdType="pubmed">28416651</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin K. The Mouse Brain in Stereotactic Coordinates. Academic; New York: 2008.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29037207</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy.</ArticleTitle><Pagination><StartPage>74</StartPage><MedlinePgn>74</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">74</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-017-0216-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Genetic variants of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) confer increased risk of developing late-onset Alzheimer's Disease (LOAD) and other neurodegenerative disorders. Recent studies provided insight into the multifaceted roles of TREM2 in regulating extracellular &#x3b2;-amyloid (A&#x3b2;) pathology, myeloid cell accumulation, and inflammation observed in AD, yet little is known regarding the role of TREM2 in regulating intracellular microtubule associated protein tau (MAPT; tau) pathology in neurodegenerative diseases and in AD, in particular.</AbstractText><AbstractText Label="RESULTS">Here we report that TREM2 deficiency leads to accelerated and exacerbated hyperphosphorylation and aggregation of tau in a humanized mouse model of tauopathy. TREM2 deficiency also results, indirectly, in dramatic widespread dysregulation of neuronal stress kinase pathways.</AbstractText><AbstractText Label="CONCLUSIONS">Our results suggest that deficiency of microglial TREM2 leads to heightened tau pathology coupled with widespread increases in activated neuronal stress kinases. These findings offer new insight into the complex, multiple roles of TREM2 in regulating A&#x3b2; and tau pathologies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bemiller</LastName><ForeName>Shane M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, The Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA. sbemille@iu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kent State University, School of Biomedical Sciences, Kent, OH, USA. sbemille@iu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Indiana University School of Medicine Stark Neuroscience Research Institute, Indianapolis, IN, USA. sbemille@iu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCray</LastName><ForeName>Tyler J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Indiana University School of Medicine Stark Neuroscience Research Institute, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Case Western Reserve University, Cleveland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Formica</LastName><ForeName>Shane V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, The Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Guixiang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, The Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Indiana University School of Medicine Stark Neuroscience Research Institute, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Gina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Northeastern Ohio Medical University, Rootstown, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kokiko-Cochran</LastName><ForeName>Olga N</ForeName><Initials>ON</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, The Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crish</LastName><ForeName>Samuel D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Northeastern Ohio Medical University, Rootstown, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasagna-Reeves</LastName><ForeName>Cristian A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Indiana University School of Medicine Stark Neuroscience Research Institute, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ransohoff</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Biogen IDEC, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landreth</LastName><ForeName>Gary E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Indiana University School of Medicine Stark Neuroscience Research Institute, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Case Western Reserve University, Cleveland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Bruce T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, The Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA. btlamb@iu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Indiana University School of Medicine Stark Neuroscience Research Institute, Indianapolis, IN, USA. btlamb@iu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG051495</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001108</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG050409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG050597</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY022358</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007250</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimers disease</Keyword><Keyword MajorTopicYN="N">Immunity</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">Tauopathy</Keyword></KeywordList><CoiStatement>ETHICS APPROVAL: All experimental design and analysis performed was overseen and approved by the Cleveland Clinic Lerner Research Institute Institutional Review Board (IRB), as well as the Cleveland Clinic Institutional Animal Care and Use Committee (IACUC). CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29037207</ArticleId><ArticleId IdType="pmc">PMC5644120</ArticleId><ArticleId IdType="doi">10.1186/s13024-017-0216-6</ArticleId><ArticleId IdType="pii">10.1186/s13024-017-0216-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hollingworth P, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429&#x2013;435. doi: 10.1038/ng.803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.803</ArticleId><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099. doi: 10.1038/ng.439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.439</ArticleId><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj A, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43:436&#x2013;441. doi: 10.1038/ng.801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2012; doi:10.1056/NEJMoa1211851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2012; doi:10.1056/NEJMoa1211103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol. 2003;3:445&#x2013;453. doi: 10.1038/nri1106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1106</ArticleId><ArticleId IdType="pubmed">12776204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C, et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem. 2009;109:1144&#x2013;1156. doi: 10.1111/j.1471-4159.2009.06042.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06042.x</ArticleId><ArticleId IdType="pmc">PMC3087597</ArticleId><ArticleId IdType="pubmed">19302484</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieber M, et al. Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PLoS One. 2013;8:e52982. doi: 10.1371/journal.pone.0052982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052982</ArticleId><ArticleId IdType="pmc">PMC3536811</ArticleId><ArticleId IdType="pubmed">23301011</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiialainen A, Hovanes K, Paloneva J, Kopra O, Peltonen L. Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS. Neurobiol Dis. 2005;18:314&#x2013;322. doi: 10.1016/j.nbd.2004.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2004.09.007</ArticleId><ArticleId IdType="pubmed">15686960</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnartz B, Wang Y, Neumann H. Microglial immunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation. Int J Alzheimers Dis. 2010; doi:10.4061/2010/587463 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2915791</ArticleId><ArticleId IdType="pubmed">20721346</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Holtzman DM. TREM2 function in Alzheimer's disease and Neurodegeneration. ACS Chem Neurosci. 2016; doi:10.1021/acschemneuro.5b00313.</Citation><ArticleIdList><ArticleId IdType="pubmed">26854967</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage JC, et al. Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease. J Neurosci. 2015;35:6532&#x2013;6543. doi: 10.1523/JNEUROSCI.4586-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4586-14.2015</ArticleId><ArticleId IdType="pmc">PMC4405560</ArticleId><ArticleId IdType="pubmed">25904803</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird TD, Koerker RM, Leaird BJ, Vlcek BW, Thorning DR. Lipomembranous polycystic osteodysplasia (brain, bone, and fat disease): a genetic cause of presenile dementia. Neurology. 1983;33:81&#x2013;86. doi: 10.1212/WNL.33.1.81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.33.1.81</ArticleId><ArticleId IdType="pubmed">6681564</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouery E, et al. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum Mutat. 2008;29:E194&#x2013;E204. doi: 10.1002/humu.20836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.20836</ArticleId><ArticleId IdType="pubmed">18546367</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunemann H, et al. The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology. 2005;64:1502&#x2013;7. disease. J Neurosci. 2005;64:1502&#x2013;7. doi:10.1212/01.WNL.0000160304.00003.CA.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883308</ArticleId></ArticleIdList></Reference><Reference><Citation>Numasawa Y, et al. Nasu-Hakola disease with a splicing mutation of TREM2 in a Japanese family. Eur J Neurol. 2011;18:1179&#x2013;1183. doi: 10.1111/j.1468-1331.2010.03311.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2010.03311.x</ArticleId><ArticleId IdType="pubmed">21834902</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014;71:449&#x2013;453. doi: 10.1001/jamaneurol.2013.6237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6237</ArticleId><ArticleId IdType="pmc">PMC4087113</ArticleId><ArticleId IdType="pubmed">24535663</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, et al. Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging. 2014;35 doi:10.1016/j.neurobiolaging.2013.09.017.ARTN 934.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24139279</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener. 2013;8 doi:10.1186/1750-1326-8-19.Artn 19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691612</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med. 2015;212:287&#x2013;295. doi: 10.1084/jem.20142322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142322</ArticleId><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener. 2014;9:20. doi: 10.1186/1750-1326-9-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-20</ArticleId><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. J Neurosci. 2017;37:637&#x2013;647. doi:10.1523/JNEUROSCI.2110-16.2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213:667&#x2013;675. doi: 10.1084/jem.20151948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YM, et al. TREM2 lipid sensing sustains the Microglial response in an Alzheimer's disease model. Cell. 2015;160:1061&#x2013;1071. doi: 10.1016/j.cell.2015.01.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, et al. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005;25:5446&#x2013;5454. doi: 10.1523/JNEUROSCI.4637-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4637-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582&#x2013;590. doi: 10.1046/j.1471-4159.2003.01879.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.01879.x</ArticleId><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien C, Bretteville A, Planel E. Biochemical isolation of insoluble tau in transgenic mouse models of tauopathies. Methods Mol Biol. 2012;849:473&#x2013;491. doi: 10.1007/978-1-61779-551-0_32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-551-0_32</ArticleId><ArticleId IdType="pubmed">22528110</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. J Neurosci. 2016; doi:10.1523/jneurosci.2110-16.2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskar K, et al. Regulation of tau pathology by the microglial fractalkine receptor. Neuron. 2010;68:19&#x2013;31. doi: 10.1016/j.neuron.2010.08.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.08.023</ArticleId><ArticleId IdType="pmc">PMC2950825</ArticleId><ArticleId IdType="pubmed">20920788</ArticleId></ArticleIdList></Reference><Reference><Citation>Maphis N, et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain. 2015;138:1738&#x2013;1755. doi: 10.1093/brain/awv081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv081</ArticleId><ArticleId IdType="pmc">PMC4542622</ArticleId><ArticleId IdType="pubmed">25833819</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokiko-Cochran O, et al. Altered Neuroinflammation and Behavior after Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease. J Neurotrauma. 2015; doi:10.1089/neu.2015.3970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4971425</ArticleId><ArticleId IdType="pubmed">26414955</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai H, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584&#x2013;1593. doi: 10.1038/nn.4132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4132</ArticleId><ArticleId IdType="pmc">PMC4694577</ArticleId><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14:389&#x2013;394. doi: 10.1038/embor.2013.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2013.15</ArticleId><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, et al. Opposing effects of membrane-anchored CX3CL1 on Amyloid and tau pathologies via the p38 MAPK pathway. J Neurosci. 2014;34:12538&#x2013;12546. doi: 10.1523/JNEUROSCI.0853-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0853-14.2014</ArticleId><ArticleId IdType="pmc">PMC4160782</ArticleId><ArticleId IdType="pubmed">25209291</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S, et al. Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci. 2013;33:5053&#x2013;5064. doi: 10.1523/JNEUROSCI.4361-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4361-12.2013</ArticleId><ArticleId IdType="pmc">PMC3637949</ArticleId><ArticleId IdType="pubmed">23486975</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med. 2017; doi:10.1084/jem.20160844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5339672</ArticleId><ArticleId IdType="pubmed">28209725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29049480</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>12</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.</ArticleTitle><Pagination><StartPage>1481</StartPage><EndPage>1491</EndPage><MedlinePgn>1481-1491</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.2712</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Biomarkers do not determine conversion to Alzheimer disease (AD) perfectly, and criteria do not specify how to take patient characteristics into account. Consequently, biomarker use may be challenging for clinicians, especially in patients with mild cognitive impairment (MCI).</AbstractText><AbstractText Label="OBJECTIVE">To construct biomarker-based prognostic models that enable determination of future AD dementia in patients with MCI.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This study is part of the Alzheimer's Biomarkers in Daily Practice (ABIDE) project. A total of 525 patients with MCI from the Amsterdam Dementia Cohort (longitudinal cohort, tertiary referral center) were studied. All patients had their baseline visit to a memory clinic from September 1, 1997, through August 31, 2014. Prognostic models were constructed by Cox proportional hazards regression with patient characteristics (age, sex, and Mini-Mental State Examination [MMSE] score), magnetic resonance imaging (MRI) biomarkers (hippocampal volume, normalized whole-brain volume), cerebrospinal fluid (CSF) biomarkers (amyloid-&#x3b2;1-42, tau), and combined biomarkers. Data were analyzed from November 1, 2015, to October 1, 2016.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Clinical end points were AD dementia and any type of dementia after 1 and 3 years.</AbstractText><AbstractText Label="RESULTS">Of the 525 patients, 210 (40.0%) were female, and the mean (SD) age was 67.3&#x2009;(8.4) years. On the basis of age, sex, and MMSE score only, the 3-year progression risk to AD dementia ranged from 26% (95% CI, 19%-34%) in younger men with MMSE scores of 29 to 76% (95% CI, 65%-84%) in older women with MMSE scores of 24 (1-year risk: 6% [95% CI, 4%-9%] to 24% [95% CI, 18%-32%]). Three- and 1-year progression risks were 86% (95% CI, 71%-95%) and 27% (95% CI, 17%-41%) when MRI results were abnormal, 82% (95% CI, 73%-89%) and 26% (95% CI, 20%-33%) when CSF test results were abnormal, and 89% (95% CI, 79%-95%) and 26% (95% CI, 18%-36%) when the results of both tests were abnormal. Conversely, 3- and 1-year progression risks were 18% (95% CI, 13%-27%) and 3% (95% CI, 2%-5%) after normal MRI results, 6% (95% CI, 3%-9%) and 1% (95% CI, 0.5%-2%) after normal CSF test results, and 4% (95% CI, 2%-7%) and 0.5% (95% CI, 0.2%-1%) after combined normal MRI and CSF test results. The prognostic value of models determining any type of dementia were in the same order of magnitude although somewhat lower. External validation in Alzheimer's Disease Neuroimaging Initiative 2 showed that our models were highly robust.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study provides biomarker-based prognostic models that may help determine AD dementia and any type of dementia in patients with MCI at the individual level. This finding supports clinical decision making and application of biomarkers in daily practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Maurik</LastName><ForeName>Ingrid S</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwan</LastName><ForeName>Marissa D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tijms</LastName><ForeName>Betty M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouwman</LastName><ForeName>Femke H</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wattjes</LastName><ForeName>Mike P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barkhof</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institutes of Neurology and Healthcare Engineering, University College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berkhof</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Scheltens reported receiving grant support (for the institution) from GE Healthcare, Danone Research, Piramal, and Merck and, in the past 2 years, receiving consultancy/speaker fees (paid to the institution) from Lilly, GE Healthcare, Novartis, Sanofi, Nutricia, Probiodrug, Biogen, Roche, Avraham, and EIP Pharma. Dr Barkhof reported serving as a consultant for Biogen-Idec, Janssen Alzheimer Immunotherapy, Bayer Schering, Merck Serono, Roche, Novartis, Genzume, and Sanofi; receiving sponsorship from European Horizon 2020, Netherlands Organisation for Scientific Research, National Institute for Health Research&#x2013;University College London Hospitals Biomedical Research Centre, Scottish Multiple Sclerosis Register, Teva, Novartis, and Toshiba; and serving on the editorial boards of Radiology, Brain, Neuroradiology, MSJ, and Neurology. Dr van der Flier reported performing contract research and serving as an invited speaker for Boehringer Ingelheim and working on research programs funded by ZonMW, Netherlands Organisation for Scientific Research, European 7th Framework Programme, Alzheimer Nederland, Cardiovasculair Onderzoek Nederland, stichting Dioraphte, Gieskes-Strijbis fonds, Boehringer Ingelheim, Piramal Neuroimaging, Roche BV, Janssen Stellar, and Combinostics (all funding is paid to her institution). No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29049480</ArticleId><ArticleId IdType="pmc">PMC5822193</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.2712</ArticleId><ArticleId IdType="pii">2657326</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scheltens P, Blennow K, Breteler MM, et al. . Alzheimer&#x2019;s disease. Lancet. 2016;388(10043):505-517.</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Verhey F, Knol DL, et al. . Prevalence and prognostic value of CSF markers of Alzheimer&#x2019;s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8(7):619-627.</Citation><ArticleIdList><ArticleId IdType="pubmed">19523877</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):270-279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer&#x2019;s disease. Neuron. 2013;80(6):1347-1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwman FH, Schoonenboom SN, van der Flier WM, et al. . CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging. 2007;28(7):1070-1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">16782233</ArticleId></ArticleIdList></Reference><Reference><Citation>Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging. 2011;32(12):2322-2327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951483</ArticleId><ArticleId IdType="pubmed">20594615</ArticleId></ArticleIdList></Reference><Reference><Citation>van Harten AC, Visser PJ, Pijnenburg YA, et al. . Cerebrospinal fluid A&#x3b2;42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement. 2013;9(5):481-487.</Citation><ArticleIdList><ArticleId IdType="pubmed">23232269</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard E, Schmand BA, Eikelenboom P, Van Gool WA; Alzheimer&#x2019;s Disease Neuroimaging Initiative . MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer&#x2019;s disease in patients with mild cognitive impairment: a diagnostic accuracy study. BMJ Open. 2013;3(6):e002541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3686215</ArticleId><ArticleId IdType="pubmed">23794572</ArticleId></ArticleIdList></Reference><Reference><Citation>Duits FH, Prins ND, Lemstra AW, et al. . Diagnostic impact of CSF biomarkers for Alzheimer&#x2019;s disease in a tertiary memory clinic. Alzheimers Dement. 2015;11(5):523-532.</Citation><ArticleIdList><ArticleId IdType="pubmed">25156643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester MI, Boelaarts L, Bouwman FH, et al. . Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord. 2010;29(6):491-497.</Citation><ArticleIdList><ArticleId IdType="pubmed">20523047</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303-308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. . Research criteria for the diagnosis of Alzheimer&#x2019;s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Perani D, Bastianello S, et al. . Biomarkers for the diagnosis of Alzheimer&#x2019;s disease in clinical practice: an Italian intersocietal roadmap. Neurobiol Aging. 2017;52:119-131.</Citation><ArticleIdList><ArticleId IdType="pubmed">28317643</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wilde A, van Maurik IS, Kunneman M, et al. . Alzheimer&#x2019;s Biomarkers in Daily Practice (ABIDE) project: rationale and design. Alzheimers Dement (Amst). 2017;6:143-151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5318541</ArticleId><ArticleId IdType="pubmed">28239639</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Flier WM, Pijnenburg YA, Prins N, et al. . Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41(1):313-327.</Citation><ArticleIdList><ArticleId IdType="pubmed">24614907</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939-944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Rom&#xe1;n GC, Tatemichi TK, Erkinjuntti T, et al. . Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250-260.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094895</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. ; Consortium on DLB . Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863-1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, et al. . Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546-1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(pt 9):2456-2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattjes MP, Henneman WJ, van der Flier WM, et al. . Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. Radiology. 2009;253(1):174-183.</Citation><ArticleIdList><ArticleId IdType="pubmed">19635835</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol. 1995;242(9):557-560.</Citation><ArticleIdList><ArticleId IdType="pubmed">8551316</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996;36(5):268-272.</Citation><ArticleIdList><ArticleId IdType="pubmed">8864706</ArticleId></ArticleIdList></Reference><Reference><Citation>Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage. 2011;56(3):907-922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3417233</ArticleId><ArticleId IdType="pubmed">21352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Zhang Y, Jenkinson M, et al. . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002;17(1):479-489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482100</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder C, Verwey NA, van der Flier WM, et al. . Amyloid-&#x3b2;(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem. 2010;56(2):248-253.</Citation><ArticleIdList><ArticleId IdType="pubmed">19833838</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, Petzold A, Bennett JL, et al. . A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22):1914-1922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839806</ArticleId><ArticleId IdType="pubmed">19949037</ArticleId></ArticleIdList></Reference><Reference><Citation>Duits FH, Teunissen CE, Bouwman FH, et al. . The cerebrospinal fluid &#x201c;Alzheimer profile&#x201d;: easily said, but what does it mean? Alzheimers Dement. 2014;10(6):713-723.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">24721526</ArticleId></ArticleIdList></Reference><Reference><Citation>Newson RB. Comparing the predictive powers of survival models using Harrell&#x2019;s C or Somers&#x2019; D. Stata J. 2010;10(3):339-358.</Citation></Reference><Reference><Citation>Cefalu M. Pointwise confidence intervals for the covariate-adjusted survivor function in the Cox model. Stata J. 2011;11(1):64-81.</Citation></Reference><Reference><Citation>Verhage F. Intelligence and Age: Research Among the Dutch Aged 12 to 77 [in Dutch]. Assen, the Netherlands: van Gorcum; 1964.</Citation></Reference><Reference><Citation>Dubois B, Hampel H, Feldman HH, et al. ; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer&#x2019;s Association on &#x201c;The Preclinical State of AD&#x201d;; July 23, 2015; Washington DC, USA . Preclinical Alzheimer&#x2019;s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292-323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417794</ArticleId><ArticleId IdType="pubmed">27012484</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlawish J. Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology. 2011;77(15):1487-1493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4561233</ArticleId><ArticleId IdType="pubmed">21917767</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos S, van Rossum I, Burns L, et al. . Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging. 2012;33(10):2272-2281.</Citation><ArticleIdList><ArticleId IdType="pubmed">22264648</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhovd KB, Fjell AM, Brewer J, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol. 2010;31(2):347-354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821467</ArticleId><ArticleId IdType="pubmed">20075088</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Wolk DA; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Biomarker-based prediction of progression in MCI: comparison of AD signature and hippocampal volume with spinal fluid amyloid-&#x3b2; and tau. Front Aging Neurosci. 2013;5:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795312</ArticleId><ArticleId IdType="pubmed">24130528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Walsh C, Trojanowski JQ, et al. ; North American Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) . Prediction of conversion from mild cognitive impairment to Alzheimer&#x2019;s disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging. 2012;33(7):1203-1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328615</ArticleId><ArticleId IdType="pubmed">21159408</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaffer JL, Petrella JR, Sheldon FC, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology. 2013;266(2):583-591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558874</ArticleId><ArticleId IdType="pubmed">23232293</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuff N, Woerner N, Boreta L, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . MRI of hippocampal volume loss in early Alzheimer&#x2019;s disease in relation to ApoE genotype and biomarkers. Brain. 2009;132(pt 4):1067-1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668943</ArticleId><ArticleId IdType="pubmed">19251758</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. ; Amyloid Biomarker Study Group . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Ros&#xe9;n E, Hansson O, et al. . Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology. 2012;78(7):468-476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280049</ArticleId><ArticleId IdType="pubmed">22302554</ArticleId></ArticleIdList></Reference><Reference><Citation>Clerx L, van Rossum IA, Burns L, et al. . Measurements of medial temporal lobe atrophy for prediction of Alzheimer&#x2019;s disease in subjects with mild cognitive impairment. Neurobiol Aging. 2013;34(8):2003-2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">23540941</ArticleId></ArticleIdList></Reference><Reference><Citation>Antila K, L&#xf6;tj&#xf6;nen J, Thurfjell L, et al. . The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer&#x2019;s disease. Interface Focus. 2013;3(2):20120072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3638476</ArticleId><ArticleId IdType="pubmed">24427524</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall A, Mu&#xf1;oz-Ruiz M, Mattila J, et al. ; Alzheimer Disease Neuroimaging Initiative; AddNeuroMed consortium; DESCRIPA and Kuopio L-MCI . Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer&#x2019;s disease. J Alzheimers Dis. 2015;44(1):79-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">25201784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bron EE, Smits M, van der Flier WM, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: the CADDementia challenge. Neuroimage. 2015;111:562-579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4943029</ArticleId><ArticleId IdType="pubmed">25652394</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertens D, Tijms BM, Scheltens P, Teunissen CE, Visser PJ. Unbiased estimates of cerebrospinal fluid &#x3b2;-amyloid 1-42 cutoffs in a large memory clinic population. Alzheimers Res Ther. 2017;9(1):8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5307885</ArticleId><ArticleId IdType="pubmed">28193256</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Sutphen CL, Teunissen C, et al. . Upward drift in cerebrospinal fluid amyloid &#x3b2; 42 assay values for more than 10 years [published online July 12, 2017]. Alzheimers Dement. doi:10.1016/j.jalz.2017.06.2264</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2264</ArticleId><ArticleId IdType="pmc">PMC5750131</ArticleId><ArticleId IdType="pubmed">28710906</ArticleId></ArticleIdList></Reference><Reference><Citation>Willemse EAJ, van Uffelen KWJ, van der Flier WM, Teunissen CE. Effect of long-term storage in biobanks on cerebrospinal fluid biomarker A&#x3b2;1-42, T-tau, and P-tau values. Alzheimers Dement (Amst). 2017;8:45-50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5403783</ArticleId><ArticleId IdType="pubmed">28462389</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29046362</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>20</Issue><PubDate><Year>2017</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>In vivo staging of regional amyloid deposition.</ArticleTitle><Pagination><StartPage>2031</StartPage><EndPage>2038</EndPage><MedlinePgn>2031-2038</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000004643</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To estimate a regional progression pattern of amyloid deposition from cross-sectional amyloid-sensitive PET data and evaluate its potential for in vivo staging of an individual's amyloid pathology.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Multiregional analysis of florbetapir (<sup>18</sup>F-AV45)-PET data was used to determine individual amyloid distribution profiles in a sample of 667 participants from the Alzheimer's Disease Neuroimaging Initiative cohort, including cognitively normal older individuals (CN) as well as patients with mild cognitive impairment and Alzheimer disease (AD) dementia. The frequency of regional amyloid positivity across CN individuals was used to construct a 4-stage model of progressing amyloid pathology, and individual distribution profiles were used to evaluate the consistency of this hierarchical stage model across the full cohort.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">According to a 4-stage model, amyloid deposition begins in temporobasal and frontomedial areas, and successively affects the remaining associative neocortex, primary sensory-motor areas and the medial temporal lobe, and finally the striatum. Amyloid deposition in these brain regions showed a highly consistent hierarchical nesting across participants, where only 2% exhibited distribution profiles that deviated from the staging scheme. The earliest in vivo amyloid stages were mostly missed by conventional dichotomous classification approaches based on global florbetapir-PET signal, but were associated with significantly reduced CSF A&#x3b2;42 levels. Advanced in vivo amyloid stages were most frequent in patients with AD and correlated with cognitive impairment in individuals without dementia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The highly consistent regional hierarchy of PET-evidenced amyloid deposition across participants resembles neuropathologic observations and suggests a predictable regional sequence that may be used to stage an individual's progress of amyloid pathology in vivo.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grothe</LastName><ForeName>Michel J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>From the German Center for Neurodegenerative Diseases (DZNE) (M.J.G., M.D., S.J.T.), Rostock; Department of Nuclear Medicine (H.B., O.S.), University of Leipzig, Germany; Gordon Center for Medical Imaging (J.S.), Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (J.S.), Charlestown, MA; and Department of Psychosomatic Medicine (S.J.T.), University of Rostock, Germany. michel.grothe@dzne.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barthel</LastName><ForeName>Henryk</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the German Center for Neurodegenerative Diseases (DZNE) (M.J.G., M.D., S.J.T.), Rostock; Department of Nuclear Medicine (H.B., O.S.), University of Leipzig, Germany; Gordon Center for Medical Imaging (J.S.), Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (J.S.), Charlestown, MA; and Department of Psychosomatic Medicine (S.J.T.), University of Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepulcre</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the German Center for Neurodegenerative Diseases (DZNE) (M.J.G., M.D., S.J.T.), Rostock; Department of Nuclear Medicine (H.B., O.S.), University of Leipzig, Germany; Gordon Center for Medical Imaging (J.S.), Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (J.S.), Charlestown, MA; and Department of Psychosomatic Medicine (S.J.T.), University of Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dyrba</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the German Center for Neurodegenerative Diseases (DZNE) (M.J.G., M.D., S.J.T.), Rostock; Department of Nuclear Medicine (H.B., O.S.), University of Leipzig, Germany; Gordon Center for Medical Imaging (J.S.), Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (J.S.), Charlestown, MA; and Department of Psychosomatic Medicine (S.J.T.), University of Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabri</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the German Center for Neurodegenerative Diseases (DZNE) (M.J.G., M.D., S.J.T.), Rostock; Department of Nuclear Medicine (H.B., O.S.), University of Leipzig, Germany; Gordon Center for Medical Imaging (J.S.), Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (J.S.), Charlestown, MA; and Department of Psychosomatic Medicine (S.J.T.), University of Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teipel</LastName><ForeName>Stefan J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>From the German Center for Neurodegenerative Diseases (DZNE) (M.J.G., M.D., S.J.T.), Rostock; Department of Nuclear Medicine (H.B., O.S.), University of Leipzig, Germany; Gordon Center for Medical Imaging (J.S.), Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (J.S.), Charlestown, MA; and Department of Psychosomatic Medicine (S.J.T.), University of Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 EB015922</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 89(20):2029.</RefSource><PMID Version="1">29046365</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017072" MajorTopicYN="N">Neostriatum</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Enchi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felmlee</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandy</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor-Reinwald</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Les</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VMY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Betty</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva-Meyer</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsis</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romirowsky</LastName><ForeName>Aliza</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coleman</LastName><ForeName>R Edward</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makino</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mc-Adams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiceno</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DHS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Brandy R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robin Hsiung</LastName><ForeName>Ging-Yuek</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudge</LastName><ForeName>Benita</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek-Marsel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipowski</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Barton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budson</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Patricia Lynn</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolday</LastName><ForeName>Saba</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bwayo</LastName><ForeName>Salome K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T-Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Eben S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longmire</LastName><ForeName>Crystal Flynn</ForeName><Initials>CF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabether</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rachinsky</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomara</LastName><ForeName>Nunzio</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernando</LastName><ForeName>Raymundo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarrael</LastName><ForeName>Antero</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boles Ponto</LastName><ForeName>Laura L</ForeName><Initials>LL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shim</LastName><ForeName>Hyungsub</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Karen Elizabeth</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaing</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raudin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargher</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Balebail Ashok</ForeName><Initials>BA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>11</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29046362</ArticleId><ArticleId IdType="pmc">PMC5711511</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004643</ArticleId><ArticleId IdType="pii">WNL.0000000000004643</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Lowe VJ, Graff-Radford NR, et al. . Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain 2015;138:1370&#x2013;1381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407190</ArticleId><ArticleId IdType="pubmed">25805643</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 1991;12:295&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">1961359</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Hof PR, Vallet PG, Giannakopoulos AS, Charnay Y, Bouras C. Quantitative analysis of neuropathologic changes in the cerebral cortex of centenarians. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:577&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">8588057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol 2012;72:599&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490232</ArticleId><ArticleId IdType="pubmed">23109154</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel S, Drzezga A, Grothe MJ, et al. . Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. Lancet Neurol 2015;14:1037&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">26318837</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabri O, Sabbagh MN, Seibyl J, et al. . Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: phase 3 study. Alzheimers Dement 2015;11:964&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">25824567</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, et al. . Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305:275&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Beach TG, Zanette M, et al. . [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-beta pathology. Alzheimers Dement 2015;11:975&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">26141264</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. . Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 2015;138:2020&#x2013;2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806716</ArticleId><ArticleId IdType="pubmed">25953778</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, et al. . Updated TDP-43 in Alzheimer's disease staging scheme. Acta Neuropathol 2016;131:571&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5946692</ArticleId><ArticleId IdType="pubmed">26810071</ArticleId></ArticleIdList></Reference><Reference><Citation>Gertz HJ, Xuereb J, Huppert F, et al. . Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease. Acta Neuropathol 1998;95:154&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">9498050</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 2008;116:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">18592254</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe MJ, Teipel SJ. Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer's disease correspond to dissociable functional brain networks. Hum Brain Mapp 2016;37:35&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4715545</ArticleId><ArticleId IdType="pubmed">26441321</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe MJ, Heinsen H, Amaro E Jr, Grinberg LT, Teipel SJ. Cognitive correlates of basal forebrain atrophy and associated cortical hypometabolism in mild cognitive impairment. Cereb Cortex 2016;26:2411&#x2013;2426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869802</ArticleId><ArticleId IdType="pubmed">25840425</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel S, Grothe MJ. Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease? Eur J Nucl Med Mol Imaging 2016;43:526&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166099</ArticleId><ArticleId IdType="pubmed">26555082</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, Kurth J, Krause B, Grothe MJ. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment: beyond classical regression. Neuroimage Clin 2015;8:583&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4506984</ArticleId><ArticleId IdType="pubmed">26199870</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller-Gartner HW, Links JM, Prince JL, et al. . Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12:571&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">1618936</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Escamilla G, Lange C, Teipel S, Buchert R, Grothe MJ. PETPVE12: an SPM toolbox for partial volume effects correction in brain PET: application to amyloid imaging with AV45-PET. Neuroimage 2017;147:669&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">28039094</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Segonne F, Fischl B, et al. . An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Catafau AM, Bullich S, Seibyl JP, et al. . Cerebellar amyloid-beta plaques: how frequent are they, and do they influence 18F-florbetaben SUV ratios? J Nucl Med 2016;57:1740&#x2013;1745.</Citation><ArticleIdList><ArticleId IdType="pubmed">27363836</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi AD, Pontecorvo MJ, Clark CM, et al. . Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer&#x2019;s disease and cognitively normal subjects. J Nucl Med 2012;53:378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">22331215</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Breault C, Joshi AD, et al. . Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013;54:70&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747730</ArticleId><ArticleId IdType="pubmed">23166389</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Liu X, et al. . Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011;68:1404&#x2013;1411.</Citation><ArticleIdList><ArticleId IdType="pubmed">21747008</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, et al. . Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol 2013;74:826&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimmer T, Riemenschneider M, Forstl H, et al. . Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009;65:927&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700302</ArticleId><ArticleId IdType="pubmed">19268916</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. . Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Benzinger TL, Morris JC. PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochim Biophys Acta 2012;1822:370&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264790</ArticleId><ArticleId IdType="pubmed">22108203</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, et al. . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol 2016;80:247&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Sue LI, Walker DG, et al. . Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging. J Alzheimers Dis 2012;28:869&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3760731</ArticleId><ArticleId IdType="pubmed">22112552</ArticleId></ArticleIdList></Reference><Reference><Citation>Annus T, Wilson LR, Hong YT, et al. . The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement 2016;12:538&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867786</ArticleId><ArticleId IdType="pubmed">26362596</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Price JC, Mathis CA, et al. . Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007;27:6174&#x2013;6184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265970</ArticleId><ArticleId IdType="pubmed">17553989</ArticleId></ArticleIdList></Reference><Reference><Citation>Koivunen J, Verkkoniemi A, Aalto S, et al. . PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 2008;131:1845&#x2013;1853.</Citation><ArticleIdList><ArticleId IdType="pubmed">18583368</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Ataka S, Mizuno T, et al. . High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol 2009;66:1537&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pubmed">20008660</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Thal DR, Zanette M, Smith A, Buckley C. Detection of striatal amyloid plaques with [18F]flutemetamol: validation with postmortem histopathology. J Alzheimers Dis 2016;52:863&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">27031469</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah N, Frey KA, Muller ML, et al. . Striatal and cortical beta-amyloidopathy and cognition in Parkinson's disease. Mov Disord 2016;31:111&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4724301</ArticleId><ArticleId IdType="pubmed">26380951</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29054878</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>47</Issue><PubDate><Year>2017</Year><Month>Nov</Month><Day>22</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain.</ArticleTitle><Pagination><StartPage>11406</StartPage><EndPage>11423</EndPage><MedlinePgn>11406-11423</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1230-17.2017</ELocationID><Abstract><AbstractText>Pathological tau aggregates occur in Alzheimer's disease (AD) and other neurodegenerative tauopathies. It is not clearly understood why tauopathies vary greatly in the neuroanatomical and histopathological patterns of tau aggregation, which contribute to clinical heterogeneity in these disorders. Recent studies have shown that tau aggregates may form distinct structural conformations, known as tau strains. Here, we developed a novel model to test the hypothesis that cell-to-cell transmission of different tau strains occurs in nontransgenic (non-Tg) mice, and to investigate whether there are strain-specific differences in the pattern of tau transmission. By injecting pathological tau extracted from postmortem brains of AD (AD-tau), progressive supranuclear palsy (PSP-tau), and corticobasal degeneration (CBD-tau) patients into different brain regions of female non-Tg mice, we demonstrated the induction and propagation of endogenous mouse tau aggregates. Specifically, we identified differences in tau strain potency between AD-tau, CBD-tau, and PSP-tau in non-Tg mice. Moreover, differences in cell-type specificity of tau aggregate transmission were observed between tau strains such that only PSP-tau and CBD-tau strains induce astroglial and oligodendroglial tau inclusions, recapitulating the diversity of neuropathology in human tauopathies. Furthermore, we demonstrated that the neuronal connectome, but not the tau strain, determines which brain regions develop tau pathology. Finally, CBD-tau- and PSP-tau-injected mice showed spatiotemporal transmission of glial tau pathology, suggesting glial tau transmission contributes to the progression of tauopathies. Together, our data suggest that different tau strains determine seeding potency and cell-type specificity of tau aggregation that underlie the diversity of human tauopathies.<b>SIGNIFICANCE STATEMENT</b> Tauopathies show great clinical and neuropathological heterogeneity, despite the fact that tau aggregates in each disease. This heterogeneity could be due to tau aggregates forming distinct structural conformations, or strains. We now report the development of a sporadic tauopathy model to study human tau strains by intracerebrally injecting nontransgenic mice with pathological tau enriched from human tauopathy brains. We show human tau strains seed different types and cellular distributions of tau neuropathology in our model that recapitulate the heterogeneity seen in these human diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 the authors 0270-6474/17/3711406-18$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Narasimhan</LastName><ForeName>Sneha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1665-9681</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jing L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Changolkar</LastName><ForeName>Lakshmi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stieber</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McBride</LastName><ForeName>Jennifer D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0001-6423-0735</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Luisa V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zhuohao</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-1505-8750</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gathagan</LastName><ForeName>Ronald J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0001-5706-0803</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VMY</Initials><Identifier Source="ORCID">0000-0003-3536-6902</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 vmylee@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">human tauopathies</Keyword><Keyword MajorTopicYN="N">tau mouse model</Keyword><Keyword MajorTopicYN="N">tau strains</Keyword><Keyword MajorTopicYN="N">tau transmission</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29054878</ArticleId><ArticleId IdType="pmc">PMC5700423</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1230-17.2017</ArticleId><ArticleId IdType="pii">JNEUROSCI.1230-17.2017</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42:631&#x2013;639. 10.1212/WNL.42.3.631</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.42.3.631</ArticleId><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663&#x2013;672. 10.1038/nrn2194</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2194</ArticleId><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Boluda S, Iba M, Zhang B, Raible KM, Lee VM, Trojanowski JQ (2015) Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. Acta Neuropathol 129:221&#x2013;237. 10.1007/s00401-014-1373-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1373-0</ArticleId><ArticleId IdType="pmc">PMC4305460</ArticleId><ArticleId IdType="pubmed">25534024</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239&#x2013;259. 10.1007/BF00308809</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K (2012) Where, when, and in what form does sporadic Alzheimer's disease begin? Curr Opin Neurol 25:708&#x2013;714. 10.1097/WCO.0b013e32835a3432</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e32835a3432</ArticleId><ArticleId IdType="pubmed">23160422</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70:960&#x2013;969. 10.1097/NEN.0b013e318232a379</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HM, Lyoo CH, Ryu YH, Lee MS (2016a) Tau PET in Alzheimer disease and mild cognitive impairment. Neurology 87:375&#x2013;383. 10.1212/WNL.0000000000002892</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002892</ArticleId><ArticleId IdType="pubmed">27358341</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, Lee JH, Ryu YH, Lee MS, Lyoo CH (2016b) In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol 80:247&#x2013;258. 10.1002/ana.24711</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24711</ArticleId><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909&#x2013;913. 10.1038/ncb1901</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1901</ArticleId><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, Probst A, Winkler DT, Reichwald J, Staufenbiel M, Ghetti B, Goedert M, Tolnay M (2013) Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A 110:9535&#x2013;9540. 10.1073/pnas.1301175110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1301175110</ArticleId><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, Clarke AR (2007) A general model of prion strains and their pathogenicity. Science 318:930&#x2013;936. 10.1126/science.1138718</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1138718</ArticleId><ArticleId IdType="pubmed">17991853</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Cavallini A, Angers R, Glover S, Murray TK, Barnham L, Jackson S, O'Neill MJ, Isaacs AM, Hutton ML, Szekeres PG, Goedert M, Bose S (2015) Conformation determines the seeding potencies of native and recombinant tau aggregates. J Biol Chem 290:1049&#x2013;1065. 10.1074/jbc.M114.589309</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.589309</ArticleId><ArticleId IdType="pmc">PMC4294473</ArticleId><ArticleId IdType="pubmed">25406315</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Zhukareva V, Bergeron C, Chin SS, Grossman M, Clark C, Lee VM, Trojanowski JQ (2002) Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol 160:2045&#x2013;2053. 10.1016/S0002-9440(10)61154-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)61154-6</ArticleId><ArticleId IdType="pmc">PMC1850831</ArticleId><ArticleId IdType="pubmed">12057909</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284:12845&#x2013;12852. 10.1074/jbc.M808759200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808759200</ArticleId><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Herrmann FR, Bussi&#xe8;re T, Bouras C, K&#xf6;vari E, Perl DP, Morrison JH, Gold G, Hof PR (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60:1495&#x2013;1500. 10.1212/01.WNL.0000063311.58879.01</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000063311.58879.01</ArticleId><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Mabon ME, Duda JE, Montine TJ, Robertson D, Hurtig HI, Lee VM, Trojanowski JQ (2003) Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy. Acta Neuropathol 106:243&#x2013;250. 10.1007/s00401-003-0726-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-003-0726-x</ArticleId><ArticleId IdType="pubmed">12811584</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaume C, Koulakoff A, Roux L, Holcman D, Rouach N (2010) Astroglial networks: a step further in neuroglial and gliovascular interactions. Nat Rev Neurosci 11:87&#x2013;99. 10.1038/nrn2757</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2757</ArticleId><ArticleId IdType="pubmed">20087359</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41:17&#x2013;24. 10.1002/ana.410410106</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410106</ArticleId><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P, Schein JD, Binder LI (1992) Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem 267:564&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">1370450</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VM (2013) Neurofibrillary tangle-like tau pathology induced by synthetic tau fibrils in primary neurons over-expressing mutant tau. FEBS Lett 587:717&#x2013;723. 10.1016/j.febslet.2013.01.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2013.01.051</ArticleId><ArticleId IdType="pmc">PMC3678381</ArticleId><ArticleId IdType="pubmed">23395797</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B, Gathagan RJ, Iba M, McBride JD, Trojanowski JQ, Lee VM (2016a) Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice. J Exp Med 213:2635&#x2013;2654. 10.1084/jem.20160833</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20160833</ArticleId><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Buist A, Soares A, Callaerts K, Calafate S, Stevenaert F, Daniels JP, Zoll BE, Crowe A, Brunden KR, Moechars D, Lee VM (2016b) The dynamics and turnover of tau aggregates in cultured cells: insights into therapies for tauopathies. J Biol Chem 291:13175&#x2013;13193. 10.1074/jbc.M115.712083</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.712083</ArticleId><ArticleId IdType="pmc">PMC4933232</ArticleId><ArticleId IdType="pubmed">27129267</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM (2013) Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci 33:1024&#x2013;1037. 10.1523/JNEUROSCI.2642-12.2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2642-12.2013</ArticleId><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, McBride JD, Guo JL, Zhang B, Trojanowski JQ, Lee VM (2015) Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections. Acta Neuropathol 130:349&#x2013;362. 10.1007/s00401-015-1458-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1458-4</ArticleId><ArticleId IdType="pmc">PMC4545685</ArticleId><ArticleId IdType="pubmed">26150341</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, Lee VM, Trojanowski JQ (2015) Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol 129:469&#x2013;491. 10.1007/s00401-014-1380-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1380-1</ArticleId><ArticleId IdType="pmc">PMC4369168</ArticleId><ArticleId IdType="pubmed">25549971</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, Lee VM (1999) Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24:751&#x2013;762. 10.1016/s0896-6273(00)81127-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0896-6273(00)81127-7</ArticleId><ArticleId IdType="pubmed">10595524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, Davies P (1997a) Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res 48:128&#x2013;132. 10.1002/(SICI)1097-4547(19970415)48:2%3C128::AID-JNR5%3E3.0.CO;2-E</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19970415)48:2%3C128::AID-JNR5%3E3.0.CO;2-E</ArticleId><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Lane E, Vincent I, Otvos L Jr, Hoffmann R, Davies P (1997b) A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J Neurochem 69:2087&#x2013;2095. 10.1046/j.1471-4159.1997.69052087.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.69052087.x</ArticleId><ArticleId IdType="pubmed">9349554</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer-Alicea J, Sharma AM, Miller TM, Diamond MI (2016) Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. Neuron 92:796&#x2013;812. 10.1016/j.neuron.2016.09.055</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.055</ArticleId><ArticleId IdType="pmc">PMC5392364</ArticleId><ArticleId IdType="pubmed">27974162</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna MR, Kovalevich J, Lee VM, Trojanowski JQ, Brunden KR (2016) Therapeutic strategies for the treatment of tauopathies: hopes and challenges. Alzheimers Dement 12:1051&#x2013;1065. 10.1016/j.jalz.2016.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.06.006</ArticleId><ArticleId IdType="pmc">PMC5116305</ArticleId><ArticleId IdType="pubmed">27751442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Orecchio LD, Binder L, Trojanowski JQ, Lee VM, Lee G (1988) Epitopes that span the tau molecule are shared with paired helical filaments. Neuron 1:817&#x2013;825. 10.1016/0896-6273(88)90129-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(88)90129-8</ArticleId><ArticleId IdType="pubmed">2483104</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121&#x2013;1159. 10.1146/annurev.neuro.24.1.1121</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.24.1.1121</ArticleId><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Page CD, Wu HL, Schlaepfer WW (1984) Monoclonal antibodies to gel-excised glial filament protein and their reactivities with other intermediate filament proteins. J Neurochem 42:25&#x2013;32. 10.1111/j.1471-4159.1984.tb09692.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1984.tb09692.x</ArticleId><ArticleId IdType="pubmed">6358415</ArticleId></ArticleIdList></Reference><Reference><Citation>Legname G, Nguyen HO, Peretz D, Cohen FE, DeArmond SJ, Prusiner SB (2006) Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc Natl Acad Sci U S A 103:19105&#x2013;19110. 10.1073/pnas.0608970103</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0608970103</ArticleId><ArticleId IdType="pmc">PMC1748184</ArticleId><ArticleId IdType="pubmed">17142317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H, Kovacs GG, Vonsattel JP, Davey K, Mok KY, Hardy J, Morris HR, Warner TT, Holton JL, Revesz T (2016) Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain 139:3237&#x2013;3252. 10.1093/brain/aww256</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww256</ArticleId><ArticleId IdType="pubmed">27797812</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Monsell SE, Beach TG, Bigio EH, Bu Y, Cairns NJ, Frosch M, Henriksen J, Kofler J, Kukull WA, Lee EB, Nelson PT, Schantz AM, Schneider JA, Sonnen JA, Trojanowski JQ, Vinters HV, Zhou XH, Hyman BT (2016) Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease. Alzheimers Dement 12:164&#x2013;169. 10.1016/j.jalz.2015.07.492</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.07.492</ArticleId><ArticleId IdType="pmc">PMC4562409</ArticleId><ArticleId IdType="pubmed">26327235</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, Miller TM, Grinberg LT, Seeley WW, Diamond MI (2014) Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82:1271&#x2013;1288. 10.1016/j.neuron.2014.04.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.04.047</ArticleId><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Sha S, Hou C, Viskontas IV, Miller BL (2006) Are frontotemporal lobar degeneration, progressive supranuclear palsy and corticobasal degeneration distinct diseases? Nat Clin Pract Neurol 2:658&#x2013;665. 10.1038/ncpneuro0357</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpneuro0357</ArticleId><ArticleId IdType="pubmed">17117169</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S, Arai T, Kametani F, Nonaka T, Masuda-Suzukake M, Tarutani A, Murayama S, Saito Y, Arima K, Yoshida M, Akiyama H, Robinson A, Mann DM, Iwatsubo T, Hasegawa M (2016) Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol 131:267&#x2013;280. 10.1007/s00401-015-1503-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1503-3</ArticleId><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchihara T, Nakamura A, Shibuya K, Yagishita S (2011) Specific detection of pathological three-repeat tau after pretreatment with potassium permanganate and oxalic acid in PSP/CBD brains. Brain Pathol 21:180&#x2013;188. 10.1111/j.1750-3639.2010.00433.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2010.00433.x</ArticleId><ArticleId IdType="pmc">PMC8094262</ArticleId><ArticleId IdType="pubmed">20825412</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM (2011) Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72:57&#x2013;71. 10.1016/j.neuron.2011.08.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.08.033</ArticleId><ArticleId IdType="pmc">PMC3204802</ArticleId><ArticleId IdType="pubmed">21982369</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, McConathy J, Cairns NJ, Fagan AM, Morris JC, Ances BM (2016) Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between &#x3b2;-amyloid and tauopathy. JAMA Neurol 73:1070&#x2013;1077. 10.1001/jamaneurol.2016.2078</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.2078</ArticleId><ArticleId IdType="pmc">PMC5237382</ArticleId><ArticleId IdType="pubmed">27454922</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR, Lees AJ (2009) Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 8:270&#x2013;279. 10.1016/S1474-4422(09)70042-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70042-0</ArticleId><ArticleId IdType="pubmed">19233037</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL, Revesz T, Lees AJ (2005) Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 128:1247&#x2013;1258. 10.1093/brain/awh488</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh488</ArticleId><ArticleId IdType="pubmed">15788542</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, Revesz T (2007) Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 130:1566&#x2013;1576. 10.1093/brain/awm104</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm104</ArticleId><ArticleId IdType="pubmed">17525140</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C, Makaretz SJ, Caso C, McGinnis S, Gomperts SN, Sepulcre J, Gomez-Isla T, Hyman BT, Schultz A, Vasdev N, Johnson KA, Dickerson BC (2017) Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol 74:427&#x2013;436. 10.1001/jamaneurol.2016.5755</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.5755</ArticleId><ArticleId IdType="pmc">PMC5470368</ArticleId><ArticleId IdType="pubmed">28241163</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M. (2006) Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology 26:457&#x2013;470. 10.1111/j.1440-1789.2006.00743.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2006.00743.x</ArticleId><ArticleId IdType="pubmed">17080726</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M. (2014) Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 34:555&#x2013;570. 10.1111/neup.12143</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12143</ArticleId><ArticleId IdType="pubmed">25124031</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Barres BA, Wu JQ (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34:11929&#x2013;11947. 10.1523/JNEUROSCI.1860-14.2014</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1860-14.2014</ArticleId><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29022597</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>550</Volume><Issue>7675</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Genetic effects on gene expression across human tissues.</ArticleTitle><Pagination><StartPage>204</StartPage><EndPage>213</EndPage><MedlinePgn>204-213</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature24277</ELocationID><Abstract><AbstractText>Characterization of the molecular function of the human genome and its variation across individuals is essential for identifying the cellular mechanisms that underlie human genetic traits and diseases. The Genotype-Tissue Expression (GTEx) project aims to characterize variation in gene expression levels across individuals and diverse tissues of the human body, many of which are not easily accessible. Here we describe genetic effects on gene expression levels across 44 human tissues. We find that local genetic variation affects gene expression levels for the majority of genes, and we further identify inter-chromosomal genetic effects for 93 genes and 112 loci. On the basis of the identified genetic effects, we characterize patterns of tissue specificity, compare local and distal effects, and evaluate the functional properties of the genetic effects. We also demonstrate that multi-tissue, multi-individual data can be used to identify genes and pathways affected by human disease-associated variation, enabling a mechanistic interpretation of gene regulation and the genetic basis of disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><CollectiveName>GTEx Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Laboratory, Data Analysis &amp;Coordinating Center (LDACC)&#x2014;Analysis Working Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Statistical Methods groups&#x2014;Analysis Working Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Enhancing GTEx (eGTEx) groups</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>NIH Common Fund</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>NIH/NCI</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>NIH/NHGRI</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>NIH/NIMH</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>NIH/NIDA</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Biospecimen Collection Source Site&#x2014;NDRI</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Biospecimen Collection Source Site&#x2014;RPCI</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Biospecimen Core Resource&#x2014;VARI</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Brain Bank Repository&#x2014;University of Miami Brain Endowment Bank</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Leidos Biomedical&#x2014;Project Management</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>ELSI Study</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Genome Browser Data Integration &amp;Visualization&#x2014;EBI</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Genome Browser Data Integration &amp;Visualization&#x2014;UCSC Genomics Institute, University of California Santa Cruz</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Lead analysts:</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Laboratory, Data Analysis &amp;Coordinating Center (LDACC):</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>NIH program management:</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Biospecimen collection:</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Pathology:</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>eQTL manuscript working group:</CollectiveName></Author><Author ValidYN="Y"><LastName>Battle</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Johns Hopkins University, Baltimore, Maryland 21218, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Genetics and Institute for Biomedical Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelhardt</LastName><ForeName>Barbara E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Department of Computer Science and Center for Statistics and Machine Learning, Princeton University, Princeton, New Jersey 08540, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM007057</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH101782</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH101810</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH106842</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 HG008901</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HG007840</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007033</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG009080</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HG000044</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH101822</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201000009C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA006227</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U41 HG002371</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG008150</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH101819</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH109905</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG009125</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG007900</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 DK105566</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG007436</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH101820</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG007990</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG007591</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>HHSN261200800001C</GrantID><Acronym>RC</Acronym><Agency>CCR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH090937</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 HG006265</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM104371</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K22 HG000044</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201000029C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN261200800001E</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH101814</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HG003284</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201000002C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Oct 11;550(7675):190-191. doi: 10.1038/550190a.</RefSource><PMID Version="1">29022577</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Oct 11;550(7675):157. doi: 10.1038/550157a.</RefSource><PMID Version="1">29022932</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Oct 11;550(7675):169-170. doi: 10.1038/550169a.</RefSource><PMID Version="1">29022940</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Genet. 2017 Dec;18(12):701. doi: 10.1038/nrg.2017.94.</RefSource><PMID Version="1">29109523</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2018 Jan 25;553(7689):530. doi: 10.1038/nature25160.</RefSource><PMID Version="1">29258290</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2018 Jul;33(7):1097. doi: 10.1002/mds.27445.</RefSource><PMID Version="1">30153387</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002877" MajorTopicYN="N">Chromosomes, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004194" MajorTopicYN="N">Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="Y">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare competing financial interests: details are available in the online version of the paper.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Aguet</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ardlie</LastName><ForeName>Kristin G</ForeName><Initials>KG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Beryl B</ForeName><Initials>BB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gelfand</LastName><ForeName>Ellen T</ForeName><Initials>ET</Initials></Investigator><Investigator ValidYN="Y"><LastName>Getz</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hadley</LastName><ForeName>Kane</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Handsaker</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Katherine H</ForeName><Initials>KH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kashin</LastName><ForeName>Seva</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karczewski</LastName><ForeName>Konrad J</ForeName><Initials>KJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lek</LastName><ForeName>Monkol</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacArthur</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nedzel</LastName><ForeName>Jared L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Duyen T</ForeName><Initials>DT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noble</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Segr&#xe8;</LastName><ForeName>Ayellet V</ForeName><Initials>AV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trowbridge</LastName><ForeName>Casandra A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tukiainen</LastName><ForeName>Taru</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abell</LastName><ForeName>Nathan S</ForeName><Initials>NS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balliu</LastName><ForeName>Brunilda</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barshir</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Basha</LastName><ForeName>Omer</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Battle</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bogu</LastName><ForeName>Gireesh K</ForeName><Initials>GK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castel</LastName><ForeName>Stephane E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Lin S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiang</LastName><ForeName>Colby</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>Donald F</ForeName><Initials>DF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cox</LastName><ForeName>Nancy J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damani</LastName><ForeName>Farhan N</ForeName><Initials>FN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Joe R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delaneau</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dermitzakis</LastName><ForeName>Emmanouil T</ForeName><Initials>ET</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engelhardt</LastName><ForeName>Barbara E</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eskin</LastName><ForeName>Eleazar</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Pedro G</ForeName><Initials>PG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fr&#xe9;sard</LastName><ForeName>Laure</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamazon</LastName><ForeName>Eric R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrido-Mart&#xed;n</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gewirtz</LastName><ForeName>Ariel D H</ForeName><Initials>ADH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gliner</LastName><ForeName>Genna</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gloudemans</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guigo</LastName><ForeName>Roderic</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Ira M</ForeName><Initials>IM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Han</LastName><ForeName>Buhm</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>He</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hormozdiari</LastName><ForeName>Farhad</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Howald</LastName><ForeName>Cedric</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kyung Im</LastName><ForeName>Hae</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jo</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yong Kang</LastName><ForeName>Eun</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Yungil</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim-Hellmuth</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lappalainen</LastName><ForeName>Tuuli</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Gen</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Boxiang</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mangul</LastName><ForeName>Serghei</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Mark I</ForeName><Initials>MI</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDowell</LastName><ForeName>Ian C</ForeName><Initials>IC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohammadi</LastName><ForeName>Pejman</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monlong</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mu&#xf1;oz-Aguirre</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ndungu</LastName><ForeName>Anne W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicolae</LastName><ForeName>Dan L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nobel</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliva</LastName><ForeName>Meritxell</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ongen</LastName><ForeName>Halit</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palowitch</LastName><ForeName>John J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panousis</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papasaikas</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>YoSon</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parsana</LastName><ForeName>Princy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Payne</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson</LastName><ForeName>Christine B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quan</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reverter</LastName><ForeName>Ferran</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabatti</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saha</LastName><ForeName>Ashis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sammeth</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>Alexandra J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shabalin</LastName><ForeName>Andrey A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sodaei</LastName><ForeName>Reza</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephens</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stranger</LastName><ForeName>Barbara E</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strober</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sul</LastName><ForeName>Jae Hoon</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsang</LastName><ForeName>Emily K</ForeName><Initials>EK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Urbut</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>van de Bunt</LastName><ForeName>Martijn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Gao</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wen</LastName><ForeName>Xiaoquan</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wright</LastName><ForeName>Fred A</ForeName><Initials>FA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xi</LastName><ForeName>Hualin S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yeger-Lotem</LastName><ForeName>Esti</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zappala</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaugg</LastName><ForeName>Judith B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yi-Hui</ForeName><Initials>YH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akey</LastName><ForeName>Joshua M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Lin S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Claussnitzer</LastName><ForeName>Melina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demanelis</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diegel</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doherty</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feinberg</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernando</LastName><ForeName>Marian S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Halow</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hansen</LastName><ForeName>Kasper D</ForeName><Initials>KD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haugen</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hickey</LastName><ForeName>Peter F</ForeName><Initials>PF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hou</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jasmine</LastName><ForeName>Farzana</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jian</LastName><ForeName>Ruiqi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lihua</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Audra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaul</LastName><ForeName>Rajinder</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kellis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kibriya</LastName><ForeName>Muhammad G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Billy Li</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Qin</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Shin</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linder</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linke</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Yaping</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maurano</LastName><ForeName>Matthew T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molinie</LastName><ForeName>Benoit</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>Jemma</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neri</LastName><ForeName>Fidencio J</ForeName><Initials>FJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliva</LastName><ForeName>Meritxell</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Yongjin</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierce</LastName><ForeName>Brandon L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizzardi</LastName><ForeName>Lindsay F</ForeName><Initials>LF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandstrom</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skol</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Kevin S</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stamatoyannopoulos</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stranger</LastName><ForeName>Barbara E</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang</LastName><ForeName>Hua</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsang</LastName><ForeName>Emily K</ForeName><Initials>EK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Meng</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Wittenberghe</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Fan</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Rui</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nierras</LastName><ForeName>Concepcion R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Branton</LastName><ForeName>Philip A</ForeName><Initials>PA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carithers</LastName><ForeName>Latarsha J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guan</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Helen M</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>Abhi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaught</LastName><ForeName>Jimmie B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gould</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lockart</LastName><ForeName>Nicole C</ForeName><Initials>NC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Casey</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Struewing</LastName><ForeName>Jeffery P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Volpi</LastName><ForeName>Simona</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Addington</LastName><ForeName>Anjene M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koester</LastName><ForeName>Susan E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Little</LastName><ForeName>A Roger</ForeName><Initials>AR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brigham</LastName><ForeName>Lori E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hasz</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johns</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kopen</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leinweber</LastName><ForeName>William F</ForeName><Initials>WF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lonsdale</LastName><ForeName>John T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonald</LastName><ForeName>Alisa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mestichelli</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myer</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roe</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salvatore</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shad</LastName><ForeName>Saboor</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walters</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Washington</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wheeler</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bridge</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillard</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karasik</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumar</LastName><ForeName>Rachna</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miklos</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moser</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jewell</LastName><ForeName>Scott D</ForeName><Initials>SD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montroy</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valley</LastName><ForeName>Dana R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mash</LastName><ForeName>Deborah C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Undale</LastName><ForeName>Anita H</ForeName><Initials>AH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tabor</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roche</LastName><ForeName>Nancy V</ForeName><Initials>NV</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLean</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vatanian</LastName><ForeName>Negin</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>Karna L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sobin</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barcus</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valentino</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qi</LastName><ForeName>Liqun</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hariharan</LastName><ForeName>Pushpa</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>Shilpi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Um</LastName><ForeName>Ki Sung</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matose</LastName><ForeName>Takunda</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomaszewski</LastName><ForeName>Maria M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barker</LastName><ForeName>Laura K</ForeName><Initials>LK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mosavel</LastName><ForeName>Maghboeba</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siminoff</LastName><ForeName>Laura A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traino</LastName><ForeName>Heather M</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flicek</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juettemann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruffier</LastName><ForeName>Magali</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheppard</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Kieron</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trevanion</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zerbino</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craft</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldman</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haeussler</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kent</LastName><ForeName>W James</ForeName><Initials>WJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paten</LastName><ForeName>Benedict</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenbloom</LastName><ForeName>Kate R</ForeName><Initials>KR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vivian</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jingchun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craft</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldman</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haeussler</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kent</LastName><ForeName>W James</ForeName><Initials>WJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paten</LastName><ForeName>Benedict</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenbloom</LastName><ForeName>Kate R</ForeName><Initials>KR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vivian</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jingchun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aguet</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castel</LastName><ForeName>Stephane E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Joe R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>He</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jo</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohammadi</LastName><ForeName>Pejman</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>YoSon</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parsana</LastName><ForeName>Princy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Segr&#xe8;</LastName><ForeName>Ayellet V</ForeName><Initials>AV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strober</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zappala</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Beryl B</ForeName><Initials>BB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gelfand</LastName><ForeName>Ellen T</ForeName><Initials>ET</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hadley</LastName><ForeName>Kane</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Katherine H</ForeName><Initials>KH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lek</LastName><ForeName>Monkol</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nedzel</LastName><ForeName>Jared L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Duyen Y</ForeName><Initials>DY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noble</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tukiainen</LastName><ForeName>Taru</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacArthur</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Getz</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Addington</LastName><ForeName>Anjene</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guan</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koester</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Little</LastName><ForeName>A Roger</ForeName><Initials>AR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lockhart</LastName><ForeName>Nicole C</ForeName><Initials>NC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Helen M</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>Abhi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Struewing</LastName><ForeName>Jeffery P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Volpi</LastName><ForeName>Simona</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brigham</LastName><ForeName>Lori E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hasz</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johns</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kopen</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leinweber</LastName><ForeName>William F</ForeName><Initials>WF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lonsdale</LastName><ForeName>John T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonald</LastName><ForeName>Alisa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mestichelli</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myer</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roe</LastName><ForeName>Bryan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salvatore</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shad</LastName><ForeName>Saboor</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walters</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Washington</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wheeler</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bridge</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillard</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karasik</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumar</LastName><ForeName>Rachna</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miklos</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moser</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jewell</LastName><ForeName>Scott D</ForeName><Initials>SD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montroy</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valley</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mash</LastName><ForeName>Deborah C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sobin</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barcus</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Branton</LastName><ForeName>Philip A</ForeName><Initials>PA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abell</LastName><ForeName>Nathan S</ForeName><Initials>NS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balliu</LastName><ForeName>Brunilda</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delaneau</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fr&#xe9;sard</LastName><ForeName>Laure</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamazon</LastName><ForeName>Eric R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrido-Mart&#xed;n</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gewirtz</LastName><ForeName>Ariel D H</ForeName><Initials>ADH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gliner</LastName><ForeName>Genna</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gloudemans</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Han</LastName><ForeName>Buhm</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>He</LastName><ForeName>Amy Z</ForeName><Initials>AZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hormozdiari</LastName><ForeName>Farhad</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Boxiang</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kang</LastName><ForeName>Eun Yong</ForeName><Initials>EY</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDowell</LastName><ForeName>Ian C</ForeName><Initials>IC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ongen</LastName><ForeName>Halit</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palowitch</LastName><ForeName>John J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson</LastName><ForeName>Christine B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quon</LastName><ForeName>Gerald</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ripke</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saha</LastName><ForeName>Ashis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shabalin</LastName><ForeName>Andrey A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimko</LastName><ForeName>Tyler C</ForeName><Initials>TC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sul</LastName><ForeName>Jae Hoon</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teran</LastName><ForeName>Nicole A</ForeName><Initials>NA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsang</LastName><ForeName>Emily K</ForeName><Initials>EK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hailei</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yi-Hui</ForeName><Initials>YH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bustamante</LastName><ForeName>Carlos D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cox</LastName><ForeName>Nancy J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guig&#xf3;</LastName><ForeName>Roderic</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kellis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Mark I</ForeName><Initials>MI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>Donald F</ForeName><Initials>DF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eskin</LastName><ForeName>Eleazar</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Gen</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nobel</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabatti</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stranger</LastName><ForeName>Barbara E</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wen</LastName><ForeName>Xiaoquan</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wright</LastName><ForeName>Fred A</ForeName><Initials>FA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ardlie</LastName><ForeName>Kristin G</ForeName><Initials>KG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dermitzakis</LastName><ForeName>Emmanouil T</ForeName><Initials>ET</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lappalainen</LastName><ForeName>Tuuli</ForeName><Initials>T</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>1</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29022597</ArticleId><ArticleId IdType="mid">NIHMS925370</ArticleId><ArticleId IdType="pmc">PMC5776756</ArticleId><ArticleId IdType="doi">10.1038/nature24277</ArticleId><ArticleId IdType="pii">nature24277</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>ENCODE Project Consortium. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447:799&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212820</ArticleId><ArticleId IdType="pubmed">17571346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundaje A, et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518:317&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530010</ArticleId><ArticleId IdType="pubmed">25693563</ArticleId></ArticleIdList></Reference><Reference><Citation>Stunnenberg HG, Hirst M. The International Human Epigenome Consortium: a blueprint for scientific collaboration and discovery. Cell. 2016;167:1145&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">27863232</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundberg E, et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet. 2012;44:1084&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3784328</ArticleId><ArticleId IdType="pubmed">22941192</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert FW, Kruglyak L. The role of regulatory variation in complex traits and disease. Nat Rev Genet. 2015;16:197&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">25707927</ArticleId></ArticleIdList></Reference><Reference><Citation>Westra HJ, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013;45:1238&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3991562</ArticleId><ArticleId IdType="pubmed">24013639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lappalainen T, et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature. 2013;501:506&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918453</ArticleId><ArticleId IdType="pubmed">24037378</ArticleId></ArticleIdList></Reference><Reference><Citation>Battle A, et al. Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. Genome Res. 2014;24:14&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875855</ArticleId><ArticleId IdType="pubmed">24092820</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright FA, et al. Heritability and genomics of gene expression in peripheral blood. Nat Genet. 2014;46:430&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4012342</ArticleId><ArticleId IdType="pubmed">24728292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardlie KG, et al. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348:648&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4547484</ArticleId><ArticleId IdType="pubmed">25954001</ArticleId></ArticleIdList></Reference><Reference><Citation>1000 Genomes Project Consortium et al. A global reference for human genetic variation. Nature. 2015;526:68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegle O, Parts L, Piipari M, Winn J, Durbin R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. Nat Protocols. 2012;7:500&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3398141</ArticleId><ArticleId IdType="pubmed">22343431</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivas MA, et al. Effect of predicted protein-truncating genetic variants on the human transcriptome. Science. 2015;348:666&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4537935</ArticleId><ArticleId IdType="pubmed">25954003</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran Y, et al. The landscape of genomic imprinting across diverse adult human tissues. Genome Res. 2015;25:927&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4484390</ArticleId><ArticleId IdType="pubmed">25953952</ArticleId></ArticleIdList></Reference><Reference><Citation>Sul JH, Han B, Ye C, Choi T, Eskin E. Effectively identifying eQTLs from multiple tissues by combining mixed model and meta-analytic approaches. PLoS Genet. 2013;9:e1003491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681686</ArticleId><ArticleId IdType="pubmed">23785294</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003;100:9440&#x2013;9445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170937</ArticleId><ArticleId IdType="pubmed">12883005</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogomolov M, Peterson CB, Benjamini Y, Sabatti C. Testing hypotheses on a tree: New error rates and controlling strategies. 2017 Preprint at  https://arxiv.org/abs/1705.07529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9945647</ArticleId><ArticleId IdType="pubmed">36825068</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Shabalin AA, Rusyn I, Wright FA, Nobel AB. An empirical Bayes approach for multiple tissue eQTL analysis. 2013 Preprint at  https://arxiv.org/abs/1311.2948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6366007</ArticleId><ArticleId IdType="pubmed">29029013</ArticleId></ArticleIdList></Reference><Reference><Citation>Buil A, et al.  Quantifying the degree of sharing of genetic and non-genetic causes of gene expression variability across four tissues. 2016 Preprint at  http://www.biorxiv.org/content/early/2016/05/13/053355.</Citation></Reference><Reference><Citation>Flutre T, Wen X, Pritchard J, Stephens M. A statistical framework for joint eQTL analysis in multiple tissues. PLoS Genet. 2013;9:e1003486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3649995</ArticleId><ArticleId IdType="pubmed">23671422</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown CD, Mangravite LM, Engelhardt BE. Integrative modeling of eQTLs and cis-regulatory elements suggests mechanisms underlying cell type specificity of eQTLs. PLoS Genet. 2013;9:e1003649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3731231</ArticleId><ArticleId IdType="pubmed">23935528</ArticleId></ArticleIdList></Reference><Reference><Citation>Das A, et al. Bayesian integration of genetics and epigenetics detects causal regulatory SNPs underlying expression variability. Nat Commun. 2015;6:8555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4633824</ArticleId><ArticleId IdType="pubmed">26456756</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Rendon A, Wernisch L. Transcription factor and chromatin features predict genes associated with eQTLs. Nucleic Acids Res. 2013;41:1450&#x2013;1463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3561974</ArticleId><ArticleId IdType="pubmed">23275551</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Lee Y, Luca F, Pique-Regi R. Efficient integrative multi-SNP association analysis via deterministic approximation of posteriors. Am J Hum Genet. 2016;98:1114&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4908152</ArticleId><ArticleId IdType="pubmed">27236919</ArticleId></ArticleIdList></Reference><Reference><Citation>Hormozdiari F, Kostem E, Kang EY, Pasaniuc B, Eskin E. Identifying causal variants at loci with multiple signals of association. Genetics. 2014;198:497&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4196608</ArticleId><ArticleId IdType="pubmed">25104515</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AA, et al.  Predicting causal variants affecting expression using whole genome sequence and RNA-seq from multiple human tissues. 2016 Preprint at  http://www.biorxiv.org/content/early/2016/11/21/088872.</Citation><ArticleIdList><ArticleId IdType="pubmed">29058714</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadi P, Castel SE, Brown AA, Lappalainen T. Quantifying the regulatory effect size of cis-acting genetic variation using allelic fold change. Genome Res. 2017  http://dx.doi.org/10.1101/gr.216747.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.216747.116</ArticleId><ArticleId IdType="pmc">PMC5668944</ArticleId><ArticleId IdType="pubmed">29021289</ArticleId></ArticleIdList></Reference><Reference><Citation>Brem RB, Yvert G, Clinton R, Kruglyak L. Genetic dissection of transcriptional regulation in budding yeast. Science. 2002;296:752&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">11923494</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakitsch B, Stegle O. Modelling local gene networks increases power to detect trans-acting genetic effects on gene expression. Genome Biol. 2016;17:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765046</ArticleId><ArticleId IdType="pubmed">26911988</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 2007;3:1724&#x2013;1735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994707</ArticleId><ArticleId IdType="pubmed">17907809</ArticleId></ArticleIdList></Reference><Reference><Citation>Heintzman ND, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature. 2009;459:108&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910248</ArticleId><ArticleId IdType="pubmed">19295514</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf3;th KF, Pezic D, Stuwe E, Webster A. Non-Coding RNA and the Reproductive System. Springer; 2016. pp. 51&#x2013;77.</Citation></Reference><Reference><Citation>Ha H, et al. A comprehensive analysis of piRNAs from adult human testis and their relationship with genes and mobile elements. BMC Genomics. 2014;15:545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4094622</ArticleId><ArticleId IdType="pubmed">24981367</ArticleId></ArticleIdList></Reference><Reference><Citation>Buil A, et al. Gene-gene and gene-environment interactions detected by transcriptome sequence analysis in twins. Nat Genet. 2015;47:88&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643454</ArticleId><ArticleId IdType="pubmed">25436857</ArticleId></ArticleIdList></Reference><Reference><Citation>Innocenti F, et al. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet. 2011;7:e1002078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102751</ArticleId><ArticleId IdType="pubmed">21637794</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeller T, et al. Genetics and beyond&#x2014;the transcriptome of human monocytes and disease susceptibility. PLoS One. 2010;5:e10693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872668</ArticleId><ArticleId IdType="pubmed">20502693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsten H, et al. Dissecting the genetics of the human transcriptome identifies novel trait-related trans-eQTLs and corroborates the regulatory relevance of non-protein coding loci. Hum Mol Genet. 2015;24:4746&#x2013;4763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4512630</ArticleId><ArticleId IdType="pubmed">26019233</ArticleId></ArticleIdList></Reference><Reference><Citation>Nica AC, et al. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet. 2011;7:e1002003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033383</ArticleId><ArticleId IdType="pubmed">21304890</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchini J, et al. Tensor decomposition for multiple-tissue gene expression experiments. Nat Genet. 2016;48:1094&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010142</ArticleId><ArticleId IdType="pubmed">27479908</ArticleId></ArticleIdList></Reference><Reference><Citation>Small KS, et al. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat Genet. 2011;43:561&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192952</ArticleId><ArticleId IdType="pubmed">21572415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Farh KKH, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2015;518:337&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336207</ArticleId><ArticleId IdType="pubmed">25363779</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10:e1004383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48:481&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">27019110</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryois J, et al. Cis and trans effects of human genomic variants on gene expression. PLoS Genet. 2014;10:e1004461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4091791</ArticleId><ArticleId IdType="pubmed">25010687</ArticleId></ArticleIdList></Reference><Reference><Citation>Huan T, et al. A meta-analysis of gene expression signatures of blood pressure and hypertension. PLoS Genet. 2015;11:e1005035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4365001</ArticleId><ArticleId IdType="pubmed">25785607</ArticleId></ArticleIdList></Reference><Reference><Citation>Welter D, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42:D1001&#x2013;D1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965119</ArticleId><ArticleId IdType="pubmed">24316577</ArticleId></ArticleIdList></Reference><Reference><Citation>Lidral AC, et al. A single nucleotide polymorphism associated with isolated cleft lip and palate, thyroid cancer and hypothyroidism alters the activity of an oral epithelium and thyroid enhancer near FOXE1. Hum Mol Genet. 2015;24:3895&#x2013;3907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4476440</ArticleId><ArticleId IdType="pubmed">25652407</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC, et al. Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet. 2011;89:529&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3188836</ArticleId><ArticleId IdType="pubmed">21981779</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal N, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243044</ArticleId><ArticleId IdType="pubmed">25417114</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001;19:623&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244049</ArticleId></ArticleIdList></Reference><Reference><Citation>Penninger JM, et al. The interferon regulatory transcription factor IRF-1 controls positive and negative selection of CD8+ thymocytes. Immunity. 1997;7:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">9285409</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehghan A, et al. Association of novel genetic loci with circulating fibrinogen levels: a genome-wide association study in 6 population-based cohorts. Circ Cardiovasc Genet. 2009;2:125&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764985</ArticleId><ArticleId IdType="pubmed">20031576</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012;34:43&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">22037947</ArticleId></ArticleIdList></Reference><Reference><Citation>Suelves M, et al. uPA deficiency exacerbates muscular dystrophy in MDX mice. J Cell Biol. 2007;178:1039&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064626</ArticleId><ArticleId IdType="pubmed">17785520</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal B, et al. Fibrinogen drives dystrophic muscle fibrosis via a TGF-&#x3b2;/ alternative macrophage activation pathway. Genes Dev. 2008;22:1747&#x2013;1752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2492661</ArticleId><ArticleId IdType="pubmed">18593877</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707969</ArticleId><ArticleId IdType="pubmed">26771021</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann TJ, et al. Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation. Nat Genet. 2017;49:54&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5370207</ArticleId><ArticleId IdType="pubmed">27841878</ArticleId></ArticleIdList></Reference><Reference><Citation>Horikoshi M, et al. Genome-wide associations for birth weight and correlations with adult disease. Nature. 2016;538:248&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5164934</ArticleId><ArticleId IdType="pubmed">27680694</ArticleId></ArticleIdList></Reference><Reference><Citation>Long T, et al. Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. Nat Genet. 2017;49:568&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">28263315</ArticleId></ArticleIdList></Reference><Reference><Citation>Okbay A, et al. Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. Nat Genet. 2016;48:624&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4884152</ArticleId><ArticleId IdType="pubmed">27089181</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, et al.  The impact of rare variation on gene expression across tissues. Nature. 2017  http://dx.doi.org/10.1038/nature24267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24267</ArticleId><ArticleId IdType="pmc">PMC5877409</ArticleId><ArticleId IdType="pubmed">29022581</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha A, et al.  Co-expression networks reveal the tissue-specific regulation of transcription and splicing. Genome Res. 2017  http://dx.doi.org/10.1101/gr.216721.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.216721.116</ArticleId><ArticleId IdType="pmc">PMC5668942</ArticleId><ArticleId IdType="pubmed">29021288</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan MH, et al.  Dynamic landscape and regulation of RNA editing in mammals. Nature. 2017  http://dx.doi.org/10.1038/nature24041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24041</ArticleId><ArticleId IdType="pmc">PMC5723435</ArticleId><ArticleId IdType="pubmed">29022589</ArticleId></ArticleIdList></Reference><Reference><Citation>Tukiainen T, et al.  Landscape of X chromosome inactivation across human tissues. Nature. 2017  http://dx.doi.org/10.1038/nature24265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24265</ArticleId><ArticleId IdType="pmc">PMC5685192</ArticleId><ArticleId IdType="pubmed">29022598</ArticleId></ArticleIdList></Reference><Reference><Citation>Regev A, et al.  The human cell atlas. 2017 Preprint at  http://www.biorxiv.org/content/early/2017/05/08/121202.</Citation></Reference><Reference><Citation>The eGTEx Project. Enhancing GTEx by bridging the gaps between genotype, gene expression and disease. Nat Genet. 2017  http://dx.doi.org/10.1038/ng.3969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3969</ArticleId><ArticleId IdType="pmc">PMC6636856</ArticleId><ArticleId IdType="pubmed">29019975</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connell J, et al. A general approach for haplotype phasing across the full spectrum of relatedness. PLoS Genet. 2014;10:e1004234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990520</ArticleId><ArticleId IdType="pubmed">24743097</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3 (Bethesda) 2011;1:457&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3276165</ArticleId><ArticleId IdType="pubmed">22384356</ArticleId></ArticleIdList></Reference><Reference><Citation>1000 Genomes Project Consortium et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498066</ArticleId><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ongen H, Buil A, Brown AA, Dermitzakis ET, Delaneau O. Fast and efficient QTL mapper for thousands of molecular phenotypes. Bioinformatics. 2016;32:1479&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4866519</ArticleId><ArticleId IdType="pubmed">26708335</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics. 2012;28:1353&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348564</ArticleId><ArticleId IdType="pubmed">22492648</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Han B, Eskin E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am J Hum Genet. 2011;88:586&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146723</ArticleId><ArticleId IdType="pubmed">21565292</ArticleId></ArticleIdList></Reference><Reference><Citation>Castel SE, Levy-Moonshine A, Mohammadi P, Banks E, Lappalainen T. Tools and best practices for data processing in allelic expression analysis. Genome Biol. 2015;16:195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574606</ArticleId><ArticleId IdType="pubmed">26381377</ArticleId></ArticleIdList></Reference><Reference><Citation>Panousis NI, Gutierrez-Arcelus M, Dermitzakis ET, Lappalainen T. Allelic mapping bias in RNA-sequencing is not a major confounder in eQTL studies. Genome Biol. 2014;15:467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4212091</ArticleId><ArticleId IdType="pubmed">25239376</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832824</ArticleId><ArticleId IdType="pubmed">20110278</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi H, et al. PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res. 2017;45:D183&#x2013;D189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210595</ArticleId><ArticleId IdType="pubmed">27899595</ArticleId></ArticleIdList></Reference><Reference><Citation>Supek F, Bo&#x161;njak M, &#x160;kunca N, &#x160;muc T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One. 2011;6:e21800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138752</ArticleId><ArticleId IdType="pubmed">21789182</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, et al. Molecular QTL discovery incorporating genomic annotations using Bayesian false discovery rate control. Ann Appl Stat. 2016;10:1619&#x2013;1638.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29022581</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>550</Volume><Issue>7675</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>The impact of rare variation on gene expression across tissues.</ArticleTitle><Pagination><StartPage>239</StartPage><EndPage>243</EndPage><MedlinePgn>239-243</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature24267</ELocationID><Abstract><AbstractText>Rare genetic variants are abundant in humans and are expected to contribute to individual disease risk. While genetic association studies have successfully identified common genetic variants associated with susceptibility, these studies are not practical for identifying rare variants. Efforts to distinguish pathogenic variants from benign rare variants have leveraged the genetic code to identify deleterious protein-coding alleles, but no analogous code exists for non-coding variants. Therefore, ascertaining which rare variants have phenotypic effects remains a major challenge. Rare non-coding variants have been associated with extreme gene expression in studies using single tissues, but their effects across tissues are unknown. Here we identify gene expression outliers, or individuals showing extreme expression levels for a particular gene, across 44 human tissues by using combined analyses of whole genomes and multi-tissue RNA-sequencing data from the Genotype-Tissue Expression (GTEx) project v6p release. We find that 58% of underexpression and 28% of overexpression outliers have nearby conserved rare variants compared to 8% of non-outliers. Additionally, we developed RIVER (RNA-informed variant effect on regulation), a Bayesian statistical model that incorporates expression data to predict a regulatory effect for rare variants with higher accuracy than models using genomic annotations alone. Overall, we demonstrate that rare variants contribute to large gene expression changes across tissues and provide an integrative method for interpretation of rare variants in individual genomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yungil</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Johns Hopkins University, Baltimore 21218, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsang</LastName><ForeName>Emily K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Informatics Program, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Joe R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damani</LastName><ForeName>Farhan N</ForeName><Initials>FN</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Johns Hopkins University, Baltimore 21218, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Colby</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>McDonnell Genome Institute, Washington University School of Medicine, St Louis, Missouri 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hess</LastName><ForeName>Gaelen T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zappala</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strober</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland 21218, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Alexandra J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>McDonnell Genome Institute, Washington University School of Medicine, St Louis, Missouri 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganna</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassik</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merker</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>GTEx Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Laboratory, Data Analysis &amp;Coordinating Center (LDACC)&#x2014;Analysis Working Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Statistical Methods groups&#x2014;Analysis Working Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Enhancing GTEx (eGTEx) groups</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>NIH Common Fund</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>NIH/NCI</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>NIH/NHGRI</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>NIH/NIMH</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>NIH/NIDA</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Biospecimen Collection Source Site&#x2014;NDRI</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Biospecimen Collection Source Site&#x2014;RPCI</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Biospecimen Core Resource&#x2014;VARI</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Brain Bank Repository&#x2014;University of Miami Brain Endowment Bank</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Leidos Biomedical&#x2014;Project Management</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>ELSI Study</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Genome Browser Data Integration &amp;Visualization&#x2014;EBI</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Genome Browser Data Integration &amp;Visualization&#x2014;UCSC Genomics Institute, University of California Santa Cruz</CollectiveName></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Ira M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>McDonnell Genome Institute, Washington University School of Medicine, St Louis, Missouri 63108, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Battle</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Johns Hopkins University, Baltimore 21218, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R01MH109905-01</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007057</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG007610</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH109905</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG009080</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HG000044</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG007436</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG008150</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K22 HG000044</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH101814</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM120167</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA006227</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG008150</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Oct 11;550(7675):190-191. doi: 10.1038/550190a.</RefSource><PMID Version="1">29022577</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Oct 11;550(7675):157. doi: 10.1038/550157a.</RefSource><PMID Version="1">29022932</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Oct 11;550(7675):169-170. doi: 10.1038/550169a.</RefSource><PMID Version="1">29022940</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Genet. 2017 Dec;18(12):701. doi: 10.1038/nrg.2017.94.</RefSource><PMID Version="1">29109523</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2018 Jul;33(7):1097. doi: 10.1002/mds.27445.</RefSource><PMID Version="1">30153387</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="Y">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Aguet</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ardlie</LastName><ForeName>Kristin G</ForeName><Initials>KG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Beryl B</ForeName><Initials>BB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gelfand</LastName><ForeName>Ellen T</ForeName><Initials>ET</Initials></Investigator><Investigator ValidYN="Y"><LastName>Getz</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hadley</LastName><ForeName>Kane</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Handsaker</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Katherine H</ForeName><Initials>KH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kashin</LastName><ForeName>Seva</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karczewski</LastName><ForeName>Konrad J</ForeName><Initials>KJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lek</LastName><ForeName>Monkol</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacArthur</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nedzel</LastName><ForeName>Jared L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Duyen T</ForeName><Initials>DT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noble</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Segr&#xe8;</LastName><ForeName>Ayellet V</ForeName><Initials>AV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trowbridge</LastName><ForeName>Casandra A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tukiainen</LastName><ForeName>Taru</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abell</LastName><ForeName>Nathan S</ForeName><Initials>NS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balliu</LastName><ForeName>Brunilda</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barshir</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Basha</LastName><ForeName>Omer</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Battle</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bogu</LastName><ForeName>Gireesh K</ForeName><Initials>GK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castel</LastName><ForeName>Stephane E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Lin S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiang</LastName><ForeName>Colby</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>Donald F</ForeName><Initials>DF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cox</LastName><ForeName>Nancy J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damani</LastName><ForeName>Farhan N</ForeName><Initials>FN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Joe R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delaneau</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dermitzakis</LastName><ForeName>Emmanouil T</ForeName><Initials>ET</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engelhardt</LastName><ForeName>Barbara E</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eskin</LastName><ForeName>Eleazar</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Pedro G</ForeName><Initials>PG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fr&#xe9;sard</LastName><ForeName>Laure</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamazon</LastName><ForeName>Eric R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrido-Mart&#xed;n</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gewirtz</LastName><ForeName>Ariel D H</ForeName><Initials>ADH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gliner</LastName><ForeName>Genna</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gloudemans</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guigo</LastName><ForeName>Roderic</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Ira M</ForeName><Initials>IM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Han</LastName><ForeName>Buhm</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>He</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hormozdiari</LastName><ForeName>Farhad</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Howald</LastName><ForeName>Cedric</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kyung Im</LastName><ForeName>Hae</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jo</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yong Kang</LastName><ForeName>Eun</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Yungil</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim-Hellmuth</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lappalainen</LastName><ForeName>Tuuli</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Gen</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Boxiang</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mangul</LastName><ForeName>Serghei</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Mark I</ForeName><Initials>MI</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDowell</LastName><ForeName>Ian C</ForeName><Initials>IC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohammadi</LastName><ForeName>Pejman</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monlong</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mu&#xf1;oz-Aguirre</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ndungu</LastName><ForeName>Anne W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicolae</LastName><ForeName>Dan L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nobel</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliva</LastName><ForeName>Meritxell</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ongen</LastName><ForeName>Halit</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palowitch</LastName><ForeName>John J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panousis</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papasaikas</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>YoSon</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parsana</LastName><ForeName>Princy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Payne</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson</LastName><ForeName>Christine B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quan</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reverter</LastName><ForeName>Ferran</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabatti</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saha</LastName><ForeName>Ashis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sammeth</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>Alexandra J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shabalin</LastName><ForeName>Andrey A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sodaei</LastName><ForeName>Reza</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephens</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stranger</LastName><ForeName>Barbara E</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strober</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sul</LastName><ForeName>Jae Hoon</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsang</LastName><ForeName>Emily K</ForeName><Initials>EK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Urbut</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>van de Bunt</LastName><ForeName>Martijn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Gao</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wen</LastName><ForeName>Xiaoquan</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wright</LastName><ForeName>Fred A</ForeName><Initials>FA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xi</LastName><ForeName>Hualin S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yeger-Lotem</LastName><ForeName>Esti</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zappala</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaugg</LastName><ForeName>Judith B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yi-Hui</ForeName><Initials>YH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akey</LastName><ForeName>Joshua M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Lin S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Claussnitzer</LastName><ForeName>Melina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demanelis</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diegel</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doherty</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feinberg</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernando</LastName><ForeName>Marian S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Halow</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hansen</LastName><ForeName>Kasper D</ForeName><Initials>KD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haugen</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hickey</LastName><ForeName>Peter F</ForeName><Initials>PF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hou</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jasmine</LastName><ForeName>Farzana</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jian</LastName><ForeName>Ruiqi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lihua</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Audra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaul</LastName><ForeName>Rajinder</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kellis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kibriya</LastName><ForeName>Muhammad G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Billy Li</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Qin</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Shin</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linder</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linke</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Yaping</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maurano</LastName><ForeName>Matthew T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molinie</LastName><ForeName>Benoit</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>Jemma</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neri</LastName><ForeName>Fidencio J</ForeName><Initials>FJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliva</LastName><ForeName>Meritxell</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Yongjin</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierce</LastName><ForeName>Brandon L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizzardi</LastName><ForeName>Lindsay F</ForeName><Initials>LF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandstrom</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skol</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Kevin S</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stamatoyannopoulos</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stranger</LastName><ForeName>Barbara E</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang</LastName><ForeName>Hua</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsang</LastName><ForeName>Emily K</ForeName><Initials>EK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Meng</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Wittenberghe</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Fan</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Rui</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nierras</LastName><ForeName>Concepcion R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Branton</LastName><ForeName>Philip A</ForeName><Initials>PA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carithers</LastName><ForeName>Latarsha J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guan</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Helen M</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>Abhi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaught</LastName><ForeName>Jimmie B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gould</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lockart</LastName><ForeName>Nicole C</ForeName><Initials>NC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Casey</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Struewing</LastName><ForeName>Jeffery P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Volpi</LastName><ForeName>Simona</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Addington</LastName><ForeName>Anjene M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koester</LastName><ForeName>Susan E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Little</LastName><ForeName>A Roger</ForeName><Initials>AR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brigham</LastName><ForeName>Lori E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hasz</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johns</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kopen</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leinweber</LastName><ForeName>William F</ForeName><Initials>WF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lonsdale</LastName><ForeName>John T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonald</LastName><ForeName>Alisa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mestichelli</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myer</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roe</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salvatore</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shad</LastName><ForeName>Saboor</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walters</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Washington</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wheeler</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bridge</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillard</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karasik</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumar</LastName><ForeName>Rachna</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miklos</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moser</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jewell</LastName><ForeName>Scott D</ForeName><Initials>SD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montroy</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valley</LastName><ForeName>Dana R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mash</LastName><ForeName>Deborah C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Undale</LastName><ForeName>Anita H</ForeName><Initials>AH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tabor</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roche</LastName><ForeName>Nancy V</ForeName><Initials>NV</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLean</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vatanian</LastName><ForeName>Negin</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>Karna L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sobin</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barcus</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valentino</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qi</LastName><ForeName>Liqun</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hariharan</LastName><ForeName>Pushpa</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>Shilpi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Um</LastName><ForeName>Ki Sung</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matose</LastName><ForeName>Takunda</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomaszewski</LastName><ForeName>Maria M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barker</LastName><ForeName>Laura K</ForeName><Initials>LK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mosavel</LastName><ForeName>Maghboeba</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siminoff</LastName><ForeName>Laura A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traino</LastName><ForeName>Heather M</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flicek</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juettemann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruffier</LastName><ForeName>Magali</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheppard</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Kieron</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trevanion</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zerbino</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craft</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldman</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haeussler</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kent</LastName><ForeName>W James</ForeName><Initials>WJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paten</LastName><ForeName>Benedict</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenbloom</LastName><ForeName>Kate R</ForeName><Initials>KR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vivian</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jingchun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craft</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldman</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haeussler</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kent</LastName><ForeName>W James</ForeName><Initials>WJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paten</LastName><ForeName>Benedict</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenbloom</LastName><ForeName>Kate R</ForeName><Initials>KR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vivian</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jingchun</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>4</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29022581</ArticleId><ArticleId IdType="mid">NIHMS906203</ArticleId><ArticleId IdType="pmc">PMC5877409</ArticleId><ArticleId IdType="doi">10.1038/nature24267</ArticleId><ArticleId IdType="pii">nature24267</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tennessen JA, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337:64&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3708544</ArticleId><ArticleId IdType="pubmed">22604720</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson MR, et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science. 2012;337:100&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4319976</ArticleId><ArticleId IdType="pubmed">22604722</ArticleId></ArticleIdList></Reference><Reference><Citation>The UK10K Consortium. The UK10K project identifies rare variants in health and disease. Nature. 2015;526:82&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4773891</ArticleId><ArticleId IdType="pubmed">26367797</ArticleId></ArticleIdList></Reference><Reference><Citation>Keinan A, Clark AG. Recent explosive human population growth has resulted in an excess of rare genetic variants. Science. 2012;336:740&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586590</ArticleId><ArticleId IdType="pubmed">22582263</ArticleId></ArticleIdList></Reference><Reference><Citation>Uricchio LH, Zaitlen NA, Ye CJ, Witte JS, Hernandez RD. Selection and explosive growth alter genetic architecture and hamper the detection of causal rare variants. Genome Res. 2016;26:863&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4937562</ArticleId><ArticleId IdType="pubmed">27197206</ArticleId></ArticleIdList></Reference><Reference><Citation>MacArthur DG, et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science. 2012;335:823&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299548</ArticleId><ArticleId IdType="pubmed">22344438</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan VM, et al. Health and population effects of rare gene knockouts in adult humans with related parents. Science. 2016;352:474&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4985238</ArticleId><ArticleId IdType="pubmed">26940866</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery SB, Lappalainen T, Gutierrez-Arcelus M, Dermitzakis ET. Rare and common regulatory variation in population-scale sequenced human genomes. PLoS Genet. 2011;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3141000</ArticleId><ArticleId IdType="pubmed">21811411</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, et al. A burden of rare variants associated with extremes of gene expression in human peripheral blood. Am. J. Hum. Genet. 2016;98:299&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4746369</ArticleId><ArticleId IdType="pubmed">26849112</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Y, et al. Aberrant gene expression in humans. PLoS Genet. 2015;11:e1004942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4305293</ArticleId><ArticleId IdType="pubmed">25617623</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, et al. Transcriptome sequencing of a large human family identifies the impact of rare noncoding variants. Am. J. Hum. Genet. 2014;95:245&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4157143</ArticleId><ArticleId IdType="pubmed">25192044</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegle O, Parts L, Piipari M, Winn J, Durbin R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. Nat. Protoc. 2012;7:500&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3398141</ArticleId><ArticleId IdType="pubmed">22343431</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C, et al. The impact of structural variation on human gene expression. Nat. Genet. 2017 doi: 10.1038/ng.3834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3834</ArticleId><ArticleId IdType="pmc">PMC5406250</ArticleId><ArticleId IdType="pubmed">28369037</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res. 2010;20:110&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798823</ArticleId><ArticleId IdType="pubmed">19858363</ArticleId></ArticleIdList></Reference><Reference><Citation>Siepel A, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 2005;15:1034&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182216</ArticleId><ArticleId IdType="pubmed">16024819</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper GM, et al. Distribution and intensity of constraint in mammalian genomic sequence. Genome Res. 2005;15:901&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1172034</ArticleId><ArticleId IdType="pubmed">15965027</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbiza L, et al. Genome-wide inference of natural selection on human transcription factor binding sites. Nat. Genet. 2013;45:723&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932982</ArticleId><ArticleId IdType="pubmed">23749186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher M, et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 2014;46:310&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992975</ArticleId><ArticleId IdType="pubmed">24487276</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 2013;15:565&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3727274</ArticleId><ArticleId IdType="pubmed">23788249</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum MJ, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016;44:D862&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702865</ArticleId><ArticleId IdType="pubmed">26582918</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendel A, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 2015;33:985&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4729442</ArticleId><ArticleId IdType="pubmed">26121415</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess GT, et al. Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. Nat. Methods. 2016;13:1036&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5557288</ArticleId><ArticleId IdType="pubmed">27798611</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundberg E, et al. Global analysis of DNA methylation variation in adipose tissue from twins reveals links to disease-associated variants in distal regulatory elements. Am. J. Hum. Genet. 2013;93:876&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824131</ArticleId><ArticleId IdType="pubmed">24183450</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamazon ER, et al. Enrichment of cis-regulatory gene expression SNPs and methylation quantitative trait loci among bipolar disorder susceptibility variants. Mol. Psychiatry. 2013;18:340&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3601550</ArticleId><ArticleId IdType="pubmed">22212596</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell JT, et al. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 2011;12:R10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091299</ArticleId><ArticleId IdType="pubmed">21251332</ArticleId></ArticleIdList></Reference><Reference><Citation>Waszak SM, et al. Population variation and genetic control of modular chromatin architecture in humans. Cell. 2015;162:1039&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">26300124</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubert F, et al. Genetic control of chromatin states in humans involves local and distal chromosomal interactions. Cell. 2015;162:1051&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4556133</ArticleId><ArticleId IdType="pubmed">26300125</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526:68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>The Roadmap Epigenomics Consortium. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518:317&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530010</ArticleId><ArticleId IdType="pubmed">25693563</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren W, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893825</ArticleId><ArticleId IdType="pubmed">27268795</ArticleId></ArticleIdList></Reference><Reference><Citation>Panousis NI, Gutierrez-Arcelus M, Dermitzakis ET, Lappalainen T. Allelic mapping bias in RNA-sequencing is not a major confounder in eQTL studies. Genome Biol. 2014;15:467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4212091</ArticleId><ArticleId IdType="pubmed">25239376</ArticleId></ArticleIdList></Reference><Reference><Citation>Sul JH, Han B, Ye C, Choi T, Eskin E. Effectively identifying eQTLs from multiple tissues by combining mixed model and meta-analytic approaches. PLoS Genet. 2013;9:e1003491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681686</ArticleId><ArticleId IdType="pubmed">23785294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Welter D, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42:D1001&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965119</ArticleId><ArticleId IdType="pubmed">24316577</ArticleId></ArticleIdList></Reference><Reference><Citation>Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature. 2015;519:223&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5955210</ArticleId><ArticleId IdType="pubmed">25533962</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempster A, Laird N, Rubin D. Maximum Likelihood from incomplete data via the EM algorithm. J. R. Stat. Soc. 1977;39:1&#x2013;38.</Citation></Reference><Reference><Citation>Adzhubei IA, et al. A method and server for predicting damaging missense mutations. Nat. Methods. 2010;7:248&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855889</ArticleId><ArticleId IdType="pubmed">20354512</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11:863&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311071</ArticleId><ArticleId IdType="pubmed">11337480</ArticleId></ArticleIdList></Reference><Reference><Citation>Quang D, Chen Y, Xie X. DANN: a deep learning approach for annotating the pathogenicity of genetic variants. Bioinformatics. 2015;31:761&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4341060</ArticleId><ArticleId IdType="pubmed">25338716</ArticleId></ArticleIdList></Reference><Reference><Citation>ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439153</ArticleId><ArticleId IdType="pubmed">22955616</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal. 2011;17:10.</Citation></Reference><Reference><Citation>Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan M, Pag&#xe8;s H, Obenchain V, Hayden N. Rsamtools: Binary alignment (BAM), FASTA, variant call (BCF), and tabix file import</Citation></Reference><Reference><Citation>Dror Y, Freedman MH. Shwachman-diamond syndrome. Br. J. Haematol. 2002;118:701&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">12181037</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin KM, et al. Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome. J. Clin. Invest. 2008;118:1511&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2263145</ArticleId><ArticleId IdType="pubmed">18324336</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt A, et al. Severely altered guanidino compound levels, disturbed body weight homeostasis and impaired fertility in a mouse model of guanidinoacetate N-methyltransferase (GAMT) deficiency. Hum. Mol. Genet. 2004;13:905&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15028668</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29056226</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6605</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>A Dementia-Associated Risk Variant near TMEM106B Alters Chromatin Architecture and Gene Expression.</ArticleTitle><Pagination><StartPage>643</StartPage><EndPage>663</EndPage><MedlinePgn>643-663</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajhg.2017.09.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-9297(17)30371-3</ELocationID><Abstract><AbstractText>Neurodegenerative diseases pose an extraordinary threat to the world's aging population, yet no disease-modifying therapies are available. Although genome-wide association studies (GWASs) have identified hundreds of risk loci for neurodegeneration, the mechanisms by which these loci influence disease risk are largely unknown. Here, we investigated the association between common genetic variants at the 7p21 locus and risk of the neurodegenerative disease frontotemporal lobar degeneration. We showed that variants associated with disease risk correlate with increased expression of the 7p21 gene TMEM106B and no other genes; co-localization analyses implicated a common causal variant underlying both association with disease and association with TMEM106B expression in lymphoblastoid cell lines and human brain. Furthermore, increases in the amount of TMEM106B resulted in increases in abnormal lysosomal phenotypes and cell toxicity in both immortalized cell lines and neurons. We then combined fine-mapping, bioinformatics, and bench-based approaches to functionally characterize all candidate causal variants at this locus. This approach identified a noncoding variant, rs1990620, that differentially recruits CTCF in lymphoblastoid cell lines and human brain to influence CTCF-mediated long-range chromatin-looping interactions between multiple cis-regulatory elements, including the TMEM106B promoter. Our findings thus provide an in-depth analysis of the 7p21 locus linked by GWASs to frontotemporal lobar degeneration, nominating a causal variant and causal mechanism for allele-specific expression and disease association at this locus. Finally, we show that genetic variants associated with risk of neurodegenerative diseases beyond frontotemporal lobar degeneration are enriched in CTCF-binding sites found in brain-relevant tissues, implicating CTCF-mediated gene regulation in risk of neurodegeneration more generally.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gallagher</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posavi</LastName><ForeName>Marijan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Center for Spatial and Functional Genomics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unger</LastName><ForeName>Travis L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berlyand</LastName><ForeName>Yosef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruenewald</LastName><ForeName>Analise L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chesi</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Spatial and Functional Genomics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manduchi</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Spatial and Functional Genomics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Institute for Biomedical Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wells</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Center for Spatial and Functional Genomics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Struan F A</ForeName><Initials>SFA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Center for Spatial and Functional Genomics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blobel</LastName><ForeName>Gerd A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Center for Spatial and Functional Genomics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen-Plotkin</LastName><ForeName>Alice S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: chenplot@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 NS090892</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH101822</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS082265</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL129998</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076246">CCCTC-Binding Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000619697">CTCF protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002843">Chromatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556915">TMEM106B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076246" MajorTopicYN="N">CCCTC-Binding Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002843" MajorTopicYN="N">Chromatin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CTCF</Keyword><Keyword MajorTopicYN="N">Capture-C</Keyword><Keyword MajorTopicYN="N">GWAS</Keyword><Keyword MajorTopicYN="N">TMEM106B</Keyword><Keyword MajorTopicYN="N">causal variant</Keyword><Keyword MajorTopicYN="N">chromatin architecture</Keyword><Keyword MajorTopicYN="N">eQTL</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">functional variant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29056226</ArticleId><ArticleId IdType="pmc">PMC5673619</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2017.09.004</ArticleId><ArticleId IdType="pii">S0002-9297(17)30371-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen S., Zheng J.C. Translational Neurodegeneration, a platform to share knowledge and experience in translational study of neurodegenerative diseases. Transl. Neurodegener. 2012;1:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506994</ArticleId><ArticleId IdType="pubmed">23211032</ArticleId></ArticleIdList></Reference><Reference><Citation>Welter D., MacArthur J., Morales J., Burdett T., Hall P., Junkins H., Klemm A., Flicek P., Manolio T., Hindorff L., Parkinson H. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42:D1001&#x2013;D1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965119</ArticleId><ArticleId IdType="pubmed">24316577</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham G., Inouye M. Genomic risk prediction of complex human disease and its clinical application. Curr. Opin. Genet. Dev. 2015;33:10&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">26210231</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls M.A., Pankratz N., Lill C.M., Do C.B., Hernandez D.G., Saad M., DeStefano A.L., Kara E., Bras J., Sharma M., International Parkinson&#x2019;s Disease Genomics Consortium (IPDGC) Parkinson&#x2019;s Study Group (PSG) Parkinson&#x2019;s Research: The Organized GENetics Initiative (PROGENI) 23andMe. GenePD. NeuroGenetics Research Consortium (NGRC) Hussman Institute of Human Genomics (HIHG) Ashkenazi Jewish Dataset Investigator. Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE) North American Brain Expression Consortium (NABEC) United Kingdom Brain Expression Consortium (UKBEC) Greek Parkinson&#x2019;s Disease Consortium. Alzheimer Genetic Analysis Group Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nat. Genet. 2014;46:989&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan V.K., Saykin A.J. Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, and related disorders. Am. J. Neurodegener. Dis. 2013;2:145&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3783830</ArticleId><ArticleId IdType="pubmed">24093081</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards S.L., Beesley J., French J.D., Dunning A.M. Beyond GWASs: illuminating the dark road from association to function. Am. J. Hum. Genet. 2013;93:779&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824120</ArticleId><ArticleId IdType="pubmed">24210251</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldner F., Stelzer Y., Shivalila C.S., Abraham B.J., Latourelle J.C., Barrasa M.I., Goldmann J., Myers R.H., Young R.A., Jaenisch R. Parkinson-associated risk variant in distal enhancer of &#x3b1;-synuclein modulates target gene expression. Nature. 2016;533:95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042324</ArticleId><ArticleId IdType="pubmed">27096366</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang J., Spina S., Miller B.L. Frontotemporal dementia. Lancet. 2015;386:1672&#x2013;1682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5970949</ArticleId><ArticleId IdType="pubmed">26595641</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelaar H., Rohrer J.D., Pijnenburg Y.A., Fox N.C., van Swieten J.C. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J.&#xa0;Neurol. Neurosurg. Psychiatry. 2011;82:476&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">20971753</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin V.M., Sleiman P.M., Martinez-Lage M., Chen-Plotkin A., Wang L.S., Graff-Radford N.R., Dickson D.W., Rademakers R., Boeve B.F., Grossman M. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat. Genet. 2010;42:234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J., Van Langenhove T., Kleinberger G., Sleegers K., Engelborghs S., Vandenberghe R., Santens P., Van den Broeck M., Joris G., Brys J. TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain. 2011;134:808&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044834</ArticleId><ArticleId IdType="pubmed">21354975</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N., Carrasquillo M.M., Baker M., Rutherford N.J., Coppola G., Dejesus-Hernandez M., Crook R., Hunter T., Ghidoni R., Benussi L. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology. 2011;76:467&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034409</ArticleId><ArticleId IdType="pubmed">21178100</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez I., Rosende-Roca M., Alegret M., Maule&#xf3;n A., Espinosa A., Vargas L., Sotolongo-Grau O., T&#xe1;rraga L., Boada M., Ruiz A. Association of TMEM106B rs1990622 marker and frontotemporal dementia: evidence for a recessive effect and meta-analysis. J.&#xa0;Alzheimers Dis. 2015;43:325&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">25096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C., Graff C., Chiang H.H., Wang J., Hinrichs A.L., Spiegel N., Bertelsen S., Mayo K., Norton J.B., Morris J.C., Goate A. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch. Neurol. 2011;68:581&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090529</ArticleId><ArticleId IdType="pubmed">21220649</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher M.D., Suh E., Grossman M., Elman L., McCluskey L., Van Swieten J.C., Al-Sarraj S., Neumann M., Gelpi E., Ghetti B. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol. 2014;127:407&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003885</ArticleId><ArticleId IdType="pubmed">24442578</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M., Mullen B., Nicholson A.M., Bieniek K.F., Heckman M.G., Baker M.C., DeJesus-Hernandez M., Finch N.A., Brown P.H., Murray M.E. TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol. 2014;127:397&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944829</ArticleId><ArticleId IdType="pubmed">24385136</ArticleId></ArticleIdList></Reference><Reference><Citation>Vass R., Ashbridge E., Geser F., Hu W.T., Grossman M., Clay-Falcone D., Elman L., McCluskey L., Lee V.M., Van Deerlin V.M. Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol. 2011;121:373&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3095217</ArticleId><ArticleId IdType="pubmed">21104415</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H., Abeliovich A. Differential Aging Analysis in Human Cerebral Cortex Identifies Variants in TMEM106B and GRN that Regulate Aging Phenotypes. Cell Syst. 2017;4:404&#x2013;415.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28330615</ArticleId></ArticleIdList></Reference><Reference><Citation>White C.C., Yang H.S., Yu L., Chibnik L.B., Dawe R.J., Yang J., Klein H.U., Felsky D., Ramos-Miguel A., Arfanakis K. Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional data. PLoS Med. 2017;14:e1002287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404753</ArticleId><ArticleId IdType="pubmed">28441426</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang C.M., Fellerer K., Schwenk B.M., Kuhn P.H., Kremmer E., Edbauer D., Capell A., Haass C. Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J.&#xa0;Biol. Chem. 2012;287:19355&#x2013;19365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365973</ArticleId><ArticleId IdType="pubmed">22511793</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady O.A., Zheng Y., Murphy K., Huang M., Hu F. The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum. Mol. Genet. 2013;22:685&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554197</ArticleId><ArticleId IdType="pubmed">23136129</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin A.S., Unger T.L., Gallagher M.D., Bill E., Kwong L.K., Volpicelli-Daley L., Busch J.I., Akle S., Grossman M., Van Deerlin V. TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J.&#xa0;Neurosci. 2012;32:11213&#x2013;11227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446826</ArticleId><ArticleId IdType="pubmed">22895706</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun M.H., Han J.H., Lee Y.K., Jang D.J., Kaang B.K., Lee J.A. TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III. Mol. Brain. 2015;8:85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676093</ArticleId><ArticleId IdType="pubmed">26651479</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson A.M., Finch N.A., Wojtas A., Baker M.C., Perkerson R.B., 3rd, Castanedes-Casey M., Rousseau L., Benussi L., Binetti G., Ghidoni R. TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J.&#xa0;Neurochem. 2013;126:781&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766501</ArticleId><ArticleId IdType="pubmed">23742080</ArticleId></ArticleIdList></Reference><Reference><Citation>Stagi M., Klein Z.A., Gould T.J., Bewersdorf J., Strittmatter S.M. Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. Mol. Cell. Neurosci. 2014;61:226&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145808</ArticleId><ArticleId IdType="pubmed">25066864</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348:648&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4547484</ArticleId><ArticleId IdType="pubmed">25954001</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold M., Raffler J., Pfeufer A., Suhre K., Kastenm&#xfc;ller G. SNiPA: an interactive, genetic variant-centered annotation browser. Bioinformatics. 2015;31:1334&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393511</ArticleId><ArticleId IdType="pubmed">25431330</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranger B.E., Montgomery S.B., Dimas A.S., Parts L., Stegle O., Ingle C.E., Sekowska M., Smith G.D., Evans D., Gutierrez-Arcelus M. Patterns of cis regulatory variation in diverse human populations. PLoS Genet. 2012;8:e1002639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330104</ArticleId><ArticleId IdType="pubmed">22532805</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown C.D., Mangravite L.M., Engelhardt B.E. Integrative modeling of eQTLs and cis-regulatory elements suggests mechanisms underlying cell type specificity of eQTLs. PLoS Genet. 2013;9:e1003649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3731231</ArticleId><ArticleId IdType="pubmed">23935528</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellcome Trust Case Control Consortium Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719288</ArticleId><ArticleId IdType="pubmed">17554300</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C., Vukcevic D., Schadt E.E., Franke L., Hingorani A.D., Wallace C., Plagnol V. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10:e1004383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Altshuler D.M., Gibbs R.A., Peltonen L., Altshuler D.M., Gibbs R.A., Peltonen L., Dermitzakis E., Schaffner S.F., Yu F., Peltonen L., International HapMap 3 Consortium Integrating common and rare genetic variation in diverse human populations. Nature. 2010;467:52&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3173859</ArticleId><ArticleId IdType="pubmed">20811451</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297300</ArticleId></ArticleIdList></Reference><Reference><Citation>Abecasis G.R., Auton A., Brooks L.D., DePristo M.A., Durbin R.M., Handsaker R.E., Kang H.M., Marth G.T., McVean G.A., 1000 Genomes Project Consortium An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498066</ArticleId><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward L.D., Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012;40:D930&#x2013;D934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245002</ArticleId><ArticleId IdType="pubmed">22064851</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch J.I., Unger T.L., Jain N., Tyler Skrinak R., Charan R.A., Chen-Plotkin A.S. Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes. Hum. Mol. Genet. 2016;25:2681&#x2013;2697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181637</ArticleId><ArticleId IdType="pubmed">27126638</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinrichs A.S., Raney B.J., Speir M.L., Rhead B., Casper J., Karolchik D., Kuhn R.M., Rosenbloom K.R., Zweig A.S., Haussler D., Kent W.J. UCSC Data Integrator and Variant Annotation Integrator. Bioinformatics. 2016;32:1430&#x2013;1432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848401</ArticleId><ArticleId IdType="pubmed">26740527</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurman R.E., Rynes E., Humbert R., Vierstra J., Maurano M.T., Haugen E., Sheffield N.C., Stergachis A.B., Wang H., Vernot B. The accessible chromatin landscape of the human genome. Nature. 2012;489:75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3721348</ArticleId><ArticleId IdType="pubmed">22955617</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstein M.B., Kundaje A., Hariharan M., Landt S.G., Yan K.K., Cheng C., Mu X.J., Khurana E., Rozowsky J., Alexander R. Architecture of the human regulatory network derived from ENCODE data. Nature. 2012;489:91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154057</ArticleId><ArticleId IdType="pubmed">22955619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst J., Kheradpour P., Mikkelsen T.S., Shoresh N., Ward L.D., Epstein C.B., Zhang X., Wang L., Issner R., Coyne M. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature. 2011;473:43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3088773</ArticleId><ArticleId IdType="pubmed">21441907</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X., Wang T. Using the Wash U Epigenome Browser to examine genome-wide sequencing data. Curr. Protoc. Bioinformatics. 2012;Chapter 10:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643794</ArticleId><ArticleId IdType="pubmed">23255151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundaje A., Meuleman W., Ernst J., Bilenky M., Yen A., Heravi-Moussavi A., Kheradpour P., Zhang Z., Wang J., Ziller M.J., Roadmap Epigenomics Consortium Integrative analysis of 111 reference human epigenomes. Nature. 2015;518:317&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530010</ArticleId><ArticleId IdType="pubmed">25693563</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathelier A., Zhao X., Zhang A.W., Parcy F., Worsley-Hunt R., Arenillas D.J., Buchman S., Chen C.Y., Chou A., Ienasescu H. JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles. Nucleic Acids Res. 2014;42:D142&#x2013;D147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965086</ArticleId><ArticleId IdType="pubmed">24194598</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle A.P., Hong E.L., Hariharan M., Cheng Y., Schaub M.A., Kasowski M., Karczewski K.J., Park J., Hitz B.C., Weng S. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22:1790&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431494</ArticleId><ArticleId IdType="pubmed">22955989</ArticleId></ArticleIdList></Reference><Reference><Citation>Abecasis G.R., Altshuler D., Auton A., Brooks L.D., Durbin R.M., Gibbs R.A., Hurles M.E., McVean G.A., 1000 Genomes Project Consortium A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042601</ArticleId><ArticleId IdType="pubmed">20981092</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao S.S., Huntley M.H., Durand N.C., Stamenova E.K., Bochkov I.D., Robinson J.T., Sanborn A.L., Machol I., Omer A.D., Lander E.S., Aiden E.L. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell. 2014;159:1665&#x2013;1680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5635824</ArticleId><ArticleId IdType="pubmed">25497547</ArticleId></ArticleIdList></Reference><Reference><Citation>Durand N.C., Robinson J.T., Shamim M.S., Machol I., Mesirov J.P., Lander E.S., Aiden E.L. Juicebox Provides a Visualization System for Hi-C Contact Maps with Unlimited Zoom. Cell Syst. 2016;3:99&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5596920</ArticleId><ArticleId IdType="pubmed">27467250</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes J.R., Roberts N., McGowan S., Hay D., Giannoulatou E., Lynch M., De Gobbi M., Taylor S., Gibbons R., Higgs D.R. Analysis of hundreds of cis-regulatory landscapes at high resolution in a single, high-throughput experiment. Nat. Genet. 2014;46:205&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">24413732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakim O., Misteli T. SnapShot: Chromosome confirmation capture. Cell. 2012;148:1068.e1&#x2013;1068.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6374129</ArticleId><ArticleId IdType="pubmed">22385969</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies J.O., Telenius J.M., McGowan S.J., Roberts N.A., Taylor S., Higgs D.R., Hughes J.R. Multiplexed analysis of chromosome conformation at vastly improved sensitivity. Nat. Methods. 2016;13:74&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4724891</ArticleId><ArticleId IdType="pubmed">26595209</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B., Trapnell C., Pop M., Salzberg S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690996</ArticleId><ArticleId IdType="pubmed">19261174</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams R.L., Jr., Starmer J., Mugford J.W., Calabrese J.M., Mieczkowski P., Yee D., Magnuson T. fourSig: a method for determining chromosomal interactions in 4C-Seq data. Nucleic Acids Res. 2014;42:e68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4005674</ArticleId><ArticleId IdType="pubmed">24561615</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns J., Freire-Pritchett P., Wingett S.W., V&#xe1;rnai C., Dimond A., Plagnol V., Zerbino D., Schoenfelder S., Javierre B.M., Osborne C. CHiCAGO: robust detection of DNA looping interactions in Capture Hi-C data. Genome Biol. 2016;17:127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4908757</ArticleId><ArticleId IdType="pubmed">27306882</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt E.M., Zhang J., Zhou W., Chen J., Mohlke K.L., Chen Y.E., Willer C.J. GREGOR: evaluating global enrichment of trait-associated variants in epigenomic features using a systematic, data-driven approach. Bioinformatics. 2015;31:2601&#x2013;2606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4612390</ArticleId><ArticleId IdType="pubmed">25886982</ArticleId></ArticleIdList></Reference><Reference><Citation>Landt S.G., Marinov G.K., Kundaje A., Kheradpour P., Pauli F., Batzoglou S., Bernstein B.E., Bickel P., Brown J.B., Cayting P. ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res. 2012;22:1813&#x2013;1831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431496</ArticleId><ArticleId IdType="pubmed">22955991</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurano M.T., Humbert R., Rynes E., Thurman R.E., Haugen E., Wang H., Reynolds A.P., Sandstrom R., Qu H., Brody J. Systematic localization of common disease-associated variation in regulatory DNA. Science. 2012;337:1190&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771521</ArticleId><ArticleId IdType="pubmed">22955828</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaub M.A., Boyle A.P., Kundaje A., Batzoglou S., Snyder M. Linking disease associations with regulatory information in the human genome. Genome Res. 2012;22:1748&#x2013;1759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431491</ArticleId><ArticleId IdType="pubmed">22955986</ArticleId></ArticleIdList></Reference><Reference><Citation>Musunuru K., Strong A., Frank-Kamenetsky M., Lee N.E., Ahfeldt T., Sachs K.V., Li X., Li H., Kuperwasser N., Ruda V.M. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466:714&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3062476</ArticleId><ArticleId IdType="pubmed">20686566</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q., Whitington T., Gao P., Lindberg J.F., Yang Y., Sun J., V&#xe4;is&#xe4;nen M.R., Szulkin R., Annala M., Yan J. A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. Nat. Genet. 2014;46:126&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">24390282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer D.E., Kamran S.C., Lessard S., Xu J., Fujiwara Y., Lin C., Shao Z., Canver M.C., Smith E.C., Pinello L. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science. 2013;342:253&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4018826</ArticleId><ArticleId IdType="pubmed">24115442</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunning A.M., Michailidou K., Kuchenbaecker K.B., Thompson D., French J.D., Beesley J., Healey C.S., Kar S., Pooley K.A., Lopez-Knowles E., EMBRACE. GEMO Study Collaborators. HEBON. kConFab Investigators Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat. Genet. 2016;48:374&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4938803</ArticleId><ArticleId IdType="pubmed">26928228</ArticleId></ArticleIdList></Reference><Reference><Citation>Smemo S., Tena J.J., Kim K.H., Gamazon E.R., Sakabe N.J., G&#xf3;mez-Mar&#xed;n C., Aneas I., Credidio F.L., Sobreira D.R., Wasserman N.F. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature. 2014;507:371&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113484</ArticleId><ArticleId IdType="pubmed">24646999</ArticleId></ArticleIdList></Reference><Reference><Citation>Claussnitzer M., Dankel S.N., Kim K.H., Quon G., Meuleman W., Haugen C., Glunk V., Sousa I.S., Beaudry J.L., Puviindran V. FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. N.&#xa0;Engl. J. Med. 2015;373:895&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4959911</ArticleId><ArticleId IdType="pubmed">26287746</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon A.L., Liang L., Moffatt M.F., Chen W., Heath S., Wong K.C., Taylor J., Burnett E., Gut I., Farrall M. A genome-wide association study of global gene expression. Nat. Genet. 2007;39:1202&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pubmed">17873877</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang L., Morar N., Dixon A.L., Lathrop G.M., Abecasis G.R., Moffatt M.F., Cookson W.O. A cross-platform analysis of 14,177 expression quantitative trait loci derived from lymphoblastoid cell lines. Genome Res. 2013;23:716&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613588</ArticleId><ArticleId IdType="pubmed">23345460</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L., De Jager P.L., Yang J., Trojanowski J.Q., Bennett D.A., Schneider J.A. The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology. 2015;84:927&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351662</ArticleId><ArticleId IdType="pubmed">25653292</ArticleId></ArticleIdList></Reference><Reference><Citation>Auton A., Brooks L.D., Durbin R.M., Garrison E.P., Kang H.M., Korbel J.O., Marchini J.L., McCarthy S., McVean G.A., Abecasis G.R., 1000 Genomes Project Consortium A global reference for human genetic variation. Nature. 2015;526:68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunning A.M., Durocher F., Healey C.S., Teare M.D., McBride S.E., Carlomagno F., Xu C.F., Dawson E., Rhodes S., Ueda S. The extent of linkage disequilibrium in four populations with distinct demographic histories. Am. J. Hum. Genet. 2000;67:1544&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1287929</ArticleId><ArticleId IdType="pubmed">11078480</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraldi A., Klein A.D., Medina D.L., Settembre C. Brain Disorders Due to Lysosomal Dysfunction. Annu. Rev. Neurosci. 2016;39:277&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">27090953</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R.A. The role of autophagy in neurodegenerative disease. Nat. Med. 2013;19:983&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimas A.S., Deutsch S., Stranger B.E., Montgomery S.B., Borel C., Attar-Cohen H., Ingle C., Beazley C., Gutierrez Arcelus M., Sekowska M. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science. 2009;325:1246&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867218</ArticleId><ArticleId IdType="pubmed">19644074</ArticleId></ArticleIdList></Reference><Reference><Citation>ENCODE Project Consortium An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439153</ArticleId><ArticleId IdType="pubmed">22955616</ArticleId></ArticleIdList></Reference><Reference><Citation>Creyghton M.P., Cheng A.W., Welstead G.G., Kooistra T., Carey B.W., Steine E.J., Hanna J., Lodato M.A., Frampton G.M., Sharp P.A. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA. 2010;107:21931&#x2013;21936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003124</ArticleId><ArticleId IdType="pubmed">21106759</ArticleId></ArticleIdList></Reference><Reference><Citation>Rada-Iglesias A., Bajpai R., Swigut T., Brugmann S.A., Flynn R.A., Wysocka J. A unique chromatin signature uncovers early developmental enhancers in humans. Nature. 2011;470:279&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4445674</ArticleId><ArticleId IdType="pubmed">21160473</ArticleId></ArticleIdList></Reference><Reference><Citation>Zentner G.E., Tesar P.J., Scacheri P.C. Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. Genome Res. 2011;21:1273&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149494</ArticleId><ArticleId IdType="pubmed">21632746</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford G.E., Holt I.E., Whittle J., Webb B.D., Tai D., Davis S., Margulies E.H., Chen Y., Bernat J.A., Ginsburg D. Genome-wide mapping of DNase hypersensitive sites using massively parallel signature sequencing (MPSS) Genome Res. 2006;16:123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1356136</ArticleId><ArticleId IdType="pubmed">16344561</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurano M.T., Haugen E., Sandstrom R., Vierstra J., Shafer A., Kaul R., Stamatoyannopoulos J.A. Large-scale identification of sequence variants influencing human transcription factor occupancy in&#xa0;vivo. Nat. Genet. 2015;47:1393&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4666772</ArticleId><ArticleId IdType="pubmed">26502339</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkenschlager M., Nora E.P. CTCF and Cohesin in Genome Folding and Transcriptional Gene Regulation. Annu. Rev. Genomics Hum. Genet. 2016;17:17&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">27089971</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong C.T., Corces V.G. CTCF: an architectural protein bridging genome topology and function. Nat. Rev. Genet. 2014;15:234&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4610363</ArticleId><ArticleId IdType="pubmed">24614316</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y., Xu Q., Canzio D., Shou J., Li J., Gorkin D.U., Jung I., Wu H., Zhai Y., Tang Y. CRISPR Inversion of CTCF Sites Alters Genome Topology and Enhancer/Promoter Function. Cell. 2015;162:900&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4642453</ArticleId><ArticleId IdType="pubmed">26276636</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupi&#xe1;&#xf1;ez D.G., Kraft K., Heinrich V., Krawitz P., Brancati F., Klopocki E., Horn D., Kayserili H., Opitz J.M., Laxova R. Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions. Cell. 2015;161:1012&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4791538</ArticleId><ArticleId IdType="pubmed">25959774</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon J.R., Selvaraj S., Yue F., Kim A., Li Y., Shen Y., Hu M., Liu J.S., Ren B. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature. 2012;485:376&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3356448</ArticleId><ArticleId IdType="pubmed">22495300</ArticleId></ArticleIdList></Reference><Reference><Citation>Nora E.P., Lajoie B.R., Schulz E.G., Giorgetti L., Okamoto I., Servant N., Piolot T., van Berkum N.L., Meisig J., Sedat J. Spatial partitioning of the regulatory landscape of the X-inactivation centre. Nature. 2012;485:381&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555144</ArticleId><ArticleId IdType="pubmed">22495304</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson R., Gebhard C., Miguel-Escalada I., Hoof I., Bornholdt J., Boyd M., Chen Y., Zhao X., Schmidl C., Suzuki T. An atlas of active enhancers across human cell types and tissues. Nature. 2014;507:455&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5215096</ArticleId><ArticleId IdType="pubmed">24670763</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z., Luo O.J., Li X., Zheng M., Zhu J.J., Szalaj P., Trzaskoma P., Magalska A., Wlodarczyk J., Ruszczycki B. CTCF-Mediated Human 3D Genome Architecture Reveals Chromatin Topology for Transcription. Cell. 2015;163:1611&#x2013;1627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4734140</ArticleId><ArticleId IdType="pubmed">26686651</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters J.E., Lyons P.A., Lee J.C., Richard A.C., Fortune M.D., Newcombe P.J., Richardson S., Smith K.G. Insight into Genotype-Phenotype Associations through eQTL Mapping in Multiple Cell Types in Health and Immune-Mediated Disease. PLoS Genet. 2016;12:e1005908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4807835</ArticleId><ArticleId IdType="pubmed">27015630</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T., Rothamel K., Mostafavi S., Ye C., Lee M.N., Replogle J.M., Feng T., Lee M., Asinovski N., Frohlich I. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science. 2014;344:519&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910825</ArticleId><ArticleId IdType="pubmed">24786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Won H., de la Torre-Ubieta L., Stein J.L., Parikshak N.N., Huang J., Opland C.K., Gandal M.J., Sutton G.J., Hormozdiari F., Lu D. Chromosome conformation elucidates regulatory relationships in developing human brain. Nature. 2016;538:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5358922</ArticleId><ArticleId IdType="pubmed">27760116</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewhey R., Kotliar D., Park D.S., Liu B., Winnicki S., Reilly S.K., Andersen K.G., Mikkelsen T.S., Lander E.S., Schaffner S.F., Sabeti P.C. Direct Identification of Hundreds of Expression-Modulating Variants using a Multiplexed Reporter Assay. Cell. 2016;165:1519&#x2013;1529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4957403</ArticleId><ArticleId IdType="pubmed">27259153</ArticleId></ArticleIdList></Reference><Reference><Citation>Patwardhan R.P., Hiatt J.B., Witten D.M., Kim M.J., Smith R.P., May D., Lee C., Andrie J.M., Lee S.I., Cooper G.M. Massively parallel functional dissection of mammalian enhancers in&#xa0;vivo. Nat. Biotechnol. 2012;30:265&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3402344</ArticleId><ArticleId IdType="pubmed">22371081</ArticleId></ArticleIdList></Reference><Reference><Citation>Spis&#xe1;k S., Lawrenson K., Fu Y., Csabai I., Cottman R.T., Seo J.H., Haiman C., Han Y., Lenci R., Li Q., GAME-ON/ELLIPSE Consortium CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants. Nat. Med. 2015;21:1357&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4746056</ArticleId><ArticleId IdType="pubmed">26398868</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekar A., Bialas A.R., de Rivera H., Davis A., Hammond T.R., Kamitaki N., Tooley K., Presumey J., Baum M., Van Doren V., Schizophrenia Working Group of the Psychiatric Genomics Consortium Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530:177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752392</ArticleId><ArticleId IdType="pubmed">26814963</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolae D.L., Gamazon E., Zhang W., Duan S., Dolan M.E., Cox N.J. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 2010;6:e1000888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848547</ArticleId><ArticleId IdType="pubmed">20369019</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z., Zhang F., Hu H., Bakshi A., Robinson M.R., Powell J.E., Montgomery G.W., Goddard M.E., Wray N.R., Visscher P.M., Yang J. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat. Genet. 2016;48:481&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">27019110</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu J., Wolfs M.G., Deelen P., Westra H.J., Fehrmann R.S., Te Meerman G.J., Buurman W.A., Rensen S.S., Groen H.J., Weersma R.K. Unraveling the regulatory mechanisms underlying tissue-dependent genetic variation of gene expression. PLoS Genet. 2012;8:e1002431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261927</ArticleId><ArticleId IdType="pubmed">22275870</ArticleId></ArticleIdList></Reference><Reference><Citation>Finucane H.K., Bulik-Sullivan B., Gusev A., Trynka G., Reshef Y., Loh P.R., Anttila V., Xu H., Zang C., Farh K., ReproGen Consortium. Schizophrenia Working Group of the Psychiatric Genomics Consortium. RACI Consortium Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 2015;47:1228&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626285</ArticleId><ArticleId IdType="pubmed">26414678</ArticleId></ArticleIdList></Reference><Reference><Citation>Adrianto I., Wen F., Templeton A., Wiley G., King J.B., Lessard C.J., Bates J.S., Hu Y., Kelly J.A., Kaufman K.M., BIOLUPUS and GENLES Networks Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat. Genet. 2011;43:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3103780</ArticleId><ArticleId IdType="pubmed">21336280</ArticleId></ArticleIdList></Reference><Reference><Citation>Harismendy O., Notani D., Song X., Rahim N.G., Tanasa B., Heintzman N., Ren B., Fu X.D., Topol E.J., Rosenfeld M.G., Frazer K.A. 9p21 DNA variants associated with coronary artery disease impair interferon-&#x3b3; signalling response. Nature. 2011;470:264&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079517</ArticleId><ArticleId IdType="pubmed">21307941</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29059270</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.</ArticleTitle><Pagination><StartPage>44</StartPage><EndPage>50</EndPage><MedlinePgn>44-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.2954</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The goal of Alzheimer disease (AD) prevention together with advances in understanding the pathophysiology of AD have led to clinical trials testing drugs in cognitively unimpaired persons who show evidence of AD biomarkers. Data are needed to inform the processes of describing AD biomarkers to cognitively normal adults and assessing their understanding of this knowledge.</AbstractText><AbstractText Label="OBJECTIVE">To determine the comprehension of an elevated amyloid positron emission tomographic (PET) biomarker result by cognitively unimpaired adults.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The Study of Knowledge and Reactions to Amyloid Testing, a substudy of an AD prevention trial, involved 2 semistructured telephone interviews with 80 participants recruited from 9 study sites: 50 received elevated and 30 received not elevated amyloid PET scan results. Interviews were conducted 4 to 12 weeks after result disclosure and again 1 year later. Data presented here were collected from November 5, 2014, through December 10, 2015. The 50 participants included in this study were cognitively normal, aged 65 to 85 years, evenly distributed by gender, and had elevated amyloid PET results. Subsequent reports will examine persons with "not elevated" results and compare the influence of the different results.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Participant comprehension of an elevated amyloid result was assessed by analyzing their responses to the following questions: "What was the result of your amyloid PET scan?" (followed by "Can you tell me in your own words what that means?" or "How would you explain it to a friend?"), "Was it the result you expected?" and "Did the result teach you anything or clarify anything for you?"</AbstractText><AbstractText Label="RESULTS">Of the 50 participants aged 65 to 85 years, 49 (98%) were white, 40 (80%) reported a family history of AD, and 30 (60%) had a postgraduate educational level. Most participants (31 [62%]) understood that elevated amyloid conferred an increased but uncertain risk of developing AD. Some desired understanding of the term elevated other than its being a categorical result enabling trial entry eligibility; they wanted information regarding how elevated their amyloid was, how close to the study threshold they were, or percentages, numbers, or a scale to help them make sense of the result.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Including an explanation of how and why a dimensional biomarker is converted to a categorical classification would enhance future AD biomarker clinical trials and educational materials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mozersky</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with the Division of General Medical Sciences, John T. Milliken Department of Medicine, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sankar</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harkins</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Penn Memory Center at the Penn Neuroscience Center, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hachey</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Penn Memory Center at the Penn Neuroscience Center, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Memory Center at the Penn Neuroscience Center, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2018 Jan 1;75(1):18-19. doi: 10.1001/jamaneurol.2017.2558.</RefSource><PMID Version="1">29059264</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Karlawish reported receiving a grant from the National Institute on Aging and support from Eli Lilly for the Anti-Amyloid Treatment in Asymptomatic Alzheimer&#x2019;s Study (A4 study) to lead the amyloid imaging disclosure process and internal ethics committee and to serve as a site principal investigator.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29059270</ArticleId><ArticleId IdType="pmc">PMC5833492</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.2954</ArticleId><ArticleId IdType="pii">2659546</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National plan to address Alzheimer&#x2019;s disease: 2015 update. Office of the Assistant Secretary for Planning and Evaluation. https://aspe.hhs.gov/national-plan-address-alzheimers-disease-2015-update. Published July 13, 2015. Accessed December 9, 2016.</Citation></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280-292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Minoshima S, Bohnen NI, et al. . Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer&#x2019;s Association. J Nucl Med. 2013;54(3):476-490.</Citation><ArticleIdList><ArticleId IdType="pubmed">23359661</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman MB, Harkins K, Green RC, Karlawish J. Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology. 2013;81(13):1114-1121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795601</ArticleId><ArticleId IdType="pubmed">23966249</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein EP, Kaye J. Dementia specialists and early adoption of amyloid imaging. J Alzheimers Dis. 2013;33(2):445-450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640311</ArticleId><ArticleId IdType="pubmed">22976071</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingler JH, Klunk WE. Disclosure of amyloid imaging results to research participants: has the time come? Alzheimers Dement. 2013;9(6):741-744.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3758392</ArticleId><ArticleId IdType="pubmed">23415310</ArticleId></ArticleIdList></Reference><Reference><Citation>Witte MM, Foster NL, Fleisher AS, et al. . Clinical use of amyloid-positron emission tomography neuroimaging: practical and bioethical considerations. Alzheimers Dement (Amst). 2015;1(3):358-367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878065</ArticleId><ArticleId IdType="pubmed">27239516</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov. Clinical Trial of Solanezumab for Older Individuals Who May Be at Risk for Memory Loss. NCT0200857. https://clinicaltrials.gov/ct2/show/NCT02008357. Accessed May 11, 2017.</Citation></Reference><Reference><Citation>Lim YY, Maruff P, Getter C, Snyder PJ. Disclosure of positron emission tomography amyloid imaging results: a preliminary study of safety and tolerability. Alzheimers Dement. 2016;12(4):454-458.</Citation><ArticleIdList><ArticleId IdType="pubmed">26750717</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Roberts JS, Cupples LA, et al. ; REVEAL Study Group . Disclosure of APOE genotype for risk of Alzheimer&#x2019;s disease. N Engl J Med. 2009;361(3):245-254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778270</ArticleId><ArticleId IdType="pubmed">19605829</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns JM, Johnson DK, Liebmann EP, Bothwell RJ, Morris JK, Vidoni ED. Safety of disclosing amyloid status in cognitively normal older adults. Alzheimers Dement. 2017;13(9):1024-1030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5582024</ArticleId><ArticleId IdType="pubmed">28263740</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlawish J. Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology. 2011;77(15):1487-1493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4561233</ArticleId><ArticleId IdType="pubmed">21917767</ArticleId></ArticleIdList></Reference><Reference><Citation>Milne R, Karlawish J. Expanding engagement with the ethical implications of changing definitions of Alzheimer&#x2019;s disease. Lancet Psychiatry. 2017;4(4):e6-e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5898807</ArticleId><ArticleId IdType="pubmed">28347435</ArticleId></ArticleIdList></Reference><Reference><Citation>Gooblar J, Roe CM, Selsor NJ, Gabel MJ, Morris JC. Attitudes of research participants and the general public regarding disclosure of Alzheimer disease research results. JAMA Neurol. 2015;72(12):1484-1490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694568</ArticleId><ArticleId IdType="pubmed">26501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott BR, Pelosi MA, Tremont G, Snyder PJ. A survey of knowledge and views concerning genetic and amyloid PET status disclosure. Alzheimers Dement (N Y). 2016;2(1):23-29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4804344</ArticleId><ArticleId IdType="pubmed">27019867</ArticleId></ArticleIdList></Reference><Reference><Citation>Harkins K, Sankar P, Sperling R, et al. . Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7(1):26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428104</ArticleId><ArticleId IdType="pubmed">25969699</ArticleId></ArticleIdList></Reference><Reference><Citation>The A4 study. http://a4study.org/. Accessed May 11, 2017.</Citation></Reference><Reference><Citation>Institute of Medicine Cognitive Aging: Progress in Understanding and Opportunities for Action. Washington, DC: National Academies Press; 2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">25879131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lineweaver TT, Bondi MW, Galasko D, Salmon DP. Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry. 2014;171(2):201-208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4037144</ArticleId><ArticleId IdType="pubmed">24170170</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingler JH, Butters MA, Gentry AL, et al. . Development of a standardized approach to disclosing amyloid imaging research results in mild cognitive impairment. J Alzheimers Dis. 2016;52(1):17-24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860948</ArticleId><ArticleId IdType="pubmed">27060950</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29071355</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6238</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>12</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA psychiatry</Title><ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Extent of Dorsolateral Prefrontal Cortex Plasticity and Its Association With Working Memory in Patients With Alzheimer Disease.</ArticleTitle><Pagination><StartPage>1266</StartPage><EndPage>1274</EndPage><MedlinePgn>1266-1274</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2017.3292</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The extent of dorsolateral prefrontal cortex (DLPFC) plasticity in Alzheimer disease (AD) and its association with working memory are not known.</AbstractText><AbstractText Label="OBJECTIVES">To determine whether participants with AD had impaired DLPFC plasticity compared with healthy control participants, to compare working memory between participants with AD and controls, and to determine whether DLPFC plasticity was associated with working memory.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study included 32 participants with AD who were 65 years or older and met diagnostic criteria for dementia due to probable AD with a score of at least 17 on the Mini-Mental State Examination and 16 age-matched control participants. Participants were recruited from a university teaching hospital from May 2013 to October 2016.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Plasticity of the DLPFC measured as potentiation of cortical-evoked activity using paired associative stimulation (a combination of peripheral nerve electrical stimulation and transcranial magnetic stimulation) combined with electroencephalography. Working memory was assessed with the n-back task (1- and 2-back) and measured using the A' statistic.</AbstractText><AbstractText Label="RESULTS">Among the 32 participants with AD, 17 were women and 15 were men (mean [SD] age, 76.3 [6.3] years); among the 16 controls, 8 were men and 8 were women (mean [SD] age, 76.4 [5.1] years). Participants with AD had impaired DLPFC plasticity (mean [SD] potentiation, 1.18 [0.25]) compared with controls (mean [SD] potentiation, 1.40 [0.35]; F1,44&#x2009;=&#x2009;5.90; P&#x2009;=&#x2009;.02; between-group comparison, Cohen d&#x2009;=&#x2009;0.77; P&#x2009;=&#x2009;.01). Participants with AD also had impaired performances on the 1-back condition (mean [SD] A'&#x2009;=&#x2009;0.47 [0.30]) compared with controls (mean [SD] A'&#x2009;=&#x2009;0.96 [0.01]; Cohen d&#x2009;=&#x2009;1.86; P&#x2009;&lt;&#x2009;.001), with similar findings for participants with AD on the 2-back condition (mean [SD] A'&#x2009;=&#x2009;0.29 [0.2]) compared with controls (mean [SD], A'&#x2009;=&#x2009;0.85 [0.18]; Cohen d&#x2009;=&#x2009;2.83; P&#x2009;&lt;&#x2009;.001). Plasticity of DLPFC was positively associated with working memory performance on the 1-back A' (parameter estimate B [SE]&#x2009;=&#x2009;0.32 [0.13]; standardized &#x3b2;&#x2009;=&#x2009;0.29; P&#x2009;=&#x2009;.02) and 2-back A' (B&#x2009;[SE]&#x2009;=&#x2009;0.43&#x2009;[0.15]; &#x3b2;&#x2009;=&#x2009;0.39; P&#x2009;=&#x2009;.006) across both groups after controlling for age, education, and attention.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study demonstrated impaired in vivo DLPFC plasticity in patients with AD. The findings support the use of DLPFC plasticity as a measure of DLPFC function and a potential treatment target to enhance DLPFC function and working memory in patients with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Sanjeev</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Geriatric Psychiatry Division, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Campbell Family Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zomorrodi</LastName><ForeName>Reza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Geriatric Psychiatry Division, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghazala</LastName><ForeName>Zaid</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Geriatric Psychiatry Division, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Campbell Family Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodman</LastName><ForeName>Michelle S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Geriatric Psychiatry Division, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Campbell Family Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blumberger</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Geriatric Psychiatry Division, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Campbell Family Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheam</LastName><ForeName>Amay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Geriatric Psychiatry Division, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Campbell Family Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Keenan Research Centre for Biomedical Research, the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daskalakis</LastName><ForeName>Zafiris J</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Geriatric Psychiatry Division, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Campbell Family Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulsant</LastName><ForeName>Benoit H</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Geriatric Psychiatry Division, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Campbell Family Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollock</LastName><ForeName>Bruce G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Geriatric Psychiatry Division, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Campbell Family Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajji</LastName><ForeName>Tarek K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Geriatric Psychiatry Division, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Campbell Family Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Psychiatry</MedlineTA><NlmUniqueID>101589550</NlmUniqueID><ISSNLinking>2168-622X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005071" MajorTopicYN="N">Evoked Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007361" MajorTopicYN="Y">Intelligence Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004561" MajorTopicYN="N">Transcutaneous Electric Nerve Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Blumberger reports receiving research support and in-kind equipment support for an investigator-initiated study from Brainsway, Ltd; serving as the site principal investigator for 3 sponsor-initiated studies for Brainsway, Ltd; receiving in-kind equipment support from Magventure, Inc, for an investigator-initiated study; and receiving medication supplies for an investigator-initiated trial from Indivior. Dr Fischer reports participating in peer-reviewed research involving a commercial device designed to treat Alzheimer disease manufactured by Vieight. Dr Daskalakis reports receiving research and equipment in-kind support for an investigator-initiated study through Brainsway, Ltd, and Magventure, Inc, in the past 3 years and receiving monies for participation on an advisory board from Sunovion, Inc. Dr Mulsant reports receiving current research support from HAPPYneuron (software used in a study funded by Brain Canada); receiving research support from Bristol-Myers Squibb (medications for a National Institutes of Health [NIH]&#x2013;funded clinical trial), Eli Lilly and Company (medications for an NIH-funded clinical trial), and Pfizer (medications for an NIH-funded clinical trial) within the past 5 years; and directly owning stocks of General Electric (less than $5000). No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29071355</ArticleId><ArticleId IdType="pmc">PMC6583382</ArticleId><ArticleId IdType="doi">10.1001/jamapsychiatry.2017.3292</ArticleId><ArticleId IdType="pii">2658231</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lafleche G, Albert MS. Executive function deficits in mild Alzheimer&#x2019;s disease. Neuropsychology. 1995;9(3):313-320. doi:10.1037/0894-4105.9.3.313</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0894-4105.9.3.313</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry RJ, Hodges JR. Attention and executive deficits in Alzheimer&#x2019;s disease: a critical review. Brain. 1999;122(pt 3):383-404.</Citation><ArticleIdList><ArticleId IdType="pubmed">10094249</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M. Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. Arch Gen Psychiatry. 2001;58(9):853-858.</Citation><ArticleIdList><ArticleId IdType="pubmed">11545668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman LD, Pratt J, Levine B, Black SE. Executive deficits detected in mild Alzheimer&#x2019;s disease using the antisaccade task. Brain Behav. 2012;2(1):15-21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343295</ArticleId><ArticleId IdType="pubmed">22574270</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddeley AD, Bressi S, Della Sala S, Logie R, Spinnler H. The decline of working memory in Alzheimer&#x2019;s disease: a longitudinal study. Brain. 1991;114(pt 6):2521-2542.</Citation><ArticleIdList><ArticleId IdType="pubmed">1782529</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntley JD, Howard RJ. Working memory in early Alzheimer&#x2019;s disease: a neuropsychological review. Int J Geriatr Psychiatry. 2010;25(2):121-132.</Citation><ArticleIdList><ArticleId IdType="pubmed">19672843</ArticleId></ArticleIdList></Reference><Reference><Citation>Gigi A, Babai R, Penker A, Hendler T, Korczyn AD. Prefrontal compensatory mechanism may enable normal semantic memory performance in mild cognitive impairment (MCI). J Neuroimaging. 2010;20(2):163-168.</Citation><ArticleIdList><ArticleId IdType="pubmed">19490403</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, et al. . Patterns of brain activation in people at risk for Alzheimer&#x2019;s disease. N Engl J Med. 2000;343(7):450-456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady C. The cognitive neuroscience of ageing. Nat Rev Neurosci. 2012;13(7):491-505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3800175</ArticleId><ArticleId IdType="pubmed">22714020</ArticleId></ArticleIdList></Reference><Reference><Citation>van Veluw SJ, Sawyer EK, Clover L, et al. . Prefrontal cortex cytoarchitecture in normal aging and Alzheimer&#x2019;s disease: a relationship with IQ. Brain Struct Funct. 2012;217(4):797-808.</Citation><ArticleIdList><ArticleId IdType="pubmed">22302432</ArticleId></ArticleIdList></Reference><Reference><Citation>Voytek B, Davis M, Yago E, Barcel&#xf3; F, Vogel EK, Knight RT. Dynamic neuroplasticity after human prefrontal cortex damage. Neuron. 2010;68(3):401-408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3005706</ArticleId><ArticleId IdType="pubmed">21040843</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, McIntosh AR, Beig S, Keightley ML, Burian H, Black SE. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer&#x2019;s disease. J Neurosci. 2003;23(3):986-993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741917</ArticleId><ArticleId IdType="pubmed">12574428</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JT, Mintun MA, Aleva K, Wiseman MB, Nichols T, DeKosky ST. Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer&#x2019;s disease. Neurology. 1996;46(3):692-700.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618669</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebb DO. The Organization of Behavior. New York, NY: Wiley; 1949.</Citation></Reference><Reference><Citation>Maren S. Synaptic mechanisms of associative memory in the amygdala. Neuron. 2005;47(6):783-786.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157273</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberger NM. Associative representational plasticity in the auditory cortex: a synthesis of two disciplines. Learn Mem. 2007;14(1-2):1-16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3601844</ArticleId><ArticleId IdType="pubmed">17202426</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman DE. Synaptic mechanisms for plasticity in neocortex. Annu Rev Neurosci. 2009;32:33-55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071739</ArticleId><ArticleId IdType="pubmed">19400721</ArticleId></ArticleIdList></Reference><Reference><Citation>LaBar KS, Gitelman DR, Parrish TB, Mesulam M. Neuroanatomic overlap of working memory and spatial attention networks: a functional MRI comparison within subjects. Neuroimage. 1999;10(6):695-704.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600415</ArticleId></ArticleIdList></Reference><Reference><Citation>Trachtenberg JT, Chen BE, Knott GW, et al. . Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature. 2002;420(6917):788-794.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490942</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat A, Wilbrecht L, Knott GW, Welker E, Svoboda K. Experience-dependent and cell-type&#x2013;specific spine growth in the neocortex. Nature. 2006;441(7096):979-983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16791195</ArticleId></ArticleIdList></Reference><Reference><Citation>Broser P, Grinevich V, Osten P, Sakmann B, Wallace DJ. Critical period plasticity of axonal arbors of layer 2/3 pyramidal neurons in rat somatosensory cortex: layer-specific reduction of projections into deprived cortical columns. Cereb Cortex. 2008;18(7):1588-1603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430153</ArticleId><ArticleId IdType="pubmed">17998276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemann U, Paulus W, Nitsche MA, et al. . Consensus: motor cortex plasticity protocols. Brain Stimul. 2008;1(3):164-182.</Citation><ArticleIdList><ArticleId IdType="pubmed">20633383</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallence AM, Ridding MC. Non-invasive induction of plasticity in the human cortex: uses and limitations. Cortex. 2014;58:261-271.</Citation><ArticleIdList><ArticleId IdType="pubmed">24439754</ArticleId></ArticleIdList></Reference><Reference><Citation>Karabanov A, Ziemann U, Hamada M, et al. . Consensus paper: probing homeostatic plasticity of human cortex with non-invasive transcranial brain stimulation. Brain Stimul. 2015;8(5):993-1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">26598772</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YZ, Sommer M, Thickbroom G, et al. . Consensus: new methodologies for brain stimulation. Brain Stimul. 2009;2(1):2-13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5507351</ArticleId><ArticleId IdType="pubmed">20633398</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefan K, Kunesch E, Cohen LG, Benecke R, Classen J. Induction of plasticity in the human motor cortex by paired associative stimulation. Brain. 2000;123(pt 3):572-584.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686179</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller JF, Orekhov Y, Liu Y, Ziemann U. Homeostatic plasticity in human motor cortex demonstrated by two consecutive sessions of paired associative stimulation. Eur J Neurosci. 2007;25(11):3461-3468.</Citation><ArticleIdList><ArticleId IdType="pubmed">17553015</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajji TK, Sun Y, Zomorrodi-Moghaddam R, et al. . PAS-induced potentiation of cortical-evoked activity in the dorsolateral prefrontal cortex. Neuropsychopharmacology. 2013;38(12):2545-2552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799076</ArticleId><ArticleId IdType="pubmed">23820586</ArticleId></ArticleIdList></Reference><Reference><Citation>Loheswaran G, Barr MS, Zomorrodi R, et al. . Impairment of neuroplasticity in the dorsolateral prefrontal cortex by alcohol. Sci Rep. 2017;7(1):5276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5509647</ArticleId><ArticleId IdType="pubmed">28706262</ArticleId></ArticleIdList></Reference><Reference><Citation>Donoghue JP, Parham C. Afferent connections of the lateral agranular field of the rat motor cortex. J Comp Neurol. 1983;217(4):390-404.</Citation><ArticleIdList><ArticleId IdType="pubmed">6886060</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt BA, Miller MW. Cortical connections between rat cingulate cortex and visual, motor, and postsubicular cortices. J Comp Neurol. 1983;216(2):192-210.</Citation><ArticleIdList><ArticleId IdType="pubmed">6863602</ArticleId></ArticleIdList></Reference><Reference><Citation>Golmayo L, Nu&#xf1;ez A, Zaborszky L. Electrophysiological evidence for the existence of a posterior cortical-prefrontal-basal forebrain circuitry in modulating sensory responses in visual and somatosensory rat cortical areas. Neuroscience. 2003;119(2):597-609.</Citation><ArticleIdList><ArticleId IdType="pubmed">12770572</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanila H, Carlson S, Linnankoski I, Kahila H. Regional distribution of functions in dorsolateral prefrontal cortex of the the monkey. Behav Brain Res. 1993;53(1-2):63-71.</Citation><ArticleIdList><ArticleId IdType="pubmed">8466668</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a Larrea L, Bastuji H, Maugui&#xe8;re F. Unmasking of cortical SEP components by changes in stimulus rate: a topographic study. Electroencephalogr Clin Neurophysiol. 1992;84(1):71-83.</Citation><ArticleIdList><ArticleId IdType="pubmed">1370405</ArticleId></ArticleIdList></Reference><Reference><Citation>Valeriani M, Restuccia D, Di Lazzaro V, Le Pera D, Tonali P. The pathophysiology of giant SEPs in cortical myoclonus: a scalp topography and dipolar source modelling study. Electroencephalogr Clin Neurophysiol. 1997;104(2):122-131.</Citation><ArticleIdList><ArticleId IdType="pubmed">9146478</ArticleId></ArticleIdList></Reference><Reference><Citation>Koechlin E, Basso G, Pietrini P, Panzer S, Grafman J. The role of the anterior prefrontal cortex in human cognition. Nature. 1999;399(6732):148-151.</Citation><ArticleIdList><ArticleId IdType="pubmed">10335843</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EE, Jonides J. Storage and executive processes in the frontal lobes. Science. 1999;283(5408):1657-1661.</Citation><ArticleIdList><ArticleId IdType="pubmed">10073923</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuster JM. Cortex and memory: emergence of a new paradigm. J Cogn Neurosci. 2009;21(11):2047-2072.</Citation><ArticleIdList><ArticleId IdType="pubmed">19485699</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddeley A. The fractionation of working memory. Proc Natl Acad Sci U S A. 1996;93(24):13468-13472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33632</ArticleId><ArticleId IdType="pubmed">8942958</ArticleId></ArticleIdList></Reference><Reference><Citation>Manoach DS, Schlaug G, Siewert B, et al. . Prefrontal cortex fMRI signal changes are correlated with working memory load. Neuroreport. 1997;8(2):545-549.</Citation><ArticleIdList><ArticleId IdType="pubmed">9080445</ArticleId></ArticleIdList></Reference><Reference><Citation>Engel AK, Fries P, Singer W. Dynamic predictions: oscillations and synchrony in top-down processing. Nat Rev Neurosci. 2001;2(10):704-716.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584308</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzs&#xe1;ki G. Neural syntax: cell assemblies, synapsembles, and readers. Neuron. 2010;68(3):362-385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3005627</ArticleId><ArticleId IdType="pubmed">21040841</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglia F, Wang HY, Ghilardi MF, et al. . Cortical plasticity in Alzheimer&#x2019;s disease in humans and rodents. Biol Psychiatry. 2007;62(12):1405-1412.</Citation><ArticleIdList><ArticleId IdType="pubmed">17651702</ArticleId></ArticleIdList></Reference><Reference><Citation>Terranova C, SantAngelo A, Morgante F, et al. . Impairment of sensory-motor plasticity in mild Alzheimer&#x2019;s disease. Brain Stimul. 2013;6(1):62-66.</Citation><ArticleIdList><ArticleId IdType="pubmed">22476006</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch G, Di Lorenzo F, Bonn&#xec; S, Ponzo V, Caltagirone C, Martorana A. Impaired LTP- but not LTD-like cortical plasticity in Alzheimer&#x2019;s disease patients. J Alzheimers Dis. 2012;31(3):593-599.</Citation><ArticleIdList><ArticleId IdType="pubmed">22647254</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lorenzo F, Ponzo V, Bonn&#xec; S, et al. . Long-term potentiation-like cortical plasticity is disrupted in Alzheimer&#x2019;s disease patients independently from age of onset. Ann Neurol. 2016;80(2):202-210.</Citation><ArticleIdList><ArticleId IdType="pubmed">27255833</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. . Research criteria for the diagnosis of Alzheimer&#x2019;s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision Washington, DC: American Psychiatric Association; 2000.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>First MB. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. New York: Biometrics Research, New York State Psychiatric Institute; 2002.</Citation></Reference><Reference><Citation>Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988;23(3):271-284.</Citation><ArticleIdList><ArticleId IdType="pubmed">3337862</ArticleId></ArticleIdList></Reference><Reference><Citation>Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20(3):310-319.</Citation><ArticleIdList><ArticleId IdType="pubmed">9845158</ArticleId></ArticleIdList></Reference><Reference><Citation>Royall DR, Mahurin RK, Gray KF. Bedside assessment of executive cognitive impairment: the Executive Interview. J Am Geriatr Soc. 1992;40(12):1221-1226.</Citation><ArticleIdList><ArticleId IdType="pubmed">1447438</ArticleId></ArticleIdList></Reference><Reference><Citation>Gevins A, Cutillo B. Spatiotemporal dynamics of component processes in human working memory. Electroencephalogr Clin Neurophysiol. 1993;87(3):128-143.</Citation><ArticleIdList><ArticleId IdType="pubmed">7691540</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen AM, McMillan KM, Laird AR, Bullmore E. N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum Brain Mapp. 2005;25(1):46-59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871745</ArticleId><ArticleId IdType="pubmed">15846822</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajji TK, Zomorrodi R, Barr MS, Blumberger DM, Mulsant BH, Daskalakis ZJ. Ordering information in working memory and modulation of gamma by theta oscillations in humans. Cereb Cortex. 2017;27(2):1482-1490.</Citation><ArticleIdList><ArticleId IdType="pubmed">26759480</ArticleId></ArticleIdList></Reference><Reference><Citation>Snodgrass JG, Corwin J. Pragmatics of measuring recognition memory: applications to dementia and amnesia. J Exp Psychol Gen. 1988;117(1):34-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">2966230</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack I, Norman DA. A non-parametric analysis of recognition experiments. Psychon Sci. 1964;1(1):125-126. doi:10.3758/BF03342823</Citation><ArticleIdList><ArticleId IdType="doi">10.3758/BF03342823</ArticleId></ArticleIdList></Reference><Reference><Citation>Daskalakis ZJ, Farzan F, Barr MS, Maller JJ, Chen R, Fitzgerald PB. Long-interval cortical inhibition from the dorsolateral prefrontal cortex: a TMS-EEG study. Neuropsychopharmacology. 2008;33(12):2860-2869.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322469</ArticleId></ArticleIdList></Reference><Reference><Citation>Klem GH, L&#xfc;ders HO, Jasper HH, Elger C; The International Federation of Clinical Neurophysiology . The ten-twenty electrode system of the International Federation. Electroencephalogr Clin Neurophysiol Suppl. 1999;52:3-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10590970</ArticleId></ArticleIdList></Reference><Reference><Citation>Farzan F, Barr MS, Wong W, Chen R, Fitzgerald PB, Daskalakis ZJ. Suppression of gamma-oscillations in the dorsolateral prefrontal cortex following long interval cortical inhibition: a TMS-EEG study. Neuropsychopharmacology. 2009;34(6):1543-1551.</Citation><ArticleIdList><ArticleId IdType="pubmed">19037204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemann U, Ili&#x107; TV, Pauli C, Meintzschel F, Ruge D. Learning modifies subsequent induction of long-term potentiation-like and long-term depression-like plasticity in human motor cortex [published correction in J Neurosci. 2004;24(46):1]. J Neurosci. 2004;24(7):1666-1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730462</ArticleId><ArticleId IdType="pubmed">14973238</ArticleId></ArticleIdList></Reference><Reference><Citation>Frantseva MV, Fitzgerald PB, Chen R, M&#xf6;ller B, Daigle M, Daskalakis ZJ. Evidence for impaired long-term potentiation in schizophrenia and its relationship to motor skill learning. Cereb Cortex. 2008;18(5):990-996.</Citation><ArticleIdList><ArticleId IdType="pubmed">17855721</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn M, Mainberger F, Feige B, et al. . State-dependent partial occlusion of cortical ltp-like plasticity in major depression. Neuropsychopharmacology. 2016;41(6):1521-1529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832013</ArticleId><ArticleId IdType="pubmed">26442602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemann U, Muellbacher W, Hallett M, Cohen LG. Modulation of practice-dependent plasticity in human motor cortex. Brain. 2001;124(pt 6):1171-1181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11353733</ArticleId></ArticleIdList></Reference><Reference><Citation>Brem AK, Atkinson NJ, Seligson EE, Pascual-Leone A. Differential pharmacological effects on brain reactivity and plasticity in Alzheimer&#x2019;s disease. Front Psychiatry. 2013;4:124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3791426</ArticleId><ArticleId IdType="pubmed">24109459</ArticleId></ArticleIdList></Reference><Reference><Citation>German DC, White CL III, Sparkman DR. Alzheimer&#x2019;s disease: neurofibrillary tangles in nuclei that project to the cerebral cortex. Neuroscience. 1987;21(2):305-312.</Citation><ArticleIdList><ArticleId IdType="pubmed">3302759</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron. 2004;44(1):5-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450156</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC, Nicoll RA. Long-term potentiation: a decade of progress? Science. 1999;285(5435):1870-1874.</Citation><ArticleIdList><ArticleId IdType="pubmed">10489359</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SJ, Linden DJ. Ubiquitous plasticity and memory storage. Neuron. 2007;56(4):582-592.</Citation><ArticleIdList><ArticleId IdType="pubmed">18031678</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardone R, Tezzon F, H&#xf6;ller Y, Golaszewski S, Trinka E, Brigo F. Transcranial magnetic stimulation (TMS)/repetitive TMS in mild cognitive impairment and Alzheimer&#x2019;s disease. Acta Neurol Scand. 2014;129(6):351-366.</Citation><ArticleIdList><ArticleId IdType="pubmed">24506061</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X, Li G, Wang A, et al. . Repetitive transcranial magnetic stimulation as an alternative therapy for cognitive impairment in Alzheimer&#x2019;s disease: a meta-analysis. J Alzheimers Dis. 2015;48(2):463-472.</Citation><ArticleIdList><ArticleId IdType="pubmed">26402010</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu WY, Ku Y, Zanto TP, Gazzaley A. Effects of noninvasive brain stimulation on cognitive function in healthy aging and Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Neurobiol Aging. 2015;36(8):2348-2359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4496249</ArticleId><ArticleId IdType="pubmed">26022770</ArticleId></ArticleIdList></Reference><Reference><Citation>Concerto C, Babayev J, Mahmoud R, et al. . Modulation of prefrontal cortex with anodal tDCS prevents post-exercise facilitation interference during dual task. Somatosens Mot Res. 2017;34(2):80-84.</Citation><ArticleIdList><ArticleId IdType="pubmed">28276838</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutagny R, Gu N, Cavanagh C, et al. . Alterations in hippocampal network oscillations and theta-gamma coupling arise before A&#x3b2; overproduction in a mouse model of Alzheimer&#x2019;s disease. Eur J Neurosci. 2013;37(12):1896-1902.</Citation><ArticleIdList><ArticleId IdType="pubmed">23773058</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbantoglu J, Tirado-Santiago G, Lahsa&#xef;ni A, et al. . Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 1997;387(6632):500-505.</Citation><ArticleIdList><ArticleId IdType="pubmed">9168112</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitas C, Farzan F, Pascual-Leone A. Assessing brain plasticity across the lifespan with transcranial magnetic stimulation: why, how, and what is the ultimate goal? Front Neurosci. 2013;7:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613699</ArticleId><ArticleId IdType="pubmed">23565072</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual-Leone A, Freitas C, Oberman L, et al. . Characterizing brain cortical plasticity and network dynamics across the age-span in health and disease with TMS-EEG and TMS-fMRI. Brain Topogr. 2011;24(3-4):302-315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3374641</ArticleId><ArticleId IdType="pubmed">21842407</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JE, Farr SA. Hormesis and amyloid-&#x3b2; protein: physiology or pathology? J Alzheimers Dis. 2012;29(3):487-492.</Citation><ArticleIdList><ArticleId IdType="pubmed">22258515</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Privitera L, Fa&#x2019; M, et al. . Endogenous amyloid-&#x3b2; is necessary for hippocampal synaptic plasticity and memory. Ann Neurol. 2011;69(5):819-830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4071456</ArticleId><ArticleId IdType="pubmed">21472769</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. The brain&#x2019;s default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1-38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Zang Y, He Y, et al. . Changes in hippocampal connectivity in the early stages of Alzheimer&#x2019;s disease: evidence from resting state fMRI. Neuroimage. 2006;31(2):496-504.</Citation><ArticleIdList><ArticleId IdType="pubmed">16473024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafkemeijer A, van der Grond J, Rombouts SA. Imaging the default mode network in aging and dementia. Biochim Biophys Acta. 2012;1822(3):431-441.</Citation><ArticleIdList><ArticleId IdType="pubmed">21807094</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouchi Y, Kikuchi M. A review of the default mode network in aging and dementia based on molecular imaging. Rev Neurosci. 2012;23(3):263-268.</Citation><ArticleIdList><ArticleId IdType="pubmed">22752783</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo V, Siebner HS, Morgante F, Mastroeni C, Girlanda P, Quartarone A. Paired associative stimulation of left and right human motor cortex shapes interhemispheric motor inhibition based on a Hebbian mechanism. Cereb Cortex. 2009;19(4):907-915.</Citation><ArticleIdList><ArticleId IdType="pubmed">18791179</ArticleId></ArticleIdList></Reference><Reference><Citation>Casula EP, Pellicciari MC, Picazio S, Caltagirone C, Koch G. Spike-timing-dependent plasticity in the human dorso-lateral prefrontal cortex. Neuroimage. 2016;143:204-213.</Citation><ArticleIdList><ArticleId IdType="pubmed">27591116</ArticleId></ArticleIdList></Reference><Reference><Citation>Romei V, Thut G, Silvanto J. Information-based approaches of noninvasive transcranial brain stimulation. Trends Neurosci. 2016;39(11):782-795.</Citation><ArticleIdList><ArticleId IdType="pubmed">27697295</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll RA, Tomita S, Bredt DS. Auxiliary subunits assist AMPA-type glutamate receptors. Science. 2006;311(5765):1253-1256.</Citation><ArticleIdList><ArticleId IdType="pubmed">16513974</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsche MA, Lampe C, Antal A, et al. . Dopaminergic modulation of long-lasting direct current-induced cortical excitability changes in the human motor cortex. Eur J Neurosci. 2006;23(6):1651-1657.</Citation><ArticleIdList><ArticleId IdType="pubmed">16553629</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle JT, Price DL, DeLong MR. Alzheimer&#x2019;s disease: a disorder of cortical cholinergic innervation. Science. 1983;219(4589):1184-1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">6338589</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer&#x2019;s disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537):1237-1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">7058341</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo M-F, Grosch J, Fregni F, Paulus W, Nitsche MA. Focusing effect of acetylcholine on neuroplasticity in the human motor cortex. J Neurosci. 2007;27(52):14442-14447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673455</ArticleId><ArticleId IdType="pubmed">18160652</ArticleId></ArticleIdList></Reference><Reference><Citation>Esser SK, Huber R, Massimini M, Peterson MJ, Ferrarelli F, Tononi G. A direct demonstration of cortical LTP in humans: a combined TMS/EEG study. Brain Res Bull. 2006;69(1):86-94.</Citation><ArticleIdList><ArticleId IdType="pubmed">16464689</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabey JM, Dobronevsky E, Aichenbaum S, Gonen O, Marton RG, Khaigrekht M. Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer&#x2019;s disease: a randomized, double-blind study. J Neural Transm (Vienna). 2013;120(5):813-819.</Citation><ArticleIdList><ArticleId IdType="pubmed">23076723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed MA, Darwish ES, Khedr EM, El Serogy YM, Ali AM. Effects of low versus high frequencies of repetitive transcranial magnetic stimulation on cognitive function and cortical excitability in Alzheimer&#x2019;s dementia. J Neurol. 2012;259(1):83-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">21671144</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Choi BH, Oh E, Sohn EH, Lee AY. Treatment of Alzheimer&#x2019;s disease with repetitive transcranial magnetic stimulation combined with cognitive training: a prospective, randomized, double-blind, placebo-controlled study. J Clin Neurol. 2016;12(1):57-64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4712287</ArticleId><ArticleId IdType="pubmed">26365021</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunoni AR, Vanderhasselt MA. Working memory improvement with non-invasive brain stimulation of the dorsolateral prefrontal cortex: a systematic review and meta-analysis. Brain Cogn. 2014;86:1-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24514153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Kim DW, Chang WH, Kim YH, Im CH. Inconsistent outcomes of transcranial direct current stimulation (tDCS) may be originated from the anatomical differences among individuals: a simulation study using individual MRI data. Conf Proc IEEE Eng Med Biol Soc. 2013;2013:823-825.</Citation><ArticleIdList><ArticleId IdType="pubmed">24109814</ArticleId></ArticleIdList></Reference><Reference><Citation>Alagona G, Bella R, Ferri R, et al. . Transcranial magnetic stimulation in Alzheimer disease: motor cortex excitability and cognitive severity. Neurosci Lett. 2001;314(1-2):57-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">11698146</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennisi G, Alagona G, Ferri R, et al. . Motor cortex excitability in Alzheimer disease: one year follow-up study. Neurosci Lett. 2002;329(3):293-296.</Citation><ArticleIdList><ArticleId IdType="pubmed">12183034</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lazzaro V, Oliviero A, Pilato F, et al. . Normal or enhanced short-latency afferent inhibition in Parkinson&#x2019;s disease? Brain. 2004;127(Pt 4):E8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044312</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni Z, Chen R. Transcranial magnetic stimulation to understand pathophysiology and as potential treatment for neurodegenerative diseases. Transl Neurodegener. 2015;4(1):22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4647804</ArticleId><ArticleId IdType="pubmed">26579223</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenkreis P, Witscher K, Pleger B, Malin JP, Tegenthoff M. The NMDA antagonist memantine affects training induced motor cortex plasticity: a study using transcranial magnetic stimulation. BMC Neurosci. 2005;6:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1134663</ArticleId><ArticleId IdType="pubmed">15890074</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosunen O, Soininen H, Palj&#xe4;rvi L, Heinonen O, Talasniemi S, Riekkinen PJ Sr. Diagnostic accuracy of Alzheimer&#x2019;s disease: a neuropathological study. Acta Neuropathol. 1996;91(2):185-193.</Citation><ArticleIdList><ArticleId IdType="pubmed">8787153</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Litvan I, Catt KE, et al. . Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology. 1999;53(6):1292-1299.</Citation><ArticleIdList><ArticleId IdType="pubmed">10522887</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapogiannis D, Wassermann EM. Transcranial magnetic stimulation in clinical pharmacology. Cent Nerv Syst Agents Med Chem. 2008;8(4):234-240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2613312</ArticleId><ArticleId IdType="pubmed">19122782</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulus W, Classen J, Cohen LG, et al. . State of the art: pharmacologic effects on cortical excitability measures tested by transcranial magnetic stimulation. Brain Stimul. 2008;1(3):151-163.</Citation><ArticleIdList><ArticleId IdType="pubmed">20633382</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29070659</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>21</Issue><PubDate><Year>2017</Year><Month>Nov</Month><Day>21</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration.</ArticleTitle><Pagination><StartPage>2167</StartPage><EndPage>2175</EndPage><MedlinePgn>2167-2175</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000004667</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate whether serum neurofilament light (NfL) concentration is increased in familial Alzheimer disease (FAD), both pre and post symptom onset, and whether it is associated with markers of disease stage and severity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We recruited 48 individuals from families with <i>PSEN1</i> or <i>APP</i> mutations to a cross-sectional study: 18 had symptomatic Alzheimer disease (AD) and 30 were asymptomatic but at 50% risk of carrying a mutation. Serum NfL was measured using an ultrasensitive immunoassay on the single molecule array (Simoa) platform. Cognitive testing and MRI were performed; 33 participants had serial MRI, allowing calculation of atrophy rates. Genetic testing established mutation status. A generalized least squares regression model was used to compare serum NfL among symptomatic mutation carriers, presymptomatic carriers, and noncarriers, adjusting for age and sex. Spearman coefficients assessed associations between serum NfL and (1) estimated years to/from symptom onset (EYO), (2) cognitive measures, and (3) MRI measures of atrophy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nineteen of the asymptomatic participants were mutation carriers (mean EYO -9.6); 11 were noncarriers. Compared with noncarriers, serum NfL concentration was higher in both symptomatic (<i>p</i> &lt; 0.0001) and presymptomatic mutation carriers (<i>p</i> = 0.007). Across all mutation carriers, serum NfL correlated with EYO (&#x3c1; = 0.81, <i>p</i> &lt; 0.0001) and multiple cognitive and imaging measures, including Mini-Mental State Examination (&#x3c1; = -0.62, <i>p</i> = 0.0001), Clinical Dementia Rating Scale sum of boxes (&#x3c1; = 0.79, <i>p</i> &lt; 0.0001), baseline brain volume (&#x3c1; = -0.62, <i>p</i> = 0.0002), and whole-brain atrophy rate (&#x3c1; = 0.53, <i>p</i> = 0.01).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Serum NfL concentration is increased in FAD prior to symptom onset and correlates with measures of disease stage and severity. Serum NfL may thus be a feasible biomarker of early AD-related neurodegeneration.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weston</LastName><ForeName>Philip S J</ForeName><Initials>PSJ</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poole</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Natalie S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Akshay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Yuying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macpherson</LastName><ForeName>Kirsty</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Druyeh</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malone</LastName><ForeName>Ian B</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahsan</LastName><ForeName>R Laila</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pemberton</LastName><ForeName>Hugh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klimova</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schott</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>From the Dementia Research Centre (P.S.J.W., T.P., N.S.R., A.N., Y.L., K.M., I.B.M., R.L.A., H.P., J.K., M.N.R., J.M.S., N.C.F.) and MRC Prion Unit (R.D., S.M.), Department of Neurodegenerative Diseases, UCL Institute of Neurology; Department of Medical Statistics (T.P.), London School of Hygiene &amp; Tropical Medicine, UK; and Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology (K.B., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden. n.fox@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0900421</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123160651</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M003108/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 89(21):2126.</RefSource><PMID Version="1">29070663</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="N">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>11</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29070659</ArticleId><ArticleId IdType="pmc">PMC5696646</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004667</ArticleId><ArticleId IdType="pii">WNL.0000000000004667</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. Neurobiol Aging 1998;19:109&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">9558143</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Lautner R, Andreasson U, et al. . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 2016;15:673&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Skillback T, Mattsson N, et al. . Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol 2016;73:60&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5624219</ArticleId><ArticleId IdType="pubmed">26524180</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005;4:32&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15620855</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherling CS, Hall T, Berisha F, et al. . Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014;75:116&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020786</ArticleId><ArticleId IdType="pubmed">24242746</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, Ruggieri M, Cortese R, et al. . Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 2012;19:1561&#x2013;1567.</Citation><ArticleIdList><ArticleId IdType="pubmed">22680408</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves S, Churlaud G, Audrain M, et al. . Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice. Brain 2016;140:826&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">28003243</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiottino J, Norgren N, Dobson R, et al. . Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 2013;8:e75091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779219</ArticleId><ArticleId IdType="pubmed">24073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacioglu M, Maia LF, Preische O, et al. . Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 2016;91:56&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">27292537</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Barro C, Andreasson U, et al. . Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 2016;54:1655&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pubmed">27071153</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissin DM, Kan CW, Campbell TG, et al. . Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010;28:595&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919230</ArticleId><ArticleId IdType="pubmed">20495550</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Aisen PS, De Strooper B, et al. . Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011;3:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, et al. . Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 2014;83:253&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Abbreviated Scale of Intelligence (WASI). San Antonio: Psychological Corporation; 1999.</Citation></Reference><Reference><Citation>Nelson HE, Wilson JR. National Adult Reading Test (NART), 2nd ed. Windsor: NFER-Nelson; 1991.</Citation></Reference><Reference><Citation>Warrington EK. Recognition Memory Test. Windsor: NFER-Nelson; 1984.</Citation></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Woollacott IO, Dick KM, et al. . Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 2016;87:1329&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047041</ArticleId><ArticleId IdType="pubmed">27581216</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 1997;53:15&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">9113464</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging 1997;16:623&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">9368118</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer's Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2017;74:557&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjogren M, Blomberg M, Jonsson M, et al. . Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 2001;66:510&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746370</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Oeckl P, Huss A, et al. . Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 2016;79:152&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridha BH, Barnes J, Bartlett JW, et al. . Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 2006;5:828&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987729</ArticleId></ArticleIdList></Reference><Reference><Citation>Weston PS, Nicholas JM, Lehmann M, et al. . Presymptomatic cortical thinning in familial Alzheimer disease: a longitudinal MRI study. Neurology 2016;87:2050&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5109950</ArticleId><ArticleId IdType="pubmed">27733562</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. . Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Warrington EK, Seiffer AL, Agnew SK, Rossor MN. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. Brain 1998;121:1631&#x2013;1639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9762953</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas JC, Karydas A, Bang J, et al. . Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 2016;3:216&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774256</ArticleId><ArticleId IdType="pubmed">27042681</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Martos CM, King AE, Atkinson RA, Woodhouse A, Vickers JC. Neurofilament light gene deletion exacerbates amyloid, dystrophic neurite, and synaptic pathology in the APP/PS1 transgenic model of Alzheimer's disease. Neurobiol Aging 2015;36:2757&#x2013;2767.</Citation><ArticleIdList><ArticleId IdType="pubmed">26344875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lista S, O'Bryant SE, Blennow K, et al. . Biomarkers in sporadic and familial Alzheimer's disease. J Alzheimers Dis 2015;47:291&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">26401553</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Wilson D, Andreasson U, et al. . Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther 2013;5:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707015</ArticleId><ArticleId IdType="pubmed">23551972</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S, Britschgi M, Herbert C, et al. . Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007;13:1359&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Rozen S, Boyle SH, et al. . Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 2011;6:e21643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136924</ArticleId><ArticleId IdType="pubmed">21779331</ArticleId></ArticleIdList></Reference><Reference><Citation>Booij BB, Lindahl T, Wetterberg P, et al. . A gene expression pattern in blood for the early detection of Alzheimer's disease. J Alzheimers Dis 2011;23:109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">20930264</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, Breteler M. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann NY Acad Sci 2009;1180:56&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">19906261</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Haughey NJ, Bandaru VV, et al. . Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis 2011;27:259&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218198</ArticleId><ArticleId IdType="pubmed">21841258</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova R, Varma S, Simpson B, et al. . Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals. Alzheimers Dement 2016;12:815&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947451</ArticleId><ArticleId IdType="pubmed">26806385</ArticleId></ArticleIdList></Reference><Reference><Citation>Gisslen M, Price RW, Andreasson U, et al. . Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 2016;3:135&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29086767</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Blood-derived amyloid-&#x3b2; protein induces Alzheimer's disease pathologies.</ArticleTitle><Pagination><StartPage>1948</StartPage><EndPage>1956</EndPage><MedlinePgn>1948-1956</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2017.204</ELocationID><Abstract><AbstractText>The amyloid-&#x3b2; protein (A&#x3b2;) protein plays a pivotal role in the pathogenesis of Alzheimer's disease (AD). It is believed that A&#x3b2; deposited in the brain originates from the brain tissue itself. However, A&#x3b2; is generated in both brain and peripheral tissues. Whether circulating A&#x3b2; contributes to brain AD-type pathologies remains largely unknown. In this study, using a model of parabiosis between APPswe/PS1dE9 transgenic AD mice and their wild-type littermates, we observed that the human A&#x3b2; originated from transgenic AD model mice entered the circulation and accumulated in the brains of wild-type mice, and formed cerebral amyloid angiopathy and A&#x3b2; plaques after a 12-month period of parabiosis. AD-type pathologies related to the A&#x3b2; accumulation including tau hyperphosphorylation, neurodegeneration, neuroinflammation and microhemorrhage were found in the brains of the parabiotic wild-type mice. More importantly, hippocampal CA1 long-term potentiation was markedly impaired in parabiotic wild-type mice. To the best of our knowledge, our study is the first to reveal that blood-derived A&#x3b2; can enter the brain, form the A&#x3b2;-related pathologies and induce functional deficits of neurons. Our study provides novel insight into AD pathogenesis and provides evidence that supports the development of therapies for AD by targeting A&#x3b2; metabolism in both the brain and the periphery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Bu</LastName><ForeName>X-L</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Xiang</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>W-S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>L-L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Z-L</ForeName><Initials>ZL</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Child Development and Disorders and Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Brain Research Center and State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Y-H</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>J-H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Separation Sciences for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>H-L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Z-Q</ForeName><Initials>ZQ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>S-H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>X-Q</ForeName><Initials>XQ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giunta</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neuroimmunology Laboratory, Department of Psychiatry and Behavioral Neurosciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Y-C</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Separation Sciences for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Rashid Laboratory for Developmental Neurobiology, Silver Child Development Center, Department of Psychiatry and Behavioral Neurosciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>X-W</ForeName><Initials>XW</Initials><AffiliationInfo><Affiliation>Brain Research Center and State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Z-F</ForeName><Initials>ZF</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Child Development and Disorders and Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>H-D</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>X-F</ForeName><Initials>XF</Initials><AffiliationInfo><Affiliation>School of Pharmacy and Medical Sciences and Sansom Institute, University of South Australia, Adelaide, SA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Townsend Family Laboratories, Department of Psychiatry, The University of British Columbia, Vancouver, BC, Canada. weihong@mail.ubc.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Y-J</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China. yanjiang_wang@tmmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TAD-117948</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C538248">Amyloid angiopathy</SupplMeshName></SupplMeshList><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2018 Jan;14(1):4. doi: 10.1038/nrneurol.2017.160.</RefSource><PMID Version="1">29123251</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010227" MajorTopicYN="N">Parabiosis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29086767</ArticleId><ArticleId IdType="doi">10.1038/mp.2017.204</ArticleId><ArticleId IdType="pii">10.1038/mp.2017.204</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.2001.81.2.741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Martel CL, Mackic JB, Matsubara E, Wisniewski T, McComb JG et al. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta. Biochem Biophys Res Commun 1994; 205: 1431&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1994.2825</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2007; 4: 191&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720507780362245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD et al. Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. J Neurosci 2000; 20: 3606&#x2013;3611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-10-03606.2000</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006; 313: 1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1131864</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010; 330: 980&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1194516</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Fritschi SK, Hamaguchi T, Obermuller U, Fuger P, Skodras A et al. Multiple factors contribute to the peripheral induction of cerebral beta-amyloidosis. J Neurosci 2014; 34: 10264&#x2013;10273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1608-14.2014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013; 501: 45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12481</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaunmuktane Z, Mead S, Ellis M, Wadsworth JD, Nicoll AJ, Kenny J et al. Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature 2015; 525: 247&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie DL, Adlard P, Peden AH, Lowrie S, Le Grice M, Burns K et al. Amyloid-beta accumulation in the CNS in human growth hormone recipients in the UK. Acta Neuropathol 2017; 134: 221&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1703-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Li QX, Evin G, Small DH, Multhaup G, Beyreuther K, Masters CL. Proteolytic processing of Alzheimer's disease beta A4 amyloid precursor protein in human platelets. J Biol Chem 1995; 270: 14140&#x2013;14147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.23.14140</ArticleId></ArticleIdList></Reference><Reference><Citation>Evin G, Zhu A, Holsinger RM, Masters CL, Li QX. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. J Neurosci Res 2003; 74: 386&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10745</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA 1994; 91: 11993&#x2013;11997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.25.11993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Kokjohn TA, Watson MD, Woods AS, Cotter RJ, Sue LI et al. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am J Pathol 2000; 156: 797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64947-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Nostrand WE, Melchor JP. Disruption of pathologic amyloid beta-protein fibril assembly on the surface of cultured human cerebrovascular smooth muscle cells. Amyloid 2001; 8(Suppl 1): 20&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">11676286</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Y, Bu XL, Liu YH, Zhu C, Shen LL, Jiao SS et al. Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease. Acta Neuropathol 2015; 130: 487&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1477-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin WS, Shen LL, Bu XL, Zhang WW, Chen SH, Huang ZL et al. Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. Acta Neuropathol 2017; 134: 207&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1721-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris RB, Martin RJ. Specific depletion of body fat in parabiotic partners of tube-fed obese rats. Am J Physiol 1984; 247(Pt 2): R380&#x2013;R386.</Citation><ArticleIdList><ArticleId IdType="pubmed">6431831</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris RB. Parabiosis between db/db and ob/ob or db/+ mice. Endocrinology 1999; 140: 138&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endo.140.1.6449</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson LN, Gografe S, Costa DA, Hughes T, Dressler D, Potter H. Use of fused circulations to investigate the role of apolipoprotein E as amyloid catalyst and peripheral sink in Alzheimer's disease. Technol Innov 2012; 14: 199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/194982412X13462021398010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Bai Y, Tan T, Li H, Xia S, Chang X et al. Lithium ameliorates autistic-like behaviors induced by neonatal isolation in rats. Front Behav Neurosci 2014; 8: 234.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2014.00234</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993; 361: 31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/361031a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandybur TI. The incidence of cerebral amyloid angiopathy in Alzheimer's disease. Neurology 1975; 25: 120&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.25.2.120</ArticleId></ArticleIdList></Reference><Reference><Citation>Esiri MM, Wilcock GK. Cerebral amyloid angiopathy in dementia and old age. J Neurol Neurosurg Psychiatry 1986; 49: 1221&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.49.11.1221</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996; 46: 1592&#x2013;1596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.46.6.1592</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenowitz WD, Nelson PT, Besser LM, Heller KB, Kukull WA. Cerebral amyloid angiopathy and its co-occurrence with Alzheimer's disease and other cerebrovascular neuropathologic changes. Neurobiol Aging 2015; 36: 2702&#x2013;2708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.06.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Potier MC, Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 2008; 115: 5&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0312-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL et al. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 2009; 14: 469&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2008.96</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RF, Fritz JJ, Dooyema J, Cintron AF, Hamaguchi T, Lah JJ et al. Exogenous seeding of cerebral beta-amyloid deposition in betaAPP-transgenic rats. J Neurochem 2012; 120: 660&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07551.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C. De novo induction of amyloid-beta deposition in vivo. Mol Psychiatry 2012; 17: 1347&#x2013;1353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2011.120</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontzek K, Lutz MI, Aguzzi A, Kovacs GG, Budka H. Amyloid-beta pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt-Jakob disease after dural grafting. Swiss Med Wkly 2016; 146: w14287.</Citation><ArticleIdList><ArticleId IdType="pubmed">26812492</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 2001; 17: 157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1389-0344(01)00067-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuchi K, Ho L, Younkin SG, Kunkel DD, Ogburn CE, LeBoeuf RC et al. High levels of circulating beta-amyloid peptide do not cause cerebral beta-amyloidosis in transgenic mice. Am J Pathol 1996; 149: 219&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">8686746</ArticleId><ArticleId IdType="pmc">1865218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA et al. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem 2007; 282: 22707&#x2013;22720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M611050200</ArticleId></ArticleIdList></Reference><Reference><Citation>Li QX, Whyte S, Tanner JE, Evin G, Beyreuther K, Masters CL. Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets. Lab Invest 1998; 78: 461&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">9564890</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Podlisny MB, Joachim CL, Vickers EA, Lee G, Fritz LC et al. Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc Natl Acad Sci USA 1988; 85: 7341&#x2013;7345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.85.19.7341</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandbrink R, Masters CL, Beyreuther K. Beta A4-amyloid protein precursor mRNA isoforms without exon 15 are ubiquitously expressed in rat tissues including brain, but not in neurons. J Biol Chem 1994; 269: 1510&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pubmed">8288617</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 1995; 213: 96&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1995.2103</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WW, Todd S, Craig D, Passmore AP, Coulson DT, Murphy S et al. Elevated platelet beta-secretase activity in mild cognitive impairment. Dement Geriatr Cogn Disord 2007; 24: 464&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000110739</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston JA, Liu WW, Coulson DT, Todd S, Murphy S, Brennan S et al. Platelet beta-secretase activity is increased in Alzheimer's disease. Neurobiol Aging 2008; 29: 661&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.11.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Liu B, Zhang L, Rong L. Amyloid beta peptide is elevated in osteoporotic bone tissues and enhances osteoclast function. Bone 2014; 61: 164&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bone.2014.01.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R, Deng J, Zhang M, Zhou HD, Wang YJ. Association between bone mineral density and the risk of Alzheimer's disease. J Alzheimers Dis 2011; 24: 101&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-101467</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol 2015; 11: 457&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. J Neurochem 2010; 115: 1077&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.07002.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Storck SE, Meister S, Nahrath J, Meissner JN, Schubert N, Di Spiezio A et al. Endothelial LRP1 transports amyloid-beta(1-42) across the blood-brain barrier. J Clin Invest 2016; 126: 123&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI81108</ArticleId></ArticleIdList></Reference><Reference><Citation>Elali A, Rivest S. The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease. Front Physiol 2013; 4: 45.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2013.00045</ArticleId></ArticleIdList></Reference><Reference><Citation>Do TM, Noel-Hudson MS, Ribes S, Besengez C, Smirnova M, Cisternino S et al. ABCG2- and ABCG4-mediated efflux of amyloid-beta peptide 1-40 at the mouse blood-brain barrier. J Alzheimers Dis 2012; 30: 155&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-112189</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9: 907&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm890</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu XL, Yao XQ, Jiao SS, Zeng F, Liu YH, Xiang Y et al. A study on the association between infectious burden and Alzheimer's disease. Eur J Neurol 2015; 22: 1519&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12477</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YR, Wang QH, Zhang T, Liu YH, Yao XQ, Zeng F et al. Associations between hepatic functions and plasma amyloid-beta levels&#x2014;implications for the capacity of liver in peripheral amyloid-beta clearance. Mol Neurobiol 2016; 54: 2338&#x2013;2344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-9826-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu XL, Cao GQ, Shen LL, Xiang Y, Jiao SS, Liu YH et al. Serum amyloid-beta levels are increased in patients with chronic obstructive pulmonary disease. Neurotox Res 2015; 28: 346&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-015-9552-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncone L, Luciani M, Coggins M, Wilker EH, Ho CY, Codispoti KE et al. Abeta amyloid pathology affects the hearts of patients with Alzheimer's disease: mind the heart. J Am Coll Cardiol 2016; 68: 2395&#x2013;2407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.08.073</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Gu B, Masters CL, Wang YJ. A systemic view of Alzheimer's disease: insights from amyloid-beta metabolism beyond the brain. Nat Rev Neurol 2017; 13: 612&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.111</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29089479</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Earliest accumulation of &#x3b2;-amyloid occurs within the default-mode network and concurrently affects brain connectivity.</ArticleTitle><Pagination><StartPage>1214</StartPage><MedlinePgn>1214</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1214</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-017-01150-x</ELocationID><Abstract><AbstractText>It is not known exactly where amyloid-&#x3b2; (A&#x3b2;) fibrils begin to accumulate in individuals with Alzheimer's disease (AD). Recently, we showed that abnormal levels of A&#x3b2;42 in cerebrospinal fluid (CSF) can be detected before abnormal amyloid can be detected using PET in individuals with preclinical AD. Using these approaches, here we identify the earliest preclinical AD stage in subjects from the ADNI and BioFINDER cohorts. We show that A&#x3b2; accumulation preferentially starts in the precuneus, medial orbitofrontal, and posterior cingulate cortices, i.e., several of the core regions of the default mode network (DMN). This early pattern of A&#x3b2; accumulation is already evident in individuals with normal A&#x3b2;42 in the CSF and normal amyloid PET who subsequently convert to having abnormal CSF A&#x3b2;42. The earliest A&#x3b2; accumulation is further associated with hypoconnectivity within the DMN and between the DMN and the frontoparietal network, but not with brain atrophy or glucose hypometabolism. Our results suggest that A&#x3b2; fibrils start to accumulate predominantly within certain parts of the DMN in preclinical AD and already then affect brain connectivity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden. sebastian.palmqvist@med.lu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden. sebastian.palmqvist@med.lu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xf6;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7800-1781</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine and the Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Olof</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemstry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemstry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden. oskar.hansson@med.lu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden. oskar.hansson@med.lu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>S.P., M.S., O.S., N.M., and E.S. report no competing financial interests. K.B. has served as a consultant or at advisory boards for Alzheon, Eli Lilly, Fujirebio Europe, I.B.L. International, Novartis, and Roche Diagnostics. K.B. and H.Z. are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. S.L. has consulted for Biogen, Synarc, and Genentech. W.J. serves as a consultant to Bioclinica, Genentech, and Novartis pharmaceuticals. O.H. has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun and in the past 2 years, he has received consultancy or speaker fees (paid to the institution) from Lilly, Roche, and Fujirebio. <sup>18</sup>F-flutemetamol was generously provided by GE Healthcare in the BioFINDER study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29089479</ArticleId><ArticleId IdType="pmc">PMC5663717</ArticleId><ArticleId IdType="doi">10.1038/s41467-017-01150-x</ArticleId><ArticleId IdType="pii">10.1038/s41467-017-01150-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack, C. R. Jr. et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207&#x2013;216, (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer&#x2019;s disease: implications for prevention trials. Neuron. 2014;84:608&#x2013;622. doi: 10.1016/j.neuron.2014.10.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.10.038</ArticleId><ArticleId IdType="pmc">PMC4285623</ArticleId><ArticleId IdType="pubmed">25442939</ArticleId></ArticleIdList></Reference><Reference><Citation>Suva D, et al. Primary motor cortex involvement in Alzheimer disease. J Neuropathol. Exp. Neurol. 1999;58:1125&#x2013;1134. doi: 10.1097/00005072-199911000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199911000-00002</ArticleId><ArticleId IdType="pubmed">10560655</ArticleId></ArticleIdList></Reference><Reference><Citation>Villain N, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer&#x2019;s disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135:2126&#x2013;2139. doi: 10.1093/brain/aws125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws125</ArticleId><ArticleId IdType="pubmed">22628162</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;1800. doi: 10.1212/WNL.58.12.1791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.12.1791</ArticleId><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TL, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA. 2013;110:E4502&#x2013;4509. doi: 10.1073/pnas.1317918110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1317918110</ArticleId><ArticleId IdType="pmc">PMC3839740</ArticleId><ArticleId IdType="pubmed">24194552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N. Engl. J. Med. 2012;367:795&#x2013;804. doi: 10.1056/NEJMoa1202753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012;2:a006221. doi: 10.1101/cshperspect.a006221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006221</ArticleId><ArticleId IdType="pmc">PMC3426814</ArticleId><ArticleId IdType="pubmed">22951438</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer&#x2019;s disease. EMBO Mol. Med. 2009;1:371&#x2013;380. doi: 10.1002/emmm.200900048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.200900048</ArticleId><ArticleId IdType="pmc">PMC2806678</ArticleId><ArticleId IdType="pubmed">20049742</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, et al. Independent information from cerebrospinal fluid &#x3b2;-amyloid and florbetapir imaging in Alzheimer&#x2019;s disease. Brain. 2014;138:772&#x2013;783. doi: 10.1093/brain/awu367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu367</ArticleId><ArticleId IdType="pmc">PMC4339769</ArticleId><ArticleId IdType="pubmed">25541191</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 2010;67:122&#x2013;131. doi: 10.1002/ana.21843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21843</ArticleId><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Mattsson N, Hansson O, Alzheimer&#x2019;s Disease Neuroimaging Initiative Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain. 2016;139:1226&#x2013;1236. doi: 10.1093/brain/aww015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww015</ArticleId><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, et al. Predicting reduction of cerebrospinal fluid beta-amyloid 42 in cognitively healthy controls. JAMA Neurol. 2015;72:554&#x2013;560. doi: 10.1001/jamaneurol.2014.4530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.4530</ArticleId><ArticleId IdType="pubmed">25775167</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, et al. Emerging beta-amyloid pathology and accelerated cortical atrophy. JAMA Neurol. 2014;71:725&#x2013;734. doi: 10.1001/jamaneurol.2014.446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.446</ArticleId><ArticleId IdType="pmc">PMC4410966</ArticleId><ArticleId IdType="pubmed">24781145</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo BT, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J. Neurophysiol. 2011;106:1125&#x2013;1165. doi: 10.1152/jn.00338.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00338.2011</ArticleId><ArticleId IdType="pmc">PMC3174820</ArticleId><ArticleId IdType="pubmed">21653723</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann. Neurol. 2011;69:181&#x2013;192. doi: 10.1002/ana.22248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22248</ArticleId><ArticleId IdType="pmc">PMC3045039</ArticleId><ArticleId IdType="pubmed">21280088</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138:2020&#x2013;2033. doi: 10.1093/brain/awv112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv112</ArticleId><ArticleId IdType="pmc">PMC4806716</ArticleId><ArticleId IdType="pubmed">25953778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann. Neurol. 2016;80:247&#x2013;258. doi: 10.1002/ana.24711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24711</ArticleId><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews-Hanna JR, Smallwood J, Spreng RN. The default network and self-generated thought: component processes, dynamic control, and clinical relevance. Ann. N. Y. Acad. Sci. 2014;1316:29&#x2013;52. doi: 10.1111/nyas.12360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.12360</ArticleId><ArticleId IdType="pmc">PMC4039623</ArticleId><ArticleId IdType="pubmed">24502540</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, et al. Persistent default-mode network connectivity during light sedation. Hum. Brain Mapp. 2008;29:839&#x2013;847. doi: 10.1002/hbm.20537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.20537</ArticleId><ArticleId IdType="pmc">PMC2580760</ArticleId><ArticleId IdType="pubmed">18219620</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME. The brain&#x2019;s default mode network. Annu. Rev. Neurosci. 2015;38:433&#x2013;447. doi: 10.1146/annurev-neuro-071013-014030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-071013-014030</ArticleId><ArticleId IdType="pubmed">25938726</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Molecular, structural, and functional characterization of Alzheimer&#x2019;s disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 2005;25:7709&#x2013;7717. doi: 10.1523/JNEUROSCI.2177-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2177-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188. doi: 10.1016/j.neuron.2009.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.07.003</ArticleId><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers N, et al. Within-patient correspondence of amyloid-beta and intrinsic network connectivity in Alzheimer&#x2019;s disease. Brain. 2014;137:2052&#x2013;2064. doi: 10.1093/brain/awu103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu103</ArticleId><ArticleId IdType="pmc">PMC4065018</ArticleId><ArticleId IdType="pubmed">24771519</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, Sabuncu MR, Becker A, Sperling R, Johnson KA. In vivo characterization of the early states of the amyloid-beta network. Brain. 2013;136:2239&#x2013;2252. doi: 10.1093/brain/awt146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt146</ArticleId><ArticleId IdType="pmc">PMC3692037</ArticleId><ArticleId IdType="pubmed">23801740</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42&#x2013;51. doi: 10.1016/j.neuron.2008.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.02.003</ArticleId><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, et al. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937. doi: 10.1016/S0896-6273(03)00124-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00124-7</ArticleId><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, et al. Neuronal activity and secreted amyloid beta lead to altered amyloid beta precursor protein and presenilin 1 interactions. Neurobiol. Dis. 2013;50:127&#x2013;134. doi: 10.1016/j.nbd.2012.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.10.002</ArticleId><ArticleId IdType="pmc">PMC3534898</ArticleId><ArticleId IdType="pubmed">23064434</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann M, et al. Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA. 2013;110:11606&#x2013;11611. doi: 10.1073/pnas.1221536110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1221536110</ArticleId><ArticleId IdType="pmc">PMC3710820</ArticleId><ArticleId IdType="pubmed">23798398</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer&#x2019;s disease. J. Neurosci. 2009;29:1860&#x2013;1873. doi: 10.1523/JNEUROSCI.5062-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5062-08.2009</ArticleId><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Elman JA, et al. Effects of beta-amyloid on resting state functional connectivity within and between networks reflect known patterns of regional vulnerability. Cereb. Cortex. 2016;26:695&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4712800</ArticleId><ArticleId IdType="pubmed">25405944</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch K, et al. Disrupted intrinsic networks link amyloid-beta pathology and impaired cognition in prodromal Alzheimer&#x2019;s disease. Cereb. Cortex. 2015;25:4678&#x2013;4688. doi: 10.1093/cercor/bhu151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhu151</ArticleId><ArticleId IdType="pmc">PMC4635914</ArticleId><ArticleId IdType="pubmed">24996404</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat. Neurosci. 2011;14:750&#x2013;756. doi: 10.1038/nn.2801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2801</ArticleId><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, et al. Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA. 2012;109:8740&#x2013;8745. doi: 10.1073/pnas.1206171109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206171109</ArticleId><ArticleId IdType="pmc">PMC3365221</ArticleId><ArticleId IdType="pubmed">22592800</ArticleId></ArticleIdList></Reference><Reference><Citation>Augutis K, et al. Cerebrospinal fluid biomarkers of beta-amyloid metabolism in multiple sclerosis. Mult. Scler. 2013;19:543&#x2013;552. doi: 10.1177/1352458512460603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458512460603</ArticleId><ArticleId IdType="pubmed">23069872</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult. Scler. 2009;15:448&#x2013;454. doi: 10.1177/1352458508100031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458508100031</ArticleId><ArticleId IdType="pubmed">19153172</ArticleId></ArticleIdList></Reference><Reference><Citation>van Westen D, et al. Cerebral white matter lesions - associations with Abeta isoforms and amyloid PET. Sci. Rep. 2016;6:20709. doi: 10.1038/srep20709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep20709</ArticleId><ArticleId IdType="pmc">PMC4746584</ArticleId><ArticleId IdType="pubmed">26856756</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl, M. et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology79, 229&#x2013;236, (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22700814</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberghe R, Adamczuk K, Dupont P, Laere KV, Chetelat G. Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer&#x2019;s disease. Neuroimage Clin. 2013;2:497&#x2013;511. doi: 10.1016/j.nicl.2013.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2013.03.014</ArticleId><ArticleId IdType="pmc">PMC3777773</ArticleId><ArticleId IdType="pubmed">24179802</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehlin D, et al. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer&#x2019;s disease. Nat. Commun. 2016;7:10759. doi: 10.1038/ncomms10759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10759</ArticleId><ArticleId IdType="pmc">PMC4762893</ArticleId><ArticleId IdType="pubmed">26892305</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1&#x2013;15.e4. doi: 10.1016/j.jalz.2014.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.07.003</ArticleId><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangen KJ, et al. Cortical amyloid burden differences across empirically-derived mild cognitive impairment subtypes and interaction with APOE varepsilon4 genotype. J. Alzheimers Dis. 2016;52:849&#x2013;861. doi: 10.3233/JAD-150900.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150900</ArticleId><ArticleId IdType="pmc">PMC4884141</ArticleId><ArticleId IdType="pubmed">27031472</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmonds EC, et al. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimers Dement. 2015;11:415&#x2013;424. doi: 10.1016/j.jalz.2014.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.03.005</ArticleId><ArticleId IdType="pmc">PMC4241187</ArticleId><ArticleId IdType="pubmed">24857234</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmonds EC, et al. Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. J. Int. Neuropsychol. Soc. 2014;20:836&#x2013;847. doi: 10.1017/S135561771400068X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S135561771400068X</ArticleId><ArticleId IdType="pmc">PMC4172502</ArticleId><ArticleId IdType="pubmed">25156329</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12:189&#x2013;198. doi: 10.1016/0022-3956(75)90026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414. doi: 10.1212/WNL.43.11.2412-a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.11.2412-a</ArticleId><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): MRI methods. J. Magn. Reson. Imaging. 2008;27:685&#x2013;691. doi: 10.1002/jmri.21049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.21049</ArticleId><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, et al. Measurement of longitudinal beta-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J. Nucl. Med. 2015;56:567&#x2013;574. doi: 10.2967/jnumed.114.148981.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.114.148981</ArticleId><ArticleId IdType="pmc">PMC5313473</ArticleId><ArticleId IdType="pubmed">25745095</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen JM, et al. Empirical derivation of the reference region for computing diagnostic sensitive (1)(8)fluorodeoxyglucose ratios in Alzheimer&#x2019;s disease based on the ADNI sample. Biochim. Biophys. Acta. 2012;1822:457&#x2013;466. doi: 10.1016/j.bbadis.2011.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2011.09.008</ArticleId><ArticleId IdType="pmc">PMC5849233</ArticleId><ArticleId IdType="pubmed">21958592</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J. Nucl. Med. 1998;39:904&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Fischl B. Atlas renormalization for improved brain MR image segmentation across scanner platforms. IEEE Trans. Med. Imaging. 2007;26:479&#x2013;486. doi: 10.1109/TMI.2007.893282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TMI.2007.893282</ArticleId><ArticleId IdType="pubmed">17427735</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabner, G., Janke, A. L., Budge, M. M., Smith, D., Pruessner, J., &amp; Collins, D. L. in Medical Image Computing and Computer-Assisted Intervention -- MICCAI 2006: 9th International Conference, Copenhagen, Denmark, October 1-6, 2006. Proceedings, Part II. (eds Larsen, R., Nielsen, M. &amp; Sporring J.) 58&#x2013;66 (Berlin, Heidelberg, Springer, 2006).</Citation></Reference><Reference><Citation>Avants BB, et al. The Insight ToolKit image registration framework. Front. Neuroinform. 2014;8:44. doi: 10.3389/fninf.2014.00044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fninf.2014.00044</ArticleId><ArticleId IdType="pmc">PMC4009425</ArticleId><ArticleId IdType="pubmed">24817849</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas BA, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer&#x2019;s disease. Eur. J. Nucl. Med. Mol. Imaging. 2011;38:1104&#x2013;1119. doi: 10.1007/s00259-011-1745-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-011-1745-9</ArticleId><ArticleId IdType="pubmed">21336694</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson A, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 2009;51:336&#x2013;345. doi: 10.1373/clinchem.2004.039347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2004.039347</ArticleId><ArticleId IdType="pubmed">15563479</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann. Neurol. 2009;65:403&#x2013;413. doi: 10.1002/ana.21610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21610</ArticleId><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>De Meyer G, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol. 2010;67:949&#x2013;956. doi: 10.1001/archneurol.2010.179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.179</ArticleId><ArticleId IdType="pmc">PMC2963067</ArticleId><ArticleId IdType="pubmed">20697045</ArticleId></ArticleIdList></Reference><Reference><Citation>Weigand SD, et al. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid. Alzheimers Dement. 2011;7:133&#x2013;141. doi: 10.1016/j.jalz.2010.08.230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.08.230</ArticleId><ArticleId IdType="pmc">PMC3060961</ArticleId><ArticleId IdType="pubmed">21282074</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71:1282&#x2013;1289. doi: 10.1001/jamaneurol.2014.1358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1358</ArticleId><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, et al. Nonlinear association between cerebrospinal fluid and florbetapir F-18 beta-amyloid measures across the spectrum of Alzheimer disease. JAMA Neurol. 2015;72:571&#x2013;581. doi: 10.1001/jamaneurol.2014.4829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.4829</ArticleId><ArticleId IdType="pmc">PMC5642905</ArticleId><ArticleId IdType="pubmed">25822737</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer&#x2019;s disease. Neurology. 2015;85:1240&#x2013;1249. doi: 10.1212/WNL.0000000000001991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001991</ArticleId><ArticleId IdType="pmc">PMC4607601</ArticleId><ArticleId IdType="pubmed">26354982</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL. NeuroImage. 2012;62:782&#x2013;790. doi: 10.1016/j.neuroimage.2011.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.09.015</ArticleId><ArticleId IdType="pubmed">21979382</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput. Biomed. Res. 1996;29:162&#x2013;173. doi: 10.1006/cbmr.1996.0014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cbmr.1996.0014</ArticleId><ArticleId IdType="pubmed">8812068</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants BB, et al. The Insight ToolKit image registration framework. Front. Neuroinform. 2014;8:44. doi: 10.3389/fninf.2014.00044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fninf.2014.00044</ArticleId><ArticleId IdType="pmc">PMC4009425</ArticleId><ArticleId IdType="pubmed">24817849</ArticleId></ArticleIdList></Reference><Reference><Citation>Behzadi Y, Restom K, Liau J, Liu TT. A component based noise correction method (CompCor) for BOLD and perfusion based fMRI. NeuroImage. 2007;37:90&#x2013;101. doi: 10.1016/j.neuroimage.2007.04.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2007.04.042</ArticleId><ArticleId IdType="pmc">PMC2214855</ArticleId><ArticleId IdType="pubmed">17560126</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston KJ, Williams S, Howard R, Frackowiak RSJ. Movement-related effects in fMRI time-series. Magn. Reson. Med. 1996;35:346&#x2013;55. doi: 10.1002/mrm.1910350312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrm.1910350312</ArticleId><ArticleId IdType="pubmed">8699946</ArticleId></ArticleIdList></Reference><Reference><Citation>Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. NeuroImage. 2012;59:2142&#x2013;2154. doi: 10.1016/j.neuroimage.2011.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.10.018</ArticleId><ArticleId IdType="pmc">PMC3254728</ArticleId><ArticleId IdType="pubmed">22019881</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston KJ, Williams S, Howard R, Frackowiak RS, Turner R. Movement-related effects in fMRI time-series. Magn. Reson. Med. 1996;35:346&#x2013;355. doi: 10.1002/mrm.1910350312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrm.1910350312</ArticleId><ArticleId IdType="pubmed">8699946</ArticleId></ArticleIdList></Reference><Reference><Citation>He H, Liu TT. A geometric view of global signal confounds in resting-state functional MRI. NeuroImage. 2012;59:2339&#x2013;2348. doi: 10.1016/j.neuroimage.2011.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.09.018</ArticleId><ArticleId IdType="pmc">PMC3254803</ArticleId><ArticleId IdType="pubmed">21982929</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo BTT, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J. Neurophysiol. 2011;106:1125&#x2013;1165. doi: 10.1152/jn.00338.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00338.2011</ArticleId><ArticleId IdType="pmc">PMC3174820</ArticleId><ArticleId IdType="pubmed">21653723</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage. 2006;31:968&#x2013;980. doi: 10.1016/j.neuroimage.2006.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.01.021</ArticleId><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalesky A, Fornito A, Bullmore ET. Network-based statistic: identifying differences in brain networks. NeuroImage. 2010;53:1197&#x2013;1207. doi: 10.1016/j.neuroimage.2010.06.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2010.06.041</ArticleId><ArticleId IdType="pubmed">20600983</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg J. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 1995;57:289&#x2013;300.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29093073</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>22</Issue><PubDate><Year>2017</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study.</ArticleTitle><Pagination><StartPage>2262</StartPage><EndPage>2270</EndPage><MedlinePgn>2262-2270</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000004688</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To clarify the temporal relationship between systemic inflammation and neurodegeneration, we examined whether a higher level of circulating inflammatory markers during midlife was associated with smaller brain volumes in late life using a large biracial prospective cohort study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Plasma levels of systemic inflammatory markers (fibrinogen, albumin, white blood cell count, von Willebrand factor, and Factor VIII) were assessed at baseline in 1,633 participants (mean age 53 [5] years, 60% female, 27% African American) enrolled in the Atherosclerosis Risk in Communities Study. Using all 5 inflammatory markers, an inflammation composite score was created for each participant. We assessed episodic memory and regional brain volumes, using 3T MRI, 24 years later.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Each SD increase in midlife inflammation composite score was associated with 1,788 mm<sup>3</sup> greater ventricular (<i>p</i> = 0.013), 110 mm<sup>3</sup> smaller hippocampal (<i>p</i> = 0.013), 519 mm<sup>3</sup> smaller occipital (<i>p</i> = 0.009), and 532 mm<sup>3</sup> smaller Alzheimer disease signature region (<i>p</i> = 0.008) volumes, and reduced episodic memory (<i>p</i> = 0.046) 24 years later. Compared to participants with no elevated (4th quartile) midlife inflammatory markers, participants with elevations in 3 or more markers had, on average, 5% smaller hippocampal and Alzheimer disease signature region volumes. The association between midlife inflammation and late-life brain volume was modified by age and race, whereby younger participants and white participants with higher levels of systemic inflammation during midlife were more likely to show reduced brain volumes subsequently.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our prospective findings provide evidence for what may be an early contributory role of systemic inflammation in neurodegeneration and cognitive aging.</AbstractText><CopyrightInformation>&#xa9; 2017 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Keenan A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G.), Johns Hopkins University School of Medicine, Baltimore, MD; Section of Cardiology (R.C.H., C.M.B.), Baylor College of Medicine; Center for Cardiovascular Disease Prevention (R.C.H., C.M.B.), Houston Methodist DeBakey Heart and Vascular Center, TX; Division of Epidemiology and Community Health (A.R.F.), School of Public Health, University of Minnesota, Minneapolis; Departments of Neurology (D.S.K.) and Radiology (C.R.J.), Mayo Clinic, Rochester, MN; and Department of Medicine (B.G.W.), University of Mississippi Medical Center, Jackson. Kwalke26@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoogeveen</LastName><ForeName>Ron C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G.), Johns Hopkins University School of Medicine, Baltimore, MD; Section of Cardiology (R.C.H., C.M.B.), Baylor College of Medicine; Center for Cardiovascular Disease Prevention (R.C.H., C.M.B.), Houston Methodist DeBakey Heart and Vascular Center, TX; Division of Epidemiology and Community Health (A.R.F.), School of Public Health, University of Minnesota, Minneapolis; Departments of Neurology (D.S.K.) and Radiology (C.R.J.), Mayo Clinic, Rochester, MN; and Department of Medicine (B.G.W.), University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Folsom</LastName><ForeName>Aaron R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G.), Johns Hopkins University School of Medicine, Baltimore, MD; Section of Cardiology (R.C.H., C.M.B.), Baylor College of Medicine; Center for Cardiovascular Disease Prevention (R.C.H., C.M.B.), Houston Methodist DeBakey Heart and Vascular Center, TX; Division of Epidemiology and Community Health (A.R.F.), School of Public Health, University of Minnesota, Minneapolis; Departments of Neurology (D.S.K.) and Radiology (C.R.J.), Mayo Clinic, Rochester, MN; and Department of Medicine (B.G.W.), University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballantyne</LastName><ForeName>Christie M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G.), Johns Hopkins University School of Medicine, Baltimore, MD; Section of Cardiology (R.C.H., C.M.B.), Baylor College of Medicine; Center for Cardiovascular Disease Prevention (R.C.H., C.M.B.), Houston Methodist DeBakey Heart and Vascular Center, TX; Division of Epidemiology and Community Health (A.R.F.), School of Public Health, University of Minnesota, Minneapolis; Departments of Neurology (D.S.K.) and Radiology (C.R.J.), Mayo Clinic, Rochester, MN; and Department of Medicine (B.G.W.), University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G.), Johns Hopkins University School of Medicine, Baltimore, MD; Section of Cardiology (R.C.H., C.M.B.), Baylor College of Medicine; Center for Cardiovascular Disease Prevention (R.C.H., C.M.B.), Houston Methodist DeBakey Heart and Vascular Center, TX; Division of Epidemiology and Community Health (A.R.F.), School of Public Health, University of Minnesota, Minneapolis; Departments of Neurology (D.S.K.) and Radiology (C.R.J.), Mayo Clinic, Rochester, MN; and Department of Medicine (B.G.W.), University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windham</LastName><ForeName>B Gwen</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G.), Johns Hopkins University School of Medicine, Baltimore, MD; Section of Cardiology (R.C.H., C.M.B.), Baylor College of Medicine; Center for Cardiovascular Disease Prevention (R.C.H., C.M.B.), Houston Methodist DeBakey Heart and Vascular Center, TX; Division of Epidemiology and Community Health (A.R.F.), School of Public Health, University of Minnesota, Minneapolis; Departments of Neurology (D.S.K.) and Radiology (C.R.J.), Mayo Clinic, Rochester, MN; and Department of Medicine (B.G.W.), University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G.), Johns Hopkins University School of Medicine, Baltimore, MD; Section of Cardiology (R.C.H., C.M.B.), Baylor College of Medicine; Center for Cardiovascular Disease Prevention (R.C.H., C.M.B.), Houston Methodist DeBakey Heart and Vascular Center, TX; Division of Epidemiology and Community Health (A.R.F.), School of Public Health, University of Minnesota, Minneapolis; Departments of Neurology (D.S.K.) and Radiology (C.R.J.), Mayo Clinic, Rochester, MN; and Department of Medicine (B.G.W.), University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottesman</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G.), Johns Hopkins University School of Medicine, Baltimore, MD; Section of Cardiology (R.C.H., C.M.B.), Baylor College of Medicine; Center for Cardiovascular Disease Prevention (R.C.H., C.M.B.), Houston Methodist DeBakey Heart and Vascular Center, TX; Division of Epidemiology and Community Health (A.R.F.), School of Public Health, University of Minnesota, Minneapolis; Departments of Neurology (D.S.K.) and Radiology (C.R.J.), Mayo Clinic, Rochester, MN; and Department of Medicine (B.G.W.), University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL096812</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG027668</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096902</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096814</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096899</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG052573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-27-8</RegistryNumber><NameOfSubstance UI="D005169">Factor VIII</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-32-5</RegistryNumber><NameOfSubstance UI="D005340">Fibrinogen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neurology. 2023 Aug 22;101(8):375. doi: 10.1212/WNL.0000000000207420.</RefSource><PMID Version="1">37604669</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005169" MajorTopicYN="N">Factor VIII</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005340" MajorTopicYN="N">Fibrinogen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="N">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014841" MajorTopicYN="N">von Willebrand Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>11</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29093073</ArticleId><ArticleId IdType="pmc">PMC5705246</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004688</ArticleId><ArticleId IdType="pii">WNL.0000000000004688</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tan ZS, Beiser AS, Vasan RS, et al. . Inflammatory markers and the risk of Alzheimer disease: the Framingham study. Neurology 2007;68:1902&#x2013;1908.</Citation><ArticleIdList><ArticleId IdType="pubmed">17536046</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Ikonomovic MD, Wang X, et al. . Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann Neurol 2003;53:81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">12509851</ArticleId></ArticleIdList></Reference><Reference><Citation>Minett T, Classey J, Matthews FE, et al. . Microglial immunophenotype in dementia with Alzheimer's pathology. J Neuroinflammation 2016;13:135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4890505</ArticleId><ArticleId IdType="pubmed">27256292</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Sachdev PS, Wen W, et al. . The relationship between inflammatory markers and voxel-based gray matter volumes in nondemented older adults. Neurobiol Aging 2016;37:138&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">26559883</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferson AL, Massaro JM, Wolf PA, et al. . Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study 43. Neurology 2007;68:1032&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758770</ArticleId><ArticleId IdType="pubmed">17389308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wersching H, Duning T, Lohmann H, et al. . Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology 2010;74:1022&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">20350977</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettcher BM, Wilheim R, Rigby T, et al. . C-reactive protein is related to memory and medial temporal brain volume in older adults. Brain Behav Immun 2012;26:103&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3221922</ArticleId><ArticleId IdType="pubmed">21843630</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt MF, Freeman KB, Windham BG, et al. . Associations between serum inflammatory markers and hippocampal volume in a community sample. J Am Geriatr Soc 2016;64:1823&#x2013;1829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5026883</ArticleId><ArticleId IdType="pubmed">27549073</ArticleId></ArticleIdList></Reference><Reference><Citation>Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology 2012;78:720&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">22357713</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C, Gerardo D, James F, et al. . The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives: The ARIC Investigators. Am J Epidemiol 1989;129:687&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">2646917</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Griswold ME, Lirette ST, et al. . Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: Atherosclerosis Risk in Communities: neurocognitive study. Stroke 2015;46:433&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4308430</ArticleId><ArticleId IdType="pubmed">25563642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">9971870</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp AC, Hatzakis H, Bracey A, Wu KK. ARIC hemostasis study: I: development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 1989;61:15&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">2526384</ArticleId></ArticleIdList></Reference><Reference><Citation>Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997;96:1102&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">9286936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambless LE, McMahon R, Wu K, Folsom A, Finch A, Shen YL. Short-term intraindividual variability in hemostasis factors: The ARIC study: Atherosclerosis Risk in Communities intraindividual variability study. Ann Epidemiol 1992;2:723&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">1342324</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckfeldt JH, Chambless LE, Shen YL. Short-term, within-person variability in clinical chemistry test results: experience from the Atherosclerosis Risk in Communities Study. Arch Pathol Lab Med 1994;118:496&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">8192558</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, et al. . Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Stoub TR, Shah RC, et al. . Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011;76:1395&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087406</ArticleId><ArticleId IdType="pubmed">21490323</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider ALC, Sharrett AR, Gottesman RF, et al. . Normative data for 8 Neuropsychological tests in older blacks and whites from the Atherosclerosis Risk in Communities (ARIC) study. Alzheimer Dis Assoc Disord 2015;29:32&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206681</ArticleId><ArticleId IdType="pubmed">24759546</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Gottesman RF, Sharrett AR, et al. . Mild cognitive impairment and dementia prevalence: the Atherosclerosis Risk in Communities neurocognitive study: Alzheimer's dementia diagnosis. Assess Dis Monit 2016;2:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772876</ArticleId><ArticleId IdType="pubmed">26949733</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;gele U, H&#xe4;gele EO, Sauer G, et al. . Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. Clin Chem Lab Med 1984;22:165&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">6716056</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983;29:1075&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pubmed">6851096</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamara JR, Cohn JS, Wilson PWF, Schaefer EJ. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem 1990;36:36&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">2297935</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Baron JC. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage 2003;18:525&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">12595205</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Albert M, et al. . Midlife hypertension and 20-year cognitive change. JAMA Neurol 2014;71:1218&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226067</ArticleId><ArticleId IdType="pubmed">25090106</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala EL, H&#xe4;nninen T, et al. . Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001;56:1683&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425934</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawlings AM, Sharrett AR, Schneider ALC, et al. . Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med 2014;161:785&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432464</ArticleId><ArticleId IdType="pubmed">25437406</ArticleId></ArticleIdList></Reference><Reference><Citation>Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 2013;9:25&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">23183882</ArticleId></ArticleIdList></Reference><Reference><Citation>Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. Circulation 2005;111:1233&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">15769763</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Cupples LA, Go R, et al. . Risk of dementia among white and African American relatives of patients with Alzheimer disease. J Am Med Assoc 2002;287:329&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790212</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurgens HA, Johnson RW. Dysregulated neuronal-microglial cross-talk during aging, stress and inflammation. Exp Neurol 2012;233:40&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071456</ArticleId><ArticleId IdType="pubmed">21110971</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix S, Feinstein D, Rivest S. The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations. Brain Pathol 1998;8:625&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098216</ArticleId><ArticleId IdType="pubmed">9804372</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston GR, Webster NR. Cytokines and the immunomodulatory function of the vagus nerve. Br J Anaesth 2009;102:453&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">19258380</ArticleId></ArticleIdList></Reference><Reference><Citation>Baune BT, Konrad C, Grotegerd D, et al. . Tumor necrosis factor gene variation predicts hippocampus volume in healthy individuals. Biol Psychiatry 2012;72:655&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">22554453</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 2005;25:9275&#x2013;9284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725757</ArticleId><ArticleId IdType="pubmed">16207887</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastre M, Walter J, Gentleman SSM, et al. . Interactions between APP secretases and inflammatory mediators. J Neuroinflammation 2008;5:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442055</ArticleId><ArticleId IdType="pubmed">18564425</ArticleId></ArticleIdList></Reference><Reference><Citation>Krstic D, Madhusudan A, Doehner J, et al. . Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation 2012;9:151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483167</ArticleId><ArticleId IdType="pubmed">22747753</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Rawlings AM, Sharrett AR, et al. . Impact of differential attrition on the association of education with cognitive change over 20 years of follow-up. Am J Epidemiol 2014;179:956&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3966720</ArticleId><ArticleId IdType="pubmed">24627572</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedman AM, van Haren NEM, Schnack HG, Kahn RS, Hulshoff Pol HE. Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. Hum Brain Mapp 2012;33:1987&#x2013;2002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870052</ArticleId><ArticleId IdType="pubmed">21915942</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29097166</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>12</Issue><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.</ArticleTitle><Pagination><StartPage>965</StartPage><EndPage>975</EndPage><MedlinePgn>965-975</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(17)30332-0</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(17)30332-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Nutrition is an important modifiable risk factor in Alzheimer's disease. Previous trials of the multinutrient Fortasyn Connect showed benefits in mild Alzheimer's disease dementia. LipiDiDiet investigated the effects of Fortasyn Connect on cognition and related measures in prodromal Alzheimer's disease. Here, we report the 24-month results of the trial.</AbstractText><AbstractText Label="METHODS">LipiDiDiet was a 24-month randomised, controlled, double-blind, parallel-group, multicentre trial (11 sites in Finland, Germany, the Netherlands, and Sweden), with optional 12-month double-blind extensions. The trial enrolled individuals with prodromal Alzheimer's disease, defined according to the International Working Group (IWG)-1 criteria. Participants were randomly assigned (1:1) to active product (125 mL once-a-day drink containing Fortasyn Connect) or control product. Randomisation was computer-generated centrally in blocks of four, stratified by site. All study personnel and participants were masked to treatment assignment. The primary endpoint was change in a neuropsychological test battery (NTB) score. Analysis was by modified intention to treat. Safety analyses included all participants who consumed at least one study product dose. This trial is registered with the Dutch Trial Register, number NTR1705.</AbstractText><AbstractText Label="FINDINGS">Between April 20, 2009, and July 3, 2013, 311 of 382 participants screened were randomly assigned to the active group (n=153) or control group (n=158). Mean change in NTB primary endpoint was -0&#xb7;028 (SD 0&#xb7;453) in the active group and -0&#xb7;108 (0&#xb7;528) in the control group; estimated mean treatment difference was 0&#xb7;098 (95% CI -0&#xb7;041 to 0&#xb7;237; p=0&#xb7;166). The decline in the control group was less than the prestudy estimate of -0&#xb7;4 during 24 months. 66 (21%) participants dropped out of the study. Serious adverse events occurred in 34 (22%) participants in the active group and 30 (19%) in control group (p=0&#xb7;487), none of which were regarded as related to the study intervention.</AbstractText><AbstractText Label="INTERPRETATION">The intervention had no significant effect on the NTB primary endpoint over 2 years in prodromal Alzheimer's disease. However, cognitive decline in this population was much lower than expected, rendering the primary endpoint inadequately powered. Group differences on secondary endpoints of disease progression measuring cognition and function and hippocampal atrophy were observed. Further study of nutritional approaches with larger sample sizes, longer duration, or a primary endpoint more sensitive in this pre-dementia population, is needed.</AbstractText><AbstractText Label="FUNDING">European Commission 7th Framework Programme.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland. Electronic address: hilkka.soininen@uef.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; Department of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Huddinge, Sweden; Clinical Trials Unit, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Pieter Jelle</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, Netherlands; Department of Neurology, Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendrix</LastName><ForeName>Suzanne B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Pentara Corporation, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivipelto</LastName><ForeName>Miia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; Department of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Huddinge, Sweden; Clinical Trials Unit, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>German Institute for Dementia Prevention (DIDP), Medical Faculty, and Department of Experimental Neurology, Saarland University, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>LipiDiDiet clinical study group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>NTR</DataBankName><AccessionNumberList><AccessionNumber>NTR1705</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000609944">Fortasyn Connect</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>25167-62-8</RegistryNumber><NameOfSubstance UI="D004281">Docosahexaenoic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>AAN7QOV9EA</RegistryNumber><NameOfSubstance UI="D015118">Eicosapentaenoic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2017 Dec;16(12):946-947. doi: 10.1016/S1474-4422(17)30372-1.</RefSource><PMID Version="1">29097165</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2017 Dec;16(12):945. doi: 10.1016/S1474-4422(17)30376-9.</RefSource><PMID Version="1">29165249</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>MMW Fortschr Med. 2018 May;160(8):31. doi: 10.1007/s15006-018-0474-4.</RefSource><PMID Version="1">29721881</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol. 2018 Sep;265(9):2162-2163. doi: 10.1007/s00415-018-9018-1.</RefSource><PMID Version="1">30132064</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004281" MajorTopicYN="N">Docosahexaenoic Acids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015118" MajorTopicYN="N">Eicosapentaenoic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Hallikainen</LastName><ForeName>Ilona</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hallikainen</LastName><ForeName>Merja</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Helisalmi</LastName><ForeName>Seppo</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lappalainen</LastName><ForeName>Tarja</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Yawu</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paajanen</LastName><ForeName>Teemu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wahlund</LastName><ForeName>Lars-Olof</ForeName><Initials>LO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freund-Levi</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andreasen</LastName><ForeName>Niels</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagman</LastName><ForeName>G&#xf6;ran</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lindblom</LastName><ForeName>Stina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fassbender</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riemenschneider</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grimm</LastName><ForeName>Marcus Ow</ForeName><Initials>MO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klees-Rollmann</LastName><ForeName>Aline</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luley</LastName><ForeName>Maxine</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyros</LastName><ForeName>Epameinondas</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schomburg</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kennel</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramelli</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fr&#xf6;lich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hausner</LastName><ForeName>Lucrezia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laske</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leyhe</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mychajliw</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koehler</LastName><ForeName>Niklas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schiekofer</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kl&#xfc;nemann</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schr&#xf6;der</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xfc;tjohann</LastName><ForeName>Dieter</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Rossum</LastName><ForeName>Ineke</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Nienke</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertens</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ten Kate</LastName><ForeName>Mara</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barkhof</LastName><ForeName>Frederik</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henselmans</LastName><ForeName>Johanna Ml</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roks</LastName><ForeName>Gerwin</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Hees</LastName><ForeName>Anneke Mj</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellison</LastName><ForeName>Noel</ForeName><Initials>N</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29097166</ArticleId><ArticleId IdType="pmc">PMC5697936</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(17)30332-0</ArticleId><ArticleId IdType="pii">S1474-4422(17)30332-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aisen PS, Andrieu S, Sampaio C. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011;76:280&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034393</ArticleId><ArticleId IdType="pubmed">21178097</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Blennow K, Breteler MM. Alzheimer's disease. Lancet. 2016;388:505&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngandu T, Lehtisalo J, Solomon A. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">25771249</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrieu S, Guyonnet S, Coley N. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16:377&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">28359749</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. Arch Neurol. 2009;66:216&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2653223</ArticleId><ArticleId IdType="pubmed">19204158</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AD, Smith SM, de Jager CA. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5:e12244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935890</ArticleId><ArticleId IdType="pubmed">20838622</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wijk N, Broersen LM, de Wilde MC. Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination. J Alzheimers Dis. 2014;38:459&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">23985420</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wilde MC, Hogyes E, Kiliaan AJ, Farkas T, Luiten PG, Farkas E. Dietary fatty acids alter blood pressure, behavior and brain membrane composition of hypertensive rats. Brain Res. 2003;988:9&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">14519522</ArticleId></ArticleIdList></Reference><Reference><Citation>Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, Marzloff G. Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res. 2006;1088:83&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631143</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wilde MC, Penke B, van der Beek EM, Kuipers AA, Kamphuis PJ, Broersen LM. Neuroprotective effects of a specific multi-nutrient intervention against Abeta42-induced toxicity in rats. J Alzheimers Dis. 2011;27:327&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">21811020</ArticleId></ArticleIdList></Reference><Reference><Citation>Savelkoul PJM, Merkes MMP, Jan&#xed;&#xe8;kov&#xe1; H. A specific multi-nutrient formulation enhances M1 muscarinic acetylcholine receptor responses in vitro. J Neurochem. 2012;120:631&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">22146060</ArticleId></ArticleIdList></Reference><Reference><Citation>Broersen LM, Kuipers AA, Balvers M. A specific multi-nutrient diet reduces alzheimer-like pathology in young adult AbetaPPswe/PS1dE9 mice. J Alzheimers Dis. 2013;33:177&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">22914588</ArticleId></ArticleIdList></Reference><Reference><Citation>Koivisto H, Grimm MO, Rothhaar TL. Special lipid-based diets alleviate cognitive deficits in the APPswe/PS1dE9 transgenic mouse model of Alzheimer's disease independent of brain amyloid deposition. J Nutr Biochem. 2014;25:157&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">24445040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbi V, Jansen D, Wiesmann M. Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer's disease. Neurobiol Aging. 2014;35:600&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">24210253</ArticleId></ArticleIdList></Reference><Reference><Citation>Holguin S, Martinez J, Chow C, Wurtman R. Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J. 2008;22:3938&#x2013;3946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2574024</ArticleId><ArticleId IdType="pubmed">18606862</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen D, Zerbi V, Arnoldussen IA. Effects of specific multi-nutrient enriched diets on cerebral metabolism, cognition and neuropathology in AbetaPPswe-PS1dE9 mice. PLoS One. 2013;8:e75393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3782450</ArticleId><ArticleId IdType="pubmed">24086523</ArticleId></ArticleIdList></Reference><Reference><Citation>Cansev M, van Wijk N, Turkyilmaz M, Orhan F, Sijben JWC, Broersen LM. A specific multi-nutrient enriched diet enhances hippocampal cholinergic transmission in aged rats. Neurobiol Aging. 2015;36:344&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">25146455</ArticleId></ArticleIdList></Reference><Reference><Citation>Janickova H, Rudajev V, Dolejsi E. Lipid-based diets improve muscarinic neurotransmission in the hippocampus of transgenic APPswe/PS1dE9 Mice. Curr Alzheimer Res. 2015;12:923&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">26502816</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wilde MC, Vellas B, Girault E, Yavuz AC, Sijben JW. Lower brain and blood nutrient status in Alzheimer's disease: results from meta-analyses. Alzheimers Dement. 2017;3:416&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651428</ArticleId><ArticleId IdType="pubmed">29067348</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Kamphuis PJ, verhey FRJ. Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimers Dement. 2010;6:1&#x2013;10.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">20129316</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Twisk JW, Blesa R. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis. 2012;31:225&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">22766770</ArticleId></ArticleIdList></Reference><Reference><Citation>de Waal H, Stam CJ, Lansbergen MM. The effect of Souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. PLoS One. 2014;9:e86558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903587</ArticleId><ArticleId IdType="pubmed">24475144</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah RC, Kamphuis PJ, Leurgans S. The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. Alzheimers Res Ther. 2013;5:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978853</ArticleId><ArticleId IdType="pubmed">24280255</ArticleId></ArticleIdList></Reference><Reference><Citation>Olde Rikkert MG, Verhey FR, Blesa R. Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study. J Alzheimers Dis. 2015;44:471&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">25322923</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J, Scheltens P, McKeith I. Effect size analyses of Souvenaid in patients with Alzheimer's disease. J Alzheimers Dis. 2017;55:1131&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5147481</ArticleId><ArticleId IdType="pubmed">27767993</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007;64:1323&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846273</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamel R, Kohler S, Sistermans N. The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study. Psychol Med. 2015;45:1509&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pubmed">25407094</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis KA, Szoeke C, Bush AI. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) Int Psychogeriatr. 2014;26:543&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">24252258</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphuis PJ, Verhey FR, Olde Rikkert MG, Twisk JW, Swinkels SH, Scheltens P. Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging. 2011;15:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">21968871</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellas B, Bateman R, Blennow K. Endpoints for pre-dementia AD trials: a report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis. 2015;2:128&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4523051</ArticleId><ArticleId IdType="pubmed">26247004</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 2008;7:436&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">18420157</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research  Guidance for industry, Alzheimer's Disease: developing drugs for the treatment of early stage disease, draft guidance. 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf (accessed Dec 20, 2016).</Citation></Reference><Reference><Citation>European Medicines Agency  Draft guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. Jan 28, 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/02/WC500200830.pdf (accessed Dec 20, 2016).</Citation></Reference><Reference><Citation>Vos SJ, Verhey F, Frolich L. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain. 2015;138:1327&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5013930</ArticleId><ArticleId IdType="pubmed">25693589</ArticleId></ArticleIdList></Reference><Reference><Citation>Coric V, Salloway S, van Dyck CH. Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol. 2015;72:1324&#x2013;1333.</Citation><ArticleIdList><ArticleId IdType="pubmed">26414022</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29113975</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>G-quadruplex-binding small molecules ameliorate <i>C9orf72</i> FTD/ALS pathology <i>in&#xa0;vitro</i> and <i>in&#xa0;vivo</i>.</ArticleTitle><Pagination><StartPage>22</StartPage><EndPage>31</EndPage><MedlinePgn>22-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.201707850</ELocationID><Abstract><AbstractText>Intronic GGGGCC repeat expansions in <i>C9orf72</i> are the most common known cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), which are characterised by degeneration of cortical and motor neurons, respectively. Repeat expansions have been proposed to cause disease by both the repeat RNA forming foci that sequester RNA-binding proteins and through toxic dipeptide repeat proteins generated by repeat-associated non-ATG translation. GGGGCC repeat RNA folds into a G-quadruplex secondary structure, and we investigated whether targeting this structure is a potential therapeutic strategy. We performed a screen that identified three structurally related small molecules that specifically stabilise GGGGCC repeat G-quadruplex RNA We investigated their effect in <i>C9orf72</i> patient iPSC-derived motor and cortical neurons and show that they significantly reduce RNA foci burden and the levels of dipeptide repeat proteins. Furthermore, they also reduce dipeptide repeat proteins and improve survival <i>in&#xa0;vivo</i>, in GGGGCC repeat-expressing <i>Drosophila</i> Therefore, small molecules that target GGGGCC repeat G-quadruplexes can ameliorate the two key pathologies associated with <i>C9orf72</i> FTD/ALS These data provide proof of principle that&#xa0;targeting GGGGCC repeat G-quadruplexes has therapeutic potential.</AbstractText><CopyrightInformation>&#xa9; 2017 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simone</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balendra</LastName><ForeName>Rubika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moens</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preza</LastName><ForeName>Elisavet</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Katherine M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heslegrave</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodling</LastName><ForeName>Nathan S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niccoli</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert-Jaramillo</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelkarim</LastName><ForeName>Samir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MRC Centre for Neuromuscular Disease UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clayton</LastName><ForeName>Emma L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Mica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konrad</LastName><ForeName>Marie-Therese</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicoll</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Prion Unit at UCL Institute of Prion Diseases, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Jamie S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, ALS Centre University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chio</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, ALS Centre University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houlden</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polke</LastName><ForeName>James M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Neurogenetics Unit UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Mohamed A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Georgia State University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>Chad E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Georgia State University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vo</LastName><ForeName>Tam</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Georgia State University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farahat</LastName><ForeName>Abdelbasset A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Georgia State University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>W David</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Georgia State University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boykin</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Georgia State University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory Institute of Neuroscience and Physiology Department of Psychiatry and Neurochemistry The Sahlgrenska Academy University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Partridge</LastName><ForeName>Linda</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9615-0094</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max Planck Institute for Biology of Ageing, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wray</LastName><ForeName>Selina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parkinson</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>UCL School of Pharmacy, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neidle</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0622-6548</Identifier><AffiliationInfo><Affiliation>UCL School of Pharmacy, London, UK s.neidle@ucl.ac.uk rickie.patani@ucl.ac.uk p.fratta@ucl.ac.uk a.isaacs@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patani</LastName><ForeName>Rickie</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3825-7675</Identifier><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK s.neidle@ucl.ac.uk rickie.patani@ucl.ac.uk p.fratta@ucl.ac.uk a.isaacs@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratta</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8762-8188</Identifier><AffiliationInfo><Affiliation>MRC Centre for Neuromuscular Disease UCL Institute of Neurology, London, UK s.neidle@ucl.ac.uk rickie.patani@ucl.ac.uk p.fratta@ucl.ac.uk a.isaacs@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isaacs</LastName><ForeName>Adrian M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-6820-5534</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK s.neidle@ucl.ac.uk rickie.patani@ucl.ac.uk p.fratta@ucl.ac.uk a.isaacs@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M008606/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>FRATTA/JAN15/946-795</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>107196/Z/14/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>101149/Z/13/A</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 GM111749</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ISAACS/APR13/818-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>EMBO Mol Med. 2018 Jan;10(1):4-6. doi: 10.15252/emmm.201708572.</RefSource><PMID Version="1">29175945</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="Y">Drug Discovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054856" MajorTopicYN="N">G-Quadruplexes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012091" MajorTopicYN="N">Repetitive Sequences, Nucleic Acid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">G&#x2010;quadruplex</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29113975</ArticleId><ArticleId IdType="pmc">PMC5760849</ArticleId><ArticleId IdType="doi">10.15252/emmm.201707850</ArticleId><ArticleId IdType="pii">emmm.201707850</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus&#x2010;Hernandez M, van Blitterswijk MM, Jansen&#x2010;West K, Paul JW III, Rademakers R et&#xa0;al (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77: 639&#x2013;646</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, Campbell T, Uphill J, Borg A, Fratta P et&#xa0;al (2013) Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet 92: 345&#x2013;353</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3591848</ArticleId><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi G, Di Antonio M, Tannahill D, Balasubramanian S (2014) Visualization and selective chemical targeting of RNA G&#x2010;quadruplex structures in the cytoplasm of human cells. Nat Chem 6: 75&#x2013;80</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4081541</ArticleId><ArticleId IdType="pubmed">24345950</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Dejesus&#x2010;Hernandez M, Niemantsverdriet E, Murray ME, Heckman MG, Diehl NN, Brown PH, Baker MC, Finch NA, Bauer PO et&#xa0;al (2013) Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize&#x2010;72): a cross&#x2010;sectional cohort study. Lancet Neurol 12: 978&#x2013;988</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3879782</ArticleId><ArticleId IdType="pubmed">24011653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugaut A, Balasubramanian S (2012) 5&#x2019;&#x2010;UTR RNA G&#x2010;quadruplexes: translation regulation and targeting. Nucleic Acids Res 40: 4727&#x2013;4741</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367173</ArticleId><ArticleId IdType="pubmed">22351747</ArticleId></ArticleIdList></Reference><Reference><Citation>Collie GW, Promontorio R, Hampel SM, Micco M, Neidle S, Parkinson GN (2012) Structural basis for telomeric G&#x2010;quadruplex targeting by naphthalene diimide ligands. J Am Chem Soc 134: 2723&#x2013;2731</Citation><ArticleIdList><ArticleId IdType="pubmed">22280460</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon EG, Lu L, Sharma A, Yamazaki T, Tang T, Shneider NA, Manley JL (2016) The C9ORF72 GGGGCC expansion forms RNA G&#x2010;quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. Elife 5: e17820</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5050020</ArticleId><ArticleId IdType="pubmed">27623008</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejesus&#x2010;Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J et&#xa0;al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2010;Linked FTD and ALS. Neuron 72: 245&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Antonio M, Biffi G, Mariani A, Raiber EA, Rodriguez R, Balasubramanian S (2012) Selective RNA versus DNA G&#x2010;quadruplex targeting by in&#xa0;situ click chemistry. Angew Chem Int Ed Engl 51: 11073&#x2013;11078</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3652031</ArticleId><ArticleId IdType="pubmed">23038154</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Mizielinska S, Nicoll AJ, Zloh M, Fisher EM, Parkinson G, Isaacs AM (2012) C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms RNA G&#x2010;quadruplexes. Sci Rep 2: 1016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3527825</ArticleId><ArticleId IdType="pubmed">23264878</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Poulter M, Lashley T, Rohrer JD, Polke JM, Beck J, Ryan N, Hensman D, Mizielinska S, Waite AJ et&#xa0;al (2013) Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol 126: 401&#x2013;409</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753468</ArticleId><ArticleId IdType="pubmed">23818065</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Bieniek KF, Zhang YJ, Jansen&#x2010;West K, Ash PE, Caulfield T, Daughrity L, Dunmore JH, Castanedes&#x2010;Casey M, Chew J et&#xa0;al (2013) Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat&#x2010;associated non&#x2010;ATG translation in c9FTD/ALS. Acta Neuropathol 126: 829&#x2013;844</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlomagno Y, Daughrity LM, Jansen&#x2010;West K, Perkerson EA et&#xa0;al (2017) Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72&#x2010;associated amyotrophic lateral sclerosis. Sci Transl Med 9: eaai7866</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JU, Bartel DP (2016) RNA G&#x2010;quadruplexes are globally unfolded in eukaryotic cells and depleted in bacteria. Science 353: aaf5371</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5367264</ArticleId><ArticleId IdType="pubmed">27708011</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyen B, Schultes CM, Hazel P, Mann J, Neidle S (2004) Synthesis and evaluation of analogues of 10H&#x2010;indolo[3,2&#x2010;b]quinoline as G&#x2010;quadruplex stabilising ligands and potential inhibitors of the enzyme telomerase. Org Biomol Chem 2: 981&#x2013;988</Citation><ArticleIdList><ArticleId IdType="pubmed">15034620</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, Simko EA, Shaw PG, Kim MS, Maragakis NJ, Troncoso JC, Pandey A, Sattler R et&#xa0;al (2014) C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 507: 195&#x2013;200</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Rothstein JD (2016) The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nat Rev Neurosci 17: 383&#x2013;395</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7376590</ArticleId><ArticleId IdType="pubmed">27150398</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall CE, Yao Z, Choi M, Tyzack GE, Serio A, Luisier R, Harley J, Preza E, Arber C, Crisp SJ et&#xa0;al (2017) Progressive motor neuron pathology and the role of astrocytes in a human stem cell model of VCP&#x2010;related ALS. Cell Rep 19: 1739&#x2013;1749</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5464993</ArticleId><ArticleId IdType="pubmed">28564594</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppert JL, Balasubramanian S (2007) G&#x2010;quadruplexes in promoters throughout the human genome. Nucleic Acids Res 35: 406&#x2013;413</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1802602</ArticleId><ArticleId IdType="pubmed">17169996</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppert JL, Bugaut A, Kumari S, Balasubramanian S (2008) G&#x2010;quadruplexes: the beginning and end of UTRs. Nucleic Acids Res 36: 6260&#x2013;6268</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577360</ArticleId><ArticleId IdType="pubmed">18832370</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier&#x2010;Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, Jiang J, Watt AT, Chun S, Katz M et&#xa0;al (2013) Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci USA 110: E4530&#x2013;E4539</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Lv C, Ding B, Wang J, Li S, Zhang Y (2014) Antitumor activity of G&#x2010;quadruplex&#x2010;interactive agent TMPyP4 with photodynamic therapy in ovarian carcinoma cells. Oncol Lett 8: 409&#x2013;413</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063630</ArticleId><ArticleId IdType="pubmed">24959286</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P, Isaacs AM (2013) C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol 126: 845&#x2013;857</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, Moens T, Norona FE, Woollacott IO, Pietrzyk J et&#xa0;al (2014) C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine&#x2010;rich proteins. Science 345: 1192&#x2013;1194</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Isaacs AM (2014) C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: gain or loss of function? Curr Opin Neurol 27: 515&#x2013;523</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4165481</ArticleId><ArticleId IdType="pubmed">25188012</ArticleId></ArticleIdList></Reference><Reference><Citation>Moens TG, Partridge L, Isaacs AM (2017) Genetic models of C9orf72: what is toxic? Curr Opin Genet Dev 44: 92&#x2013;101</Citation><ArticleIdList><ArticleId IdType="pubmed">28364657</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore MJ, Schultes CM, Cuesta J, Cuenca F, Gunaratnam M, Tanious FA, Wilson WD, Neidle S (2006) Trisubstituted acridines as G&#x2010;quadruplex telomere targeting agents. Effects of extensions of the 3,6&#x2010; and 9&#x2010;side chains on quadruplex binding, telomerase activity, and cell proliferation. J Med Chem 49: 582&#x2013;599</Citation><ArticleIdList><ArticleId IdType="pubmed">16420044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Arzberger T, Grasser FA, Gijselinck I, May S, Rentzsch K, Weng SM, Schludi MH, van der ZJ, Cruts M et&#xa0;al (2013a) Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol 126: 881&#x2013;893</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C et&#xa0;al (2013b) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide&#x2010;repeat proteins in FTLD/ALS. Science 339: 1335&#x2013;1338</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohnmacht SA, Varavipour E, Nanjunda R, Pazitna I, Di Vita G, Gunaratnam M, Kumar A, Ismail MA, Boykin DW, Wilson WD et&#xa0;al (2014) Discovery of new G&#x2010;quadruplex binding chemotypes. Chem Commun (Camb) 50: 960&#x2013;963</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3901018</ArticleId><ArticleId IdType="pubmed">24302123</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy K, Zamiri B, Stanley SY, Macgregor RB Jr, Pearson CE (2013) The disease&#x2010;associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length&#x2010;dependent uni&#x2010; and multimolecular RNA G&#x2010;quadruplex structures. J Biol Chem 288: 9860&#x2013;9866</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617286</ArticleId><ArticleId IdType="pubmed">23423380</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon&#x2010;Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L et&#xa0;al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron 72: 257&#x2013;268</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultes CM, Guyen B, Cuesta J, Neidle S (2004) Synthesis, biophysical and biological evaluation of 3,6&#x2010;bis&#x2010;amidoacridines with extended 9&#x2010;anilino substituents as potent G&#x2010;quadruplex&#x2010;binding telomerase inhibitors. Bioorg Med Chem Lett 14: 4347&#x2013;4351</Citation><ArticleIdList><ArticleId IdType="pubmed">15261300</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Kirwan P, Livesey FJ (2012) Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc 7: 1836&#x2013;1846</Citation><ArticleIdList><ArticleId IdType="pubmed">22976355</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone R, Fratta P, Neidle S, Parkinson GN, Isaacs AM (2015) G&#x2010;quadruplexes: emerging roles in neurodegenerative diseases and the non&#x2010;coding transcriptome. FEBS Lett 589: 1653&#x2013;1668</Citation><ArticleIdList><ArticleId IdType="pubmed">25979174</ArticleId></ArticleIdList></Reference><Reference><Citation>Sket P, Pohleven J, Kovanda A, Stalekar M, Zupunski V, Zalar M, Plavec J, Rogelj B (2015) Characterization of DNA G&#x2010;quadruplex species forming from C9ORF72 G4C2&#x2010;expanded repeats associated with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Neurobiol Aging 36: 1091&#x2013;1096</Citation><ArticleIdList><ArticleId IdType="pubmed">25442110</ArticleId></ArticleIdList></Reference><Reference><Citation>Sposito T, Preza E, Mahoney CJ, Seto&#x2010;Salvia N, Ryan NS, Morris HR, Arber C, Devine MJ, Houlden H, Warner TT et&#xa0;al (2015) Developmental regulation of tau splicing is disrupted in stem cell&#x2010;derived neurons from frontotemporal dementia patients with the 10 + 16 splice&#x2010;site mutation in MAPT. Hum Mol Genet 24: 5260&#x2013;5269</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550814</ArticleId><ArticleId IdType="pubmed">26136155</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, Fostvedt E, Jansen&#x2010;West K, Belzil VV, Desaro P et&#xa0;al (2014) Discovery of a biomarker and lead small molecules to target r(GGGGCC)&#x2010;associated defects in c9FTD/ALS. Neuron 83: 1043&#x2013;1050</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference><Reference><Citation>Tricoire H, Battisti V, Trannoy S, Lasbleiz C, Pret AM, Monnier V (2009) The steroid hormone receptor EcR finely modulates Drosophila lifespan during adulthood in a sex&#x2010;specific manner. Mech Ageing Dev 130: 547&#x2013;552</Citation><ArticleIdList><ArticleId IdType="pubmed">19486910</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y, Lin S, Shneider NA, Monaghan J, Pandey UB et&#xa0;al (2014) Antisense proline&#x2010;arginine RAN dipeptides linked to C9ORF72&#x2010;ALS/FTD form toxic nuclear aggregates that initiate in&#xa0;vitro and in&#xa0;vivo neuronal death. Neuron 84: 1213&#x2013;1225</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamiri B, Reddy K, Macgregor RB Jr, Pearson CE (2014) TMPyP4 porphyrin distorts RNA G&#x2010;quadruplex structures of the disease&#x2010;associated r(GGGGCC)n repeat of the C9orf72 gene and blocks interaction of RNA&#x2010;binding proteins. J Biol Chem 289: 4653&#x2013;4659</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3931028</ArticleId><ArticleId IdType="pubmed">24371143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen&#x2010;West K, Xu YF, Katzman RB, Gass J, Murray ME, Shinohara M et&#xa0;al (2016) C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat Neurosci 19: 668&#x2013;677</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Banez&#x2010;Coronel M, Reid T, Pletnikova O, Lewis J, Miller TM, Harms MB, Falchook AE, Subramony SH et&#xa0;al (2013) RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci USA 110: E4968&#x2013;E4977</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29114732</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Amyloid &#x3b2; Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.</ArticleTitle><Pagination><StartPage>88</StartPage><EndPage>96</EndPage><MedlinePgn>88-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.3029</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The prevalence of pathologic conditions of the brain associated with Alzheimer disease increases strongly with age. Little is known about the distribution and clinical significance of preclinical biomarker staging in the oldest old, when most individuals without dementia are likely to have positive biomarkers.</AbstractText><AbstractText Label="OBJECTIVE">To compare the patterns of long-term cognitive decline in multiple domains by preclinical biomarker status in the oldest old without dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">A longitudinal observational study with a mean (SD) of 12.2 (2.2) years (range 7.2-15.1 years) of follow-up was conducted in an academic medical center from August 24, 2000, to January 14, 2016, including and extending observations from the Ginkgo Evaluation of Memory study. A total of 197 adults who had completed the Ginkgo Evaluation of Memory study, were free of dementia, and were able to undergo magnetic resonance imaging were eligible for a neuroimaging study in 2009. Of these patients, 175 were included in the present analyses; 140 (80%) were cognitively normal and 35 (20%) had mild cognitive impairment.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Biomarker groups included amyloid &#x3b2; negative (A&#x3b2;-)/neurodegeneration negative (ND-), amyloid &#x3b2; positive (A&#x3b2;+)/ND-, A&#x3b2;-/neurodegeneration positive (ND+), and A&#x3b2;+/ND+ based on Pittsburgh Compound B retention and hippocampal volume in 2009. Participants completed baseline neuropsychological testing from 2000 to 2002 and annual testing from 2004 to 2016. Domains included memory, executive function, language, visual-spatial reasoning, and attention and psychomotor speed. Slopes of decline were evaluated with linear mixed models adjusted for age, sex, and years of education.</AbstractText><AbstractText Label="RESULTS">Of the 175 participants (71 women and 104 men), at imaging, mean (SD) age was 86.0 (2.9) years (range, 82-95 years). A total of 42 participants (24.0%) were A&#x3b2;-/ND-, 32 (18.3%) were A&#x3b2;+/ND-, 35 (20.0%) were A&#x3b2;-/ND+, and 66 (37.7%) were A&#x3b2;+/ND+. On all cognitive measures, the A&#x3b2;+/ND+ group showed the steepest decline. Compared with the A&#x3b2;-/ND- group, the amyloid deposition alone (A&#x3b2;+/ND-) group showed faster decline on tests of verbal and visual memory (-0.3513; 95% CI, -0.5269 to -0.1756), executive function (0.0158; 95% CI, 0.0013-0.0303), and language (-0.1934; 95% CI, -0.3520 to -0.0348). The A&#x3b2;-/ND+ group showed faster visual memory decline than the A&#x3b2;-/ND- reference group (-0.3007; 95% CI, -0.4736 to -0.1279).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In the oldest old without dementia, presence of either or both A&#x3b2; and hippocampal atrophy is typical (&gt;75%). Isolated hippocampal volume atrophy is associated only with greater decline in memory. However, isolated A&#x3b2; is associated with decline in memory plus language and executive functions. These findings suggest different underlying pathophysiologic processes in the A&#x3b2;+/ND- and A&#x3b2;-/ND+ groups.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yujing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tudorascu</LastName><ForeName>Dana L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ann D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aizenstein</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>now with the Department of Radiology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuller</LastName><ForeName>Lewis H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamboh</LastName><ForeName>M Ilyas</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Florida, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snitz</LastName><ForeName>Beth E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG024827</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG052521</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG025204</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> General Electric Healthcare holds a license agreement with the University of Pittsburgh based on the technology described in this article. Drs Mathis and Klunk are coinventors of Pittsburgh Compound B and, as such, have a financial interest in this license agreement. General Electric Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this manuscript. Dr DeKosky reported serving as a consultant for Amgen, Acumen Pharmaceuticals, Biogen, and Cognition Therapeutics. No other conflicts were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>11</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29114732</ArticleId><ArticleId IdType="pmc">PMC5833487</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.3029</ArticleId><ArticleId IdType="pii">2659477</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR Jr, Wiste HJ, Knopman DS, et al. . Rates of &#x3b2;-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology. 2014;82(18):1605-1612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4013810</ArticleId><ArticleId IdType="pubmed">24706010</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280-292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Weigand SD, et al. . An operational approach to National Institute on Aging&#x2013;Alzheimer&#x2019;s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71(6):765-775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Weiner MW, Wolk DA, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun. 2014;2:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008258</ArticleId><ArticleId IdType="pubmed">24602322</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen P, Boeve BF, et al. . Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013;74(2):199-208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804562</ArticleId><ArticleId IdType="pubmed">23686697</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroli A, Prestia A, Galluzzi S, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology. 2015;84(5):508-515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336071</ArticleId><ArticleId IdType="pubmed">25568301</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. . Synergistic effect of &#x3b2;-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71(11):1379-1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293023</ArticleId><ArticleId IdType="pubmed">25222039</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Verhey F, Fr&#xf6;lich L, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Prevalence and prognosis of Alzheimer&#x2019;s disease at the mild cognitive impairment stage. Brain. 2015;138(pt 5):1327-1338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5013930</ArticleId><ArticleId IdType="pubmed">25693589</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, et al. . Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80(19):1784-1791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Villeneuve S, Haase CM, et al. . Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol. 2013;70(12):1512-1519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962545</ArticleId><ArticleId IdType="pubmed">24166579</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Ch&#xe9;telat G, et al. . Suspected non-Alzheimer disease pathophysiology&#x2014;concept and controversy. Nat Rev Neurol. 2016;12(2):117-124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4784257</ArticleId><ArticleId IdType="pubmed">26782335</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. . Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>van Harten AC, Smits LL, Teunissen CE, et al. . Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology. 2013;81(16):1409-1416.</Citation><ArticleIdList><ArticleId IdType="pubmed">24049134</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisse LEM, Butala N, Das SR, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Suspected non-AD pathology in mild cognitive impairment. Neurobiol Aging. 2015;36(12):3152-3162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641774</ArticleId><ArticleId IdType="pubmed">26422359</ArticleId></ArticleIdList></Reference><Reference><Citation>Prestia A, Caroli A, van der Flier WM, et al. . Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology. 2013;80(11):1048-1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">23390179</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR Jr, Wiste HJ, et al. . Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012;78(20):1576-1582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348848</ArticleId><ArticleId IdType="pubmed">22551733</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldan A, Pettigrew C, Cai Q, et al. ; BIOCARD Research Team . Hypothetical preclinical Alzheimer disease groups and longitudinal cognitive change. JAMA Neurol. 2016;73(6):698-705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173327</ArticleId><ArticleId IdType="pubmed">27064267</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham SC, Bourgeat P, Dor&#xe9; V, et al. ; AIBL Research Group . Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer&#x2019;s disease pathophysiology (SNAP) or Alzheimer&#x2019;s disease pathology: a longitudinal study. Lancet Neurol. 2016;15(10):1044-1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">27450471</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Papp KV, Rentz DM, et al. . Heterogeneity in suspected non&#x2013;Alzheimer disease pathophysiology among clinically normal older individuals. JAMA Neurol. 2016;73(10):1185-1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5266522</ArticleId><ArticleId IdType="pubmed">27548655</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, et al. . Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837-1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, et al. . Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509-1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Santa Cruz K, Hemmy LS, et al. . Ecology of the aging human brain. Arch Neurol. 2011;68(8):1049-1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218566</ArticleId><ArticleId IdType="pubmed">21825242</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Williamson JD, Fitzpatrick AL, et al. ; Ginkgo Evaluation of Memory (GEM) Study Investigators . Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300(19):2253-2262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823569</ArticleId><ArticleId IdType="pubmed">19017911</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Fitzpatrick A, Ives DG, et al. ; GEMS Investigators . The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials. 2006;27(3):238-253.</Citation><ArticleIdList><ArticleId IdType="pubmed">16627007</ArticleId></ArticleIdList></Reference><Reference><Citation>Snitz BE, Weissfeld LA, Lopez OL, et al. . Cognitive trajectories associated with &#x3b2;-amyloid deposition in the oldest-old without dementia. Neurology. 2013;80(15):1378-1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3662268</ArticleId><ArticleId IdType="pubmed">23516317</ArticleId></ArticleIdList></Reference><Reference><Citation>Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th ed New York, NY: Oxford University Press; 2004.</Citation></Reference><Reference><Citation>Becker JT, Boller F, Saxton J, McGonigle-Gibson KL. Normal rates of forgetting of verbal and non-verbal material in Alzheimer&#x2019;s disease. Cortex. 1987;23(1):59-72.</Citation><ArticleIdList><ArticleId IdType="pubmed">3568706</ArticleId></ArticleIdList></Reference><Reference><Citation>Trenerry MR, Crosson B, DeBoe J, Leber WR. Stroop Neuropsychological Screening Test. Odessa, FL: Psychological Assessment Resources; 1989.</Citation></Reference><Reference><Citation>Lopez OL, Becker JT, Jagust WJ, et al. . Neuropsychological characteristics of mild cognitive impairment subgroups. J Neurol Neurosurg Psychiatry. 2006;77(2):159-165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077558</ArticleId><ArticleId IdType="pubmed">16103044</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton J, Ratcliff G, Munro CA, et al. . Normative data on the Boston Naming Test and two equivalent 30-item short forms. Clin Neuropsychol. 2000;14(4):526-534.</Citation><ArticleIdList><ArticleId IdType="pubmed">11262721</ArticleId></ArticleIdList></Reference><Reference><Citation>Fai AH-T, Cornelius PL. Approximate F-tests of multiple degree of freedom hypotheses in generalized least squares analyses of unbalanced split-plot experiments. J Stat Comput Simul. 1996;54(4):363-378.</Citation></Reference><Reference><Citation>Wirth M, Oh H, Mormino EC, Markley C, Landau SM, Jagust WJ. The effect of amyloid &#x3b2; on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimers Dement. 2013;9(6):687-698.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3823816</ArticleId><ArticleId IdType="pubmed">23474040</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Age-specific population frequencies of cerebral &#x3b2;-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 2014;13(10):997-1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324499</ArticleId><ArticleId IdType="pubmed">25201514</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351-357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz N, Lindenberger U, Rodrigue KM, et al. . Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex. 2005;15(11):1676-1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">15703252</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Dickson DW, Parisi JE, et al. . Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58(5):750-757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745935</ArticleId><ArticleId IdType="pubmed">11889239</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Jack CR Jr, Parisi JE, et al. . Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration? Neurology. 2010;75(24):2212-2220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013590</ArticleId><ArticleId IdType="pubmed">21172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR., Jr PART and SNAP. Acta Neuropathol. 2014;128(6):773-776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4231211</ArticleId><ArticleId IdType="pubmed">25380757</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paola M, Caltagirone C, Fadda L, Sabatini U, Serra L, Carlesimo GA. Hippocampal atrophy is the critical brain change in patients with hypoxic amnesia. Hippocampus. 2008;18(7):719-728.</Citation><ArticleIdList><ArticleId IdType="pubmed">18446831</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Papp KV. Cognitive decline in preclinical stage 2 Alzheimer disease and implications for prevention trials. JAMA Neurol. 2016;73(6):640-642.</Citation><ArticleIdList><ArticleId IdType="pubmed">27064971</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;ckman L, Jones S, Berger AK, Laukka EJ, Small BJ. Cognitive impairment in preclinical Alzheimer&#x2019;s disease: a meta-analysis. Neuropsychology. 2005;19(4):520-531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16060827</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton J, Lopez OL, Ratcliff G, et al. . Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology. 2004;63(12):2341-2347.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623697</ArticleId></ArticleIdList></Reference><Reference><Citation>Masur DM, Sliwinski M, Lipton RB, Blau AD, Crystal HA. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology. 1994;44(8):1427-1432.</Citation><ArticleIdList><ArticleId IdType="pubmed">8058143</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Perani D. Amyloid and neurodegeneration: converging and diverging paths. Neurology. 2013;81(20):1728-1729.</Citation><ArticleIdList><ArticleId IdType="pubmed">24132372</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, et al. . Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755-766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Blazey T, Su Y, et al. . Longitudinal &#x3b2;-amyloid deposition and hippocampal volume in preclinical Alzheimer disease and suspected non&#x2013;Alzheimer disease pathophysiology. JAMA Neurol. 2016;73(10):1192-1200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237381</ArticleId><ArticleId IdType="pubmed">27548756</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C; Medical Research Council Cognitive Function and Ageing Study . Age, neuropathology, and dementia. N Engl J Med. 2009;360(22):2302-2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Schnaider-Beeri M, Schmeidler J, et al. . Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol. 2008;65(9):1211-1217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071251</ArticleId><ArticleId IdType="pubmed">18779425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas CH, Kim RC, Sonnen JA, Bullain SS, Trieu T, Corrada MM. Multiple pathologies are common and related to dementia in the oldest-old: the 90+ Study. Neurology. 2015;85(6):535-542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4540246</ArticleId><ArticleId IdType="pubmed">26180144</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard E, Schmand B, Eikelenboom P, Westendorp RG, Van Gool WA. The Alzheimer myth and biomarker research in dementia. J Alzheimers Dis. 2012;31(suppl 3):S203-S209.</Citation><ArticleIdList><ArticleId IdType="pubmed">22810091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuller LH, Lopez OL. Dementia and Alzheimer&#x2019;s disease: a new direction: the 2010 Jay L. Foster Memorial Lecture. Alzheimers Dement. 2011;7(5):540-550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197274</ArticleId><ArticleId IdType="pubmed">21889117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Klunk WE, Mathis C, et al. . Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. Neurology. 2014;83(20):1804-1811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240431</ArticleId><ArticleId IdType="pubmed">25305156</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29086766</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Secreted &#x3b1;Klotho isoform protects against age-dependent memory deficits.</ArticleTitle><Pagination><StartPage>1937</StartPage><EndPage>1947</EndPage><MedlinePgn>1937-1947</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2017.211</ELocationID><Abstract><AbstractText>&#x3b1;Klotho is a gene regulator of aging, increasing life expectancy when overexpressed and accelerating the development of aging phenotypes when inhibited. In mice, expression levels of the secreted isoform Klotho (s-KL) are very high in the brain, suggesting that s-KL activity may have an important role in the nervous system. Here we study the functional relevance at behavioural level of modifying s-KL levels in the aging brain. We used AAVrh10 vectors to deliver and sustained expression of s-KL in 6- and 12-month-old wild-type C57BL/6J males. This study demonstrates for we believe the first time in vivo that 6 months after a single injection of s-KL into the central nervous system, long-lasting and quantifiable enhancement of learning and memory capabilities are found. More importantly, cognitive improvement is also observable in 18-month-old mice treated once, at 12 months of age. These findings demonstrate the therapeutic potential of s-KL as a treatment for cognitive decline associated with aging.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mass&#xf3;</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Universitat Aut&#xf2;noma Barcelona 5th level, Edifici H, Institut Neurociencies, Campus UAB, Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Universitat Aut&#xf2;noma Barcelona 5th level, Edifici H, Institut Neurociencies, Campus UAB, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute de Neuroci&#xe8;nces (INc), Universitat Aut&#xf2;noma Barcelona, Campus UAB, Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Universitat Aut&#xf2;noma Barcelona 5th level, Edifici H, Institut Neurociencies, Campus UAB, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute de Neuroci&#xe8;nces (INc), Universitat Aut&#xf2;noma Barcelona, Campus UAB, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre enfermedades Neurodegenerativas (CIBERNED), Instituto Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gim&#xe9;nez-Llort</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute de Neuroci&#xe8;nces (INc), Universitat Aut&#xf2;noma Barcelona, Campus UAB, Bellaterra, Spain. lidia.gimenez@uab.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Forensic Medicine, School of Medicine, Universitat Aut&#xf2;noma de Barcelona, Campus UAB, Bellaterra, Spain. lidia.gimenez@uab.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chill&#xf3;n</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Universitat Aut&#xf2;noma Barcelona 5th level, Edifici H, Institut Neurociencies, Campus UAB, Bellaterra, Spain. miguel.chillon@uab.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute de Neuroci&#xe8;nces (INc), Universitat Aut&#xf2;noma Barcelona, Campus UAB, Bellaterra, Spain. miguel.chillon@uab.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vall d'Hebron Institut de Recerca (VHIR), Research Group on Gene Therapy at Nervous System, Passeig de la Vall d'Hebron, Barcelona, Spain. miguel.chillon@uab.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituci&#xf3; Catalana de Recerca i Estudis Avan&#xe7;ats (ICREA), Barcelona, Spain. miguel.chillon@uab.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.31</RegistryNumber><NameOfSubstance UI="D005966">Glucuronidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.31</RegistryNumber><NameOfSubstance UI="D000090265">Klotho Proteins</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005966" MajorTopicYN="N">Glucuronidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090265" MajorTopicYN="N">Klotho Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29086766</ArticleId><ArticleId IdType="doi">10.1038/mp.2017.211</ArticleId><ArticleId IdType="pii">10.1038/mp.2017.211</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/36285</ArticleId><ArticleId IdType="pubmed">9363890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Sun Z. Current understanding of klotho. Ageing Res Rev 2009; 8: 43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2008.10.002</ArticleId><ArticleId IdType="pubmed">19022406</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiozaki M, Yoshimura K, Shibata M, Koike M, Matsuura N, Uchiyama Y et al. Morphological and biochemical signs of age-related neurodegenerative changes in klotho mutant mice. Neuroscience 2008; 152: 924&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.01.032</ArticleId><ArticleId IdType="pubmed">18343589</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CD, Sloane JA, Li H, Aytan N, Giannaris EL, Zeldich E et al. The antiaging protein Klotho enhances oligodendrocyte maturation and myelination of the CNS. J Neurosci 2013; 33: 1927&#x2013;1939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2080-12.2013</ArticleId><ArticleId IdType="pubmed">23365232</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida A, Komiya Y, Tashiro T, Yorifuji H, Kishimoto T, Nabeshima Y et al. Neurofilaments of Klotho, the mutant mouse prematurely displaying symptoms resembling human aging. J Neurosci Res 2001; 64: 364&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.1087</ArticleId><ArticleId IdType="pubmed">11340643</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A et al. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J 2003; 17: 50&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.02-0448fje</ArticleId><ArticleId IdType="pubmed">12475907</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Zhu L, Sanchez PE, Worden K, Broestl L, Johnson E et al. Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice. J Neurosci 2015; 35: 2358&#x2013;2371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5791-12.2015</ArticleId><ArticleId IdType="pubmed">25673831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuang X, Chen YS, Wang LF, Li YJ, Liu K, Zhang MX et al. Klotho upregulation contributes to the neuroprotection of ligustilide in an Alzheimer's disease mouse model. Neurobiol Aging 2014; 35: 169&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.07.019</ArticleId><ArticleId IdType="pubmed">23973442</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Bona D, Accardi G, Virruso C, Candore G, Caruso C. Association of Klotho polymorphisms with healthy aging: a systematic review and meta-analysis. Rejuvenation Res 2014; 17: 212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/rej.2013.1523</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster RE, Jurutka PW, Hsieh JC, Haussler CA, Lowmiller CL, Kaneko I et al. Vitamin D receptor controls expression of the anti-aging klotho gene in mouse and human renal cells. Biochem Biophys Res Commun 2011; 414: 557&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2011.09.117</ArticleId><ArticleId IdType="pubmed">21982773</ArticleId></ArticleIdList></Reference><Reference><Citation>Masso A, Sanchez A, Gimenez-Llort L, Lizcano JM, Canete M, Garcia B et al. Secreted and transmembrane alphaKlotho isoforms have different spatio-temporal profiles in the brain during aging and Alzheimer's disease progression. PLoS ONE 2015; 10: e0143623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0143623</ArticleId><ArticleId IdType="pubmed">4658185</ArticleId></ArticleIdList></Reference><Reference><Citation>Piedra J, Ontiveros M, Miravet S, Penalva C, Monfar M, Chillon M. Development of a rapid, robust, and universal picogreen-based method to titer adeno-associated vectors. Hum Gene Ther Methods 2015; 26: 35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hgtb.2014.120</ArticleId></ArticleIdList></Reference><Reference><Citation>Olton DS, Papas BC. Spatial memory and hippocampal function. Neuropsychologia 1979; 17: 669&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0028-3932(79)90042-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimenez-Llort L, Blazquez G, Canete T, Johansson B, Oddo S, Tobena A et al. Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Neurosci Biobehav Rev 2007; 31: 125&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2006.07.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P et al. Suppression of aging in mice by the hormone Klotho. Science 2005; 309: 1829&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1112766</ArticleId><ArticleId IdType="pubmed">2536606</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahlstrom A, Yu Q, Ulfhake B. Behavioral changes in aging female C57BL/6 mice. Neurobiol Aging 2011; 32: 1868&#x2013;1880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.11.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford SC. The open field test: reinventing the wheel. J Psychopharmacol 2007; 21: 134&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881107073199</ArticleId><ArticleId IdType="pubmed">17329288</ArticleId></ArticleIdList></Reference><Reference><Citation>Duce JA, Podvin S, Hollander W, Kipling D, Rosene DL, Abraham CR. Gene profile analysis implicates Klotho as an important contributor to aging changes in brain white matter of the rhesus monkey. Glia 2008; 56: 106&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20593</ArticleId><ArticleId IdType="pubmed">17963266</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartke A. Long-lived Klotho mice: new insights into the roles of IGF-1 and insulin in aging. Trends Endocrinol Metab 2006; 17: 33&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2006.01.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Yokoyama JS, Zhu L, Broestl L, Worden K, Wang D et al. Life extension factor klotho enhances cognition. Cell Rep 2014; 7: 1065&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.03.076</ArticleId><ArticleId IdType="pubmed">4176932</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagasu H, Satoh M, Kuwabara A, Yorimitsu D, Kidokoro K, Nishi Y et al. Overexpression of klotho protein modulates uninephrectomy-induced compensatory renal hypertrophy by suppressing IGF-I signals. Biochem Biophys Res Commun 2011; 407: 39&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2011.02.089</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007; 317: 803&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1143578</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda H, Chikuda H, Suga T, Kawaguchi H, Kuro-o M. Regulation of multiple ageing-like phenotypes by inducible klotho gene expression in klotho mutant mice. Mech Ageing Dev 2005; 126: 1274&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2005.07.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, Suzuki T et al. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 2002; 39: 838&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000013734.33441.EA</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension 2009; 54: 810&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.109.134320</ArticleId><ArticleId IdType="pubmed">2814175</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes CA, Markowska AL, Ingram DK, Kametani H, Spangler EL, Lemken VJ et al. Acetyl-1-carnitine. 2: effects on learning and memory performance of aged rats in simple and complex mazes. Neurobiol Aging 1990; 11: 499&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(90)90110-L</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowska AL, Ingram DK, Barnes CA, Spangler EL, Lemken VJ, Kametani H et al. Acetyl-1-carnitine. 1: effects on mortality, pathology and sensory-motor performance in aging rats. Neurobiol Aging 1990; 11: 491&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(90)90109-D</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodefer JS, Baxter MG Neuropsychology of cognitive aging in rodents. In: Brain Aging: Models, Methods, and Mechanisms. Boca Raton (FL): CRC Press/Taylor &amp; Francis, 2007.</Citation></Reference><Reference><Citation>Phelps M, Pettan-Brewer C, Ladiges W, Yablonka-Reuveni Z. Decline in muscle strength and running endurance in klotho deficient C57BL/6 mice. Biogerontology 2013; 14: 729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10522-013-9447-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramovitz L, Rubinek T, Ligumsky H, Bose S, Barshack I, Avivi C et al. KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res 2011; 17: 4254&#x2013;4266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-10-2749</ArticleId><ArticleId IdType="pubmed">21571866</ArticleId></ArticleIdList></Reference><Reference><Citation>Amitani M, Asakawa A, Amitani H, Kaimoto K, Sameshima N, Koyama KI et al. Plasma klotho levels decrease in both anorexia nervosa and obesity. Nutrition 2013; 29: 1106&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2013.02.005</ArticleId><ArticleId IdType="pubmed">23790542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf I, Stein D, Shahmoon S, Ziv SI, Hemi R, Kanety H et al. Alteration in serum klotho levels in anorexia nervosa patients. Clin Nutr 2016; 35: 958&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2015.07.013</ArticleId><ArticleId IdType="pubmed">26243062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lhotellier L, Cohen-Salmon C. Genetics and senescence. I. Age-related changes in activity and exploration in three inbred strains of mice. Physiol Behav 1989; 45: 491&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0031-9384(89)90063-2</ArticleId><ArticleId IdType="pubmed">2756040</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LJ, Cheng MF, Ku PM, Cheng JT. Cerebral klotho protein as a humoral factor for maintenance of baroreflex. Horm Metab Res 2015; 47: 125&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">24867139</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LJ, Cheng MF, Ku PM, Lin JW. Rosiglitazone increases cerebral klotho expression to reverse baroreflex in type 1-like diabetic rats. Biomed Res Int 2014; 2014: 309151.</Citation><ArticleIdList><ArticleId IdType="pmc">3943406</ArticleId><ArticleId IdType="pubmed">24683546</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Sun Z. RNAi silencing of brain klotho potentiates cold-induced elevation of blood pressure via the endothelin pathway. Physiol Genomics 2010; 41: 120&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.00192.2009</ArticleId><ArticleId IdType="pubmed">20086041</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick KM, Burlingame LA, Arters JA, Berger-Sweeney J. Reference memory, anxiety and estrous cyclicity in C57BL/6NIA mice are affected by age and sex. Neuroscience 2000; 95: 293&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(99)00418-2</ArticleId><ArticleId IdType="pubmed">10619486</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29127332</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Nov</Month><Day>10</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Outflow of cerebrospinal fluid is predominantly through lymphatic vessels and is reduced in aged mice.</ArticleTitle><Pagination><StartPage>1434</StartPage><MedlinePgn>1434</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1434</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-017-01484-6</ELocationID><Abstract><AbstractText>Cerebrospinal fluid (CSF) has been commonly accepted to drain through arachnoid projections from the subarachnoid space to the dural venous sinuses. However, a lymphatic component to CSF outflow has long been known. Here, we utilize lymphatic-reporter mice and high-resolution stereomicroscopy to characterize the anatomical routes and dynamics of outflow of CSF. After infusion into a lateral ventricle, tracers spread into the paravascular spaces of the pia mater and cortex of the brain. Tracers also rapidly reach lymph nodes using perineural routes through foramina in the skull. Using noninvasive imaging techniques that can quantify the transport of tracers to the blood and lymph nodes, we find that lymphatic vessels are the major outflow pathway for both large and small molecular tracers in mice. A significant decline in CSF lymphatic outflow is found in aged compared to young mice, suggesting that the lymphatic system may represent a target for age-associated neurological conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Qiaoli</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, 8093, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ineichen</LastName><ForeName>Benjamin V</ForeName><Initials>BV</Initials><AffiliationInfo><Affiliation>Brain Research Institute, University of Zurich, 8057, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Detmar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5351-5054</Identifier><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, 8093, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proulx</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials><Identifier Source="ORCID">0000-0003-2154-8502</Identifier><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, 8093, Zurich, Switzerland. steven.proulx@pharma.ethz.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001099" MajorTopicYN="N">Arachnoid</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004396" MajorTopicYN="N">Coloring Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008208" MajorTopicYN="N">Lymphatic System</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042601" MajorTopicYN="N">Lymphatic Vessels</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>11</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29127332</ArticleId><ArticleId IdType="pmc">PMC5681558</ArticleId><ArticleId IdType="doi">10.1038/s41467-017-01484-6</ArticleId><ArticleId IdType="pii">10.1038/s41467-017-01484-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davson, H. &amp; Segal, M. B. Physiology of the CSF and Blood-Brain Barriers (CRC, Boca Raton, FL, 1996).</Citation></Reference><Reference><Citation>Cserr, H. F. in Hydrocephalus (eds Shapiro, K., Marmarou, A. &amp; Portnoy, H.) 59&#x2013;68 (Raven, New York, NY, 1984).</Citation></Reference><Reference><Citation>Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 1969;40:648&#x2013;677. doi: 10.1083/jcb.40.3.648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.40.3.648</ArticleId><ArticleId IdType="pmc">PMC2107650</ArticleId><ArticleId IdType="pubmed">5765759</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabeshima S, Reese TS, Landis DM, Brightman MW. Junctions in the meninges and marginal glia. J. Comp. Neurol. 1975;164:127&#x2013;169. doi: 10.1002/cne.901640202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.901640202</ArticleId><ArticleId IdType="pubmed">810497</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci. Transl. Med. 2012;4:147ra111. doi: 10.1126/scitranslmed.3003748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003748</ArticleId><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Weed LH. Studies on cerebro-spinal fluid. No. III: The pathways of escape from the subarachnoid spaces with particular reference to the arachnoid villi. J. Med. Res. 1914;31:51&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2094443</ArticleId><ArticleId IdType="pubmed">19972194</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollay M. The function and structure of the cerebrospinal fluid outflow system. Cerebrospinal Fluid Res. 2010;7:9. doi: 10.1186/1743-8454-7-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-8454-7-9</ArticleId><ArticleId IdType="pmc">PMC2904716</ArticleId><ArticleId IdType="pubmed">20565964</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabo AL, Maxwell DS. Morphology of arachnoid villi&#x2014;a light and electron microscopic study in monkey. J. Neurosurg. 1968;29:451&#x2013;463. doi: 10.3171/jns.1968.29.5.0451.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.1968.29.5.0451</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch K, Pollay M. The spinal arachnoid villi of the monkeys Cercopithecus aethiops sabaeus and Macaca irus. Anat. Rec. 1963;145:43&#x2013;48. doi: 10.1002/ar.1091450107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ar.1091450107</ArticleId><ArticleId IdType="pubmed">13999821</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch K, Friedman V. The cerebrospinal fluid valves. Brain. 1960;83:454&#x2013;469. doi: 10.1093/brain/83.3.454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/83.3.454</ArticleId><ArticleId IdType="pubmed">13784191</ArticleId></ArticleIdList></Reference><Reference><Citation>Alksne JF, White LE., Jr. Electron-microscope study of the effect of increased intracranial pressure on the arachnoid villus. J. Neurosurg. 1965;22:481&#x2013;488. doi: 10.3171/jns.1965.22.5.0481.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.1965.22.5.0481</ArticleId><ArticleId IdType="pubmed">5825610</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler, A. B. et al. in Neurobiology of Cerebrospinal Fluid 2 (ed. Wood, J. H.) 707&#x2013;725 (Plenum, New York, NY, 1983).</Citation></Reference><Reference><Citation>Zakharov A, et al. Integrating the roles of extracranial lymphatics and intracranial veins in cerebrospinal fluid absorption in sheep. Microvasc. Res. 2004;67:96&#x2013;104. doi: 10.1016/j.mvr.2003.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mvr.2003.08.004</ArticleId><ArticleId IdType="pubmed">14709407</ArticleId></ArticleIdList></Reference><Reference><Citation>McComb JG. Recent research into the nature of cerebrospinal fluid formation and absorption. J. Neurosurg. 1983;59:369&#x2013;383. doi: 10.3171/jns.1983.59.3.0369.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.1983.59.3.0369</ArticleId><ArticleId IdType="pubmed">6886750</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwalbe G. Die Arachnoidalraum ein Lymphraum und sein Zusammenhang mit den Perichorioidalraum. [The arachnoidal space as a lymphatic space with connection to the perichoroidal compartment.] Zbl. Med. Wiss. 1869;7:465&#x2013;467.</Citation></Reference><Reference><Citation>Bradbury, M. W. B. &amp; Cserr, H. F. in Experimental Biology of the Lymphatic Circulation (ed. Johnston, M. G.) 355&#x2013;394 (Elsevier, Amsterdam, 1985).</Citation></Reference><Reference><Citation>Koh L, Zakharov A, Johnston M. Integration of the subarachnoid space and lymphatics: is it time to embrace a new concept of cerebrospinal fluid absorption? Cerebrospinal Fluid Res. 2005;2:6. doi: 10.1186/1743-8454-2-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-8454-2-6</ArticleId><ArticleId IdType="pmc">PMC1266390</ArticleId><ArticleId IdType="pubmed">16174293</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradbury MW, Cole DF. The role of the lymphatic system in drainage of cerebrospinal fluid and aqueous humour. J. Physiol. 1980;299:353&#x2013;365. doi: 10.1113/jphysiol.1980.sp013129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.1980.sp013129</ArticleId><ArticleId IdType="pmc">PMC1279229</ArticleId><ArticleId IdType="pubmed">6155466</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulton M, Flessner M, Armstrong D, Hay J, Johnston M. Determination of volumetric cerebrospinal fluid absorption into extracranial lymphatics in sheep. Am. J. Physiol. 1998;274:R88&#x2013;R96.</Citation><ArticleIdList><ArticleId IdType="pubmed">9458903</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradbury MW, Westrop RJ. Factors influencing exit of substances from cerebrospinal fluid into deep cervical lymph of the rabbit. J. Physiol. 1983;339:519&#x2013;534. doi: 10.1113/jphysiol.1983.sp014731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.1983.sp014731</ArticleId><ArticleId IdType="pmc">PMC1199176</ArticleId><ArticleId IdType="pubmed">6411905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kida S, Pantazis A, Weller RO. CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol. Appl. Neurobiol. 1993;19:480&#x2013;488. doi: 10.1111/j.1365-2990.1993.tb00476.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1993.tb00476.x</ArticleId><ArticleId IdType="pubmed">7510047</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen JY, Kelly DE, Hyman S, McComb JG. Intraorbital cerebrospinal fluid outflow and the posterior uveal compartment of the hamster eye. Cell Tissue Res. 1985;240:77&#x2013;87. doi: 10.1007/BF00217560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00217560</ArticleId><ArticleId IdType="pubmed">3995547</ArticleId></ArticleIdList></Reference><Reference><Citation>Erlich SS, McComb JG, Hyman S, Weiss MH. Ultrastructure of the orbital pathway for cerebrospinal fluid drainage in rabbits. J. Neurosurg. 1989;70:926&#x2013;931. doi: 10.3171/jns.1989.70.6.0926.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.1989.70.6.0926</ArticleId><ArticleId IdType="pubmed">2715821</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludemann W, von Rautenfeld DB, Samii M, Brinker T. Ultrastructure of the cerebrospinal fluid outflow along the optic nerve into the lymphatic system. Child Nerv. Syst. 2005;21:96&#x2013;103. doi: 10.1007/s00381-004-1040-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00381-004-1040-1</ArticleId><ArticleId IdType="pubmed">15338179</ArticleId></ArticleIdList></Reference><Reference><Citation>Erlich SS, McComb JG, Hyman S, Weiss MH. Ultrastructural morphology of the olfactory pathway for cerebrospinal fluid drainage in the rabbit. J. Neurosurg. 1986;64:466&#x2013;473. doi: 10.3171/jns.1986.64.3.0466.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.1986.64.3.0466</ArticleId><ArticleId IdType="pubmed">3950724</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston M, Zakharov A, Papaiconomou C, Salmasi G, Armstrong D. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res. 2004;1:2. doi: 10.1186/1743-8454-1-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-8454-1-2</ArticleId><ArticleId IdType="pmc">PMC546409</ArticleId><ArticleId IdType="pubmed">15679948</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakharov A, Papaiconomou C, Johnston M. Lymphatic vessels gain access to cerebrospinal fluid through unique association with olfactory nerves. Lymphat. Res. Biol. 2004;2:139&#x2013;146. doi: 10.1089/lrb.2004.2.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/lrb.2004.2.139</ArticleId><ArticleId IdType="pubmed">15609813</ArticleId></ArticleIdList></Reference><Reference><Citation>Brierley JB, Field EJ. The connexions of the spinal sub-arachnoid space with the lymphatic system. J. Anat. 1948;82:153&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">18873158</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakharov A, Papaiconomou C, Djenic J, Midha R, Johnston M. Lymphatic cerebrospinal fluid absorption pathways in neonatal sheep revealed by subarachnoid injection of Microfil. Neuropathol. Appl. Neurobiol. 2003;29:563&#x2013;573. doi: 10.1046/j.0305-1846.2003.00508.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0305-1846.2003.00508.x</ArticleId><ArticleId IdType="pubmed">14636163</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337&#x2013;341. doi: 10.1038/nature14432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14432</ArticleId><ArticleId IdType="pmc">PMC4506234</ArticleId><ArticleId IdType="pubmed">26030524</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspelund A, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 2015;212:991&#x2013;999. doi: 10.1084/jem.20142290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142290</ArticleId><ArticleId IdType="pmc">PMC4493418</ArticleId><ArticleId IdType="pubmed">26077718</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx ST, et al. Use of a PEG-conjugated bright near-infrared dye for functional imaging of rerouting of tumor lymphatic drainage after sentinel lymph node metastasis. Biomaterials. 2013;34:5128&#x2013;5137. doi: 10.1016/j.biomaterials.2013.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2013.03.034</ArticleId><ArticleId IdType="pmc">PMC3646951</ArticleId><ArticleId IdType="pubmed">23566803</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong C, et al. In vivo visualization and quantification of collecting lymphatic vessel contractility using near-infrared imaging. Sci. Rep. 2016;6:22930. doi: 10.1038/srep22930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep22930</ArticleId><ArticleId IdType="pmc">PMC4785392</ArticleId><ArticleId IdType="pubmed">26960708</ArticleId></ArticleIdList></Reference><Reference><Citation>Karaman S, et al. Decline of lymphatic vessel density and function in murine skin during aging. Angiogenesis. 2015;18:489&#x2013;498. doi: 10.1007/s10456-015-9479-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10456-015-9479-0</ArticleId><ArticleId IdType="pubmed">26260189</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx ST, Ma Q, Andina D, Leroux JC, Detmar M. Quantitative measurement of lymphatic function in mice by noninvasive near-infrared imaging of a peripheral vein. JCI Insight. 2017;2:e90861. doi: 10.1172/jci.insight.90861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.90861</ArticleId><ArticleId IdType="pmc">PMC5214224</ArticleId><ArticleId IdType="pubmed">28097238</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtice FC, Simmonds WJ. The removal of protein from the subarachnoid space. Aust. J. Exp. Biol. Med. Sci. 1951;29:255&#x2013;263. doi: 10.1038/icb.1951.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.1951.30</ArticleId><ArticleId IdType="pubmed">14886262</ArticleId></ArticleIdList></Reference><Reference><Citation>Pile-Spellman JM, McKusick KA, Strauss HW, Cooney J, Taveras JM. Experimental in vivo imaging of the cranial perineural lymphatic pathway. AJNR. 1984;5:539&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8335123</ArticleId><ArticleId IdType="pubmed">6435420</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu E, Gupta N, Macdonald RL, Ai J, Yucel YH. In vivo imaging of lymphatic drainage of cerebrospinal fluid in mouse. Fluids Barriers CNS. 2013;10:35. doi: 10.1186/2045-8118-10-35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2045-8118-10-35</ArticleId><ArticleId IdType="pmc">PMC3879644</ArticleId><ArticleId IdType="pubmed">24360130</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene, E. C. Anatomy of the Rat (Hafner, New York, NY, 1968).</Citation></Reference><Reference><Citation>Cook, M. J. The Anatomy of the Laboratory Mouse (Academic, New York, NY, 1966).</Citation></Reference><Reference><Citation>Mancini M, et al. Head and neck veins of the mouse. a magnetic resonance, micro computed tomography and high frequency color doppler ultrasound study. PLoS ONE. 2015;10:e0129912. doi: 10.1371/journal.pone.0129912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0129912</ArticleId><ArticleId IdType="pmc">PMC4466257</ArticleId><ArticleId IdType="pubmed">26067061</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarasoff-Conway JM, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat. Rev. Neurol. 2015;11:457&#x2013;470. doi: 10.1038/nrneurol.2015.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.119</ArticleId><ArticleId IdType="pmc">PMC4694579</ArticleId><ArticleId IdType="pubmed">26195256</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston JE. Ageing choroid plexus-cerebrospinal fluid system. Microsc. Res. Tech. 2001;52:31&#x2013;37. doi: 10.1002/1097-0029(20010101)52:1&lt;31::AID-JEMT5&gt;3.0.CO;2-T.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0029(20010101)52:1&lt;31::AID-JEMT5&gt;3.0.CO;2-T</ArticleId><ArticleId IdType="pubmed">11135446</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolla V, et al. Aging-related anatomical and biochemical changes in lymphatic collectors impair lymph transport, fluid homeostasis, and pathogen clearance. Aging Cell. 2015;14:582&#x2013;594. doi: 10.1111/acel.12330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12330</ArticleId><ArticleId IdType="pmc">PMC4531072</ArticleId><ArticleId IdType="pubmed">25982749</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson RT, Tigges J, Arnold W. Subarachnoid space of the CNS, nasal mucosa, and lymphatic system. Arch. Otolaryngol. 1979;105:180&#x2013;184. doi: 10.1001/archotol.1979.00790160014003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archotol.1979.00790160014003</ArticleId><ArticleId IdType="pubmed">85446</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold W, Nitze HR, Ritter R, von Ilberg C, Ganzer U. Qualitative Untersuchungen der Verbindungswege des Subarachnoidalraumes mit dem Lymphatischen System des Kopfes und des Halses [Qualitative study of the connections of the subarachnoid space with the lymphatic system of the head and neck] Acta Otolaryngol. 1972;74:411&#x2013;424. doi: 10.3109/00016487209128471.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00016487209128471</ArticleId><ArticleId IdType="pubmed">4656171</ArticleId></ArticleIdList></Reference><Reference><Citation>Field EJ, Brierley JB. The lymphatic connexions of the subarachnoid space; an experimental study of the dispersion of particulate matter in the cerebrospinal fluid, with special reference to the pathogenesis of poliomyelitis. Br. Med. J. 1948;1:1167&#x2013;1171. doi: 10.1136/bmj.1.4563.1167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.1.4563.1167</ArticleId><ArticleId IdType="pmc">PMC2089910</ArticleId><ArticleId IdType="pubmed">18865968</ArticleId></ArticleIdList></Reference><Reference><Citation>Mascagni, P. Vasorum Lymphaticorum Corporis Humani Historia et Ichnographia (Pazzini Carli, Siena, 1787).</Citation></Reference><Reference><Citation>Foldi M, et al. Acta Anat. 1966. New contributions to the anatomical connections of the brain and the lymphatic system; pp. 498&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">5957959</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler, A. B., van Landingham, K. &amp; McComb, J. G. in Intracranial Pressure V (eds Ishii, S., Nagai, H. &amp; Brock, M.) 598&#x2013;604 (Springer Berlin, Heidelberg, 1983).</Citation></Reference><Reference><Citation>Andres KH, von During M, Muszynski K, Schmidt RF. Nerve fibres and their terminals of the dura mater encephali of the rat. Anat. Embryol. 1987;175:289&#x2013;301. doi: 10.1007/BF00309843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00309843</ArticleId><ArticleId IdType="pubmed">3826655</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabo AL, Maxwell DS. The subarachnoid space following the introduction of a foreign protein: an electron microscopic study with peroxidase. J. Neuropathol. Exp. Neurol. 1971;30:506&#x2013;524. doi: 10.1097/00005072-197107000-00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-197107000-00013</ArticleId><ArticleId IdType="pubmed">4327886</ArticleId></ArticleIdList></Reference><Reference><Citation>Coles JA, Myburgh E, Brewer JM, McMenamin PG. Where are we? The anatomy of the murine cortical meninges revisited for intravital imaging, immunology, and clearance of waste from the brain. Prog. Neurobiol. 2017;156:107&#x2013;148. doi: 10.1016/j.pneurobio.2017.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2017.05.002</ArticleId><ArticleId IdType="pubmed">28552391</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollanji R, et al. Intracranial pressure accommodation is impaired by blocking pathways leading to extracranial lymphatics. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001;280:R1573&#x2013;R1581.</Citation><ArticleIdList><ArticleId IdType="pubmed">11294783</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa M, Shimoda H, Kajiwara T, Kato S, Yanagisawa S. Topographic study on nerve-associated lymphatic vessels in the murine craniofacial region by immunohistochemistry and electron microscopy. Biomed. Res. 2008;29:289&#x2013;296. doi: 10.2220/biomedres.29.289.</Citation><ArticleIdList><ArticleId IdType="doi">10.2220/biomedres.29.289</ArticleId><ArticleId IdType="pubmed">19129672</ArticleId></ArticleIdList></Reference><Reference><Citation>Killer HE, Laeng HR, Groscurth P. Lymphatic capillaries in the meninges of the human optic nerve. J. Neuroophthalmol. 1999;19:222&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">10608671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagshul, M. E. &amp; Johnston, M. in Immunology of the Lymphatic System (ed. Santambrogio, L.) 143&#x2013;164 (Springer, New York, NY, 2013).</Citation></Reference><Reference><Citation>Yoffey JM, Drinker CK. Some observations on the lymphatics of the nasal mucous membrane in the cat and monkey. J. Anat. 1939;74:45&#x2013;52 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1252556</ArticleId><ArticleId IdType="pubmed">17104799</ArticleId></ArticleIdList></Reference><Reference><Citation>Key, A. &amp; Retzius, G. Studien in der Anatomie des Nervensystems und des Bindegewebes (P.A. Norstedt &amp; Soner, Stockholm, 1875).</Citation></Reference><Reference><Citation>Welch K, Pollay M. Perfusion of particles through arachnoid villi of the monkey. Am. J. Physiol. 1961;201:651&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">14005969</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi BJ, Tripathi RC. Vacuolar transcellular channels as a drainage pathway for cerebrospinal fluid. J. Physiol. 1974;239:195&#x2013;206. doi: 10.1113/jphysiol.1974.sp010563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.1974.sp010563</ArticleId><ArticleId IdType="pmc">PMC1330945</ArticleId><ArticleId IdType="pubmed">4369428</ArticleId></ArticleIdList></Reference><Reference><Citation>Prockop LD, Schanker LS, Brodie BB. Passage of lipid-insoluble substances from cerebrospinal fluid to blood. J. Pharmacol. Exp. Ther. 1962;135:266&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">14488879</ArticleId></ArticleIdList></Reference><Reference><Citation>Davson H, Domer FR, Hollingsworth JR. The mechanism of drainage of the cerebrospinal fluid. Brain. 1973;96:329&#x2013;336. doi: 10.1093/brain/96.2.329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/96.2.329</ArticleId><ArticleId IdType="pubmed">4197586</ArticleId></ArticleIdList></Reference><Reference><Citation>McComb JG, Davson H, Hyman S, Weiss MH. Cerebrospinal fluid drainage as influenced by ventricular pressure in the rabbit. J. Neurosurg. 1982;56:790&#x2013;797. doi: 10.3171/jns.1982.56.6.0790.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.1982.56.6.0790</ArticleId><ArticleId IdType="pubmed">7077378</ArticleId></ArticleIdList></Reference><Reference><Citation>Foeldi M, Gatai G, Zoltan TO. Der Abtransport des mit Jod131 markierten Serumalbumins aus dem Subarachnoidalraum beim Hunde [The removal of iodine 131-labeled serum albumin from the subarachnoid space in the dog] Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol. 1959;237:65&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">13823646</ArticleId></ArticleIdList></Reference><Reference><Citation>McComb, J. G., Hyman, S. &amp; Weiss, M. H. in Hydrocephalus (eds Shapiro, K., Marmarou, A. &amp; Portnoy, H.) 83&#x2013;98 (Raven, New York, NY, 1984).</Citation></Reference><Reference><Citation>McComb, J. G., Hyman, S. &amp; Weiss, M. H. in Pathophysiology of the Blood-Brain Barrier (eds Johansson, B. B., Owman, C. &amp; Widner, H.) 421&#x2013;438 (Elsevier, Amsterdam, 1990).</Citation></Reference><Reference><Citation>Mann JD, Butler AB, Johnson RN, Bass NH. Clearance of macromolecular and particulate substances from the cerebrospinal fluid system of the rat. J. Neurosurg. 1979;50:343&#x2013;348. doi: 10.3171/jns.1979.50.3.0343.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.1979.50.3.0343</ArticleId><ArticleId IdType="pubmed">422986</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagra G, Johnston MG. Impact of ageing on lymphatic cerebrospinal fluid absorption in the rat. Neuropathol. Appl. Neurobiol. 2007;33:684&#x2013;691. doi: 10.1111/j.1365-2990.2007.00857.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2007.00857.x</ArticleId><ArticleId IdType="pubmed">17931359</ArticleId></ArticleIdList></Reference><Reference><Citation>May C, et al. Cerebrospinal fluid production is reduced in healthy aging. Neurology. 1990;40:500&#x2013;503. doi: 10.1212/WNL.40.3_Part_1.500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.40.3_Part_1.500</ArticleId><ArticleId IdType="pubmed">2314595</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumae M, et al. Age-related changes in intracranial compartment volumes in normal adults assessed by magnetic resonance imaging. J. Neurosurg. 1996;84:982&#x2013;991. doi: 10.3171/jns.1996.84.6.0982.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.1996.84.6.0982</ArticleId><ArticleId IdType="pubmed">8847593</ArticleId></ArticleIdList></Reference><Reference><Citation>Iijima T, Iwao Y, Sankawa H. Circulating blood volume measured by pulse dye-densitometry: comparison with (131)I-HSA analysis. Anesthesiology. 1998;89:1329&#x2013;1335. doi: 10.1097/00000542-199812000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-199812000-00009</ArticleId><ArticleId IdType="pubmed">9856706</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi I, et al. Visualization of lymphatic vessels by Prox1-promoter directed GFP reporter in a bacterial artificial chromosome-based transgenic mouse. Blood. 2011;117:362&#x2013;365. doi: 10.1182/blood-2010-07-298562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-07-298562</ArticleId><ArticleId IdType="pmc">PMC3037757</ArticleId><ArticleId IdType="pubmed">20962325</ArticleId></ArticleIdList></Reference><Reference><Citation>Ineichen BV, et al. Direct, long-term intrathecal application of therapeutics to the rodent CNS. Nat. Protoc. 2017;12:104&#x2013;131. doi: 10.1038/nprot.2016.151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.151</ArticleId><ArticleId IdType="pubmed">27977023</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29079686</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>22</Issue><PubDate><Year>2017</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.</ArticleTitle><Pagination><StartPage>2230</StartPage><EndPage>2237</EndPage><MedlinePgn>2230-2237</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000004683</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the effects of disease activity, disability, and disease-modifying therapies (DMTs) on serum neurofilament light (NFL) and the correlation between NFL concentrations in serum and CSF in multiple sclerosis (MS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">NFL concentrations were measured in paired serum and CSF samples (n = 521) from 373 participants: 286 had MS, 45 had other neurologic conditions, and 42 were healthy controls (HCs). In 138 patients with MS, the serum and CSF samples were obtained before and after DMT treatment with a median interval of 12 months. The CSF NFL concentration was measured with the UmanDiagnostics NF-light enzyme-linked immunosorbent assay. The serum NFL concentration was measured with an in-house ultrasensitive single-molecule array assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In MS, the correlation between serum and CSF NFL was <i>r</i> = 0.62 (<i>p</i> &lt; 0.001). Serum concentrations were significantly higher in patients with relapsing-remitting MS (16.9 ng/L) and in patients with progressive MS (23 ng/L) than in HCs (10.5 ng/L, <i>p</i> &lt; 0.001 and <i>p</i> &lt; 0.001, respectively). Treatment with DMT reduced median serum NFL levels from 18.6 (interquartile range [IQR] 12.6-32.7) ng/L to 15.7 (IQR 9.6-22.7) ng/L (<i>p</i> &lt; 0.001). Patients with relapse or with radiologic activity had significantly higher serum NFL levels than those in remission (<i>p</i> &lt; 0.001) or those without new lesions on MRI (<i>p</i> &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Serum and CSF NFL levels were highly correlated, indicating that blood sampling can replace CSF taps for this particular marker. Disease activity and DMT had similar effects on serum and CSF NFL concentrations. Repeated NFL determinations in peripheral blood for detecting axonal damage may represent new possibilities in MS monitoring.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Novakova</LastName><ForeName>Lenka</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (L.N., M.A., C.M., J.L.) and Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, London, UK; Department of Pharmacology and Clinical Neuroscience (P.S.), Ume&#xe5; University; University Department of Clinical Neuroscience (M.K., T.O., F.P.), Neuroimmunology Unit, and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Stockholm; and Department of Neurology (M.G.), Faculty of Medicine and Health, &#xd6;rebro University, Sweden. lenka.novakova@vgregion.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (L.N., M.A., C.M., J.L.) and Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, London, UK; Department of Pharmacology and Clinical Neuroscience (P.S.), Ume&#xe5; University; University Department of Clinical Neuroscience (M.K., T.O., F.P.), Neuroimmunology Unit, and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Stockholm; and Department of Neurology (M.G.), Faculty of Medicine and Health, &#xd6;rebro University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundstr&#xf6;m</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (L.N., M.A., C.M., J.L.) and Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, London, UK; Department of Pharmacology and Clinical Neuroscience (P.S.), Ume&#xe5; University; University Department of Clinical Neuroscience (M.K., T.O., F.P.), Neuroimmunology Unit, and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Stockholm; and Department of Neurology (M.G.), Faculty of Medicine and Health, &#xd6;rebro University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Axelsson</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (L.N., M.A., C.M., J.L.) and Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, London, UK; Department of Pharmacology and Clinical Neuroscience (P.S.), Ume&#xe5; University; University Department of Clinical Neuroscience (M.K., T.O., F.P.), Neuroimmunology Unit, and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Stockholm; and Department of Neurology (M.G.), Faculty of Medicine and Health, &#xd6;rebro University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khademi</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (L.N., M.A., C.M., J.L.) and Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, London, UK; Department of Pharmacology and Clinical Neuroscience (P.S.), Ume&#xe5; University; University Department of Clinical Neuroscience (M.K., T.O., F.P.), Neuroimmunology Unit, and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Stockholm; and Department of Neurology (M.G.), Faculty of Medicine and Health, &#xd6;rebro University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunnarsson</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (L.N., M.A., C.M., J.L.) and Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, London, UK; Department of Pharmacology and Clinical Neuroscience (P.S.), Ume&#xe5; University; University Department of Clinical Neuroscience (M.K., T.O., F.P.), Neuroimmunology Unit, and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Stockholm; and Department of Neurology (M.G.), Faculty of Medicine and Health, &#xd6;rebro University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malmestr&#xf6;m</LastName><ForeName>Clas</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (L.N., M.A., C.M., J.L.) and Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, London, UK; Department of Pharmacology and Clinical Neuroscience (P.S.), Ume&#xe5; University; University Department of Clinical Neuroscience (M.K., T.O., F.P.), Neuroimmunology Unit, and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Stockholm; and Department of Neurology (M.G.), Faculty of Medicine and Health, &#xd6;rebro University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svenningsson</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (L.N., M.A., C.M., J.L.) and Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, London, UK; Department of Pharmacology and Clinical Neuroscience (P.S.), Ume&#xe5; University; University Department of Clinical Neuroscience (M.K., T.O., F.P.), Neuroimmunology Unit, and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Stockholm; and Department of Neurology (M.G.), Faculty of Medicine and Health, &#xd6;rebro University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Tomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (L.N., M.A., C.M., J.L.) and Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, London, UK; Department of Pharmacology and Clinical Neuroscience (P.S.), Ume&#xe5; University; University Department of Clinical Neuroscience (M.K., T.O., F.P.), Neuroimmunology Unit, and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Stockholm; and Department of Neurology (M.G.), Faculty of Medicine and Health, &#xd6;rebro University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piehl</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (L.N., M.A., C.M., J.L.) and Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, London, UK; Department of Pharmacology and Clinical Neuroscience (P.S.), Ume&#xe5; University; University Department of Clinical Neuroscience (M.K., T.O., F.P.), Neuroimmunology Unit, and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Stockholm; and Department of Neurology (M.G.), Faculty of Medicine and Health, &#xd6;rebro University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (L.N., M.A., C.M., J.L.) and Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, London, UK; Department of Pharmacology and Clinical Neuroscience (P.S.), Ume&#xe5; University; University Department of Clinical Neuroscience (M.K., T.O., F.P.), Neuroimmunology Unit, and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Stockholm; and Department of Neurology (M.G.), Faculty of Medicine and Health, &#xd6;rebro University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lycke</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (L.N., M.A., C.M., J.L.) and Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, London, UK; Department of Pharmacology and Clinical Neuroscience (P.S.), Ume&#xe5; University; University Department of Clinical Neuroscience (M.K., T.O., F.P.), Neuroimmunology Unit, and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Stockholm; and Department of Neurology (M.G.), Faculty of Medicine and Health, &#xd6;rebro University, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008991" MajorTopicYN="N">Monitoring, Physiologic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N">Sweden</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>11</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29079686</ArticleId><ArticleId IdType="pmc">PMC5705244</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004683</ArticleId><ArticleId IdType="pii">WNL.0000000000004683</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003;987:25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">14499942</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">9445407</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelsson M, Malmestrom C, Gunnarsson M, et al. . Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014;20:43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">23702432</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunnarsson M, Malmestrom C, Axelsson M, et al. . Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011;69:83&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">21280078</ArticleId></ArticleIdList></Reference><Reference><Citation>Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:402&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2170011</ArticleId><ArticleId IdType="pubmed">9527161</ArticleId></ArticleIdList></Reference><Reference><Citation>Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003;61:1720&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">14694036</ArticleId></ArticleIdList></Reference><Reference><Citation>Novakova L, Axelsson M, Khademi M, et al. . Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Mult Scler 2017;23:62&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">27003946</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010;16:287&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">20086018</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez MA, Olsson B, Bau L, et al. . Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler 2015;21:550&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4390605</ArticleId><ArticleId IdType="pubmed">25732842</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissin DM, Kan CW, Campbell TG, et al. . Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010;28:595&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919230</ArticleId><ArticleId IdType="pubmed">20495550</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Barro C, Andreasson U, et al. . Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 2016;54:1655&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pubmed">27071153</ArticleId></ArticleIdList></Reference><Reference><Citation>Gisslen M, Price RW, Andreasson U, et al. . Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 2016;3:135&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahim P, Gren M, Liman V, et al. . Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep 2016;6:36791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5098187</ArticleId><ArticleId IdType="pubmed">27819296</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahim PZH, Tegner Y, Blennow K. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology 2017;88:1788&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5419986</ArticleId><ArticleId IdType="pubmed">28404801</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahim P, Tegner Y, Gustafsson B, et al. . Neurochemical aftermath of repetitive mild traumatic brain injury. JAMA Neurol 2016;73:1308&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">27654934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman J, Dring A, Zetterberg H, et al. . Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol Neuroimmunol Neuroinflamm 2016;3:e271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4972001</ArticleId><ArticleId IdType="pubmed">27536708</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotton F, Weiner HL, Jolesz FA, Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60:640&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">12601106</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen C, Menge T, Altintas A, et al. . Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 2013;19:1802&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pubmed">23695446</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandberg L, Bistrom M, Salzer J, Vagberg M, Svenningsson A, Sundstrom P. Vitamin D and axonal injury in multiple sclerosis. Mult Scler 2016;22:1027&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pubmed">26462862</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444&#x2013;1452.</Citation><ArticleIdList><ArticleId IdType="pubmed">6685237</ArticleId></ArticleIdList></Reference><Reference><Citation>Roxburgh RH, Seaman SR, Masterman T, et al. . Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">15824338</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald WI, Compston A, Edan G, et al. . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">11456302</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni G, Tomic D, Bright JR, Havrdova E. &#x201c;No evident disease activity&#x201d;: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 2017;23:1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536258</ArticleId><ArticleId IdType="pubmed">28381105</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiendl H, Meuth SG. Pharmacological approaches to delaying disability progression in patients with multiple sclerosis. Drugs 2015;75:947&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4464731</ArticleId><ArticleId IdType="pubmed">26033077</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, Petzold A, Bennett JL, et al. . A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009;73:1914&#x2013;1922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839806</ArticleId><ArticleId IdType="pubmed">19949037</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Woollacott IO, Dick KM, et al. . Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 2016;87:1329&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047041</ArticleId><ArticleId IdType="pubmed">27581216</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagberg M, Norgren N, Dring A, et al. . Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction. PLoS One 2015;10:e0135886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552591</ArticleId><ArticleId IdType="pubmed">26317831</ArticleId></ArticleIdList></Reference><Reference><Citation>Burman J, Zetterberg H, Fransson M, Loskog AS, Raininko R, Fagius J. Assessing tissue damage in multiple sclerosis: a biomarker approach. Acta Neurol Scand 2014;130:81&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571714</ArticleId></ArticleIdList></Reference><Reference><Citation>Novakova L, Axelsson M, Khademi M, et al. . Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem 2017;141:296&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">27787906</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese M, Magliozzi R, Ciccarelli O, Geurts JJ, Reynolds R, Martin R. Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci 2015;16:147&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">25697158</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnan M, Marasescu R, Demasles S, Krim E, Barroso B. No evidence of disease activity (NEDA) in MS should include CSF biology: towards a &#x201c;disease-free status score.&#x201d; Mult Scler Relat Disord 2017;11:51&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">28104257</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29142083</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>24</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>12</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Evidence of CNS &#x3b2;-amyloid deposition in Nasu-Hakola disease due to the <i>TREM2</i> Q33X mutation.</ArticleTitle><Pagination><StartPage>2503</StartPage><EndPage>2505</EndPage><MedlinePgn>2503-2505</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000004747</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghezzi</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy. lauraghezzi@me.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carandini</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arighi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenoglio</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arcaro</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Riz</LastName><ForeName>Milena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietroboni</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>Giorgio G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basilico</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarioni</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombi</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serpente</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marotta</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benti</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From University of Milan, Centro Dino Ferrari, Fondazione Ca' Granda, IRCCS Ospedale Policlinico (L.G., T.C., A.A., C.F., M.A., M.D.R., A.M.P., G.G.F., P.B., A.C., M. Scarioni., A.C., M. Serpente, E.S., D.G.), and Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence (G.G.F.), Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C536329">Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008060" MajorTopicYN="N">Lipodystrophy</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009778" MajorTopicYN="N">Occipital Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010009" MajorTopicYN="N">Osteochondrodysplasias</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013344" MajorTopicYN="N">Subacute Sclerosing Panencephalitis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29142083</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004747</ArticleId><ArticleId IdType="pii">WNL.0000000000004747</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29273772</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo.</ArticleTitle><Pagination><StartPage>72</StartPage><EndPage>80</EndPage><MedlinePgn>72-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-017-0022-z</ELocationID><Abstract><AbstractText>Emerging studies suggest a role for tau in regulating the biology of RNA binding proteins (RBPs). We now show that reducing the RBP T-cell intracellular antigen 1 (TIA1) in vivo protects against neurodegeneration and prolongs survival in transgenic P301S Tau mice. Biochemical fractionation shows co-enrichment and co-localization of tau oligomers and RBPs in transgenic P301S Tau mice. Reducing TIA1 decreased the number and size of granules co-localizing with stress granule markers. Decreasing TIA1 also inhibited the accumulation of tau oligomers at the expense of increasing neurofibrillary tangles. Despite the increase in neurofibrillary tangles, TIA1 reduction increased neuronal survival and rescued behavioral deficits and lifespan. These data provide in vivo evidence that TIA1 plays a key role in mediating toxicity and further suggest that RBPs direct the pathway of tau aggregation and the resulting neurodegeneration. We propose a model in which dysfunction of the translational stress response leads to tau-mediated pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Apicco</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ash</LastName><ForeName>Peter E A</ForeName><Initials>PEA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maziuk</LastName><ForeName>Brandon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LeBlang</LastName><ForeName>Chelsey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medalla</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Abdullatif</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferragud</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botelho</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballance</LastName><ForeName>Heather I</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhawan</LastName><ForeName>Uma</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boudeau</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Anna Lourdes</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kashy</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Aria</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Lisa R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazdani</LastName><ForeName>Neema</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology &amp; Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ung</LastName><ForeName>Choong Y</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology &amp; Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripodis</LastName><ForeName>Yorghos</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Environmental Health, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanaan</LastName><ForeName>Nicholas M</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0002-4362-2593</Identifier><AffiliationInfo><Affiliation>Department of Translational Science and Molecular Medicine, College of Human Medicine, Michigan State University, East Lansing, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikezu</LastName><ForeName>Tsuneya</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3979-8596</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cottone</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leszyk</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pathology, University of Massachusetts Medical Center, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5957-5472</Identifier><AffiliationInfo><Affiliation>Department of Molecular Pharmacology &amp; Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luebke</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryant</LastName><ForeName>Camron D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolozin</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-2068-1475</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA. bwolozin@bu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA. bwolozin@bu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG054199</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD023663</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056318</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG050471</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089544</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054199</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES020395</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008541</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489665">Tial1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="D004722">Endoribonucleases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="C466280">smad4-interacting protein SMIF, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2017 Dec 14;19(1):1. doi: 10.1038/nrn.2017.163.</RefSource><PMID Version="1">29238082</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004722" MajorTopicYN="N">Endoribonucleases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008124" MajorTopicYN="N">Locomotion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Statement:</b> Benjamin Wolozin is Co-Founder and Chief Scientific Officer for Aquinnah Pharmaceuticals Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29273772</ArticleId><ArticleId IdType="mid">NIHMS910977</ArticleId><ArticleId IdType="pmc">PMC5745051</ArticleId><ArticleId IdType="doi">10.1038/s41593-017-0022-z</ArticleId><ArticleId IdType="pii">10.1038/s41593-017-0022-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gitler AD, Shorter J. RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion. 2011;5:179&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3226045</ArticleId><ArticleId IdType="pubmed">21847013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Vanderweyde TE, Youmans KL, Apicco DJ, Wolozin B. Pathological stress granules in Alzheimer&#x2019;s disease. Brain Res. 2014;1584:52&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4256948</ArticleId><ArticleId IdType="pubmed">25108040</ArticleId></ArticleIdList></Reference><Reference><Citation>Banani SF, Lee HO, Hyman AA, Rosen MK. Biomolecular condensates: organizers of cellular biochemistry. Nat Rev Mol Cell Biol. 2017;18:285&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7434221</ArticleId><ArticleId IdType="pubmed">28225081</ArticleId></ArticleIdList></Reference><Reference><Citation>Feric M, et al. Coexisting Liquid Phases Underlie Nucleolar Subcompartments. Cell. 2016;165:1686&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127388</ArticleId><ArticleId IdType="pubmed">27212236</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson P, Kedersha N. Stress granules: the Tao of RNA triage. Trends Biochem Sci. 2008;33:141&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">18291657</ArticleId></ArticleIdList></Reference><Reference><Citation>Panas MD, Ivanov P, Anderson P. Mechanistic insights into mammalian stress granule dynamics. J Cell Biol. 2016;215:313&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5100297</ArticleId><ArticleId IdType="pubmed">27821493</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2015;129:469&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369168</ArticleId><ArticleId IdType="pubmed">25549971</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain A, Vale RD. RNA phase transitions in repeat expansion disorders. Nature. 2017;546:243&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5555642</ArticleId><ArticleId IdType="pubmed">28562589</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, et al. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell. 2015;162:1066&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott TJ, et al. Phase transition of a disordered nuage protein generates environmentally responsive membraneless organelles. Mol Cell. 2015;57:936&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352761</ArticleId><ArticleId IdType="pubmed">25747659</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A, et al. Phase Separation by Low Complexity Domains Promotes Stress Granule Assembly and Drives Pathological Fibrillization. Cell. 2015;163:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Protter DS, Rosen MK, Parker R. Formation and Maturation of Phase-Separated Liquid Droplets by RNA-Binding Proteins. Mol Cell. 2015;60:208&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609299</ArticleId><ArticleId IdType="pubmed">26412307</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderweyde T, et al. Interaction of tau with the RNA-binding Protein TIA1 Regulates tau Pathophysiology and Toxicity. Cell reports. 2016;15:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325702</ArticleId><ArticleId IdType="pubmed">27160897</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderweyde T, et al. Contrasting Pathology of Stress Granule Proteins TIA-1 and G3BP in Tauopathies. J Neurosci. 2012;32:8270&#x2013;8283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3402380</ArticleId><ArticleId IdType="pubmed">22699908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17:5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips K, Kedersha N, Shen L, Blackshear PJ, Anderson P. Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis. Proc Natl Acad Sci U S A. 2004;101:2011&#x2013;2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357043</ArticleId><ArticleId IdType="pubmed">14769925</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi H, et al. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS One. 2011;6:e21050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115982</ArticleId><ArticleId IdType="pubmed">21698260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde R. The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev. 2002;26:91&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">11835987</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SJ, Stackman RW., Jr Assessing rodent hippocampal involvement in the novel object recognition task. A review. Behav Brain Res. 2015;285:105&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008635</ArticleId><ArticleId IdType="pubmed">25169255</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraha A, et al. C-terminal inhibition of tau assembly in vitro and in Alzheimer&#x2019;s disease. J Cell Sci. 2000;113(Pt 21):3737&#x2013;3745.</Citation><ArticleIdList><ArticleId IdType="pubmed">11034902</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding H, Matthews TA, Johnson GV. Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J Biol Chem. 2006;281:19107&#x2013;19114.</Citation><ArticleIdList><ArticleId IdType="pubmed">16687396</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocher AB, et al. Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol. 2010;223:385&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864360</ArticleId><ArticleId IdType="pubmed">19665462</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, et al. Caspase activation precedes and leads to tangles. Nature. 2010;464:1201&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091360</ArticleId><ArticleId IdType="pubmed">20357768</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82:1271&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, et al. Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc Natl Acad Sci U S A. 2014;111:510&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3890777</ArticleId><ArticleId IdType="pubmed">24368848</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N, et al. Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain. J Alzheimers Dis. 2013;33:249&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514650</ArticleId><ArticleId IdType="pubmed">22941973</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci. 2007;27:3650&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672413</ArticleId><ArticleId IdType="pubmed">17409229</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs B, Hamel C, Kanaan NM. Pathological conformations involving the amino terminus of tau occur early in Alzheimer&#x2019;s disease and are differentially detected by monoclonal antibodies. Neurobiol Dis. 2016;94:18&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4983528</ArticleId><ArticleId IdType="pubmed">27260838</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YR, King OD, Shorter J, Gitler AD. Stress granules as crucibles of ALS pathogenesis. J Cell Biol. 2013;201:361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B. Regulated protein aggregation: stress granules and neurodegeneration. Mol Neurodegener. 2012;7:56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3519755</ArticleId><ArticleId IdType="pubmed">23164372</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson CM. Protein folding and misfolding. Nature. 2003;426:884&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685248</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, et al. Phase transitions in the assembly of multivalent signalling proteins. Nature. 2012;483:336&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343696</ArticleId><ArticleId IdType="pubmed">22398450</ArticleId></ArticleIdList></Reference><Reference><Citation>Maziuk B, Ballance HI, Wolozin B. Dysregulation of RNA Binding Protein Aggregation in Neurodegenerative Disorders. Frontiers in molecular neuroscience. 2017;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378767</ArticleId><ArticleId IdType="pubmed">28420962</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Banani SF, et al. Compositional Control of Phase-Separated Cellular Bodies. Cell. 2016;166:651&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4967043</ArticleId><ArticleId IdType="pubmed">27374333</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunello CA, Yan X, Huttunen HJ. Internalized Tau sensitizes cells to stress by promoting formation and stability of stress granules. Sci Rep. 2016;6:30498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962319</ArticleId><ArticleId IdType="pubmed">27460788</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier S, et al. Pathological Tau Promotes Neuronal Damage by Impairing Ribosomal Function and Decreasing Protein Synthesis. J Neurosci. 2016;36:1001&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4719006</ArticleId><ArticleId IdType="pubmed">26791227</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, et al. RNA stores tau reversibly in complex coacervates. PLoS Biol. 2017;15:e2002183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5500003</ArticleId><ArticleId IdType="pubmed">28683104</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Mandelkow E. Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. Trends Neurosci. 2014;37:721&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">25223701</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Darnell RB. RNA protein interaction in neurons. Annu Rev Neurosci. 2013;36:243&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3889695</ArticleId><ArticleId IdType="pubmed">23701460</ArticleId></ArticleIdList></Reference><Reference><Citation>Leger M, et al. Object recognition test in mice. Nat Protoc. 2013;8:2531&#x2013;2537.</Citation><ArticleIdList><ArticleId IdType="pubmed">24263092</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29158413</PMID><DateCompleted><Year>2018</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>49</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>13018</StartPage><EndPage>13023</EndPage><MedlinePgn>13018-13023</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1713215114</ELocationID><Abstract><AbstractText>The molecular architecture of amyloids formed in vivo can be interrogated using luminescent conjugated oligothiophenes (LCOs), a unique class of amyloid dyes. When bound to amyloid, LCOs yield fluorescence emission spectra that reflect the 3D structure of the protein aggregates. Given that synthetic amyloid-&#x3b2; peptide (A&#x3b2;) has been shown to adopt distinct structural conformations with different biological activities, we asked whether A&#x3b2; can assume structurally and functionally distinct conformations within the brain. To this end, we analyzed the LCO-stained cores of &#x3b2;-amyloid plaques in postmortem tissue sections from frontal, temporal, and occipital neocortices in 40 cases of familial Alzheimer's disease (AD) or sporadic (idiopathic) AD (sAD). The spectral attributes of LCO-bound plaques varied markedly in the brain, but the mean spectral properties of the amyloid cores were generally similar in all three cortical regions of individual patients. Remarkably, the LCO amyloid spectra differed significantly among some of the familial and sAD subtypes, and between typical patients with sAD and those with posterior cortical atrophy AD. Neither the amount of A&#x3b2; nor its protease resistance correlated with LCO spectral properties. LCO spectral amyloid phenotypes could be partially conveyed to A&#x3b2; plaques induced by experimental transmission in a mouse model. These findings indicate that polymorphic A&#x3b2;-amyloid deposits within the brain cluster as clouds of conformational variants in different AD cases. Heterogeneity in the molecular architecture of pathogenic A&#x3b2; among individuals and in etiologically distinct subtypes of AD justifies further studies to assess putative links between A&#x3b2; conformation and clinical phenotype.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>Jay</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, 72074 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahler</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, 72074 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beschorner</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, 72074 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe4;sler</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nystr&#xf6;m</LastName><ForeName>Sofie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physics, Chemistry and Biology, Division of Chemistry, Link&#xf6;ping University, SE-581 83 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, SE-431 80 M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, SE-431 80 M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, SE-431 80 M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, SE-431 80 M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lashley</LastName><ForeName>Tammaryn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Queen Square Brain Bank for Neurological Diseases, Department of Molecular Neuroscience, Institute of Neurology, University College London, London WC1N 1PJ, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, London WC1N 3BG, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepulveda-Falla</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Group of Antioquia, University of Antioquia, 1226 Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Antioquia, 1226 Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glatzel</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oblak</LastName><ForeName>Adrian L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>K Peter R</ForeName><Initials>KPR</Initials><AffiliationInfo><Affiliation>Department of Physics, Chemistry and Biology, Division of Chemistry, Link&#xf6;ping University, SE-581 83 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammarstr&#xf6;m</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Physics, Chemistry and Biology, Division of Chemistry, Link&#xf6;ping University, SE-581 83 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Lary C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, GA 30322.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9045-1072</Identifier><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076 T&#xfc;bingen, Germany; mathias.jucker@uni-tuebingen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P51 OD011132</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS055077</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P51 RR000165</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013876">Thiophenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009778" MajorTopicYN="N">Occipital Lobe</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="Y">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013050" MajorTopicYN="N">Spectrometry, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013876" MajorTopicYN="N">Thiophenes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">prion</Keyword><Keyword MajorTopicYN="N">strains</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>6</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29158413</ArticleId><ArticleId IdType="pmc">PMC5724274</ArticleId><ArticleId IdType="doi">10.1073/pnas.1713215114</ArticleId><ArticleId IdType="pii">1713215114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Morris JC. Clinical presentation and course of Alzheimer disease. In: Terry RD, Katzman R, Bick KL, Sisodia SS, editors. Alzheimer Disease. Lippincott Williams &amp; Wilkins; Philadelphia: 1999. pp. 11&#x2013;24.</Citation></Reference><Reference><Citation>Nelson PT, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol. 2012;71:362&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam B, Masellis M, Freedman M, Stuss DT, Black SE. Clinical, imaging, and pathological heterogeneity of the Alzheimer&#x2019;s disease syndrome. Alzheimers Res Ther. 2013;5:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580331</ArticleId><ArticleId IdType="pubmed">23302773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan NS, et al. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer&#x2019;s disease: A case series. Lancet Neurol. 2016;15:1326&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">27777022</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Goate A, Kelly J, Sperling R. Mapping the road forward in Alzheimer&#x2019;s disease. Sci Transl Med. 2011;3:114ps48.</Citation><ArticleIdList><ArticleId IdType="pubmed">22190237</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012;148:1188&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353745</ArticleId><ArticleId IdType="pubmed">22424229</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko R. Amyloid polymorphism: Structural basis and neurobiological relevance. Neuron. 2015;86:632&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4425266</ArticleId><ArticleId IdType="pubmed">25950632</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilbronner G, et al. Seeded strain-like transmission of &#x3b2;-amyloid morphotypes in APP transgenic mice. EMBO Rep. 2013;14:1017&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3818077</ArticleId><ArticleId IdType="pubmed">23999102</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC, et al. Serial propagation of distinct strains of A&#x3b2; prions from Alzheimer&#x2019;s disease patients. Proc Natl Acad Sci USA. 2014;111:10323&#x2013;10328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104857</ArticleId><ArticleId IdType="pubmed">24982139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, et al. Molecular structure of &#x3b2;-amyloid fibrils in Alzheimer&#x2019;s disease brain tissue. Cell. 2013;154:1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang W, Yau WM, Lu JX, Collinge J, Tycko R. Structural variation in amyloid-&#x3b2; fibrils from Alzheimer&#x2019;s disease clinical subtypes. Nature. 2017;541:217&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233555</ArticleId><ArticleId IdType="pubmed">28052060</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen ML, et al. Rapidly progressive Alzheimer&#x2019;s disease features distinct structures of amyloid-&#x3b2;. Brain. 2015;138:1009&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014074</ArticleId><ArticleId IdType="pubmed">25688081</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RF, et al. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer&#x2019;s disease. Acta Neuropathol. 2010;119:221&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045810</ArticleId><ArticleId IdType="pubmed">19690877</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, et al. Amyloid structure exhibits polymorphism on multiple length scales in human brain tissue. Sci Rep. 2016;6:33079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024092</ArticleId><ArticleId IdType="pubmed">27629394</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagliavini F, Giaccone G, Frangione B, Bugiani O. Preamyloid deposits in the cerebral cortex of patients with Alzheimer&#x2019;s disease and nondemented individuals. Neurosci Lett. 1988;93:191&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">3241644</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Ihara Y. A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by beta protein immunostaining. Acta Neuropathol. 1988;76:541&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">3059748</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda S, Allsop D, Glenner GG. Morphology and distribution of plaque and related deposits in the brains of Alzheimer&#x2019;s disease and control cases. An immunohistochemical study using amyloid beta-protein antibody. Lab Invest. 1989;60:113&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">2642985</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM, Bancher C, Barcikowska M, Wen GY, Currie J. Spectrum of morphological appearance of amyloid deposits in Alzheimer&#x2019;s disease. Acta Neuropathol. 1989;78:337&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">2551122</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer&#x2019;s disease. Neuroscience. 2001;105:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483304</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ. 2006;2006:re1.</Citation><ArticleIdList><ArticleId IdType="pubmed">16525193</ArticleId></ArticleIdList></Reference><Reference><Citation>Maarouf CL, et al. Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations. Mol Neurodegener. 2008;3:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600784</ArticleId><ArticleId IdType="pubmed">19021905</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC. Proteopathic strains and the heterogeneity of neurodegenerative diseases. Annu Rev Genet. 2016;50:329&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6690197</ArticleId><ArticleId IdType="pubmed">27893962</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslund A, et al. Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. ACS Chem Biol. 2009;4:673&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886514</ArticleId><ArticleId IdType="pubmed">19624097</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegenast-Braun BM, et al. Spectral discrimination of cerebral amyloid lesions after peripheral application of luminescent conjugated oligothiophenes. Am J Pathol. 2012;181:1953&#x2013;1960.</Citation><ArticleIdList><ArticleId IdType="pubmed">23041059</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann US, et al. Structure-based drug design identifies polythiophenes as antiprion compounds. Sci Transl Med. 2015;7:299ra123.</Citation><ArticleIdList><ArticleId IdType="pubmed">26246168</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;ck M, Appelqvist H, LeVine H, 3rd, Nilsson KP. Anionic oligothiophenes compete for binding of X-34 but not PIB to recombinant A&#x3b2; amyloid fibrils and Alzheimer&#x2019;s disease brain-derived A&#x3b2;. Chemistry. 2016;22:18335&#x2013;18338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5215536</ArticleId><ArticleId IdType="pubmed">27767229</ArticleId></ArticleIdList></Reference><Reference><Citation>Psonka-Antonczyk KM, et al. Nanoscale structure and spectroscopic probing of A&#x3b2;1-40 fibril bundle formation. Front Chem. 2016;4:44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5118468</ArticleId><ArticleId IdType="pubmed">27921029</ArticleId></ArticleIdList></Reference><Reference><Citation>Nystr&#xf6;m S, et al. Evidence for age-dependent in vivo conformational rearrangement within A&#x3b2; amyloid deposits. ACS Chem Biol. 2013;8:1128&#x2013;1133.</Citation><ArticleIdList><ArticleId IdType="pubmed">23521783</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer F, et al. Soluble A&#x3b2; seeds are potent inducers of cerebral &#x3b2;-amyloid deposition. J Neurosci. 2011;31:14488&#x2013;14495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229270</ArticleId><ArticleId IdType="pubmed">21994365</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;hr J, et al. Purified and synthetic Alzheimer&#x2019;s amyloid beta (A&#x3b2;) prions. Proc Natl Acad Sci USA. 2012;109:11025&#x2013;11030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390876</ArticleId><ArticleId IdType="pubmed">22711819</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L, et al. A&#x3b2; seeding potency peaks in the early stages of cerebral &#x3b2;-amyloidosis. EMBO Rep. 2017;18:1536&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5579388</ArticleId><ArticleId IdType="pubmed">28701326</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, et al. Comparison of Alzheimer Abeta(1-40) and Abeta(1-42) amyloid fibrils reveals similar protofilament structures. Proc Natl Acad Sci USA. 2009;106:19813&#x2013;19818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764733</ArticleId><ArticleId IdType="pubmed">19843697</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, et al. Peptide dimer structure in an A&#x3b2;(1-42) fibril visualized with cryo-EM. Proc Natl Acad Sci USA. 2015;112:11858&#x2013;11863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586870</ArticleId><ArticleId IdType="pubmed">26351699</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, et al. A&#x3b2;(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer&#x2019;s disease. Nat Struct Mol Biol. 2015;22:499&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4476499</ArticleId><ArticleId IdType="pubmed">25938662</ArticleId></ArticleIdList></Reference><Reference><Citation>Gremer L, et al. Fibril structure of amyloid-&#x3b2;(1-42) by cryo-electron microscopy. Science. 2017;358:116&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080689</ArticleId><ArticleId IdType="pubmed">28882996</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Stohr J. Abeta propagation and strains: Implications for the phenotypic diversity in Alzheimer&#x2019;s disease. Neurobiol Dis. March 28, 2017 doi: 10.1016/j.nbd.2017.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2017.03.014</ArticleId><ArticleId IdType="pubmed">28359847</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;slund J, et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA. 1994;91:8378&#x2013;8382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44609</ArticleId><ArticleId IdType="pubmed">8078890</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer&#x2019;s disease. Acta Neuropathol. 2010;120:185&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568930</ArticleId><ArticleId IdType="pubmed">20419305</ArticleId></ArticleIdList></Reference><Reference><Citation>Crutch SJ, et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017;13:870&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5788455</ArticleId><ArticleId IdType="pubmed">28259709</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson K, et al. Multimodal fluorescence microscopy of prion strain specific PrP deposits stained by thiophene-based amyloid ligands. Prion. 2014;8:319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4601348</ArticleId><ArticleId IdType="pubmed">25495506</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingstedt T, et al. Distinct spacing between anionic groups: An essential chemical determinant for achieving thiophene-based ligands to distinguish &#x3b2;-amyloid or Tau polymorphic aggregates. Chemistry. 2015;21:9072&#x2013;9082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517144</ArticleId><ArticleId IdType="pubmed">26013403</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013;501:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C. Darwinian evolution of prions in cell culture. Science. 2010;327:869&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848070</ArticleId><ArticleId IdType="pubmed">20044542</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer&#x2019;s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer&#x2019;s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res. 2007;6:4433&#x2013;4439.</Citation><ArticleIdList><ArticleId IdType="pubmed">17927230</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 2010;330:980&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondolfi L, et al. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci. 2002;22:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758656</ArticleId><ArticleId IdType="pubmed">11784797</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29359764</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-4349</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature chemistry</Title><ISOAbbreviation>Nat Chem</ISOAbbreviation></Journal><ArticleTitle>Structure-based inhibitors of tau aggregation.</ArticleTitle><Pagination><StartPage>170</StartPage><EndPage>176</EndPage><MedlinePgn>170-176</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nchem.2889</ELocationID><Abstract><AbstractText>Aggregated tau protein is associated with over 20 neurological disorders, which include Alzheimer's disease. Previous work has shown that tau's sequence segments VQIINK and VQIVYK drive its aggregation, but inhibitors based on the structure of the VQIVYK segment only partially inhibit full-length tau aggregation and are ineffective at inhibiting seeding by full-length fibrils. Here we show that the VQIINK segment is the more powerful driver of tau aggregation. Two structures of this segment determined by the cryo-electron microscopy method micro-electron diffraction explain its dominant influence on tau aggregation. Of practical significance, the structures lead to the design of inhibitors that not only inhibit tau aggregation but also inhibit the ability of exogenous full-length tau fibrils to seed intracellular tau in HEK293 biosensor cells into amyloid. We also raise the possibility that the two VQIINK structures represent amyloid polymorphs of tau that may account for a subset of prion-like strains of tau.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seidler</LastName><ForeName>P M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0001-8530-7244</Identifier><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyer</LastName><ForeName>D R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawaya</LastName><ForeName>M R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cascio</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonen</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Janelia Research Campus, 19700 Helix Drive, Ashburn, Virginia 20147, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenberg</LastName><ForeName>D S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0003-2432-5419</Identifier><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS095661</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029430</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054022</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Chem</MedlineTA><NlmUniqueID>101499734</NlmUniqueID><ISSNLinking>1755-4330</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29359764</ArticleId><ArticleId IdType="mid">NIHMS910990</ArticleId><ArticleId IdType="pmc">PMC5784779</ArticleId><ArticleId IdType="doi">10.1038/nchem.2889</ArticleId><ArticleId IdType="pii">nchem.2889</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Margittai M, Langen R. Side Chain-dependent Stacking Modulates Tau Filament Structure. Journal of Biological Chemistry. 2006;281:37820&#x2013;37827. doi: 10.1074/jbc.M605336200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M605336200</ArticleId><ArticleId IdType="pubmed">17023423</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, et al. Assembly of &#x3c4; protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming &#x3b2; structure. Proceedings of the National Academy of Sciences. 2000;97:5129&#x2013;5134. doi: 10.1073/pnas.97.10.5129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.10.5129</ArticleId><ArticleId IdType="pmc">PMC25793</ArticleId><ArticleId IdType="pubmed">10805776</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Eisenberg DS, Crowther RA. Annual Review of Neuroscience. 2017;40 doi: 10.1146/annurev-neuro-072116-031153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-072116-031153</ArticleId><ArticleId IdType="pubmed">28772101</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz AJ, et al. Regional profiles of the candidate tau PET ligand recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539&#x2013;1550. doi: 10.1093/brain/aww023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww023</ArticleId><ArticleId IdType="pubmed">26936940</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M, Reddy PH. Abnormal interaction of oligomeric amyloid-&#x3b2; with phosphorylated tau: implications to synaptic dysfunction and neuronal damage. Journal of Alzheimer&#x2019;s disease: JAD. 2013;36:285&#x2013;295. doi: 10.3233/JAD-130275.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-130275</ArticleId><ArticleId IdType="pmc">PMC3943249</ArticleId><ArticleId IdType="pubmed">23594602</ArticleId></ArticleIdList></Reference><Reference><Citation>Seward ME, et al. Amyloid-&#x3b2; signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer&#x2019;s disease. Journal of Cell Science. 2013;126:1278&#x2013;1286. doi: 10.1242/jcs.1125880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.1125880</ArticleId><ArticleId IdType="pmc">PMC3635465</ArticleId><ArticleId IdType="pubmed">23345405</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, et al. Tau and A&#x3b2; imaging, CSF measures, and cognition in Alzheimer&#x2019;s disease. Science Translational Medicine. 2016;8:338ra366&#x2013;338ra366. doi: 10.1126/scitranslmed.aaf2362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf2362</ArticleId><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular Propagation of Tau Aggregation by Fibrillar Species. The Journal of Biological Chemistry. 2012;287:19440&#x2013;19451. doi: 10.1074/jbc.M112.346072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.346072</ArticleId><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, et al. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. Journal of Biological Chemistry. 2001 doi: 10.1074/jbc.M105196200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M105196200</ArticleId><ArticleId IdType="pubmed">11606569</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR, et al.  Atomic structures of amyloid cross-[bgr] spines reveal varied steric zippers. Nature. 2007;447:453&#x2013;457.  http://www.nature.com/nature/journal/v447/n7143/suppinfo/nature05695_S1.html.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers SA, et al.  Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature. 2011;475:96&#x2013;100.  http://www.nature.com/nature/journal/v475/n7354/abs/nature10154-f1.2.html#supplementary-information.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4073670</ArticleId><ArticleId IdType="pubmed">21677644</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, et al. Macrocyclic &#x3b2;-Sheet Peptides That Inhibit the Aggregation of a Tau-Protein-Derived Hexapeptide. Journal of the American Chemical Society. 2011;133:3144&#x2013;3157. doi: 10.1021/ja110545h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja110545h</ArticleId><ArticleId IdType="pmc">PMC3048834</ArticleId><ArticleId IdType="pubmed">21319744</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi D, Nannenga BL, Iadanza MG, Gonen T. Three-dimensional electron crystallography of protein microcrystals. eLife. 2013;2:e01345. doi: 10.7554/eLife.01345.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.01345</ArticleId><ArticleId IdType="pmc">PMC3831942</ArticleId><ArticleId IdType="pubmed">24252878</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez JA, et al. Structure of the toxic core of [agr]-synuclein from invisible crystals. Nature. 2015;525:486&#x2013;490. doi: 10.1038/nature15368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15368</ArticleId><ArticleId IdType="pmc">PMC4791177</ArticleId><ArticleId IdType="pubmed">26352473</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez JA, Gonen T. In: Methods in Enzymology. Crowther RA, editor. Vol. 579. Academic Press; 2016. pp. 369&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5656567</ArticleId><ArticleId IdType="pubmed">27572734</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg DS, Sawaya MR. Annu Rev Biochem. 2017:3.1&#x2013;3.27.</Citation><ArticleIdList><ArticleId IdType="pubmed">28125289</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood SJ, Wetzel R, Martin JD, Hurle MR. Prolines and Aamyloidogenicity in Fragments of the Alzheimer&#x2019;s Peptide.beta./A4. Biochemistry. 1995;34:724&#x2013;730. doi: 10.1021/bi00003a003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00003a003</ArticleId><ArticleId IdType="pubmed">7827029</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore CL, et al. Secondary nucleating sequences affect kinetics and thermodynamics of tau aggregation. Biochemistry. 2011;50:10876&#x2013;10886. doi: 10.1021/bi2014745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi2014745</ArticleId><ArticleId IdType="pmc">PMC3237831</ArticleId><ArticleId IdType="pubmed">22085312</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, et al. Mutations of Tau Protein in Frontotemporal Dementia Promote Aggregation of Paired Helical Filaments by Enhancing Local &#x3b2;-Structure. Journal of Biological Chemistry. 2001;276:48165&#x2013;48174.</Citation><ArticleIdList><ArticleId IdType="pubmed">11606569</ArticleId></ArticleIdList></Reference><Reference><Citation>Margittai M, Langen R. Fibrils with parallel in-register structure constitute a major class of amyloid fibrils: molecular insights from electron paramagnetic resonance spectroscopy. Quarterly Reviews of Biophysics. 2008;41:265&#x2013;297. doi: 10.1017/S0033583508004733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033583508004733</ArticleId><ArticleId IdType="pubmed">19079806</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirbaha H, Holmes BB, Sanders DW, Bieschke J, Diamond MI. Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. Journal of Biological Chemistry. 2015 doi: 10.1074/jbc.M115.652693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.652693</ArticleId><ArticleId IdType="pmc">PMC4463437</ArticleId><ArticleId IdType="pubmed">25887395</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders David W, et al.  Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies. Neuron. 2014;82:1271&#x2013;1288.  http://dx.doi.org/10.1016/j.neuron.2014.04.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.04.047</ArticleId><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqua A, et al. Conformational Basis for Asymmetric Seeding Barrier in Filaments of Three- and Four-Repeat Tau. Journal of the American Chemical Society. 2012;134:10271&#x2013;10278. doi: 10.1021/ja303498q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja303498q</ArticleId><ArticleId IdType="pmc">PMC3381011</ArticleId><ArticleId IdType="pubmed">22656332</ArticleId></ArticleIdList></Reference><Reference><Citation>Margittai M, Langen R. Template-assisted filament growth by parallel stacking of tau. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:10278&#x2013;10283. doi: 10.1073/pnas.0401911101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0401911101</ArticleId><ArticleId IdType="pmc">PMC478563</ArticleId><ArticleId IdType="pubmed">15240881</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature. 2017;547:185&#x2013;190. doi: 10.1038/nature23002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23002</ArticleId><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman Sarah K, et al.  Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. Neuron. 2016;92:796&#x2013;812.  http://dx.doi.org/10.1016/j.neuron.2016.09.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.055</ArticleId><ArticleId IdType="pmc">PMC5392364</ArticleId><ArticleId IdType="pubmed">27974162</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltzius JJW, et al.  Molecular mechanisms for protein-encoded inheritance. Nat Struct Mol Biol. 2009;16:973&#x2013;978.  http://www.nature.com/nsmb/journal/v16/n9/suppinfo/nsmb.1643_S1.html.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640378</ArticleId><ArticleId IdType="pubmed">19684598</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabsch W, XDS Acta Crystallographica Section D: Biological Crystallography. 2010;66:125&#x2013;132. doi: 10.1107/S0907444909047337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909047337</ArticleId><ArticleId IdType="pmc">PMC2815665</ArticleId><ArticleId IdType="pubmed">20124692</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy AJ, et al. Phaser crystallographic software. Journal of Applied Crystallography. 2007;40:658&#x2013;674. doi: 10.1107/S0021889807021206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0021889807021206</ArticleId><ArticleId IdType="pmc">PMC2483472</ArticleId><ArticleId IdType="pubmed">19461840</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov GN, Vagin AA, Dodson EJ. Refinement of Macromolecular Structures by the Maximum-Likelihood Method. Acta Crystallographica Section D. 1997;53:240&#x2013;255. doi: 10.1107/S0907444996012255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444996012255</ArticleId><ArticleId IdType="pubmed">15299926</ArticleId></ArticleIdList></Reference><Reference><Citation>Bricogne G, BE, Brandl M, Flensburg C, Keller P, Paciorek W, Roversi P, Sharff A, Smart OS, Vonrhein C, Womack TO. BUSTER 2.10.0. Cambridge, United Kingdom: Global Phasing Ltd; 2016.</Citation></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallographica Section D. 2010;66:486&#x2013;501. doi: 10.1107/S0907444910007493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444910007493</ArticleId><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, et al. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. The EMBO Journal. 1992;11:1593&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556608</ArticleId><ArticleId IdType="pubmed">1563356</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Meth. 2012;9:671&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29188296</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6238</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA psychiatry</Title><ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association of Cerebral Amyloid-&#x3b2; Aggregation With Cognitive Functioning in Persons Without Dementia.</ArticleTitle><Pagination><StartPage>84</StartPage><EndPage>95</EndPage><MedlinePgn>84-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2017.3391</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Cerebral amyloid-&#x3b2; aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials.</AbstractText><AbstractText Label="OBJECTIVE">To investigate whether amyloid-&#x3b2; aggregation is associated with cognitive functioning in persons without dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Global cognitive performance as assessed by the Mini-Mental State Examination (MMSE) and episodic memory performance as assessed by a verbal word learning test. Amyloid aggregation was measured with positron emission tomography or cerebrospinal fluid biomarkers and dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. Generalized estimating equations were used to examine the association between amyloid aggregation and low cognitive scores (MMSE score &#x2264;27 or memory z score&#x2264;-1.28) and to assess whether this association was moderated by age, sex, educational level, or apolipoprotein E genotype.</AbstractText><AbstractText Label="RESULTS">Among 2908 persons with normal cognition (mean [SD] age, 67.4 [12.8] years), amyloid positivity was associated with low memory scores after age 70 years (mean difference in amyloid positive vs negative, 4% [95% CI, 0%-7%] at 72 years and 21% [95% CI, 10%-33%] at 90 years) but was not associated with low MMSE scores (mean difference, 3% [95% CI, -1% to 6%], P&#x2009;=&#x2009;.16). Among 4133 patients with MCI (mean [SD] age, 70.2 [8.5] years), amyloid positivity was associated with low memory (mean difference, 16% [95% CI, 12%-20%], P&#x2009;&lt;&#x2009;.001) and low MMSE (mean difference, 14% [95% CI, 12%-17%], P&#x2009;&lt;&#x2009;.001) scores, and this association decreased with age. Low cognitive scores had limited utility for screening of amyloid positivity in persons with normal cognition and those with MCI. In persons with normal cognition, the age-related increase in low memory score paralleled the age-related increase in amyloid positivity with an intervening period of 10 to 15 years.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Although low memory scores are an early marker of amyloid positivity, their value as a screening measure for early AD among persons without dementia is limited.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Willemijn J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tijms</LastName><ForeName>Betty M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals, and University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Department, Hospital de Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallin</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Na</LastName><ForeName>Duk L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ch&#xe9;telat</LastName><ForeName>G&#xe4;el</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), CHU de Caen, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinuevo</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, IDIBAPS, Clinic University Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornhuber</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabri</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parnetti</LastName><ForeName>Lucilla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Section of Neurology, Center for Memory Disturbances, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popp</LastName><ForeName>Julius</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Service of Old Age Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fladby</LastName><ForeName>Tormod</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aalten</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Young</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Seoul National University, College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology and Alzheimer Research Centre KU Leuven, Catholic University Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resende de Oliveira</LastName><ForeName>Catarina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology, Faculty of Medicine, Centro Hospitalar e Universit&#xe1;rio de Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapaki</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>First Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Froelich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanoiu</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory Clinic and Neurochemistry Laboratory, Saint Luc University Hospital, Institute of Neuroscience, Universit&#xe9; catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabryelewicz</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre Polish Academy of Sciences, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verbeek</LastName><ForeName>Marcel M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Laboratory Medicine, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Juan</LastName><ForeName>P&#xe1;scual</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neurology Service, Universitary Hospital Marqu&#xe9;s de Valdecilla, IDIVAL, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildebrandt</LastName><ForeName>Helmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Neurology, Hospital of Bremen-Ost, Bremen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camus</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>CHRU de Tours, CIC INSERM 1415, INSERM U930, and Universit&#xe9; Fran&#xe7;ois Rabelais de Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zboch</LastName><ForeName>Marzena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Wroclaw Medical University, Scinawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Neuroscience, Medical Research Council Clinical Sciences Centre, Imperial College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drzezga</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>Juha O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Turku PET Centre and Division of Clinical Neurosciences Turku, University of Turku and Turku University Hospital, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newberg</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Myrna Brind Center of Integrative Medicine, Thomas Jefferson University and Hospital, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mendon&#xe7;a</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine and Faculty of Medicine, University of Lisbon, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarazin</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurologie de la M&#xe9;moire et du Langage, Centre Hospitalier Sainte-Anne, Universit&#xe9; Paris 5, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madsen</LastName><ForeName>Karine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurobiology Research Unit, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramberger</LastName><ForeName>Milica G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Center for Cognitive Impairments, University Medical Centre Ljubljana, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordberg</LastName><ForeName>Agneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department NVS, Center for Alzheimer Research, Translational Alzheimer Neurobiology, Karolinska Institutet, and Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Lui Che Woo Institute of Innovative Medicine, Department of Medicine and Therapeutics, Therese Pei Fong Chow Research Centre for Prevention of Dementia, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mroczko</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurodegeneration Diagnostics, Leading National Research Centre in Bia&#x142;ystok (KNOW), Medical University of Bia&#x142;ystok, Bia&#x142;ystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Philipp T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans R J</ForeName><Initials>FRJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Pieter Jelle</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Amyloid Biomarker Study Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcolea</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurology Department, Hospital de Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Roche Products, Welwyn Garden City, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almdahl</LastName><ForeName>Ina S</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldeiras</LastName><ForeName>In&#xea;s</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology, Faculty of Medicine, Centro Hospitalar e Universit&#xe1;rio de Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barthel</LastName><ForeName>Henryk</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Berckel</LastName><ForeName>Bart N M</ForeName><Initials>BNM</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Buchem</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavedo</LastName><ForeName>Enrica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>D&#xe9;partement de Neurologie, Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A), H&#xf4;pital Piti&#xe9;-Stijmsalp&#xea;tri&#xe8;re, Boulevard de l'h&#xf4;pital, F-75013, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AXA Research Fund &amp; UPMC Chair, Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Inserm, CNRS, Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chipi</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Section of Neurology, Center for Memory Disturbances, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ann D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xf6;rster</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Technische Universitaet M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology Department, Hospital de Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frederiksen</LastName><ForeName>Kristian S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Danish Dementia Research Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freund-Levi</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Karolinska University Hospital Huddinge, Section of Clinical Geriatrics, Institution of NVS, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gkatzima</LastName><ForeName>Olymbia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Mark Forrest</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimmer</LastName><ForeName>Timo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitaet M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de Neurologie, Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A), H&#xf4;pital Piti&#xe9;-Stijmsalp&#xea;tri&#xe8;re, Boulevard de l'h&#xf4;pital, F-75013, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AXA Research Fund &amp; UPMC Chair, Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Inserm, CNRS, Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Ludwig-Maximilian University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hausner</LastName><ForeName>Lucrezia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellwig</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Geriatrics and Gerontology, University Hospital Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herukka</LastName><ForeName>Sanna-Kaisa</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johannsen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Memory Clinic, Danish Dementia Research Center, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klimkowicz-Mrowiec</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Jagiellonian University College of Medicine, Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;hler</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koglin</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Piramal Imaging GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Laere</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Imaging and Pathology, Catholic University Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Medicine, Center for Brain Health, New York University, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lisetti</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Section of Neurology, Center for Memory Disturbances, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Bonn, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcusson</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Geriatric Medicine, Department of Clinical and Experimental Medicine, University of Link&#xf6;ping, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meulenbroek</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;llerg&#xe5;rd</LastName><ForeName>Hanne M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordlund</LastName><ForeName>Arto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novak</LastName><ForeName>Gerald P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paraskevas</LastName><ForeName>George P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>First Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perera</LastName><ForeName>Gayan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Roche Products, Welwyn Garden City, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Kings College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charit&#xe9; Berlin, German Center for Neurodegenrative Diseases (DZNE), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramakers</LastName><ForeName>Inez H G B</ForeName><Initials>IHGB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rami</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, IDIBAPS, Clinic University Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Rodr&#xed;guez</LastName><ForeName>Eloy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurology Service, Universitary Hospital Marqu&#xe9;s de Valdecilla, IDIVAL, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rot</LastName><ForeName>Uros</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Center for Cognitive Impairments, University Medical Centre Ljubljana, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xfc;ther</LastName><ForeName>Eckart</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August University, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology, Faculty of Medicine, Centro Hospitalar e Universit&#xe1;rio de Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schr&#xf6;der</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sektion Gerontopsychiatrie, Universit&#xe4;t Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Sang W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spiru</LastName><ForeName>Luiza</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Geriatrics-Gerontology-Gerontopsychiatry, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Struyfs</LastName><ForeName>Hanne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vos</LastName><ForeName>Stephanie J B</ForeName><Initials>SJB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Waalwijk van Doorn</LastName><ForeName>Linda J C</ForeName><Initials>LJC</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Laboratory Medicine, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldemar</LastName><ForeName>Gunhild</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Technische Universitaet M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallin</LastName><ForeName>&#xc5;sa K</ForeName><Initials>&#xc5;K</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August University, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018898</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG025204</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Psychiatry</MedlineTA><NlmUniqueID>101589550</NlmUniqueID><ISSNLinking>2168-622X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Psychiatry. 2018 Mar 1;75(3):303. doi: 10.1001/jamapsychiatry.2017.4558.</RefSource><PMID Version="1">29417129</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Aarsland
reports receiving research support or honoraria from AstraZeneca, H. Lundbeck, Novartis
Pharmaceuticals, and GE Health. Dr Alexander reports being an employee of Roche Products.
Dr Barthel reports receiving speaker, consultant honoraria, and travel expenses from
Piramal Imaging (Berlin) and personal fees from Siemens Healthcare. Dr Blennow reports
receiving personal fees (advisory boards or consulting) from Roche Diagnostics, IBL
International, Novartis, Fujirebio Europe, and Eli Lilly and Company and is a cofounder of
Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the
University of Gothenburg. Dr Chen reports receiving grants from the National Institutes of
Health (NIH). Dr Drzezga reports receiving speaker honoraria and consulting fees from GE
Healthcare, Avid Radiopharmaceuticals/Eli Lilly and Company, and Piramal. Dr Fagan reports
receiving grants from the NIH, DiamiR, Fred Simmons and Olga Mohan, and Charles and Joanne
Knight Alzheimer&#x2019;s Research Initiative of the Washington University Knight
Alzheimer&#x2019;s Disease Research Center and personal fees from IBL International, Roche,
and AbbVie. Dr Fladby reports having a patent on methods and compositions for monitoring
phagocytic activity (PCT/US2011/062233) pending. Dr Fleisher reports having been a
full-time employee of the Banner Alzheimer&#x2019;s Institute; being a full-time employee
of Eli Lilly and Company; maintaining a voluntary faculty appointment at the University of
California, San Diego; having been a member of data and safety monitoring boards for
Merck, Pfizer, and the National Institute of Aging (NIA); receiving grant funding from the
NIA and Avid Radiopharmaceuticals; and having been a consultant for Eli Lilly and Company,
Grifols, Avid Radiopharmaceuticals, and Siemens Imaging. Dr van der Flier reports
receiving grants from Boehringer Ingelheim, Piramal Imaging, and Roche. Dr F&#xf6;rster
reports receiving personal fees (consultancy) from Piramal, Bayer, and GE. Dr Frisoni
reports receiving grants and/or personal fees from Eli Lilly and Company, Bristol-Myers
Squibb, Bayer, Lundbeck, Elan, AstraZeneca, Pfizer, Taurx, Wyeth, GE, Baxter, Avid
Radiopharmaceuticals, Roche, Piramal, and the Alzheimer&#x2019;s Association. Dr Gordon
reports being a salaried employee of Boehringer Ingelheim Pharmaceuticals. Dr Grimmer
reports receiving personal fees from Eli Lilly and Company. Dr Hampel reports support from
the AXA Research Fund, the Fondation Universit&#xe9; Pierre et Marie Curie, and the
Fondation pour la Recherche sur Alzheimer, Paris, France; receiving grants, personal fees,
and/or nonfinancial support from Boehringer-Ingelheim, Bristol-Myers Squibb, Elan,
Novartis, Eisai, Pfizer, Sanofi, Roche, GE Healthcare, Avid Radiopharmaceuticals, Eli
Lilly and Company, GlaxoSmithKline Biologicals, Jung Diagnostics, and Cytox; and having a
patent on method for predicting whether subjects with mild cognitive impairment will
develop Alzheimer&#x2019;s disease pending, a patent on 3-hydroxykynurenin in serum as
diagnostic marker for Alzheimer-type dementia pending, a patent on neurodegenerative
markers for 10 psychiatric conditions pending, a patent on plasma A&#x3b2;42/40 ratio for
early and differential diagnosis of Alzheimer disease pending, a patent in liquor
diagnostics in vitro procedures for the diagnosis of dementia and neuroinflammatory
disease pending, and a patent on in vitro procedures for the diagnosis of
neurodegenerative diseases pending. Dr Hansson reports receiving research support from GE
Healthcare, Avid Radiopharmaceuticals, and Hoffmann-La Roche. Dr Hellwig reports receiving
grants from GE Healthcare and Medical Faculty, University of Freiburg. Dr Jagust reports
receiving personal fees from Banner Alzheimer Institute/Genentech, Synarc/Bioclinica, and
Novartis. Dr Jansen reports receiving research support from Biogen. Dr Kapaki reports
receiving grants from the European Union (European Regional Development Fund) and Greek
national funds through the Operational Program &#x201c;Competitiveness and
Entrepreneurship&#x201d; of the National Strategic Reference Framework Research Funding
Program: Joint Programming Neurodegenerative Disease, &#x201c;Biomarkers for
Alzheimer&#x2019;s Disease and Parkinson&#x2019;s Disease.&#x201d; Dr Klunk reports being a
co-inventor of the amyloid imaging tracer PiB and having a financial interest in the
license agreement (PiB intellectual property is owned by the University of Pittsburgh, and
GE Healthcare holds a license agreement with the University of Pittsburgh based on the PiB
technology described in this article. Dr Klunk receives inventors share payments from the
University of Pittsburgh based on income from that license). Dr Koglin reports receiving
personal fees from employment at Piramal Imaging. Dr Kornhuber reports receiving grants
from the German Federal Ministry of Education and Research (grant 01GI0420 from the
Kompetenznetz Demenzen and German Federal Ministry of Education and Research and grant
01GI1007A from the Frontotemporo-Lobar Degeneration Consortium) and having a patent on
diagnosis of Alzheimer&#x2019;s disease (PCT/ EP2004/003963) issued, a patent on large
A&#xdf;-peptide binding particles in diagnosis and therapy of Alzheimer&#x2019;s dementia
(EP 1811304 A1) issued, a patent on immunoglobulin-bound Ab-peptides and
immunoglobulins-binding Ab-peptides in diagnosis and therapy of Alzheimer&#x2019;s dementia
(WO2007/082750 A1) issued, a patent on methods of differentially diagnosing dementias (EP
2437067A2) issued, and a patent on new formulations for diagnosis of Alzheimer&#x2019;s
disease pending. Dr Van Laere reported having received grants through KU Leuven from
Merck, Janssen Pharmaceuticals, UCB, Novartis, Pfizer, and GE Healthcare. Dr Landau
reported having received grants from the NIH and personal fees from Biogen Idec,
Genentech, and Synarc. Dr Lleo reports receiving grants PI10/ 01878, PI13/01532, PI11/242,
and PI11/3035 from Instituto de Salud Carlos III (Fondo de Investigaci&#xf3;n Sanitario
and the CIBERNED program). Dr Madsen reports receiving grants from the Lundbeck
Foundation, Danish Medical Research Council, and Rigshospitalet. Dr Meyer reportd
receiving money from GE Healthcare for an ongoing research study. Dr Mintun reports being
an employee of Avid Radiopharmaceuticals. Dr Morris reports receiving grants P50AG005681,
P01AG003991, P01AG026276, and U19AG032438 from the NIH. Dr Mroczko reports receiving
grants and personal fees from the Leading National Research Centre (KNOW), Medical
University of Bialystok, Poland, and consultation and/or lecture honoraria from Roche,
Cormay, and Biameditek. Dr Novak reports being an employee of and holding stock in Janssen
Research and Development. Dr Paraskevas reports receiving grants from the European Union
(European Regional Development Fund) and Greek national funds through the Operational
Program &#x201c;Competitiveness and Entrepreneurship&#x201d; of the National Strategic
Reference Framework Research Funding Program: Joint Programming Neurodegenerative Disease,
&#x201c;Biomarkers for Alzheimer&#x2019;s Disease and Parkinson&#x2019;s Disease.&#x201d; Dr
Perera reports research support from grant ES/L002825/1 by the British Cross-research
Council Lifelong Health and Wellbeing Programme under Extending Working Lives as part of
an interdisciplinary consortium on Wellbeing, Health, Retirement and the Lifecourse and
receiving funding from the National Institute for Health Research Biomedical Research
Centre and Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation
Trust and King&#x2019;s College London. Dr Peters reports receiving grants and/or personal
fees from Eli Lilly and Company, Roche, Genentech, Lundbeck, Affiris, Piramal, Novartis,
and Trx-Pharmaceuticals. Dr Popp reports receiving grant 320030L_141179 from the Swiss
National Science Foundation and from the Nestl&#xe9; Institute of Health Sciences. Dr
Rabinovici reports receiving grants from Avid Radiopharmaceuticals and personal fees from
GE Healthcare and Piramal. Dr Rinne reports receiving grants from Sigrid Juselius
Foundation and Turku University Hospital. Dr Rot reports receiving grants from EU Joint
Programme&#x2013;Neurodegenerative Disease Research&#x2013;Biomarkers for Alzheimer Disease
and Parkinson Disease. Dr Rowe reports receiving grants from Avid Radiopharmaceuticals,
Piramal Imaging, AstraZeneca, GE Healthcare, Avid Radiopharmaceuticals/Eli Lilly and
Company, Navidea, Australian Commonwealth Scientific Industrial and Research Organization,
National Health and Medical Research Council, Alzheimer&#x2019;s Association, and an
anonymous foundation and having had a patent licensed for positron emission tomography
image processing. Dr Sabri reports receiving grants and/or personal fees from Piramal
Imaging, Bayer Healthcare, and Siemens Healthcare. Dr Sarazin reports receiving personal
lecture fees from Novartis and Allianz. Dr Scheltens reports receiving grants from GE
Healthcare, Piramal, and Merck paid to his institution. Dr Soininen reports receiving
grants from the Academy of Finland, European Union 7ThFP 601055 VPH-DARE, Kuopio
University Hospital VTR, and University of Eastern Finland. Dr Teunissen reports being a
member of the international advisory board at Innogenetics and Roche and having research
contracts at Probiodrug, Boehringer, Roche, EIP Pharma, and IBL. Dr Vandenberghe reports
receiving clinical trial agreements with GE Health Care, Merck, Forum, and Roche; grants
from Research Foundation&#x2013;Flanders (FWO) and KU Leuven; and nonfinancial support from
GEHC. Dr Verbeek reports serving on an advisory board for Roche. Dr Verhey reports
receiving compensation as a speaker and consultant for Nutricia Advanced Medical Food. Dr
Visser reports receiving research support from Biogen, grants from the European Federation
of Pharmaceutical Industries and Associations (EFPIA) Innovative Medicines Initiative
Joint Undertaking, EU Joint Programme&#x2013;Neurodegenerative Disease Research, ZonMw, and
Bristol-Myers Squibb; having served as member of the advisory board of Roche Diagnostics;
and having received nonfinancial support from GE Healthcare. Dr Vos reports receiving
research support from ZonMW and from the Innovative Medicines Initiative Joint Undertaking
under EMIF grant agreement 115372, resources that are composed of financial contributions
from EU FP7 (FP7/2007-2013) and in-kind contributions from EFPIA. Dr Waldemar reports
being a board member of the Lundbeck Foundation. Dr Anders Wallin reports receiving
speakers&#x2019; bureau fees from Esai and Triolab and serving on the advisory board for
Nutrica and Esai. Dr Wolk reports receiving personal fees from GE Healthcare and Piramal
Pharma and grants from Avid Radiopharmaceuticals. Dr Zetterberg reports being a cofounder
of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the
University of Gothenburg. The authors received compensation (ie, salary) as employees of
their respective organizations. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>11</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29188296</ArticleId><ArticleId IdType="mid">NIHMS927770</ArticleId><ArticleId IdType="pmc">PMC5786156</ArticleId><ArticleId IdType="doi">10.1001/jamapsychiatry.2017.3391</ArticleId><ArticleId IdType="pii">2664259</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. ; Amyloid Biomarker Study Group . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, et al. ; Dominantly Inherited Alzheimer Network . Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci Transl Med. 2014;6(226):226ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Age-specific population frequencies of cerebral &#x3b2;-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 2014;13(10):997-1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324499</ArticleId><ArticleId IdType="pubmed">25201514</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Johnson KA, Doraiswamy PM, et al. ; AV45-A05 Study Group . Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging. 2013;34(3):822-831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3518678</ArticleId><ArticleId IdType="pubmed">22878163</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. . Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham SC, Bourgeat P, Dor&#xe9; V, et al. ; AIBL Research Group . Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer&#x2019;s disease pathophysiology (SNAP) or Alzheimer&#x2019;s disease pathology: a longitudinal study. Lancet Neurol. 2016;15(10):1044-1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">27450471</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. . Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Wiste HJ, Weigand SD, et al. . Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol. 2016;73(1):85-92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4710552</ArticleId><ArticleId IdType="pubmed">26595683</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Savage G, Villemagne VL, et al. . Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer&#x2019;s disease. Brain. 2007;130(pt 11):2837-2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Engler H, Almkvist O, et al. . PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29(10):1456-1465.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology. 2013;80(14):1341-1348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656457</ArticleId><ArticleId IdType="pubmed">23547267</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Machulda MM, Hagen CE, et al. . Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort. Alzheimers Dement. 2016;12(3):281-291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4850495</ArticleId><ArticleId IdType="pubmed">26602629</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentz DM, Amariglio RE, Becker JA, et al. . Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011;49(9):2776-2783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137730</ArticleId><ArticleId IdType="pubmed">21689670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. ; Amyloid PET Study Group . Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939-1949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517678</ArticleId><ArticleId IdType="pubmed">25988463</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Age, sex, and APOE &#x3b5;4 effects on memory, brain structure, and &#x3b2;-amyloid across the adult life span. JAMA Neurol. 2015;72(5):511-519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428984</ArticleId><ArticleId IdType="pubmed">25775353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Boyle PA, Yu L, Barnes LL, Schneider JA, Bennett DA. Life-span cognitive activity, neuropathologic burden, and cognitive aging. Neurology. 2013;81(4):314-321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772831</ArticleId><ArticleId IdType="pubmed">23825173</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, et al. . Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain. 2015;138(Pt 3):761-771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339775</ArticleId><ArticleId IdType="pubmed">25595145</ArticleId></ArticleIdList></Reference><Reference><Citation>Amieva H, Mokri H, Le Goff M, et al. . Compensatory mechanisms in higher-educated subjects with Alzheimer&#x2019;s disease: a study of 20 years of cognitive decline. Brain. 2014;137(Pt 4):1167-1175.</Citation><ArticleIdList><ArticleId IdType="pubmed">24578544</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre-Acevedo DC, Lopera F, Henao E, et al. . Cognitive decline in a Colombian kindred with autosomal dominant Alzheimer disease: a retrospective cohort study. JAMA Neurol. 2016;73(4):431-438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505685</ArticleId><ArticleId IdType="pubmed">26902171</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, et al. . Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80(19):1784-1791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study . Amyloid and APOE &#x3b5;4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760-1767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Villemagne VL, Pietrzak RH, et al. ; Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group . APOE &#x3b5;4 moderates amyloid-related memory decline in preclinical Alzheimer&#x2019;s disease. Neurobiol Aging. 2015;36(3):1239-1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">25559335</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo EH, Kim SH, Park SH, Kang SH, Choo IH; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Independent and interactive influences of the APOE genotype and beta-amyloid burden on cognitive function in mild cognitive impairment. J Korean Med Sci. 2016;31(2):286-295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4729511</ArticleId><ArticleId IdType="pubmed">26839485</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Boyle PA, Leurgans S, Schneider JA, Bennett DA. Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiol Aging. 2014;35(4):819-826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3882071</ArticleId><ArticleId IdType="pubmed">24199961</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer&#x2019;s disease: allelic variation and receptor interactions. Neuron. 1993;11(4):575-580.</Citation><ArticleIdList><ArticleId IdType="pubmed">8398148</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowell NG, Evans SL, Tofts PS, King SL, Tabet N, Rusted JM. Structural and resting-state MRI detects regional brain differences in young and mid-age healthy APOE-e4 carriers compared with non-APOE-e4 carriers. NMR Biomed. 2016;29(5):614-624.</Citation><ArticleIdList><ArticleId IdType="pubmed">26929040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. . The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29197216</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Early Cognitive, Structural, and Microstructural Changes in Presymptomatic C9orf72 Carriers Younger Than 40 Years.</ArticleTitle><Pagination><StartPage>236</StartPage><EndPage>245</EndPage><MedlinePgn>236-245</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.4266</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Presymptomatic carriers of chromosome 9 open reading frame 72 (C9orf72) mutation, the most frequent genetic cause of frontotemporal lobar degeneration and amyotrophic lateral sclerosis, represent the optimal target population for the development of disease-modifying drugs. Preclinical biomarkers are needed to monitor the effect of therapeutic interventions in this population.</AbstractText><AbstractText Label="OBJECTIVES">To assess the occurrence of cognitive, structural, and microstructural changes in presymptomatic C9orf72 carriers.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The PREV-DEMALS study is a prospective, multicenter, observational study of first-degree relatives of individuals carrying the C9orf72 mutation. Eighty-four participants entered the study between October 2015 and April 2017; 80 (95%) were included in cross-sectional analyses of baseline data. All participants underwent neuropsychological testing and magnetic resonance imaging; 63 (79%) underwent diffusion tensor magnetic resonance imaging. Gray matter volumes and diffusion tensor imaging metrics were calculated within regions of interest. Anatomical and microstructural differences between individuals who carried the C9orf72 mutation (C9+) and those who did not carry the C9orf72 mutation (C9-) were assessed using linear mixed-effects models. Data were analyzed from October 2015 to April 2017.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Differences in neuropsychological scores, gray matter volume, and white matter integrity between C9+ and C9- individuals.</AbstractText><AbstractText Label="RESULTS">Of the 80 included participants, there were 41 C9+ individuals (24 [59%] female; mean [SD] age, 39.8 [11.1] years) and 39 C9- individuals (24 [62%] female; mean [SD] age, 45.2 [13.9] years). Compared with C9- individuals, C9+ individuals had lower mean (SD) praxis scores (163.4 [6.1] vs 165.3 [5.9]; P&#x2009;=&#x2009;.01) and intransitive gesture scores (34.9 [1.6] vs 35.7 [1.5]; P&#x2009;=&#x2009;.004), atrophy in 8 cortical regions of interest and in the right thalamus, and white matter alterations in 8 tracts. When restricting the analyses to participants younger than 40 years, compared with C9- individuals, C9+ individuals had lower praxis scores and intransitive gesture scores, atrophy in 4 cortical regions of interest and in the right thalamus, and white matter alterations in 2 tracts.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Cognitive, structural, and microstructural alterations are detectable in young C9+ individuals. Early and subtle praxis alterations, underpinned by focal atrophy of the left supramarginal gyrus, may represent an early and nonevolving phenotype related to neurodevelopmental effects of C9orf72 mutation. White matter alterations reflect the future phenotype of frontotemporal lobar degeneration/amyotrophic lateral sclerosis, while atrophy appears more diffuse. Our results contribute to a better understanding of the preclinical phase of C9orf72 disease and of the respective contribution of magnetic resonance biomarkers.</AbstractText><AbstractText Label="TRIAL REGISTRATION">clinicaltrials.gov Identifier: NCT02590276.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aramis Project Team, Inria Research Center of Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroradiology, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, H&#xf4;pital Saint Antoine, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Junhao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Aramis Project Team, Inria Research Center of Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Daisy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence des D&#xe9;mences Rares ou Pr&#xe9;coces, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houot</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Memory and Alzheimer's Disease, Centre of Excellence of Neurodegenerative Disease, Department of Neurology, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sayah</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camuzat</LastName><ForeName>Agn&#xe8;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fournier</LastName><ForeName>Cl&#xe9;mence</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontanella</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Aramis Project Team, Inria Research Center of Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Routier</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Aramis Project Team, Inria Research Center of Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Amyotrophic Lateral Sclerosis Center, Centre Hospitalier Universitaire de Limoges, Limoges, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Limoges University, Institut d'Epid&#xe9;miologie Neurologique et Neurologie Tropicale, Centre National de la Recherche Scientifique, F&#xe9;d&#xe9;ration de Recherche 3503, Institut G&#xe9;nomique, Environnement, Immunit&#xe9;, Sant&#xe9; et Th&#xe9;rapeutiques, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neurology Department, National Reference Center for Young Onset Dementia, Centre Hospitalier R&#xe9;gional Universitaire de Lille, INSERM U1171, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Equipe d'accueil 1046, Maladie d'Alzheimer et Pathologies Vasculaires, Lille University, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habert</LastName><ForeName>Marie-Odile</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire d'Imagerie Biom&#xe9;dicale, Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, INSERM U1146, Centre National de la Recherche Scientifique, UMR 7371, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannequin</LastName><ForeName>Didier</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre National de R&#xe9;f&#xe9;rence pour les Malades Alzheimer Jeunes, Centre Hospitalier Universitaire de Rouen, INSERM 1245, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Centre Hospitalier Universitaire de Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinaud</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Centre National de R&#xe9;f&#xe9;rence pour les Malades Alzheimer Jeunes, Centre Hospitalier Universitaire de Rouen, INSERM 1245, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Centre Hospitalier Universitaire de Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caroppo</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology V and Neuropathology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence des D&#xe9;mences Rares ou Pr&#xe9;coces, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Memory and Alzheimer's Disease, Centre of Excellence of Neurodegenerative Disease, Department of Neurology, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence des D&#xe9;mences Rares ou Pr&#xe9;coces, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Memory and Alzheimer's Disease, Centre of Excellence of Neurodegenerative Disease, Department of Neurology, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durrleman</LastName><ForeName>Stanley</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Aramis Project Team, Inria Research Center of Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colliot</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aramis Project Team, Inria Research Center of Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre pour l'Acquisition et le Traitement des Images, Institut du Cerveau et la Moelle, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Ber</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie Paris 06, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence des D&#xe9;mences Rares ou Pr&#xe9;coces, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Memory and Alzheimer's Disease, Centre of Excellence of Neurodegenerative Disease, Department of Neurology, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Predict to Prevent Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis (PREV-DEMALS) Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02590276</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2019 Aug 1;76(8):986. doi: 10.1001/jamaneurol.2019.1298.</RefSource><PMID Version="1">31081868</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="Y">Asymptomatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Couratier has received consultant fees from Boehringer Ingelheim and funding for his institution from Cytokinetics. Dr Habert has received payments for lectures from Piramal and Eli Lilly. Dr Dubois has received consultant fees from Eli Lilly, Cytox, and Boehringer Ingelheim, and he has received funding for his institution from Merck, Pfizer, and Roche. Drs Durrleman and Colliot are funded by the European Union Horizon 2020 research and innovation program under grant 666992 (EuroPOND) and 720270 (HBP SGA1). Dr Durrleman is funded by the European Research Council under grant 678304. Dr Colliot is supported by a Contrat d&#x2019;Interface Local from the Assistance Publique&#x2013;H&#xf4;pitaux de Paris. No other disclosures were reported. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>12</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29197216</ArticleId><ArticleId IdType="pmc">PMC5838615</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.4266</ArticleId><ArticleId IdType="pii">2665213</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245-256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. ; ITALSGEN Consortium . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257-268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, Van Langenhove T, van der Zee J, Van Broeckhoven C. Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci. 2013;36(8):450-459.</Citation><ArticleIdList><ArticleId IdType="pubmed">23746459</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang P-W, Pham JT, et al. . RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention [published correction appears in Neuron. 2013;80(4):1102]. Neuron. 2013;80(2):415-428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, et al. . Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90(3):535-550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, et al. ; Dominantly Inherited Alzheimer Network . Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367(9):795-804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Nicholas JM, Cash DM, et al. . Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis [published correction appears in Lancet Neurol. 2015;14(12):1151]. Lancet Neurol. 2015;14(3):253-262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="pubmed">25662776</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhout R, Schmidt R, Westeneng H-J, et al. . Brain morphologic changes in asymptomatic C9orf72 repeat expansion carriers. Neurology. 2015;85(20):1780-1788.</Citation><ArticleIdList><ArticleId IdType="pubmed">26497991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Sias AC, Mandelli ML, et al. . Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. Neuroimage Clin. 2016;14:286-297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349617</ArticleId><ArticleId IdType="pubmed">28337409</ArticleId></ArticleIdList></Reference><Reference><Citation>Operto G, Chupin M, Batrancourt B, et al. ; CATI Consortium . CATI: a large distributed infrastructure for the neuroimaging of cohorts. Neuroinformatics. 2016;14(3):253-264.</Citation><ArticleIdList><ArticleId IdType="pubmed">27066973</ArticleId></ArticleIdList></Reference><Reference><Citation>Leemans A, Jones DK. The B-matrix must be rotated when correcting for subject motion in DTI data. Magn Reson Med. 2009;61(6):1336-1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">19319973</ArticleId></ArticleIdList></Reference><Reference><Citation>Jezzard P, Balaban RS. Correction for geometric distortion in echo planar images from B0 field variations. Magn Reson Med. 1995;34(1):65-73.</Citation><ArticleIdList><ArticleId IdType="pubmed">7674900</ArticleId></ArticleIdList></Reference><Reference><Citation>Tustison NJ, Avants BB. Explicit B-spline regularization in diffeomorphic image registration. Front Neuroinform. 2013;7:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870320</ArticleId><ArticleId IdType="pubmed">24409140</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeurissen B, Tournier J-D, Dhollander T, Connelly A, Sijbers J. Multi-tissue constrained spherical deconvolution for improved analysis of multi-shell diffusion MRI data. Neuroimage. 2014;103:411-426.</Citation><ArticleIdList><ArticleId IdType="pubmed">25109526</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori S, Wakana S, van Zijl PCM, Nagae-Poetscher LM. MRI Atlas of Human White Matter. 1st ed Amsterdam, the Netherlands: Elsevier Science; 2005.</Citation></Reference><Reference><Citation>Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal. 2008;12(1):26-41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276735</ArticleId><ArticleId IdType="pubmed">17659998</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TLS, Blazey T, Jack CR Jr, et al. . Regional variability of imaging biomarkers in autosomal dominant Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2013;110(47):E4502-E4509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839740</ArticleId><ArticleId IdType="pubmed">24194552</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Tortosa E, Gallego J, Guerrero-L&#xf3;pez R, et al. . C9ORF72 hexanucleotide expansions of 20-22 repeats are associated with frontotemporal deterioration. Neurology. 2013;80(4):366-370.</Citation><ArticleIdList><ArticleId IdType="pubmed">23284068</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan BK, Yokoyama JS, Takada LT, et al. . Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J Neurol Neurosurg Psychiatry. 2012;83(4):358-364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388906</ArticleId><ArticleId IdType="pubmed">22399793</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhonen N-M, Kaivorinne A-L, Moilanen V, et al. . Slowly progressive frontotemporal lobar degeneration caused by the C9ORF72 repeat expansion: a 20-year follow-up study. Neurocase. 2015;21(1):85-89.</Citation><ArticleIdList><ArticleId IdType="pubmed">24417314</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Boeve BF, Weigand SD, et al. . Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. Eur J Neurol. 2015;22(5):745-752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4390434</ArticleId><ArticleId IdType="pubmed">25683866</ArticleId></ArticleIdList></Reference><Reference><Citation>Peigneux P, van der Linden M. Influence of ageing and educational level on the prevalence of body-part-as-objects in normal subjects. J Clin Exp Neuropsychol. 1999;21(4):547-552.</Citation><ArticleIdList><ArticleId IdType="pubmed">10550811</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues Cavalcante K, Caramelli P. Evaluation of the performance of normal elderly in a limb praxis protocol: influence of age, gender, and education. J Int Neuropsychol Soc. 2009;15(4):618-622.</Citation><ArticleIdList><ArticleId IdType="pubmed">19573281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xf3;liczak G, Piper BJ, Frey SH. Specialization of the left supramarginal gyrus for hand-independent praxis representation is not related to hand dominance. Neuropsychologia. 2016;93(pt B):501-512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5036996</ArticleId><ArticleId IdType="pubmed">27020138</ArticleId></ArticleIdList></Reference><Reference><Citation>Floris G, Borghero G, Cannas A, et al. . Constructional apraxia in frontotemporal dementia associated with the C9orf72 mutation: broadening the clinical and neuropsychological phenotype. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(1-2):8-15.</Citation><ArticleIdList><ArticleId IdType="pubmed">25285776</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Beck J, Rohrer JD, et al. . Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain. 2012;135(pt 3):736-750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286330</ArticleId><ArticleId IdType="pubmed">22366791</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Downey LE, Ridgway GR, et al. . Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions. Alzheimers Res Ther. 2012;4(5):41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580398</ArticleId><ArticleId IdType="pubmed">23006986</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Langenhove T, van der Zee J, Gijselinck I, et al. . Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort. JAMA Neurol. 2013;70(3):365-373.</Citation><ArticleIdList><ArticleId IdType="pubmed">23338682</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney E, Hornberger M, Irish M, et al. . Frontotemporal dementia associated with the C9ORF72 mutation: a unique clinical profile. JAMA Neurol. 2014;71(3):331-339.</Citation><ArticleIdList><ArticleId IdType="pubmed">24445580</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Traynor BJ, Farren J, et al. . Disease progression in C9orf72 mutation carriers. Neurology. 2017;89(3):234-241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5513817</ArticleId><ArticleId IdType="pubmed">28615433</ArticleId></ArticleIdList></Reference><Reference><Citation>Sha SJ, Takada LT, Rankin KP, et al. . Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology. 2012;79(10):1002-1011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3430713</ArticleId><ArticleId IdType="pubmed">22875087</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhonen N-M, Haanp&#xe4;&#xe4; RM, Korhonen V, et al. . Neuropsychological profile in the C9ORF72 associated behavioral variant frontotemporal dementia. J Alzheimers Dis. 2017;58(2):479-489.</Citation><ArticleIdList><ArticleId IdType="pubmed">28453474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Frick P, Neumann M. The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol. 2014;127(3):347-357.</Citation><ArticleIdList><ArticleId IdType="pubmed">24356984</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Bageac D, Danielian LE, Braun LE, Traynor BJ, Kwan JY. Longitudinal imaging in C9orf72 mutation carriers: relationship to phenotype. Neuroimage Clin. 2016;12:1035-1043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5153604</ArticleId><ArticleId IdType="pubmed">27995069</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Ferraro PM, Riva N, et al. . Structural and functional brain signatures of C9orf72 in motor neuron disease. Neurobiol Aging. 2017;57:206-219.</Citation><ArticleIdList><ArticleId IdType="pubmed">28666709</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson Y, Robinson AC, Liu X, et al. . Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDP-43 pathology and not associated with aggregated forms of dipeptide repeat proteins. Neuropathol Appl Neurobiol. 2016;42(3):242-254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832296</ArticleId><ArticleId IdType="pubmed">26538301</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson YS, Barker H, Robinson AC, et al. . Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun. 2014;2:70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229740</ArticleId><ArticleId IdType="pubmed">24950788</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Deza J, Lee Y-B, Troakes C, et al. . Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration. Acta Neuropathol Commun. 2015;3:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479315</ArticleId><ArticleId IdType="pubmed">26108573</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Frick P, Gr&#xe4;sser FA, et al. . Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol. 2015;130(6):845-861.</Citation><ArticleIdList><ArticleId IdType="pubmed">26374446</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC, Yoon SJ, Gardner RC, et al. . Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain. 2016;139(pt 12):3202-3216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790143</ArticleId><ArticleId IdType="pubmed">27797809</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Truax AC, et al. . TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol. 2007;66(3):177-183.</Citation><ArticleIdList><ArticleId IdType="pubmed">17356379</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, van der Zee J, Gijselinck I, et al. ; Belgian Neurology (BELNEU) Consortium . Clinical evidence of disease anticipation in families segregating a C9orf72 repeat expansion. JAMA Neurol. 2017;74(4):445-452.</Citation><ArticleIdList><ArticleId IdType="pubmed">28192553</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Truax AC, et al. . TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol. 2007;66(3):177-183.</Citation><ArticleIdList><ArticleId IdType="pubmed">17356379</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29200205</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Amyloid-&#x3b2; plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation.</ArticleTitle><Pagination><StartPage>29</StartPage><EndPage>38</EndPage><MedlinePgn>29-38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.4443</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by extracellular amyloid-&#x3b2; (A&#x3b2;) plaques and intracellular tau inclusions. However, the exact mechanistic link between these two AD lesions remains enigmatic. Through injection of human AD-brain-derived pathological tau (AD-tau) into A&#x3b2; plaque-bearing mouse models that do not overexpress tau, we recapitulated the formation of three major types of AD-relevant tau pathologies: tau aggregates in dystrophic neurites surrounding A&#x3b2; plaques (NP tau), AD-like neurofibrillary tangles (NFTs) and neuropil threads (NTs). These distinct tau pathologies have different temporal onsets and functional consequences on neural activity and behavior. Notably, we found that A&#x3b2; plaques created a unique environment that facilitated the rapid amplification of proteopathic AD-tau seeds into large tau aggregates, initially appearing as NP tau, which was followed by the formation and spread of NFTs and NTs, likely through secondary seeding events. Our study provides insights into a new multistep mechanism underlying A&#x3b2; plaque-associated tau pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zhuohao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jing L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McBride</LastName><ForeName>Jennifer D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narasimhan</LastName><ForeName>Sneha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyesung</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Changolkar</LastName><ForeName>Lakshmi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gathagan</LastName><ForeName>Ronald J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Cuiyong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dengler</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stieber</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitla</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coulter</LastName><ForeName>Douglas A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Division of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neuroscience and of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abel</LastName><ForeName>Ted</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Iowa Neuroscience Institute and Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunden</LastName><ForeName>Kurt R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017628</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HD086984</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>COMPETING FINANCIAL INTERESTS</b>. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29200205</ArticleId><ArticleId IdType="mid">NIHMS926960</ArticleId><ArticleId IdType="pmc">PMC5760353</ArticleId><ArticleId IdType="doi">10.1038/nm.4443</ArticleId><ArticleId IdType="pii">nm.4443</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease. Ann Neurol. 1997;41:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz AJ, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">26936940</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, et al. In vivo tau, amyloid, and gray matter profiles in the aging brain. J Neurosci. 2016;36:7364&#x2013;7374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4945661</ArticleId><ArticleId IdType="pubmed">27413148</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, et al. Tau and A&#x3b2; imaging, CSF measures, and cognition in Alzheimer&#x2019;s disease. Sci Transl Med. 2016;8:338ra66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, et al. Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between &#x3b2;-amyloid and tauopathy. JAMA Neurol. 2016;73:1070&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237382</ArticleId><ArticleId IdType="pubmed">27454922</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A&#x3b2;42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, et al. Induction of tau pathology by intracerebral infusion of amyloid-&#x3b2;-containing brain extract and by amyloid-&#x3b2; deposition in APP &#xd7; Tau transgenic mice. Am J Pathol. 2007;171:2012&#x2013;2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2111123</ArticleId><ArticleId IdType="pubmed">18055549</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurtado DE, et al. A&#x3b2; accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol. 2010;177:1977&#x2013;1988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947292</ArticleId><ArticleId IdType="pubmed">20802182</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, et al. Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer&#x2019;s disease. Acta Neuropathol Commun. 2015;3:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371800</ArticleId><ArticleId IdType="pubmed">25853174</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett RE, et al. Enhanced tau aggregation in the presence of amyloid &#x3b2;. Am J Pathol. 2017;187:1601&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5500829</ArticleId><ArticleId IdType="pubmed">28500862</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, et al. Unique pathological tau conformers from Alzheimer&#x2019;s brains transmit tau pathology in nontransgenic mice. J Exp Med. 2016;213:2635&#x2013;2654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, et al. Single App knock-in mouse models of Alzheimer&#x2019;s disease. Nat Neurosci. 2014;17:661&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol. 2009;68:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692822</ArticleId><ArticleId IdType="pubmed">19104448</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Esiri MM. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down&#x2019;s syndrome. J Neurol Sci. 1989;89:169&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">2522541</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadleir KR, et al. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A&#x3b2; generation in Alzheimer&#x2019;s disease. Acta Neuropathol. 2016;132:235&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947125</ArticleId><ArticleId IdType="pubmed">26993139</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, et al. National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannerman DM, et al. Regional dissociations within the hippocampus&#x2014;memory and anxiety. Neurosci Biobehav Rev. 2004;28:273&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">15225971</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213:667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90:724&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci. 2003;6:370&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12598899</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Exogenous induction of cerebral &#x3b2;-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, et al. Peripherally applied A&#x3b2;-containing inoculates induce cerebral &#x3b2;-amyloidosis. Science. 2010;330:980&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer F, et al. Soluble A&#x3b2; seeds are potent inducers of cerebral &#x3b2;-amyloid deposition. J Neurosci. 2011;31:14488&#x2013;14495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229270</ArticleId><ArticleId IdType="pubmed">21994365</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RF, et al. Exogenous seeding of cerebral &#x3b2;-amyloid deposition in &#x3b2;APP-transgenic rats. J Neurochem. 2012;120:660&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3293176</ArticleId><ArticleId IdType="pubmed">22017494</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida CG, Takahashi RH, Gouras GK. &#x3b2;-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin&#x2013;proteasome system. J Neurosci. 2006;26:4277&#x2013;4288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673997</ArticleId><ArticleId IdType="pubmed">16624948</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, et al. Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer&#x2019;s disease. Alzheimers Dement. 2016;12:164&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562409</ArticleId><ArticleId IdType="pubmed">26327235</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Lee VM. Characterization of two VQIXXK motifs for tau fibrillization in vitro. Biochemistry. 2006;45:15692&#x2013;15701.</Citation><ArticleIdList><ArticleId IdType="pubmed">17176091</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. J Neurosci. 2013;33:1024&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VM. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem. 2011;286:15317&#x2013;15331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Skovronsky DM, Abtahian F, Doms RW, Lee VM. Secretion and intracellular generation of truncated A&#x3b2; in &#x3b2;-site amyloid-&#x3b2; precursor protein&#x2013;cleaving enzyme expressing human neurons. J Biol Chem. 2003;278:4458&#x2013;4466.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480937</ArticleId></ArticleIdList></Reference><Reference><Citation>King DL, Arendash GW. Behavioral characterization of the Tg2576 transgenic model of Alzheimer&#x2019;s disease through 19 months. Physiol Behav. 2002;75:627&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">12020728</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29216449</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>06</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>ApoE4 Accelerates Early Seeding of Amyloid Pathology.</ArticleTitle><Pagination><StartPage>1024</StartPage><EndPage>1032.e3</EndPage><MedlinePgn>1024-1032.e3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2017.11.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(17)31066-8</ELocationID><Abstract><AbstractText>Accumulation and aggregation of amyloid-&#x3b2; (A&#x3b2;) in the brain is an initiating step in the pathogenesis of Alzheimer's disease (AD). The &#x3b5;4 allele of apolipoprotein E (apoE) gene is the strongest genetic risk factor for late-onset AD. Although there is strong evidence showing that apoE4 enhances amyloid pathology, it is not clear what the critical stage(s) is during amyloid development in which apoE4 has the strongest impact. Using apoE inducible mouse models, we show that increased expression of astrocytic apoE4, but not apoE3, during the seeding stage of amyloid development enhanced amyloid deposition and neuritic dystrophy in amyloid model mice. ApoE4, but not apoE3, significantly increased brain A&#x3b2; half-life measured by in&#xa0;vivo microdialysis. Furthermore, apoE4 expression increased whereas apoE3 reduced amyloid-related gliosis in the mouse brains. Together, our results demonstrate that apoE4 has the greatest impact on amyloid during the seeding stage, likely by perturbing A&#x3b2; clearance and enhancing A&#x3b2; aggregation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chen</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA. Electronic address: liu.chiachen@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linares</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Chih-Wei</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361005, China. Electronic address: bu.guojun@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG035355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056130</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2017 Dec 6;96(5):953-955. doi: 10.1016/j.neuron.2017.11.022.</RefSource><PMID Version="1">29216455</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyloid pathology</Keyword><Keyword MajorTopicYN="N">apolipoprotein E</Keyword><Keyword MajorTopicYN="N">seeding</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>12</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29216449</ArticleId><ArticleId IdType="mid">NIHMS922001</ArticleId><ArticleId IdType="pmc">PMC5948105</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.11.013</ArticleId><ArticleId IdType="pii">S0896-6273(17)31066-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol. 2002;22:5100&#x2013;5113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139771</ArticleId><ArticleId IdType="pubmed">12077339</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Liu F, Wu S, Lin S, Koger D, DeLong C, Hansen JC, Sullivan PM, Paul SM. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci. 2009;29:6771&#x2013;6779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665579</ArticleId><ArticleId IdType="pubmed">19474305</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu G. Apolipoprotein E and its receptors in Alzheimer&#x2019;s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908393</ArticleId><ArticleId IdType="pubmed">19339974</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgold S, Filser S, Dorostkar MM, Schmidt B, Herms J. In vivo imaging reveals sigmoidal growth kinetic of beta-amyloid plaques. Acta Neuropathol Commun. 2014;2:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050984</ArticleId><ArticleId IdType="pubmed">24678659</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Science translational medicine. 2011;3:89ra57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Durakoglugil MS, Xian X, Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci USA. 2010;107:12011&#x2013;12016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900641</ArticleId><ArticleId IdType="pubmed">20547867</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012;148:1188&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353745</ArticleId><ArticleId IdType="pubmed">22424229</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis. 2006;24:516&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029828</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong JS, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, Yanagisawa K, Michikawa M. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem. 2002;277:29919&#x2013;29926.</Citation><ArticleIdList><ArticleId IdType="pubmed">12042316</ArticleId></ArticleIdList></Reference><Reference><Citation>Grace EA, Busciglio J. Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. J Neurosci. 2003;23:493&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741895</ArticleId><ArticleId IdType="pubmed">12533609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatters DM, Zhong N, Rutenber E, Weisgraber KH. Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J Mol Biol. 2006;361:932&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">16890957</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 2015;14:388&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Holtzman DM. Biomarker modeling of Alzheimer&#x2019;s disease. Neuron. 2013;80:1347&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ, Aalten P, Aarsland D, Alcolea D, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924&#x2013;1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011;70:532&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203752</ArticleId><ArticleId IdType="pubmed">22028219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, Karhunen PJ. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol. 2009;65:650&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">19557866</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, Shah JA, Reardon CA, Getz GS, Bu G, Hu J, Guo L, Van Eldik LJ. Apolipoprotein E and apolipoprotein E receptors modulate Abeta-induced glial neuroinflammatory responses. Neurochem Int. 2001;39:427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">11578778</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, Stine WB, Jr, Narita M, Getz GS, Reardon CA, Bu G. Self-assembly of HEK cell-secreted ApoE particles resembles ApoE enrichment of lipoproteins as a ligand for the LDL receptor-related protein. Biochemistry. 2006;45:381&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564845</ArticleId><ArticleId IdType="pubmed">16401069</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Hu J, Tsai CW, Yue M, Melrose HL, Kanekiyo T, Bu G. Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain. J Neurosci. 2015a;35:5851&#x2013;5859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4388937</ArticleId><ArticleId IdType="pubmed">25855193</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Tsai CW, Deak F, Rogers J, Penuliar M, Sung YM, Maher JN, Fu Y, Li X, Xu H, et al. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer&#x2019;s disease. Neuron. 2014;84:63&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4199382</ArticleId><ArticleId IdType="pubmed">25242217</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Zhao N, Yamaguchi Y, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G. Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-beta clearance and aggregation in Alzheimer&#x2019;s disease. Sci Transl Med. 2016;8:332ra344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5512541</ArticleId><ArticleId IdType="pubmed">27030596</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu DS, Pan XD, Zhang J, Shen H, Collins NC, Cole AM, Koster KP, Ben Aissa M, Dai XM, Zhou M, et al. APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. Mol Neurodegener. 2015b;10:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4391134</ArticleId><ArticleId IdType="pubmed">25871877</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS beta-amyloid in Alzheimer&#x2019;s disease. Science. 2010;330:1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki S, Miyazaki T, Tashiro F, Yamato E, Miyazaki J. Development of a single-cassette system for spatiotemporal gene regulation in mice. Biochem Biophys Res Commun. 2005;338:1083&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">16256950</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer&#x2019;s disease. Nature. 2009;461:916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2009;106:6820&#x2013;6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, Cummings JL, Cole GM. Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. Arch Neurol. 2012;69:757&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668092</ArticleId><ArticleId IdType="pubmed">22689192</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Capetillo-Zarate E, Schultz C, Rub U, Saido TC, Yamaguchi H, Haass C, Griffin WS, Del Tredici K, Braak H, Ghebremedhin E. Apolipoprotein E co-localizes with newly formed amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of Abeta in a genotype-dependent manner. Acta Neuropathol. 2005;110:459&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">16195918</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer&#x2019;s fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887417</ArticleId><ArticleId IdType="pubmed">7977635</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Fu Y, Liu CC, Shinohara M, Nielsen HM, Dong Q, Kanekiyo T, Bu G. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway. J Biol Chem. 2014;289:11282&#x2013;11292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036266</ArticleId><ArticleId IdType="pubmed">24599963</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29216448</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>06</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of &#x3b2;-amyloidosis.</ArticleTitle><Pagination><StartPage>1013</StartPage><EndPage>1023.e4</EndPage><MedlinePgn>1013-1023.e4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2017.11.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(17)31067-X</ELocationID><Abstract><AbstractText>The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset Alzheimer disease. Previous studies suggest that reduction of apoE levels through genetic manipulation can reduce A&#x3b2; pathology. However, it is not clear how reduction of apoE levels after birth would affect amyloid deposition. We utilize an antisense oligonucleotide (ASO) to reduce apoE expression in the brains of APP/PS1-21 mice homozygous for the APOE-&#x3b5;4 or APOE-&#x3b5;3 allele. ASO treatment starting after birth led to a significant decrease in A&#x3b2; pathology when assessed at 4&#xa0;months. Interestingly, ASO treatment starting at the onset of amyloid deposition led to an increase in A&#x3b2; plaque size and a reduction in plaque-associated neuritic dystrophy with no change in overall plaque load. These results suggest that lowering apoE levels prior to plaque deposition can strongly affect the initiation of A&#x3b2; pathology while lowering apoE after A&#x3b2; seeding modulates plaque size and toxicity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huynh</LastName><ForeName>Tien-Phat V</ForeName><Initials>TV</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA; Medical Scientist Training Program (MSTP), Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>Caroline M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Grace O</ForeName><Initials>GO</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Javier Remolina</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roh</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University Medical Center, Durham Veterans Health Administration Medical Center's Geriatric Research, Education and Clinical Center, Durham, NC 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esparza</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Floy R</ForeName><Initials>FR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahan</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Tracy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Inc., 2855 Gazelle Ct. Carlsbad, CA 92024, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: holtzman@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007200</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2017 Dec 6;96(5):953-955. doi: 10.1016/j.neuron.2017.11.022.</RefSource><PMID Version="1">29216455</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOE</Keyword><Keyword MajorTopicYN="N">ASO</Keyword><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">amyloid-&#x3b2;</Keyword><Keyword MajorTopicYN="N">antisense oligonucleotides</Keyword><Keyword MajorTopicYN="N">apolipoprotein E</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>12</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29216448</ArticleId><ArticleId IdType="mid">NIHMS920654</ArticleId><ArticleId IdType="pmc">PMC5728673</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.11.014</ArticleId><ArticleId IdType="pii">S0896-6273(17)31067-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annual review of pharmacology and toxicology. 2010;50:259&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">20055705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Bauer AQ, Stewart FR, White BR, Cirrito JR, Raichle ME, Culver JP, Holtzman DM. Bidirectional relationship between functional connectivity and amyloid-beta deposition in mouse brain. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2012;32:4334&#x2013;4340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3326343</ArticleId><ArticleId IdType="pubmed">22457485</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nature neuroscience. 2011;14:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nature genetics. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y. Reducing human apolipoprotein E levels attenuates age-dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2012;32:4803&#x2013;4811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433173</ArticleId><ArticleId IdType="pubmed">22492035</ArticleId></ArticleIdList></Reference><Reference><Citation>Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, Frangione B. Fibrillogenesis in Alzheimer&#x2019;s disease of amyloid beta peptides and apolipoprotein E. The Biochemical journal. 1995;306(Pt 2):599&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1136559</ArticleId><ArticleId IdType="pubmed">7534068</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Science translational medicine. 2011;3:89ra57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheruvallath ZS, Kumar RK, Rentel C, Cole DL, Ravikumar VT. Solid phase synthesis of phosphorothioate oligonucleotides utilizing diethyldithiocarbonate disulfide (DDD) as an efficient sulfur transfer reagent. Nucleosides, nucleotides &amp; nucleic acids. 2003;22:461&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">12885126</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. The Journal of clinical investigation. 2008;118:4002&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Miller TM. Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics. 2013a;10:486&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701770</ArticleId><ArticleId IdType="pubmed">23686823</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Miller TM. Direct intraventricular delivery of drugs to the rodent central nervous system. Journal of visualized experiments: JoVE. 2013b:e50326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679837</ArticleId><ArticleId IdType="pubmed">23712122</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza TJ, Wildburger NC, Jiang H, Gangolli M, Cairns NJ, Bateman RJ, Brody DL. Soluble Amyloid-beta Aggregates from Human Alzheimer&#x2019;s Disease Brains. Scientific reports. 2016;6:38187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5137165</ArticleId><ArticleId IdType="pubmed">27917876</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2005;25:2803&#x2013;2810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725147</ArticleId><ArticleId IdType="pubmed">15772340</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowrishankar S, Yuan P, Wu Y, Schrag M, Paradise S, Grutzendler J, De Camilli P, Ferguson SM. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer&#x2019;s disease amyloid plaques. Proceedings of the National Academy of Sciences of the United States of America. 2015;112:E3699&#x2013;3708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4507205</ArticleId><ArticleId IdType="pubmed">26124111</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer&#x2019;s disease. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, Scheel M, Spires-Jones T, Arbel-Ornath M, Betensky R, et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Science translational medicine. 2013;5:212ra161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334150</ArticleId><ArticleId IdType="pubmed">24259049</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh TV, Davis AA, Ulrich JD, Holtzman DM. Apolipoprotein E and Alzheimer&#x2019;s disease: the influence of apolipoprotein E on amyloid-beta and other amyloidogenic proteins. Journal of lipid research. 2017;58:824&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408619</ArticleId><ArticleId IdType="pubmed">28246336</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Holtzman DM. Biomarker modeling of Alzheimer&#x2019;s disease. Neuron. 2013;80:1347&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Lansbury PT., Jr Seeding &#x201c;one-dimensional crystallization&#x201d; of amyloid: a pathogenic mechanism in Alzheimer&#x2019;s disease and scrapie? Cell. 1993;73:1055&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">8513491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2011;31:18007&#x2013;18012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257514</ArticleId><ArticleId IdType="pubmed">22159114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, et al. Sustained therapeutic reversal of Huntington&#x2019;s disease by transient repression of huntingtin synthesis. Neuron. 2012;74:1031&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383626</ArticleId><ArticleId IdType="pubmed">22726834</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, Holtzman DM. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta neuropathologica communications. 2015;3:70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641345</ArticleId><ArticleId IdType="pubmed">26556230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Yee A, Brewer HB, Jr, Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994;372:92&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969426</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay RA, Miraglia LJ, Cummins LL, Owens SR, Sasmor H, Dean NM. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. The Journal of biological chemistry. 1999;274:1715&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pubmed">9880552</ArticleId></ArticleIdList></Reference><Reference><Citation>Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer&#x2019;s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain research. 1991;541:163&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">2029618</ArticleId></ArticleIdList></Reference><Reference><Citation>Passini MA, Wolfe JH. Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector. Journal of virology. 2001;75:12382&#x2013;12392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC116134</ArticleId><ArticleId IdType="pubmed">11711628</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochimica et biophysica acta. 1987;917:148&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">3539206</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, Wolburg H, Gengler S, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO reports. 2006;7:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Roychaudhuri R, Yang M, Hoshi MM, Teplow DB. Amyloid beta-protein assembly and Alzheimer disease. The Journal of biological chemistry. 2009;284:4749&#x2013;4753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3837440</ArticleId><ArticleId IdType="pubmed">18845536</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer&#x2019;s disease pathology. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2000;48:1223&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pubmed">10950879</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. The Journal of biological chemistry. 1997;272:17972&#x2013;17980.</Citation><ArticleIdList><ArticleId IdType="pubmed">9218423</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, Landreth GE, Castellano JM, Jiang H, Cirrito JR, Holtzman DM. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Molecular neurodegeneration. 2013;8:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640999</ArticleId><ArticleId IdType="pubmed">23601557</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:E1807&#x2013;1816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651443</ArticleId><ArticleId IdType="pubmed">23620513</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer&#x2019;s fibril formation by apolipoprotein E in vitro. The American journal of pathology. 1994;145:1030&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887417</ArticleId><ArticleId IdType="pubmed">7977635</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29220873</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Effect of sleep on overnight cerebrospinal fluid amyloid &#x3b2; kinetics.</ArticleTitle><Pagination><StartPage>197</StartPage><EndPage>204</EndPage><MedlinePgn>197-204</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.25117</ELocationID><Abstract><AbstractText>Sleep disturbances are associated with future risk of Alzheimer disease. Disrupted sleep increases soluble amyloid &#x3b2;, suggesting a mechanism for sleep disturbances to increase Alzheimer disease risk. We tested this response in humans using indwelling lumbar catheters to serially sample cerebrospinal fluid while participants were sleep-deprived, treated with sodium oxybate, or allowed to sleep normally. All participants were infused with <sup>13</sup> C<sub>6</sub> -leucine to measure amyloid &#x3b2; kinetics. We found that sleep deprivation increased overnight amyloid &#x3b2;38, amyloid &#x3b2;40, and amyloid &#x3b2;42 levels by 25 to 30% via increased overnight amyloid &#x3b2; production relative to sleeping controls. These findings suggest that disrupted sleep increases Alzheimer disease risk via increased amyloid &#x3b2; production. Ann Neurol 2018;83:197-204.</AbstractText><CopyrightInformation>&#xa9; 2017 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lucey</LastName><ForeName>Brendan P</ForeName><Initials>BP</Initials><Identifier Source="ORCID">0000-0001-5400-825X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hicks</LastName><ForeName>Terry J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLeland</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toedebusch</LastName><ForeName>Cristina D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elbert</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Dell Medical School, University of Texas, Austin, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Bruce W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baty</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ovod</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mawuenyega</LastName><ForeName>Kwasi G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R03 AG047999</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103422</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR002346</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K76 AG054863</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR000450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000777">Anesthetics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>7G33012534</RegistryNumber><NameOfSubstance UI="D012978">Sodium Oxybate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Neurol. 2018 Mar;83(3):650-651. doi: 10.1002/ana.25185.</RefSource><PMID Version="1">29457845</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Neurol. 2018 Mar;83(3):650. doi: 10.1002/ana.25186.</RefSource><PMID Version="1">29460297</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000777" MajorTopicYN="N">Anesthetics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012978" MajorTopicYN="N">Sodium Oxybate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b><u>Potential Conflicts of Interest</u></b>: Brendan P. Lucey, Terry J. Hicks, Jennifer S. McLeland, Cristina D. Toedebusch, Jill Boyd, Jack Baty, John C. Morris: None. Donald L. Elbert: Dr. Elbert receives royalties from C2N Diagnostics for a patent related to modeling &#x3b2;-amyloid stable isotope labeling kinetics. Bruce W. Patterson: Dr. Patterson receives royalties from C2N Diagnostics for a patent related to modeling &#x3b2;-amyloid stable isotope labeling kinetics and has provided consultations on &#x3b2;-amyloid peptide turnover kinetics for C2N Diagnostics. Vitaliy Ovod: Mr. Ovod may receive royalty income based on technology licensed by Washington University to C2N Diagnostics and tied to agreement 010395-0001. Kwasi G. Mawuenyega: Dr. Mawuenyega may receive royalty income based on a patent of methods for simultaneously measuring the in vivo metabolism of 2 or more isoforms of a biomolecule, licensed by Washington University to C2N Diagnostics. Randall J. Bateman: Washington University, Dr. Bateman, and Dr. David Holtzman have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. Dr. Bateman receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University, with Dr. Bateman as co-inventor, has submitted the US nonprovisional patent applications &#x201c;Methods for Measuring the Metabolism of CNS Derived Biomolecules In Vivo&#x201d; and provisional patent application &#x201c;Plasma Based Methods for Detecting CNS Amyloid Deposition.&#x201d;</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29220873</ArticleId><ArticleId IdType="mid">NIHMS926458</ArticleId><ArticleId IdType="pmc">PMC5876097</ArticleId><ArticleId IdType="doi">10.1002/ana.25117</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blackwell T, Yaffe K, Ancoli-Israel S, et al. Poor sleep is associated with impaired cognitive function in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci. 2006;61(4):405&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16611709</ArticleId></ArticleIdList></Reference><Reference><Citation>Tranah GJ, Blackwell T, Stone KL, et al. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol. 2011;70:722&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244839</ArticleId><ArticleId IdType="pubmed">22162057</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Laffan AM, Harrison SL, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA. 2011;306(6):613&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3600944</ArticleId><ArticleId IdType="pubmed">21828324</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J-E, Lim MM, Bateman RJ, et al. Amyloid-&#x3b2; dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Potter R, Sigurdson W, et al. Effects of age and amyloid deposition on A&#x3b2; dynamics in the human central nervous system. Arch Neurol. 2012;69(1):51&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254706</ArticleId><ArticleId IdType="pubmed">21911660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, Gonzales C, Das U, et al. An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-&#x3b2; concentrations collected by lumbar puncture and indwelling lumbar catheter. Alzheimers Res Ther. 2015;7:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4518529</ArticleId><ArticleId IdType="pubmed">26225140</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, Mawuenyega KG, Patterson BW, et al. Associations Between &#x3b2;-Amyloid Kinetics and the &#x3b2;-Amyloid Diurnal Pattern in the Central Nervous System. JAMA Neurol. 2017;74(2):207&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5305432</ArticleId><ArticleId IdType="pubmed">27992627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid &#x3b2;-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol. 2014;71(8):971&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24887018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju Y-ES, Ooms SJ, Sutphen C, et al. Slow wave sleep disruption increases cerebrospinal fluid amyloid-&#x3b2; levels. Brain. 2017;140:2104&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790144</ArticleId><ArticleId IdType="pubmed">28899014</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh JK, Hall-Porter JM, Griffin KS, et al. Enhancing slow wave sleep with sodium oxybate reduces the behavioral and physiological impact of sleep loss. Sleep. 2010;33(9):1217&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938863</ArticleId><ArticleId IdType="pubmed">20857869</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BW, Elbert DL, Mawuenyega KG, et al. Age and amyloid effects on human CNS amyloid-beta kinetics. Ann Neurol. 2015;78(3):439&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546566</ArticleId><ArticleId IdType="pubmed">26040676</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbert DL, Patterson BW, Bateman RJ. Analysis of a compartmental model of amyloid beta production, irreversible loss and exchange in humans. Math Biosci. 2015;261:48&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4323682</ArticleId><ArticleId IdType="pubmed">25497960</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R, Patterson BW, Elbert DL, et al. Increased in vivo amyloid-&#x3b2;42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5(189):189ra77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedeker D. Generalized linear mixed models. In: Everitt BS, Howell DC, editors. Encyclopedia of statistics in behavioral science. Chichester: John Wiley &amp; Sons, Ltd; 2005. pp. 729&#x2013;38.</Citation></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-&#x3b2; levels in vivo. Neuron. 2005;48:913&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, et al. Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat Neurosci. 2011;14(6):750&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342:373&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolska JA, Kasten T, Huang Y, et al. Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLoS ONE. 2014;9(3):e89998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960093</ArticleId><ArticleId IdType="pubmed">24646516</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29228071</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Associations Between Tau, &#x3b2;-Amyloid, and Cognition in Parkinson Disease.</ArticleTitle><Pagination><StartPage>227</StartPage><EndPage>235</EndPage><MedlinePgn>227-235</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.3713</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Multiple disease processes are associated with cognitive impairment in Parkinson disease (PD), including Lewy bodies, cerebrovascular disease, and Alzheimer disease. It remains unknown whether tau pathology relates to cognition in patients with PD without dementia.</AbstractText><AbstractText Label="OBJECTIVE">To compare tau aggregation in patients with PD who are cognitively normal (PD-CN), patients with PD with mild cognitive impairment (PD-MCI), and healthy control participants, and evaluate the relationships between &#x3b2;-amyloid (A&#x3b2;), tau, and cognition in patients with PD who did not have dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study recruited 30 patients with Parkinson disease (15 with PD-CN and 15 with PD-MCI) from a tertiary care medical center and research institutions from July 2015 through October 2016. One patient with PD-MCI did not receive a magnetic resonance imaging scan and thus was excluded from all analyses; 29 patients with PD were included in the present study. Participants underwent tau positron emission tomographic (PET) scanning with fluorine 18-labeled AV-1451, A&#x3b2; PET scanning with carbon 11-labeled Pittsburgh compound B, magnetic resonance imaging, cognitive testing, and neurologic evaluation. Imaging measures were compared with 49 healthy control participants.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Outcomes were tau PET measurements of groups of patients with PD-CN and PD-MCI. We hypothesized that tau aggregation across groups would be related to age and A&#x3b2; status.</AbstractText><AbstractText Label="RESULTS">Of the 78 participants, 47 (60%) were female, and the mean (SD) age was 71.1 (6.6) years. Six patients with PD (21%) were A&#x3b2;-positive, of whom 1 was mildly cognitively impaired; 23 were A&#x3b2;-negative (79%). (Of the 49 healthy controls, 25 were A&#x3b2;-negative and 24 A&#x3b2;-positive.) Voxelwise contrasts of whole-brain tau PET uptake between patients with PD-CN and patients with PD-MCI, and additionally between all patients with PD and A&#x3b2;-negative controls, did not reveal significant differences. Tau PET binding did not differ between patients with PD-MCI and PD-CN in brain regions reflecting Alzheimer disease Braak stages 1/2, 3/4, or 5/6, and did not differ from A&#x3b2;-negative healthy older adults. Mean (SD) tau PET binding was significantly elevated in A&#x3b2;-positive patients with PD relative to A&#x3b2;-negative patients with PD within brain regions reflecting Alzheimer disease Braak stage 3/4 (1.22 [0.07] vs 1.14 [0.07]; P&#x2009;=&#x2009;.03) and Braak stage 5/6 (1.20 [0.07] vs 1.11 [0.08]; P&#x2009;=&#x2009;.02).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">These findings suggest that patterns of cortical A&#x3b2; and tau do not differ in people with PD-CN, people with PD-MCI, and healthy older adults. Age, A&#x3b2;, and tau do not differentiate patients with PD-CN and PD-MCI. Tau deposition is related to A&#x3b2; status and age in both people with PD and healthy older adults. Cognitive deficits in people with PD without dementia do not appear to reflect measureable Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winer</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maass</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Magdeburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pressman</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rocky Mountain Alzheimer's Disease Center, University of Colorado, Denver.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stiver</LastName><ForeName>Jordan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schonhaut</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Suzanne L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Lab, Berkeley, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Lab, Berkeley, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Associate Editor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Lab, Berkeley, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Rabinovici receives research support from Avid/Lilly, GE, and Piramal; consulting or speaking honoraria for Eisai, Genentech, Lundbeck, Roche, Merck, and Putnam; and fees for serving as Associate Editor for <i>JAMA Neurology</i>. Dr Jagust serves as a consultant to Bioclinica, Biogen, Novartis, and Genentech. No other disclosures are reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>12</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29228071</ArticleId><ArticleId IdType="pmc">PMC5838622</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.3713</ArticleId><ArticleId IdType="pii">2664949</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson&#x2019;s disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11(8):697-707.</Citation><ArticleIdList><ArticleId IdType="pubmed">22814541</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler CH, Caviness JN, Sabbagh MN, et al. . Heterogeneous neuropathological findings in Parkinson&#x2019;s disease with mild cognitive impairment. Acta Neuropathol. 2010;120(6):827-828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100801</ArticleId><ArticleId IdType="pubmed">20838798</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger K. Heterogenous mechanisms of mild cognitive impairment in Parkinson&#x2019;s disease. J Neural Transm (Vienna). 2012;119(3):381-382.</Citation><ArticleIdList><ArticleId IdType="pubmed">21960008</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between a&#x3b2;, tau, and &#x3b1;-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30(21):7281-7289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308018</ArticleId><ArticleId IdType="pubmed">20505094</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Lee VM-Y, Trojanowski JQ. Parkinson&#x2019;s disease dementia: convergence of &#x3b1;-synuclein, tau and amyloid-&#x3b2; pathologies. Nat Rev Neurosci. 2013;14(9):626-636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4017235</ArticleId><ArticleId IdType="pubmed">23900411</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. Induction of intracellular tau aggregation is promoted by &#x3b1;-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci. 2011;31(21):7604-7618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122484</ArticleId><ArticleId IdType="pubmed">21613474</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol. 2003;62(4):389-397.</Citation><ArticleIdList><ArticleId IdType="pubmed">12722831</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Locascio JJ, Makaretz SJ, et al. . Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol. 2016;73(11):1334-1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5287290</ArticleId><ArticleId IdType="pubmed">27654968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Lowe VJ, Boeve BF, et al. . AV-1451 tau and &#x3b2;-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol. 2017;81(1):58-67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299616</ArticleId><ArticleId IdType="pubmed">27863444</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen AK, Damholdt MF, Fedorova TD, et al. . In vivo cortical tau in Parkinson&#x2019;s disease using 18F-AV-1451 positron emission tomography. Mov Disord. 2017;32(6):922-927.</Citation><ArticleIdList><ArticleId IdType="pubmed">28256006</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, Gordon B, Friedrichsen K, et al. . Tau and A&#x3b2; imaging, CSF measures, and cognition in Alzheimer&#x2019;s disease. Sci Transl Med. 2016;8(338):338ra366-338ra366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. . PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971-982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Locascio JJ, Rentz D, et al. . Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 2013;80(1):85-91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3589197</ArticleId><ArticleId IdType="pubmed">23243071</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson&#x2019;s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014720</ArticleId><ArticleId IdType="pubmed">1564476</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Goldman JG, Tr&#xf6;ster AI, et al. . Diagnostic criteria for mild cognitive impairment in Parkinson&#x2019;s disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3):349-356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3641655</ArticleId><ArticleId IdType="pubmed">22275317</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG, Tilley BC, Shaftman SR, et al. ; Movement Disorder Society UPDRS Revision Task Force . Movement Disorder Society-sponsored revision of the Unified Parkinson&#x2019;s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-2170.</Citation><ArticleIdList><ArticleId IdType="pubmed">19025984</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;&#x2014;A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351-357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, et al. . Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain. 2016;139(Pt 5):1551-1567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, Landau S, Baker SL, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer&#x2019;s disease. Neuroimage. 2017;157:448-463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wang G-J, Ding Y-S, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834-840.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45(3):358-368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SL, Lockhart SN, Price JC, et al. . Reference tissue-based kinetic evaluation of 18f-av-1451 for tau imaging. J Nucl Med. 2017;58(2):332-338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5288744</ArticleId><ArticleId IdType="pubmed">27587706</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904-911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lowe VJ, Knopman DS, et al. . Tau-PET uptake: regional variation in average SUVR and impact of amyloid deposition. Alzheimers Dement (Amst). 2016;6:21-30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5257031</ArticleId><ArticleId IdType="pubmed">28138510</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Tacik P, et al. . [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132(6):931-933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5107140</ArticleId><ArticleId IdType="pubmed">27645292</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen AK, Knudsen K, Lillethorup TP, et al. . In vivo imaging of neuromelanin in Parkinson&#x2019;s disease using 18F-AV-1451 PET. Brain. 2016;139(pt 7):2039-2049.</Citation><ArticleIdList><ArticleId IdType="pubmed">27190023</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster JL, Woldorff MG, Parsons LM, et al. . Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp. 2000;10(3):120-131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871915</ArticleId><ArticleId IdType="pubmed">10912591</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Brandel MG, Madison CM, et al. . Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 2012;59(2):1152-1160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230690</ArticleId><ArticleId IdType="pubmed">21884802</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. . Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138(Pt 7):2020-2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806716</ArticleId><ArticleId IdType="pubmed">25953778</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Curran G, Fang P, et al. . An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4(1):58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4906968</ArticleId><ArticleId IdType="pubmed">27296779</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. ; Amyloid Biomarker Study Group . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson&#x2019;s disease. J Neural Transm (Vienna). 2002;109(3):329-339.</Citation><ArticleIdList><ArticleId IdType="pubmed">11956955</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 2008;115(4):427-436.</Citation><ArticleIdList><ArticleId IdType="pubmed">18273624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurtig HI, Trojanowski JQ, Galvin J, et al. . Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson&#x2019;s disease. Neurology. 2000;54(10):1916-1921.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822429</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattila PM, Rinne JO, Helenius H, Dickson DW, R&#xf6;ytt&#xe4; M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson&#x2019;s disease. Acta Neuropathol. 2000;100(3):285-290.</Citation><ArticleIdList><ArticleId IdType="pubmed">10965798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K, Nagano-Saito A, Kato T, et al. . Striatal and extrastriatal dysfunction in Parkinson&#x2019;s disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain. 2002;125(Pt 6):1358-1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">12023324</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Cholerton B, Shi M, et al. ; Parkinson Study Group DATATOP Investigators . CSF tau and tau/A&#x3b2;42 predict cognitive decline in Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2015;21(3):271-276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4603566</ArticleId><ArticleId IdType="pubmed">25596881</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan CT, Wolk DA. Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2016;87(10):1112-1122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5154297</ArticleId><ArticleId IdType="pubmed">27288043</ArticleId></ArticleIdList></Reference><Reference><Citation>Melzer TR, Watts R, MacAskill MR, et al. . Grey matter atrophy in cognitively impaired Parkinson&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2012;83(2):188-194.</Citation><ArticleIdList><ArticleId IdType="pubmed">21890574</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarnall AJ, Breen DP, Duncan GW, et al. ; ICICLE-PD Study Group . Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology. 2014;82(4):308-316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929202</ArticleId><ArticleId IdType="pubmed">24363137</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan GW, Firbank MJ, Yarnall AJ, et al. . Gray and white matter imaging: a biomarker for cognitive impairment in early Parkinson&#x2019;s disease? Mov Disord. 2016;31(1):103-110.</Citation><ArticleIdList><ArticleId IdType="pubmed">26202802</ArticleId></ArticleIdList></Reference><Reference><Citation>Song I-U, Kim Y-D, Cho H-J, Chung S-W, Chung Y-A. An FP-CIT PET comparison of the differences in dopaminergic neuronal loss between idiopathic Parkinson disease with dementia and without dementia. Alzheimer Dis Assoc Disord. 2013;27(1):51-55.</Citation><ArticleIdList><ArticleId IdType="pubmed">22354157</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology. 2008;70(16, pt 2):1470-1477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4454398</ArticleId><ArticleId IdType="pubmed">18367705</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushpanathan ME, Loftus AM, Thomas MG, Gasson N, Bucks RS. The relationship between sleep and cognition in Parkinson&#x2019;s disease: A meta-analysis. Sleep Med Rev. 2016;26:21-32.</Citation><ArticleIdList><ArticleId IdType="pubmed">26365136</ArticleId></ArticleIdList></Reference><Reference><Citation>Scullin MK, Trotti LM, Wilson AG, Greer SA, Bliwise DL. Nocturnal sleep enhances working memory training in Parkinson&#x2019;s disease but not Lewy body dementia. Brain. 2012;135(pt 9):2789-2797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577106</ArticleId><ArticleId IdType="pubmed">22907117</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Vanderburg CR, et al. . Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787-800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29293211</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>552</Volume><Issue>7685</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Microglia-derived ASC specks cross-seed amyloid-&#x3b2; in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>355</StartPage><EndPage>361</EndPage><MedlinePgn>355-361</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature25158</ELocationID><Abstract><AbstractText>The spreading of pathology within and between brain areas is a hallmark of neurodegenerative disorders. In patients with Alzheimer's disease, deposition of amyloid-&#x3b2; is accompanied by activation of the innate immune system and involves inflammasome-dependent formation of ASC specks in microglia. ASC specks released by microglia bind rapidly to amyloid-&#x3b2; and increase the formation of amyloid-&#x3b2; oligomers and aggregates, acting as an inflammation-driven cross-seed for amyloid-&#x3b2; pathology. Here we show that intrahippocampal injection of ASC specks resulted in spreading of amyloid-&#x3b2; pathology in transgenic double-mutant APP<sub>Swe</sub>PSEN1<sub>dE9</sub> mice. By contrast, homogenates from brains of APP<sub>Swe</sub>PSEN1<sub>dE9</sub> mice failed to induce seeding and spreading of amyloid-&#x3b2; pathology in ASC-deficient APP<sub>Swe</sub>PSEN1<sub>dE9</sub> mice. Moreover, co-application of an anti-ASC antibody blocked the increase in amyloid-&#x3b2; pathology in APP<sub>Swe</sub>PSEN1<sub>dE9</sub> mice. These findings support the concept that inflammasome activation is connected to seeding and spreading of amyloid-&#x3b2; pathology in patients with Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Venegas</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Sathish</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franklin</LastName><ForeName>Bernardo S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dierkes</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Innate Immunity, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinkschulte</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tejera</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira-Saecker</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santarelli</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kummer</LastName><ForeName>Markus P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griep</LastName><ForeName>Angelika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelpi</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurological Tissue Bank, University of Barcelona-Hospital Clinic, IDIBAPS, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beilharz</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riedel</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Electron Microscopy Group, Max Planck Institute for Biophysical Chemistry, 37077 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golenbock</LastName><ForeName>Douglas T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geyer</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latz</LastName><ForeName>Eicke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen (DZNE), 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen (DZNE), 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053468">CARD Signaling Adaptor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C402202">PYCARD protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498534">Pycard protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C580804">presenilin 1, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Dec 21;552(7685):342-343. doi: 10.1038/d41586-017-08668-6.</RefSource><PMID Version="1">29293227</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053468" MajorTopicYN="N">CARD Signaling Adaptor Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="Y">Protein Aggregation, Pathological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065852" MajorTopicYN="N">Spatial Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29293211</ArticleId><ArticleId IdType="doi">10.1038/nature25158</ArticleId><ArticleId IdType="pii">nature25158</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Immunol. 2015 Mar;16(3):229-36</Citation><ArticleIdList><ArticleId IdType="pubmed">25689443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Metab. 2013 Oct 1;18(4):519-32</Citation><ArticleIdList><ArticleId IdType="pubmed">24093676</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2014 Aug;15(8):738-48</Citation><ArticleIdList><ArticleId IdType="pubmed">24952504</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Protoc Cell Biol. 2009 Sep;Chapter 3:Unit 3.33 3.33.1-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19731227</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2012 Nov 28;32(48):17321-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23197723</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2014 Oct;128(4):477-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25193240</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2016 Jun 22;7:11929</Citation><ArticleIdList><ArticleId IdType="pubmed">27329339</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Sep 5;501(7465):45-51</Citation><ArticleIdList><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2014 Jul 2;83(1):11-26</Citation><ArticleIdList><ArticleId IdType="pubmed">24991952</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2015 Jun;18(6):800-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26007213</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Feb 19;518(7539):365-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25693568</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 Mar 13;156(6):1207-1222</Citation><ArticleIdList><ArticleId IdType="pubmed">24630723</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2011 May 27;145(5):745-57</Citation><ArticleIdList><ArticleId IdType="pubmed">21565393</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1999 Nov 26;274(48):33835-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10567338</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 2008;442:251-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18662574</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2014 Aug;15(8):727-37</Citation><ArticleIdList><ArticleId IdType="pubmed">24952505</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2011 Jun 1;30(11):2255-65</Citation><ArticleIdList><ArticleId IdType="pubmed">21527912</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2016 Jun 1;73(6):691-7</Citation><ArticleIdList><ArticleId IdType="pubmed">27088644</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2014 Jul;14 (7):463-77</Citation><ArticleIdList><ArticleId IdType="pubmed">24962261</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 Mar 13;156(6):1193-1206</Citation><ArticleIdList><ArticleId IdType="pubmed">24630722</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Feb 11;10 (2):e0117208</Citation><ArticleIdList><ArticleId IdType="pubmed">25671600</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2013 Dec;45(12):1452-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2009 Dec;111(6):1369-82</Citation><ArticleIdList><ArticleId IdType="pubmed">19804379</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Dec 6;26(49):12838-46</Citation><ArticleIdList><ArticleId IdType="pubmed">17151287</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2007 Sep;14(9):1590-604</Citation><ArticleIdList><ArticleId IdType="pubmed">17599095</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Jan 31;493(7434):674-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2006 Sep 22;313(5794):1781-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 1996 Aug;2(8):864-70</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2013 Feb;12(2):207-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1996 Nov;17(5):1005-13</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2013 Apr 25;153(3):707-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2008 Mar;63(3):377-87</Citation><ArticleIdList><ArticleId IdType="pubmed">18300294</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2014 May 2;344(6183):519-23</Citation><ArticleIdList><ArticleId IdType="pubmed">24786080</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29263232</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>421</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaai7635</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aai7635</ELocationID><Abstract><AbstractText>Microglia are emerging as a key cell type in neurodegenerative diseases, yet human microglia are challenging to study in vitro. We developed an in vitro cell model system composed of human monocyte-derived microglia-like (MDMi) cells that recapitulated key aspects of microglia phenotype and function. We then used this model system to perform an expression quantitative trait locus (eQTL) study examining 94 genes from loci associated with Alzheimer's disease, Parkinson's disease, and multiple sclerosis. We found six loci (<i>CD33</i>, <i>PILRB</i>, <i>NUP160</i>, <i>LRRK2</i>, <i>RGS1</i>, and <i>METTL21B</i>) in which the risk haplotype drives the association with both disease susceptibility and altered expression of a nearby gene (cis-eQTL). In the <i>PILRB</i> and <i>LRRK2</i> loci, the cis-eQTL was found in the MDMi cells but not in human peripheral blood monocytes, suggesting that differentiation of monocytes into microglia-like cells led to the acquisition of a cellular state that could reveal the functional consequences of certain genetic variants. We further validated the effect of risk haplotypes at the protein level for <i>PILRB</i> and <i>CD33</i>, and we confirmed that the <i>CD33</i> risk haplotype altered phagocytosis by the MDMi cells. We propose that increased <i>LRRK2</i> gene expression by MDMi cells could be a functional outcome of <i>rs76904798</i>, a single-nucleotide polymorphism in the <i>LRKK2</i> locus that is associated with Parkinson's disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Katie J</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0002-8842-331X</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB168, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Charles C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB168, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Kruti</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-4303-8717</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB168, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jishu</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3139-5194</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB168, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olah</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Replogle</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB168, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frangieh</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB168, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cimpean</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3735-2643</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB168, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winn</LastName><ForeName>Phoebe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB168, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McHenry</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB168, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaskow</LastName><ForeName>Belinda J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB168, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Gail</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB168, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuerdon</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0833-6409</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB168, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0003-3689-554X</Identifier><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>Justin D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-5197-4724</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imitola</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2008-3133</Identifier><AffiliationInfo><Affiliation>Laboratory of Neural Stem Cells and Functional Neurogenetics, Departments of Neurology and Neuroscience, The Ohio State University College of Medicine, 333 West 10th Avenue, Columbus, OH 43210, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elyaman</LastName><ForeName>Wassim</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-8057-2505</Identifier><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradshaw</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-6766-4325</Identifier><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA. emb2280@cumc.columbia.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 NS089674</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089674</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D063268">Sialic Acid Binding Ig-like Lectin 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016764" MajorTopicYN="N">Cell Polarity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063268" MajorTopicYN="N">Sialic Acid Binding Ig-like Lectin 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29263232</ArticleId><ArticleId IdType="mid">NIHMS962702</ArticleId><ArticleId IdType="pmc">PMC5945290</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aai7635</ArticleId><ArticleId IdType="pii">9/421/eaai7635</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboywa S, Lee M, Von Korff A, Morris MC, Evans DA, Johnson K, Sperling RA, Schneider JA, Bennett DA, De Jager PL. CD33 Alzheimer&#x2019;s disease locus: altered monocyte function and amyloid biology. Nature neuroscience. 2013;16:848&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703870</ArticleId><ArticleId IdType="pubmed">23708142</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE. Alzheimer&#x2019;s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78:631&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik M, Simpson JF, Parikh I, Wilfred BR, Fardo DW, Nelson PT, Estus S. CD33 Alzheimer&#x2019;s risk-altering polymorphism, CD33 expression, and exon 2 splicing. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2013;33:13320&#x2013;13325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742922</ArticleId><ArticleId IdType="pubmed">23946390</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, Lohmann E, Bras JM, Gibbs JR, Rohrer JD, Gurunlian N, Dursun B, Bilgic B, Hanagasi H, Gurvit H, Emre M, Singleton A, Hardy J. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA neurology. 2013;70:78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001789</ArticleId><ArticleId IdType="pubmed">23318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J. TREM2 variants in Alzheimer&#x2019;s disease. The New England journal of medicine. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. The New England journal of medicine. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH, Pestronk A, Goate AM, Miller TM, Cruchaga C, Harms MB. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA neurology. 2014;71:449&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087113</ArticleId><ArticleId IdType="pubmed">24535663</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, Kertesz A, Bigio EH, Lippa C, Josephs KA, Knopman DS, White CL, 3rd, Caselli R, Mackenzie IR, Miller BL, Boczarska-Jedynak M, Opala G, Krygowska-Wajs A, Barcikowska M, Younkin SG, Petersen RC, Ertekin-Taner N, Uitti RJ, Meschia JF, Boylan KB, Boeve BF, Graff-Radford NR, Wszolek ZK, Dickson DW, Rademakers R, Ross OA. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson&#x2019;s disease. Molecular neurodegeneration. 2013;8:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691612</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Liu Y, Jiang Q, Jiang Y, Feng R, Zhang L, Chen Z, Li K, Liu J. Convergent Genetic and Expression Datasets Highlight TREM2 in Parkinson&#x2019;s Disease Susceptibility. Molecular neurobiology. 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">26365049</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MN, Ye C, Villani AC, Raj T, Li W, Eisenhaure TM, Imboywa SH, Chipendo PI, Ran FA, Slowikowski K, Ward LD, Raddassi K, McCabe C, Lee MH, Frohlich IY, Hafler DA, Kellis M, Raychaudhuri S, Zhang F, Stranger BE, Benoist CO, De Jager PL, Regev A, Hacohen N. Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science (New York, NY) 2014;343:1246980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4124741</ArticleId><ArticleId IdType="pubmed">24604203</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye CJ, Feng T, Kwon HK, Raj T, Wilson MT, Asinovski N, McCabe C, Lee MH, Frohlich I, Paik HI, Zaitlen N, Hacohen N, Stranger B, De Jager P, Mathis D, Regev A, Benoist C. Intersection of population variation and autoimmunity genetics in human T cell activation. Science (New York, NY) 2014;345:1254665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751028</ArticleId><ArticleId IdType="pubmed">25214635</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfax BP, Humburg P, Makino S, Naranbhai V, Wong D, Lau E, Jostins L, Plant K, Andrews R, McGee C, Knight JC. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science (New York, NY) 2014;343:1246949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064786</ArticleId><ArticleId IdType="pubmed">24604202</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, Feng T, Lee M, Asinovski N, Frohlich I, Imboywa S, Von Korff A, Okada Y, Patsopoulos NA, Davis S, McCabe C, Paik HI, Srivastava GP, Raychaudhuri S, Hafler DA, Koller D, Regev A, Hacohen N, Mathis D, Benoist C, Stranger BE, De Jager PL. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science (New York, NY) 2014;344:519&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910825</ArticleId><ArticleId IdType="pubmed">24786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard JW. Trophic macrophages in development and disease. Nature reviews Immunology. 2009;9:259&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648866</ArticleId><ArticleId IdType="pubmed">19282852</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay ME, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A. The role of microglia in the healthy brain. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2011;31:16064&#x2013;16069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633221</ArticleId><ArticleId IdType="pubmed">22072657</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinet J, Weering HR, Heinrich A, Kalin RE, Wegner A, Brouwer N, Heppner FL, Rooijen N, Boddeke HW, Biber K. Neuroprotective function for ramified microglia in hippocampal excitotoxicity. Journal of neuroinflammation. 2012;9:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292937</ArticleId><ArticleId IdType="pubmed">22293457</ArticleId></ArticleIdList></Reference><Reference><Citation>Priller J, Flugel A, Wehner T, Boentert M, Haas CA, Prinz M, Fernandez-Klett F, Prass K, Bechmann I, de Boer BA, Frotscher M, Kreutzberg GW, Persons DA, Dirnagl U. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nature medicine. 2001;7:1356&#x2013;1361.</Citation><ArticleIdList><ArticleId IdType="pubmed">11726978</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, Cohen H, Schwartz M. Glatiramer acetate fights against Alzheimer&#x2019;s disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:11784&#x2013;11789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544247</ArticleId><ArticleId IdType="pubmed">16864778</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer&#x2019;s disease brain and damage the blood-brain barrier. European journal of clinical investigation. 2002;32:360&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">12027877</ArticleId></ArticleIdList></Reference><Reference><Citation>Rektor I, Goldemund D, Sheardova K, Rektorova I, Michalkova Z, Dufek M. Vascular pathology in patients with idiopathic Parkinson&#x2019;s disease. Parkinsonism &amp; related disorders. 2009;15:24&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">18403246</ArticleId></ArticleIdList></Reference><Reference><Citation>Song IU, Kim YD, Cho HJ, Chung SW. The effects of silent cerebral ischemic lesions on the prognosis of idiopathic Parkinson&#x2019;s disease. Parkinsonism &amp; related disorders. 2013;19:761&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">23660543</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer SP, Simonsen H, Frederiksen JL, Rostrup E, Larsson HB. Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI. NeuroImage Clinical. 2014;4:182&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3872721</ArticleId><ArticleId IdType="pubmed">24371801</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan SE, Young-Pearse TL. Induced pluripotent stem cells as a discovery tool for Alzheimers disease. Brain research. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4833689</ArticleId><ArticleId IdType="pubmed">26459988</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang PW, Haidet-Phillips AM, Pham JT, Lee Y, Huo Y, Tienari PJ, Maragakis NJ, Sattler R, Rothstein JD. Generation of GFAP::GFP astrocyte reporter lines from human adult fibroblast-derived iPS cells using zinc-finger nuclease technology. Glia. 2016;64:63&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4715664</ArticleId><ArticleId IdType="pubmed">26295203</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao MC, Muratore CR, Gierahn TM, Sullivan SE, Srikanth P, De Jager PL, Love JC, Young-Pearse TL. Single-Cell Detection of Secreted Abeta and sAPPalpha from Human IPSC-Derived Neurons and Astrocytes. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2016;36:1730&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4737781</ArticleId><ArticleId IdType="pubmed">26843653</ArticleId></ArticleIdList></Reference><Reference><Citation>Muffat J, Li Y, Yuan B, Mitalipova M, Omer A, Corcoran S, Bakiasi G, Tsai LH, Aubourg P, Ransohoff RM, Jaenisch R. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nature medicine. 2016;22:1358&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5101156</ArticleId><ArticleId IdType="pubmed">27668937</ArticleId></ArticleIdList></Reference><Reference><Citation>Etemad S, Zamin RM, Ruitenberg MJ, Filgueira L. A novel in vitro human microglia model: characterization of human monocyte-derived microglia. Journal of neuroscience methods. 2012;209:79&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">22659341</ArticleId></ArticleIdList></Reference><Reference><Citation>Leone C, Le Pavec G, Meme W, Porcheray F, Samah B, Dormont D, Gras G. Characterization of human monocyte-derived microglia-like cells. Glia. 2006;54:183&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">16807899</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgidani M, Kato TA, Setoyama D, Sagata N, Hashimoto R, Shigenobu K, Yoshida T, Hayakawa K, Shimokawa N, Miura D, Utsumi H, Kanba S. Direct induction of ramified microglia-like cells from human monocytes: dynamic microglial dysfunction in Nasu-Hakola disease. Scientific reports. 2014;4:4957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019954</ArticleId><ArticleId IdType="pubmed">24825127</ArticleId></ArticleIdList></Reference><Reference><Citation>Noto D, Sakuma H, Takahashi K, Saika R, Saga R, Yamada M, Yamamura T, Miyake S. Development of a culture system to induce microglia-like cells from haematopoietic cells. Neuropathology and applied neurobiology. 2014;40:697&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282385</ArticleId><ArticleId IdType="pubmed">24016036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers J, Parwaresch R, Wottge HU. Blood monocytes and spleen macrophages differentiate into microglia-like cells on monolayers of astrocytes: morphology. Glia. 1994;12:245&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">7890329</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellgren CM, Sheridan SD, Gracias J, Xuan D, Fu T, Perlis RH. Patient-specific models of microglia-mediated engulfment of synapses and neural progenitors. Molecular psychiatry. 2017;22:170&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5285468</ArticleId><ArticleId IdType="pubmed">27956744</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science (New York, NY) 2010;330:841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>De Simone R, Ambrosini E, Carnevale D, Ajmone-Cat MA, Minghetti L. NGF promotes microglial migration through the activation of its high affinity receptor: modulation by TGF-beta. Journal of neuroimmunology. 2007;190:53&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">17868907</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nature medicine. 2007;13:432&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Esen N, Kielian T. Effects of low dose GM-CSF on microglial inflammatory profiles to diverse pathogen-associated molecular patterns (PAMPs) Journal of neuroinflammation. 2007;4:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839084</ArticleId><ArticleId IdType="pubmed">17374157</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling T, Nitsch R, Heinemann U, Haas D, Eder C. Astrocyte-released cytokines induce ramification and outward K+ channel expression in microglia via distinct signalling pathways. The European journal of neuroscience. 2001;14:463&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">11553296</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Szretter KJ, Vermi W, Gilfillan S, Rossini C, Cella M, Barrow AD, Diamond MS, Colonna M. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nature immunology. 2012;13:753&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941469</ArticleId><ArticleId IdType="pubmed">22729249</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MS, Li G, Duncan JA, 3rd, Cheshier SH, Shuer LM, Chang EF, Grant GA, Gephart MG, Barres BA. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron. 2016;89:37&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, Mulinyawe SB, Bohlen CJ, Adil A, Tucker A, Weissman IL, Chang EF, Li G, Grant GA, Hayden Gephart MG, Barres BA. New tools for studying microglia in the mouse and human CNS. Proceedings of the National Academy of Sciences of the United States of America. 2016;113:E1738&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Durafourt BA, Moore CS, Zammit DA, Johnson TA, Zaguia F, Guiot MC, Bar-Or A, Antel JP. Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia. 2012;60:717&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">22290798</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thorton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Moron FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fievet N, Huentelman MW, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuiness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossu P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O&#x2019;Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH, Jr, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltuenen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nothen MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nature genetics. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Replogle JM, Chan G, White CC, Raj T, Winn PA, Evans DA, Sperling RA, Chibnik LB, Bradshaw EM, Schneider JA, Bennett DA, De Jager PL. A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology. Annals of neurology. 2015;77:469&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4461024</ArticleId><ArticleId IdType="pubmed">25545807</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nature genetics. 2014;46:989&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D&#x2019;Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF, Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Sondergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelcic I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppa V, Liberatore G, Lie BA, Lill CM, Linden M, Link J, Luessi F, Lycke J, Macciardi F, Mannisto S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature genetics. 2013;45:1353&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832895</ArticleId><ArticleId IdType="pubmed">24076602</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy DG, O&#x2019;Sullivan SS, Falchi M, Bonifati V, Durr A, Bressman S, Aasly A, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AHV, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson&#x2019;s disease: a case-control study.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832754</ArticleId><ArticleId IdType="pubmed">18539534</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, Plagnol V. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS genetics. 2014;10:e1004383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM. Expression of novel Alzheimer&#x2019;s disease risk genes in control and Alzheimer&#x2019;s disease brains. PloS one. 2012;7:e50976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511432</ArticleId><ArticleId IdType="pubmed">23226438</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Caselles T, Martinez-Esparza M, Perez-Oliva AB, Quintanilla-Cecconi AM, Garcia-Alonso A, Alvarez-Lopez DM, Garcia-Penarrubia P. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. Journal of leukocyte biology. 2006;79:46&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">16380601</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Cribbs DH, Rosenthal M, Bernard G. Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer&#x2019;s disease. Journal of Alzheimer&#x2019;s disease: JAD. 2007;11:457&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">17656824</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z, Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nature neuroscience. 2014;17:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialas AR, Stevens B. TGF-beta signaling regulates neuronal C1q expression and developmental synaptic refinement. Nature neuroscience. 2013;16:1773&#x2013;1782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3973738</ArticleId><ArticleId IdType="pubmed">24162655</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourgeaud L, Traves PG, Tufail Y, Leal-Bailey H, Lew ED, Burrola PG, Callaway P, Zagorska A, Rothlin CV, Nimmerjahn A, Lemke G. TAM receptors regulate multiple features of microglial physiology. Nature. 2016;532:240&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5358512</ArticleId><ArticleId IdType="pubmed">27049947</ArticleId></ArticleIdList></Reference><Reference><Citation>Monif M, Reid CA, Powell KL, Smart ML, Williams DA. The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2009;29:3781&#x2013;3791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665035</ArticleId><ArticleId IdType="pubmed">19321774</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nature medicine. 2008;14:681&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649699</ArticleId><ArticleId IdType="pubmed">18516051</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O&#x2019;Banion MK. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. The Journal of clinical investigation. 2007;117:1595&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1878531</ArticleId><ArticleId IdType="pubmed">17549256</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki R, Lu H, Butovsky O, Ohno N, Rietsch AM, Cialic R, Wu PM, Doykan CE, Lin J, Cotleur AC, Kidd G, Zorlu MM, Sun N, Hu W, Liu L, Lee JC, Taylor SE, Uehlein L, Dixon D, Gu J, Floruta CM, Zhu M, Charo IF, Weiner HL, Ransohoff RM. Differential roles of microglia and monocytes in the inflamed central nervous system. The Journal of experimental medicine. 2014;211:1533&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113947</ArticleId><ArticleId IdType="pubmed">25002752</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nature neuroscience. 2011;14:1142&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">21804537</ArticleId></ArticleIdList></Reference><Reference><Citation>Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB. Cloning of the gene containing mutations that cause PARK8-linked Parkinson&#x2019;s disease. Neuron. 2004;44:595&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541308</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference><Reference><Citation>Thevenet J, Pescini Gobert R, Hooft van Huijsduijnen R, Wiessner C, Sagot YJ. Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PloS one. 2011;6:e21519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124520</ArticleId><ArticleId IdType="pubmed">21738687</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, West AB. LRRK2 inhibition attenuates microglial inflammatory responses. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2012;32:1602&#x2013;1611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532034</ArticleId><ArticleId IdType="pubmed">22302802</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T, Ryan KJ, Replogle JM, Chibnik LB, Rosenkrantz L, Tang A, Rothamel K, Stranger BE, Bennett DA, Evans DA, De Jager PL, Bradshaw EM. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer&#x2019;s disease susceptibility. Human molecular genetics. 2014;23:2729&#x2013;2736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990171</ArticleId><ArticleId IdType="pubmed">24381305</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nature genetics. 2011;43:436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao YF, Guo ZY, Pu JL, Chen YX, Zhang BR. Association of CD33 and MS4A cluster variants with Alzheimer&#x2019;s disease in East Asian populations. Neuroscience letters. 2015;609:235&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">26455864</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BN, Wang LS, Valladares O, Lin CF, Larson EB, Graff-Radford NR, Evans D, De Jager PL, Crane PK, Buxbaum JD, Murrell JR, Raj T, Ertekin-Taner N, Logue M, Baldwin CT, Green RC, Barnes LL, Cantwell LB, Fallin MD, Go RCP, Griffith P, Obisesan TO, Manly JJ, Lunetta KL, Kamboh MI, Lopez OL, Bennett DA, Hendrie H, Hall KS, Goate AM, Byrd GS, Kukull WA, Foroud TM, Haines JL, Farrer LA, Pericak-Vance MA, Schellenberg GD, Mayeux R. Variants in the ATP-Binding Cassette Transporter (ABCA7), Apolipoprotein E &#x3b5;4, and the Risk of Late-Onset Alzheimer Disease in African Americans. JAMA: the journal of the American Medical Association. 2013;309:1483&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3667653</ArticleId><ArticleId IdType="pubmed">23571587</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F, Crook JE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, Passmore P, Morgan K, Younkin SG. Replication of EPHA1 and CD33 associations with late-onset Alzheimer&#x2019;s disease: a multi-centre case-control study. Molecular neurodegeneration. 2011;6:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157442</ArticleId><ArticleId IdType="pubmed">21798052</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan G, White CC, Winn PA, Cimpean M, Replogle JM, Glick LR, Cuerdon NE, Ryan KJ, Johnson KA, Schneider JA, Bennett DA, Chibnik LB, Sperling RA, Bradshaw EM, De Jager PL. CD33 modulates TREM2: convergence of Alzheimer loci. Nature neuroscience. 2015;18:1556&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4682915</ArticleId><ArticleId IdType="pubmed">26414614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachamitr P, Hackett S, Fairchild PJ. Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4029000</ArticleId><ArticleId IdType="pubmed">24860566</ArticleId></ArticleIdList></Reference><Reference><Citation>Haw RT, Tong CK, Yew A, Lee HC, Phillips JB, Vidyadaran S. A three-dimensional collagen construct to model lipopolysaccharide-induced activation of BV2 microglia. Journal of neuroinflammation. 2014;11:134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4128540</ArticleId><ArticleId IdType="pubmed">25074682</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgidani M, Kato TA, Kanba S. Introducing directly induced microglia-like (iMG) cells from fresh human monocytes: a novel translational research tool for psychiatric disorders. Frontiers in cellular neuroscience. 2015;9:184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4444822</ArticleId><ArticleId IdType="pubmed">26074765</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas BJ, Papanicolaou A, Yassour M, Grabherr M, Blood PD, Bowden J, Couger MB, Eccles D, Li B, Lieber M, Macmanes MD, Ott M, Orvis J, Pochet N, Strozzi F, Weeks N, Westerman R, William T, Dewey CN, Henschel R, Leduc RD, Friedman N, Regev A. De novo transcript sequence reconstruction from RNA-seq using the Trinity platform for reference generation and analysis. Nature protocols. 2013;8:1494&#x2013;1512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875132</ArticleId><ArticleId IdType="pubmed">23845962</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC bioinformatics. 2011;12:323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163565</ArticleId><ArticleId IdType="pubmed">21816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. Journal of immunology (Baltimore, Md: 1950) 2009;182:4415&#x2013;4422.</Citation><ArticleIdList><ArticleId IdType="pubmed">19299742</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim AS, Srivastava GP, Yu L, Chibnik LB, Xu J, Buchman AS, Schneider JA, Myers AJ, Bennett DA, De Jager PL. 24-hour rhythms of DNA methylation and their relation with rhythms of RNA expression in the human dorsolateral prefrontal cortex. PLoS genetics. 2014;10:e1004792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222754</ArticleId><ArticleId IdType="pubmed">25375876</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush Memory and Aging Project. Current Alzheimer research. 2012;9:646&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. Current Alzheimer research. 2012;9:628&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer CJ. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics (Oxford, England) 2010;26:2336&#x2013;2337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935401</ArticleId><ArticleId IdType="pubmed">20634204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29282330</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Jan</Month><Day>16</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Whole genome sequence analyses of brain imaging measures in the Framingham Study.</ArticleTitle><Pagination><StartPage>e188</StartPage><EndPage>e196</EndPage><MedlinePgn>e188-e196</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000004820</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We sought to identify rare variants influencing brain imaging phenotypes in the Framingham Heart Study by performing whole genome sequence association analyses within the Trans-Omics for Precision Medicine Program.</AbstractText><AbstractText Label="METHODS">We performed association analyses of cerebral and hippocampal volumes and white matter hyperintensity (WMH) in up to 2,180 individuals by testing the association of rank-normalized residuals from mixed-effect linear regression models adjusted for sex, age, and total intracranial volume with individual variants while accounting for familial relatedness. We conducted gene-based tests for rare variants using (1) a sliding-window approach, (2) a selection of functional exonic variants, or (3) all variants.</AbstractText><AbstractText Label="RESULTS">We detected new loci in 1p21 for cerebral volume (minor allele frequency [MAF] 0.005, <i>p</i> = 10<sup>-8</sup>) and in 16q23 for hippocampal volume (MAF 0.05, <i>p</i> = 2.7 &#xd7; 10<sup>-8</sup>). Previously identified associations in 12q24 for hippocampal volume (rs7294919, <i>p</i> = 4.4 &#xd7; 10<sup>-4</sup>) and in 17q25 for WMH (rs7214628, <i>p</i> = 2.0 &#xd7; 10<sup>-3</sup>) were confirmed. Gene-based tests detected associations (<i>p</i> &#x2264; 2.3 &#xd7; 10<sup>-6</sup>) in new loci for cerebral (5q13, 8p12, 9q31, 13q12-q13, 15q24, 17q12, 19q13) and hippocampal volumes (2p12) and WMH (3q13, 4p15) including Alzheimer disease- (<i>UNC5D</i>) and Parkinson disease-associated genes (<i>GBA</i>). Pathway analyses evidenced enrichment of associated genes in immunity, inflammation, and Alzheimer disease and Parkinson disease pathways.</AbstractText><AbstractText Label="CONCLUSIONS">Whole genome sequence-wide search reveals intriguing new loci associated with brain measures. Replication of novel loci is needed to confirm these findings.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarnowski</LastName><ForeName>Chlo&#xe9;</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Epidemiology (C.S., L.A.C., A.S.B., A.L.D., J.D.), Boston University School of Public Health; Boston University and the NHLBI's Framingham Heart Study (C.L.S., A.N.P., L.A.C., R.S.V., A.S.B., A.L.D., J.D., S.S.); Departments of Neurology (C.L.S., A.S.B., A.L.D., S.S.) and Cardiology, Preventive Medicine &amp; Epidemiology (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Neurology and Center for Neuroscience (C.D.), University of California at Davis; Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, University of Washington, Seattle; and Institute of Molecular Medicine (M.F.), University of Texas Health Science Center, Houston. chloesar@bu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satizabal</LastName><ForeName>Claudia L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>From the Department of Epidemiology (C.S., L.A.C., A.S.B., A.L.D., J.D.), Boston University School of Public Health; Boston University and the NHLBI's Framingham Heart Study (C.L.S., A.N.P., L.A.C., R.S.V., A.S.B., A.L.D., J.D., S.S.); Departments of Neurology (C.L.S., A.S.B., A.L.D., S.S.) and Cardiology, Preventive Medicine &amp; Epidemiology (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Neurology and Center for Neuroscience (C.D.), University of California at Davis; Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, University of Washington, Seattle; and Institute of Molecular Medicine (M.F.), University of Texas Health Science Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Epidemiology (C.S., L.A.C., A.S.B., A.L.D., J.D.), Boston University School of Public Health; Boston University and the NHLBI's Framingham Heart Study (C.L.S., A.N.P., L.A.C., R.S.V., A.S.B., A.L.D., J.D., S.S.); Departments of Neurology (C.L.S., A.S.B., A.L.D., S.S.) and Cardiology, Preventive Medicine &amp; Epidemiology (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Neurology and Center for Neuroscience (C.D.), University of California at Davis; Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, University of Washington, Seattle; and Institute of Molecular Medicine (M.F.), University of Texas Health Science Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pitsillides</LastName><ForeName>Achilleas N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>From the Department of Epidemiology (C.S., L.A.C., A.S.B., A.L.D., J.D.), Boston University School of Public Health; Boston University and the NHLBI's Framingham Heart Study (C.L.S., A.N.P., L.A.C., R.S.V., A.S.B., A.L.D., J.D., S.S.); Departments of Neurology (C.L.S., A.S.B., A.L.D., S.S.) and Cardiology, Preventive Medicine &amp; Epidemiology (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Neurology and Center for Neuroscience (C.D.), University of California at Davis; Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, University of Washington, Seattle; and Institute of Molecular Medicine (M.F.), University of Texas Health Science Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cupples</LastName><ForeName>L Adrienne</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>From the Department of Epidemiology (C.S., L.A.C., A.S.B., A.L.D., J.D.), Boston University School of Public Health; Boston University and the NHLBI's Framingham Heart Study (C.L.S., A.N.P., L.A.C., R.S.V., A.S.B., A.L.D., J.D., S.S.); Departments of Neurology (C.L.S., A.S.B., A.L.D., S.S.) and Cardiology, Preventive Medicine &amp; Epidemiology (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Neurology and Center for Neuroscience (C.D.), University of California at Davis; Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, University of Washington, Seattle; and Institute of Molecular Medicine (M.F.), University of Texas Health Science Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasan</LastName><ForeName>Ramachandran S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>From the Department of Epidemiology (C.S., L.A.C., A.S.B., A.L.D., J.D.), Boston University School of Public Health; Boston University and the NHLBI's Framingham Heart Study (C.L.S., A.N.P., L.A.C., R.S.V., A.S.B., A.L.D., J.D., S.S.); Departments of Neurology (C.L.S., A.S.B., A.L.D., S.S.) and Cardiology, Preventive Medicine &amp; Epidemiology (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Neurology and Center for Neuroscience (C.D.), University of California at Davis; Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, University of Washington, Seattle; and Institute of Molecular Medicine (M.F.), University of Texas Health Science Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>James G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>From the Department of Epidemiology (C.S., L.A.C., A.S.B., A.L.D., J.D.), Boston University School of Public Health; Boston University and the NHLBI's Framingham Heart Study (C.L.S., A.N.P., L.A.C., R.S.V., A.S.B., A.L.D., J.D., S.S.); Departments of Neurology (C.L.S., A.S.B., A.L.D., S.S.) and Cardiology, Preventive Medicine &amp; Epidemiology (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Neurology and Center for Neuroscience (C.D.), University of California at Davis; Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, University of Washington, Seattle; and Institute of Molecular Medicine (M.F.), University of Texas Health Science Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bis</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>From the Department of Epidemiology (C.S., L.A.C., A.S.B., A.L.D., J.D.), Boston University School of Public Health; Boston University and the NHLBI's Framingham Heart Study (C.L.S., A.N.P., L.A.C., R.S.V., A.S.B., A.L.D., J.D., S.S.); Departments of Neurology (C.L.S., A.S.B., A.L.D., S.S.) and Cardiology, Preventive Medicine &amp; Epidemiology (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Neurology and Center for Neuroscience (C.D.), University of California at Davis; Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, University of Washington, Seattle; and Institute of Molecular Medicine (M.F.), University of Texas Health Science Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornage</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Epidemiology (C.S., L.A.C., A.S.B., A.L.D., J.D.), Boston University School of Public Health; Boston University and the NHLBI's Framingham Heart Study (C.L.S., A.N.P., L.A.C., R.S.V., A.S.B., A.L.D., J.D., S.S.); Departments of Neurology (C.L.S., A.S.B., A.L.D., S.S.) and Cardiology, Preventive Medicine &amp; Epidemiology (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Neurology and Center for Neuroscience (C.D.), University of California at Davis; Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, University of Washington, Seattle; and Institute of Molecular Medicine (M.F.), University of Texas Health Science Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beiser</LastName><ForeName>Alexa S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>From the Department of Epidemiology (C.S., L.A.C., A.S.B., A.L.D., J.D.), Boston University School of Public Health; Boston University and the NHLBI's Framingham Heart Study (C.L.S., A.N.P., L.A.C., R.S.V., A.S.B., A.L.D., J.D., S.S.); Departments of Neurology (C.L.S., A.S.B., A.L.D., S.S.) and Cardiology, Preventive Medicine &amp; Epidemiology (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Neurology and Center for Neuroscience (C.D.), University of California at Davis; Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, University of Washington, Seattle; and Institute of Molecular Medicine (M.F.), University of Texas Health Science Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeStefano</LastName><ForeName>Anita L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>From the Department of Epidemiology (C.S., L.A.C., A.S.B., A.L.D., J.D.), Boston University School of Public Health; Boston University and the NHLBI's Framingham Heart Study (C.L.S., A.N.P., L.A.C., R.S.V., A.S.B., A.L.D., J.D., S.S.); Departments of Neurology (C.L.S., A.S.B., A.L.D., S.S.) and Cardiology, Preventive Medicine &amp; Epidemiology (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Neurology and Center for Neuroscience (C.D.), University of California at Davis; Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, University of Washington, Seattle; and Institute of Molecular Medicine (M.F.), University of Texas Health Science Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupuis</LastName><ForeName>Jos&#xe9;e</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Epidemiology (C.S., L.A.C., A.S.B., A.L.D., J.D.), Boston University School of Public Health; Boston University and the NHLBI's Framingham Heart Study (C.L.S., A.N.P., L.A.C., R.S.V., A.S.B., A.L.D., J.D., S.S.); Departments of Neurology (C.L.S., A.S.B., A.L.D., S.S.) and Cardiology, Preventive Medicine &amp; Epidemiology (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Neurology and Center for Neuroscience (C.D.), University of California at Davis; Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, University of Washington, Seattle; and Institute of Molecular Medicine (M.F.), University of Texas Health Science Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Epidemiology (C.S., L.A.C., A.S.B., A.L.D., J.D.), Boston University School of Public Health; Boston University and the NHLBI's Framingham Heart Study (C.L.S., A.N.P., L.A.C., R.S.V., A.S.B., A.L.D., J.D., S.S.); Departments of Neurology (C.L.S., A.S.B., A.L.D., S.S.) and Cardiology, Preventive Medicine &amp; Epidemiology (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Neurology and Center for Neuroscience (C.D.), University of California at Davis; Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, University of Washington, Seattle; and Institute of Molecular Medicine (M.F.), University of Texas Health Science Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>TOPMed Neurocognitive Working Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000262</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201500014C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL117626</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115428</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL120393</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2018 Jan 16;90(3):109. doi: 10.1212/WNL.0000000000004838.</RefSource><PMID Version="1">29282334</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008404" MajorTopicYN="N" Type="Geographic">Massachusetts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Arnett</LastName><ForeName>Donna K</ForeName><Initials>DK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bis</LastName><ForeName>Joshua</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boerwinkle</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowers</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bressler</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correa</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeStefano</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ding</LastName><ForeName>Jingzhong Ding</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fardo</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fornage</LastName><ForeName>Myriam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lugo</LastName><ForeName>Alex Garcia</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glahn</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Hector</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayden</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heckbert</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoth</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hughes</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaquish</LastName><ForeName>Cashell</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jian</LastName><ForeName>Xueqiu</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knowles</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Honghuang</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longstreth</LastName><ForeName>Will</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Misra</LastName><ForeName>Biswapriya</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mosley</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nyquist</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olivier</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peprah</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Psaty</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Purcell</LastName><ForeName>Shaun</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rotter</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarnowski</LastName><ForeName>Chlo&#xe9;</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Satizabal</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simino</LastName><ForeName>Jeannette</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smoller</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snively</LastName><ForeName>Beverly</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sokolow</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wehr</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yanek</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Namiko</LastName><ForeName>Abe</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goncalo</LastName><ForeName>Abecasis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christine</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicholette Nichole Palmer</LastName><ForeName>Allred</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laura</LastName><ForeName>Almasy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alvaro</LastName><ForeName>Alonso</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seth</LastName><ForeName>Ament</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peter</LastName><ForeName>Anderson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pramod</LastName><ForeName>Anugu</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deborah</LastName><ForeName>Applebaum-Bowden</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dan</LastName><ForeName>Arking</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donna K</LastName><ForeName>Arnett</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allison</LastName><ForeName>Ashley-Koch</ForeName><Initials>AK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stella</LastName><ForeName>Aslibekyan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tim</LastName><ForeName>Assimes</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paul</LastName><ForeName>Auer</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dimitrios</LastName><ForeName>Avramopoulos</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>John</LastName><ForeName>Barnard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kathleen</LastName><ForeName>Barnes</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>Barr R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emily</LastName><ForeName>Barron-Casella</ForeName><Initials>BC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terri</LastName><ForeName>Beaty</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diane</LastName><ForeName>Becker</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lewis</LastName><ForeName>Becker</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rebecca</LastName><ForeName>Beer</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferdouse</LastName><ForeName>Begum</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amber</LastName><ForeName>Beitelshees</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emelia</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marcos</LastName><ForeName>Bezerra</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larry</LastName><ForeName>Bielak</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joshua</LastName><ForeName>Bis</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Blackwell</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>John</LastName><ForeName>Blangero</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eric</LastName><ForeName>Boerwinkle</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingrid</LastName><ForeName>Borecki</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russell</LastName><ForeName>Bowler</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jennifer</LastName><ForeName>Brody</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Broeckel</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jai</LastName><ForeName>Broome</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karen</LastName><ForeName>Bunting</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Esteban</LastName><ForeName>Burchard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jonathan</LastName><ForeName>Cardwell</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sara</LastName><ForeName>Carlson</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cara</LastName><ForeName>Carty</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richard</LastName><ForeName>Casaburi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Casella</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mark</LastName><ForeName>Chaffin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christy</LastName><ForeName>Chang</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daniel</LastName><ForeName>Chasman</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sameer</LastName><ForeName>Chavan</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bo-Juen</LastName><ForeName>Chen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wei-Min</LastName><ForeName>Chen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yii-Der Ida</LastName><ForeName>Chen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michael</LastName><ForeName>Cho</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoan</LastName><ForeName>Choi Seung</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee-Ming</LastName><ForeName>Chuang</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mina</LastName><ForeName>Chung</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elaine</LastName><ForeName>Cornell</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adolfo</LastName><ForeName>Correa</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carolyn</LastName><ForeName>Crandall</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Crapo</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adrienne</LastName><ForeName>Cupples L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joanne</LastName><ForeName>Curran</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeffrey</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brian</LastName><ForeName>Custer</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coleen</LastName><ForeName>Damcott</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dawood</LastName><ForeName>Darbar</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sayantan</LastName><ForeName>Das</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sean</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colleen</LastName><ForeName>Davis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Andrade Mariza</LastName><ForeName>Daya Michelle</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michael</LastName><ForeName>DeBaun</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ranjan</LastName><ForeName>Deka</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dawn</LastName><ForeName>DeMeo</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>Devine</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ron</LastName><ForeName>Do</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qing</LastName><ForeName>Duan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravi</LastName><ForeName>Duggirala</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peter</LastName><ForeName>Durda</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Susan</LastName><ForeName>Dutcher</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charles</LastName><ForeName>Eaton</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lynette</LastName><ForeName>Ekunwe</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patrick</LastName><ForeName>Ellinor</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leslie</LastName><ForeName>Emery</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charles</LastName><ForeName>Farber</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leanna</LastName><ForeName>Farnam</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tasha</LastName><ForeName>Fingerlin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthew</LastName><ForeName>Flickinger</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myriam</LastName><ForeName>Fornage</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nora</LastName><ForeName>Franceschini</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mao</LastName><ForeName>Fu</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malia</LastName><ForeName>Fullerton</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lucinda</LastName><ForeName>Fulton</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stacey</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiniu</LastName><ForeName>Gan</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yan</LastName><ForeName>Gao</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Margery</LastName><ForeName>Gass</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiaoqi Priscilla</LastName><ForeName>Geng</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soren</LastName><ForeName>Germer</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chris</LastName><ForeName>Gignoux</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mark</LastName><ForeName>Gladwin</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>David</LastName><ForeName>Glahn</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephanie</LastName><ForeName>Gogarten</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Da-Wei</LastName><ForeName>Gong</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harald</LastName><ForeName>Goring</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charles</LastName><ForeName>Gu C</ForeName><Initials>GC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yue</LastName><ForeName>Guan</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiuqing</LastName><ForeName>Guo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeff</LastName><ForeName>Haessler</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michael</LastName><ForeName>Hall</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daniel</LastName><ForeName>Harris</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicola</LastName><ForeName>Hawley</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiang</LastName><ForeName>He</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ben</LastName><ForeName>Heavner</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Susan</LastName><ForeName>Heckbert</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>Hernandez</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>David</LastName><ForeName>Herrington</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craig</LastName><ForeName>Hersh</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertha</LastName><ForeName>Hidalgo</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Hixson</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>John</LastName><ForeName>Hokanson</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elliott</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karin</LastName><ForeName>Hoth</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chao Agnes</LastName><ForeName>Hsiung</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haley</LastName><ForeName>Huston</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Min</LastName><ForeName>Hwu Chii</ForeName><Initials>HC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>Irvin Marguerite</ForeName><Initials>IM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rebecca</LastName><ForeName>Jackson</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deepti</LastName><ForeName>Jain</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cashell</LastName><ForeName>Jaquish</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Min A</LastName><ForeName>Jhun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jill</LastName><ForeName>Johnsen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrew</LastName><ForeName>Johnson</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craig</LastName><ForeName>Johnson</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rich</LastName><ForeName>Johnston</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kimberly</LastName><ForeName>Jones</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Min</LastName><ForeName>Kang Hyun</ForeName><Initials>KH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robert</LastName><ForeName>Kaplan</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharon</LastName><ForeName>Kardia</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sekar</LastName><ForeName>Kathiresan</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laura</LastName><ForeName>Kaufman</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shannon</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eimear</LastName><ForeName>Kenny</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michael</LastName><ForeName>Kessler</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alyna</LastName><ForeName>Khan</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greg</LastName><ForeName>Kinney</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbara</LastName><ForeName>Konkle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charles</LastName><ForeName>Kooperberg</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holly</LastName><ForeName>Kramer</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephanie</LastName><ForeName>Krauter</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christoph</LastName><ForeName>Lange</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ethan</LastName><ForeName>Lange</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leslie</LastName><ForeName>Lange</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cathy</LastName><ForeName>Laurie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cecelia</LastName><ForeName>Laurie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meryl</LastName><ForeName>LeBoff</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shawn</LastName><ForeName>Lee Seunggeun</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wen-Jane</LastName><ForeName>Lee</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jonathon</LastName><ForeName>LeFaive</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>David</LastName><ForeName>Levine</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dan</LastName><ForeName>Levy</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joshua</LastName><ForeName>Lewis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yun</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honghuang</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Han</LastName><ForeName>Lin Keng</ForeName><Initials>LK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simin</LastName><ForeName>Liu</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yongmei</LastName><ForeName>Liu</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruth</LastName><ForeName>Loos</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steven</LastName><ForeName>Lubitz</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kathryn</LastName><ForeName>Lunetta</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Luo</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michael</LastName><ForeName>Mahaney</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barry</LastName><ForeName>Make</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ani</LastName><ForeName>Manichaikul</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>JoAnn</LastName><ForeName>Manson</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lauren</LastName><ForeName>Margolin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lisa</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Susan</LastName><ForeName>Mathai</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rasika</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patrick</LastName><ForeName>McArdle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merry-Lynn</LastName><ForeName>McDonald</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sean</LastName><ForeName>McFarland</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephen</LastName><ForeName>McGarvey</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hao</LastName><ForeName>Mei</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deborah A</LastName><ForeName>Meyers</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Julie</LastName><ForeName>Mikulla</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nancy</LastName><ForeName>Min</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mollie</LastName><ForeName>Minear</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan L</LastName><ForeName>Minster</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Braxton</LastName><ForeName>Mitchell</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>May E</LastName><ForeName>Montasser</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solomon</LastName><ForeName>Musani</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stanford</LastName><ForeName>Mwasongwe</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Josyf C</LastName><ForeName>Mychaleckyj</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Girish</LastName><ForeName>Nadkarni</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rakhi</LastName><ForeName>Naik</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pradeep</LastName><ForeName>Natarajan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sergei</LastName><ForeName>Nekhai</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deborah</LastName><ForeName>Nickerson</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kari</LastName><ForeName>North</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeff</LastName><ForeName>O'Connell</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tim</LastName><ForeName>O'Connor</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heather</LastName><ForeName>Ochs-Balcom</ForeName><Initials>OB</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Pankow</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>George</LastName><ForeName>Papanicolaou</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Margaret</LastName><ForeName>Parker</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Afshin</LastName><ForeName>Parsa</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tangarone</LastName><ForeName>Pattison Jessica</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sara</LastName><ForeName>Penchev</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manuel</LastName><ForeName>Peralta Juan</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marco</LastName><ForeName>Perez</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Perry</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ulrike</LastName><ForeName>Peters</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patricia</LastName><ForeName>Peyser</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larry</LastName><ForeName>Phillips</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sam</LastName><ForeName>Phillips</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toni</LastName><ForeName>Pollin</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wendy</LastName><ForeName>Post</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Julia</LastName><ForeName>Powers Becker</ForeName><Initials>PB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meher</LastName><ForeName>Preethi Boorgula</ForeName><Initials>PB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michael</LastName><ForeName>Preuss</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dmitry</LastName><ForeName>Prokopenko</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruce</LastName><ForeName>Psaty</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pankaj</LastName><ForeName>Qasba</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dandi</LastName><ForeName>Qiao</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhaohui</LastName><ForeName>Qin</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicholas</LastName><ForeName>Rafaels</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laura</LastName><ForeName>Raffield</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vasan</LastName><ForeName>Ramachandran</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laura</LastName><ForeName>Rasmussen-Torvik</ForeName><Initials>RT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aakrosh</LastName><ForeName>Ratan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Susan</LastName><ForeName>Redline</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robert</LastName><ForeName>Reed</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elizabeth</LastName><ForeName>Regan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alex</LastName><ForeName>Reiner</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ken</LastName><ForeName>Rice</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephen</LastName><ForeName>Rich</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dan</LastName><ForeName>Roden</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carolina</LastName><ForeName>Roselli</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jerome</LastName><ForeName>Rotter</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingo</LastName><ForeName>Ruczinski</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pamela</LastName><ForeName>Russell</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarah</LastName><ForeName>Ruuska</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kathleen</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phuwanat</LastName><ForeName>Sakornsakolpat</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shabnam</LastName><ForeName>Salimi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steven</LastName><ForeName>Salzberg</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kevin</LastName><ForeName>Sandow</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vijay</LastName><ForeName>Sankaran</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christopher</LastName><ForeName>Scheller</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellen</LastName><ForeName>Schmidt</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karen</LastName><ForeName>Schwander</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>David</LastName><ForeName>Schwartz</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Sciurba</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vivien</LastName><ForeName>Sheehan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amol</LastName><ForeName>Shetty</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aniket</LastName><ForeName>Shetty</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hui-Heng</LastName><ForeName>Sheu Wayne</ForeName><Initials>SW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benjamin</LastName><ForeName>Shoemaker M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brian</LastName><ForeName>Silver</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edwin</LastName><ForeName>Silverman</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jennifer</LastName><ForeName>Smith</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Josh</LastName><ForeName>Smith</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicholas</LastName><ForeName>Smith</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanja</LastName><ForeName>Smith</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sylvia</LastName><ForeName>Smoller</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beverly</LastName><ForeName>Snively</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tamar</LastName><ForeName>Sofer</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nona</LastName><ForeName>Sotoodehnia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adrienne</LastName><ForeName>Stilp</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elizabeth</LastName><ForeName>Streeten</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ju</LastName><ForeName>Sung Yun</ForeName><Initials>SY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jody</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adam</LastName><ForeName>Szpiro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carole</LastName><ForeName>Sztalryd</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daniel</LastName><ForeName>Taliun</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hua</LastName><ForeName>Tang</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Margaret</LastName><ForeName>Taub</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kent</LastName><ForeName>Taylor</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simeon</LastName><ForeName>Taylor</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marilyn</LastName><ForeName>Telen</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Timothy A</LastName><ForeName>Thornton</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesley</LastName><ForeName>Tinker</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>David</LastName><ForeName>Tirschwell</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hemant</LastName><ForeName>Tiwari</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russell</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michael</LastName><ForeName>Tsai</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dhananjay</LastName><ForeName>Vaidya</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peter</LastName><ForeName>VandeHaar</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>Vrieze</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tarik</LastName><ForeName>Walker</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robert</LastName><ForeName>Wallace</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avram</LastName><ForeName>Walts</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emily</LastName><ForeName>Wan</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fei</LastName><ForeName>Wang Fei</ForeName><Initials>WF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karol</LastName><ForeName>Watson</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daniel E</LastName><ForeName>Weeks</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruce</LastName><ForeName>Weir</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>Weiss</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu-Chen</LastName><ForeName>Weng</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cristen</LastName><ForeName>Willer</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kayleen</LastName><ForeName>Williams</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keoki</LastName><ForeName>Williams L</ForeName><Initials>WL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carla</LastName><ForeName>Wilson</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Wilson</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quenna</LastName><ForeName>Wong</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huichun</LastName><ForeName>Xu</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lisa</LastName><ForeName>Yanek</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ivana</LastName><ForeName>Yang</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rongze</LastName><ForeName>Yang</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norann</LastName><ForeName>Zaghloul</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yingze</LastName><ForeName>Zhang</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xueyan</LastName><ForeName>Zhao Snow</ForeName><Initials>ZS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wei</LastName><ForeName>Zhao</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiuwen</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Degui</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiang</LastName><ForeName>Zhou</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michael</LastName><ForeName>Zody</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sebastian</LastName><ForeName>Zoellner</ForeName><Initials>Z</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>1</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29282330</ArticleId><ArticleId IdType="pmc">PMC5772158</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004820</ArticleId><ArticleId IdType="pii">WNL.0000000000004820</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braskie MN, Ringman JM, Thompson PM. Neuroimaging measures as endophenotypes in Alzheimer's disease. Int J Alzheimers Dis 2011;2011:490140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087508</ArticleId><ArticleId IdType="pubmed">21547229</ArticleId></ArticleIdList></Reference><Reference><Citation>Bis JC, DeCarli C, Smith AV, et al. . Common variants at 12q14 and 12q24 are associated with hippocampal volume. Nat Genet 2012;44:545&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3427729</ArticleId><ArticleId IdType="pubmed">22504421</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibar DP, Stein JL, Renteria ME, et al. . Common genetic variants influence human subcortical brain structures. Nature 2015;520:224&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393366</ArticleId><ArticleId IdType="pubmed">25607358</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein JL, Medland SE, Vasquez AA, et al. . Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet 2012;44:552&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3635491</ArticleId><ArticleId IdType="pubmed">22504417</ArticleId></ArticleIdList></Reference><Reference><Citation>Traylor M, Zhang CR, Adib-Samii P, et al. . Genome-wide meta-analysis of cerebral white matter hyperintensities in patients with stroke. Neurology 2016;86:146&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731688</ArticleId><ArticleId IdType="pubmed">26674333</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhaaren BF, Debette S, Bis JC, et al. . Multiethnic genome-wide association study of cerebral white matter hyperintensities on MRI. Circ Cardiovasc Genet 2015;8:398&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4427240</ArticleId><ArticleId IdType="pubmed">25663218</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornage M, Debette S, Bis JC, et al. . Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol 2011;69:928&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122147</ArticleId><ArticleId IdType="pubmed">21681796</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawber TR, Kannel WB. The Framingham Study: an epidemiological approach to coronary heart disease. Circulation 1966;34:553&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">5921755</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study: design and preliminary data. Prev Med 1975;4:518&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">1208363</ArticleId></ArticleIdList></Reference><Reference><Citation>Splansky GL, Corey D, Yang Q, et al. . The third generation cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol 2007;165:1328&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">17372189</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Massaro J, Harvey D, et al. . Measures of brain morphology and infarction in the Framingham Heart Study: establishing what is normal. Neurobiol Aging 2005;26:491&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur B, Himali JJ, Seshadri S, et al. . Association between neuropathology and brain volume in the Framingham Heart Study. Alzheimer Dis Assoc Disord 2014;28:219&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4139422</ArticleId><ArticleId IdType="pubmed">24614264</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Fletcher E, Ramey V, Harvey D, Jagust WJ. Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke 2005;36:50&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3816357</ArticleId><ArticleId IdType="pubmed">15576652</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Miller BL, Swan GE, et al. . Predictors of brain morphology for the men of the NHLBI twin study. Stroke 1999;30:529&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">10066847</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljabar P, Heckemann RA, Hammers A, Hajnal JV, Rueckert D. Multi-atlas based segmentation of brain images: atlas selection and its effect on accuracy. Neuroimage 2009;46:726&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">19245840</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael O, Mungas D, Beckett L, et al. . MRI predictors of cognitive change in a diverse and carefully characterized elderly population. Neurobiol Aging 2012;33:83&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909327</ArticleId><ArticleId IdType="pubmed">20359776</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C, Tachmazidou I, Walter K, Ciampi A, Zeggini E, Greenwood CM; UK10K Consortium. Estimating genome-wide significance for whole-genome sequencing studies. Genet Epidemiol 2014;38:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4489336</ArticleId><ArticleId IdType="pubmed">24676807</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WY, Lou XY, Gao G, Liu N. Rare variant association testing by adaptive combination of P-values. PLoS One 2014;9:e85728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893264</ArticleId><ArticleId IdType="pubmed">24454922</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang R, Feng T, Sha Q, Zhang S. A variable-sized sliding-window approach for genetic association studies via principal component analysis. Ann Hum Genet 2009;73:631&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784738</ArticleId><ArticleId IdType="pubmed">19735491</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>Segre AV; DIAGRAM Consortium, MAGIC Investigators, Groop L, Mootha VK, Daly MJ, Altshuler D. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet 2010;6:e100105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920848</ArticleId><ArticleId IdType="pubmed">20714348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res 2016;44:D877&#x2013;D881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702929</ArticleId><ArticleId IdType="pubmed">26657631</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung HC, Hai T, Zhu W, et al. . Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines. Brain 2009;132:2277&#x2013;2288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724917</ArticleId><ArticleId IdType="pubmed">19506066</ArticleId></ArticleIdList></Reference><Reference><Citation>Takemoto M, Hattori Y, Zhao H, et al. . Laminar and areal expression of unc5d and its role in cortical cell survival. Cereb Cortex 2011;21:1925&#x2013;1934.</Citation><ArticleIdList><ArticleId IdType="pubmed">21216843</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium. Human genomics: the genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 2015;348:648&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4547484</ArticleId><ArticleId IdType="pubmed">25954001</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetzel-Smith MK, Hunkapiller J, Bhangale TR, et al. . A rare mutation in UNC5C predisposes to late-onset Alzheimer&#x2019;s disease and increases neuronal cell death. Nat Med 2014;20:1452&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301587</ArticleId><ArticleId IdType="pubmed">25419706</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JH, Wang HF, Zhu XC, et al. . The impact of UNC5C genetic variations on neuroimaging in Alzheimer's disease. Mol Neurobiol 2016;53:6759&#x2013;6767.</Citation><ArticleIdList><ArticleId IdType="pubmed">26660111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Hwang Y, Webster MJ, Lee D. Differential activation of immune/inflammatory response-related co-expression modules in the hippocampus across the major psychiatric disorders. Mol Psychiatry 2016;21:376&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">26077692</ArticleId></ArticleIdList></Reference><Reference><Citation>Debette S, Ibrahim Verbaas CA, Bressler J, et al. . Genome-wide studies of verbal declarative memory in nondemented older people: the cohorts for heart and aging research in genomic epidemiology consortium. Biol Psychiatry 2015;77:749&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513651</ArticleId><ArticleId IdType="pubmed">25648963</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying Z, Wang H, Wang G. The ubiquitin proteasome system as a potential target for the treatment of neurodegenerative diseases. Curr Pharm Des 2013;19:3305&#x2013;3314.</Citation><ArticleIdList><ArticleId IdType="pubmed">23151138</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Ullrich B, Zhang JZ, Anderson RG, Brose N, Sudhof TC. Ca(2+)-dependent and -independent activities of neural and non-neural synaptotagmins. Nature 1995;375:594&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">7791877</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wit J, O'Sullivan ML, Savas JN, et al. . Unbiased discovery of glypican as a receptor for LRRTM4 in regulating excitatory synapse development. Neuron 2013;79:696&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003527</ArticleId><ArticleId IdType="pubmed">23911103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cayrol R, Wosik K, Berard JL, et al. . Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol 2008;9:137&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">18157132</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutler E, Beutler L, West C. Mutations in the gene encoding cytosolic beta-glucosidase in Gaucher disease. J Lab Clin Med 2004;144:65&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322500</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamez-Valero A, Prada-Dacasa P, Santos C, et al. . GBA mutations are associated with earlier onset and male sex in dementia with Lewy bodies. Mov Disord 2016;31:1066&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">27027900</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiger JT, Ding J, Crain B, et al. . Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies. Neurobiol Dis 2016;94:55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4983488</ArticleId><ArticleId IdType="pubmed">27312774</ArticleId></ArticleIdList></Reference><Reference><Citation>Swan M, Doan N, Ortega RA, et al. . Neuropsychiatric characteristics of GBA-associated Parkinson disease. J Neurol Sci 2016;370:63&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5268078</ArticleId><ArticleId IdType="pubmed">27772789</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofer E, Cavalieri M, Bis JC, et al. . White matter lesion progression: genome-wide search for genetic influences. Stroke 2015;46:3048&#x2013;3057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4749149</ArticleId><ArticleId IdType="pubmed">26451028</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, Whetzel AM, Lue LF. Expression of suppressor of cytokine signaling genes in human elderly and Alzheimer&#x2019;s disease brains and human microglia. Neuroscience 2015;302:121&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4385752</ArticleId><ArticleId IdType="pubmed">25286386</ArticleId></ArticleIdList></Reference><Reference><Citation>Krebs DL, Metcalf D, Merson TD, et al. . Development of hydrocephalus in mice lacking SOCS7. Proc Natl Acad Sci USA 2004;101:15446&#x2013;15451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524464</ArticleId><ArticleId IdType="pubmed">15494444</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29293892</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>141</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.</ArticleTitle><Pagination><StartPage>550</StartPage><EndPage>567</EndPage><MedlinePgn>550-567</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awx347</ELocationID><Abstract><AbstractText>Alzheimer's disease and progressive supranuclear palsy (PSP) represent neurodegenerative tauopathies with predominantly cortical versus subcortical disease burden. In Alzheimer's disease, neuropathology and atrophy preferentially affect 'hub' brain regions that are densely connected. It was unclear whether hubs are differentially affected by neurodegeneration because they are more likely to receive pathological proteins that propagate trans-neuronally, in a prion-like manner, or whether they are selectively vulnerable due to a lack of local trophic factors, higher metabolic demands, or differential gene expression. We assessed the relationship between tau burden and brain functional connectivity, by combining in vivo PET imaging using the ligand AV-1451, and graph theoretic measures of resting state functional MRI in 17 patients with Alzheimer's disease, 17 patients with PSP, and 12 controls. Strongly connected nodes displayed more tau pathology in Alzheimer's disease, independently of intrinsic connectivity network, validating the predictions of theories of trans-neuronal spread but not supporting a role for metabolic demands or deficient trophic support in tau accumulation. This was not a compensatory phenomenon, as the functional consequence of increasing tau burden in Alzheimer's disease was a progressive weakening of the connectivity of these same nodes, reducing weighted degree and local efficiency and resulting in weaker 'small-world' properties. Conversely, in PSP, unlike in Alzheimer's disease, those nodes that accrued pathological tau were those that displayed graph metric properties associated with increased metabolic demand and a lack of trophic support rather than strong functional connectivity. Together, these findings go some way towards explaining why Alzheimer's disease affects large scale connectivity networks throughout cortex while neuropathology in PSP is concentrated in a small number of subcortical structures. Further, we demonstrate that in PSP increasing tau burden in midbrain and deep nuclei was associated with strengthened cortico-cortical functional connectivity. Disrupted cortico-subcortical and cortico-brainstem interactions meant that information transfer took less direct paths, passing through a larger number of cortical nodes, reducing closeness centrality and eigenvector centrality in PSP, while increasing weighted degree, clustering, betweenness centrality and local efficiency. Our results have wide-ranging implications, from the validation of models of tau trafficking in humans to understanding the relationship between regional tau burden and brain functional reorganization.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2018). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cope</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rittman</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borchert</LastName><ForeName>Robin J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>P Simon</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vatansever</LastName><ForeName>Deniz</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of York, York, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allinson</LastName><ForeName>Kieren</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passamonti</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vazquez Rodriguez</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bevan-Jones</LastName><ForeName>W Richard</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>John T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Council Cognition and Brain Sciences Unit, Cambridge, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G1100464</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U105597119</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC-A060-5PQ30</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M009041/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M024873/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>JBR 103838</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00005/12</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063132" MajorTopicYN="N">Connectome</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012146" MajorTopicYN="N">Rest</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">functional connectivity</Keyword><Keyword MajorTopicYN="N">graph theory</Keyword><Keyword MajorTopicYN="N">progressive supranuclear palsy</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>1</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29293892</ArticleId><ArticleId IdType="pmc">PMC5837359</ArticleId><ArticleId IdType="doi">10.1093/brain/awx347</ArticleId><ArticleId IdType="pii">4775021</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abdelnour F, Voss HU, Raj A. Network diffusion accurately models the relationship between structural and functional brain connectivity networks. Neuroimage 2014; 90: 335&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951650</ArticleId><ArticleId IdType="pubmed">24384152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, Cooper J, Murray TK, Garn K, McNaughton E, Clarke H, et al.A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol 2014; 127: 667&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252866</ArticleId><ArticleId IdType="pubmed">24531916</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert ML, Feldman RG, Willis AL. The &#x2018;subcortical dementia&#x2019; of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974; 37: 121&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC494589</ArticleId><ArticleId IdType="pubmed">4819905</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander-Bloch AF, Gogtay N, Meunier D, Birn R, Clasen L, Lalonde F, et al.Disrupted modularity and local connectivity of brain functional networks in childhood-onset schizophrenia. Front Syst Neurosci 2010; 4: 147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965020</ArticleId><ArticleId IdType="pubmed">21031030</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann Neurol 1981; 10: 499&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">6173010</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007; 38: 95&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761438</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker H, Ridley R, Duchen L, Crow T, Bruton C. Induction of &#x3b2; (A4)-amyloid in primates by injection of Alzheimer&#x2019;s disease brain homogenate. Mol Neurobiol 1994; 8: 25&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8086126</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8: 663&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevan-Jones W, Cope T, Jones P, Passamonti L, Hong Y, Fryer T, et al.[18F] AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry 2017a, doi: 10.1136/jnnp-2017-316402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166613</ArticleId><ArticleId IdType="pubmed">28912300</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevan-Jones WR, Surendranathan A, Passamonti L, Rodr&#xed;guez PV, Arnold R, Mak E, et al.Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. BMJ Open 2017b; 7: e013187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5223666</ArticleId><ArticleId IdType="pubmed">28064175</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Del Tredici K. Amyotrophic lateral sclerosis&#x2014;a model of corticofugal axonal spread. Nat Rev Neurol 2013; 9: 708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3943211</ArticleId><ArticleId IdType="pubmed">24217521</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, et al.Tau and Abeta imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med 2016; 8: 338ra66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, et al.Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci 2009; 29: 1860&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Chennu S, Annen J, Wannez S, Thibaut A, Chatelle C, Cassol H, et al.Brain networks predict metabolism, diagnosis and prognosis at the bedside in disorders of consciousness. Brain 2017; 140: 2120&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">28666351</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al.Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013; 34: 457&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, et al.Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA 2013; 110: 9535&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al.Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11: 909&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordato N, Duggins A, Halliday G, Morris J, Pantelis C. Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain 2005; 128: 1259&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">15843423</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordato N, Pantelis C, Halliday G, Velakoulis D, Wood S, Stuart G, et al.Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 2002; 125: 789&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">11912112</ArticleId></ArticleIdList></Reference><Reference><Citation>Crossley NA, Mechelli A, Scott J, Carletti F, Fox PT, McGuire P, et al.The hubs of the human connectome are generally implicated in the anatomy of brain disorders. Brain 2014; 137: 2382&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107735</ArticleId><ArticleId IdType="pubmed">25057133</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Antona R, Baron JC, Samson Y, Serdaru M, Viader F, Agid Y, et al.Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain 1985; 108 (Pt 3): 785&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">3876136</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai Z, Yan C, Li K, Wang Z, Wang J, Cao M, et al.Identifying and mapping connectivity patterns of brain network hubs in Alzheimer's disease. Cereb Cortex 2014: bhu246.</Citation><ArticleIdList><ArticleId IdType="pubmed">25331602</ArticleId></ArticleIdList></Reference><Reference><Citation>de Haan W, Mott K, van Straaten EC, Scheltens P, Stam CJ. Activity dependent degeneration explains hub vulnerability in Alzheimer's disease. PLoS Comput Biol 2012; 8: e1002582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3420961</ArticleId><ArticleId IdType="pubmed">22915996</ArticleId></ArticleIdList></Reference><Reference><Citation>Durrett R. Some features of the spread of epidemics and information on a random graph. Proc Natl Acad Sci USA 2010; 107: 4491&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824603</ArticleId><ArticleId IdType="pubmed">20167800</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison D, Love S, Chimelli LMC, Harding B, Lowe JS, Vinters HV, et al.Neuropathology: a reference text of CNS pathology. Elsevier Health Sciences; 2012.</Citation></Reference><Reference><Citation>Falcon B, Cavallini A, Angers R, Glover S, Murray TK, Barnham L, et al.Conformation determines the seeding potencies of native and recombinant Tau aggregates. J Biol Chem 2015; 290: 1049&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4294473</ArticleId><ArticleId IdType="pubmed">25406315</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, et al.Cryo-EM structures of tau filaments from Alzheimer's disease. Nature 2017; 547: 185&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 1988; 24: 399&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">3265862</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner RC, Boxer AL, Trujillo A, Mirsky JB, Guo CC, Gennatas ED, et al.Intrinsic connectivity network disruption in progressive supranuclear palsy. Ann Neurol 2013; 73: 603&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3732833</ArticleId><ArticleId IdType="pubmed">23536287</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Alzheimer&#x2019;s and Parkinson&#x2019;s diseases: the prion concept in relation to assembled A&#x3b2;, tau, and &#x3b1;-synuclein. Science 2015; 349: 1255555.</Citation><ArticleIdList><ArticleId IdType="pubmed">26250687</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006; 314: 777&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082447</ArticleId></ArticleIdList></Reference><Reference><Citation>Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007; 130: 1552&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">17405767</ArticleId></ArticleIdList></Reference><Reference><Citation>Granovetter M. The strength of weak ties: a network theory revisited. Soc Theory 1983: 201&#x2013;33.</Citation></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA 2003; 100: 253&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 2004; 101: 4637&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VM. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 2014; 20: 130&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4011661</ArticleId><ArticleId IdType="pubmed">24504409</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B, et al.Unique pathological tau conformers from Alzheimer&#x2019;s brains transmit tau pathology in nontransgenic mice. J Exp Med 2016; 213: 2635&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al.Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society Criteria. Mov Disord 2017; 32: 853&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516529</ArticleId><ArticleId IdType="pubmed">28467028</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci 2013; 33: 1024&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, G&#xf6;tz J. Amyloid-[beta] and tau&#x2013;a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011; 12: 65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21193853</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al.Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016; 79: 110&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DT, Knopman DS, Gunter JL, Graff-Radford J, Vemuri P, Boeve BF, et al.Cascading network failure across the Alzheimer&#x2019;s disease spectrum. Brain 2015; 139: 547&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4805086</ArticleId><ArticleId IdType="pubmed">26586695</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce KE, Laurienti PJ, Burdette JH, Hayasaka S. A new measure of centrality for brain networks. PLoS One 2010; 5: e12200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922375</ArticleId><ArticleId IdType="pubmed">20808943</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al.Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundu P, Brenowitz ND, Voon V, Worbe Y, V&#xe9;rtes PE, Inati SJ, et al.Integrated strategy for improving functional connectivity mapping using multiecho fMRI. Proc Natl Acad Sci USA 2013; 110: 16187&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3791700</ArticleId><ArticleId IdType="pubmed">24038744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundu P, Inati SJ, Evans JW, Luh WM, Bandettini PA. Differentiating BOLD and non-BOLD signals in fMRI time series using multi-echo EPI. Neuroimage 2012; 60: 1759&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3350785</ArticleId><ArticleId IdType="pubmed">22209809</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird AR, Fox PM, Eickhoff SB, Turner JA, Ray KL, McKay DR, et al.Behavioral interpretations of intrinsic connectivity networks. J Cogn Neurosci 2011; 23: 4022&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690655</ArticleId><ArticleId IdType="pubmed">21671731</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann M, Ghosh PM, Madison C, Laforce R, Corbetta-Rastelli C, Weiner MW, et al.Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer&#x2019;s disease. Brain 2013; 136: 844&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580269</ArticleId><ArticleId IdType="pubmed">23358601</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin R, et al.Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) Report of the NINDS-SPSP International Workshop*. Neurology 1996; 47: 1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710059</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al.Trans-synaptic spread of tau pathology in vivo. PLoS One 2012; 7: e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WK, Le TV, Adamson J, Baker M, Cookson N, Hardy J, et al.Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy. Ann Neurol 2001; 50: 494&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">11601500</ArticleId></ArticleIdList></Reference><Reference><Citation>Maest&#xfa; F, Pe&#xf1;a JM, Garc&#xe9;s P, Gonz&#xe1;lez S, Bajo R, Bagic A, et al.A multicenter study of the early detection of synaptic dysfunction in mild cognitive impairment using magnetoencephalography-derived functional connectivity. Neuroimage Clin 2015; 9: 103&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552812</ArticleId><ArticleId IdType="pubmed">26448910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelli ML, Vilaplana E, Brown JA, Hubbard HI, Binney RJ, Attygalle S, et al.Healthy brain connectivity predicts atrophy progression in non-fluent variant of primary progressive aphasia. Brain 2016; 139 (Pt 10): 2778&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5035819</ArticleId><ArticleId IdType="pubmed">27497488</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery WR. Neuropathologic alterations in mild cognitive impairment: a review. J Alzheimers Dis 2010; 19: 221&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872776</ArticleId><ArticleId IdType="pubmed">20061641</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al.The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL, et al.Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med 2016; 22: 46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4787271</ArticleId><ArticleId IdType="pubmed">26692334</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisbet RM, Polanco JC, Ittner LM, G&#xf6;tz J. Tau aggregation and its interplay with amyloid-&#x3b2;. Acta Neuropathol 2015; 129: 207&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4305093</ArticleId><ArticleId IdType="pubmed">25492702</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Watanabe ST, Iwatsubo T, Hasegawa M. Seeded aggregation and toxicity of &#x3b1;-synuclein and tau: cellular models of neurodegenerative diseases. J Biol Chem 2010; 285: 34885&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966103</ArticleId><ArticleId IdType="pubmed">20805224</ArticleId></ArticleIdList></Reference><Reference><Citation>Okello A, Koivunen J, Edison P, Archer H, Turkheimer F, N&#xe5;gren Ku, et al.Conversion of amyloid positive and negative MCI to AD over 3 years An 11C-PIB PET study. Neurology 2009; 73: 754&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830881</ArticleId><ArticleId IdType="pubmed">19587325</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Baker SL, O'Neil JP, Janabi M, Ghosh PM, et al.Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol 2015; 77: 338&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382124</ArticleId><ArticleId IdType="pubmed">25448043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, Lockhart SN, Ayakta N, Baker SL, et al.Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain 2016; 139 (Pt 5): 1551&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Passamonti L, V&#xe1;zquez Rodr&#xed;guez P, Hong YT, Allinson KS, Williamson D, Borchert RJ, et al.18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain 2017; 140: 781&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382948</ArticleId><ArticleId IdType="pubmed">28122879</ArticleId></ArticleIdList></Reference><Reference><Citation>Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage 2012; 59: 2142&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254728</ArticleId><ArticleId IdType="pubmed">22019881</ArticleId></ArticleIdList></Reference><Reference><Citation>Power JD, Schlaggar BL, Lessov-Schlaggar CN, Petersen SE. Evidence for hubs in human functional brain networks. Neuron 2013; 79: 798&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838673</ArticleId><ArticleId IdType="pubmed">23972601</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Some speculations about prions, amyloid, and Alzheimer's disease. N Engl J Med 1984; 310: 661&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">6363926</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016.</Citation></Reference><Reference><Citation>Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron 2012; 73: 1204&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623298</ArticleId><ArticleId IdType="pubmed">22445347</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, LoCastro E, Kuceyeski A, Tosun D, Relkin N, Weiner M, et al.Network diffusion model of progression predicts longitudinal patterns of atrophy and metabolism in Alzheimer&#x2019;s disease. Cell Rep 2015; 10: 359&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5747552</ArticleId><ArticleId IdType="pubmed">25600871</ArticleId></ArticleIdList></Reference><Reference><Citation>Rittman T, Rubinov M, V&#xe9;rtes PE, Patel AX, Ginestet CE, Ghosh BC, et al.Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. Neurobiol Aging 2016; 48: 153&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5096886</ArticleId><ArticleId IdType="pubmed">27697694</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al.Reducing endogenous tau ameliorates amyloid &#xdf;-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316: 750&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz-Arigita EJ, Schoonheim MM, Damoiseaux JS, Rombouts SA, Maris E, Barkhof F, et al.Loss of &#x2018;small-world&#x2019;networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. PLoS One 2010; 5: e13788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967467</ArticleId><ArticleId IdType="pubmed">21072180</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 2011; 71: 35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">21745636</ArticleId></ArticleIdList></Reference><Reference><Citation>Schofield EC, Hodges JR, Bak TH, Xuereb JH, Halliday GM. The relationship between clinical and pathological variables in Richardson&#x2019;s syndrome. J Neurol 2012; 259: 482&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">21837549</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, O&#x2019;Neil JP, Janabi M, Ossenkoppele R, et al.PET imaging of tau deposition in the aging human brain. Neuron 2016; 89: 971&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Ossenkoppele R, Strandberg O, Palmqvist S, J&#xf6;gi J, Ohlsson T, et al.Distinct 18F-AV-1451 tau PET retention patterns in early-and late-onset Alzheimer&#x2019;s disease. Brain 2017; 140: 2286&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">29050382</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, et al.Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 2016; 139: 1539&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">26936940</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia S, Koo E, Beyreuther K, Unterbeck A, Price D. Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science 1990; 248: 492&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1691865</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Puschmann A, Sch&#xf6;ll M, Ohlsson T, Van Swieten J, Honer M, et al.18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 2016; 139: 2372&#x2013;2379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995360</ArticleId><ArticleId IdType="pubmed">27357347</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Fox PT, Miller KL, Glahn DC, Fox PM, Mackay CE, et al.Correspondence of the brain's functional architecture during activation and rest. Proc Natl Acad Sci USA 2009; 106: 13040&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722273</ArticleId><ArticleId IdType="pubmed">19620724</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam C, Jones B, Nolte G, Breakspear M, Scheltens P. Small-world networks and functional connectivity in Alzheimer's disease. Cereb Cortex 2006; 17: 92&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16452642</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam CJ. Modern network science of neurological disorders. Nat Rev Neurosci 2014; 15: 683&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">25186238</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S, Arai T, Kametani F, Nonaka T, Masuda-Suzukake M, Tarutani A, et al.Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol 2016; 131: 267&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference><Reference><Citation>The Mathworks Inc. Matlab and statistics and machine learning toolbox. Release 2015b ed. Natick, MA: The Mathworks Inc; 2015.</Citation></Reference><Reference><Citation>Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. Brain Connect 2012; 2: 125&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">22642651</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, et al.Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007; 130: 1566&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">17525140</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al.[18 F] T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 2013; 9: 666&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411393</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C, Dickerson BC. Multimodal PET imaging of amyloid and Tau pathology in Alzheimer disease and non&#x2013;Alzheimer disease dementias. PET Clin 2017; 12: 351&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5690983</ArticleId><ArticleId IdType="pubmed">28576172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ypma RJ, Bullmore ET. Statistical analysis of tract-tracing experiments demonstrates a dense, complex cortical network in the mouse. PLoS Comput Biol 2016; 12: e1005104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5019374</ArticleId><ArticleId IdType="pubmed">27617835</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 2012; 73: 1216&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3361461</ArticleId><ArticleId IdType="pubmed">22445348</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29298417</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode.</ArticleTitle><Pagination><StartPage>149</StartPage><EndPage>162</EndPage><MedlinePgn>149-162</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2017.12.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(17)31815-6</ELocationID><Abstract><AbstractText>Receptors show promise for the transport of monoclonal antibodies (mAbs) across the blood-brain barrier. However, safety liabilities associated with peripheral receptor binding and Fc effector function have been reported. We present the Brain Shuttle-mAb (BS-mAb) technology, and we investigate the role of Fc effector function in&#xa0;vitro and in an Fc&#x3b3; receptor (Fc&#x3b3;R)-humanized mouse model. Strong first infusion reactions (FIRs) were observed for a conventional mAb against transferrin receptor (TfR) with a wild-type immunoglobulin G1 (IgG1) Fc. Fc effector-dead constructs completely eliminated all FIRs. Remarkably, no FIR was observed for the BS-mAb construct with a native IgG1 Fc function. Using various BS-mAb constructs, we show that TfR binding through the C-terminal BS module attenuates Fc-Fc&#x3b3;R interactions, primarily because of steric hindrance. Nevertheless, BS-mAbs maintain effector function activity when binding their brain target. Thus, mAbs with full effector function can be transported in a stealth mode in the periphery while fully active when engaged with their brain target.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohrmann</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development (pRED), Neurodegeneration and Regeneration, Roche Innovation Center, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niewoehner</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development (pRED), Therapeutic Modalities, Large Molecule Research, Roche Innovation Center, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Jens A A</ForeName><Initials>JAA</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development (pRED), Therapeutic Modalities, Large Molecule Research, Roche Innovation Center, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rueger</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development (pRED), Therapeutic Modalities, Large Molecule Research, Roche Innovation Center, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiefenthaler</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development (pRED), Therapeutic Modalities, Large Molecule Research, Roche Innovation Center, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moelleken</LastName><ForeName>Joerg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development (pRED), Therapeutic Modalities, Large Molecule Research, Roche Innovation Center, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bujotzek</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development (pRED), Therapeutic Modalities, Large Molecule Research, Roche Innovation Center, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brady</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebeling</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iglesias</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland. Electronic address: antonio.iglesias@roche.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freskg&#xe5;rd</LastName><ForeName>Per-Ola</ForeName><Initials>PO</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development (pRED), Neurodegeneration and Regeneration, Roche Innovation Center, Basel, Switzerland. Electronic address: per-ola.freskgard@roche.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017452">Receptors, IgG</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="Y">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017452" MajorTopicYN="N">Receptors, IgG</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Brain Shuttle</Keyword><Keyword MajorTopicYN="N">antibody effector function</Keyword><Keyword MajorTopicYN="N">antibody engineering</Keyword><Keyword MajorTopicYN="N">blood-brain barrier</Keyword><Keyword MajorTopicYN="N">brain delivery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29298417</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2017.12.019</ArticleId><ArticleId IdType="pii">S2211-1247(17)31815-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29295920</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>115</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Jan</Month><Day>16</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Migration-based selections of antibodies that convert bone marrow into trafficking microglia-like cells that reduce brain amyloid &#x3b2;.</ArticleTitle><Pagination><StartPage>E372</StartPage><EndPage>E381</EndPage><MedlinePgn>E372-E381</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1719259115</ELocationID><Abstract><AbstractText>One goal of regenerative medicine is to repair damaged tissue. This requires not only generating new cells of the proper phenotype, but also selecting for those that properly integrate into sites of injury. In our laboratory we are using a cell-migration-based in vivo selection system to generate antibodies that induce cells to both differentiate and selectively localize to different tissues. Here we describe an antibody that induces bone marrow stem cells to differentiate into microglia-like cells that traffic to the brain where they organize into typical networks. Interestingly, in the APP/PS1 Alzheimer's disease mouse model, these induced microglia-like cells are found at sites of plaque formation and significantly reduce their number. These results raise the intriguing question as to whether one can use such antibody-induced differentiation of stem cells to essentially recapitulate embryogenesis in adults to discover cells that can regenerate damaged organ systems.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 the Author(s). Published by PNAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Kyung Ho</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arlian</LastName><ForeName>Britni M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macauley</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paulson</LastName><ForeName>James C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerner</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037; rlerner@scripps.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001854" MajorTopicYN="N">Bone Marrow Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008163" MajorTopicYN="N">Luminescent Measurements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008815" MajorTopicYN="N">Mice, Inbred Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">stem cell</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>1</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29295920</ArticleId><ArticleId IdType="pmc">PMC5777004</ArticleId><ArticleId IdType="doi">10.1073/pnas.1719259115</ArticleId><ArticleId IdType="pii">1719259115</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Han KH, et al. An agonist antibody that blocks autoimmunity by inducing anti-inflammatory macrophages. FASEB J. 2016;30:738&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6188224</ArticleId><ArticleId IdType="pubmed">26481307</ArticleId></ArticleIdList></Reference><Reference><Citation>Yea K, Xie J, Zhang H, Zhang W, Lerner RA. Selection of multiple agonist antibodies from intracellular combinatorial libraries reveals that cellular receptors are functionally pleiotropic. Curr Opin Chem Biol. 2015;26:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25621729</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner RA, et al. Antibodies from combinatorial libraries use functional receptor pleiotropism to regulate cell fates. Q Rev Biophys. 2015;48:389&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">26537396</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Xie J, Lerner RA. A proximity based general method for identification of ligand and receptor interactions in living cells. Biochem Biophys Res Commun. 2014;454:251&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">25451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, et al. Prevention of cell death by antibodies selected from intracellular combinatorial libraries. Chem Biol. 2014;21:274&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">24440080</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, et al. Selecting agonists from single cells infected with combinatorial antibody libraries. Chem Biol. 2013;20:734&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">23706638</ArticleId></ArticleIdList></Reference><Reference><Citation>Yea K, et al. Converting stem cells to dendritic cells by agonist antibodies from unbiased morphogenic selections. Proc Natl Acad Sci USA. 2013;110:14966&#x2013;14971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773771</ArticleId><ArticleId IdType="pubmed">23980154</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Zhang H, Yea K, Lerner RA. Autocrine signaling based selection of combinatorial antibodies that transdifferentiate human stem cells. Proc Natl Acad Sci USA. 2013;110:8099&#x2013;8104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657831</ArticleId><ArticleId IdType="pubmed">23613575</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Wilson IA, Lerner RA. Selection of antibodies that regulate phenotype from intracellular combinatorial antibody libraries. Proc Natl Acad Sci USA. 2012;109:15728&#x2013;15733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465454</ArticleId><ArticleId IdType="pubmed">23019357</ArticleId></ArticleIdList></Reference><Reference><Citation>Yea K, et al. Agonist antibody that induces human malignant cells to kill one another. Proc Natl Acad Sci USA. 2015;112:E6158&#x2013;E6165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653151</ArticleId><ArticleId IdType="pubmed">26487683</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci. 2007;10:1544&#x2013;1553.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007;10:1538&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of microglia. Front Cell Neurosci. 2013;7:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3627983</ArticleId><ArticleId IdType="pubmed">23616747</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16:1896&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Muffat J, et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med. 2016;22:1358&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5101156</ArticleId><ArticleId IdType="pubmed">27668937</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett ML, et al. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci USA. 2016;113:E1738&#x2013;E1746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, et al. An environment-dependent transcriptional network specifies human microglia identity. Science. 2017;356:eaal3222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernoivanenko IS, Minin AA, Minin AA. Role of vimentin in cell migration. Ontogenez. 2013;44:186&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">23885566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivaska J, Pallari HM, Nevo J, Eriksson JE. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res. 2007;313:2050&#x2013;2062.</Citation><ArticleIdList><ArticleId IdType="pubmed">17512929</ArticleId></ArticleIdList></Reference><Reference><Citation>Helfand BT, Chou YH, Shumaker DK, Goldman RD. Intermediate filament proteins participate in signal transduction. Trends Cell Biol. 2005;15:568&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">16213139</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra A, et al. Cell-surface vimentin: A mislocalized protein for isolating csVimentin(+) CD133(&#x2212;) novel stem-like hepatocellular carcinoma cells expressing EMT markers. Int J Cancer. 2015;137:491&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4429009</ArticleId><ArticleId IdType="pubmed">25487874</ArticleId></ArticleIdList></Reference><Reference><Citation>Du N, et al. Cell surface vimentin is an attachment receptor for enterovirus 71. J Virol. 2014;88:5816&#x2013;5833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019121</ArticleId><ArticleId IdType="pubmed">24623428</ArticleId></ArticleIdList></Reference><Reference><Citation>Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM. Vimentin is secreted by activated macrophages. Nat Cell Biol. 2003;5:59&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">12483219</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang SX, Slinn J, Aylsworth A, Hou ST. Vimentin participates in microglia activation and neurotoxicity in cerebral ischemia. J Neurochem. 2012;122:764&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">22681613</ArticleId></ArticleIdList></Reference><Reference><Citation>Wohl SG, Schmeer CW, Friese T, Witte OW, Isenmann S. In situ dividing and phagocytosing retinal microglia express nestin, vimentin, and NG2 in vivo. PLoS One. 2011;6:e22408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3151247</ArticleId><ArticleId IdType="pubmed">21850226</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphuis W, et al. GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer&#x2019;s disease. Glia. 2015;63:1036&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">25731615</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N, et al. Requirement of vimentin filament assembly for beta3-adrenergic receptor activation of ERK MAP kinase and lipolysis. J Biol Chem. 2007;282:9244&#x2013;9250.</Citation><ArticleIdList><ArticleId IdType="pubmed">17251187</ArticleId></ArticleIdList></Reference><Reference><Citation>Virtakoivu R, et al. Vimentin-ERK signaling uncouples slug gene regulatory function. Cancer Res. 2015;75:2349&#x2013;2362.</Citation><ArticleIdList><ArticleId IdType="pubmed">25855378</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberis L, et al. Leukocyte transmigration is modulated by chemokine-mediated PI3Kgamma-dependent phosphorylation of vimentin. Eur J Immunol. 2009;39:1136&#x2013;1146.</Citation><ArticleIdList><ArticleId IdType="pubmed">19291697</ArticleId></ArticleIdList></Reference><Reference><Citation>Li QF, et al. Critical role of vimentin phosphorylation at Ser-56 by p21-activated kinase in vimentin cytoskeleton signaling. J Biol Chem. 2006;281:34716&#x2013;34724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1634890</ArticleId><ArticleId IdType="pubmed">16990256</ArticleId></ArticleIdList></Reference><Reference><Citation>Okonogi N, et al. Cranial irradiation induces bone marrow-derived microglia in adult mouse brain tissue. J Radiat Res (Tokyo) 2014;55:713&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4100007</ArticleId><ArticleId IdType="pubmed">24706998</ArticleId></ArticleIdList></Reference><Reference><Citation>Asheuer M, et al. Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein. Proc Natl Acad Sci USA. 2004;101:3557&#x2013;3562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373501</ArticleId><ArticleId IdType="pubmed">14990803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinze A, Stolzing A. Differentiation of mouse bone marrow derived stem cells toward microglia-like cells. BMC Cell Biol. 2011;12:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175184</ArticleId><ArticleId IdType="pubmed">21854582</ArticleId></ArticleIdList></Reference><Reference><Citation>McLarnon JG. Microglial chemotactic signaling factors in Alzheimer&#x2019;s disease. Am J Neurodegener Dis. 2012;1:199&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560464</ArticleId><ArticleId IdType="pubmed">23383392</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29309493</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia.</ArticleTitle><Pagination><StartPage>342</StartPage><EndPage>352</EndPage><MedlinePgn>342-352</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.4309</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The ability to predict the pathology underlying different neurodegenerative syndromes is of critical importance owing to the advent of molecule-specific therapies.</AbstractText><AbstractText Label="OBJECTIVE">To determine the rates of positron emission tomography (PET) amyloid positivity in the main clinical variants of primary progressive aphasia (PPA).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This prospective clinical-pathologic case series was conducted at a tertiary research clinic specialized in cognitive disorders. Patients were evaluated as part of a prospective, longitudinal research study between January 2002 and December 2015. Inclusion criteria included clinical diagnosis of PPA; availability of complete speech, language, and cognitive testing; magnetic resonance imaging performed within 6 months of the cognitive evaluation; and PET carbon 11-labeled Pittsburgh Compound-B or florbetapir F 18 brain scan results. Of 109 patients referred for evaluation of language symptoms who underwent amyloid brain imaging, 3 were excluded because of incomplete language evaluations, 5 for absence of significant aphasia, and 12 for presenting with significant initial symptoms outside of the language domain, leaving a cohort of 89 patients with PPA.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Clinical, cognitive, neuroimaging, and pathology results.</AbstractText><AbstractText Label="RESULTS">Twenty-eight cases were classified as imaging-supported semantic variant PPA (11 women [39.3%]; mean [SD] age, 64 [7] years), 31 nonfluent/agrammatic variant PPA (22 women [71.0%]; mean [SD] age, 68 [7] years), 26 logopenic variant PPA (17 women [65.4%]; mean [SD] age, 63 [8] years), and 4 mixed PPA cases. Twenty-four of 28 patients with semantic variant PPA (86%) and 28 of 31 patients with nonfluent/agrammatic variant PPA (90%) had negative amyloid PET scan results, while 25 of 26 patients with logopenic variant PPA (96%) and 3 of 4 mixed PPA cases (75%) had positive scan results. The amyloid positive semantic variant PPA and nonfluent/agrammatic variant PPA cases with available autopsy data (2 of 4 and 2 of 3, respectively) all had a primary frontotemporal lobar degeneration and secondary Alzheimer disease pathologic diagnoses, whereas autopsy of 2 patients with amyloid PET-positive logopenic variant PPA confirmed Alzheimer disease. One mixed PPA patient with a negative amyloid PET scan had Pick disease at autopsy.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Primary progressive aphasia variant diagnosis according to the current classification scheme is associated with Alzheimer disease biomarker status, with the logopenic variant being associated with carbon 11-labeled Pittsburgh Compound-B positivity in more than 95% of cases. Furthermore, in the presence of a clinical syndrome highly predictive of frontotemporal lobar degeneration pathology, biomarker positivity for Alzheimer disease may be associated more with mixed pathology rather than primary Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Santos-Santos</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Autonomous University of Barcelona, Cerdanyola del Valles, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Alzheimer Memory Clinic and Research Center, Institut Catal&#xe1; de Neuroci&#xe8;ncies Aplicades, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iaccarino</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayakta</LastName><ForeName>Nagehan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tammewar</LastName><ForeName>Gautam</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobach</LastName><ForeName>Iryna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Maya L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Communication Sciences and Disorders, University of Texas, Austin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hubbard</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelli</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinelli</LastName><ForeName>Edoardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Zachary A</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pressman</LastName><ForeName>Peter S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Colorado Denver, Denver.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neil</LastName><ForeName>James P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Pia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazaris</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Marita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Christa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Soo Jin</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Eulji University Hospital, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorno-Tempini</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS050915</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG029577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 DC015544</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS100440</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018888" MajorTopicYN="N">Aphasia, Primary Progressive</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Jagust is a consultant to Genentech, Novartis, Bioclinica, and Biogen. Dr Seeley is a consultant for Merck and Biogen. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29309493</ArticleId><ArticleId IdType="mid">NIHMS952772</ArticleId><ArticleId IdType="pmc">PMC5885868</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.4309</ArticleId><ArticleId IdType="pii">2668464</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mesulam MM. Slowly progressive aphasia without generalized dementia. Ann Neurol. 1982;11(6):592-598.</Citation><ArticleIdList><ArticleId IdType="pubmed">7114808</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Thomas BA, Thurfjell L, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Amyloid PET imaging in Alzheimer&#x2019;s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41(7):1398-1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055504</ArticleId><ArticleId IdType="pubmed">24647577</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Weintraub S, Rogalski EJ, Wieneke C, Geula C, Bigio EH. Asymmetry and heterogeneity of Alzheimer&#x2019;s and frontotemporal pathology in primary progressive aphasia. Brain. 2014;137(Pt 4):1176-1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959558</ArticleId><ArticleId IdType="pubmed">24574501</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JM, Gall C, Thompson JC, et al. . Classification and pathology of primary progressive aphasia. Neurology. 2013;81(21):1832-1839.</Citation><ArticleIdList><ArticleId IdType="pubmed">24142474</ArticleId></ArticleIdList></Reference><Reference><Citation>Chare L, Hodges JR, Leyton CE, et al. . New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. J Neurol Neurosurg Psychiatry. 2014;85(8):865-870.</Citation><ArticleIdList><ArticleId IdType="pubmed">24421286</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyton CE, Villemagne VL, Savage S, et al. . Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using &#x3b2;-amyloid imaging. Brain. 2011;134(Pt 10):3030-3043.</Citation><ArticleIdList><ArticleId IdType="pubmed">21908392</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Bigio EH, et al. . Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119(1):1-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799633</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil-Navarro S, Llad&#xf3; A, Rami L, et al. . Neuroimaging and biochemical markers in the three variants of primary progressive aphasia. Dement Geriatr Cogn Disord. 2013;35(1-2):106-117.</Citation><ArticleIdList><ArticleId IdType="pubmed">23392204</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Duffy JR, Strand EA, et al. . Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain Lang. 2015;142:45-53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380294</ArticleId><ArticleId IdType="pubmed">25658633</ArticleId></ArticleIdList></Reference><Reference><Citation>Mat&#xed;as-Guiu JA, Cabrera-Mart&#xed;n MN, Moreno-Ramos T, et al. . Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes. J Neurol. 2015;262(6):1463-1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">25860346</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Ridgway GR, Crutch SJ, et al. . Progressive logopenic/phonological aphasia: erosion of the language network. Neuroimage. 2010;49(1):984-993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2943046</ArticleId><ArticleId IdType="pubmed">19679189</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogalski E, Sridhar J, Rader B, et al. . Aphasic variant of Alzheimer disease: clinical, anatomic, and genetic features. Neurology. 2016;87(13):1337-1343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047036</ArticleId><ArticleId IdType="pubmed">27566743</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. . Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol. 2004;55(3):335-346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2362399</ArticleId><ArticleId IdType="pubmed">14991811</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Jagust WJ, Furst AJ, et al. . Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64(4):388-401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648510</ArticleId><ArticleId IdType="pubmed">18991338</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer JH, Jurik J, Sha SJ, et al. . Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol. 2003;16(4):211-218.</Citation><ArticleIdList><ArticleId IdType="pubmed">14665820</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Murray RC, Rankin KP, Weiner MW, Miller BL. Clinical, cognitive and anatomical evolution from nonfluent progressive aphasia to corticobasal syndrome: a case report. Neurocase. 2004;10(6):426-436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2365737</ArticleId><ArticleId IdType="pubmed">15788282</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Santos MA, Mandelli ML, Binney RJ, et al. . Features of patients with nonfluent/agrammatic primary progressive aphasia with underlying progressive supranuclear palsy pathology or corticobasal degeneration. JAMA Neurol. 2016;73(6):733-742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4924620</ArticleId><ArticleId IdType="pubmed">27111692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wertz R, LaPointe L, Rosenbek J. Apraxia of Speech: The Disorders and Its Management. New York, NY: Grune and Stratton; 1984.</Citation></Reference><Reference><Citation>Dunn LM. Peabody Picture Vocabulary Test-Revised (PPVT-R). Circle Pines, MN: American Guidance Service; 1981.</Citation></Reference><Reference><Citation>About the test. CYCLE website. http://thecycletest.com/test/. Accessed November 20, 2017.</Citation></Reference><Reference><Citation>Wilson SM, Dronkers NF, Ogar JM, et al. . Neural correlates of syntactic processing in the nonfluent variant of primary progressive aphasia. J Neurosci. 2010;30(50):16845-16854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024013</ArticleId><ArticleId IdType="pubmed">21159955</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Smiljic A, Hayenga AO, et al. . Relationships between &#x3b2;-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex. 2011;21(10):2399-2407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169663</ArticleId><ArticleId IdType="pubmed">21383234</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettcher BM, Wilheim R, Rigby T, et al. . C-reactive protein is related to memory and medial temporal brain volume in older adults. Brain Behav Immun. 2012;26(1):103-108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3221922</ArticleId><ArticleId IdType="pubmed">21843630</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Schuff N, Ching C, et al. . Joint assessment of structural, perfusion, and diffusion MRI in Alzheimer&#x2019;s disease and frontotemporal dementia. Int J Alzheimers Dis. 2011;2011:546871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132541</ArticleId><ArticleId IdType="pubmed">21760989</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. . Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138(Pt 7):2020-2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806716</ArticleId><ArticleId IdType="pubmed">25953778</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Rosen HJ, Alkalay A, et al. . Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77(23):2034-2042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236517</ArticleId><ArticleId IdType="pubmed">22131541</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Pontecorvo MJ, Beach TG, et al. ; AV-45-A16 Study Group . Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-&#x3b2; plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669-678.</Citation><ArticleIdList><ArticleId IdType="pubmed">22749065</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, et al. ; AV45-A07 Study Group . Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275-283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et al. . National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8(1):1-13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. ; Amyloid Biomarker Study Group . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Caso F, Gesierich B, Henry M, et al. . Nonfluent/agrammatic PPA with in-vivo cortical amyloidosis and Pick&#x2019;s disease pathology. Behav Neurol. 2013;26(1-2):95-106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3526142</ArticleId><ArticleId IdType="pubmed">22713404</ArticleId></ArticleIdList></Reference><Reference><Citation>Botha H, Duffy JR, Whitwell JL, et al. . Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. Cortex. 2015;69:220-236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522343</ArticleId><ArticleId IdType="pubmed">26103600</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JM, Jones M. Pathology in primary progressive aphasia syndromes. Curr Neurol Neurosci Rep. 2014;14(8):466.</Citation><ArticleIdList><ArticleId IdType="pubmed">24952480</ArticleId></ArticleIdList></Reference><Reference><Citation>Alladi S, Xuereb J, Bak T, et al. . Focal cortical presentations of Alzheimer&#x2019;s disease. Brain. 2007;130(Pt 10):2636-2645.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898010</ArticleId></ArticleIdList></Reference><Reference><Citation>Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol. 2006;59(1):156-165.</Citation><ArticleIdList><ArticleId IdType="pubmed">16374817</ArticleId></ArticleIdList></Reference><Reference><Citation>Pa J, Possin KL, Wilson SM, et al. . Gray matter correlates of set-shifting among neurodegenerative disease, mild cognitive impairment, and healthy older adults. J Int Neuropsychol Soc. 2010;16(4):640-650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891121</ArticleId><ArticleId IdType="pubmed">20374676</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Crutch SJ, Warrington EK, Warren JD. Progranulin-associated primary progressive aphasia: a distinct phenotype? Neuropsychologia. 2010;48(1):288-297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808475</ArticleId><ArticleId IdType="pubmed">19766663</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajjadi SA, Patterson K, Arnold RJ, Watson PC, Nestor PJ. Primary progressive aphasia: a tale of two syndromes and the rest. Neurology. 2012;78(21):1670-1677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3359509</ArticleId><ArticleId IdType="pubmed">22573633</ArticleId></ArticleIdList></Reference><Reference><Citation>Wicklund MR, Duffy JR, Strand EA, Machulda MM, Whitwell JL, Josephs KA. Quantitative application of the primary progressive aphasia consensus criteria. Neurology. 2014;82(13):1119-1126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3966800</ArticleId><ArticleId IdType="pubmed">24598709</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Wieneke C, Thompson C, Rogalski E, Weintraub S. Quantitative classification of primary progressive aphasia at early and mild impairment stages. Brain. 2012;135(Pt 5):1537-1553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577099</ArticleId><ArticleId IdType="pubmed">22525158</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29309488</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Progression in the LRRK2-Asssociated Parkinson Disease Population.</ArticleTitle><Pagination><StartPage>312</StartPage><EndPage>319</EndPage><MedlinePgn>312-319</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.4019</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Few prospective longitudinal studies have evaluated the progression of Parkinson disease (PD) in patients with the leucine-rich repeat kinase 2 (LRRK2 [OMIM 609007]) mutation. Knowledge about such progression will aid clinical trials.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether the longitudinal course of PD in patients with the LRRK2 mutation differs from the longitudinal course of PD in patients without the mutation.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">A prospective comprehensive assessment of a large cohort of patients from 3 sites with LRRK2 PD or with nonmutation PD was conducted from July 21, 2009, to September 30, 2016. All patients of Ashkenazi Jewish ancestry with PD were approached at each site; approximately 80% agreed to an initial visit. A total of 545 patients of Ashkenazi Jewish descent with PD who had 1 to 4 study visits were evaluated. A total of 144 patients (26.4%) had the LRRK2 G2019S mutation. Patients with GBA (OMIM 606463) mutations were excluded from the analysis.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Linear mixed-effects models for longitudinal motor scores were used to examine the association of LRRK2 mutation status with the rate of change in Unified Parkinson's Disease Rating Scale III scores using disease duration as the time scale, adjusting for sex, site, age, disease duration, cognitive score, and levodopa-equivalent dose at baseline. Mixed-effects models were used to assess change in cognition, as measured by Montreal Cognitive Assessment scores.</AbstractText><AbstractText Label="RESULTS">Among the 545 participants, 233 were women, 312 were men, and the mean (SD) age was 68.2 (9.1) years for participants with the LRRK2 mutation and 67.8 (10.7) years for those without it. Seventy-two of 144 participants with the LRRK2 mutation and 161 of 401 participants with no mutation were women. The estimate (SE) of the rate of change in the Unified Parkinson's Disease Rating Scale III motor score per year among those with the LRRK2 mutation (0.689 [0.192] points per year) was less than among those without the mutation (1.056 [0.187] points per year; difference, -0.367 [0.149] points per year; P&#x2009;=&#x2009;.02). The estimate (SE) of the difference in the rate of change of the Montreal Cognitive Assessment score between those with the LRRK2 mutation (-0.096 [0.090] points per year) and those without the mutation (-0.192 [0.102] points per year) did not reach statistical significance (difference, 0.097 [0.055] points per year; P&#x2009;=&#x2009;.08).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Prospective longitudinal follow-up of patients with PD with or without the LRRK2 G2019S mutation supports data from a cross-sectional study and demonstrates a slower decline in motor Unified Parkinson's Disease Rating Scale scores among those with LRRK2 G2019S-associated PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saunders-Pullman</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mount Sinai Beth Israel Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirelman</LastName><ForeName>Anat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Movement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Sagol School for Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Therapy, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcalay</LastName><ForeName>Roy N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Physicians and Surgeons, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Cuiling</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Physicians and Surgeons, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Family Health, Albert Einstein College of Medicine, Yeshiva University, Bronx, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Albert Einstein College of Medicine, Yeshiva University, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortega</LastName><ForeName>Roberto A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mount Sinai Beth Israel Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raymond</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mount Sinai Beth Israel Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mejia-Santana</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orbe-Reilly</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johannes</LastName><ForeName>Brooke A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mount Sinai Beth Israel Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thaler</LastName><ForeName>Avner</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Movement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Sagol School for Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozelius</LastName><ForeName>Laurie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orr-Urtreger</LastName><ForeName>Avi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Movement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Sagol School for Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetic Institute, Tel Aviv Medical Center, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marder</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Physicians and Surgeons, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giladi</LastName><ForeName>Nir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Movement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Sagol School for Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bressman</LastName><ForeName>Susan B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mount Sinai Beth Israel Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>LRRK2 Ashkenazi Jewish Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 NS094148</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 NS073836</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS036630</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 NS080915</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000040</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024156</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C495280">LRRK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071158">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.45</RegistryNumber><NameOfSubstance UI="C000633564">GBA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.45</RegistryNumber><NameOfSubstance UI="D005962">Glucosylceramidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2018 Jun 1;75(6):763. doi: 10.1001/jamaneurol.2018.0748.</RefSource><PMID Version="1">29630713</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005962" MajorTopicYN="N">Glucosylceramidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071158" MajorTopicYN="N">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29309488</ArticleId><ArticleId IdType="pmc">PMC5885854</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.4019</ArticleId><ArticleId IdType="pii">2668463</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>West AB. Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov Disord. 2015;30(2):180-189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4318704</ArticleId><ArticleId IdType="pubmed">25448543</ArticleId></ArticleIdList></Reference><Reference><Citation>Giladi N, Mirelman A, Thaler A, Orr-Urtreger A. A personalized approach to Parkinson&#x2019;s disease patients based on founder mutation analysis. Front Neurol. 2016;7(7):71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4861838</ArticleId><ArticleId IdType="pubmed">27242656</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy DG, Falchi M, O&#x2019;Sullivan SS, et al. ; International LRRK2 Consortium . Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson&#x2019;s disease: a case-control study. Lancet Neurol. 2008;7(7):583-590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832754</ArticleId><ArticleId IdType="pubmed">18539534</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcalay RN, Mirelman A, Saunders-Pullman R, et al. . Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord. 2013;28(14):1966-1971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859844</ArticleId><ArticleId IdType="pubmed">24243757</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahalom G, Orlev Y, Cohen OS, et al. . Motor progression of Parkinson&#x2019;s disease with the leucine-rich repeat kinase 2 G2019S mutation. Mov Disord. 2014;29(8):1057-1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">24903616</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabli F, Ben Sassi S, Amouri R, Duda JE, Farrer MJ, Hentati F. Motor phenotype of LRRK2-associated Parkinson&#x2019;s disease: a Tunisian longitudinal study. Mov Disord. 2015;30(2):253-258.</Citation><ArticleIdList><ArticleId IdType="pubmed">25487881</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosterveld LP, Allen JC Jr, Ng EY, et al. . Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants. Neurology. 2015;85(12):1039-1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">26311745</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcalay RN, Mejia-Santana H, Mirelman A, et al. ; LRRK2 Ashkenazi Jewish Consortium . Neuropsychological performance in LRRK2 G2019S carriers with Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2015;21(2):106-110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4306614</ArticleId><ArticleId IdType="pubmed">25434972</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders-Pullman R, Mirelman A, Wang C, et al. . Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker? Ann Clin Transl Neurol. 2014;1(9):670-678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4241794</ArticleId><ArticleId IdType="pubmed">25493281</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan-Or Z, Giladi N, Rozovski U, et al. . Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology. 2008;70(24):2277-2283.</Citation><ArticleIdList><ArticleId IdType="pubmed">18434642</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr-Urtreger A, Shifrin C, Rozovski U, et al. . The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology. 2007;69(16):1595-1602.</Citation><ArticleIdList><ArticleId IdType="pubmed">17938369</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahn S, Elton RL; Members of the UPDRS Development Committee . Unified Parkinson&#x2019;s Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson&#x2019;s Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.</Citation></Reference><Reference><Citation>Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-442.</Citation><ArticleIdList><ArticleId IdType="pubmed">6067254</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab R, England A. Projection technique for evaluating surgery in Parkinson&#x2019;s disease. In: Gillingham F, Donaldson I, eds. Third Symposium on Parkinson&#x2019;s Disease. Edinburgh, Scotland: E&amp;S Livingstone, 1969:152-157.</Citation></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V, et al. . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Diggle P, Heagerty P, Liang K-Y, Zeger Sl. Analysis of Longitudinal Data. New York, NY: Oxford University Press; 2002.</Citation></Reference><Reference><Citation>Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963-974.</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson&#x2019;s disease. Mov Disord. 2010;25(15):2649-2653.</Citation><ArticleIdList><ArticleId IdType="pubmed">21069833</ArticleId></ArticleIdList></Reference><Reference><Citation>Zadikoff C, Fox SH, Tang-Wai DF, et al. . A comparison of the Mini Mental State Exam to the Montreal Cognitive Assessment in identifying cognitive deficits in Parkinson&#x2019;s disease. Mov Disord. 2008;23(2):297-299.</Citation><ArticleIdList><ArticleId IdType="pubmed">18044697</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazem S, Siderowf AD, Duda JE, et al. . Montreal Cognitive Assessment performance in patients with Parkinson&#x2019;s disease with &#x201c;normal&#x201d; global cognition according to Mini-Mental State Examination score. J Am Geriatr Soc. 2009;57(2):304-308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2754699</ArticleId><ArticleId IdType="pubmed">19170786</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoops S, Nazem S, Siderowf AD, et al. . Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738-1745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788810</ArticleId><ArticleId IdType="pubmed">19933974</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34(2):187-220.</Citation></Reference><Reference><Citation>Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58(10):1611-1615.</Citation><ArticleIdList><ArticleId IdType="pubmed">11594919</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG, Stebbins GT, Blasucci LM. Differential progression of motor impairment in levodopa-treated Parkinson&#x2019;s disease. Mov Disord. 2000;15(3):479-484.</Citation><ArticleIdList><ArticleId IdType="pubmed">10830412</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson&#x2019;s disease: a prospective study. Mov Disord. 2007;22(7):938-945.</Citation><ArticleIdList><ArticleId IdType="pubmed">17415791</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifati V. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)&#x2014;linking familial and sporadic Parkinson&#x2019;s disease. Neurochem Res. 2007;32(10):1700-1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">17440812</ArticleId></ArticleIdList></Reference><Reference><Citation>Marder K, Wang Y, Alcalay RN, et al. ; LRRK2 Ashkenazi Jewish Consortium . Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology. 2015;85(1):89-95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4501942</ArticleId><ArticleId IdType="pubmed">26062626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Cai Y, Zheng Z, et al. ; Chinese Parkinson Study Group (CPSG) . Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. Parkinsonism Relat Disord. 2012;18(8):958-963.</Citation><ArticleIdList><ArticleId IdType="pubmed">22658533</ArticleId></ArticleIdList></Reference><Reference><Citation>Marras C, Alcalay RN, Caspell-Garcia C, et al. ; LRRK2 Cohort Consortium . Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson&#x2019;s disease. Mov Disord. 2016;31(8):1192-1202.</Citation><ArticleIdList><ArticleId IdType="pubmed">27091104</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-S&#xe1;nchez J, Mart&#xed;-Mass&#xf3; JF, S&#xe1;nchez-Mut JV, et al. . Parkinson&#x2019;s disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. Mov Disord. 2006;21(11):1954-1959.</Citation><ArticleIdList><ArticleId IdType="pubmed">16991141</ArticleId></ArticleIdList></Reference><Reference><Citation>von Coelln R, Shulman LM. Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. Curr Opin Neurol. 2016;29(6):727-734.</Citation><ArticleIdList><ArticleId IdType="pubmed">27749396</ArticleId></ArticleIdList></Reference><Reference><Citation>Fereshtehnejad S-M, Romenets SR, Anang JB, Latreille V, Gagnon J-F, Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol. 2015;72(8):863-873.</Citation><ArticleIdList><ArticleId IdType="pubmed">26076039</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol. 2011;69(1):193-197.</Citation><ArticleIdList><ArticleId IdType="pubmed">21280089</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaler A, Helmich RC, Or-Borichev A, et al. ; LRRK2 Ashkenazi Jewish Consortium . Intact working memory in non-manifesting LRRK2 carriers&#x2014;an fMRI study. Eur J Neurosci. 2016;43(1):106-112.</Citation><ArticleIdList><ArticleId IdType="pubmed">26536050</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday GM, McCann H. The progression of pathology in Parkinson&#x2019;s disease. Ann N Y Acad Sci. 2010;1184(1):188-195.</Citation><ArticleIdList><ArticleId IdType="pubmed">20146698</ArticleId></ArticleIdList></Reference><Reference><Citation>Compta Y, Parkkinen L, O&#x2019;Sullivan SS, et al. . Lewy- and Alzheimer-type pathologies in Parkinson&#x2019;s disease dementia: which is more important? Brain. 2011;134(pt 5):1493-1505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4194668</ArticleId><ArticleId IdType="pubmed">21596773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalia LV, Lang AE, Hazrati LN, et al. . Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol. 2015;72(1):100-105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4399368</ArticleId><ArticleId IdType="pubmed">25401511</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaig C, Mart&#xed; MJ, Ezquerra M, Rey MJ, Cardozo A, Tolosa E. G2019S LRRK2 mutation causing Parkinson&#x2019;s disease without Lewy bodies. J Neurol Neurosurg Psychiatry. 2007;78(6):626-628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077973</ArticleId><ArticleId IdType="pubmed">17210620</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders-Pullman R, Alcalay RN, Mirelman A, et al. ; AJ LRRK2 Consortium . REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers. Mov Disord. 2015;30(13):1834-1839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4715645</ArticleId><ArticleId IdType="pubmed">26366513</ArticleId></ArticleIdList></Reference><Reference><Citation>Pont-Sunyer C, Iranzo A, Gaig C, et al. . Sleep disorders in parkinsonian and nonparkinsonian LRRK2 mutation carriers. PLoS One. 2015;10(7):e0132368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503402</ArticleId><ArticleId IdType="pubmed">26177462</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinh J, Amouri R, Duda JE, et al. . Comparative study of Parkinson&#x2019;s disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. Neurobiol Aging. 2014;35(5):1125-1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">24355527</ArticleId></ArticleIdList></Reference><Reference><Citation>Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol. 2002;59(11):1724-1728.</Citation><ArticleIdList><ArticleId IdType="pubmed">12433259</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology. 2005;65(9):1436-1441.</Citation><ArticleIdList><ArticleId IdType="pubmed">16275832</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29318278</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>319</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Jan</Month><Day>09</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.</ArticleTitle><Pagination><StartPage>130</StartPage><EndPage>142</EndPage><MedlinePgn>130-142</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2017.20373</ELocationID><Abstract><AbstractText Label="IMPORTANCE">New therapeutic approaches for Alzheimer disease (AD) are needed.</AbstractText><AbstractText Label="OBJECTIVE">To assess whether idalopirdine, a selective 5-hydroxytryptamine-6 receptor antagonist, is effective for symptomatic treatment of mild to moderate AD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Three randomized clinical trials that included 2525 patients aged 50 years or older with mild to moderate AD (study 1: n&#x2009;=&#x2009;933 patients at 119 sites; study 2: n&#x2009;=&#x2009;858 at 158 sites; and study 3: n&#x2009;=&#x2009;734 at 126 sites). The 24-week studies were conducted from October 2013 to January 2017; final follow-up on January 12, 2017.</AbstractText><AbstractText Label="INTERVENTIONS">Idalopirdine (10, 30, or 60 mg/d) or placebo added to cholinesterase inhibitor treatment (donepezil in studies 1 and 2; donepezil, rivastigmine, or galantamine in study 3).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Primary end point in all 3 studies: change in cognition total score (range, 0-70; a lower score indicates less impairment) from baseline to 24 weeks measured by the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog); key secondary end points: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Scale and 23-item Activities of Daily Living Inventory scores. Dose group efficacy required a significant benefit over placebo for the primary end point and 1 or more key secondary end points. Safety data and adverse event profiles were recorded.</AbstractText><AbstractText Label="RESULTS">Among 2525 patients randomized in the 3 trials (mean age, 74 years; mean baseline ADAS-Cog total score, 26; between 62% and 65% of participants were women), 2254 (89%) completed the studies. In study 1, the mean change in ADAS-Cog total score between baseline and 24 weeks was 0.37 for the 60-mg dose of idalopirdine group, 0.61 for the 30-mg dose group, and 0.41 for the placebo group (adjusted mean difference vs placebo, 0.05 [95% CI, -0.88 to 0.98] for the 60-mg dose group and 0.33 [95% CI, -0.59 to 1.26] for the 30-mg dose group). In study 2, the mean change in ADAS-Cog total score between baseline and 24 weeks was 1.01 for the 30-mg dose of idalopirdine group, 0.53 for the 10-mg dose group, and 0.56 for the placebo group (adjusted mean difference vs placebo, 0.63 [95% CI, -0.38 to 1.65] for the 30-mg dose group; given the gated testing strategy and the null findings at the 30-mg dose, statistical comparison of the 10-mg dose was not performed). In study 3, the mean change in ADAS-Cog total score between baseline and 24 weeks was 0.38 for the 60-mg dose of idalopirdine group and 0.82 for the placebo group (adjusted mean difference vs placebo, -0.55 [95% CI, -1.45 to 0.36]). Treatment-emergent adverse events occurred in between 55.4% and 69.7% of participants in the idalopirdine groups vs between 56.7% and 61.4% of participants in the placebo groups.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In patients with mild to moderate AD, the use of idalopirdine compared with placebo did not improve cognition over 24 weeks of treatment. These findings do not support the use of idalopirdine for the treatment of AD.</AbstractText><AbstractText Label="TRIAL REGISTRATION">clinicaltrials.gov Identifiers: NCT01955161, NCT02006641, and NCT02006654.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Atri</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ray Dolby Brain Health Center, California Pacific Medical Center, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fr&#xf6;lich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, Exeter, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinuevo</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, IDIBAPS, Hospital Clinic i Universitari, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Centre, Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boneva</LastName><ForeName>Neli</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>H. Lundbeck A/S, Valby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windfeld</LastName><ForeName>Kristian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>H. Lundbeck A/S, Valby, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with Genmab, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raket</LastName><ForeName>Lars L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>H. Lundbeck A/S, Valby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01955161</AccessionNumber><AccessionNumber>NCT02006641</AccessionNumber><AccessionNumber>NCT02006654</AccessionNumber><AccessionNumber>NCT01955161</AccessionNumber><AccessionNumber>NCT02006641</AccessionNumber><AccessionNumber>NCT02006654</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568612">(2-(6-fluoro-1H-indol-3-yl)-ethyl)-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)amine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001596">Benzylamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0D3Q044KCA</RegistryNumber><NameOfSubstance UI="D005702">Galantamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2018 Jan 9;319(2):123-125. doi: 10.1001/jama.2017.19700.</RefSource><PMID Version="1">29318261</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000058" MajorTopicYN="N">Accidental Falls</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001596" MajorTopicYN="N">Benzylamines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005702" MajorTopicYN="N">Galantamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012702" MajorTopicYN="N">Serotonin Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Atri reported receiving honoraria for consulting, providing educational lectures, programs, and materials, or serving on advisory boards for Allergan, the Alzheimer&#x2019;s Association, Axovant, Biogen, Grifols, Harvard Medical School Graduate Continuing Education, Lundbeck, Merck, Sunovion, and Suven; receiving book royalties from Oxford University Press; and having institutional contracts or receiving investigational clinical trial&#x2013;related funding from the American College of Radiology, AbbVie, Avid, Biogen, Lilly, Lundbeck, Merck, and vTV. Dr Fr&#xf6;lich reported receiving honoraria for consulting, providing educational lectures, materials, and programs, or serving on advisory boards for Avid&#x2013;Eli Lilly &amp; Co, Avraham Pharmaceuticals, Axon Neuroscience, Boehringer Ingelheim, GE Healthcare, H. Lundbeck A/S, Merck Sharpe &amp; Dohme, Novartis, Nutricia, Pfizer, Piramal Imaging, Schwabe Pharma, TAD Pharma, and Takeda. Dr Ballard reported receiving research grants from Acadia and H. Lundbeck A/S; and receiving honoraria from Acadia, Bristol-Myers Squibb, Heptares, Lilly, H. Lundbeck A/S, Novartis, Orion, Otsuka, and Roche. Dr Tariot reported receiving consulting fees from Abbott Laboratories, AbbVie, AC Immune, Auspex, Boehringer Ingelheim, California Pacific Medical Center, Clintara, CME Inc, Corium, GliaCure, INSYS, and T3D; receiving consulting fees and research support from AstraZeneca, Avanir, Cognoptix, Lilly, H. Lundbeck A/S, Merck and Company, and Takeda; receiving research support from Elan, Functional Neuromodulation, Genentech, Novartis, Roche, Targacept, the National Institute on Aging, and the Arizona Department of Health Services; owning stock options in Adamas; and being listed as a contributor to a patent owned by the University of Rochester. Dr Molinuevo reported receiving honoraria for consulting, providing educational lectures, or serving on advisory boards for ABL, Axovant, Boehringer Ingelheim, Eli Lilly &amp; Co, Fujirebio, GE Healthcare, H. Lundbeck A/S, Merck Sharpe &amp; Dohme, Novartis, Pfizer, Piramal Imaging, Roche, and Roche Diagnostics. Drs Boneva and Raket are full-time employees of H. Lundbeck A/S. Dr Windfeld was a full-time employee of H. Lundbeck A/S during the design and implementation of the studies reported herein and through the drafting and submission of the first version of the manuscript. Dr Cummings reported serving as a consultant to AbbVie, Acadia, Actinogen, Adamas, Alzheon, Anavex, Astellas, Avanir, Avid, Axovant, Boehringer Ingelheim, Bracket, Eisai, GE Healthcare, Genentech, Intra-Cellular Therapies, Lilly, H. Lundbeck A/S, MedAvante, Merck, Neurocog, Novartis, Orion, Otsuka, Pfizer, Piramal, QR Pharma, reMYND, Resverlogix, Roche, Suven, Takeda, Toyama, and Transition; receiving research support from Avid and Teva; owning stock options in Prana, Neurokos, Adamas, MedAvante, and QR Pharma; and owning the copyright of the Neuropsychiatric Inventory and all its derivatives. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29318278</ArticleId><ArticleId IdType="pmc">PMC5833662</ArticleId><ArticleId IdType="doi">10.1001/jama.2017.20373</ArticleId><ArticleId IdType="pii">2668349</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association 2016 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2016;12(4):459-509.</Citation><ArticleIdList><ArticleId IdType="pubmed">27570871</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS. A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer&#x2019;s disease. Dialogues Clin Neurosci. 2000;2(2):111-128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181592</ArticleId><ArticleId IdType="pubmed">22033801</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow MR, Salloway S, Tariot PN, et al. . Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer&#x2019;s disease: a 24-week, randomized, double-blind study. Clin Ther. 2010;32(7):1234-1251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068609</ArticleId><ArticleId IdType="pubmed">20678673</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez JJ, Noristani HN, Verkhratsky A. The serotonergic system in ageing and Alzheimer&#x2019;s disease. Prog Neurobiol. 2012;99(1):15-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">22766041</ArticleId></ArticleIdList></Reference><Reference><Citation>Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer&#x2019;s disease. Neurotherapeutics. 2008;5(3):458-469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084247</ArticleId><ArticleId IdType="pubmed">18625457</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez MJ. 5-HT6 receptors and Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2013;5(2):15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706851</ArticleId><ArticleId IdType="pubmed">23607787</ArticleId></ArticleIdList></Reference><Reference><Citation>Geldenhuys WJ, Van der Schyf CJ. Role of serotonin in Alzheimer&#x2019;s disease: a new therapeutic target? CNS Drugs. 2011;25(9):765-781.</Citation><ArticleIdList><ArticleId IdType="pubmed">21870888</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. . Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2010;7(5):374-385.</Citation><ArticleIdList><ArticleId IdType="pubmed">20043816</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher-Edwards G, Dixon R, Hunter J, et al. . SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry. 2011;26(5):536-544.</Citation><ArticleIdList><ArticleId IdType="pubmed">20872778</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson D, Windfeld K, Colding-J&#xf8;rgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer&#x2019;s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2014;13(11):1092-1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">25297016</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher-Edwards G, Watson C, Ascher J, et al. . Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer&#x2019;s disease. Alzheimers Dement. 2015;1(1):23-36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5974972</ArticleId><ArticleId IdType="pubmed">29854923</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services; US Food and Drug Administration  ICH harmonised tripartite guideline E6: guideline for good clinical practice. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073122.pdf. Accessed October 31, 2016.</Citation></Reference><Reference><Citation>World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.</Citation><ArticleIdList><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939-944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer&#x2019;s disease. Am J Psychiatry. 1984;141(11):1356-1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. . An inventory to assess activities of daily living for clinical trials in Alzheimer&#x2019;s disease: the Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33-S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Olin JT, Doody RS, et al. . Validity and reliability of the Alzheimer&#x2019;s Disease Cooperative Study&#x2013;Clinical Global Impression of Change: the Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S22-S32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236949</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner K, Brown GK, Stanley B, et al. . The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893686</ArticleId><ArticleId IdType="pubmed">22193671</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research  Guidance for industry: drug-induced liver injury: premarketing clinical evaluation. https://www.fda.gov/downloads/Guidances/UCM174090.pdf. Accessed December 7, 2017.</Citation></Reference><Reference><Citation>Birks J. Cholinesterase inhibitors for Alzheimer&#x2019;s disease. Cochrane Database Syst Rev. 2006;(1):CD005593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006343</ArticleId><ArticleId IdType="pubmed">16437532</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayele BT, Lipkovich I, Molenberghs G, Mallinckrodt CH. A multiple-imputation-based approach to sensitivity analyses and effectiveness assessments in longitudinal clinical trials. J Biopharm Stat. 2014;24(2):211-228.</Citation><ArticleIdList><ArticleId IdType="pubmed">24605966</ArticleId></ArticleIdList></Reference><Reference><Citation>Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med. 2009;28(4):586-604.</Citation><ArticleIdList><ArticleId IdType="pubmed">19051220</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research  Guidance for industry: exposure-response relationships&#x2014;study design, data analysis, and regulatory applications. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072109.pdf. Accessed December 7, 2017.</Citation></Reference><Reference><Citation>Schmidt E, Kuwabara H, Areberg J, et al. . A clinical positron emission tomography (PET) study investigating occupancy at the 5-HT6 receptor after multiple oral doses of LU AE58054 to healthy men. Alzheimers Dement. 2014;10(4):P925.</Citation></Reference><Reference><Citation>Lorke DE, Lu G, Cho E, Yew DT. Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci. 2006;7:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1523198</ArticleId><ArticleId IdType="pubmed">16640790</ArticleId></ArticleIdList></Reference><Reference><Citation>Axovant Sciences Inc  Axovant announces negative topline results of intepirdine phase 3 MINDSET trial in Alzheimer's disease. http://investors.axovant.com/news-releases/news-release-details/axovant-announces-negative-topline-results-intepirdine-phase-3. Accessed November 28, 2017.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29321258</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>423</Issue><PubDate><Year>2018</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn's disease and Parkinson's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaai7795</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aai7795</ELocationID><Abstract><AbstractText>Crohn's disease (CD), a form of inflammatory bowel disease, has a higher prevalence in Ashkenazi Jewish than in non-Jewish European populations. To define the role of nonsynonymous mutations, we performed exome sequencing of Ashkenazi Jewish patients with CD, followed by array-based genotyping and association analysis in 2066 CD cases and 3633 healthy controls. We detected association signals in the <i>LRRK2</i> gene that conferred risk for CD (N2081D variant, <i>P</i> = 9.5 &#xd7; 10<sup>-10</sup>) or protection from CD (N551K variant, tagging R1398H-associated haplotype, <i>P</i> = 3.3 &#xd7; 10<sup>-8</sup>). These variants affected CD age of onset, disease location, LRRK2 activity, and autophagy. Bayesian network analysis of CD patient intestinal tissue further implicated <i>LRRK2</i> in CD pathogenesis. Analysis of the extended <i>LRRK2</i> locus in 24,570 CD cases, patients with Parkinson's disease (PD), and healthy controls revealed extensive pleiotropy, with shared genetic effects between CD and PD in both Ashkenazi Jewish and non-Jewish cohorts. The <i>LRRK2</i> N2081D CD risk allele is located in the same kinase domain as G2019S, a mutation that is the major genetic cause of familial and sporadic PD. Like the G2019S mutation, the N2081D variant was associated with increased kinase activity, whereas neither N551K nor R1398H variants on the protective haplotype altered kinase activity. We also confirmed that R1398H, but not N551K, increased guanosine triphosphate binding and hydrolyzing enzyme (GTPase) activity, thereby deactivating LRRK2. The presence of shared <i>LRRK2</i> alleles in CD and PD provides refined insight into disease mechanisms and may have major implications for the treatment of these two seemingly unrelated diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>Ken Y</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Hernandez</LastName><ForeName>Heriberto</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Jianzhong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaffner</LastName><ForeName>Adam</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8864-5633</Identifier><AffiliationInfo><Affiliation>Departments of Neurology and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pankratz</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5958-693X</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Nai-Yun</ForeName><Initials>NY</Initials><Identifier Source="ORCID">0000-0002-1653-2998</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Ling-Shiang</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0001-5054-1305</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmi</LastName><ForeName>Shai</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0188-2610</Identifier><AffiliationInfo><Affiliation>Braun School of Public Health and Community Medicine, The Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villaverde</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1421-8305</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xianting</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-3153-0931</Identifier><AffiliationInfo><Affiliation>Departments of Neurology and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivas</LastName><ForeName>Manual</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1457-9925</Identifier><AffiliationInfo><Affiliation>Department of Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Adam P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0003-1333-9938</Identifier><AffiliationInfo><Affiliation>Centre for Molecular Medicine, Division of Medicine, University College, London WC1E 6JF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Xiuliang</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-2042-7090</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labrias</LastName><ForeName>Philippe R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0001-7281-9339</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haritunians</LastName><ForeName>Talin</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9005-7750</Identifier><AffiliationInfo><Affiliation>Translational Genomics Group, F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruane</LastName><ForeName>Darren</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Immunology and Inflammation, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gettler</LastName><ForeName>Kyle</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ernie</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-1573-7577</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dalin</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4738-0074</Identifier><AffiliationInfo><Affiliation>Translational Genomics Group, F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiff</LastName><ForeName>Elena R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0002-9848-1302</Identifier><AffiliationInfo><Affiliation>Centre for Molecular Medicine, Division of Medicine, University College, London WC1E 6JF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontikos</LastName><ForeName>Nikolas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-1782-4711</Identifier><AffiliationInfo><Affiliation>Centre for Molecular Medicine, Division of Medicine, University College, London WC1E 6JF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barzilai</LastName><ForeName>Nir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Departments of Genetics and Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brant</LastName><ForeName>Steven R</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0003-3019-4240</Identifier><AffiliationInfo><Affiliation>Harvey M. and Lyn P. Meyerhoff Inflammatory Bowel Disease Center, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21231, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bressman</LastName><ForeName>Susan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3513-8048</Identifier><AffiliationInfo><Affiliation>Alan and Barbara Mirken Department of Neurology, Beth Israel Medical Center, New York, NY 10003, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheifetz</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Lorraine N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daly</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0949-8752</Identifier><AffiliationInfo><Affiliation>Department of Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desnick</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0001-5501-2971</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duerr</LastName><ForeName>Richard H</ForeName><Initials>RH</Initials><Identifier Source="ORCID">0000-0001-6586-3905</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Seymour</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3492-9200</Identifier><AffiliationInfo><Affiliation>New York University School of Medicine, New York City, NY 10016, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>North Shore University-Long Island Jewish Medical Center, Manhasset, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Francis Hospital, Roslyn, NY 11576, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lencz</LastName><ForeName>Todd</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8586-338X</Identifier><AffiliationInfo><Affiliation>Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY 11030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Richard H</ForeName><Initials>RH</Initials><Identifier Source="ORCID">0000-0002-8365-2674</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostrer</LastName><ForeName>Harry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2209-5376</Identifier><AffiliationInfo><Affiliation>Departments of Pathology and Pediatrics, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozelius</LastName><ForeName>Laurie</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7820-1684</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deparment of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Payami</LastName><ForeName>Haydeh</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9084-5338</Identifier><AffiliationInfo><Affiliation>Departments of Neurology and Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HudsonAlpha Institute for Biotechnology, Huntsville, AL 35805, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peter</LastName><ForeName>Yakov</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-8822-3334</Identifier><AffiliationInfo><Affiliation>Department of Biology, Touro College, Queens, NY 10033, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY 10033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rioux</LastName><ForeName>John D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0001-7560-8326</Identifier><AffiliationInfo><Affiliation>Research Center, Montreal Heart Institute, Montreal, Quebec H1T1C8, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facult&#xe9; de M&#xe9;decine, Universit&#xe9; de Montr&#xe9;al, Montreal, Quebec H1T1C8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segal</LastName><ForeName>Anthony W</ForeName><Initials>AW</Initials><Identifier Source="ORCID">0000-0001-7602-9043</Identifier><AffiliationInfo><Affiliation>Centre for Molecular Medicine, Division of Medicine, University College, London WC1E 6JF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>William K</ForeName><Initials>WK</Initials><Identifier Source="ORCID">0000-0001-9336-6404</Identifier><AffiliationInfo><Affiliation>Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverberg</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario M5T3L9, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario M5G1X5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>Jeffery M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-3815-8199</Identifier><AffiliationInfo><Affiliation>Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ubarretxena-Belandia</LastName><ForeName>Iban</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5549-2212</Identifier><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atzmon</LastName><ForeName>Gil</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6895-3607</Identifier><AffiliationInfo><Affiliation>Departments of Genetics and Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Natural Sciences, University of Haifa, Haifa 3498838, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pe'er</LastName><ForeName>Itsik</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-6128-7231</Identifier><AffiliationInfo><Affiliation>Center for Computational Biology and Bioinformatics, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ioannou</LastName><ForeName>Yiannis</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGovern</LastName><ForeName>Dermot P B</ForeName><Initials>DPB</Initials><AffiliationInfo><Affiliation>Translational Genomics Group, F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Zhenyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schadt</LastName><ForeName>Eric E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Genetics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sema4, a Mount Sinai venture, Stamford, CT 06902, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Judy H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-7959-0466</Identifier><AffiliationInfo><Affiliation>Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Gastroenterology and Hepatology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peter</LastName><ForeName>Inga</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-5638-9137</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. inga.peter@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Genetics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 NS094733</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS050487</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS036960</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007205</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK106593</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DK062423</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS036711</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS071674</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK092235</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH095458</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG042188</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA141743</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DK062413</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS037167</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH084098</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK043351</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L000261/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG021654</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 DK062429</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HD007149</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HS021747</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 DK098927</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DK062429</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS060809</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DK062422</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA121852</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS060113</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS037167</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG038072</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 MH089964</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI067068</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 DK046763</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS076843</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DK062420</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DK062431</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071158">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):330-331. doi: 10.1038/s41575-018-0006-9.</RefSource><PMID Version="1">29666431</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2018 Jul;33(7):1098. doi: 10.1002/mds.27407.</RefSource><PMID Version="1">29737560</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="N">Crohn Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059472" MajorTopicYN="N">Exome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071158" MajorTopicYN="N">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016366" MajorTopicYN="N">Open Reading Frames</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073359" MajorTopicYN="N">Exome Sequencing</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests</b>. RJD has consulted for Amicus Therapeutics, Alexion Pharmaceuticals, Genzyme-Sanofi, Kiniksa Pharmaceuticals, Mitsubishi-Tanabe, Synageva Pharmaceuticals, Recordati Rare Diseases, Sangamo Therapeutics, and has received royalties from Shire. Shire: Royalties. YI has consulted for Neurotrope, Inc and Amathus Therapeutics, Inc. SC has consulted for MyHeritage. ASC has consulted for AbbVie Pharmaceuticals, Janssen Pharmaceuticals, Takeda Pharmaceuticals, Pfeizer Pharmaceuticals, Ferring Pharmaceuticals, Miraca Life Sciences. DM has consulted for Janssen Pharmaceutical, UCB, Merck, Cidara, Qu Biologics. The other authors declare no competing interests. Data Availability: Samples from the Ashkenazi Genome Consortium are available from member institutions through a Material Transfer Agreement.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29321258</ArticleId><ArticleId IdType="mid">NIHMS969987</ArticleId><ArticleId IdType="pmc">PMC6028002</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aai7795</ArticleId><ArticleId IdType="pii">10/423/eaai7795</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Buning C, Cohain A, Cichon S, D&#x2019;Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H, Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3491803</ArticleId><ArticleId IdType="pubmed">23128233</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, Abedian S, Cheon JH, Cho J, Daryani NE, Franke L, Fuyuno Y, Hart A, Juyal RC, Juyal G, Kim WH, Morris AP, Poustchi H, Newman WG, Midha V, Orchard TR, Vahedi H, Sood A, Sung JJ, Malekzadeh R, Westra HJ, Yamazaki K, Yang SK, C. International Multiple Sclerosis Genetics, I. B. D. G. C. International. Barrett JC, Franke A, Alizadeh BZ, Parkes M, B KT, Daly MJ, Kubo M, Anderson CA, Weersma RK, I. B. D. G. Consortium Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47:979&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4881818</ArticleId><ArticleId IdType="pubmed">26192919</ArticleId></ArticleIdList></Reference><Reference><Citation>Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461&#x2013;1463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410764</ArticleId><ArticleId IdType="pubmed">17068223</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, He Y, Raymond EL, Ahlberg J, Frego LE, Amodeo LM, Catron KM, Presky DH, Hanke JH. Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. mAbs. 2015;7:778&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4622456</ArticleId><ArticleId IdType="pubmed">25905918</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy A, Li Y, Peng I, Reichelt M, Katakam AK, Noubade R, Roose-Girma M, DeVoss J, Diehl L, Graham RR, van Lookeren Campagne M. A Crohn&#x2019;s disease variant in Atg16l1 enhances its degradation by caspase 3. Nature. 2014;506:456&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">24553140</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarroll SA, Huett A, Kuballa P, Chilewski SD, Landry A, Goyette P, Zody MC, Hall JL, Brant SR, Cho JH, Duerr RH, Silverberg MS, Taylor KD, Rioux JD, Altshuler D, Daly MJ, Xavier RJ. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn&#x2019;s disease. Nat Genet. 2008;40:1107&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2731799</ArticleId><ArticleId IdType="pubmed">19165925</ArticleId></ArticleIdList></Reference><Reference><Citation>Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V, Mari B, Barbry P, Mosnier JF, Hebuterne X, Harel-Bellan A, Mograbi B, Darfeuille-Michaud A, Hofman P. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn&#x2019;s disease. Nat Genet. 2011;43:242&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">21278745</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein CN, Rawsthorne P, Cheang M, Blanchard JF. A population-based case control study of potential risk factors for IBD. Am J Gastroenterol. 2006;101:993&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">16696783</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, McElree C, Roth MP, Shanahan F, Targan SR, Rotter JI. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut. 1993;34:517&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1374314</ArticleId><ArticleId IdType="pubmed">8491401</ArticleId></ArticleIdList></Reference><Reference><Citation>Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB. Cloning of the gene containing mutations that cause PARK8-linked Parkinson&#x2019;s disease. Neuron. 2004;44:595&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny EE, Pe&#x2019;er I, Karban A, Ozelius L, Mitchell AA, Ng SM, Erazo M, Ostrer H, Abraham C, Abreu MT, Atzmon G, Barzilai N, Brant SR, Bressman S, Burns ER, Chowers Y, Clark LN, Darvasi A, Doheny D, Duerr RH, Eliakim R, Giladi N, Gregersen PK, Hakonarson H, Jones MR, Marder K, McGovern DP, Mulle J, Orr-Urtreger A, Proctor DD, Pulver A, Rotter JI, Silverberg MS, Ullman T, Warren ST, Waterman M, Zhang W, Bergman A, Mayer L, Katz S, Desnick RJ, Cho JH, Peter I. A genome-wide scan of ashkenazi jewish Crohn&#x2019;s disease suggests novel susceptibility Loci. PLoS Genet. 2012;8:e1002559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297573</ArticleId><ArticleId IdType="pubmed">22412388</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Van Broeckhoven C, Carr J, Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Ferraris A, Fiske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lesage S, Lin CH, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C, Opala G, Park SS, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Theuns J, Tomiyama H, Uitti RJ, Valente EM, van de Loo S, Vassilatis DK, Vilarino-Guell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Farrer MJ, C. Genetic Epidemiology Of Parkinson&#x2019;s Disease Association of LRRK2 exonic variants with susceptibility to Parkinson&#x2019;s disease: a case-control study. The Lancet Neurology. 2011;10:898&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208320</ArticleId><ArticleId IdType="pubmed">21885347</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorostidi A, Marti-Masso JF, Bergareche A, Rodriguez-Oroz MC, Lopez de Munain A, Ruiz-Martinez J. Genetic Mutation Analysis of Parkinson&#x2019;s Disease Patients Using Multigene Next-Generation Sequencing Panels. Molecular diagnosis &amp; therapy. 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">27294386</ArticleId></ArticleIdList></Reference><Reference><Citation>Biskup S, West AB. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson&#x2019;s disease. Biochim Biophys Acta. 2009;1792:625&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745057</ArticleId><ArticleId IdType="pubmed">18973807</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez BA, Davis AA, Jin SC, Ibanez L, Ortega-Cubero S, Pastor P, Choi J, Cooper B, Perlmutter JS, Cruchaga C. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson&#x2019;s Disease. Molecular neurodegeneration. 2016;11:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4837564</ArticleId><ArticleId IdType="pubmed">27094865</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn&#x2019;s disease. Nat Genet. 2008;40:955&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2574810</ArticleId><ArticleId IdType="pubmed">18587394</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D&#x2019;Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panes J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D&#x2019;Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn&#x2019;s disease susceptibility loci. Nat Genet. 2010;42:1118&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299551</ArticleId><ArticleId IdType="pubmed">21102463</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Lee J, Krummey S, Lu W, Cai H, Lenardo MJ. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol. 2011;12:1063&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4140245</ArticleId><ArticleId IdType="pubmed">21983832</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhu J, Lum PY, Yang X, Pinto S, MacNeil DJ, Zhang C, Lamb J, Edwards S, Sieberts SK, Leonardson A, Castellini LW, Wang S, Champy MF, Zhang B, Emilsson V, Doss S, Ghazalpour A, Horvath S, Drake TA, Lusis AJ, Schadt EE. Variations in DNA elucidate molecular networks that cause disease. Nature. 2008;452:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841398</ArticleId><ArticleId IdType="pubmed">18344982</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG, C. S. Group Ustekinumab induction and maintenance therapy in refractory Crohn&#x2019;s disease. N Engl J Med. 2012;367:1519&#x2013;1528.</Citation><ArticleIdList><ArticleId IdType="pubmed">23075178</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Lee CH, Peters LA, Mastropaolo LA, Thoeni C, Elkadri A, Schwerd T, Zhu J, Zhang B, Zhao Y, Hao K, Dinarzo A, Hoffman G, Kidd BA, Murchie R, Al Adham Z, Guo C, Kotlarz D, Cutz E, Walters TD, Shouval DS, Curran M, Dobrin R, Brodmerkel C, Snapper SB, Klein C, Brumell JH, Hu M, Nanan R, Snanter-Nanan B, Wong M, Le Deist F, Haddad E, Roifman CM, Deslandres C, Griffiths AM, Gaskin KJ, Uhlig HH, Schadt EE, Muise AM. Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease. Gastroenterology. 2016;150:1196&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4842103</ArticleId><ArticleId IdType="pubmed">26836588</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow J, Pankratz ND, Wojcieszek J, Foroud T. In: SourceGeneReviews&#xae; [Internet] A M, Pagon RA, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. University of Washington; Seattle, WA: 2004. May 25, [updated 2014 Feb 27]</Citation></Reference><Reference><Citation>Lassen KG, McKenzie CI, Mari M, Murano T, Begun J, Baxt LA, Goel G, Villablanca EJ, Kuo SY, Huang H, Macia L, Bhan AK, Batten M, Daly MJ, Reggiori F, Mackay CR, Xavier RJ. Genetic Coding Variant in GPR65 Alters Lysosomal pH and Links Lysosomal Dysfunction with Colitis Risk. Immunity. 2016;44:1392&#x2013;1405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4936415</ArticleId><ArticleId IdType="pubmed">27287411</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyette P, Boucher G, Mallon D, Ellinghaus E, Jostins L, Huang H, Ripke S, Gusareva ES, Annese V, Hauser SL, Oksenberg JR, Thomsen I, Leslie S, C. International Inflammatory Bowel Disease Genetics, Australia, I. New Zealand, I. B. D. G. C. Belgium, I. B. D. G. C. Italian Group for, N. I. B. D. G. Consortium, I. United Kingdom, C. Wellcome Trust Case Control, I. B. D. G. C. Quebec. Daly MJ, Van Steen K, Duerr RH, Barrett JC, McGovern DP, Schumm LP, Traherne JA, Carrington MN, Kosmoliaptsis V, Karlsen TH, Franke A, Rioux JD. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet. 2015;47:172&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310771</ArticleId><ArticleId IdType="pubmed">25559196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, Wang Y, Vandrovcova J, Guelfi S, Witeolar A, Karch CM, Schork AJ, Fan CC, Brewer JB, F. T. D. G. C. International, C. International Parkinson&#x2019;s Disease Genomics, P. International Genomics of Alzheimer&#x2019;s. Momeni P, Schellenberg GD, Dillon WP, Sugrue LP, Hess CP, Yokoyama JS, Bonham LW, Rabinovici GD, Miller BL, Andreassen OA, Dale AM, Hardy J, Desikan RS. Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Journal of neurology, neurosurgery, and psychiatry. 2017;88:152&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237405</ArticleId><ArticleId IdType="pubmed">27899424</ArticleId></ArticleIdList></Reference><Reference><Citation>Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, Wachter S, Lorentzen E, Duddy G, Wilson S, Baptista MA, Fiske BK, Fell MJ, Morrow JA, Reith AD, Alessi DR, Mann M. Phosphoproteomics reveals that Parkinson&#x2019;s disease kinase LRRK2 regulates a subset of Rab GTPases. eLife. 2016;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4769169</ArticleId><ArticleId IdType="pubmed">26824392</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y, Dawson VL, Dawson TM. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson&#x2019;s disease. Biochem Soc Trans. 2012;40:1074&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701022</ArticleId><ArticleId IdType="pubmed">22988868</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Tan YC, Poulose S, Olanow CW, Huang XY, Yue Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson&#x2019;s disease R1441C/G mutants. J Neurochem. 2007;103:238&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827244</ArticleId><ArticleId IdType="pubmed">17623048</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackeh R, Lorin S, Ratier A, Mejdoubi-Charef N, Baillet A, Bruneel A, Hamai A, Codogno P, Pous C, Perdiz D. Reactive oxygen species, AMP-activated protein kinase, and the transcription cofactor p300 regulate alpha-tubulin acetyltransferase-1 (alphaTAT-1/MEC-17)-dependent microtubule hyperacetylation during cell stress. J Biol Chem. 2014;289:11816&#x2013;11828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4002089</ArticleId><ArticleId IdType="pubmed">24619423</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Pan Y, Yan R, Zeng B, Wang H, Zhang X, Li W, Wei H, Liu Z. Commensal bacteria direct selective cargo sorting to promote symbiosis. Nat Immunol. 2015;16:918&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">26237551</ArticleId></ArticleIdList></Reference><Reference><Citation>Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet. 2005;76:672&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1199304</ArticleId><ArticleId IdType="pubmed">15726496</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB. LRRK2 G2019S as a cause of Parkinson&#x2019;s disease in Ashkenazi Jews. N Engl J Med. 2006;354:424&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">16436782</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JC, Lin CS, Hsu CW, Lin CL, Kao CH. Association Between Parkinson&#x2019;s Disease and Inflammatory Bowel Disease: a Nationwide Taiwanese Retrospective Cohort Study. Inflamm Bowel Dis. 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">26919462</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallings R, Manzoni C, Bandopadhyay R. Cellular processes associated with LRRK2 function and dysfunction. The FEBS journal. 2015;282:2806&#x2013;2826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522467</ArticleId><ArticleId IdType="pubmed">25899482</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava VM, Manry J, Cobat A, Orlova M, Van Thuc N, Ba NN, Thai VH, Abel L, Alcais A, Schurr E, T. Canadian Lrrk2 in Inflammation A Missense LRRK2 Variant Is a Risk Factor for Excessive Inflammatory Responses in Leprosy. PLoS neglected tropical diseases. 2016;10:e0004412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4742274</ArticleId><ArticleId IdType="pubmed">26844546</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine MJ, Plun-Favreau H, Wood NW. Parkinson&#x2019;s disease and cancer: two wars, one front. Nat Rev Cancer. 2011;11:812&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pubmed">22020207</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardet A, Benita Y, Li C, Sands BE, Ballester I, Stevens C, Korzenik JR, Rioux JD, Daly MJ, Xavier RJ, Podolsky DK. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol. 2010;185:5577&#x2013;5585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156100</ArticleId><ArticleId IdType="pubmed">20921534</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu TC, Naito T, Liu Z, VanDussen KL, Haritunians T, Li D, Endo K, Kawai Y, Nagasaki M, Kinouchi Y, McGovern DPB, Shimosegawa T, Kakuta Y, Stappenbeck TS. LRRK2 but not ATG16L1 is associated with Paneth cell defect in Japanese Crohn&#x2019;s disease patients. JCI Insight. 2017 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5358495</ArticleId><ArticleId IdType="pubmed">28352666</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S, Brant SR, Cho JH, Daly MJ, Dubinsky M, Duerr RH, Ferguson LR, Franke A, Gearry RB, Goyette P, Hakonarson H, Halfvarson J, Hov JR, Huang H, Kennedy NA, Kupcinskas L, Lawrance IC, Lee JC, Satsangi J, Schreiber S, Theatre E, van der Meulen-de Jong AE, Weersma RK, Wilson DC, C. International Inflammatory Bowel Disease Genetics. Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern DP, Barrett JC, Lees CW. Inherited determinants of Crohn&#x2019;s disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016;387:156&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4714968</ArticleId><ArticleId IdType="pubmed">26490195</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteves AR, Cardoso SM. LRRK2 at the Crossroad Between Autophagy and Microtubule Trafficking: Insights into Parkinson&#x2019;s Disease. The Neuroscientist: a review journal bringing neurobiology, neurology and psychiatry. 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">26740081</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon-Abell J, Berwick DC, Granno S, Spain VA, Blackstone C, Harvey K. Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity. Frontiers in molecular neuroscience. 2016;9:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4781896</ArticleId><ArticleId IdType="pubmed">27013965</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Hui KY, Gusev A, Warner N, Ng SM, Ferguson J, Choi M, Burberry A, Abraham C, Mayer L, Desnick RJ, Cardinale CJ, Hakonarson H, Waterman M, Chowers Y, Karban A, Brant SR, Silverberg MS, Gregersen PK, Katz S, Lifton RP, Zhao H, Nunez G, Pe&#x2019;er I, Peter I, Cho JH. Extended haplotype association study in Crohn&#x2019;s disease identifies a novel, Ashkenazi Jewish-specific missense mutation in the NF-kappaB pathway gene, HEATR3. Genes Immun. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785105</ArticleId><ArticleId IdType="pubmed">23615072</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter I, Mitchell AA, Ozelius L, Erazo M, Hu J, Doheny D, Abreu MT, Present DH, Ullman T, Benkov K, Korelitz BI, Mayer L, Desnick RJ. Evaluation of 22 genetic variants with Crohn&#x2019;s Disease risk in the Ashkenazi Jewish population: a case-control study. BMC Med Genet. 2011;12:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3212904</ArticleId><ArticleId IdType="pubmed">21548950</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, C. International Parkinson&#x2019;s Disease Genomics, G. I. Parkinson&#x2019;s Study Group Parkinson&#x2019;s Research: The Organized, and Me, GenePd, C. NeuroGenetics Research, G. Hussman Institute of Human, I. Ashkenazi Jewish Dataset, H. Cohorts for, E. Aging Research in Genetic, C. North American Brain Expression, C. United Kingdom Brain Expression, C. Greek Parkinson&#x2019;s Disease, G. Alzheimer Genetic Analysis. Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nat Genet. 2014;46:989&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacic V, Ozelius LJ, Clark LN, Bar-Shira A, Gana-Weisz M, Gurevich T, Gusev A, Kedmi M, Kenny EE, Liu X, Mejia-Santana H, Mirelman A, Raymond D, Saunders-Pullman R, Desnick RJ, Atzmon G, Burns ER, Ostrer H, Hakonarson H, Bergman A, Barzilai N, Darvasi A, Peter I, Guha S, Lencz T, Giladi N, Marder K, Pe&#x2019;er I, Bressman SB, Orr-Urtreger A. Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes. Hum Mol Genet. 2014;23:4693&#x2013;4702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4119402</ArticleId><ArticleId IdType="pubmed">24842889</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson&#x2019;s disease: a clinico-pathological study of 100 cases. Journal of neurology, neurosurgery, and psychiatry. 1992;55:181&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014720</ArticleId><ArticleId IdType="pubmed">1564476</ArticleId></ArticleIdList></Reference><Reference><Citation>Grove ML, Yu B, Cochran BJ, Haritunians T, Bis JC, Taylor KD, Hansen M, Borecki IB, Cupples LA, Fornage M, Gudnason V, Harris TB, Kathiresan S, Kraaij R, Launer LJ, Levy D, Liu Y, Mosley T, Peloso GM, Psaty BM, Rich SS, Rivadeneira F, Siscovick DS, Smith AV, Uitterlinden A, van Duijn CM, Wilson JG, O&#x2019;Donnell CJ, Rotter JI, Boerwinkle E. Best Practices and Joint Calling of the HumanExome BeadChip: The CHARGE Consortium. PLoS ONE. 2013;8:e68095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709915</ArticleId><ArticleId IdType="pubmed">23874508</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190&#x2013;2191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol. 2010;34:816&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175618</ArticleId><ArticleId IdType="pubmed">21058334</ArticleId></ArticleIdList></Reference><Reference><Citation>Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, Carlson S, Helgason A, Walters GB, Gunnarsdottir S, Mouy M, Steinthorsdottir V, Eiriksdottir GH, Bjornsdottir G, Reynisdottir I, Gudbjartsson D, Helgadottir A, Jonasdottir A, Jonasdottir A, Styrkarsdottir U, Gretarsdottir S, Magnusson KP, Stefansson H, Fossdal R, Kristjansson K, Gislason HG, Stefansson T, Leifsson BG, Thorsteinsdottir U, Lamb JR, Gulcher JR, Reitman ML, Kong A, Schadt EE, Stefansson K. Genetics of gene expression and its effect on disease. Nature. 2008;452:423&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">18344981</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong H, Beaulaurier J, Lum PY, Molony C, Yang X, Macneil DJ, Weingarth DT, Zhang B, Greenawalt D, Dobrin R, Hao K, Woo S, Fabre-Suver C, Qian S, Tota MR, Keller MP, Kendziorski CM, Yandell BS, Castro V, Attie AD, Kaplan LM, Schadt EE. Liver and adipose expression associated SNPs are enriched for association to type 2 diabetes. PLoS Genet. 2010;6:e1000932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2865508</ArticleId><ArticleId IdType="pubmed">20463879</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong H, Yang X, Kaplan LM, Molony C, Schadt EE. Integrating pathway analysis and genetics of gene expression for genome-wide association studies. Am J Hum Genet. 2010;86:581&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850442</ArticleId><ArticleId IdType="pubmed">20346437</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunyavanich S, Schadt EE, Himes BE, Lasky-Su J, Qiu W, Lazarus R, Ziniti JP, Cohain A, Linderman M, Torgerson DG, Eng CS, Pino-Yanes M, Padhukasahasram B, Yang JJ, Mathias RA, Beaty TH, Li X, Graves P, Romieu I, Navarro Bdel R, Salam MT, Vora H, Nicolae DL, Ober C, Martinez FD, Bleecker ER, Meyers DA, Gauderman WJ, Gilliland F, Burchard EG, Barnes KC, Williams LK, London SJ, Zhang B, Raby BA, Weiss ST. Integrated genome-wide association, coexpression network, and expression single nucleotide polymorphism analysis identifies novel pathway in allergic rhinitis. BMC Med Genomics. 2014;7:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4127082</ArticleId><ArticleId IdType="pubmed">25085501</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo S, Takikawa S, Geraghty P, Argmann C, Campbell J, Lin L, Huang T, Tu Z, Feronjy R, Spira A, Schadt EE, Powell CA, Zhu J. Integrative analysis of DNA methylation and gene expression data identifies EPAS1 as a key regulator of COPD. PLoS Genet. 2015;11:e1004898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287352</ArticleId><ArticleId IdType="pubmed">25569234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, Fluder E, Clurman B, Melquist S, Narayanan M, Suver C, Shah H, Mahajan M, Gillis T, Mysore J, MacDonald ME, Lamb JR, Bennett DA, Molony C, Stone DJ, Gudnason V, Myers AJ, Schadt EE, Neumann H, Zhu J, Emilsson V. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell. 2013;153:707&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuiper R, Klugkist I, Hoijtink H. A Fortran 90 program for confirmatory analysis of variance. J Stat Softw. 2010;34:1&#x2013;31.</Citation></Reference><Reference><Citation>Sahani MH, Itakura E, Mizushima N. Expression of the autophagy substrate SQSTM1/p62 is restored during prolonged starvation depending on transcriptional upregulation and autophagy-derived amino acids. Autophagy. 2014;10:431&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4077882</ArticleId><ArticleId IdType="pubmed">24394643</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H, Diekhans M, Furey TS, Harte RA, Hsu F, Hillman-Jackson J, Kuhn RM, Pedersen JS, Pohl A, Raney BJ, Rosenbloom KR, Siepel A, Smith KE, Sugnet CW, Sultan-Qurraie A, Thomas DJ, Trumbower H, Weber RJ, Weirauch M, Zweig AS, Haussler D, Kent WJ. The UCSC Genome Browser Database: update 2006. Nucleic acids research. 2006;34:D590&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347506</ArticleId><ArticleId IdType="pubmed">16381938</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Briefings in bioinformatics. 2013;14:178&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3603213</ArticleId><ArticleId IdType="pubmed">22517427</ArticleId></ArticleIdList></Reference><Reference><Citation>Browning SR, Browning BL. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum Genet. 2007;81:1084&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265661</ArticleId><ArticleId IdType="pubmed">17924348</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang LS, Villaverde N, Hui KY, Mortha A, Rahman A, Levine AP, Haritunians T, Ng SM, Zhang W, Hsu NY, Facey JA, Luong T, Fernandez-Hernandez H, Li D, Rivas M, Schiff ER, Gusev A, Schumm LP, Bowen BM, Sharma Y, Ning K, Remark R, Gnjatic S, Legnani P, George J, Sands BE, Stempak JM, Datta LW, Lipka S, Katz S, Cheifetz AS, Barzilai N, Pontikos N, Abraham C, Dubinsky MJ, Targan S, Taylor K, Rotter JI, Scherl EJ, Desnick RJ, Abreu MT, Zhao H, Atzmon G, Pe&#x2019;er I, Kugathasan S, Hakonarson H, McCauley JL, Lencz T, Darvasi A, Plagnol V, Silverberg MS, Muise AM, Brant SR, Daly MJ, Segal AW, Duerr RH, Merad M, McGovern DP, Peter I, Cho JH. A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn&#x2019;s Disease and Reduces Monocyte Signaling via GMCSF. Gastroenterology. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5037012</ArticleId><ArticleId IdType="pubmed">27377463</ArticleId></ArticleIdList></Reference><Reference><Citation>C. Genomes Project. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498066</ArticleId><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmi S, Hui KY, Kochav E, Liu X, Xue J, Grady F, Guha S, Upadhyay K, Ben-Avraham D, Mukherjee S, Bowen BM, Thomas T, Vijai J, Cruts M, Froyen G, Lambrechts D, Plaisance S, Van Broeckhoven C, Van Damme P, Van Marck H, Barzilai N, Darvasi A, Offit K, Bressman S, Ozelius LJ, Peter I, Cho JH, Ostrer H, Atzmon G, Clark LN, Lencz T, Pe&#x2019;er I. Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. Nature communications. 2014;5:4835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4164776</ArticleId><ArticleId IdType="pubmed">25203624</ArticleId></ArticleIdList></Reference><Reference><Citation>Guha S, Rosenfeld JA, Malhotra AK, Lee AT, Gregersen PK, Kane JM, Pe&#x2019;er I, Darvasi A, Lencz T. Implications for health and disease in the genetic signature of the Ashkenazi Jewish population. Genome biology. 2012;13:R2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334583</ArticleId><ArticleId IdType="pubmed">22277159</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29321225</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>215</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Mar</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism.</ArticleTitle><Pagination><StartPage>745</StartPage><EndPage>760</EndPage><MedlinePgn>745-760</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20171529</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a neurodegenerative disease that causes late-onset dementia. The R47H variant of the microglial receptor TREM2 triples AD risk in genome-wide association studies. In mouse AD models, TREM2-deficient microglia fail to proliferate and cluster around the amyloid-&#x3b2; plaques characteristic of AD. In vitro, the common variant (CV) of TREM2 binds anionic lipids, whereas R47H mutation impairs binding. However, in vivo, the identity of TREM2 ligands and effect of the R47H variant remain unknown. We generated transgenic mice expressing human CV or R47H TREM2 and lacking endogenous TREM2 in the 5XFAD AD model. Only the CV transgene restored amyloid-&#x3b2;-induced microgliosis and microglial activation, indicating that R47H impairs TREM2 function in vivo. Remarkably, soluble TREM2 was found on neurons and plaques in CV- but not R47H-expressing 5XFAD brains, although in vitro CV and R47H were shed similarly via Adam17 proteolytic activity. These results demonstrate that TREM2 interacts with neurons and plaques duing amyloid-&#x3b2; accumulation and R47H impairs this interaction.</AbstractText><CopyrightInformation>&#xa9; 2018 Song et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Wilbur M</ForeName><Initials>WM</Initials><Identifier Source="ORCID">0000-0002-6608-4628</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshita</LastName><ForeName>Satoru</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6364-9654</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yingyue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulland</LastName><ForeName>Tyler K</ForeName><Initials>TK</Initials><Identifier Source="ORCID">0000-0002-6507-4989</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilfillan</LastName><ForeName>Susan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1672-0996</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5222-4987</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO mcolonna@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 DK052574</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009547</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA091842</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 NS086741</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051485</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.86</RegistryNumber><NameOfSubstance UI="D000072198">ADAM17 Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000072198" MajorTopicYN="N">ADAM17 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29321225</ArticleId><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="doi">10.1084/jem.20171529</ArticleId><ArticleId IdType="pii">jem.20171529</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atagi Y., Liu C.C., Painter M.M., Chen X.F., Verbeeck C., Zheng H., Li X., Rademakers R., Kang S.S., Xu H., et al. . 2015. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J. Biol. Chem. 290:26043&#x2013;26050. 10.1074/jbc.M115.679043</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.679043</ArticleId><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey C.C., DeVaux L.B., and Farzan M.. 2015. The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E. J. Biol. Chem. 290:26033&#x2013;26042. 10.1074/jbc.M115.677286</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.677286</ArticleId><ArticleId IdType="pmc">PMC4646256</ArticleId><ArticleId IdType="pubmed">26374897</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchon A., Hern&#xe1;ndez-Munain C., Cella M., and Colonna M.. 2001. A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J. Exp. Med. 194:1111&#x2013;1122. 10.1084/jem.194.8.1111</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.194.8.1111</ArticleId><ArticleId IdType="pmc">PMC2193511</ArticleId><ArticleId IdType="pubmed">11602640</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A.. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 261:921&#x2013;923. 10.1126/science.8346443</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer W.A., and Vassar R.. 2013. Neuron loss in the 5XFAD mouse model of Alzheimer&#x2019;s disease correlates with intraneuronal A&#x3b2;42 accumulation and Caspase-3 activation. Mol. Neurodegener. 8:2 10.1186/1750-1326-8-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-2</ArticleId><ArticleId IdType="pmc">PMC3552866</ArticleId><ArticleId IdType="pubmed">23316765</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Z., Brooks D.J., Okello A., and Edison P.. 2017. An early and late peak in microglial activation in Alzheimer&#x2019;s disease trajectory. Brain. 140:792&#x2013;803. 10.1093/brain/aww349</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww349</ArticleId><ArticleId IdType="pmc">PMC5837520</ArticleId><ArticleId IdType="pubmed">28122877</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuerbach D., Schindler P., Barske C., Joller S., Beng-Louka E., Worringer K.A., Kommineni S., Kaykas A., Ho D.J., Ye C., et al. . 2017. ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157. Neurosci. Lett. 660:109&#x2013;114. 10.1016/j.neulet.2017.09.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.09.034</ArticleId><ArticleId IdType="pubmed">28923481</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A., Serrano-Pozo A., Parrado A.R., Lesinski A.N., Asselin C.N., Mullin K., Hooli B., Choi S.H., Hyman B.T., and Tanzi R.E.. 2013. Alzheimer&#x2019;s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 78:631&#x2013;643. 10.1016/j.neuron.2013.04.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.04.014</ArticleId><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., et al. Alzheimer Genetic Analysis Group . 2013. TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 368:117&#x2013;127. 10.1056/NEJMoa1211851</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamerman J.A., Jarjoura J.R., Humphrey M.B., Nakamura M.C., Seaman W.E., and Lanier L.L.. 2006. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J. Immunol. 177:2051&#x2013;2055. 10.4049/jimmunol.177.4.2051</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.4.2051</ArticleId><ArticleId IdType="pubmed">16887962</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka M.T., Carson M.J., El Khoury J., Landreth G.E., Brosseron F., Feinstein D.L., Jacobs A.H., Wyss-Coray T., Vitorica J., Ransohoff R.M., et al. . 2015. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 14:388&#x2013;405. 10.1016/S1474-4422(15)70016-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)70016-5</ArticleId><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C.L., Koike M., Spusta S.C., Niemi E.C., Yenari M., Nakamura M.C., and Seaman W.E.. 2009. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J. Neurochem. 109:1144&#x2013;1156. 10.1111/j.1471-4159.2009.06042.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06042.x</ArticleId><ArticleId IdType="pmc">PMC3087597</ArticleId><ArticleId IdType="pubmed">19302484</ArticleId></ArticleIdList></Reference><Reference><Citation>Itagaki S., McGeer P.L., Akiyama H., Zhu S., and Selkoe D.. 1989. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 24:173&#x2013;182. 10.1016/0165-5728(89)90115-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(89)90115-X</ArticleId><ArticleId IdType="pubmed">2808689</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay T.R., Miller C.M., Cheng P.J., Graham L.C., Bemiller S., Broihier M.L., Xu G., Margevicius D., Karlo J.C., Sousa G.L., et al. . 2015. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J. Exp. Med. 212:287&#x2013;295. 10.1084/jem.20142322</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142322</ArticleId><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay T.R., Hirsch A.M., Broihier M.L., Miller C.M., Neilson L.E., Ransohoff R.M., Lamb B.T., and Landreth G.E.. 2017. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer&#x2019;s disease. J. Neurosci. 37:637&#x2013;647. 10.1523/JNEUROSCI.2110-16.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2110-16.2016</ArticleId><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S.C., Benitez B.A., Karch C.M., Cooper B., Skorupa T., Carrell D., Norton J.B., Hsu S., Harari O., Cai Y., et al. . 2014. Coding variants in TREM2 increase risk for Alzheimer&#x2019;s disease. Hum. Mol. Genet. 23:5838&#x2013;5846. 10.1093/hmg/ddu277</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu277</ArticleId><ArticleId IdType="pmc">PMC4189899</ArticleId><ArticleId IdType="pubmed">24899047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.V., Snaedal J., Bjornsson S., Huttenlocher J., Levey A.I., Lah J.J., et al. . 2013. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N. Engl. J. Med. 368:107&#x2013;116. 10.1056/NEJMoa1211103</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T.K., David E., Baruch K., Lara-Astaiso D., Toth B., et al. . 2017. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell. 169:1276&#x2013;1290. 10.1016/j.cell.2017.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G., Yamanishi Y., Su&#xe1;rez-Calvet M., Czirr E., Lohmann E., Cuyvers E., Struyfs H., Pettkus N., Wenninger-Weinzierl A., Mazaheri F., et al. . 2014. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med. 6:243ra86 10.1126/scitranslmed.3009093</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3009093</ArticleId><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober D.L., Alexander-Brett J.M., Karch C.M., Cruchaga C., Colonna M., Holtzman M.J., and Brett T.J.. 2016. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. eLife. 5:707&#x2013;720. 10.7554/eLife.20391</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.20391</ArticleId><ArticleId IdType="pmc">PMC5173322</ArticleId><ArticleId IdType="pubmed">27995897</ArticleId></ArticleIdList></Reference><Reference><Citation>Korvatska O., Leverenz J.B., Jayadev S., McMillan P., Kurtz I., Guo X., Rumbaugh M., Matsushita M., Girirajan S., Dorschner M.O., et al. . 2015. R47H Variant of TREM2 Associated With Alzheimer Disease in a Large Late-Onset Family: Clinical, Genetic, and Neuropathological Study. JAMA Neurol. 72:920&#x2013;927. 10.1001/jamaneurol.2015.0979</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.0979</ArticleId><ArticleId IdType="pmc">PMC4825672</ArticleId><ArticleId IdType="pubmed">26076170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl W.C., Lyoo C.H., McGwier M., Snow J., Jenko K.J., Kimura N., Corona W., Morse C.L., Zoghbi S.S., Pike V.W., et al. Biomarkers Consortium PET Radioligand Project Team . 2013. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer&#x2019;s disease. Brain. 136:2228&#x2013;2238. 10.1093/brain/awt145</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt145</ArticleId><ArticleId IdType="pmc">PMC3692038</ArticleId><ArticleId IdType="pubmed">23775979</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M.-T., Tseng L.H., Kamiyama H., Kamiyama M., Lim P., Hidalgo M., Wheelan S., and Eshleman J.. 2010. Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. Biotechniques. 48:211&#x2013;218. 10.2144/000113363</Citation><ArticleIdList><ArticleId IdType="doi">10.2144/000113363</ArticleId><ArticleId IdType="pmc">PMC3065779</ArticleId><ArticleId IdType="pubmed">20359302</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M., and Prinz M.. 2015. Myeloid cells in Alzheimer&#x2019;s disease: culprits, victims or innocent bystanders? Trends Neurosci. 38:659&#x2013;668. 10.1016/j.tins.2015.08.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2015.08.011</ArticleId><ArticleId IdType="pubmed">26442698</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., et al. . 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26:10129&#x2013;10140. 10.1523/JNEUROSCI.1202-06.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre M., Kamphuis W., Osborn L.M., Jansen A.H.P., Kooijman L., Bossers K., and Hol E.M.. 2014. Isolation of glia from Alzheimer&#x2019;s mice reveals inflammation and&#xa0;dysfunction. Neurobiol. Aging. 35:2746&#x2013;2760. 10.1016/j.neurobiolaging.2014.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.06.004</ArticleId><ArticleId IdType="pubmed">25002035</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero K., Turnbull I.R., Poliani P.L., Vermi W., Cerutti E., Aoshi T., Tassi I., Takai T., Stanley S.L., Miller M., et al. . 2009. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and &#x3b2;-catenin. Nat. Immunol. 10:734&#x2013;743. 10.1038/ni.1744</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1744</ArticleId><ArticleId IdType="pmc">PMC4004764</ArticleId><ArticleId IdType="pubmed">19503107</ArticleId></ArticleIdList></Reference><Reference><Citation>Painter M.M., Atagi Y., Liu C.C., Rademakers R., Xu H., Fryer J.D., and Bu G.. 2015. TREM2 in CNS homeostasis and neurodegenerative disease. Mol. Neurodegener. 10:43 10.1186/s13024-015-0040-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0040-9</ArticleId><ArticleId IdType="pmc">PMC4560063</ArticleId><ArticleId IdType="pubmed">26337043</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth H.W., and LaFerla F.M.. 2010. Alzheimer&#x2019;s disease. N. Engl. J. Med. 362:329&#x2013;344. 10.1056/NEJMra0909142</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra0909142</ArticleId><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebeck G.W., Reiter J.S., Strickland D.K., and Hyman B.T.. 1993. Apolipoprotein E in sporadic Alzheimer&#x2019;s disease: allelic variation and receptor interactions. Neuron. 11:575&#x2013;580. 10.1016/0896-6273(93)90070-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(93)90070-8</ArticleId><ArticleId IdType="pubmed">8398148</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K., Kleinberger G., Fukumori A., Feederle R., Lichtenthaler S.F., Steiner H., and Haass C.. 2017. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol. Med. 9:1356&#x2013;1365. 10.15252/emmm.201707672</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707672</ArticleId><ArticleId IdType="pmc">PMC5623859</ArticleId><ArticleId IdType="pubmed">28855300</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R., van der Lee S.J., Naj A.C., Bellenguez C., Badarinarayan N., Jakobsdottir J., Kunkle B.W., Boland A., Raybould R., Bis J.C., et al. GERAD/PERADES, CHARGE, ADGC, EADI . 2017. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat. Genet. 49:1373&#x2013;1384. 10.1038/ng.3916</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3916</ArticleId><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W., Hooli B., Mullin K., Jin S.C., Cella M., Ulland T.K., Wang Y., Tanzi R.E., and Colonna M.. 2017. Alzheimer&#x2019;s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement. 13:381&#x2013;387. 10.1016/j.jalz.2016.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.07.004</ArticleId><ArticleId IdType="pmc">PMC5299056</ArticleId><ArticleId IdType="pubmed">27520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg S., Stefansson H., Jonsson T., Johannsdottir H., Ingason A., Helgason H., Sulem P., Magnusson O.T., Gudjonsson S.A., Unnsteinsdottir U., et al. DemGene . 2015. Loss-of-function variants in ABCA7 confer risk of Alzheimer&#x2019;s disease. Nat. Genet. 47:445&#x2013;447. 10.1038/ng.3246</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3246</ArticleId><ArticleId IdType="pubmed">25807283</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Rochford C.D.P., and Neumann H.. 2005. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J. Exp. Med. 201:647&#x2013;657. 10.1084/jem.20041611</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041611</ArticleId><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton P., Sevalle J., Deery M.J., Fraser G., Zhou Y., St&#xe5;hl S., Franssen E.H., Dodd R.B., Qamar S., Gomez Perez-Nievas B., et al. . 2017. TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer&#x2019;s disease-associated H157Y variant. EMBO Mol. Med. 9:1366&#x2013;1378. 10.15252/emmm.201707673</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707673</ArticleId><ArticleId IdType="pmc">PMC5623839</ArticleId><ArticleId IdType="pubmed">28855301</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull I.R., Gilfillan S., Cella M., Aoshi T., Miller M., Piccio L., Hernandez M., and Colonna M.. 2006. Cutting edge: TREM-2 attenuates macrophage activation. J. Immunol. 177:3520&#x2013;3524. 10.4049/jimmunol.177.6.3520</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.6.3520</ArticleId><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland T.K., Song W.M., Huang S.C., Ulrich J.D., Sergushichev A., Beatty W.L., Loboda A.A., Zhou Y., Cairns N.J., Kambal A., et al. . 2017. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer&#x2019;s Disease. Cell. 170:649&#x2013;663.e13. 10.1016/j.cell.2017.07.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.023</ArticleId><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich J.D., Finn M.B., Wang Y., Shen A., Mahan T.E., Jiang H., Stewart F.R., Piccio L., Colonna M., and Holtzman D.M.. 2014. Altered microglial response to A&#x3b2; plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener. 9:20 10.1186/1750-1326-9-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-20</ArticleId><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich J.D., Ulland T.K., Colonna M., and Holtzman D.M.. 2017. Elucidating the Role of TREM2 in Alzheimer&#x2019;s Disease. Neuron. 94:237&#x2013;248. 10.1016/j.neuron.2017.02.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.02.042</ArticleId><ArticleId IdType="pubmed">28426958</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Spandidos A., Wang H., and Seed B.. 2012. PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res. 40(Database issue, D1):D1144&#x2013;D1149. 10.1093/nar/gkr1013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr1013</ArticleId><ArticleId IdType="pmc">PMC3245149</ArticleId><ArticleId IdType="pubmed">22086960</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cella M., Mallinson K., Ulrich J.D., Young K.L., Robinette M.L., Gilfillan S., Krishnan G.M., Sudhakar S., Zinselmeyer B.H., et al. . 2015. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 160:1061&#x2013;1071. 10.1016/j.cell.2015.01.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Ulland T.K., Ulrich J.D., Song W., Tzaferis J.A., Hole J.T., Yuan P., Mahan T.E., Shi Y., Gilfillan S., et al. . 2016. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213:667&#x2013;675. 10.1084/jem.20151948</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K., Byers D.E., Jin X., Agapov E., Alexander-Brett J., Patel A.C., Cella M., Gilfilan S., Colonna M., Kober D.L., et al. . 2015. TREM-2 promotes macrophage survival and lung disease after respiratory viral infection. J. Exp. Med. 212:681&#x2013;697. 10.1084/jem.20141732</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20141732</ArticleId><ArticleId IdType="pmc">PMC4419356</ArticleId><ArticleId IdType="pubmed">25897174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderlich P., Glebov K., Kemmerling N., Tien N.T., Neumann H., and Walter J.. 2013. Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and &#x3b3;-secretase-dependent intramembranous cleavage. J. Biol. Chem. 288:33027&#x2013;33036. 10.1074/jbc.M113.517540</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.517540</ArticleId><ArticleId IdType="pmc">PMC3829152</ArticleId><ArticleId IdType="pubmed">24078628</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing J., Titus A.R., and Humphrey M.B.. 2015. The TREM2-DAP12 signaling pathway in Nasu-Hakola disease: a molecular genetics perspective. Res. Rep. Biochem. 5:89&#x2013;100. 10.2147/RRBC.S58057</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/RRBC.S58057</ArticleId><ArticleId IdType="pmc">PMC4605443</ArticleId><ArticleId IdType="pubmed">26478868</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh F.L., Wang Y., Tom I., Gonzalez L.C., and Sheng M.. 2016. TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron. 91:328&#x2013;340. 10.1016/j.neuron.2016.06.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.06.015</ArticleId><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh F.L., Hansen D.V., and Sheng M.. 2017. TREM2, Microglia, and Neurodegenerative Diseases. Trends Mol. Med. 23:512&#x2013;533. 10.1016/j.molmed.2017.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2017.03.008</ArticleId><ArticleId IdType="pubmed">28442216</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P., Condello C., Keene C.D., Wang Y., Bird T.D., Paul S.M., Luo W., Colonna M., Baddeley D., and Grutzendler J.. 2016. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron. 90:724&#x2013;739. 10.1016/j.neuron.2016.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.003</ArticleId><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L., Chen X.F., Wang T., Wang Z., Liao C., Wang Z., Huang R., Wang D., Li X., Wu L., et al. . 2017. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J. Exp. Med. 214:597&#x2013;607. 10.1084/jem.20160844</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20160844</ArticleId><ArticleId IdType="pmc">PMC5339672</ArticleId><ArticleId IdType="pubmed">28209725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29340569</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis.</ArticleTitle><Pagination><StartPage>328</StartPage><EndPage>341</EndPage><MedlinePgn>328-341</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.4198</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Late-onset Alzheimer disease (AD) is highly heritable. Genome-wide association studies have identified more than 20 AD risk genes. The precise mechanism through which many of these genes are associated with AD remains unknown.</AbstractText><AbstractText Label="OBJECTIVE">To investigate the association of the top 20 AD risk variants with brain amyloidosis.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This study analyzed the genetic and florbetapir F 18 data from 322 cognitively normal control individuals, 496 individuals with mild cognitive impairment, and 159 individuals with AD dementia who had genome-wide association studies and 18F-florbetapir positron emission tomographic data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a prospective, observational, multisite tertiary center clinical and biomarker study. This ongoing study began in 2005.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The study tested the association of AD risk allele carrier status (exposure) with florbetapir mean standard uptake value ratio (outcome) using stepwise multivariable linear regression while controlling for age, sex, and apolipoprotein E &#x3b5;4 genotype. The study also reports on an exploratory 3-dimensional stepwise regression model using an unbiased voxelwise approach in Statistical Parametric Mapping 8 with cluster and significance thresholds at 50 voxels and uncorrected P&#x2009;&lt;&#x2009;.01.</AbstractText><AbstractText Label="RESULTS">This study included 977 participants (mean [SD] age, 74 [7.5] years; 535 [54.8%] male and 442 [45.2%] female) from the ADNI-1, ADNI-2, and ADNI-Grand Opportunity. The adenosine triphosphate-binding cassette subfamily A member 7 (ABCA7) gene had the strongest association with amyloid deposition (&#x3c7;2&#x2009;=&#x2009;8.38, false discovery rate-corrected P &lt; .001), after apolioprotein E &#x3b5;4. Significant associations were found between ABCA7 in the asymptomatic and early symptomatic disease stages, suggesting an association with rapid amyloid accumulation. The fermitin family homolog 2 (FERMT2) gene had a stage-dependent association with brain amyloidosis (FERMT2 &#xd7; diagnosis &#x3c7;2&#x2009;=&#x2009;3.53, false discovery rate-corrected P =&#x2009;.05), which was most pronounced in the mild cognitive impairment stage.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study found an association of several AD risk variants with brain amyloidosis. The data also suggest that AD genes might differentially regulate AD pathologic findings across the disease stages.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Center for Neuroimaging, School of Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, School of Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Risacher</LastName><ForeName>Shannon L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Center for Neuroimaging, School of Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duran</LastName><ForeName>Tugce</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stage</LastName><ForeName>Eddie C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goukasian</LastName><ForeName>Naira</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Center for Neuroimaging, School of Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do</LastName><ForeName>Triet M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grotts</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilhalme</LastName><ForeName>Holly</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nho</LastName><ForeName>Kwangsik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Center for Neuroimaging, School of Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Meredith</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elashoff</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Center for Neuroimaging, School of Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, School of Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG040770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019771</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG057195</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 LM011384</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 AG048240</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036535</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG049050</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012535</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C411895">ABCA7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2018 Apr;14(4):194-195. doi: 10.1038/nrneurol.2018.13.</RefSource><PMID Version="1">29391583</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Apostolova reported serving on an advisory board for Eli Lilly and Company and on the speaker&#x2019;s bureau for Piramal and Eli Lilly and Company and receiving research support from GE Healthcare. Dr Saykin reported receiving research support from Eli Lilly and Company and AVID Radiopharmaceuticals. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29340569</ArticleId><ArticleId IdType="mid">NIHMS953324</ArticleId><ArticleId IdType="pmc">PMC5885860</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.4198</ArticleId><ArticleId IdType="pii">2669921</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wingo TS, Lah JJ, Levey AI, Cutler DJ. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol. 2012;69(1):59-64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3332307</ArticleId><ArticleId IdType="pubmed">21911656</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, Van Broeckhoven C. The pursuit of susceptibility genes for Alzheimer&#x2019;s disease: progress and prospects. Trends Genet. 2010;26(2):84-93.</Citation><ArticleIdList><ArticleId IdType="pubmed">20080314</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Zhou H, Atchison K, et al. . Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci. 2008;28(45):11445-11453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671315</ArticleId><ArticleId IdType="pubmed">18987181</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, et al. . apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118(12):4002-4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer&#x2019;s disease. Neuron. 2009;63(3):287-303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Liu X, et al. . Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68(11):1404-1411.</Citation><ArticleIdList><ArticleId IdType="pubmed">21747008</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, et al. . Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2009;106(16):6820-6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaris A, Hwang KS, Goukasian N, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB binding. Neurol Genet. 2015;1(3):e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4809461</ArticleId><ArticleId IdType="pubmed">27066559</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta VB, Laws SM, Villemagne VL, et al. ; AIBL Research Group . Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology. 2011;76(12):1091-1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">21422459</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, et al. . Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease [published correction appears in Nat Genet. 2009;45(6):712]. Nat Genet. 2009;41(10):1088-1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; CHARGE consortium; EADI1 consortium . Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):429-435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, et al. ; European Alzheimer&#x2019;s Disease Initiative Investigators . Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41(10):1094-1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, et al.  Meta-analysis of 74,538 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet.
2013;45(12):1452-1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, et al. . Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):436-441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, et al. ; CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium . Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832-1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, Chen K, Keenan BT, et al. . Genetic susceptibility for Alzheimer disease neuritic plaque pathology. JAMA Neurol. 2013;70(9):1150-1157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773291</ArticleId><ArticleId IdType="pubmed">23836404</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Koran ME, Thornton-Wells T; Alzheimer&#x2019;s Neuroimaging Initiative . Epistatic genetic effects among Alzheimer&#x2019;s candidate genes. PLoS One. 2013;8(11):e80839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832488</ArticleId><ArticleId IdType="pubmed">24260488</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes TM, Lopez OL, Evans RW, et al. . Markers of cholesterol transport are associated with amyloid deposition in the brain. Neurobiol Aging. 2014;35(4):802-807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896052</ArticleId><ArticleId IdType="pubmed">24199960</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, An Y, Nalls M, et al. ; Baltimore Longitudinal Study of Aging and the Alzheimer&#x2019;s Disease Neuroimaging Initiative . Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry. 2013;73(5):422-428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535537</ArticleId><ArticleId IdType="pubmed">23022416</ArticleId></ArticleIdList></Reference><Reference><Citation>Chibnik LB, Shulman JM, Leurgans SE, et al. . CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol. 2011;69(3):560-569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3066288</ArticleId><ArticleId IdType="pubmed">21391232</ArticleId></ArticleIdList></Reference><Reference><Citation>Braskie MN, Ringman JM, Thompson PM Neuroimaging measures as endophenotypes in Alzheimer's disease. Int J Alzheimers Dis 2011;2011:490140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087508</ArticleId><ArticleId IdType="pubmed">21547229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez LM, Goukasian N, Porat S, et al. . Common variants in ABCA7 and MS4A6A are associated with cortical and hippocampal atrophy. Neurobiol Aging. 2016;39:82-89.</Citation><ArticleIdList><ArticleId IdType="pubmed">26923404</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ, Shen L, Foroud TM, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Alzheimer&#x2019;s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement. 2010;6(3):265-273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868595</ArticleId><ArticleId IdType="pubmed">20451875</ArticleId></ArticleIdList></Reference><Reference><Citation>Potkin SG, Guffanti G, Lakatos A, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer&#x2019;s disease. PLoS One. 2009;4(8):e6501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719581</ArticleId><ArticleId IdType="pubmed">19668339</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, et al. . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122-131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, et al. . Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201-209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Negash S. Mild cognitive impairment: an overview. CNS Spectr. 2008;13(1):45-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18204414</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RCS, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303-308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939-944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. . Research criteria for the diagnosis of Alzheimer&#x2019;s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CRJA Jr, Albert MS, Knopman DS, et al. . Introduction to the recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):257-262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096735</ArticleId><ArticleId IdType="pubmed">21514247</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MFF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>D. W. Wechsler Memory Scale&#x2013;Revised. San Antonio, TX: Psychological Corp; 1987.</Citation></Reference><Reference><Citation>Nho K, Corneveaux JJ, Kim S, et al. ; Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study; AddNeuroMed Consortium; Indiana Memory and Aging Study; Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) . Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Mol Psychiatry. 2013;18(7):781-787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777294</ArticleId><ArticleId IdType="pubmed">23608917</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Bandy D, Chen K, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . The Alzheimer&#x2019;s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010;6(3):221-229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920531</ArticleId><ArticleId IdType="pubmed">20451870</ArticleId></ArticleIdList></Reference><Reference><Citation>Risacher SL, Kim S, Shen L, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) . The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci. 2013;5:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612590</ArticleId><ArticleId IdType="pubmed">23554593</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaike H. Information theory and an extension of the maximum likelihood principle In: Parzen E, Tanabe K, Kitagawa G, eds. Selected Papers of Hirotugu Akaike. Springer Series in Statistics (Perspectives in Statistics). New York, NY: Springer; 1998.</Citation></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . The Alzheimer&#x2019;s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012;8(1)(suppl):S1-S68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329969</ArticleId><ArticleId IdType="pubmed">22047634</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuchnoi P, Nantakomol D, Chumchua V, Plabplueng C, Isarankura-Na-Ayudhya C, Prachayasittikul V. The Identification of functional non-synonymous SNP in human ATP-binding cassette (ABC), subfamily member 7 gene: application of bioinformatics tools in biomedicine. J Bioanal Biomed. 2011;3(1):26-31.</Citation></Reference><Reference><Citation>Li H, Karl T, Garner B. Understanding the function of ABCA7 in Alzheimer&#x2019;s disease. Biochem Soc Trans. 2015;43(5):920-923.</Citation><ArticleIdList><ArticleId IdType="pubmed">26517904</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh K, Abe-Dohmae S, Yokoyama S, St George-Hyslop P, Fraser PE. ATP-binding cassette transporter A7 (ABCA7) loss of function alters Alzheimer amyloid processing. J Biol Chem. 2015;290(40):24152-24165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4591804</ArticleId><ArticleId IdType="pubmed">26260791</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao QF, Wan Y, Wang HF, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . ABCA7 genotypes confer Alzheimer&#x2019;s disease risk by modulating amyloid-&#x3b2; pathology. J Alzheimers Dis. 2016;52(2):693-703.</Citation><ArticleIdList><ArticleId IdType="pubmed">27003212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sassi C, Nalls MA, Ridge PG, et al. ; ARUK Consortium . ABCA7 p.G215S as potential protective factor for Alzheimer&#x2019;s disease. Neurobiol Aging. 2016;46:235.e1-235.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024078</ArticleId><ArticleId IdType="pubmed">27289440</ArticleId></ArticleIdList></Reference><Reference><Citation>Stage E, Duran T, Risacher SL, et al. . The effect of the top 20 Alzheimer disease risk genes on gray-matter density and FDG PET brain metabolism. Alzheimers Dement (Amst). 2016;5:53-66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5198883</ArticleId><ArticleId IdType="pubmed">28054028</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy BF, Kirszbaum L, Walker ID, d&#x2019;Apice AJ. SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. J Clin Invest. 1988;81(6):1858-1864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC442636</ArticleId><ArticleId IdType="pubmed">2454950</ArticleId></ArticleIdList></Reference><Reference><Citation>Danik M, Chabot JG, Hassan-Gonzalez D, Suh M, Quirion R. Localization of sulfated glycoprotein-2/clusterin mRNA in the rat brain by in situ hybridization. J Comp Neurol. 1993;334(2):209-227.</Citation><ArticleIdList><ArticleId IdType="pubmed">8366194</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong P, Pineault J, Lakins J, et al. . Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. J Biol Chem. 1993;268(7):5021-5031.</Citation><ArticleIdList><ArticleId IdType="pubmed">7680346</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeg M, Stravalaci M, Romeo M, et al. . Clusterin binds to A&#x3b2;1-42 oligomers with high affinity and interferes with peptide aggregation by inhibiting primary and secondary nucleation. J Biol Chem. 2016;291(13):6958-6966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4807280</ArticleId><ArticleId IdType="pubmed">26884339</ArticleId></ArticleIdList></Reference><Reference><Citation>Duguid JR, Bohmont CW, Liu NG, Tourtellotte WW. Changes in brain gene expression shared by scrapie and Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86(18):7260-7264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298037</ArticleId><ArticleId IdType="pubmed">2780570</ArticleId></ArticleIdList></Reference><Reference><Citation>Miners JS, Clarke P, Love S. Clusterin levels are increased in Alzheimer&#x2019;s disease and influence the regional distribution of A&#x3b2;. Brain Pathol. 2017;27(3):305-313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029153</ArticleId><ArticleId IdType="pubmed">27248362</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamekura R, Nava P, Feng M, et al. . Inflammation-induced desmoglein-2 ectodomain shedding compromises the mucosal barrier. Mol Biol Cell. 2015;26(18):3165-3177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4569309</ArticleId><ArticleId IdType="pubmed">26224314</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch PJ, Goldschmidt MD, Walsh MJ, Zimbelmann R, Franke WW. Complete amino acid sequence of the epidermal desmoglein precursor polypeptide and identification of a second type of desmoglein gene. Eur J Cell Biol. 1991;55(2):200-208.</Citation><ArticleIdList><ArticleId IdType="pubmed">1935985</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Li ZY, Liu Y, et al. . Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med. 2011;17(1):96-104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074512</ArticleId><ArticleId IdType="pubmed">21151137</ArticleId></ArticleIdList></Reference><Reference><Citation>Besco JA, Hooft van Huijsduijnen R, Frostholm A, Rotter A. Intracellular substrates of brain-enriched receptor protein tyrosine phosphatase rho (RPTPrho/PTPRT). Brain Res. 2006;1116(1):50-57.</Citation><ArticleIdList><ArticleId IdType="pubmed">16973135</ArticleId></ArticleIdList></Reference><Reference><Citation>Kljuic A, Christiano AM. A novel mouse desmosomal cadherin family member, desmoglein 1 gamma. Exp Dermatol. 2003;12(1):20-29.</Citation><ArticleIdList><ArticleId IdType="pubmed">12631243</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata S, Yoshikawa K, Taniguchi M, et al. . Sgk1 regulates desmoglein 1 expression levels in oligodendrocytes in the mouse corpus callosum after chronic stress exposure. Biochem Biophys Res Commun. 2015;464(1):76-82.</Citation><ArticleIdList><ArticleId IdType="pubmed">26043694</ArticleId></ArticleIdList></Reference><Reference><Citation>Maru Y, Hirai H, Yoshida MC, Takaku F. Evolution, expression, and chromosomal location of a novel receptor tyrosine kinase gene, eph. Mol Cell Biol. 1988;8(9):3770-3776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC365435</ArticleId><ArticleId IdType="pubmed">3221865</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Masuda J, Omori T, Usui R, Akiyama H, Maru Y. EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility. J Cell Sci. 2009;122(Pt 2):243-255.</Citation><ArticleIdList><ArticleId IdType="pubmed">19118217</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wang Y, Zhou M, et al. . EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma. Oncol Rep. 2010;23(2):563-570.</Citation><ArticleIdList><ArticleId IdType="pubmed">20043122</ArticleId></ArticleIdList></Reference><Reference><Citation>Torii M, Hashimoto-Torii K, Levitt P, Rakic P. Integration of neuronal clones in the radial cortical columns by EphA and ephrin-A signalling. Nature. 2009;461(7263):524-528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874978</ArticleId><ArticleId IdType="pubmed">19759535</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori M, Osterfield M, Flanagan JG. Regulated cleavage of a contact-mediated axon repellent. Science. 2000;289(5483):1360-1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">10958785</ArticleId></ArticleIdList></Reference><Reference><Citation>Noberini R, Rubio de la Torre E, Pasquale EB. Profiling Eph receptor expression in cells and tissues: a targeted mass spectrometry approach. Cell Adh Migr. 2012;6(2):102-112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3499309</ArticleId><ArticleId IdType="pubmed">22568954</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HF, Tan L, Hao XK, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Effect of EPHA1 genetic variation on cerebrospinal fluid and neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer&#x2019;s disease cohorts. J Alzheimers Dis. 2015;44(1):115-123.</Citation><ArticleIdList><ArticleId IdType="pubmed">25182741</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein EJ, Bourner M, Head R, Zakeri H, Bauer C, Mazzarella R. URP1: a member of a novel family of PH and FERM domain-containing membrane-associated proteins is significantly over-expressed in lung and colon carcinomas. Biochim Biophys Acta. 2003;1637(3):207-216.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697302</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu Y, Wu S, Shi X, Chen K, Wu C. Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. Cell. 2003;113(1):37-47.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679033</ArticleId></ArticleIdList></Reference><Reference><Citation>Oksala N, P&#xe4;rssinen J, Sepp&#xe4;l&#xe4; I, et al. . Kindlin 3 (FERMT3) is associated with unstable atherosclerotic plaques, anti-inflammatory type II macrophages and upregulation of beta-2 integrins in all major arterial beds. Atherosclerosis. 2015;242(1):145-154.</Citation><ArticleIdList><ArticleId IdType="pubmed">26188538</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma YQ, Qin J, Wu C, Plow EF. Kindlin-2 (Mig-2): a co-activator of beta3 integrins. J Cell Biol. 2008;181(3):439-446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2364684</ArticleId><ArticleId IdType="pubmed">18458155</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison JA, Velier JJ, Spera P, et al. . Osteopontin and its integrin receptor &#x3b1;(v)&#x3b2;3 are upregulated during formation of the glial scar after focal stroke. Stroke. 1998;29(8):1698-1706.</Citation><ArticleIdList><ArticleId IdType="pubmed">9707214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang WS, Choi JS, Shin YJ, et al. . Differential regulation of osteopontin receptors, CD44 and the &#x3b1;(v) and &#x3b2;(3) integrin subunits, in the rat hippocampus following transient forebrain ischemia. Brain Res. 2008;1228:208-216.</Citation><ArticleIdList><ArticleId IdType="pubmed">18638458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Lopez OL, Sweet RA, et al. . Genetic determinants of disease progression in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2015;43(2):649-655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4245313</ArticleId><ArticleId IdType="pubmed">25114068</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, Imboywa S, Giagtzoglou N, et al. . Functional screening in Drosophila identifies Alzheimer&#x2019;s disease susceptibility genes and implicates tau-mediated mechanisms. Hum Mol Genet. 2014;23(4):870-877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900103</ArticleId><ArticleId IdType="pubmed">24067533</ArticleId></ArticleIdList></Reference><Reference><Citation>Tebar F, Bohlander SK, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell. 1999;10(8):2687-2702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25500</ArticleId><ArticleId IdType="pubmed">10436022</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharesouran J, Rezazadeh M, Khorrami A, Ghojazadeh M, Talebi M. Genetic evidence for the involvement of variants at APOE, BIN1, CR1, and PICALM loci in risk of late-onset Alzheimer&#x2019;s disease and evaluation for interactions with APOE genotypes. J Mol Neurosci. 2014;54(4):780-786.</Citation><ArticleIdList><ArticleId IdType="pubmed">25022885</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Q, Gil SC, Yan P, et al. . Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. J Biol Chem. 2012;287(25):21279-21289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375549</ArticleId><ArticleId IdType="pubmed">22539346</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau K, Fleming A, Imarisio S, et al. . PICALM modulates autophagy activity and tau accumulation. Nat Commun. 2014;5:4998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4199285</ArticleId><ArticleId IdType="pubmed">25241929</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgen K, Ramirez A, Fr&#xf6;lich L, et al. . Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer&#x2019;s disease. Alzheimers Dement. 2014;10(5)(suppl):S269-S276.</Citation><ArticleIdList><ArticleId IdType="pubmed">24613704</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi A, Anderson CD, Desikan RS, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) . Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol. 2010;67(6):677-685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956757</ArticleId><ArticleId IdType="pubmed">20558387</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen L, Madsen P, Moestrup SK, et al. . Molecular characterization of a novel human hybrid-type receptor that binds the alpha2-macroglobulin receptor-associated protein. J Biol Chem. 1996;271(49):31379-31383.</Citation><ArticleIdList><ArticleId IdType="pubmed">8940146</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen L, Madsen P, Jacobsen C, Nielsen MS, Gliemann J, Petersen CM. Activation and functional characterization of the mosaic receptor SorLA/LR11. J Biol Chem. 2001;276(25):22788-22796.</Citation><ArticleIdList><ArticleId IdType="pubmed">11294867</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, et al. . The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168-177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Offe K, Gearing M, et al. . Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004;61(8):1200-1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager KL, Wuu J, Leurgans SE, et al. . Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. Ann Neurol. 2007;62(6):640-647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669325</ArticleId><ArticleId IdType="pubmed">17721864</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos P, Guo LH, Tsolakidou A, et al. . Interrelations between CSF soluble A&#x3b2;PP&#x3b2;, amyloid-&#x3b2; 1-42, SORL1, and tau levels in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2012;28(3):543-552.</Citation><ArticleIdList><ArticleId IdType="pubmed">22045485</ArticleId></ArticleIdList></Reference><Reference><Citation>Assareh AA, Piguet O, Lye TC, et al. . Association of SORL1 gene variants with hippocampal and cerebral atrophy and Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2014;11(6):558-563.</Citation><ArticleIdList><ArticleId IdType="pubmed">24938503</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Hamilton K, Naj AC, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium (ADGC) . Genome-wide association meta-analysis of neuropathologic features of Alzheimer&#x2019;s disease and related dementias. PLoS Genet. 2014;10(9):e1004606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>He F, Umehara T, Saito K, et al. . Structural insight into the zinc finger CW domain as a histone modification reader. Structure. 2010;18(9):1127-1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">20826339</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Kachadoorian M, Carrasquillo MM, et al. . Late-onset Alzheimer disease risk variants mark brain regulatory loci. Neurol Genet. 2015;1(2):e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4807909</ArticleId><ArticleId IdType="pubmed">27066552</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM. Expression of novel Alzheimer&#x2019;s disease risk genes in control and Alzheimer&#x2019;s disease brains. PLoS One. 2012;7(11):e50976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511432</ArticleId><ArticleId IdType="pubmed">23226438</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29335605</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Dietary salt promotes neurovascular and cognitive dysfunction through a gut-initiated TH17 response.</ArticleTitle><Pagination><StartPage>240</StartPage><EndPage>249</EndPage><MedlinePgn>240-249</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-017-0059-z</ELocationID><Abstract><AbstractText>A diet rich in salt is linked to an increased risk of cerebrovascular diseases and dementia, but it remains unclear how dietary salt harms the brain. We report that, in mice, excess dietary salt suppresses resting cerebral blood flow and endothelial function, leading to cognitive impairment. The effect depends on expansion of TH17 cells in the small intestine, resulting in a marked increase in plasma interleukin-17 (IL-17). Circulating IL-17, in turn, promotes endothelial dysfunction and cognitive impairment by the Rho kinase-dependent inhibitory phosphorylation of endothelial nitric oxide synthase and reduced nitric oxide production in cerebral endothelial cells. The findings reveal a new gut-brain axis linking dietary habits to cognitive impairment through a gut-initiated adaptive immune response compromising brain function via circulating IL-17. Thus, the TH17 cell-IL-17 pathway is a putative target to counter the deleterious brain effects induced by dietary salt and other diseases associated with TH17 polarization.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faraco</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brea</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Bonilla</LastName><ForeName>Lidia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Racchumi</LastName><ForeName>Gianfranco</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Haejoo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buendia</LastName><ForeName>Izaskun</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santisteban</LastName><ForeName>Monica M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segarra</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koizumi</LastName><ForeName>Kenzo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiyama</LastName><ForeName>Yukio</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Henning</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2811-2074</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anrather</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iadecola</LastName><ForeName>Costantino</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA. coi2001@med.cornell.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS095441</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS089323</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000577">Amides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017673">Sodium Chloride, Dietary</NameOfSubstance></Chemical><Chemical><RegistryNumber>128559-51-3</RegistryNumber><NameOfSubstance UI="C064658">RAG-1 protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>138381-45-0</RegistryNumber><NameOfSubstance UI="C108830">Y 27632</NameOfSubstance></Chemical><Chemical><RegistryNumber>N9YNS0M02X</RegistryNumber><NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2018 Feb;21(2):154-155. doi: 10.1038/s41593-018-0068-6.</RefSource><PMID Version="1">29371655</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2018 Feb 16;19(3):122. doi: 10.1038/nrn.2018.15.</RefSource><PMID Version="1">29449716</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000577" MajorTopicYN="N">Amides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016764" MajorTopicYN="N">Cell Polarity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018398" MajorTopicYN="N">Homeodomain Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007421" MajorTopicYN="N">Intestine, Small</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069336" MajorTopicYN="N">Neurovascular Coupling</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017673" MajorTopicYN="N">Sodium Chloride, Dietary</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058504" MajorTopicYN="N">Th17 Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29335605</ArticleId><ArticleId IdType="mid">NIHMS988587</ArticleId><ArticleId IdType="pmc">PMC6207376</ArticleId><ArticleId IdType="doi">10.1038/s41593-017-0059-z</ArticleId><ArticleId IdType="pii">10.1038/s41593-017-0059-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mozaffarian D et al. Global sodium consumption and death from cardiovascular causes. N. Engl. J. Med 371, 624&#x2013;634 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25119608</ArticleId></ArticleIdList></Reference><Reference><Citation>Zemel MB &amp; Sowers JR Salt sensitivity and systemic hypertension in the elderly. Am. J. Cardiol 61, 7H&#x2013;12H (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3289354</ArticleId></ArticleIdList></Reference><Reference><Citation>Farquhar WB, Edwards DG, Jurkovitz CT &amp; Weintraub WS Dietary sodium and health: more than just blood pressure. J. Am. Coll. Cardiol 65, 1042&#x2013;1050 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5098396</ArticleId><ArticleId IdType="pubmed">25766952</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel LJ et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation 123, 1138&#x2013;1143 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21233236</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine (US) Committee on Strategies to Reduce Sodium Intake Strategies to Reduce Sodium Intake in the United States. (Henney JE, Taylor CL &amp; Boon CS eds.) (National Academies Press, Washington DC, 2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21210559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotchen TA, Cowley AW Jr. &amp; Frohlich ED Salt in health and disease&#x2014;a delicate balance. N. Engl. J. Med 368, 1229&#x2013;1237 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23534562</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls MG Population-wide dietary sodium restriction: a cautious view. Curr. Hypertens. Rep 13, 325&#x2013;327 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21681383</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh YS et al. National Heart, Lung, and Blood Institu te Working Group report on salt in human health and sickness: building on the current scientific evidence. Hypertension 68, 281&#x2013;288 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4945367</ArticleId><ArticleId IdType="pubmed">27324228</ArticleId></ArticleIdList></Reference><Reference><Citation>Heye AK et al. Blood pressure and sodium: association with MRI markers in cerebral small vessel disease. J. Cereb. Blood Flow. Metab 36, 264&#x2013;274 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758556</ArticleId><ArticleId IdType="pubmed">25899292</ArticleId></ArticleIdList></Reference><Reference><Citation>Strazzullo P, D&#x2019;Elia L, Kandala N-B &amp; Cappuccio FP Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. Br. Med. J 339, b4567 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782060</ArticleId><ArticleId IdType="pubmed">19934192</ArticleId></ArticleIdList></Reference><Reference><Citation>Boegehold MA The effect of high salt intake on endothelial function: reduced vascular nitric oxide in the absence of hypertension. J. Vasc. Res 50, 458&#x2013;467 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24192502</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosic A et al. Attenuated flow-induced dilatation of middle cerebral arteries is related to increased vascular oxidative stress in rats on a short-term high salt diet. J. Physiol. (Lond.) 594, 4917&#x2013;4931 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009804</ArticleId><ArticleId IdType="pubmed">27061200</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron 96, 17&#x2013;42 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657612</ArticleId><ArticleId IdType="pubmed">28957666</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C The pathobiology of vascular dementia. Neuron 80, 844&#x2013;866 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842016</ArticleId><ArticleId IdType="pubmed">24267647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinewietfeld M et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496, 518&#x2013;522 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746493</ArticleId><ArticleId IdType="pubmed">23467095</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 496, 513&#x2013;517 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637879</ArticleId><ArticleId IdType="pubmed">23467085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kebir H et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med 13, 1173&#x2013;1175 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5114125</ArticleId><ArticleId IdType="pubmed">17828272</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H et al. Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc. Res 97, 696&#x2013;704 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3583258</ArticleId><ArticleId IdType="pubmed">23263331</ArticleId></ArticleIdList></Reference><Reference><Citation>Powles J et al. Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open. 3, e003733 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3884590</ArticleId><ArticleId IdType="pubmed">24366578</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochet H et al. Comprehensive phenotyping of salt-induced hypertensive heart disease in living mice using cardiac magnetic resonance. Eur. Radiol 23, 332&#x2013;338 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22836163</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlote J et al. Cardiovascular and renal effects of high salt diet in GDNF+/&#x2212; mice with low nephron number. Kidney Blood Press. Res 37, 379&#x2013;391 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24247178</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackman KA et al. Dichotomous effects of chronic intermittent hypoxia on focal cerebral ischemic injury. Stroke 45, 1460&#x2013;1467 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4006286</ArticleId><ArticleId IdType="pubmed">24713530</ArticleId></ArticleIdList></Reference><Reference><Citation>Toda N, Ayajiki K &amp; Okamura T Cerebral blood flow regulation by nitric oxide: recent advances. Pharmacol. Rev 61, 62&#x2013;97 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19293146</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G et al. Angiotensin II slow-pressor hypertension enhances NMDA currents and NOX2-dependent superoxide production in hypothalamic paraventricular neurons. Am. J. Physiol. Regul. Integr. Comp. Physiol 304, R1096&#x2013;R1106 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680791</ArticleId><ArticleId IdType="pubmed">23576605</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen BR, Kozberg MG, Bouchard MB, Shaik MA &amp; Hillman EMC A critical role for the vascular endothelium in functional neurovascular coupling in the brain. J. Am. Heart Assoc 3, e000787 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4309064</ArticleId><ArticleId IdType="pubmed">24926076</ArticleId></ArticleIdList></Reference><Reference><Citation>Poggesi A, Pasi M, Pescini F, Pantoni L &amp; Inzitari D Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: a review. J. Cereb. Blood Flow. Metab. 36, 72&#x2013;94 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758546</ArticleId><ArticleId IdType="pubmed">26058695</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SJ et al. The rodent hippocampus is essential for nonspatial object memory. Curr. Biol 23, 1685&#x2013;1690 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3775586</ArticleId><ArticleId IdType="pubmed">23954431</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes CA Memory deficts associated with senescence: a neurophysiological and behavioral study in the rat. J. Comp. Physiol. Psychol 93, 74&#x2013;104 (1979).</Citation><ArticleIdList><ArticleId IdType="pubmed">221551</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon RM Assessing nest building in mice. Nat. Protoc 1, 1117&#x2013;1119 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17406392</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum WI, Nelson GH &amp; Shimizu T L-Arginine suffusion restores response to acetylcholine in brain arterioles with damaged endothelium. Am. J. Physiol 262, H961&#x2013;H964(1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1566916</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris MB et al. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J. Biol. Chem 276, 16587&#x2013;16591 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11340086</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith L, Payne JA, Sedeek MH, Granger JP &amp; Khalil RA Endothelin-induced increases in Ca2+ entry mechanisms of vascular contraction are enhanced during high-salt diet. Hypertension 41, 787&#x2013;793 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12623997</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraco G et al. Circulating endothelin-1 alters critical mechanisms regulating cerebral microcirculation. Hypertension 62, 759&#x2013;766 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3874144</ArticleId><ArticleId IdType="pubmed">23959559</ArticleId></ArticleIdList></Reference><Reference><Citation>Benakis C et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal &#x3b3;&#x3b4; T cells. Nat. Med 22, 516&#x2013;523 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860105</ArticleId><ArticleId IdType="pubmed">27019327</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez AL et al. Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells. J. Clin. Invest 125, 4212&#x2013;4222 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4639983</ArticleId><ArticleId IdType="pubmed">26524592</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipnis J Multifaceted interactions between adaptive immunity and the central nervous system. Science 353, 766&#x2013;771 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5590839</ArticleId><ArticleId IdType="pubmed">27540163</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraco G et al. Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension. J. Clin. Invest 126, 4674&#x2013;4689 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127678</ArticleId><ArticleId IdType="pubmed">27841763</ArticleId></ArticleIdList></Reference><Reference><Citation>Binger KJ et al. High salt reduces the activation of IL-4- and IL-13-stimulated macrophages. J. Clin. Invest 125, 4223&#x2013;4238 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4639967</ArticleId><ArticleId IdType="pubmed">26485286</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandala S et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296, 346&#x2013;349 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11923495</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto M et al. Rho-kinase phosphorylates eNOS at threonine 495 in endothelial cells. Biochem. Biophys. Res. Commun 361, 462&#x2013;467 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17651694</ArticleId></ArticleIdList></Reference><Reference><Citation>Guterbaum TJ et al. Endothelial nitric oxide synthase phosphorylation at Threonine 495 and mitochondrial reactive oxygen species formation in response to a high H2O2 concentration. J. Vasc. Res 50, 410&#x2013;420 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24008236</ArticleId></ArticleIdList></Reference><Reference><Citation>Katusic ZS &amp; Austin SA Endothelial nitric oxide: protector of a healthy mind. Eur. Heart J. 35, 888&#x2013;894 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3977136</ArticleId><ArticleId IdType="pubmed">24357508</ArticleId></ArticleIdList></Reference><Reference><Citation>Love S &amp; Miners JS Cerebral hypoperfusion and the energy defict in Alzheimer&#x2019;s disease. Brain Pathol 26, 607&#x2013;617 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8028913</ArticleId><ArticleId IdType="pubmed">27327656</ArticleId></ArticleIdList></Reference><Reference><Citation>Garthwaite J Concepts of neural nitric oxide-mediated transmission. Eur. J. Neurosci 27, 2783&#x2013;2802 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2610389</ArticleId><ArticleId IdType="pubmed">18588525</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu C, Wu L &amp; Li X IL-17 family: cytokines, receptors and signaling. Cytokine 64, 477&#x2013;485 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867811</ArticleId><ArticleId IdType="pubmed">24011563</ArticleId></ArticleIdList></Reference><Reference><Citation>Tablazon ILD, Al-Dabagh A, Davis SA &amp; Feldman SR Risk of cardiovascular disorders in psoriasis patients: current and future. Am. J. Clin. Dermatol 14, 1&#x2013;7 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23329076</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou T-H et al. Risk of stroke in patients with rheumatism: a nationwide longitudinal population-based study. Sci. Rep 4, 5110 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046260</ArticleId><ArticleId IdType="pubmed">24898360</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferro JM, Oliveira SN &amp; Correia L Neurologic manifestations of inflammatory bowel diseases. Handb. Clin. Neurol 120, 595&#x2013;605 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall O et al. Impaired cerebrovascular reactivity in multiple sclerosis. JAMA Neurol 71, 1275&#x2013;1281 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4376108</ArticleId><ArticleId IdType="pubmed">25133874</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L et al. Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta. Proc. Natl. Acad. Sci. USA 108, 5063&#x2013;5068 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064396</ArticleId><ArticleId IdType="pubmed">21383152</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29356823</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of &#x3b2;-Amyloid and Apolipoprotein E &#x3b5;4 With Memory Decline in Preclinical Alzheimer Disease.</ArticleTitle><Pagination><StartPage>488</StartPage><EndPage>494</EndPage><MedlinePgn>488-494</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.4325</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Older age, high levels of &#x3b2;-amyloid (A&#x3b2;), and the presence of the apolipoprotein E (APOE) &#x3b5;4 allele are risk factors for Alzheimer disease (AD). However, the extent to which increasing age, A&#x3b2;, and &#x3b5;4 are associated with memory decline remains unclear, and the age at which memory decline begins for A&#x3b2;-positive &#x3b5;4 carriers and noncarriers has not been determined.</AbstractText><AbstractText Label="OBJECTIVE">To determine the association of age, A&#x3b2; level, and APOE &#x3b5;4 with memory decline in a large group of cognitively healthy older adults.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This longitudinal observational study included cognitively healthy older adults (age &gt;60 years) enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study from March 31, 2006, through March 31, 2017; of 1583 individuals enrolled, 1136 refused or were excluded owing to other criteria (eg, having mild cognitive impairment or AD). Participants underwent A&#x3b2; imaging in research clinics in Perth and Melbourne and more than 72 months of follow-up (at 18-month intervals). The association of age with memory was fitted to a quadratic model. Age was treated as a continuous, time-dependent variable.</AbstractText><AbstractText Label="EXPOSURES">&#x3b2;-Amyloid imaging using positron emission tomography, genotyping for APOE &#x25b;4, and longitudinal neuropsychological assessments of episodic memory during the 72-month follow-up.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Episodic memory composite score.</AbstractText><AbstractText Label="RESULTS">Of the 447 participants, 203 (45.4%) were men and 244 (54.6%) were women; mean (SD) age was 72.5 (6.6) years. Equal proportions of female participants were observed in each A&#x3b2;-&#x25b;4 group (24 of 51 A&#x3b2;-positive &#x3b5;4 noncarriers [47.1%] ; 35 of 64 A&#x3b2;-negative &#x3b5;4 carriers [54.7%]; 40 of 72 A&#x3b2;-positive &#x3b5;4 carriers [55.6%]; and 145 of 260 A&#x3b2;-negative &#x3b5;4 noncarriers [55.8%]). Adults with A&#x3b2; findings (mean [SD] age, 74.4 [6.8] years) were approximately 4 years older than those negative for A&#x3b2; (mean [SD] age, 69.8 [6.1] years). Memory decline diverged significantly from A&#x3b2;-negative &#x25b;4 noncarriers at an earlier age in A&#x3b2;-positive &#x25b;4 carriers (64.5 years) than in A&#x3b2;-positive &#x25b;4 noncarriers (76.5 years), such that by 85 years of age, A&#x3b2;-positive &#x3b5;4 carriers performed approximately 1.5 SD units worse on the episodic memory composite than A&#x3b2;-negative &#x3b5;4 noncarriers and approximately 0.8 SD units worse than A&#x3b2;-positive &#x3b5;4 noncarriers. Memory performance of A&#x3b2;-negative &#x25b;4 carriers did not differ from that of the A&#x3b2;-negative &#x25b;4 noncarriers (estimate [SE], 0.001 [0.001]; t&#x2009;=&#x2009;0.526; P&#x2009;=&#x2009;.77).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Prior work has shown that A&#x3b2; and &#x3b5;4 combine to influence memory decline in nondemented older adults. Results of this study indicate that increasing age may further exacerbate these effects. The estimates provided may be used to determine the risk of memory decline associated with A&#x3b2; and &#x3b5;4 at each age.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Yen Ying</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalinowski</LastName><ForeName>Pawel</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CogState, Ltd, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietrzak</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laws</LastName><ForeName>Simon M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cooperative Research Centre for Mental Health, Carlton, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnham</LastName><ForeName>Samantha C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Commonwealth Scientific and Industrial Research Organisation Preventative Health National Research Flagship, Australian e-Health Research Centre, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Academic Unit for Psychiatry of Old Age, St Vincent's Health, University of Melbourne, Kew, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Ageing Research Institute, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET (Positron Emission Tomography), Austin Health, Heidelberg, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fowler</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rainey-Smith</LastName><ForeName>Stephanie R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET (Positron Emission Tomography), Austin Health, Heidelberg, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruff</LastName><ForeName>Paul T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CogState, Ltd, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2018 Mar;14(3):125. doi: 10.1038/nrneurol.2018.16.</RefSource><PMID Version="1">29422646</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="N">Asymptomatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Lim reports serving as a scientific consultant to CogState, Ltd, Biogen, and Lundbeck. Dr Pietrzak reports serving as a scientific consultant to CogState, Ltd. Dr Villemagne reports serving as a consultant for Bayer Pharma and receiving research support from a New Energy and Industrial Technology Development Organization grant from Japan. Dr Masters reports serving as an advisor to Prana Biotechnology, Ltd, and a consultant to Eli Lilly and Company. Dr Rowe reports serving on scientific advisory boards for Bayer Pharma, Elan Corporation, GE Healthcare, and AstraZeneca; receiving speaker honoraria from Bayer Pharma and GE Healthcare; and receiving research support from Bayer Pharma, GE Healthcare, Piramal Lifesciences, and Avid Radiopharmaceuticals not related to the content of the manuscript. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29356823</ArticleId><ArticleId IdType="pmc">PMC5933393</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.4325</ArticleId><ArticleId IdType="pii">2670442</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/&#x3b2;-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Maruff P, Pietrzak RH, et al. ; AIBL Research Group . Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer&#x2019;s disease. Brain. 2014;137(pt 1):221-231.</Citation><ArticleIdList><ArticleId IdType="pubmed">24176981</ArticleId></ArticleIdList></Reference><Reference><Citation>Doraiswamy PM, Sperling RA, Johnson K, et al. ; AV45-A11 Study Group; AV45-A11 Study Group . Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014;19(9):1044-1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4195975</ArticleId><ArticleId IdType="pubmed">24614494</ArticleId></ArticleIdList></Reference><Reference><Citation>Dor&#xe9; V, Villemagne VL, Bourgeat P, et al. . Cross-sectional and longitudinal analysis of the relationship between A&#x3b2; deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol. 2013;70(7):903-911.</Citation><ArticleIdList><ArticleId IdType="pubmed">23712469</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. ; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group . Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Bourgeat P, Ellis KA, et al. . Predicting Alzheimer disease with &#x3b2;-amyloid imaging: results from the Australian Imaging, Biomarkers, and Lifestyle study of ageing. Ann Neurol. 2013;74(6):905-913.</Citation><ArticleIdList><ArticleId IdType="pubmed">24448836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. ; Amyloid PET Study Group . Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939-1949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517678</ArticleId><ArticleId IdType="pubmed">25988463</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261(5123):921-923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study . Amyloid and APOE &#x3b5;4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760-1767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Villemagne VL, Pietrzak RH, et al. ; Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group . APOE &#x3b5;4 moderates amyloid-related memory decline in preclinical Alzheimer&#x2019;s disease. Neurobiol Aging. 2015;36(3):1239-1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">25559335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Laws SM, Villemagne VL, et al. . A&#x3b2;-related memory decline in APOE &#x3b5;4 noncarriers: implications for Alzheimer disease. Neurology. 2016;86(17):1635-1642.</Citation><ArticleIdList><ArticleId IdType="pubmed">27029632</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Age, sex, and APOE &#x3b5;4 effects on memory, brain structure, and &#x3b2;-amyloid across the adult life span. JAMA Neurol. 2015;72(5):511-519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428984</ArticleId><ArticleId IdType="pubmed">25775353</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Dueck AC, Osborne D, et al. . Longitudinal modeling of age-related memory decline and the APOE &#x3b5;4 effect. N Engl J Med. 2009;361(3):255-263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928998</ArticleId><ArticleId IdType="pubmed">19605830</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Dueck AC, Locke DE, et al. . Longitudinal modeling of frontal cognition in APOE &#x3b5;4 homozygotes, heterozygotes, and noncarriers. Neurology. 2011;76(16):1383-1388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087407</ArticleId><ArticleId IdType="pubmed">21502596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis KA, Bush AI, Darby D, et al. ; AIBL Research Group . The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer&#x2019;s disease. Int Psychogeriatr. 2009;21(4):672-687.</Citation><ArticleIdList><ArticleId IdType="pubmed">19470201</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. . Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong DF, Rosenberg PB, Zhou Y, et al. . In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913-920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101877</ArticleId><ArticleId IdType="pubmed">20501908</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberghe R, Van Laere K, Ivanoiu A, et al. . 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319-329.</Citation><ArticleIdList><ArticleId IdType="pubmed">20687209</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, et al. ; AV45-A07 Study Group . Use of florbetapir-PET for imaging &#x3b2;-amyloid pathology. JAMA. 2011;305(3):275-283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Dor&#xe9; V, Yates P, et al. . En attendant centiloid. Adv Res. 2014;2(12):723-729.</Citation></Reference><Reference><Citation>Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test&#x2013;Second Edition (CVLT-II). San Antonio, TX: Psychological Corp; 2000.</Citation></Reference><Reference><Citation>Wechsler D. WMS-R: Wechsler Memory Scale&#x2013;Revised. San Antonio, TX: Psychological Corp; 1987.</Citation></Reference><Reference><Citation>Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition Trial: Professional Manual. Lutz, FL: Psychological Assessment Resource Inc; 1995.</Citation></Reference><Reference><Citation>Cumming G. Inference by eye: reading the overlap of independent confidence intervals. Stat Med. 2009;28(2):205-220.</Citation><ArticleIdList><ArticleId IdType="pubmed">18991332</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 2004;25(5):641-650.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172743</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Xu H, Bu G. ApoE and A&#x3b2; in Alzheimer&#x2019;s disease: accidental encounters or partners? Neuron. 2014;81(4):740-754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3983361</ArticleId><ArticleId IdType="pubmed">24559670</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106-118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Pietrzak RH, Bourgeat P, et al. . Relationships between performance on the CogState Brief Battery, neurodegeneration, and A&#x3b2; accumulation in cognitively normal older adults and adults with MCI. Arch Clin Neuropsychol. 2015;30(1):49-58.</Citation><ArticleIdList><ArticleId IdType="pubmed">25467942</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Vemuri P, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Brain &#x3b2;-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer&#x2019;s disease. Brain. 2010;133(11):3336-3348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965425</ArticleId><ArticleId IdType="pubmed">20935035</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Williamson R, Laws SM, et al. ; AIBL Research Group . Effect of APOE genotype on amyloid deposition, brain volume and memory in cognitively normal older individuals. J Alzheimers Dis. 2017;58(4):1293-1302.</Citation><ArticleIdList><ArticleId IdType="pubmed">28550258</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29365294</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>378</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>321</StartPage><EndPage>330</EndPage><MedlinePgn>321-330</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1705971</ELocationID><Abstract><AbstractText Label="BACKGROUND">Alzheimer's disease is characterized by amyloid-beta (A&#x3b2;) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble A&#x3b2;, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid.</AbstractText><AbstractText Label="METHODS">We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or A&#x3b2;1-42 measurements in cerebrospinal fluid. Patients were randomly assigned to receive solanezumab at a dose of 400 mg or placebo intravenously every 4 weeks for 76 weeks. The primary outcome was the change from baseline to week 80 in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; scores range from 0 to 90, with higher scores indicating greater cognitive impairment).</AbstractText><AbstractText Label="RESULTS">A total of 2129 patients were enrolled, of whom 1057 were assigned to receive solanezumab and 1072 to receive placebo. The mean change from baseline in the ADAS-cog14 score was 6.65 in the solanezumab group and 7.44 in the placebo group, with no significant between-group difference at week 80 (difference, -0.80; 95% confidence interval, -1.73 to 0.14; P=0.10). As a result of the failure to reach significance with regard to the primary outcome in the prespecified hierarchical analysis, the secondary outcomes were considered to be descriptive and are reported without significance testing. The change from baseline in the MMSE score was -3.17 in the solanezumab group and -3.66 in the placebo group. Adverse cerebral edema or effusion lesions that were observed on magnetic resonance imaging after randomization occurred in 1 patient in the solanezumab group and in 2 in the placebo group.</AbstractText><AbstractText Label="CONCLUSIONS">Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDITION3 ClinicalTrials.gov number, NCT01900665 .).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodward</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boada</LastName><ForeName>Merc&#xe8;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bullock</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hager</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasen</LastName><ForeName>Niels</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu-Seifert</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Case</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dean</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundell</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poole Hoffmann</LastName><ForeName>Vicki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanna</LastName><ForeName>Rashna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeMattos</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selzler</LastName><ForeName>Katherine J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siemers</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); G&#xe9;rontop&#xf4;le, Centre Hospitalier Universitaire Toulouse, Unit&#xe9; Mixte de Recherche INSERM Unit&#xe9; 1027 Universit&#xe9; Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundaci&#xf3; ACE, Alzheimer Research Center and Memory Clinic, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01900665</AccessionNumber><AccessionNumber>NCT01900665</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>5D6PWO0333</RegistryNumber><NameOfSubstance UI="C550616">solanezumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2018 Jan 25;378(4):391-392. doi: 10.1056/NEJMe1714638.</RefSource><PMID Version="1">29365295</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol. 2018 Sep;265(9):2162-2163. doi: 10.1007/s00415-018-9018-1.</RefSource><PMID Version="1">30132064</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Expert Opin Biol Ther. 2018 Dec;18(12):1189-1192. doi: 10.1080/14712598.2018.1543397.</RefSource><PMID Version="1">30376649</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29365294</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1705971</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29379963</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease.</ArticleTitle><Pagination><StartPage>582</StartPage><EndPage>590</EndPage><MedlinePgn>582-590</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.4719</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Circadian rhythm disturbances occur in symptomatic Alzheimer disease (AD) and have been hypothesized to contribute to disease pathogenesis. However, it is unknown whether circadian changes occur during the presymptomatic phase of the disease.</AbstractText><AbstractText Label="OBJECTIVE">To examine the associations between circadian function, aging, and preclinical AD pathology in cognitively normal adults.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study was conducted using community volunteers from the Knight Alzheimer's Disease Research Center at Washington University in St Louis. Cognitively normal participants (n&#x2009;=&#x2009;205) underwent 7 to 14 days of actigraphy in their home environment between 2010 and 2012, in addition to clinical assessment, amyloid imaging with Pittsburgh Compound B (PiB), and cerebrospinal fluid biomarker collection. Data collected from 3 years before to 6 months after actigraphy were included. Sixteen participants were excluded owing to incomplete data collection.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Circadian rhythm analysis was performed on actigraphy data using 3 methods: cosinor, nonparametric, and empirical mode decomposition. Preclinical AD was assessed by longitudinal clinical assessment, amyloid imaging with PiB, and cerebrospinal fluid biomarker collection.</AbstractText><AbstractText Label="RESULTS">Data from 189 participants were included in the analyses. The mean (SD) age was 66.6 (8.3) years, and 121 participants (64%) were women. Older age (&#x3b2;&#x2009;=&#x2009;.247; P&#x2009;=&#x2009;.003) and male sex (&#x3b2;&#x2009;=&#x2009;.170; P&#x2009;=&#x2009;.04), in the absence of amyloid pathology, were associated with a significant increase in intradaily variability, a nonparametric measure of rest-activity rhythm fragmentation, as well as decreased amplitude by several measures. After correction for age and sex, the presence of preclinical amyloid plaque pathology, assessed by positive PiB imaging (mean [SD], 0.804 [0.187] for PiB negative vs 0.875 [0.178] for PiB positive; P&#x2009;=&#x2009;.05) or increasing cerebrospinal fluid phosphorylated-tau to amyloid &#x3b2; 42 ratio (&#x3b2;&#x2009;=&#x2009;.231; P&#x2009;=&#x2009;.008), was associated with increased intradaily variability, indicating rest-activity rhythm fragmentation.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Preclinical AD is associated with rest-activity rhythm fragmentation, independent of age or sex. Aging was also associated with circadian dysfunction independently of preclinical AD pathology, particularly in men. The presence of circadian rhythm abnormalities in the preclinical phase of AD suggests that circadian dysfunction could contribute to early disease pathogenesis or serve as a biomarker of preclinical disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Musiek</LastName><ForeName>Erik S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhimasani</LastName><ForeName>Meghana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zangrilli</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Yo-El S</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 NS079405</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS089922</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR002346</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR000450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056044" MajorTopicYN="N">Actigraphy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021081" MajorTopicYN="N">Chronobiology Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Musiek is a consultant for Eisai Pharmaceuticals. Dr Holtzman serves on the scientific advisory boards of C2N Diagnostics and Proclara Biosciences and is a consultant for Eli Lilly, AbbVie, Genentech, and GlaxosmithKline. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29379963</ArticleId><ArticleId IdType="pmc">PMC5885197</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.4719</ArticleId><ArticleId IdType="pii">2670749</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. Annu Rev Neurosci. 2012;35:582-590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710582</ArticleId><ArticleId IdType="pubmed">22483041</ArticleId></ArticleIdList></Reference><Reference><Citation>Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science. 2010;330(6009):1349-1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756146</ArticleId><ArticleId IdType="pubmed">21127246</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Lim MM, Yang G, et al. . Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. J Clin Invest. 2013;123(12):5389-5400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859381</ArticleId><ArticleId IdType="pubmed">24270424</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001;93(20):1557-1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">11604479</ArticleId></ArticleIdList></Reference><Reference><Citation>Knutsson A, Kempe A. Shift work and diabetes: a systematic review. Chronobiol Int. 2014;31(10):1146-1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">25290038</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetter C, Devore EE, Wegrzyn LR, et al. . Association between rotating night shift work and risk of coronary heart disease among women. JAMA. 2016;315(16):1726-1734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5102147</ArticleId><ArticleId IdType="pubmed">27115377</ArticleId></ArticleIdList></Reference><Reference><Citation>Karatsoreos IN, Bhagat S, Bloss EB, Morrison JH, McEwen BS. Disruption of circadian clocks has ramifications for metabolism, brain, and behavior. Proc Natl Acad Sci U S A. 2011;108(4):1657-1662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3029753</ArticleId><ArticleId IdType="pubmed">21220317</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Holtzman DM. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science. 2016;354(6315):1004-1008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5219881</ArticleId><ArticleId IdType="pubmed">27885006</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura TJ, Nakamura W, Yamazaki S, et al. . Age-related decline in circadian output. J Neurosci. 2011;31(28):10201-10205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3155746</ArticleId><ArticleId IdType="pubmed">21752996</ArticleId></ArticleIdList></Reference><Reference><Citation>Okawa M, Mishima K, Hishikawa Y, Hozumi S, Hori H, Takahashi K. Circadian rhythm disorders in sleep-waking and body temperature in elderly patients with dementia and their treatment. Sleep. 1991;14(6):478-485.</Citation><ArticleIdList><ArticleId IdType="pubmed">1798879</ArticleId></ArticleIdList></Reference><Reference><Citation>Witting W, Kwa IH, Eikelenboom P, Mirmiran M, Swaab DF. Alterations in the circadian rest-activity rhythm in aging and Alzheimer&#x2019;s disease. Biol Psychiatry. 1990;27(6):563-572.</Citation><ArticleIdList><ArticleId IdType="pubmed">2322616</ArticleId></ArticleIdList></Reference><Reference><Citation>Satlin A, Volicer L, Stopa EG, Harper D. Circadian locomotor activity and core-body temperature rhythms in Alzheimer&#x2019;s disease. Neurobiol Aging. 1995;16(5):765-771.</Citation><ArticleIdList><ArticleId IdType="pubmed">8532109</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancoli-Israel S, Klauber MR, Jones DW, et al. . Variations in circadian rhythms of activity, sleep, and light exposure related to dementia in nursing-home patients. Sleep. 1997;20(1):18-23.</Citation><ArticleIdList><ArticleId IdType="pubmed">9130329</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper DG, Volicer L, Stopa EG, McKee AC, Nitta M, Satlin A. Disturbance of endogenous circadian rhythm in aging and Alzheimer disease. Am J Geriatr Psychiatry. 2005;13(5):359-368.</Citation><ArticleIdList><ArticleId IdType="pubmed">15879584</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida K, Okamoto N, Ohara K, Morita Y. Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brain Res. 1996;717(1-2):154-159.</Citation><ArticleIdList><ArticleId IdType="pubmed">8738265</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishima K, Tozawa T, Satoh K, Matsumoto Y, Hishikawa Y, Okawa M. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer&#x2019;s type with disturbed sleep-waking. Biol Psychiatry. 1999;45(4):417-421.</Citation><ArticleIdList><ArticleId IdType="pubmed">10071710</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene DJ, Swaab DF. Melatonin rhythmicity: effect of age and Alzheimer&#x2019;s disease. Exp Gerontol. 2003;38(1-2):199-206.</Citation><ArticleIdList><ArticleId IdType="pubmed">12543278</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitiello MV, Prinz PN. Alzheimer&#x2019;s disease: sleep and sleep/wake patterns. Clin Geriatr Med. 1989;5(2):289-299.</Citation><ArticleIdList><ArticleId IdType="pubmed">2665912</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz PN, Peskind ER, Vitaliano PP, et al. . Changes in the sleep and waking EEGs of nondemented and demented elderly subjects. J Am Geriatr Soc. 1982;30(2):86-93.</Citation><ArticleIdList><ArticleId IdType="pubmed">7199061</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter-Derex L, Yammine P, Bastuji H, Croisile B. Sleep and Alzheimer&#x2019;s disease. Sleep Med Rev. 2015;19:29-38.</Citation><ArticleIdList><ArticleId IdType="pubmed">24846773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology: a bidirectional relationship. Nat Rev Neurol. 2014;10(2):115-119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979317</ArticleId><ArticleId IdType="pubmed">24366271</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchetti A, Scuratti A, Zanetti O, et al. . Predictors of mortality and institutionalization in Alzheimer disease patients 1 year after discharge from an Alzheimer dementia unit. Dementia. 1995;6(2):108-112.</Citation><ArticleIdList><ArticleId IdType="pubmed">7606278</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. ; Amyloid Biomarker Study Group . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, et al. . Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80(19):1784-1791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. ; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group . Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280-292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45(3):358-368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW Jr, Buckles VD, et al. . Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30(7):1026-1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9(1):119-128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer&#x2019;s disease. Nature. 2009;461(7266):916-922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatfield CF, Herbert J, van Someren EJ, Hodges JR, Hastings MH. Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer&#x2019;s dementia. Brain. 2004;127(Pt 5):1061-1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">14998915</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancoli-Israel S, Martin JL, Kripke DF, Marler M, Klauber MR. Effect of light treatment on sleep and circadian rhythms in demented nursing home patients. J Am Geriatr Soc. 2002;50(2):282-289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764401</ArticleId><ArticleId IdType="pubmed">12028210</ArticleId></ArticleIdList></Reference><Reference><Citation>Naismith SL, Hickie IB, Terpening Z, et al. . Circadian misalignment and sleep disruption in mild cognitive impairment [published correction appears in J Alzheimers Dis. 2014;40(2):475]. J Alzheimers Dis. 2014;38(4):857-866.</Citation><ArticleIdList><ArticleId IdType="pubmed">24100124</ArticleId></ArticleIdList></Reference><Reference><Citation>Tranah GJ, Blackwell T, Stone KL, et al. ; SOF Research Group . Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol. 2011;70(5):722-732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244839</ArticleId><ArticleId IdType="pubmed">22162057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim AS, Kowgier M, Yu L, Buchman AS, Bennett DA. Sleep fragmentation and the risk of incident Alzheimer&#x2019;s disease and cognitive decline in older persons. Sleep. 2013;36(7):1027-1032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3669060</ArticleId><ArticleId IdType="pubmed">23814339</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, McCue L, Jasielec MS, et al. . Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease. Ann Neurol. 2016;80(3):379-387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016232</ArticleId><ArticleId IdType="pubmed">27398953</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. . Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Alafuzoff I, Herukka SK, et al. . Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382-389.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, D&#x2019;Angelo G, Macy E, et al. . Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol. 2011;70(2):274-285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154071</ArticleId><ArticleId IdType="pubmed">21823155</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Someren EJ, Swaab DF, Colenda CC, Cohen W, McCall WV, Rosenquist PB. Bright light therapy: improved sensitivity to its effects on rest-activity rhythms in Alzheimer patients by application of nonparametric methods. Chronobiol Int. 1999;16(4):505-518.</Citation><ArticleIdList><ArticleId IdType="pubmed">10442243</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon&#xe7;alves BS, Cavalcanti PR, Tavares GR, Campos TF, Araujo JF. Nonparametric methods in actigraphy: an update. Sleep Sci. 2014;7(3):158-164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4559593</ArticleId><ArticleId IdType="pubmed">26483921</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YH, Yeh CH, Young HWV, Hu K, Lo MT. On the computational complexity of the empirical mode decomposition algorithm. Physica A. 2014;400:159-167. doi:10.1016/j.physa.2014.01.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.physa.2014.01.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JL, Lim AS, Chiang WY, et al. . Suprachiasmatic neuron numbers and rest-activity circadian rhythms in older humans. Ann Neurol. 2015;78(2):317-322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4515161</ArticleId><ArticleId IdType="pubmed">25921596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, et al. . Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131(pt 6):1630-1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YE, McLeland JS, Toedebusch CD, et al. . Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013;70(5):587-593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3676720</ArticleId><ArticleId IdType="pubmed">23479184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu K, Van Someren EJ, Shea SA, Scheer FA. Reduction of scale invariance of activity fluctuations with aging and Alzheimer&#x2019;s disease: involvement of the circadian pacemaker. Proc Natl Acad Sci U S A. 2009;106(8):2490-2494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2650290</ArticleId><ArticleId IdType="pubmed">19202078</ArticleId></ArticleIdList></Reference><Reference><Citation>Aton SJ, Colwell CS, Harmar AJ, Waschek J, Herzog ED. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat Neurosci. 2005;8(4):476-483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1628303</ArticleId><ArticleId IdType="pubmed">15750589</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou JN, Hofman MA, Swaab DF. VIP neurons in the human SCN in relation to sex, age, and Alzheimer&#x2019;s disease. Neurobiol Aging. 1995;16(4):571-576.</Citation><ArticleIdList><ArticleId IdType="pubmed">8544907</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin P, McCarthy MJ, Lim ASP, et al. . Circadian alterations during early stages of Alzheimer&#x2019;s disease are associated with aberrant cycles of DNA methylation in BMAL1. Alzheimers Dement. 2017;13(6):689-700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785929</ArticleId><ArticleId IdType="pubmed">27883893</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H, Moon M, Choe HK, et al. . A&#x3b2;-induced degradation of BMAL1 and CBP leads to circadian rhythm disruption in Alzheimer&#x2019;s disease. Mol Neurodegener. 2015;10(13):13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404698</ArticleId><ArticleId IdType="pubmed">25888034</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyegbami O, Collins HM, Pardon MC, Ebling FJP, Heery DM, Moran PM. Abnormal clock gene expression and locomotor activity rhythms in two month-old female APPSwe/PS1dE9 mice. Curr Alzheimer Res. 2017;14(8):850-860.</Citation><ArticleIdList><ArticleId IdType="pubmed">28317486</ArticleId></ArticleIdList></Reference><Reference><Citation>La Morgia C, Ross-Cisneros FN, Koronyo Y, et al. . Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. 2016;79(1):90-109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4737313</ArticleId><ArticleId IdType="pubmed">26505992</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell SS, Kripke DF, Gillin JC, Hrubovcak JC. Exposure to light in healthy elderly subjects and Alzheimer&#x2019;s patients. Physiol Behav. 1988;42(2):141-144.</Citation><ArticleIdList><ArticleId IdType="pubmed">3368532</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HC, Guarente L. SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell. 2013;153(7):1448-1460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748806</ArticleId><ArticleId IdType="pubmed">23791176</ArticleId></ArticleIdList></Reference><Reference><Citation>Luik AI, Zuurbier LA, Hofman A, Van Someren EJ, Tiemeier H. Stability and fragmentation of the activity rhythm across the sleep-wake cycle: the importance of age, lifestyle, and mental health. Chronobiol Int. 2013;30(10):1223-1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">23971909</ArticleId></ArticleIdList></Reference><Reference><Citation>Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A. Sundowning and circadian rhythms in Alzheimer&#x2019;s disease. Am J Psychiatry. 2001;158(5):704-711.</Citation><ArticleIdList><ArticleId IdType="pubmed">11329390</ArticleId></ArticleIdList></Reference><Reference><Citation>Abner EL, Kryscio RJ, Schmitt FA, et al. . Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. Ann Neurol. 2017;81(4):549-559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5401633</ArticleId><ArticleId IdType="pubmed">28224671</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun CH, Lee HY, Lee SK, et al. . Amyloid burden in obstructive sleep apnea. J Alzheimers Dis. 2017;59(1):21-29.</Citation><ArticleIdList><ArticleId IdType="pubmed">28550245</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson EM, Wang C, Tjho S, Khattar N, Kriegsfeld LJ. Experimental &#x201c;jet lag&#x201d; inhibits adult neurogenesis and produces long-term cognitive deficits in female hamsters. PLoS One. 2010;5(12):e15267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995744</ArticleId><ArticleId IdType="pubmed">21152025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kott J, Leach G, Yan L. Direction-dependent effects of chronic &#x201c;jet-lag&#x201d; on hippocampal neurogenesis. Neurosci Lett. 2012;515(2):177-180.</Citation><ArticleIdList><ArticleId IdType="pubmed">22465247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YS, Ooms SJ, Sutphen C, et al. . Slow wave sleep disruption increases cerebrospinal fluid amyloid-&#x3b2; levels. Brain. 2017;140(8):2104-2111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790144</ArticleId><ArticleId IdType="pubmed">28899014</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, et al. . Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005-1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid &#x3b2;-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol. 2014;71(8):971-977.</Citation><ArticleIdList><ArticleId IdType="pubmed">24887018</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman SM, Herdener N, Frankola KA, Mughal MR, Mattson MP. Chronic mild sleep restriction accentuates contextual memory impairments, and accumulations of cortical A&#x3b2; and pTau in a mouse model of Alzheimer&#x2019;s disease. Brain Res. 2013;1529:200-208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779872</ArticleId><ArticleId IdType="pubmed">23856323</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Meco A, Joshi YB, Pratic&#xf2; D. Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer&#x2019;s disease with plaques and tangles. Neurobiol Aging. 2014;35(8):1813-1820.</Citation><ArticleIdList><ArticleId IdType="pubmed">24629673</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29382695</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>215</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Regulation of amyloid-&#x3b2; dynamics and pathology by the circadian clock.</ArticleTitle><Pagination><StartPage>1059</StartPage><EndPage>1068</EndPage><MedlinePgn>1059-1068</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20172347</ELocationID><Abstract><AbstractText>Nighttime restlessness and daytime drowsiness are common and early symptoms of Alzheimer's Disease (AD). This symptomology implicates dysfunctional biological timing, yet the role of the circadian system in AD pathogenesis is unknown. To evaluate the role of the circadian clock in amyloid-&#x3b2; (A&#x3b2;) dynamics and pathology, we used a mouse model of &#x3b2;-amyloidosis and disrupted circadian clock function either globally or locally in the brain via targeted deletion of the core clock gene <i>Bmal1</i> Our results demonstrate that loss of central circadian rhythms leads to disruption of daily hippocampal interstitial fluid A&#x3b2; oscillations and accelerates amyloid plaque accumulation, whereas loss of peripheral <i>Bmal1</i> in the brain parenchyma increases expression of <i>Apoe</i> and promotes fibrillar plaque deposition. These results provide evidence that both central circadian rhythms and local clock function influence A&#x3b2; dynamics and plaque formation and demonstrate mechanisms by which poor circadian hygiene may directly influence AD pathogenesis.</AbstractText><CopyrightInformation>&#xa9; 2018 Kress et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kress</LastName><ForeName>Geraldine J</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0001-9442-8734</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disease, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimitry</LastName><ForeName>Julie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8733-9642</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cedeno</LastName><ForeName>Michelle R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0840-5101</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>FitzGerald</LastName><ForeName>Garret A</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0002-5885-6819</Identifier><AffiliationInfo><Affiliation>Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disease, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musiek</LastName><ForeName>Erik S</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0002-8873-0360</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO musieke@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disease, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG054517</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS079405</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 ES013508</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG053425</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 ES022577</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056930">ARNTL Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C538961">Bmal1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056930" MajorTopicYN="N">ARNTL Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057906" MajorTopicYN="Y">Circadian Clocks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013493" MajorTopicYN="N">Suprachiasmatic Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29382695</ArticleId><ArticleId IdType="pmc">PMC5881473</ArticleId><ArticleId IdType="doi">10.1084/jem.20172347</ArticleId><ArticleId IdType="pii">jem.20172347</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bunger M.K., Wilsbacher L.D., Moran S.M., Clendenin C., Radcliffe L.A., Hogenesch J.B., Simon M.C., Takahashi J.S., and Bradfield C.A.. 2000. Mop3 is an essential component of the master circadian pacemaker in mammals. Cell. 103:1009&#x2013;1017. 10.1016/S0092-8674(00)00205-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)00205-1</ArticleId><ArticleId IdType="pmc">PMC3779439</ArticleId><ArticleId IdType="pubmed">11163178</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q., Peng X.D., Huang C.Q., Hu X.Y., and Zhang X.M.. 2015. Association between ARNTL (BMAL1) rs2278749 polymorphism T &gt;C and susceptibility to Alzheimer disease in a Chinese population. Genet. Mol. Res. 14:18515&#x2013;18522. 10.4238/2015.December.23.39</Citation><ArticleIdList><ArticleId IdType="doi">10.4238/2015.December.23.39</ArticleId><ArticleId IdType="pubmed">26782499</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito J.R., May P.C., O&#x2019;Dell M.A., Taylor J.W., Parsadanian M., Cramer J.W., Audia J.E., Nissen J.S., Bales K.R., Paul S.M., et al. . 2003. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J. Neurosci. 23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin P., McCarthy M.J., Lim A.S.P., Salmon D.P., Galasko D., Masliah E., De Jager P.L., Bennett D.A., and Desplats P.. 2017. Circadian alterations during early stages of Alzheimer&#x2019;s disease are associated with aberrant cycles of DNA methylation in BMAL1. Alzheimers Dement. 13:689&#x2013;700. 10.1016/j.jalz.2016.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.10.003</ArticleId><ArticleId IdType="pmc">PMC5785929</ArticleId><ArticleId IdType="pubmed">27883893</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O&#x2019;Dell M.A., Taylor J.W., Harmony J.A., Aronow B.J., Bales K.R., Paul S.M., and Holtzman D.M.. 2004. ApoE and clusterin cooperatively suppress Abeta levels and deposition: Evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 41:193&#x2013;202. 10.1016/S0896-6273(03)00850-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00850-X</ArticleId><ArticleId IdType="pubmed">14741101</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A.M., Watson M., Parsadanian M., Bales K.R., Paul S.M., and Holtzman D.M.. 2002. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer&#x2019;s disease. Neurobiol. Dis. 9:305&#x2013;318. 10.1006/nbdi.2002.0483</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2002.0483</ArticleId><ArticleId IdType="pubmed">11950276</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper D.G., Volicer L., Stopa E.G., McKee A.C., Nitta M., and Satlin A.. 2005. Disturbance of endogenous circadian rhythm in aging and Alzheimer disease. Am. J. Geriatr. Psychiatry. 13:359&#x2013;368. 10.1097/00019442-200505000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00019442-200505000-00004</ArticleId><ArticleId IdType="pubmed">15879584</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper D.G., Stopa E.G., Kuo-Leblanc V., McKee A.C., Asayama K., Volicer L., Kowall N., and Satlin A.. 2008. Dorsomedial SCN neuronal subpopulations subserve different functions in human dementia. Brain. 131:1609&#x2013;1617. 10.1093/brain/awn049</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn049</ArticleId><ArticleId IdType="pmc">PMC3286014</ArticleId><ArticleId IdType="pubmed">18372313</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastings M.H., and Goedert M.. 2013. Circadian clocks and neurodegenerative diseases: time to aggregate? Curr. Opin. Neurobiol. 23:880&#x2013;887. 10.1016/j.conb.2013.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2013.05.004</ArticleId><ArticleId IdType="pmc">PMC3782660</ArticleId><ArticleId IdType="pubmed">23797088</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatfield C.F., Herbert J., van Someren E.J., Hodges J.R., and Hastings M.H.. 2004. Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer&#x2019;s dementia. Brain. 127:1061&#x2013;1074. 10.1093/brain/awh129</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh129</ArticleId><ArticleId IdType="pubmed">14998915</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D.M., Fagan A.M., Mackey B., Tenkova T., Sartorius L., Paul S.M., Bales K., Ashe K.H., Irizarry M.C., and Hyman B.T.. 2000. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer&#x2019;s disease model. Ann. Neurol. 47:739&#x2013;747. 10.1002/1531-8249(200006)47:6&lt;739::AID-ANA6&gt;3.0.CO;2-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(200006)47:6&lt;739::AID-ANA6&gt;3.0.CO;2-8</ArticleId><ArticleId IdType="pubmed">10852539</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Potter R., Sigurdson W., Santacruz A., Shih S., Ju Y.E., Kasten T., Morris J.C., Mintun M., Duntley S., and Bateman R.J.. 2012. Effects of age and amyloid deposition on A&#x3b2; dynamics in the human central nervous system. Arch. Neurol. 69:51&#x2013;58. 10.1001/archneurol.2011.235</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.235</ArticleId><ArticleId IdType="pmc">PMC3254706</ArticleId><ArticleId IdType="pubmed">21911660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J.E., Lim M.M., Bateman R.J., Lee J.J., Smyth L.P., Cirrito J.R., Fujiki N., Nishino S., and Holtzman D.M.. 2009. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 326:1005&#x2013;1007. 10.1126/science.1180962</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1180962</ArticleId><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Jiang H., Park S., Eltorai A.E., Stewart F.R., Yoon H., Basak J.M., Finn M.B., and Holtzman D.M.. 2011. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-&#x3b2; amyloidosis. J. Neurosci. 31:18007&#x2013;18012. 10.1523/JNEUROSCI.3773-11.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3773-11.2011</ArticleId><ArticleId IdType="pmc">PMC3257514</ArticleId><ArticleId IdType="pubmed">22159114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kress G.J., Yamawaki N., Wokosin D.L., Wickersham I.R., Shepherd G.M., and Surmeier D.J.. 2013. Convergent cortical innervation of striatal projection neurons. Nat. Neurosci. 16:665&#x2013;667. 10.1038/nn.3397</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3397</ArticleId><ArticleId IdType="pmc">PMC4085670</ArticleId><ArticleId IdType="pubmed">23666180</ArticleId></ArticleIdList></Reference><Reference><Citation>Laposky A., Easton A., Dugovic C., Walisser J., Bradfield C., and Turek F.. 2005. Deletion of the mammalian circadian clock gene BMAL1/Mop3 alters baseline sleep architecture and the response to sleep deprivation. Sleep. 28:395&#x2013;410. 10.1093/sleep/28.4.395</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/28.4.395</ArticleId><ArticleId IdType="pubmed">16171284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim A.S., Kowgier M., Yu L., Buchman A.S., and Bennett D.A.. 2013. Sleep Fragmentation and the Risk of Incident Alzheimer&#x2019;s Disease and Cognitive Decline in Older Persons. Sleep (Basel). 36:1027&#x2013;1032. 10.5665/sleep.2802</Citation><ArticleIdList><ArticleId IdType="doi">10.5665/sleep.2802</ArticleId><ArticleId IdType="pmc">PMC3669060</ArticleId><ArticleId IdType="pubmed">23814339</ArticleId></ArticleIdList></Reference><Reference><Citation>Maywood E.S., O&#x2019;Neill J., Wong G.K., Reddy A.B., and Hastings M.H.. 2006. Circadian timing in health and disease. Prog. Brain Res. 153:253&#x2013;269. 10.1016/S0079-6123(06)53015-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0079-6123(06)53015-8</ArticleId><ArticleId IdType="pubmed">16876580</ArticleId></ArticleIdList></Reference><Reference><Citation>Mieda M., and Sakurai T.. 2011. Bmal1 in the nervous system is essential for normal adaptation of circadian locomotor activity and food intake to periodic feeding. J. Neurosci. 31:15391&#x2013;15396. 10.1523/JNEUROSCI.2801-11.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2801-11.2011</ArticleId><ArticleId IdType="pmc">PMC6703508</ArticleId><ArticleId IdType="pubmed">22031885</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohawk J.A., Green C.B., and Takahashi J.S.. 2012. Central and peripheral circadian clocks in mammals. Annu. Rev. Neurosci. 35:445&#x2013;462. 10.1146/annurev-neuro-060909-153128</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-060909-153128</ArticleId><ArticleId IdType="pmc">PMC3710582</ArticleId><ArticleId IdType="pubmed">22483041</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek E.S., and Holtzman D.M.. 2016. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science. 354:1004&#x2013;1008. 10.1126/science.aah4968</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aah4968</ArticleId><ArticleId IdType="pmc">PMC5219881</ArticleId><ArticleId IdType="pubmed">27885006</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek E.S., Lim M.M., Yang G., Bauer A.Q., Qi L., Lee Y., Roh J.H., Ortiz-Gonzalez X., Dearborn J.T., Culver J.P., et al. . 2013. Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. J. Clin. Invest. 123:5389&#x2013;5400. 10.1172/JCI70317</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI70317</ArticleId><ArticleId IdType="pmc">PMC3859381</ArticleId><ArticleId IdType="pubmed">24270424</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek E.S., Bhimasani M., Zangrilli M.A., Morris J.C., Holtzman D.M., and Ju Y.E.. 2018. Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. JAMA Neurol. In press 10.1001./jamaneurol.2017.4719</Citation><ArticleIdList><ArticleId IdType="doi">10.1001./jamaneurol.2017.4719</ArticleId><ArticleId IdType="pmc">PMC5885197</ArticleId><ArticleId IdType="pubmed">29379963</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz L.K., Quiles C.L., Dallegrave E., Levandovski R., Hidalgo M.P., and Elisabetsky E.. 2015. Differential susceptibility of BALB/c, C57BL/6N, and CF1 mice to photoperiod changes. Rev. Bras. Psiquiatr. 37:185&#x2013;190. 10.1590/1516-4446-2014-1454</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1516-4446-2014-1454</ArticleId><ArticleId IdType="pubmed">25806472</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., J&#xe4;ggi F., Wolburg H., Gengler S., et al. . 2006. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7:940&#x2013;946. 10.1038/sj.embor.7400784</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400784</ArticleId><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh J.H., Huang Y., Bero A.W., Kasten T., Stewart F.R., Bateman R.J., and Holtzman D.M.. 2012. Disruption of the sleep-wake cycle and diurnal fluctuation of &#x3b2;-amyloid in mice with Alzheimer&#x2019;s disease pathology. Sci. Transl. Med. 4:150ra122 10.1126/scitranslmed.3004291</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3004291</ArticleId><ArticleId IdType="pmc">PMC3654377</ArticleId><ArticleId IdType="pubmed">22956200</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh J.H., Jiang H., Finn M.B., Stewart F.R., Mahan T.E., Cirrito J.R., Heda A., Snider B.J., Li M., Yanagisawa M., et al. . 2014. Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer&#x2019;s disease. J. Exp. Med. 211:2487&#x2013;2496. 10.1084/jem.20141788</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20141788</ArticleId><ArticleId IdType="pmc">PMC4267230</ArticleId><ArticleId IdType="pubmed">25422493</ArticleId></ArticleIdList></Reference><Reference><Citation>Satlin A., Volicer L., Stopa E.G., and Harper D.. 1995. Circadian locomotor activity and core-body temperature rhythms in Alzheimer&#x2019;s disease. Neurobiol. Aging. 16:765&#x2013;771. 10.1016/0197-4580(95)00059-N</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(95)00059-N</ArticleId><ArticleId IdType="pubmed">8532109</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H., Moon M., Choe H.K., Han D.H., Jang C., Kim A., Cho S., Kim K., and Mook-Jung I.. 2015. A&#x3b2;-induced degradation of BMAL1 and CBP leads to circadian rhythm disruption in Alzheimer&#x2019;s disease. Mol. Neurodegener. 10:13 10.1186/s13024-015-0007-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0007-x</ArticleId><ArticleId IdType="pmc">PMC4404698</ArticleId><ArticleId IdType="pubmed">25888034</ArticleId></ArticleIdList></Reference><Reference><Citation>Storch K.F., Paz C., Signorovitch J., Raviola E., Pawlyk B., Li T., and Weitz C.J.. 2007. Intrinsic circadian clock of the mammalian retina: importance for retinal processing of visual information. Cell. 130:730&#x2013;741. 10.1016/j.cell.2007.06.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.06.045</ArticleId><ArticleId IdType="pmc">PMC2040024</ArticleId><ArticleId IdType="pubmed">17719549</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaab D.F., Fliers E., and Partiman T.S.. 1985. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res. 342:37&#x2013;44. 10.1016/0006-8993(85)91350-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(85)91350-2</ArticleId><ArticleId IdType="pubmed">4041816</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh K.L., Jones C.R., He Y., Eide E.J., Hinz W.A., Virshup D.M., Pt&#xe1;cek L.J., and Fu Y.H.. 2001. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science. 291:1040&#x2013;1043. 10.1126/science.1057499</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1057499</ArticleId><ArticleId IdType="pubmed">11232563</ArticleId></ArticleIdList></Reference><Reference><Citation>Tranah G.J., Blackwell T., Stone K.L., Ancoli-Israel S., Paudel M.L., Ensrud K.E., Cauley J.A., Redline S., Hillier T.A., Cummings S.R., and Yaffe K.. SOF Research Group . 2011. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann. Neurol. 70:722&#x2013;732. 10.1002/ana.22468</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22468</ArticleId><ArticleId IdType="pmc">PMC3244839</ArticleId><ArticleId IdType="pubmed">22162057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.L., Lim A.S., Chiang W.Y., Hsieh W.H., Lo M.T., Schneider J.A., Buchman A.S., Bennett D.A., Hu K., and Saper C.B.. 2015. Suprachiasmatic neuron numbers and rest-activity circadian rhythms in older humans. Ann. Neurol. 78:317&#x2013;322. 10.1002/ana.24432</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24432</ArticleId><ArticleId IdType="pmc">PMC4515161</ArticleId><ArticleId IdType="pubmed">25921596</ArticleId></ArticleIdList></Reference><Reference><Citation>Witting W., Kwa I.H., Eikelenboom P., Mirmiran M., and Swaab D.F.. 1990. Alterations in the circadian rest-activity rhythm in aging and Alzheimer&#x2019;s disease. Biol. Psychiatry. 27:563&#x2013;572. 10.1016/0006-3223(90)90523-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-3223(90)90523-5</ArticleId><ArticleId IdType="pubmed">2322616</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G., Jia Z., Aoyagi T., McClain D., Mortensen R.M., and Yang T.. 2012. Systemic PPAR&#x3b3; deletion impairs circadian rhythms of behavior and metabolism. PLoS One. 7:e38117 10.1371/journal.pone.0038117</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0038117</ArticleId><ArticleId IdType="pmc">PMC3416825</ArticleId><ArticleId IdType="pubmed">22899986</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G., Chen L., Grant G.R., Paschos G., Song W.L., Musiek E.S., Lee V., McLoughlin S.C., Grosser T., Cotsarelis G., and FitzGerald G.A.. 2016. Timing of expression of the core clock gene Bmal1 influences its effects on aging and survival. Sci. Transl. Med. 8:324ra16 10.1126/scitranslmed.aad3305</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aad3305</ArticleId><ArticleId IdType="pmc">PMC4870001</ArticleId><ArticleId IdType="pubmed">26843191</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu E.A., and Weaver D.R.. 2011. Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging (Albany N.Y.). 3:479&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156599</ArticleId><ArticleId IdType="pubmed">21566258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J.N., Hofman M.A., and Swaab D.F.. 1995. VIP neurons in the human SCN in relation to sex, age, and Alzheimer&#x2019;s disease. Neurobiol. Aging. 16:571&#x2013;576. 10.1016/0197-4580(95)00043-E</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(95)00043-E</ArticleId><ArticleId IdType="pubmed">8544907</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29420472</PMID><DateCompleted><Year>2018</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>554</Volume><Issue>7691</Issue><PubDate><Year>2018</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>249</StartPage><EndPage>254</EndPage><MedlinePgn>249-254</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature25456</ELocationID><Abstract><AbstractText>To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are expected to be most efficacious at the earliest and mildest stages of the disease, supportive biomarker information is necessary. The only validated methods for identifying amyloid-&#x3b2; deposition in the brain-the earliest pathological signature of Alzheimer's disease-are amyloid-&#x3b2; positron-emission tomography (PET) imaging or measurement of amyloid-&#x3b2; in cerebrospinal fluid. Therefore, a minimally invasive, cost-effective blood-based biomarker is desirable. Despite much effort, to our knowledge, no study has validated the clinical utility of blood-based amyloid-&#x3b2; markers. Here we demonstrate the measurement of high-performance plasma amyloid-&#x3b2; biomarkers by immunoprecipitation coupled with mass spectrometry. The ability of amyloid-&#x3b2; precursor protein (APP)<sub>669-711</sub>/amyloid-&#x3b2; (A&#x3b2;)<sub>1-42</sub> and A&#x3b2;<sub>1-40</sub>/A&#x3b2;<sub>1-42</sub> ratios, and their composites, to predict individual brain amyloid-&#x3b2;-positive or -negative status was determined by amyloid-&#x3b2;-PET imaging and tested using two independent data sets: a discovery data set (Japan, n&#x2009;=&#x2009;121) and a validation data set (Australia, n&#x2009;=&#x2009;252 including 111 individuals diagnosed using <sup>11</sup>C-labelled Pittsburgh compound-B (PIB)-PET and 141 using other ligands). Both data sets included cognitively normal individuals, individuals with mild cognitive impairment and individuals with Alzheimer's disease. All test biomarkers showed high performance when predicting brain amyloid-&#x3b2; burden. In particular, the composite biomarker showed very high areas under the receiver operating characteristic curves (AUCs) in both data sets (discovery, 96.7%, n&#x2009;=&#x2009;121 and validation, 94.1%, n&#x2009;=&#x2009;111) with an accuracy approximately equal to 90% when using PIB-PET as a standard of truth. Furthermore, test biomarkers were correlated with amyloid-&#x3b2;-PET burden and levels of A&#x3b2;<sub>1-42</sub> in cerebrospinal fluid. These results demonstrate the potential clinical utility of plasma biomarkers in predicting brain amyloid-&#x3b2; burden at an individual level. These plasma biomarkers also have cost-benefit and scalability advantages over current techniques, potentially enabling broader clinical access and efficient population screening.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Akinori</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaneko</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, Kyoto 604-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Austin Health, Department of Molecular Imaging and Therapy, Center for PET, Heidelberg, Victoria 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Florey Institute, The University of Melbourne, Parkville 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doecke</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Health and Biosecurity, CSIRO, Brisbane 4029, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dor&#xe9;</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Austin Health, Department of Molecular Imaging and Therapy, Center for PET, Heidelberg, Victoria 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health and Biosecurity, CSIRO, Brisbane 4029, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fowler</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Florey Institute, The University of Melbourne, Parkville 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qiao-Xin</ForeName><Initials>QX</Initials><AffiliationInfo><Affiliation>The Florey Institute, The University of Melbourne, Parkville 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Edith Cowan University, Joondalup, Western Australia 6027, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Austin Health, Department of Molecular Imaging and Therapy, Center for PET, Heidelberg, Victoria 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Florey Institute, The University of Melbourne, Parkville 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomita</LastName><ForeName>Taisuke</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuzaki</LastName><ForeName>Katsumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Team for Neuroimaging Research, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Kazunari</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, Kindai University Faculty of Medicine, Osakasayama, Osaka 589-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arahata</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwamoto</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, Kyoto 604-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Kengo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, Kyoto 604-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>The Florey Institute, The University of Melbourne, Parkville 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanagisawa</LastName><ForeName>Katsuhiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2018 Apr;14(4):195. doi: 10.1038/nrneurol.2018.19.</RefSource><PMID Version="1">29449699</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29420472</ArticleId><ArticleId IdType="doi">10.1038/nature25456</ArticleId><ArticleId IdType="pii">nature25456</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Neurol. 2011 Sep;68(9):1137-44</Citation><ArticleIdList><ArticleId IdType="pubmed">21555603</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2014 Jan;10(1):115-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23850333</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2017 Sep 29;13(10 ):612-623</Citation><ArticleIdList><ArticleId IdType="pubmed">28960209</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2013 May;9(3):251-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23622690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2009 Apr;65(4):403-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2014 Nov 5;84(3):608-22</Citation><ArticleIdList><ArticleId IdType="pubmed">25442939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2010 Sep;68(3):319-29</Citation><ArticleIdList><ArticleId IdType="pubmed">20687209</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2017 Jul;13(7):778-782</Citation><ArticleIdList><ArticleId IdType="pubmed">28073031</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2014 Jan 28;6(1):5</Citation><ArticleIdList><ArticleId IdType="pubmed">24472496</ArticleId></ArticleIdList></Reference><Reference><Citation>Brief Funct Genomic Proteomic. 2007 Jun;6(2):149-58</Citation><ArticleIdList><ArticleId IdType="pubmed">17584762</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2017 Aug;13(8):841-849</Citation><ArticleIdList><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>J Proteome Res. 2014 Jul 7;:null</Citation><ArticleIdList><ArticleId IdType="pubmed">24965016</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1950 Jan;3(1):32-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15405679</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17569110</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):263-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2009 Aug;21(4):672-87</Citation><ArticleIdList><ArticleId IdType="pubmed">19470201</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2009 Oct 13;73(15):1193-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19822868</ArticleId></ArticleIdList></Reference><Reference><Citation>Amyloid. 2009;16(2):71-80</Citation><ArticleIdList><ArticleId IdType="pubmed">20536398</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2016 Dec 1;73(12 ):1396-1398</Citation><ArticleIdList><ArticleId IdType="pubmed">27802483</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2015 Jan;36 Suppl 1:S159-66</Citation><ArticleIdList><ArticleId IdType="pubmed">25257985</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2012 Jun;121(5):774-84</Citation><ArticleIdList><ArticleId IdType="pubmed">22375951</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2014 Jan;10 (1):53-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23491263</ArticleId></ArticleIdList></Reference><Reference><Citation>Biometrics. 1988 Sep;44(3):837-45</Citation><ArticleIdList><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2013 Aug;54(8):1472-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23740104</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):270-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1993 Sep 24;695:144-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8239273</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2014;40(1):95-104</Citation><ArticleIdList><ArticleId IdType="pubmed">24334723</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1398-407</Citation><ArticleIdList><ArticleId IdType="pubmed">24647577</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2016 Aug 31;537(7618):50-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2014 May 20;82(20):1760-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2015 ;48(1):175-87</Citation><ArticleIdList><ArticleId IdType="pubmed">26401938</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2013;33(4):1021-32</Citation><ArticleIdList><ArticleId IdType="pubmed">23076076</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2017 Jan;13(1):45-58</Citation><ArticleIdList><ArticleId IdType="pubmed">27870940</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2010 Jun;51(6):913-20</Citation><ArticleIdList><ArticleId IdType="pubmed">20501908</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2015 Sep;78(3):439-53</Citation><ArticleIdList><ArticleId IdType="pubmed">26040676</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2011 Jan 19;305(3):275-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2015 May;11(5):549-60</Citation><ArticleIdList><ArticleId IdType="pubmed">25282381</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2010 Aug;31(8):1275-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(9):353-64</Citation><ArticleIdList><ArticleId IdType="pubmed">25391320</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2012 Aug;69(8):1018-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22490326</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2016 Dec 1;73(12 ):1417-1424</Citation><ArticleIdList><ArticleId IdType="pubmed">27802513</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2014 Jan;10 (1):e9-e18</Citation><ArticleIdList><ArticleId IdType="pubmed">23541187</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(3):104-17</Citation><ArticleIdList><ArticleId IdType="pubmed">24621957</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 May 31;6:26801</Citation><ArticleIdList><ArticleId IdType="pubmed">27241045</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29398363</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau.</ArticleTitle><Pagination><StartPage>823</StartPage><EndPage>835.e8</EndPage><MedlinePgn>823-835.e8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2018.01.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(18)30047-3</ELocationID><Abstract><AbstractText>Synaptic dysfunction is an early pathological feature of neurodegenerative diseases associated with Tau, including Alzheimer's disease. Interfering with early synaptic dysfunction may be therapeutically beneficial to prevent cognitive decline and disease progression, but the mechanisms underlying synaptic defects associated with Tau are unclear. In disease conditions, Tau mislocalizes into pre- and postsynaptic compartments; here we show that, under pathological conditions, Tau binds to presynaptic vesicles in Alzheimer's disease patient brain. We define that the binding of Tau to synaptic vesicles is mediated by the transmembrane vesicle protein Synaptogyrin-3. In fly and mouse models of Tauopathy, reduction of Synaptogyrin-3 prevents the association of presynaptic Tau with vesicles, alleviates Tau-induced defects in vesicle mobility, and restores neurotransmitter release. This work therefore identifies Synaptogyrin-3 as the binding partner of Tau on synaptic vesicles, revealing a new presynapse-specific Tau interactor, which may contribute to early synaptic dysfunction in neurodegenerative diseases associated with Tau.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McInnes</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, 3000 Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wierda</LastName><ForeName>Keimpe</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, 3000 Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snellinx</LastName><ForeName>An</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, 3000 Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bounti</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, 3000 Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yu-Chun</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, 3000 Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stancu</LastName><ForeName>Ilie-Cosmin</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Alzheimer Dementia Group, Catholic University of Louvain, 1200 Brussels, Belgium; Biomedical Research Institute, Hasselt University, 3500 Hasselt, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ap&#xf3;stolo</LastName><ForeName>Nuno</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, 3000 Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gevaert</LastName><ForeName>Kris</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>VIB-UGent Center for Medical Biotechnology, 9000 Ghent, Belgium; Department of Biochemistry, Ghent University, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dewachter</LastName><ForeName>Ilse</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Alzheimer Dementia Group, Catholic University of Louvain, 1200 Brussels, Belgium; Biomedical Research Institute, Hasselt University, 3500 Hasselt, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spires-Jones</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, Euan MacDonald Centre, and Centre for Dementia Prevention, Edinburgh Neuroscience, University of Edinburgh, Edinburgh EH8 9JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, 3000 Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium; Dementia Research Institute, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Wit</LastName><ForeName>Joris</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, 3000 Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lujia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, 3000 Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verstreken</LastName><ForeName>Patrik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, 3000 Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium. Electronic address: patrik.verstreken@kuleuven.vib.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_17116</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558298">Mapt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062805">Synaptogyrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000632302">Syngr3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062805" MajorTopicYN="N">Synaptogyrins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Synaptogyrin-3</Keyword><Keyword MajorTopicYN="N">Syngr3</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">Tauopathy</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">presynapse</Keyword><Keyword MajorTopicYN="N">synapse</Keyword><Keyword MajorTopicYN="N">synaptic dysfunction</Keyword><Keyword MajorTopicYN="N">synaptic vesicles</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29398363</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.01.022</ArticleId><ArticleId IdType="pii">S0896-6273(18)30047-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29397305</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.</ArticleTitle><Pagination><StartPage>241</StartPage><EndPage>250</EndPage><MedlinePgn>241-250</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(18)30028-0</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(18)30028-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Models of Alzheimer's disease propose a sequence of amyloid &#x3b2; (A&#x3b2;) accumulation, hypometabolism, and structural decline that precedes the onset of clinical dementia. These pathological features evolve both temporally and spatially in the brain. In this study, we aimed to characterise where in the brain and when in the course of the disease neuroimaging biomarkers become abnormal.</AbstractText><AbstractText Label="METHODS">Between Jan 1, 2009, and Dec 31, 2015, we analysed data from mutation non-carriers, asymptomatic carriers, and symptomatic carriers from families carrying gene mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein (APP) enrolled in the Dominantly Inherited Alzheimer's Network. We analysed <sup>11</sup>C-Pittsburgh Compound B (<sup>11</sup>C-PiB) PET, <sup>18</sup>F-Fluorodeoxyglucose (<sup>18</sup>F-FDG) PET, and structural MRI data using regions of interest to assess change throughout the brain. We estimated rates of biomarker change as a function of estimated years to symptom onset at baseline using linear mixed-effects models and determined the earliest point at which biomarker trajectories differed between mutation carriers and non-carriers. This study is registered at ClinicalTrials.gov (number NCT00869817) FINDINGS: <sup>11</sup>C-PiB PET was available for 346 individuals (162 with longitudinal imaging), <sup>18</sup>F-FDG PET was available for 352 individuals (175 with longitudinal imaging), and MRI data were available for 377 individuals (201 with longitudinal imaging). We found a sequence to pathological changes, with rates of A&#x3b2; deposition in mutation carriers being significantly different from those in non-carriers first (across regions that showed a significant difference, at a mean of 18&#xb7;9 years [SD 3&#xb7;3] before expected onset), followed by hypometabolism (14&#xb7;1 years [5&#xb7;1] before expected onset), and lastly structural decline (4&#xb7;7 years [4&#xb7;2] before expected onset). This biomarker ordering was preserved in most, but not all, regions. The temporal emergence within a biomarker varied across the brain, with the precuneus being the first cortical region for each method to show divergence between groups (22&#xb7;2 years before expected onset for A&#x3b2; accumulation, 18&#xb7;8 years before expected onset for hypometabolism, and 13&#xb7;0 years before expected onset for cortical thinning).</AbstractText><AbstractText Label="INTERPRETATION">Mutation carriers had elevations in A&#x3b2; deposition, reduced glucose metabolism, and cortical thinning compared with non-carriers which preceded the expected onset of dementia. Accrual of these pathologies varied throughout the brain, suggesting differential regional and temporal vulnerabilities to A&#x3b2;, metabolic decline, and structural atrophy, which should be taken into account when using biomarkers in a clinical setting as well as designing and evaluating clinical trials.</AbstractText><AbstractText Label="FUNDING">US National Institutes of Health, the German Center for Neurodegenerative Diseases, and the Medical Research Council Dementias Platform UK.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University, St Louis, MO, USA; Department of Psychological &amp; Brain Sciences, Washington University, St Louis, MO, USA. Electronic address: bagordon@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blazey</LastName><ForeName>Tyler M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St Louis, MO, USA; Division of Biology and Biomedical Sciences, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hari-Raj</LastName><ForeName>Amrita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dincer</LastName><ForeName>Aylin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Shaney</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guoqiao</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, MO, USA; Department of Biostatistics, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, MO, USA; Department of Neurology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, MO, USA; Department of Neurology, Washington University, St Louis, MO, USA; Department of Psychological &amp; Brain Sciences, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, MO, USA; Department of Neurology, Washington University, St Louis, MO, USA; The Hope Center for Neurological Disorders, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornbeck</LastName><ForeName>Russ C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paumier</LastName><ForeName>Katrina L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St Louis, MO, USA; The Hope Center for Neurological Disorders, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berman</LastName><ForeName>Sarah B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brickman</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cash</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK; Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Brown University School of Medicine, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xf6;rster</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>la Foug&#xe8;re</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen, T&#xfc;bingen, Germany; Division of Nuclear Medicine and Clinical Molecular Imaging, University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany; Department of Neurology, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>The Florey Institute, University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Brown University School of Medicine, Providence, RI, USA; Department of Neurology, Brown University School of Medicine, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Brown University School of Medicine, Providence, RI, USA; Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney, NSW, Australia; School of Medical Sciences, University of New South Wales, Sydney NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Imaging Genetics Center, University of Southern California, Marina del Rey, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, MO, USA; Department of Neurology, Washington University, St Louis, MO, USA; The Hope Center for Neurological Disorders, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marcus E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St Louis, MO, USA; Department of Neurology, Washington University, St Louis, MO, USA; The Hope Center for Neurological Disorders, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, MO, USA; Department of Neurology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, MO, USA; Department of Neurology, Washington University, St Louis, MO, USA; The Hope Center for Neurological Disorders, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00869817</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P41 EB015922</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG053474</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/009076/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>S10 RR022984</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG049087</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS080675</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD018091</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB009352</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS098577</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2018 Mar;17(3):199-200. doi: 10.1016/S1474-4422(18)30043-7.</RefSource><PMID Version="1">29397304</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="Y">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Declarations of Interest</b>. BAG and BMA report participating in a clinical trial of AV-1451 sponsored by Avid Radiopharmaceuticals. EM reports grants from Dominantly Inherited Alzheimer Network Trials Unit Pharma Consortium, outside the submitted work. CX reports grants from the NIA outside the submitted work. JH reports personal fees from Biogen and Lundbeck, outside the submitted work. CRJ reports consulting services for Lilly Co. and grants from NIH, outside the submitted work. DSM reports grants from the NIH outside and support from Radiologics, Inc., both outside the conduct of the study. AMF reports personal fees from DiamiR, personal fees from LabCorp, personal fees from IBL International, personal fees from Genentech, grants from Roche Diagnostics, grants from Fujirebio, grants from Biogen, outside the submitted work. DMC reports grants from Alzheimer&#x2019;s Society, during the conduct of the study. JL reports grants from German Ministry of Reseach and Education, during the conduct of the study. AJS reports non-financial support from Avid Radiopharmaceuticals and grants from Eli Lilly, outside the submitted work. SBB reports grants from NIH, during the conduct of the study; other from Lundbeck, other from Grifols Biologicals, outside the submitted work. MNR reports support from Servier and Merck outside the submitted work. NCF reports personal fees from Janssen, Roche/Genentech, Janssen Alzheimer&#x2019;s Immunotherapy, Eli Lilly, Novartis Pharma AG, Sanofi GSK, and Biogen, outside the submitted work. NRG reports Eli Lilly Multi center Treatment Study Grant, Biogen Multi center Treatment Study Grant, and Cytox consultation. PRS reports grants from NIH/NIA, the Anonymous Foundation, the Mason Foundation, from Roth Charitable Foundation during the conduct of the study; personal fees from ICME Speakers &amp; Entertainers, outside the submitted work; and serving as the Interim Director of the Australian National Health and Medical Research Council (NHMRC). DMH co-founded and is on the scientific advisory board of C2N Diagnostics. DMH is an inventor on a submitted patent &#x201c;Antibodies to Tau&#x201d; that is licensed by Washington University to C2N Diagnostics. This patent was subsequently licensed to AbbVie. DMH is an inventor on patents licensed by Washington University to Eli Lilly and Company based on intellectual property related to the anti-Abeta antibody solanezumab. DMH consults for Genentech, AbbVie, Eli Lilly, GlaxoSmithKline, Proclara Biosciences, and Denali. MMW reports grants from NIH/NIA/NIMH, grants from DOD, grants from CA Dept. of Public Health, grants and other from Alzheimer&#x2019;s Drug Discovery Foundation (ADDF), grants from Larry L. Hillblom Foundation, grants from PCORI, grants from Global Alzheimer&#x2019;s Platform Foundation, grants from Monell Chemical Senses Center, grants and other from Alzheimer&#x2019;s Association, other from Pfizer, other from Alzheon, Inc., other from Eli Lilly, other from Dolby Ventures, other from ADNI, other from MRI Magazine, other from Alzheimer&#x2019;s &amp; Dementia Magazine, other from Synarc, other from Janssen, other from Accera Pharma, other from Avid Radiopharma, other from Araclon, other from Merck, other from Scienomics Group, other from AVOS Consulting, other from INC Research, other from Biogen Idec, other from BioClinica, other from Howard University, other from Guidepoint, other from GLG Research, other from Genentech, other from Alzeca, outside the submitted work. PMT reports grants from NIA, NIBIB, and NINDS outside of the submitted work. JCM reports grants from NIH grant P50AG005681, grants from NIH grant P01AG003991, grants from NIH grant P01AG026276, grants from NIH grant UF01AG032438, during the conduct of the study; other from Lilly USA, outside the submitted work. RJB reports grants from NIH/NIA U19AG32438 and an Anonymous Foundation, during the conduct of the study, grants from Eli Lilly, Roche, Pharma Consortium (Abbvie, AstraZeneca, Biogen, Eisai, Eli Lilly and Co., Hoffman La-Roche Inc., Janssen, Pfizer, Sanofi-Aventi), and Tau SILK/PET Consortium (Biogen/Abbvie/Lilly), non-financial support from Avid Radiopharmaceuticals, personal fees and other from Washington University, personal fees and non-financial support from Roche, IMI, FORUM, and Pfizer, and personal fees from Merck, Johnson and Johnson, outside the submitted work. TLSB reports grants, non-financial support and other from Avid Radiopharmaceuticals/Eli Lilly, other from Roche, outside the submitted work. TMB, YS, AH, AD, SF, JC, GW, NJC, RCH, KLP, AMB, JPC, SC, StF, CF, CLM, SS, and MER report no conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29397305</ArticleId><ArticleId IdType="mid">NIHMS941123</ArticleId><ArticleId IdType="pmc">PMC5816717</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(18)30028-0</ArticleId><ArticleId IdType="pii">S1474-4422(18)30028-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pike KE, Savage G, Villemagne VL, et al. &#x3b2;-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer&#x2019;s disease. Brain. 2007:130.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: The amyloid cascade hypothesis. Science (80-) 1992;256:184&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulder KL, Snider BJ, Mills SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther. 2013;5:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978584</ArticleId><ArticleId IdType="pubmed">24131566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83:253&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TLS, Blazey T, Jack CR, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2013;110:E4502&#x2013;4509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839740</ArticleId><ArticleId IdType="pubmed">24194552</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol. 2015;72:316&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355261</ArticleId><ArticleId IdType="pubmed">25580592</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau W-YW, Tudorascu DL, McDade EM, et al. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2015;14:804&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4519011</ArticleId><ArticleId IdType="pubmed">26139022</ArticleId></ArticleIdList></Reference><Reference><Citation>Weston PSJ, Nicholas JM, Lehmann M, et al. Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study. Neurology. 2016 doi: 10.1212/WNL.0000000000003322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003322</ArticleId><ArticleId IdType="pmc">PMC5109950</ArticleId><ArticleId IdType="pubmed">27733562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Gordon BA, Ryman DC, et al. Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology. 2015 doi: 10.1212/WNL.0000000000001903. published online Aug 5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001903</ArticleId><ArticleId IdType="pmc">PMC4553024</ArticleId><ArticleId IdType="pubmed">26245925</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala-Llonch R, Llad? A, Fortea J, et al. Evolving brain structural changes in PSEN1 mutation carriers. Neurobiol Aging. 2015;36:1261&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">25638532</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Fox NC, Frost C, et al. Assessing the onset of structural change in familial Alzheimer&#x2019;s disease. Ann Neurol. 2003;53:181&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12557284</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci Transl Med. 2014;6:226ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight WD, Kim LG, Douiri A, Frost C, Rossor MN, Fox NC. Acceleration of cortical thinning in familial Alzheimer&#x2019;s disease. Neurobiol Aging. 2011;32:1765&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">20005601</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinnunen KM, Cash DM, Poole T, et al. Presymptomatic atrophy in autosomal dominant Alzheimer&#x2019;s disease: a serial MRI study. Alzheimer&#x2019;s Dement. 2017 doi: 10.1016/j.jalz.2017.06.2268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2268</ArticleId><ArticleId IdType="pmc">PMC5751893</ArticleId><ArticleId IdType="pubmed">28738187</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson WK, Hallmayer J, O&#x2019;Hara R Initiative the ADN. Design Considerations for Characterizing Psychiatric Trajectories Across the Lifespan: Application to Effects of APOE-&#x3b5;4 on Cerebral Cortical Thickness in Alzheimer&#x2019;s Disease. Am J Psychiatry. 2011;168:894&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5493321</ArticleId><ArticleId IdType="pubmed">21724665</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Shen X, Pan W, et al. Longitudinal analysis is more powerful than cross-sectional analysis in detecting genetic association with neuroimaging phenotypes. PLoS One. 2014;9:e102312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123854</ArticleId><ArticleId IdType="pubmed">25098835</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills SM, Mallmann J, Santacruz AM, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) 2013;169:737&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880800</ArticleId><ArticleId IdType="pubmed">24016464</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JBS, Fleisher AS, et al. Alzheimer&#x2019;s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(Suppl 3):321&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343739</ArticleId><ArticleId IdType="pubmed">21971471</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RaA, Rentz DMM, Johnson KaA, et al. The A4 Study: Stopping AD before Symptoms Begin? Sci Transl Med Med. 2014;6:228fs13&#x2013;228fs13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43:2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CCR, Bernstein MA, Borowski BBJ, et al. Update on the magnetic resonance imaging core of the Alzheimer&#x2019;s disease neuroimaging initiative. Alzheimer&#x2019;s Dement. 2010;6:212&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886577</ArticleId><ArticleId IdType="pubmed">20451869</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B. FreeSurfer. Neuroimage. 2012;62:774&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685476</ArticleId><ArticleId IdType="pubmed">22248573</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Dale AMM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A. 2000;97:11050&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27146</ArticleId><ArticleId IdType="pubmed">10984517</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, D&#x2019;Angelo GM, Vlassenko AG, et al. Quantitative Analysis of PiB-PET with FreeSurfer ROIs. PLoS One. 2013;8:e73377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3819320</ArticleId><ArticleId IdType="pubmed">24223109</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, et al. Partial volume correction in quantitative amyloid imaging. Neuroimage. 2015;107:55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: Principle and validation. J Nucl Med. 1998;39:904&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. Neuroimage. 2009;46:154&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4308413</ArticleId><ArticleId IdType="pubmed">19457369</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal-Rusiel JL, Reuter M, Greve DN, Fischl B, Sabuncu MR. Spatiotemporal linear mixed effects modeling for the mass-univariate analysis of longitudinal neuroimage data. Neuroimage. 2013;81:358&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3816382</ArticleId><ArticleId IdType="pubmed">23702413</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal-Rusiel JL, Greve DN, Reuter M, Fischl B, Sabuncu MR. Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models. Neuroimage. 2013;66:249&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586747</ArticleId><ArticleId IdType="pubmed">23123680</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgel M, Prince JL, Wong DF, Resnick SM, Jedynak BM. A multivariate nonlinear mixed effects model for longitudinal image analysis: Application to amyloid imaging. Neuroimage. 2016;134:658&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4912927</ArticleId><ArticleId IdType="pubmed">27095307</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Lesnick TG, et al. Brain &#x3b2;-amyloid load approaches a plateau. Neurology. 2013;80:890&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Vemuri P, Wiste HJ, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol. 2012;69:856&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3595157</ArticleId><ArticleId IdType="pubmed">22409939</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter B, Lee D, Brubaker MA, et al. Stan: A Probabilistic Programming Language. J Stat Softw. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9788645</ArticleId><ArticleId IdType="pubmed">36568334</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelman A, Lee D, Guo J. Stan: A Probabilistic Programming Language for Bayesian Inference and Optimization. J Educ Behav Stat. 2015;40:530&#x2013;43.</Citation></Reference><Reference><Citation>Gordon BA, Blazey T, Benzinger TL. Regional variability in Alzheimer&#x2019;s disease biomarkers. Future Neurol. 2014;9:131&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4192718</ArticleId><ArticleId IdType="pubmed">25309132</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Perrotin A, Barr&#xe9; L, et al. Region-specific hierarchy between atrophy, hypometabolism, and &#x3b2;-amyloid (A&#x3b2;) load in Alzheimer&#x2019;s disease dementia. J Neurosci. 2012;32:16265&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794030</ArticleId><ArticleId IdType="pubmed">23152610</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe MJ, Teipel SJ. Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer&#x2019;s disease correspond to dissociable functional brain networks. Hum Brain Mapp. 2016;37:35&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4715545</ArticleId><ArticleId IdType="pubmed">26441321</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68:501&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17065593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann M, Ghosh PM, Madison C, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer&#x2019;s disease. Brain. 2013;136:844&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580269</ArticleId><ArticleId IdType="pubmed">23358601</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xf6;rster S, Grimmer T, Miederer I, et al. Regional Expansion of Hypometabolism in Alzheimer&#x2019;s Disease Follows Amyloid Deposition with Temporal Delay. Biol Psychiatry. 2012;71:792&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21679929</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos P, Kriett L, Haller B, et al. Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2014;10:684&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24857233</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xf6;rster S, Yousefi BH, Wester H-J, et al. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging. 2012;39:1927&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">22926714</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Jacqmin-Gadda H, Le Goff M, et al. Estimating long-term multivariate progression from short-term data. Alzheimer&#x2019;s Dement. 2014;10:S400&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169767</ArticleId><ArticleId IdType="pubmed">24656849</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29403032</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals.</ArticleTitle><Pagination><StartPage>424</StartPage><EndPage>431</EndPage><MedlinePgn>424-431</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-018-0070-z</ELocationID><Abstract><AbstractText>Animal models of Alzheimer's disease have suggested that tau pathology propagation, facilitated by amyloid pathology, may occur along connected pathways. To investigate these ideas in humans, we combined amyloid scans with longitudinal data on white matter connectivity, hippocampal volume, tau positron emission tomography and memory performance in 256 cognitively healthy older individuals. Lower baseline hippocampal volume was associated with increased mean diffusivity of the connecting hippocampal cingulum bundle (HCB). HCB diffusivity predicted tau accumulation in the downstream-connected posterior cingulate cortex in amyloid-positive but not in amyloid-negative individuals. Furthermore, HCB diffusivity predicted memory decline in amyloid-positive individuals with high posterior cingulate cortex tau binding. Our results provide in vivo evidence that higher amyloid pathology strengthens the association between HCB diffusivity and tau accumulation in the downstream posterior cingulate cortex and facilitates memory decline. This confirms amyloid's crucial role in potentiating neural vulnerability and memory decline marking the onset of preclinical Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Heidi I L</ForeName><Initials>HIL</Initials><Identifier Source="ORCID">0000-0001-7620-3822</Identifier><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA. hjacobs@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA. hjacobs@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, Maastricht, The Netherlands. hjacobs@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedden</LastName><ForeName>Trey</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepulcre</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perea</LastName><ForeName>Rodrigo D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>The Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amariglio</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papp</LastName><ForeName>Kathryn V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>The Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P41 EB022544</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037497</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR021110</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR019307</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034556</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB014894</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046396</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026484</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 EB019023</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG053422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG038994</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD010364</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR023043</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG040197</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 EB015896</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR023401</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2018 Mar;21(3):306-308. doi: 10.1038/s41593-018-0085-5.</RefSource><PMID Version="1">29476126</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29403032</ArticleId><ArticleId IdType="mid">NIHMS928431</ArticleId><ArticleId IdType="pmc">PMC5857215</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0070-z</ArticleId><ArticleId IdType="pii">10.1038/s41593-018-0070-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. 1996;92:197&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">8841666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 2014;127:667&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252866</ArticleId><ArticleId IdType="pubmed">24531916</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan UA, et al. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat. Neurosci. 2014;17:304&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044925</ArticleId><ArticleId IdType="pubmed">24362760</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, et al. Hyperphosphorylation determines both the spread and the morphology of tau pathology. Alzheimers Dement. 2016;12:1066&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">27133892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW. Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 2016;131:27&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">26576562</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol. 2011;121:589&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">21516512</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 2016;19:1085&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat. Rev. Neurosci. 2016;17:251&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6701169</ArticleId><ArticleId IdType="pubmed">26988744</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, et al. Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease. Acta Neuropathol. Commun. 2015;3:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371800</ArticleId><ArticleId IdType="pubmed">25853174</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 2016;79:110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquie M, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 2015;78:787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl M, et al. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron. 2016;89:971&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Madden DJ, Bennett IJ, Song AW. Cerebral white matter integrity and cognitive aging: contributions from diffusion tensor imaging. Neuropsychol. Rev. 2009;19:415&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787975</ArticleId><ArticleId IdType="pubmed">19705281</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DK, Leemans A. Diffusion tensor imaging. Methods Mol. Biol. 2011;711:127&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">21279600</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain. 2015;138:2814&#x2013;2833.</Citation><ArticleIdList><ArticleId IdType="pubmed">26283673</ArticleId></ArticleIdList></Reference><Reference><Citation>Villain N, et al. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain. 2010;133:3301&#x2013;3314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3291528</ArticleId><ArticleId IdType="pubmed">20688814</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch. Neurol. 2006;63:674&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682537</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilbronner SR, Haber SN. Frontal cortical and subcortical projections provide a basis for segmenting the cingulum bundle: implications for neuroimaging and psychiatric disorders. J. Neurosci. 2014;34:10041&#x2013;10054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107396</ArticleId><ArticleId IdType="pubmed">25057206</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, et al. In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. J. Neurosci. 2016;36:7364&#x2013;7374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4945661</ArticleId><ArticleId IdType="pubmed">27413148</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Der Heide RJ, Skipper LM, Klobusicky E, Olson IR. Dissecting the uncinate fasciculus: disorders, controversies and a hypothesis. Brain. 2013;136:1692&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3673595</ArticleId><ArticleId IdType="pubmed">23649697</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A, et al. Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp. Gerontol. 2002;37:1291&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470843</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagley A, et al. Harvard Aging Brain Study: Dataset and accessibility. Neuroimage. 2017;144:255&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4592689</ArticleId><ArticleId IdType="pubmed">25843019</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage. 1999;9:195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931269</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 1990;10:740&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">2384545</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71:1379&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293023</ArticleId><ArticleId IdType="pubmed">25222039</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging. 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch. Neurol. 2011;68:1062&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">21482918</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler-Kingshott CA, Cercignani M. About "axial" and "radial" diffusivities. Magn. Reson. Med. 2009;61:1255&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pubmed">19253405</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. Nat. Commun. 2015;6:8490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4608380</ArticleId><ArticleId IdType="pubmed">26458742</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, et al. Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron. 2010;68:428&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050043</ArticleId><ArticleId IdType="pubmed">21040845</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J. Neurosci. 2009;29:1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Dillen KN, et al. Aberrant functional connectivity differentiates retrosplenial cortex from posterior cingulate cortex in prodromal Alzheimer's disease. Neurobiol. Aging. 2016;44:114&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">27318139</ArticleId></ArticleIdList></Reference><Reference><Citation>Vann SD, Aggleton JP, Maguire EA. What does the retrosplenial cortex do? Nat. Rev. Neurosci. 2009;10:792&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">19812579</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieckmann A, et al. Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease. Neurobiol. Aging. 2016;42:177&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4857135</ArticleId><ArticleId IdType="pubmed">27143434</ArticleId></ArticleIdList></Reference><Reference><Citation>Stancu IC, Vasconcelos B, Terwel D, Dewachter I. Models of beta-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism. Mol. Neurodegener. 2014;9:51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255655</ArticleId><ArticleId IdType="pubmed">25407337</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nat. Rev. 2016;12:15&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">26635213</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurtado DE, et al. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am. J. Pathol. 2010;177:1977&#x2013;1988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947292</ArticleId><ArticleId IdType="pubmed">20802182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, et al. Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc. Natl. Acad. Sci. U.S.A. 2014;111:510&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3890777</ArticleId><ArticleId IdType="pubmed">24368848</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain. 2016;139:2249&#x2013;2260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958902</ArticleId><ArticleId IdType="pubmed">27286736</ArticleId></ArticleIdList></Reference><Reference><Citation>Frings L, et al. Asymmetries of amyloid-beta burden and neuronal dysfunction are positively correlated in Alzheimer's disease. Brain. 2015;138:3089&#x2013;3099.</Citation><ArticleIdList><ArticleId IdType="pubmed">26280595</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanits H, Budka H, Kovacs GG. Asymmetry of neurodegenerative disease-related pathologies: a cautionary note. Acta Neuropathol. 2012;123:449&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">22222584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, et al. Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann. Neurol. 2017;81:583&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404378</ArticleId><ArticleId IdType="pubmed">28253546</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh J, Yesavage J. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. in. In: Brink TL, editor. Clinical Gerontology: A Guide to Assessment and Intervention. Haworth Press; New York: 1986. pp. 165&#x2013;173.</Citation></Reference><Reference><Citation>Leemans A, Jeurissen B, Sijbers J, Jones DK. 17th Annual Meeting of Intl. Soc. Mag. Reson. Med. Hawaii, USA: 2009. Explore DTI: a graphical toolbox for processing, analyzing, and visualizing diffusion MR data. in; p. 3537.</Citation></Reference><Reference><Citation>Mori S, et al. Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage. 2008;40:570&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2478641</ArticleId><ArticleId IdType="pubmed">18255316</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein A, et al. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage. 2009;46:786&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747506</ArticleId><ArticleId IdType="pubmed">19195496</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SB, Jones DK, Viergever MA, Leemans A. Partial volume effect as a hidden covariate in DTI analyses. Neuroimage. 2011;55:1566&#x2013;1576.</Citation><ArticleIdList><ArticleId IdType="pubmed">21262366</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa S, Schielzeth H. Repeatability for Gaussian and non-Gaussian data: a practical guide for biologists. Biol. Rev. Camb. Philos. Soc. 2010;85:935&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">20569253</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999;9:179&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931268</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J. Neurosci. 2009;29:12686&#x2013;12694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012;50:2880&#x2013;2886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3473106</ArticleId><ArticleId IdType="pubmed">22940426</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoup TM, et al. A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J. Labelled Comp. Radiopharm. 2013;56:736&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114396</ArticleId><ArticleId IdType="pubmed">24339014</ArticleId></ArticleIdList></Reference><Reference><Citation>Greve DN, et al. Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage. 2014;92:225&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008670</ArticleId><ArticleId IdType="pubmed">24361666</ArticleId></ArticleIdList></Reference><Reference><Citation>Masur DM, et al. Distinguishing normal and demented elderly with the selective reminding test. J. Clin. Exp. Neuropsychol. 1989;11:615&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">2808653</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler DS. Wechsler Memory Scale-Revised. Psychological-Corp; San Antonio, TX: 1987.</Citation></Reference><Reference><Citation>Wechsler DS. WAIS-III, Wechsler Adult Intelligence Scale&#x2014;Third Edition, Administration and Scoring Manual. The Psychological Corporation; New York: 1997.</Citation></Reference><Reference><Citation>Reitan RM. Manual for administration of neuropsychological test batteries for adults and children. Reitan Neuropsychology Laboratories; Tucson, AZ: 1979.</Citation></Reference><Reference><Citation>Benton AL. Contributions to Neuropsychological Assessment: A Clinical Manual. Oxford University Press; New York: 1983.</Citation></Reference><Reference><Citation>Domen P, et al. Differential Time Course of Microstructural White Matter in Patients With Psychotic Disorder and Individuals at Risk: A 3-Year Follow-up Study. Schizophr. Bull. 2017;43:160&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5216846</ArticleId><ArticleId IdType="pubmed">27190279</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82:1760&#x2013;1767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, et al. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between beta-Amyloid and Tauopathy. JAMA Neurol. 2016;73:1070&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237382</ArticleId><ArticleId IdType="pubmed">27454922</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29414379</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><PubDate><Year>2018</Year><Month>May</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>Prion-like seeding and nucleation of intracellular amyloid-&#x3b2;.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>10</EndPage><MedlinePgn>1-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2018.01.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-9961(18)30021-4</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) brain tissue can act as a seed to accelerate aggregation of amyloid-&#x3b2; (A&#x3b2;) into plaques in AD transgenic mice. A&#x3b2; seeds have been hypothesized to accelerate plaque formation in a prion-like manner of templated seeding and intercellular propagation. However, the structure(s) and location(s) of the A&#x3b2; seeds remain unknown. Moreover, in contrast to tau and &#x3b1;-synuclein, an in vitro system with prion-like A&#x3b2; has not been reported. Here we treat human APP expressing N2a cells with AD transgenic mouse brain extracts to induce inclusions of A&#x3b2; in a subset of cells. We isolate cells with induced A&#x3b2; inclusions and using immunocytochemistry, western blot and infrared spectroscopy show that these cells produce oligomeric A&#x3b2; over multiple replicative generations. Further, we demonstrate that cell lysates of clones with induced oligomeric A&#x3b2; can induce aggregation in previously untreated N2a APP cells. These data strengthen the case that A&#x3b2; acts as a prion-like protein, demonstrate that A&#x3b2; seeds can be intracellular oligomers and for the first time provide a cellular model of nucleated seeding of A&#x3b2;.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Tomas T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Experimental Dementia Research Unit, Dept. of Experimental Medical Science, Lund University, Lund, Sweden. Electronic address: Tomas.Olsson@med.lu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klementieva</LastName><ForeName>Oxana</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Experimental Dementia Research Unit, Dept. of Experimental Medical Science, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gouras</LastName><ForeName>Gunnar K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Experimental Dementia Research Unit, Dept. of Experimental Medical Science, Lund University, Lund, Sweden. Electronic address: Gunnar.Gouras@med.lu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072002">Prion Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007424" MajorTopicYN="N">Intracellular Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072002" MajorTopicYN="N">Prion Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016548" MajorTopicYN="N">Prosencephalon</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Amyloid</Keyword><Keyword MajorTopicYN="N">FTIR</Keyword><Keyword MajorTopicYN="N">Oligomers</Keyword><Keyword MajorTopicYN="N">Prion-like</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29414379</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2018.01.015</ArticleId><ArticleId IdType="pii">S0969-9961(18)30021-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29435558</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.</ArticleTitle><Pagination><StartPage>548</StartPage><EndPage>556</EndPage><MedlinePgn>548-556</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.4907</ELocationID><Abstract><AbstractText Label="IMPORTANCE">It is critically important to improve our ability to diagnose and track Alzheimer disease (AD) as early as possible. Individuals with autosomal dominant forms of AD can provide clues as to which and when biological changes are reliably present prior to the onset of clinical symptoms.</AbstractText><AbstractText Label="OBJECTIVE">To characterize the associations between amyloid and tau deposits in the brains of cognitively unimpaired and impaired carriers of presenilin 1 (PSEN1) E280A mutation.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In this cross-sectional imaging study, we leveraged data from a homogeneous autosomal dominant AD kindred, which allowed us to examine measurable tau deposition as a function of individuals' proximity to the expected onset of dementia. Cross-sectional measures of carbon 11-labeled Pittsburgh Compound B positron emission tomography (PET) and flortaucipir F 18 (previously known as AV 1451, T807) PET imaging were assessed in 24 PSEN1 E280A kindred members (age range, 28-55 years), including 12 carriers, 9 of whom were cognitively unimpaired and 3 of whom had mild cognitive impairment, and 12 cognitively unimpaired noncarriers.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">We compared carbon 11-labeled Pittsburgh Compound B PET cerebral with cerebellar distribution volume ratios as well as flortaucipir F 18 PET cerebral with cerebellar standardized uptake value ratios in mutation carriers and noncarriers. Spearman correlations characterized the associations between age and mean cortical Pittsburgh Compound B distribution volume ratio levels or regional flortaucipir standardized uptake value ratio levels in both groups.</AbstractText><AbstractText Label="RESULTS">Of the 24 individuals, the mean (SD) age was 38.0 (7.4) years, or approximately 6 years younger than the expected onset of clinical symptoms in carriers. Compared with noncarriers, cognitively unimpaired mutation carriers had elevated mean cortical Pittsburgh Compound B distribution volume ratio levels in their late 20s, and 7 of 9 carriers older than 30 years reached the threshold for amyloidosis (distribution volume ratio level&#x2009;&gt;&#x2009;1.2). Elevated levels of tau deposition were seen within medial temporal lobe regions in amyloid-positive mutation carriers 6 years before clinical onset of AD in this kindred. Substantial tau deposition in the neocortex was only observed in 1 unimpaired carrier and in those with mild cognitive impairment. &#x3b2;-Amyloid uptake levels were diffusely elevated in unimpaired carriers approximately 15 years prior to expected onset of mild cognitive impairment. In carriers, higher levels of tau deposition were associated with worse performance on the Mini-Mental State Examination (entorhinal cortex: r&#x2009;=&#x2009;-0.60; P&#x2009;=&#x2009;.04; inferior temporal lobe: r&#x2009;=&#x2009;-0.54; P&#x2009;=&#x2009;.06) and the Consortium to Establish a Registry for Alzheimer Disease Word List Delayed Recall (entorhinal cortex: r&#x2009;=&#x2009;-0.86; P&#x2009;&lt;&#x2009;.001; inferior temporal lobe: r&#x2009;=&#x2009;-0.70; P&#x2009;=&#x2009;.01).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The present findings add to the growing evidence that molecular markers can characterize biological changes associated with AD in individuals who are still cognitively unimpaired. The findings also suggest that tau PET imaging may be useful as a biomarker to distinguish individuals at high risk to develop the clinical symptoms of AD and to track disease progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Yakeel T</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medellin, Antioquia, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baena</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medellin, Antioquia, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arboleda-Velasquez</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosio</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lapoint</LastName><ForeName>Molly</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzman-Velez</LastName><ForeName>Edmarie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>John B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Massachusetts Eye and Ear, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Leo A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts Eye and Ear, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopera</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medellin, Antioquia, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP5 OD019833</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046396</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="AssociatedDataset"><RefSource>JAMA Neurol. 2018 May 1;75(5):536-538. doi: 10.1001/jamaneurol.2017.4026.</RefSource><PMID Version="1">29435570</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003105" MajorTopicYN="N" Type="Geographic">Colombia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Quiroz was supported by grants 1200-228010 and 1200-228767 from the Massachusetts General Hospital Executive Committee on Research. Dr Sperling receives research support from grants U01 AG032438, U01 AG024904, R01 AG037497, R01 AG034556, and U19 AG010483 from the National Institutes of Health. She is a site principal investigator or coinvestigator for Avid, Bristol-Myers Squibb, Pfizer, and Janssen Alzheimer Immunotherapy clinical trials. Dr Tariot has provided consulting services for Abbott Laboratories, AbbVie, AC Immune, Boehringer-Ingelheim, California Pacific Medical Center, Chase Pharmaceuticals, CME Inc, Medavante, Otsuka, Sanofi-Aventis, Eli Lilly and Company, AstraZeneca, Avanir, Bristol-Myers Squibb, Cognoptix, Janssen, Merck and Company, and Roche; has received research support from AstraZeneca, Avanir, Bristol-Myers Squibb, Cognoptix, Janssen, Merck and Company, Roche, Baxter, Functional Neuromodulation, GE Healthcare, Genentech, Pfizer, Targacept, Avid Radiopharmaceuticals, the National Institute on Aging, and the Arizona Department of Health Services; owns stock options in Adamas Pharmaceuticals; and has contributed to a patent for biomarkers of Alzheimer disease owned by the University of Rochester. Dr Reiman has received research funding from AVID and has served as a paid consultant for Eli Lilly. Dr Johnson has provided consulting services for Lilly, Novartis, Janssen, Roche, Piramal, GE Healthcare, Siemens, ISIS Pharma, AZTherapy, and Biogen; has received support from a joint National Institutes of Health&#x2013; and Lilly-sponsored clinical trial (Anti-Amyloid Treatment in Asymptomatic Alzheimer&#x2019;s [A4] Study); and has received research support from the National Institute on Aging (grants U19AG10483 and U01AG024904-S1), Fidelity Biosciences, the Michael J. Fox Foundation, and the Alzheimer&#x2019;s Association. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>2</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29435558</ArticleId><ArticleId IdType="pmc">PMC5885174</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.4907</ArticleId><ArticleId IdType="pii">2671402</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Iqbal K, Grundke-Iqbal I. Neurofibrillary pathology leads to synaptic loss and not the other way around in Alzheimer disease. J Alzheimers Dis. 2002;4(3):235-238.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226542</ArticleId></ArticleIdList></Reference><Reference><Citation>Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer&#x2019;s disease. Hum Mol Genet. 2010;19(R1):R12-R20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875049</ArticleId><ArticleId IdType="pubmed">20413653</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer&#x2019;s disease. Cereb Cortex. 1991;1(1):103-116.</Citation><ArticleIdList><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopera F, Ardilla A, Mart&#xed;nez A, et al. . Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA. 1997;277(10):793-799.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052708</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. . Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol. 2015;72(3):316-324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355261</ArticleId><ArticleId IdType="pubmed">25580592</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Quiroz YT, Fleisher AS, et al. . Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer&#x2019;s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11(12):1048-1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. ; Dominantly Inherited Alzheimer Network . Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367(9):795-804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Baena N, Sepulveda-Falla D, Lopera-G&#xf3;mez CM, et al. . Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer&#x2019;s disease: a retrospective cohort study. Lancet Neurol. 2011;10(3):213-220.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296022</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Schultz AP, Chen K, et al. . Brain imaging and blood biomarker abnormalities in children with autosomal dominant Alzheimer disease: a cross-sectional study. JAMA Neurol. 2015;72(8):912-919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625544</ArticleId><ArticleId IdType="pubmed">26121081</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):270-279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre-Acevedo DC, G&#xf3;mez RD, Moreno S, et al. . Validity and reliability of the CERAD-Col neuropsychological battery [in Spanish]. Rev Neurol. 2007;45(11):655-660.</Citation><ArticleIdList><ArticleId IdType="pubmed">18050096</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA. Opportunities for and obstacles to treatments for dementias. J Am Geriatr Soc. 1983;31(1):59-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6848578</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B. Functional Assessment Staging (FAST). Psychopharmacol Bull. 1988;24(4):653-659.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249767</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoup TM, Yokell DL, Rice PA, et al. . A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J Labelled Comp Radiopharm. 2013;56(14):736-740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114396</ArticleId><ArticleId IdType="pubmed">24339014</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, et al. . Amyloid-&#x3b2; associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032-1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, R&#xfc;b U, Schultz C, Del Tredici K. Vulnerability of cortical neurons to Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. J Alzheimers Dis. 2006;9(3, suppl):35-44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914843</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer&#x2019;s disease. Neurobiol Aging. 1997;18(4, suppl):S85-S88.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330992</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, et al. . Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457-468.</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Benzinger TL, Su Y, et al. . Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between &#x3b2;-amyloid and tauopathy. JAMA Neurol. 2016;73(9):1070-1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237382</ArticleId><ArticleId IdType="pubmed">27454922</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, et al. . Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10(5):740-747.</Citation><ArticleIdList><ArticleId IdType="pubmed">2384545</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, Mormino EC, Pietras AC, et al. . Subjective cognitive concerns, amyloid-&#x3b2;, and neurodegeneration in clinically normal elderly. Neurology. 2015;85(1):56-62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4501939</ArticleId><ArticleId IdType="pubmed">26048028</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Van Dijk KR, Becker JA, et al. . Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29(40):12686-12694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. . Synergistic effect of &#x3b2;-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71(11):1379-1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293023</ArticleId><ArticleId IdType="pubmed">25222039</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Johnson KA, Doraiswamy PM, et al. ; AV45-A05 Study Group . Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging. 2013;34(3):822-831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3518678</ArticleId><ArticleId IdType="pubmed">22878163</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF, Saunders AM, Smith TW, et al. . Familial and sporadic Alzheimer&#x2019;s disease: neuropathology cannot exclude a final common pathway. Neurology. 1996;46(2):406-412.</Citation><ArticleIdList><ArticleId IdType="pubmed">8614503</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulveda-Falla D, Matschke J, Bernreuther C, et al. . Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer&#x2019;s disease. Brain Pathol. 2011;21(4):452-463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094246</ArticleId><ArticleId IdType="pubmed">21159009</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. . Florbetapir PET analysis of amyloid-&#x3b2; deposition in the presenilin 1 E280A autosomal dominant Alzheimer&#x2019;s disease kindred: a cross-sectional study. Lancet Neurol. 2012;11(12):1057-1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515078</ArticleId><ArticleId IdType="pubmed">23137949</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Liu X, et al. . Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68(11):1404-1411.</Citation><ArticleIdList><ArticleId IdType="pubmed">21747008</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TL, Blazey T, Jack CR Jr, et al. . Regional variability of imaging biomarkers in autosomal dominant Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2013;110(47):E4502-E4509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839740</ArticleId><ArticleId IdType="pubmed">24194552</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TLS, Gordon BA, Friedrichsen KA, et al. ; Dominantly Inherited Alzheimer Network (DIAN) Study Group . Tau PET imaging with AV-1451 in autosomal dominant Alzheimer&#x2019;s disease: update from the Dominantly Inherited Alzheimer Network (DIAN). Alzheimers Dement. 2016;12(7, suppl):378. doi:10.1016/j.jalz.2016.06.709</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.06.709</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger T, Friedrichsen K, Sul Y, et al. Patterns of tau deposition using [18F]-AV-1451 in autosomal dominant Alzheimer&#x2019;s disease: results from the DIAN. Paper presented at: Human Amyloid Imaging 2016; January 14, 2016; Miami, FL.</Citation></Reference><Reference><Citation>Reiman EM, Langbaum JB, Fleisher AS, et al. . Alzheimer&#x2019;s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(suppl 3):321-329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343739</ArticleId><ArticleId IdType="pubmed">21971471</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29437957</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>115</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>Feb</Month><Day>20</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Normal aging induces A1-like astrocyte reactivity.</ArticleTitle><Pagination><StartPage>E1896</StartPage><EndPage>E1905</EndPage><MedlinePgn>E1896-E1905</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1800165115</ELocationID><Abstract><AbstractText>The decline of cognitive function occurs with aging, but the mechanisms responsible are unknown. Astrocytes instruct the formation, maturation, and elimination of synapses, and impairment of these functions has been implicated in many diseases. These findings raise the question of whether astrocyte dysfunction could contribute to cognitive decline in aging. We used the Bac-Trap method to perform RNA sequencing of astrocytes from different brain regions across the lifespan of the mouse. We found that astrocytes have region-specific transcriptional identities that change with age in a region-dependent manner. We validated our findings using fluorescence in situ hybridization and quantitative PCR. Detailed analysis of the differentially expressed genes in aging revealed that aged astrocytes take on a reactive phenotype of neuroinflammatory A1-like reactive astrocytes. Hippocampal and striatal astrocytes up-regulated a greater number of reactive astrocyte genes compared with cortical astrocytes. Moreover, aged brains formed many more A1 reactive astrocytes in response to the neuroinflammation inducer lipopolysaccharide. We found that the aging-induced up-regulation of reactive astrocyte genes was significantly reduced in mice lacking the microglial-secreted cytokines (IL-1&#x3b1;, TNF, and C1q) known to induce A1 reactive astrocyte formation, indicating that microglia promote astrocyte activation in aging. Since A1 reactive astrocytes lose the ability to carry out their normal functions, produce complement components, and release a toxic factor which kills neurons and oligodendrocytes, the aging-induced up-regulation of reactive genes by astrocytes could contribute to the cognitive decline in vulnerable brain regions in normal aging and contribute to the greater vulnerability of the aged brain to injury.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 the Author(s). Published by PNAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Laura E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, School of Medicine, Stanford, CA 94305; lclarke2@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liddelow</LastName><ForeName>Shane A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute, NYU Langone Medical Center, New York, NY 10016.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Physiology, NYU Langone Medical Center, New York, NY 10016.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakraborty</LastName><ForeName>Chandrani</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;nch</LastName><ForeName>Alexandra E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heiman</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02142.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Cambridge, MA 02139.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barres</LastName><ForeName>Ben A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG048814</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053582">Interleukin-1alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053582" MajorTopicYN="N">Interleukin-1alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RNA sequencing</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">cognitive decline</Keyword><Keyword MajorTopicYN="N">microglia</Keyword></KeywordList><CoiStatement>Conflict of interest statement: B.A.B. was a cofounder of Annexon Biosciences Inc., a company working to make new drugs for treatment of neurological diseases.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29437957</ArticleId><ArticleId IdType="pmc">PMC5828643</ArticleId><ArticleId IdType="doi">10.1073/pnas.1800165115</ArticleId><ArticleId IdType="pii">1800165115</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Christopherson KS, et al. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell. 2005;120:421&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">15707899</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukdereli H, et al. Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. Proc Natl Acad Sci USA. 2011;108:E440&#x2013;E449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156217</ArticleId><ArticleId IdType="pubmed">21788491</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen NJ, et al. Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors. Nature. 2012;486:410&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383085</ArticleId><ArticleId IdType="pubmed">22722203</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WS, et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature. 2013;504:394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969024</ArticleId><ArticleId IdType="pubmed">24270812</ArticleId></ArticleIdList></Reference><Reference><Citation>Banker GA. Trophic interactions between astroglial cells and hippocampal neurons in culture. Science. 1980;209:809&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">7403847</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;16:675&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">8785064</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush TG, et al. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron. 1999;23:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10399936</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekar S, et al. Alzheimer&#x2019;s disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes. Neurobiol Aging. 2015;36:583&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4315763</ArticleId><ArticleId IdType="pubmed">25448601</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallmann AL, et al. Astrocyte pathology in a human neural stem cell model of frontotemporal dementia caused by mutant TAU protein. Sci Rep. 2017;7:42991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5335603</ArticleId><ArticleId IdType="pubmed">28256506</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10:615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP, Boulting GL, Bobrowicz S, Eggan KC. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell. 2008;3:637&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041780</ArticleId></ArticleIdList></Reference><Reference><Citation>Soreq L, et al. UK Brain Expression Consortium; North American Brain Expression Consortium Major shifts in glial regional identity are a transcriptional hallmark of human brain aging. Cell Rep. 2017;18:557&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5263238</ArticleId><ArticleId IdType="pubmed">28076797</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabert K, et al. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat Neurosci. 2016;19:504&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768346</ArticleId><ArticleId IdType="pubmed">26780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16:1896&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Norden DM, Godbout JP. Review: Microglia of the aged brain: Primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol. 2013;39:19&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553257</ArticleId><ArticleId IdType="pubmed">23039106</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols NR, Day JR, Laping NJ, Johnson SA, Finch CE. GFAP mRNA increases with age in rat and human brain. Neurobiol Aging. 1993;14:421&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">8247224</ArticleId></ArticleIdList></Reference><Reference><Citation>Porchet R, et al. Analysis of glial acidic fibrillary protein in the human entorhinal cortex during aging and in Alzheimer&#x2019;s disease. Proteomics. 2003;3:1476&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pubmed">12923773</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian JL, et al. Genomic analysis of reactive astrogliosis. J Neurosci. 2012;32:6391&#x2013;6410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480225</ArticleId><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle JP, et al. Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell. 2008;135:749&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763427</ArticleId><ArticleId IdType="pubmed">19013282</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman M, Kulicke R, Fenster RJ, Greengard P, Heintz N. Cell type-specific mRNA purification by translating ribosome affinity purification (TRAP) Nat Protoc. 2014;9:1282&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4102313</ArticleId><ArticleId IdType="pubmed">24810037</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougherty JD, Schmidt EF, Nakajima M, Heintz N. Analytical approaches to RNA profiling data for the identification of genes enriched in specific cells. Nucleic Acids Res. 2010;38:4218&#x2013;4230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910036</ArticleId><ArticleId IdType="pubmed">20308160</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann JE, et al. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J Neurosci. 2008;28:7231&#x2013;7243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2583788</ArticleId><ArticleId IdType="pubmed">18614693</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MA, et al. Astrocyte scar formation aids central nervous system axon regeneration. Nature. 2016;532:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5243141</ArticleId><ArticleId IdType="pubmed">27027288</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: From stressor thresholds to degeneration. Neuron. 2011;71:35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">21745636</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci. 2006;7:278&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710114</ArticleId><ArticleId IdType="pubmed">16552414</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh SK, et al. Astrocytes assemble thalamocortical synapses by bridging NRX1&#x3b1; and NL1 via Hevin. Cell. 2016;164:183&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4715262</ArticleId><ArticleId IdType="pubmed">26771491</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan AH, et al. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci. 2013;33:13460&#x2013;13474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742932</ArticleId><ArticleId IdType="pubmed">23946404</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke SN, Barnes CA. Neural plasticity in the ageing brain. Nat Rev Neurosci. 2006;7:30&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">16371948</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinonen V, et al. Amyloid and tau proteins in cortical brain biopsy and Alzheimer&#x2019;s disease. Ann Neurol. 2010;68:446&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">20976765</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386:1672&#x2013;1682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5970949</ArticleId><ArticleId IdType="pubmed">26595641</ArticleId></ArticleIdList></Reference><Reference><Citation>Molofsky AV, et al. Astrocyte-encoded positional cues maintain sensorimotor circuit integrity. Nature. 2014;509:189&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057936</ArticleId><ArticleId IdType="pubmed">24776795</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai H, et al. Neural circuit-specialized astrocytes: Transcriptomic, proteomic, morphological, and functional evidence. Neuron. 2017;95:531&#x2013;549.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5811312</ArticleId><ArticleId IdType="pubmed">28712653</ArticleId></ArticleIdList></Reference><Reference><Citation>Morel L, et al. Molecular and functional properties of regional astrocytes in the adult brain. J Neurosci. 2017;37:8706&#x2013;8717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5588463</ArticleId><ArticleId IdType="pubmed">28821665</ArticleId></ArticleIdList></Reference><Reference><Citation>Godbout JP, et al. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J. 2005;19:1329&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pubmed">15919760</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry CJ, et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation. 2008;5:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2412862</ArticleId><ArticleId IdType="pubmed">18477398</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein RS, et al. Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol. 2005;79:11457&#x2013;11466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1193600</ArticleId><ArticleId IdType="pubmed">16103196</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessy E, Griffin EW, Cunningham C. Astrocytes are primed by chronic neurodegeneration to produce exaggerated chemokine and cell infiltration responses to acute stimulation with the cytokines IL-1&#x3b2; and TNF-&#x3b1;. J Neurosci. 2015;35:8411&#x2013;8422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4452550</ArticleId><ArticleId IdType="pubmed">26041910</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q, et al. Complement C3-deficient mice fail to display age-related hippocampal decline. J Neurosci. 2015;35:13029&#x2013;13042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605437</ArticleId><ArticleId IdType="pubmed">26400934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher KI, Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer&#x2019;s disease. Biochem Pharmacol. 2014;88:594&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra A, Gottfried-Blackmore AC, McEwen BS, Bulloch K. Microglia derived from aging mice exhibit an altered inflammatory profile. Glia. 2007;55:412&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">17203473</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan S, et al. Age-related myelin degradation burdens the clearance function of microglia during aging. Nat Neurosci. 2016;19:995&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116794</ArticleId><ArticleId IdType="pubmed">27294511</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, et al. The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology. 2015;84:927&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351662</ArticleId><ArticleId IdType="pubmed">25653292</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74:691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialas AR, Stevens B. TGF-&#x3b2; signaling regulates neuronal C1q expression and developmental synaptic refinement. Nat Neurosci. 2013;16:1773&#x2013;1782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3973738</ArticleId><ArticleId IdType="pubmed">24162655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritzel RM, et al. Age-associated resident memory CD8 T cells in the central nervous system are primed to potentiate inflammation after ischemic brain injury. J Immunol. 2016;196:3318&#x2013;3330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4868658</ArticleId><ArticleId IdType="pubmed">26962232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, et al. TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053844</ArticleId><ArticleId IdType="pubmed">23618408</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: A bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W. FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W. The subread aligner: Fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 2013;41:e108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664803</ArticleId><ArticleId IdType="pubmed">23558742</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardou P, Mariette J, Escudi&#xe9; F, Djemiel C, Klopp C. jvenn: An interactive Venn diagram viewer. BMC Bioinformatics. 2014;15:293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4261873</ArticleId><ArticleId IdType="pubmed">25176396</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki R, Shimodaira H. 2014 pvclust: Hierarchial clustering with P-values via multiscale bootstrap resampling. Available at  cran.r-project.org/web/packages/pvclust/index.html. Accessed October 4, 2017.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29439243</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>359</Volume><Issue>6376</Issue><PubDate><Year>2018</Year><Month>Feb</Month><Day>09</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Atomic structures of low-complexity protein segments reveal kinked &#x3b2; sheets that assemble networks.</ArticleTitle><Pagination><StartPage>698</StartPage><EndPage>701</EndPage><MedlinePgn>698-701</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aan6398</ELocationID><Abstract><AbstractText>Subcellular membraneless assemblies are a reinvigorated area of study in biology, with spirited scientific discussions on the forces between the low-complexity protein domains within these assemblies. To illuminate these forces, we determined the atomic structures of five segments from protein low-complexity domains associated with membraneless assemblies. Their common structural feature is the stacking of segments into kinked &#x3b2; sheets that pair into protofilaments. Unlike steric zippers of amyloid fibrils, the kinked sheets interact weakly through polar atoms and aromatic side chains. By computationally threading the human proteome on our kinked structures, we identified hundreds of low-complexity segments potentially capable of forming such interactions. These segments are found in proteins as diverse as RNA binders, nuclear pore proteins, and keratins, which are known to form networks and localize to membraneless assemblies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-6239-4151</Identifier><AffiliationInfo><Affiliation>Department of Biological Chemistry and Department of Chemistry and Biochemistry, University of California Los Angeles (UCLA), Howard Hughes Medical Institute (HHMI), UCLA-Department of Energy (DOE) Institute for Genomics and Proteomics, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawaya</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0874-9043</Identifier><AffiliationInfo><Affiliation>Department of Biological Chemistry and Department of Chemistry and Biochemistry, University of California Los Angeles (UCLA), Howard Hughes Medical Institute (HHMI), UCLA-Department of Energy (DOE) Institute for Genomics and Proteomics, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyer</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-4487-0230</Identifier><AffiliationInfo><Affiliation>Department of Biological Chemistry and Department of Chemistry and Biochemistry, University of California Los Angeles (UCLA), Howard Hughes Medical Institute (HHMI), UCLA-Department of Energy (DOE) Institute for Genomics and Proteomics, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldschmidt</LastName><ForeName>Lukasz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biological Chemistry and Department of Chemistry and Biochemistry, University of California Los Angeles (UCLA), Howard Hughes Medical Institute (HHMI), UCLA-Department of Energy (DOE) Institute for Genomics and Proteomics, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Jose A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-8471-2504</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, UCLA, UCLA-DOE Institute for Genomics and Proteomics, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cascio</LastName><ForeName>Duilio</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8285-754X</Identifier><AffiliationInfo><Affiliation>Department of Biological Chemistry and Department of Chemistry and Biochemistry, University of California Los Angeles (UCLA), Howard Hughes Medical Institute (HHMI), UCLA-Department of Energy (DOE) Institute for Genomics and Proteomics, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7667-9441</Identifier><AffiliationInfo><Affiliation>Department of Biological Chemistry and Department of Chemistry and Biochemistry, University of California Los Angeles (UCLA), Howard Hughes Medical Institute (HHMI), UCLA-Department of Energy (DOE) Institute for Genomics and Proteomics, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonen</LastName><ForeName>Tamir</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>HHMI and Department of Physiology, UCLA, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenberg</LastName><ForeName>David S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0003-2432-5419</Identifier><AffiliationInfo><Affiliation>Department of Biological Chemistry and Department of Chemistry and Biochemistry, University of California Los Angeles (UCLA), Howard Hughes Medical Institute (HHMI), UCLA-Department of Energy (DOE) Institute for Genomics and Proteomics, Los Angeles, CA 90095, USA. david@mbi.ucla.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103403</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054022</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072757" MajorTopicYN="Y">Protein Conformation, beta-Strand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054730" MajorTopicYN="Y">Protein Interaction Domains and Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29439243</ArticleId><ArticleId IdType="mid">NIHMS991708</ArticleId><ArticleId IdType="pmc">PMC6192703</ArticleId><ArticleId IdType="doi">10.1126/science.aan6398</ArticleId><ArticleId IdType="pii">359/6376/698</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hennig S et al., Prion-like domains in RNA binding proteins are essential for building subnuclear paraspeckles. J. Cell Biol 210, 529&#x2013;539 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539981</ArticleId><ArticleId IdType="pubmed">26283796</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Altmeyer M, Phase Separation: Linking Cellular Compartmentalization to Disease. Trends Cell Biol 26, 547&#x2013;558 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27051975</ArticleId></ArticleIdList></Reference><Reference><Citation>Banani SF, Lee HO, Hyman AA, Rosen MK, Biomolecular condensates: organizers of cellular biochemistry. Nat. Rev. Mol. Cell Biol 18, 285&#x2013;298 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7434221</ArticleId><ArticleId IdType="pubmed">28225081</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P et al., Phase transitions in the assembly of multivalent signalling proteins. Nature 483, 336&#x2013;340 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343696</ArticleId><ArticleId IdType="pubmed">22398450</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M et al., Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell 149, 753&#x2013;767 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaum-Garfinkle S, Brangwynne CP, Liquids, Fibers, and Gels: The Many Phases of Neurodegeneration. Dev. Cell 35, 531&#x2013;532 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26651288</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Protter DSW, Rosen MK, Parker R, Formation and Maturation of Phase-Separated Liquid Droplets by RNA-Binding Proteins. Mol. Cell 60, 208&#x2013;219 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609299</ArticleId><ArticleId IdType="pubmed">26412307</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison AF, Shorter J, RNA-binding proteins with prion-like domains in health and disease. Biochem. J 474, 1417&#x2013;1438 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639257</ArticleId><ArticleId IdType="pubmed">28389532</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T et al., ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function. Neuron 88, 678&#x2013;690 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4660210</ArticleId><ArticleId IdType="pubmed">26526393</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A et al., A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell 162, 1066&#x2013;1077 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A et al., Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell 163, 123&#x2013;133 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang S et al., The LC Domain of hnRNPA2 Adopts Similar Conformations in Hydrogel Polymers, Liquid-like Droplets, and Nuclei. Cell 163, 829&#x2013;839 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879888</ArticleId><ArticleId IdType="pubmed">26544936</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari B, Kumar R, Kumar M, Low complexity and disordered regions of proteins have different structural and amino acid preferences. Mol. Biosyst 11, 585&#x2013;594 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25468592</ArticleId></ArticleIdList></Reference><Reference><Citation>Wootton JC, Non-globular domains in protein sequences: automated segmentation using complexity measures. Comput. Chem 18, 269&#x2013;285 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7952898</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz JC, Cech TR, Parker RR, Biochemical Properties and Biological Functions of FET Proteins. Annu. Rev. Biochem 84, 355&#x2013;379 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9188303</ArticleId><ArticleId IdType="pubmed">25494299</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson R et al., Structure of the cross-beta spine of amyloid-like fibrils. Nature 435, 773&#x2013;778 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1479801</ArticleId><ArticleId IdType="pubmed">15944695</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR et al., Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447, 453&#x2013;457 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray DT et al., Structure of FUS Protein Fibrils and Its Relevance to Self-Assembly and Phase Separation of Low-Complexity Domains. Cell 171, 615&#x2013;627.e16 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5650524</ArticleId><ArticleId IdType="pubmed">28942918</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinnokrot MO, Valeev EF, Sherrill CD, Estimates of the ab initio limit for pi-pi interactions: the benzene dimer. J. Am. Chem. Soc 124, 10887&#x2013;10893 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12207544</ArticleId></ArticleIdList></Reference><Reference><Citation>McGaughey GB, Gagn&#xe9; M, Rapp&#xe9; AK, pi-Stacking interactions. Alive and well in proteins. J. Biol. Chem 273, 15458&#x2013;15463 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9624131</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunan E, Gutowsky HS, The rotational spectrum, structure and dynamics of a benzene dimer. J. Chem. Phys 98 (1992).</Citation></Reference><Reference><Citation>Eisenberg D, McLachlan AD, Solvation energy in protein folding and binding. Nature 319, 199&#x2013;203 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3945310</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg DE, Wesson M, Yamashita M, Interpretation of Protein Folding and Binding with Atomic Solvation Parameters. Chem. Scr 29A, 217&#x2013;221 (1989).</Citation></Reference><Reference><Citation>Bowie JU, L&#xfc;thy R, Eisenberg D, A method to identify protein sequences that fold into a known three-dimensional structure. Science 253, 164&#x2013;170 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1853201</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldschmidt L, Teng PK, Riek R, Eisenberg D, Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc. Natl. Acad. Sci. U. S. A 107, 3487&#x2013;3492 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840437</ArticleId><ArticleId IdType="pubmed">20133726</ArticleId></ArticleIdList></Reference><Reference><Citation>Leaver-Fay A et al., ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol 487, 545&#x2013;574 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4083816</ArticleId><ArticleId IdType="pubmed">21187238</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey S, Richter RP, G&#xf6;rlich D, FG-rich repeats of nuclear pore proteins form a three-dimensional meshwork with hydrogel-like properties. Science 314, 815&#x2013;817 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17082456</ArticleId></ArticleIdList></Reference><Reference><Citation>Windoffer R, W&#xf6;ll S, Strnad P, Leube RE, Identification of novel principles of keratin filament network turnover in living cells. Mol. Biol. Cell 15, 2436&#x2013;2448 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC404035</ArticleId><ArticleId IdType="pubmed">15004233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ader C et al., Amyloid-like interactions within nucleoporin FG hydrogels. Proc. Natl. Acad. Sci. U. S. A 107, 6281&#x2013;6285 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852002</ArticleId><ArticleId IdType="pubmed">20304795</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim KL, Creamer TP, Abundance and distributions of eukaryote protein simple sequences. Mol. Cell. Proteomics MCP 1, 983&#x2013;995 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12543934</ArticleId></ArticleIdList></Reference><Reference><Citation>Toretsky JA, Wright PE, Assemblages: functional units formed by cellular phase separation. J. Cell Biol 206, 579&#x2013;588 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4151146</ArticleId><ArticleId IdType="pubmed">25179628</ArticleId></ArticleIdList></Reference><Reference><Citation>Coletta A et al., Low-complexity regions within protein sequences have position-dependent roles. BMC Syst. Biol 4, 43 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873317</ArticleId><ArticleId IdType="pubmed">20385029</ArticleId></ArticleIdList></Reference><Reference><Citation>Uversky VN, Oldfield CJ, Dunker AK, Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu. Rev. Biophys 37, 215&#x2013;246 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18573080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I et al., Phosphorylation-regulated binding of RNA polymerase II to fibrous polymers of low-complexity domains. Cell 155, 1049&#x2013;1060 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010232</ArticleId><ArticleId IdType="pubmed">24267890</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg DS, Sawaya MR, Structural Studies of Amyloid Proteins at the Molecular Level. Annu. Rev. Biochem 86, 69&#x2013;95 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28125289</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy AJ et al., Phaser crystallographic software. J. Appl. Crystallogr 40, 658&#x2013;674 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2483472</ArticleId><ArticleId IdType="pubmed">19461840</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov GN, Vagin AA, Dodson EJ, Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr 53, 240&#x2013;255 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">15299926</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheldrick GM, A short history of SHELX. Acta Crystallogr. A 64, 112&#x2013;122 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18156677</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabsch W, XDS. Acta Crystallogr. D Biol. Crystallogr 66, 125&#x2013;132 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815665</ArticleId><ArticleId IdType="pubmed">20124692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattne J et al., MicroED data collection and processing. Acta Crystallogr. Sect. Found. Adv 71, 353&#x2013;360 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4487423</ArticleId><ArticleId IdType="pubmed">26131894</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine PV et al., Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr 68, 352&#x2013;367 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322595</ArticleId><ArticleId IdType="pubmed">22505256</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanc E et al., Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr. D Biol. Crystallogr 60, 2210&#x2013;2221 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15572774</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K, Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr 66, 486&#x2013;501 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Winn MD et al., Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr 67, 235&#x2013;242 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069738</ArticleId><ArticleId IdType="pubmed">21460441</ArticleId></ArticleIdList></Reference><Reference><Citation>The UniProt Consortium, UniProt: the universal protein knowledgebase. Nucleic Acids Res 45, D158&#x2013;D169 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210571</ArticleId><ArticleId IdType="pubmed">27899622</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ontology Consortium, Gene Ontology Consortium: going forward. Nucleic Acids Res 43, D1049&#x2013;1056 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383973</ArticleId><ArticleId IdType="pubmed">25428369</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann R, A glass menagerie of low complexity sequences. Curr. Opin. Struct. Biol 38, 18&#x2013;25 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010471</ArticleId><ArticleId IdType="pubmed">27258703</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29444819</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>215</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Mar</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions.</ArticleTitle><Pagination><StartPage>927</StartPage><EndPage>940</EndPage><MedlinePgn>927-940</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20171831</ELocationID><Abstract><AbstractText>BACE1 initiates the generation of the &#x3b2;-amyloid peptide, which likely causes Alzheimer's disease (AD) when accumulated abnormally. BACE1 inhibitory drugs are currently being developed to treat AD patients. To mimic BACE1 inhibition in adults, we generated BACE1 conditional knockout (BACE1<sup>fl/fl</sup>) mice and bred BACE1<sup>fl/fl</sup> mice with ubiquitin-Cre<sup>ER</sup> mice to induce deletion of BACE1 after passing early developmental stages. Strikingly, sequential and increased deletion of BACE1 in an adult AD mouse model (5xFAD) was capable of completely reversing amyloid deposition. This reversal in amyloid deposition also resulted in significant improvement in gliosis and neuritic dystrophy. Moreover, synaptic functions, as determined by long-term potentiation and contextual fear conditioning experiments, were significantly improved, correlating with the reversal of amyloid plaques. Our results demonstrate that sustained and increasing BACE1 inhibition in adults can reverse amyloid deposition in an AD mouse model, and this observation will help to provide guidance for the proper use of BACE1 inhibitors in human patients.</AbstractText><CopyrightInformation>&#xa9; 2018 Hu et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xiangyou</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH hux@ccf.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Brati</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5800-3912</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Hailong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Wanxia</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Riqiang</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7195-7617</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH Riyan@uchc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG025493</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046929</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074256</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG046929</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="C045073">Cre recombinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="D019426">Integrases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="Y">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019426" MajorTopicYN="N">Integrases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29444819</ArticleId><ArticleId IdType="pmc">PMC5839766</ArticleId><ArticleId IdType="doi">10.1084/jem.20171831</ArticleId><ArticleId IdType="pii">jem.20171831</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baba A., Yasui T., Fujisawa S., Yamada R.X., Yamada M.K., Nishiyama N., Matsuki N., and Ikegaya Y.. 2003. Activity-evoked capacitative Ca2+ entry: implications in synaptic plasticity. J. Neurosci. 23:7737&#x2013;7741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740588</ArticleId><ArticleId IdType="pubmed">12944501</ArticleId></ArticleIdList></Reference><Reference><Citation>Bach M.E., Hawkins R.D., Osman M., Kandel E.R., and Mayford M.. 1995. Impairment of spatial but not contextual memory in CaMKII mutant mice with a selective loss of hippocampal LTP in the range of the theta frequency. Cell. 81:905&#x2013;915. 10.1016/0092-8674(95)90010-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90010-1</ArticleId><ArticleId IdType="pubmed">7781067</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar&#xe3;o S., Moechars D., Lichtenthaler S.F., and De Strooper B.. 2016. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer&#x2019;s Disease. Trends Neurosci. 39:158&#x2013;169. 10.1016/j.tins.2016.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2016.01.003</ArticleId><ArticleId IdType="pubmed">26833257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Halima S., Mishra S., Raja K.M.P., Willem M., Baici A., Simons K., Br&#xfc;stle O., Koch P., Haass C., Caflisch A., and Rajendran L.. 2016. Specific Inhibition of &#x3b2;-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein. Cell Reports. 14:2127&#x2013;2141. 10.1016/j.celrep.2016.01.076</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.01.076</ArticleId><ArticleId IdType="pubmed">26923602</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., and Braak E.. 1997. Diagnostic criteria for neuropathologic assessment of Alzheimer&#x2019;s disease. Neurobiol. Aging. 18(4, Suppl):S85&#x2013;S88. 10.1016/S0197-4580(97)00062-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(97)00062-6</ArticleId><ArticleId IdType="pubmed">9330992</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H., Wang Y., McCarthy D., Wen H., Borchelt D.R., Price D.L., and Wong P.C.. 2001. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 4:233&#x2013;234. 10.1038/85064</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/85064</ArticleId><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Corriveau R.A., Koroshetz W.J., Gladman J.T., Jeon S., Babcock D., Bennett D.A., Carmichael S.T., Dickinson S.L., Dickson D.W., Emr M., et al. . 2017. Alzheimer&#x2019;s Disease-Related Dementias Summit 2016: National research priorities. Neurology. 89:2381&#x2013;2391. 10.1212/WNL.0000000000004717</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004717</ArticleId><ArticleId IdType="pmc">PMC5719928</ArticleId><ArticleId IdType="pubmed">29117955</ArticleId></ArticleIdList></Reference><Reference><Citation>Daria A., Colombo A., Llovera G., Hampel H., Willem M., Liesz A., Haass C., and Tahirovic S.. 2017. Young microglia restore amyloid plaque clearance of aged microglia. EMBO J. 36:583&#x2013;603. 10.15252/embj.201694591</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201694591</ArticleId><ArticleId IdType="pmc">PMC5331757</ArticleId><ArticleId IdType="pubmed">28007893</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Iwatsubo T., and Wolfe M.S.. 2012. Presenilins and &#x3b3;-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2:a006304 10.1101/cshperspect.a006304</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006304</ArticleId><ArticleId IdType="pmc">PMC3253024</ArticleId><ArticleId IdType="pubmed">22315713</ArticleId></ArticleIdList></Reference><Reference><Citation>He W., Lu Y., Qahwash I., Hu X.Y., Chang A., and Yan R.. 2004. Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. Nat. Med. 10:959&#x2013;965. 10.1038/nm1088</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1088</ArticleId><ArticleId IdType="pubmed">15286784</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Shi Q., Zhou X., He W., Yi H., Yin X., Gearing M., Levey A., and Yan R.. 2007. Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities. EMBO J. 26:2755&#x2013;2767. 10.1038/sj.emboj.7601707</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601707</ArticleId><ArticleId IdType="pmc">PMC1888669</ArticleId><ArticleId IdType="pubmed">17476306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Fan Q., Hou H., and Yan R.. 2016. Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling. J. Neurochem. 136:234&#x2013;249. 10.1111/jnc.13395</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13395</ArticleId><ArticleId IdType="pmc">PMC4833723</ArticleId><ArticleId IdType="pubmed">26465092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I., Powell D., Howlett D.R., Tew D.G., Meek T.D., Chapman C., Gloger I.S., Murphy K.E., Southan C.D., Ryan D.M., et al. . 1999. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol. Cell. Neurosci. 14:419&#x2013;427. 10.1006/mcne.1999.0811</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mcne.1999.0811</ArticleId><ArticleId IdType="pubmed">10656250</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh K., Shimono K., and Lemmon V.. 2005. Dephosphorylation and internalization of cell adhesion molecule L1 induced by theta burst stimulation in rat hippocampus. Mol. Cell. Neurosci. 29:245&#x2013;249. 10.1016/j.mcn.2005.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2005.02.014</ArticleId><ArticleId IdType="pmc">PMC1382274</ArticleId><ArticleId IdType="pubmed">15911348</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T., Atwal J.K., Steinberg S., Snaedal J., Jonsson P.V., Bjornsson S., Stefansson H., Sulem P., Gudbjartsson D., Maloney J., et al. . 2012. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 488:96&#x2013;99. 10.1038/nature11283</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11283</ArticleId><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S., Sato Y., Mohan P.S., Peterhoff C., Pensalfini A., Rigoglioso A., Jiang Y., and Nixon R.A.. 2016. Evidence that the rab5 effector APPL1 mediates APP-&#x3b2;CTF-induced dysfunction of endosomes in Down syndrome and Alzheimer&#x2019;s disease. Mol. Psychiatry. 21:707&#x2013;716. 10.1038/mp.2015.97</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.97</ArticleId><ArticleId IdType="pmc">PMC4721948</ArticleId><ArticleId IdType="pubmed">26194181</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauritzen I., Pardossi-Piquard R., Bourgeois A., Pagnotta S., Biferi M.G., Barkats M., Lacor P., Klein W., Bauer C., and Checler F.. 2016. Intraneuronal aggregation of the &#x3b2;-CTF fragment of APP (C99) induces A&#x3b2;-independent lysosomal-autophagic pathology. Acta Neuropathol. 132:257&#x2013;276. 10.1007/s00401-016-1577-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1577-6</ArticleId><ArticleId IdType="pmc">PMC4947121</ArticleId><ArticleId IdType="pubmed">27138984</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X., Koelsch G., Wu S., Downs D., Dashti A., and Tang J.. 2000. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc. Natl. Acad. Sci. USA. 97:1456&#x2013;1460. 10.1073/pnas.97.4.1456</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.4.1456</ArticleId><ArticleId IdType="pmc">PMC26455</ArticleId><ArticleId IdType="pubmed">10677483</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Bolon B., Kahn S., Bennett B.D., Babu-Khan S., Denis P., Fan W., Kha H., Zhang J., Gong Y., et al. . 2001. Mice deficient in BACE1, the Alzheimer&#x2019;s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 4:231&#x2013;232. 10.1038/85059</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/85059</ArticleId><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka R.C., and Malinow R.. 2011. Alzheimer&#x2019;s disease: Recollection of lost memories. Nature. 469:44&#x2013;45. 10.1038/469044a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/469044a</ArticleId><ArticleId IdType="pmc">PMC3917549</ArticleId><ArticleId IdType="pubmed">21209657</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei L., and Nave K.A.. 2014. Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases. Neuron. 83:27&#x2013;49. 10.1016/j.neuron.2014.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.06.007</ArticleId><ArticleId IdType="pmc">PMC4189115</ArticleId><ArticleId IdType="pubmed">24991953</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., and Lannfelt L.. 1992. A pathogenic mutation for probable Alzheimer&#x2019;s disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. 1:345&#x2013;347. 10.1038/ng0892-345</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0892-345</ArticleId><ArticleId IdType="pubmed">1302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., et al. . 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26:10129&#x2013;10140. 10.1523/JNEUROSCI.1202-06.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberds S.L., Anderson J., Basi G., Bienkowski M.J., Branstetter D.G., Chen K.S., Freedman S.B., Frigon N.L., Games D., Hu K., et al. . 2001. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer&#x2019;s disease therapeutics. Hum. Mol. Genet. 10:1317&#x2013;1324. 10.1093/hmg/10.12.1317</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/10.12.1317</ArticleId><ArticleId IdType="pubmed">11406613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruzankina Y., Pinzon-Guzman C., Asare A., Ong T., Pontano L., Cotsarelis G., Zediak V.P., Velez M., Bhandoola A., and Brown E.J.. 2007. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell. 1:113&#x2013;126. 10.1016/j.stem.2007.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2007.03.002</ArticleId><ArticleId IdType="pmc">PMC2920603</ArticleId><ArticleId IdType="pubmed">18371340</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadleir K.R., Eimer W.A., Cole S.L., and Vassar R.. 2015. A&#x3b2; reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol. Neurodegener. 10:1 10.1186/1750-1326-10-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-10-1</ArticleId><ArticleId IdType="pmc">PMC4297413</ArticleId><ArticleId IdType="pubmed">25567526</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D.J., and Hardy J.. 2016. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25&#xa0;years. EMBO Mol. Med. 8:595&#x2013;608. 10.15252/emmm.201606210</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharoar M.G., Shi Q., Ge Y., He W., Hu X., Perry G., Zhu X., and Yan R.. 2016. Dysfunctional tubular endoplasmic reticulum constitutes a pathological feature of Alzheimer&#x2019;s disease. Mol. Psychiatry. 21:1263&#x2013;1271. 10.1038/mp.2015.181</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.181</ArticleId><ArticleId IdType="pmc">PMC4887420</ArticleId><ArticleId IdType="pubmed">26619807</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q., Ge Y., Sharoar M.G., He W., Xiang R., Zhang Z., Hu X., and Yan R.. 2014. Impact of RTN3 deficiency on expression of BACE1 and amyloid deposition. J. Neurosci. 34:13954&#x2013;13962. 10.1523/JNEUROSCI.1588-14.2014</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1588-14.2014</ArticleId><ArticleId IdType="pmc">PMC4198539</ArticleId><ArticleId IdType="pubmed">25319692</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimono K., Kubota D., Brucher F., Taketani M., and Lynch G.. 2002. Asymmetrical distribution of the Schaffer projections within the apical dendrites of hippocampal field CA1. Brain Res. 950:279&#x2013;287. 10.1016/S0006-8993(02)03052-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(02)03052-4</ArticleId><ArticleId IdType="pubmed">12231254</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S., Anderson J.P., Barbour R., Basi G.S., Caccavello R., Davis D., Doan M., Dovey H.F., Frigon N., Hong J., et al. . 1999. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 402:537&#x2013;540. 10.1038/990114</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/990114</ArticleId><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia S.S., and St George-Hyslop P.H.. 2002. gamma-Secretase, Notch, Abeta and Alzheimer&#x2019;s disease: where do the presenilins fit in? Nat. Rev. Neurosci. 3:281&#x2013;290. 10.1038/nrn785</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn785</ArticleId><ArticleId IdType="pubmed">11967558</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamayev R., Matsuda S., Arancio O., and D&#x2019;Adamio L.. 2012. &#x3b2;- but not &#x3b3;-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol. Med. 4:171&#x2013;179. 10.1002/emmm.201100195</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201100195</ArticleId><ArticleId IdType="pmc">PMC3376850</ArticleId><ArticleId IdType="pubmed">22170863</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R. 2014. BACE1 inhibitor drugs in clinical trials for Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 6:89 10.1186/s13195-014-0089-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-014-0089-7</ArticleId><ArticleId IdType="pmc">PMC4304279</ArticleId><ArticleId IdType="pubmed">25621019</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., et al. . 1999. Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 286:735&#x2013;741. 10.1126/science.286.5440.735</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.286.5440.735</ArticleId><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R., Kuhn P.H., Haass C., Kennedy M.E., Rajendran L., Wong P.C., and Lichtenthaler S.F.. 2014. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J. Neurochem. 130:4&#x2013;28. 10.1111/jnc.12715</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12715</ArticleId><ArticleId IdType="pmc">PMC4086641</ArticleId><ArticleId IdType="pubmed">24646365</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R. 2016. Stepping closer to treating Alzheimer&#x2019;s disease patients with BACE1 inhibitor drugs. Transl. Neurodegener. 5:13 10.1186/s40035-016-0061-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-016-0061-5</ArticleId><ArticleId IdType="pmc">PMC4944430</ArticleId><ArticleId IdType="pubmed">27418961</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R. 2017. Physiological Functions of the &#x3b2;-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2. Front. Mol. Neurosci. 10:97 10.3389/fnmol.2017.00097</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00097</ArticleId><ArticleId IdType="pmc">PMC5395628</ArticleId><ArticleId IdType="pubmed">28469554</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R., and Vassar R.. 2014. Targeting the &#x3b2; secretase BACE1 for Alzheimer&#x2019;s disease therapy. Lancet Neurol. 13:319&#x2013;329. 10.1016/S1474-4422(13)70276-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70276-X</ArticleId><ArticleId IdType="pmc">PMC4086426</ArticleId><ArticleId IdType="pubmed">24556009</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R., Bienkowski M.J., Shuck M.E., Miao H., Tory M.C., Pauley A.M., Brashier J.R., Stratman N.C., Mathews W.R., Buhl A.E., et al. . 1999. Membrane-anchored aspartyl protease with Alzheimer&#x2019;s disease beta-secretase activity. Nature. 402:533&#x2013;537. 10.1038/990107</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/990107</ArticleId><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R., Fan Q., Zhou J., and Vassar R.. 2016. Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer&#x2019;s disease. Neurosci. Biobehav. Rev. 65:326&#x2013;340. 10.1016/j.neubiorev.2016.03.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2016.03.025</ArticleId><ArticleId IdType="pmc">PMC4856578</ArticleId><ArticleId IdType="pubmed">27044452</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29450646</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>135</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>May</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Evidence of amyloid-&#x3b2; cerebral amyloid angiopathy transmission through neurosurgery.</ArticleTitle><Pagination><StartPage>671</StartPage><EndPage>679</EndPage><MedlinePgn>671-679</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-018-1822-2</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; (A&#x3b2;) is a peptide deposited in the brain parenchyma in Alzheimer's disease and in cerebral blood vessels, causing cerebral amyloid angiopathy (CAA). A&#x3b2; pathology is transmissible experimentally in animals and through medical procedures in humans, such as contaminated growth hormone or dura mater transplantation in the context of iatrogenic prion disease. Here, we present four patients who underwent neurosurgical procedures during childhood or teenage years and presented with intracerebral haemorrhage approximately three decades later, caused by severe CAA. None of these patients carried pathogenic mutations associated with early A&#x3b2; pathology development. In addition, we identified in the literature four patients with a history of neurosurgical intervention and subsequent development of CAA. These findings raise the possibility that A&#x3b2; pathology may be transmissible, as prion disease is, through neurosurgical procedures.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaunmuktane</LastName><ForeName>Zane</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quaegebeur</LastName><ForeName>Annelies</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taipa</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Portuguese Brain Bank, Neuropathology Unit, Department of Neuroscience, Centro Hospitalar Universitario do Porto, 4099-001, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viana-Baptista</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, 1449-005, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbosa</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, 1449-005, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koriath</LastName><ForeName>Carolin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sciot</LastName><ForeName>Raf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Imaging and Pathology, University of Leuven, 3000, Louvain, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Council Prion Unit at UCL, UCL Institute of Prion Diseases, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Foundation Trust, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandner</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9821-0342</Identifier><AffiliationInfo><Affiliation>Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, Queen Square, London, WC1N 3BG, UK. s.brandner@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK. s.brandner@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0701018</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100578</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00024/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N004272/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123160651</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019635" MajorTopicYN="Y">Neurosurgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyloid-&#x3b2;</Keyword><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">CAA</Keyword><Keyword MajorTopicYN="N">Cerebral amyloid angiopathy</Keyword><Keyword MajorTopicYN="N">Decontamination</Keyword><Keyword MajorTopicYN="N">Head trauma</Keyword><Keyword MajorTopicYN="N">Intracerebral haemorrhage</Keyword><Keyword MajorTopicYN="N">Neurosurgery</Keyword><Keyword MajorTopicYN="N">Prion diseases</Keyword><Keyword MajorTopicYN="N">Proteopathic seeding</Keyword><Keyword MajorTopicYN="N">TBI</Keyword><Keyword MajorTopicYN="N">Transmission</Keyword><Keyword MajorTopicYN="N">Traumatic brain injury</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29450646</ArticleId><ArticleId IdType="pmc">PMC5904220</ArticleId><ArticleId IdType="doi">10.1007/s00401-018-1822-2</ArticleId><ArticleId IdType="pii">10.1007/s00401-018-1822-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ. Induction of beta (A4)-amyloid in primates by injection of Alzheimer&#x2019;s disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol Neurobiol. 1994;8:25&#x2013;39. doi: 10.1007/BF02778005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02778005</ArticleId><ArticleId IdType="pubmed">8086126</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J, Pittman A, Adamson G, Campbell T, Kenny J, Houlden H, Rohrer JD, de Silva R, Shoai M, Uphill J, et al. Validation of next-generation sequencing technologies in genetic diagnosis of dementia. Neurobiol Aging. 2014;35:261&#x2013;265. doi: 10.1016/j.neurobiolaging.2013.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.07.017</ArticleId><ArticleId IdType="pubmed">23998997</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi A, Sonni A, Anderson CD, Kissela B, Jagiella JM, Schmidt H, Jimenez-Conde J, Hansen BM, Fernandez-Cadenas I, Cortellini L, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol. 2010;68:934&#x2013;943. doi: 10.1002/ana.22134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22134</ArticleId><ArticleId IdType="pmc">PMC3058266</ArticleId><ArticleId IdType="pubmed">21061402</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonda DJ, Manjila S, Mehndiratta P, Khan F, Miller BR, Onwuzulike K, Puoti G, Cohen ML, Schonberger LB, Cali I. Human prion diseases: surgical lessons learned from iatrogenic prion transmission. Neurosurg Focus. 2016;41:E10. doi: 10.3171/2016.5.FOCUS15126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2016.5.FOCUS15126</ArticleId><ArticleId IdType="pmc">PMC5082740</ArticleId><ArticleId IdType="pubmed">27364252</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonfield CM, Naran S, Adetayo OA, Pollack IF, Losee JE. Pediatric skull fractures: the need for surgical intervention, characteristics, complications, and outcomes. J Neurosurg Pediatr. 2014;14:205&#x2013;211. doi: 10.3171/2014.5.PEDS13414.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2014.5.PEDS13414</ArticleId><ArticleId IdType="pubmed">24905840</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404. doi: 10.1007/s00401-006-0127-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0127-z</ArticleId><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali I, Cohen ML, Hasmallyi US, Parchi P, Giaccone G, Collins SJ, Kofskey D, Wang H, McLean CA, Brandel JP, et al. Iatrogenic Creutzfeldt&#x2013;Jakob disease with Amyloid-beta pathology: an international study. Acta Neuropathol Commun. 2018;6:5. doi: 10.1186/s40478-017-0503-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0503-z</ArticleId><ArticleId IdType="pmc">PMC5759292</ArticleId><ArticleId IdType="pubmed">29310723</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell DM, Bruins S, Vogel H, Shuer LM, Wijman CA. Intracerebral hemorrhage caused by cerebral amyloid angiopathy in a 53-year-old man. J Neurol. 2008;255:597&#x2013;598. doi: 10.1007/s00415-008-0742-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-008-0742-9</ArticleId><ArticleId IdType="pubmed">18227992</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter AM, Singh IP, Gandhi CD, Prestigiacomo CJ. Genetic risk factors for spontaneous intracerebral haemorrhage. Nat Rev Neurol. 2016;12:40&#x2013;49. doi: 10.1038/nrneurol.2015.226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.226</ArticleId><ArticleId IdType="pubmed">26670299</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci. 2001;24:519&#x2013;550. doi: 10.1146/annurev.neuro.24.1.519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.24.1.519</ArticleId><ArticleId IdType="pubmed">11283320</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins S, Law MG, Fletcher A, Boyd A, Kaldor J, Masters CL. Surgical treatment and risk of sporadic Creutzfeldt&#x2013;Jakob disease: a case&#x2013;control study. Lancet. 1999;353:693&#x2013;697. doi: 10.1016/S0140-6736(98)08138-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(98)08138-0</ArticleId><ArticleId IdType="pubmed">10073510</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Gibbons LE, Dams-O&#x2019;Connor K, Trittschuh E, Leverenz JB, Keene CD, Sonnen J, Montine TJ, Bennett DA, Leurgans S, et al. Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic findings. JAMA Neurol. 2016;73:1062&#x2013;1069. doi: 10.1001/jamaneurol.2016.1948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.1948</ArticleId><ArticleId IdType="pmc">PMC5319642</ArticleId><ArticleId IdType="pubmed">27400367</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Sazdovitch V, Ando K, Seilhean D, Privat N, Yilmaz Z, Peckeu L, Amar E, Comoy E, Maceski A, et al. Neuropathology of iatrogenic Creutzfeldt&#x2013;Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology. Acta Neuropathol. 2018;135:201&#x2013;212. doi: 10.1007/s00401-017-1791-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1791-x</ArticleId><ArticleId IdType="pubmed">29209767</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgeworth JA, Sicilia A, Linehan J, Brandner S, Jackson GS, Collinge J. A standardized comparison of commercially available prion decontamination reagents using the Standard Steel-Binding Assay. J Gen Virol. 2011;92:718&#x2013;726. doi: 10.1099/vir.0.027201-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.027201-0</ArticleId><ArticleId IdType="pmc">PMC3081234</ArticleId><ArticleId IdType="pubmed">21084494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehling R, Helbok R, Beer R, Lackner P, Broessner G, Pfausler B, Rocken C, Aguzzi A, Chemelli A, Schmutzhard E. Recurrent intracerebral haemorrhage after coitus: a case report of sporadic cerebral amyloid angiopathy in a younger patient. Eur J Neurol Off J Eur Fed Neurol Soc. 2012;19:e29&#x2013;e31.</Citation><ArticleIdList><ArticleId IdType="pubmed">22329859</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan ZX, Roth K, Aguzzi A, Staufenbiel M, Walker LC, et al. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci USA. 2009;106:12926&#x2013;12931. doi: 10.1073/pnas.0903200106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0903200106</ArticleId><ArticleId IdType="pmc">PMC2722323</ArticleId><ArticleId IdType="pubmed">19622727</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 2010;330:980&#x2013;982. doi: 10.1126/science.1194516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1194516</ArticleId><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontzek K, Lutz MI, Aguzzi A, Kovacs GG, Budka H. Amyloid-beta pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt&#x2013;Jakob disease after dural grafting. Swiss Med Wkly. 2016;146:w14287.</Citation><ArticleIdList><ArticleId IdType="pubmed">26812492</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs CJ, Jr, Asher DM, Kobrine A, Amyx HL, Sulima MP, Gajdusek DC. Transmission of Creutzfeldt&#x2013;Jakob disease to a chimpanzee by electrodes contaminated during neurosurgery. J Neurol Neurosurg Psychiatry. 1994;57:757&#x2013;758. doi: 10.1136/jnnp.57.6.757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.57.6.757</ArticleId><ArticleId IdType="pmc">PMC1072988</ArticleId><ArticleId IdType="pubmed">8006664</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamaguchi T, Taniguchi Y, Sakai K, Kitamoto T, Takao M, Murayama S, Iwasaki Y, Yoshida M, Shimizu H, Kakita A, et al. Significant association of cadaveric dura mater grafting with subpial Abeta deposition and meningeal amyloid angiopathy. Acta Neuropathol. 2016;132:313&#x2013;315. doi: 10.1007/s00401-016-1588-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1588-3</ArticleId><ArticleId IdType="pubmed">27314593</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement J Alzheimer&#x2019;s Assoc. 2012;8:1&#x2013;13. doi: 10.1016/j.jalz.2011.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaunmuktane Z, Mead S, Ellis M, Wadsworth JD, Nicoll AJ, Kenny J, Launchbury F, Linehan J, Richard-Loendt A, Walker AS, et al. Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature. 2015;525:247&#x2013;250. doi: 10.1038/nature15369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15369</ArticleId><ArticleId IdType="pubmed">26354483</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S, Harari O, Cai Y, et al. Coding variants in TREM2 increase risk for Alzheimer&#x2019;s disease. Hum Mol Genet. 2014;23:5838&#x2013;5846. doi: 10.1093/hmg/ddu277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu277</ArticleId><ArticleId IdType="pmc">PMC4189899</ArticleId><ArticleId IdType="pubmed">24899047</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson VE, Stewart W, Smith DH. Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans. Brain Pathol. 2012;22:142&#x2013;149. doi: 10.1111/j.1750-3639.2011.00513.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2011.00513.x</ArticleId><ArticleId IdType="pmc">PMC3979351</ArticleId><ArticleId IdType="pubmed">21714827</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan BD, Kanik AB, Horwich MS, Sweeney D, Relkin NR, Petito CK, Gandy S. Apolipoprotein E epsilon 4 and fatal cerebral amyloid angiopathy associated with dementia pugilistica. Ann Neurol. 1995;38:698&#x2013;699. doi: 10.1002/ana.410380429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380429</ArticleId><ArticleId IdType="pubmed">7574475</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011;70:532&#x2013;540. doi: 10.1002/ana.22615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22615</ArticleId><ArticleId IdType="pmc">PMC3203752</ArticleId><ArticleId IdType="pubmed">22028219</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56:537&#x2013;539. doi: 10.1212/WNL.56.4.537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.4.537</ArticleId><ArticleId IdType="pubmed">11222803</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Lutz MI, Ricken G, Strobel T, Hoftberger R, Preusser M, Regelsberger G, Honigschnabl S, Reiner A, Fischer P, et al. Dura mater is a potential source of Abeta seeds. Acta Neuropathol. 2016;131:911&#x2013;923. doi: 10.1007/s00401-016-1565-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1565-x</ArticleId><ArticleId IdType="pmc">PMC4865536</ArticleId><ArticleId IdType="pubmed">27016065</ArticleId></ArticleIdList></Reference><Reference><Citation>Leclercq PD, Murray LS, Smith C, Graham DI, Nicoll JA, Gentleman SM. Cerebral amyloid angiopathy in traumatic brain injury: association with apolipoprotein E genotype. J Neurol Neurosurg Psychiatry. 2005;76:229&#x2013;233. doi: 10.1136/jnnp.2003.025528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2003.025528</ArticleId><ArticleId IdType="pmc">PMC1739505</ArticleId><ArticleId IdType="pubmed">15654038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H, Morris HR, Neal JW, Lees AJ, Hardy J, Holton JL, Revesz T, Williams DD. Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. Acta Neuropathol. 2017;133:337&#x2013;352. doi: 10.1007/s00401-017-1680-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1680-3</ArticleId><ArticleId IdType="pmc">PMC5325836</ArticleId><ArticleId IdType="pubmed">28205009</ArticleId></ArticleIdList></Reference><Reference><Citation>Love S, Chalmers K, Ince P, Esiri M, Attems J, Jellinger K, Yamada M, McCarron M, Minett T, Matthews F, et al. Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis. 2014;3:19&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3986608</ArticleId><ArticleId IdType="pubmed">24754000</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, Lee HS, Wojtowicz SM, Hall G, Baugh CM, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain J Neurol. 2013;136:43&#x2013;64. doi: 10.1093/brain/aws307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws307</ArticleId><ArticleId IdType="pmc">PMC3624697</ArticleId><ArticleId IdType="pubmed">23208308</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Savica R, Wiste HJ, Weigand SD, Vemuri P, Knopman DS, Lowe VJ, Roberts RO, Machulda MM, Geda YE, et al. Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study. Neurology. 2014;82:70&#x2013;76. doi: 10.1212/01.wnl.0000438229.56094.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000438229.56094.54</ArticleId><ArticleId IdType="pmc">PMC3873622</ArticleId><ArticleId IdType="pubmed">24371306</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer&#x2019;s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;486. doi: 10.1212/WNL.41.4.479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.41.4.479</ArticleId><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11. doi: 10.1007/s00401-011-0910-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0910-3</ArticleId><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama Y, Mineharu Y, Arawaka Y, Nishida S, Tsuji H, Miyake H, Yamaguchi M, Minamiguchi S, Takagi Y, Miyamoto S. Cerebral amyloid angiopathy in a young man with a history of traumatic brain injury: a case report and review of the literature. Acta Neurochir (Wien) 2017;159:15&#x2013;18. doi: 10.1007/s00701-016-3004-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00701-016-3004-0</ArticleId><ArticleId IdType="pubmed">27812816</ArticleId></ArticleIdList></Reference><Reference><Citation>Pletnikova O, Rudow GL, Hyde TM, Kleinman JE, Ali SZ, Bharadwaj R, Gangadeen S, Crain BJ, Fowler DR, Rubio AI, et al. Alzheimer lesions in the autopsied brains of people 30 to 50 years of age. Cogn Behav Neurol Off J Soc Behav Cogn Neurol. 2015;28:144&#x2013;152. doi: 10.1097/WNN.0000000000000071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNN.0000000000000071</ArticleId><ArticleId IdType="pmc">PMC4588069</ArticleId><ArticleId IdType="pubmed">26413742</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Wallon D, Rousseau S, Rovelet-Lecrux A, Richard AC, Rollin-Sillaire A, Frebourg T, Campion D, Hannequin D. TREM2 R47H variant as a risk factor for early-onset Alzheimer&#x2019;s disease. J Alzheimers Dis. 2013;35:45&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">23380991</ArticleId></ArticleIdList></Reference><Reference><Citation>Purrucker JC, Hund E, Ringleb PA, Hartmann C, Rohde S, Schonland S, Steiner T. Cerebral amyloid angiopathy&#x2014;an underdiagnosed entity in younger adults with lobar intracerebral hemorrhage? Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2013;20:45&#x2013;47. doi: 10.3109/13506129.2012.746937.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13506129.2012.746937</ArticleId><ArticleId IdType="pubmed">23231422</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie DL, Adlard P, Peden AH, Lowrie S, Le Grice M, Burns K, Jackson RJ, Yull H, Keogh MJ, Wei W, et al. Amyloid-beta accumulation in the CNS in human growth hormone recipients in the UK. Acta Neuropathol. 2017;134:221&#x2013;240. doi: 10.1007/s00401-017-1703-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1703-0</ArticleId><ArticleId IdType="pmc">PMC5508038</ArticleId><ArticleId IdType="pubmed">28349199</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts GW, Gentleman SM, Lynch A, Graham DI. Beta A4 amyloid protein deposition in brain after head trauma. Lancet. 1991;338:1422&#x2013;1423. doi: 10.1016/0140-6736(91)92724-G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(91)92724-G</ArticleId><ArticleId IdType="pubmed">1683421</ArticleId></ArticleIdList></Reference><Reference><Citation>Shively SB, Edgerton SL, Iacono D, Purohit DP, Qu BX, Haroutunian V, Davis KL, Diaz-Arrastia R, Perl DP. Localized cortical chronic traumatic encephalopathy pathology after single, severe axonal injury in human brain. Acta Neuropathol. 2017;133(3):353&#x2013;366. doi: 10.1007/s00401-016-1649-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1649-7</ArticleId><ArticleId IdType="pmc">PMC5325841</ArticleId><ArticleId IdType="pubmed">27885490</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat Genet. 2017;49:1373&#x2013;1384. doi: 10.1038/ng.3916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3916</ArticleId><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein TD, Montenigro PH, Alvarez VE, Xia W, Crary JF, Tripodis Y, Daneshvar DH, Mez J, Solomon T, Meng G, et al. Beta-amyloid deposition in chronic traumatic encephalopathy. Acta Neuropathol. 2015;130:21&#x2013;34. doi: 10.1007/s00401-015-1435-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1435-y</ArticleId><ArticleId IdType="pmc">PMC4529056</ArticleId><ArticleId IdType="pubmed">25943889</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;1800. doi: 10.1212/WNL.58.12.1791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.12.1791</ArticleId><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomzig A, Wagenfuhr K, Daus ML, Joncic M, Schulz-Schaeffer WJ, Thanheiser M, Mielke M, Beekes M. Decontamination of medical devices from pathological amyloid-beta-, tau- and alpha-synuclein aggregates. Acta Neuropathol Commun. 2014;2:151. doi: 10.1186/s40478-014-0151-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0151-5</ArticleId><ArticleId IdType="pmc">PMC4213499</ArticleId><ArticleId IdType="pubmed">25344093</ArticleId></ArticleIdList></Reference><Reference><Citation>Trefan L, Houston R, Pearson G, Edwards R, Hyde P, Maconochie I, Parslow RC, Kemp A. Epidemiology of children with head injury: a national overview. Arch Dis Child. 2016;101:527&#x2013;532. doi: 10.1136/archdischild-2015-308424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2015-308424</ArticleId><ArticleId IdType="pmc">PMC4893082</ArticleId><ArticleId IdType="pubmed">26998632</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP., Jr Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol. 1991;30:637&#x2013;649. doi: 10.1002/ana.410300503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410300503</ArticleId><ArticleId IdType="pubmed">1763890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong MP, Ng TH, Chan KH. Cerebral amyloid angiopathy and spontaneous intracerebral haemorrhage. Report of a sporadic case in a young Chinese. Clin Neurol Neurosurg. 1991;93:133&#x2013;136. doi: 10.1016/0303-8467(91)90054-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0303-8467(91)90054-S</ArticleId><ArticleId IdType="pubmed">1652394</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29452684</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.</ArticleTitle><Pagination><StartPage>213</StartPage><EndPage>222</EndPage><MedlinePgn>213-222</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(18)30039-5</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(18)30039-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Pimavanserin is a selective 5-HT<sub>2A</sub> receptor inverse agonist and antagonist approved in the USA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. No safe or effective pharmacological treatment is approved for psychosis in patients with Alzheimer's disease. Therefore, we aimed to evaluate the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis.</AbstractText><AbstractText Label="METHODS">We did a phase 2, randomised, double-blind, placebo-controlled, single-centre (with multiple affiliated nursing home sites across the UK) study. We included participants of either sex who were aged 50 years or older with possible or probable Alzheimer's disease and psychotic symptoms including visual or auditory hallucinations, delusions, or both. Participants were randomly assigned (1:1) to 12 weeks of oral treatment with either pimavanserin (two 17 mg tablets daily) or placebo, with use of permuted block sizes of four and stratified by baseline Mini-Mental State Examination (MMSE) total score (&lt;6 or &#x2265;6) and Neuropsychiatric Inventory-Nursing Home version (NPI-NH) psychosis score (&lt;12 or &#x2265;12). Participants, caregivers, the study sponsor, and study personnel at the clinic site were masked to treatment assignment. The primary endpoint was mean change from baseline to week 6 in the NPI-NH psychosis score for pimavanserin versus placebo in the modified intention-to-treat population. Sustained benefit and safety of pimavanserin were assessed through week 12. This study is registered at ClinicalTrials.gov, number NCT02035553.</AbstractText><AbstractText Label="FINDINGS">Between Jan 16, 2014, and Oct 27, 2016, 345 participants across 133 nursing homes were screened, of whom 181 were randomly assigned treatment (n=90 pimavanserin and n=91 placebo). 178 participants were included in the modified intention-to-treat population. Mean total baseline NPI-NH psychosis scores were 9&#xb7;5 (SD 4&#xb7;8) for the pimavanserin group and 10&#xb7;0 (5&#xb7;6) for the placebo group. Mean change in the NPI-NH psychosis score at week 6 was -3&#xb7;76 points (SE 0&#xb7;65) for pimavanserin and -1&#xb7;93 points (0&#xb7;63) for placebo (mean difference -1&#xb7;84 [95% CI -3&#xb7;64 to -0&#xb7;04], Cohen's d=-0&#xb7;32; p=0&#xb7;045). By week 12, no significant advantage for pimavanserin versus placebo was observed for the overall study population (treatment difference -0&#xb7;51 [95% CI -2&#xb7;23 to 1&#xb7;21]; p=0&#xb7;561). Common adverse events were falls (21 [23%] of 90 participants in the pimavanserin group vs 21 [23%] of 91 in the placebo group), urinary tract infections (20 [22%] vs 25 [28%]), and agitation (19 [21%] vs 13 [14%]). Eight (9%) participants on pimavanserin and 11 (12%) on placebo discontinued treatment because of adverse events. No detrimental effect was observed on cognition or motor function in either group.</AbstractText><AbstractText Label="INTERPRETATION">Pimavanserin showed efficacy in patients with Alzheimer's disease psychosis at the primary endpoint (week 6) with an acceptable tolerability profile and without negative effect on cognition. Further follow-up to week 12 did not show significant advantage for pimavanserin versus placebo.</AbstractText><AbstractText Label="FUNDING">ACADIA Pharmaceuticals.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Health Research, University of Exeter Medical School, Exeter, UK. Electronic address: c.ballard@exeter.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banister</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-related Diseases, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Zunera</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-related Diseases, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department Center for Brain Health, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demos</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>ACADIA Pharmaceuticals, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coate</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>ACADIA Pharmaceuticals, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youakim</LastName><ForeName>James M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>ACADIA Pharmaceuticals, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Randall</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ACADIA Pharmaceuticals, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stankovic</LastName><ForeName>Srdjan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ACADIA Pharmaceuticals, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ADP Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02035553</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P20 GM109025</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8W8T17847W</RegistryNumber><NameOfSubstance UI="D014508">Urea</NameOfSubstance></Chemical><Chemical><RegistryNumber>JZ963P0DIK</RegistryNumber><NameOfSubstance UI="C510793">pimavanserin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2018 Mar;17(3):194-195. doi: 10.1016/S1474-4422(18)30052-8.</RefSource><PMID Version="1">29452674</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Neurol. 2018 Apr;17(4):298. doi: 10.1016/S1474-4422(18)30084-X.</RefSource><PMID Version="1">29496302</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="Y">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014508" MajorTopicYN="N">Urea</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Tomkinson</LastName><ForeName>Elaine B</ForeName><Initials>EB</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDermid</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ocal</LastName><ForeName>Delik</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Testad</LastName><ForeName>Ingelin</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qayyum</LastName><ForeName>Mustabshira A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kemos'</LastName><ForeName>Polychronis</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borejko</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Megalogeni</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brookes</LastName><ForeName>Ella V</ForeName><Initials>EV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrava</LastName><ForeName>Anya</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Da Silva</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nunez</LastName><ForeName>Kayleigh</ForeName><Initials>K</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29452684</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(18)30039-5</ArticleId><ArticleId IdType="pii">S1474-4422(18)30039-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29298427</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>The Aging Astrocyte Transcriptome from Multiple Regions of the Mouse Brain.</ArticleTitle><Pagination><StartPage>269</StartPage><EndPage>285</EndPage><MedlinePgn>269-285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2017.12.039</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(17)31848-X</ELocationID><Abstract><AbstractText>Aging brains undergo cognitive decline, associated with decreased neuronal synapse number and function and altered metabolism. Astrocytes regulate neuronal synapse formation and function in development and adulthood, but whether these properties&#xa0;change during aging, contributing to neuronal dysfunction, is unknown. We addressed this by generating aged and adult astrocyte transcriptomes from multiple mouse brain regions. These data provide a comprehensive RNA-seq database of adult and aged astrocyte gene expression, available online as a resource. We identify astrocyte genes altered by&#xa0;aging across brain regions and regionally unique aging changes. Aging astrocytes show minimal alteration of homeostatic and neurotransmission-regulating genes. However, aging astrocytes upregulate genes that eliminate synapses and partially resemble reactive astrocytes. We further identified heterogeneous expression of synapse-regulating genes between astrocytes from different cortical regions. We find that alterations to astrocytes in aging create an environment permissive to synapse elimination and neuronal damage, potentially contributing to aging-associated cognitive decline.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boisvert</LastName><ForeName>Matthew M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Molecular Neurobiology Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Rd., La Jolla, CA 92037, USA; Neurosciences Graduate Program, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erikson</LastName><ForeName>Galina A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Razavi Newman Integrative Genomics and Bioinformatics Core , Salk Institute for Biological Studies, 10010 North Torrey Pines Rd., La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shokhirev</LastName><ForeName>Maxim N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Razavi Newman Integrative Genomics and Bioinformatics Core , Salk Institute for Biological Studies, 10010 North Torrey Pines Rd., La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Molecular Neurobiology Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Rd., La Jolla, CA 92037, USA. Electronic address: nallen@salk.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS089791</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030561" MajorTopicYN="N">Databases, Nucleic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="Y">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="Y">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">astrocyte</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">synapse</Keyword></KeywordList><CoiStatement><b>DECLARATION OF INTERESTS</b>. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>1</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29298427</ArticleId><ArticleId IdType="mid">NIHMS934753</ArticleId><ArticleId IdType="pmc">PMC5783200</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2017.12.039</ArticleId><ArticleId IdType="pii">S2211-1247(17)31848-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen NJ. Astrocyte regulation of synaptic behavior. Annu Rev Cell Dev Biol. 2014;30:439&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">25288116</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen NJ, Bennett ML, Foo LC, Wang GX, Chakraborty C, Smith SJ, Barres BA. Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors. Nature. 2012;486:410&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383085</ArticleId><ArticleId IdType="pubmed">22722203</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellaver B, Souza DG, Souza DO, Quincozes-Santos A. Hippocampal Astrocyte Cultures from Adult and Aged Rats Reproduce Changes in Glial Functionality Observed in the Aging Brain. Mol Neurobiol. 2017;54:2969&#x2013;2985.</Citation><ArticleIdList><ArticleId IdType="pubmed">27026184</ArticleId></ArticleIdList></Reference><Reference><Citation>Berchtold NC, Sabbagh MN, Beach TG, Kim RC, Cribbs DH, Cotman CW. Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer&#x2019;s disease. Neurobiol Aging. 2014;35:1961&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4067010</ArticleId><ArticleId IdType="pubmed">24786631</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialas AR, Stevens B. TGF-&#x3b2; signaling regulates neuronal C1q expression and developmental synaptic refinement. Nat Neurosci. 2013;16:1773&#x2013;1782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3973738</ArticleId><ArticleId IdType="pubmed">24162655</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobkova NV, Evgen&#x2019;ev M, Garbuz DG, Kulikov AM, Morozov A, Samokhin A, Velmeshev D, Medvinskaya N, Nesterova I, Pollock A, Nudler E. Exogenous Hsp70 delays senescence and improves cognitive function in aging mice. Proc Natl Acad Sci USA. 2015;112:16006&#x2013;16011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702952</ArticleId><ArticleId IdType="pubmed">26668376</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopher-son KS, Xing Y, Lubischer JL, Krieg PA, Krupenko SA, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci. 2008;28:264&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671143</ArticleId><ArticleId IdType="pubmed">18171944</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai H, Diaz-Castro B, Shigetomi E, Monte E, Octeau JC, Yu X, Cohn W, Rajendran PS, Vondriska TM, Whitelegge JP, et al. Neural Circuit-Specialized Astrocytes: Transcriptomic, Proteomic, Morphological, and Functional Evidence. Neuron. 2017;95:531&#x2013;549. e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5811312</ArticleId><ArticleId IdType="pubmed">28712653</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopherson KS, Ullian EM, Stokes CC, Mullowney CE, Hell JW, Agah A, Lawler J, Mosher DF, Bornstein P, Barres BA. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell. 2005;120:421&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">15707899</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, Joung J, Foo LC, Thompson A, Chen C, et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature. 2013;504:394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969024</ArticleId><ArticleId IdType="pubmed">24270812</ArticleId></ArticleIdList></Reference><Reference><Citation>Cluett C, Brayne C, Clarke R, Evans G, Matthews F, Rubinsztein DC, Huppert F, Llewellyn DJ, Rice N, Henley W, et al. Polymorphisms in LMNA and near a SERPINA gene cluster are associated with cognitive function in older people. Neurobiol Aging. 2010;31:1563&#x2013;1568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975102</ArticleId><ArticleId IdType="pubmed">18848371</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs DH, Berchtold NC, Perreau V, Coleman PD, Rogers J, Tenner AJ, Cotman CW. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflammation. 2012;9:179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3419089</ArticleId><ArticleId IdType="pubmed">22824372</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle JP, Dougherty JD, Heiman M, Schmidt EF, Stevens TR, Ma G, Bupp S, Shrestha P, Shah RD, Doughty ML, et al. Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell. 2008;135:749&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763427</ArticleId><ArticleId IdType="pubmed">19013282</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia ADR, Doan NB, Imura T, Bush TG, Sofroniew MV. GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. Nat Neurosci. 2004;7:1233&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">15494728</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman T, Hajihosseini MK. Hypothalamic tanycytes-masters and servants of metabolic, neuroendocrine, and neurogenic functions. Front Neurosci. 2015;9:387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624852</ArticleId><ArticleId IdType="pubmed">26578855</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabert K, Michoel T, Karavolos MH, Clohisey S, Baillie JK, Stevens MP, Freeman TC, Summers KM, McColl BW. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat Neurosci. 2016;19:504&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768346</ArticleId><ArticleId IdType="pubmed">26780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray DA, Woulfe J. Lipofuscin and aging: a matter of toxic waste. Sci SAGE KE. 2005;2005:re1.</Citation><ArticleIdList><ArticleId IdType="pubmed">15689603</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, Shatz CJ. Functional requirement for class I MHC in CNS development and plasticity. Science. 2000;290:2155&#x2013;2159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175035</ArticleId><ArticleId IdType="pubmed">11118151</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T, Cadenas E. Astrocytic metabolic and inflammatory changes as a function of age. Aging Cell. 2014;13:1059&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4244278</ArticleId><ArticleId IdType="pubmed">25233945</ArticleId></ArticleIdList></Reference><Reference><Citation>Khakh BS, Sofroniew MV. Diversity of astrocyte functions and phenotypes in neural circuits. Nat Neurosci. 2015;18:942&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5258184</ArticleId><ArticleId IdType="pubmed">26108722</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukdereli H, Allen NJ, Lee AT, Feng A, Ozlu MI, Conatser LM, Chakraborty C, Workman G, Weaver M, Sage EH, et al. Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. Proc Natl Acad Sci USA. 2011;108:E440&#x2013;E449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156217</ArticleId><ArticleId IdType="pubmed">21788491</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, M&#xfc;nch AE, Chung WS, Peterson TC, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin M, Dotti CG, Ledesma MD. Brain cholesterol in normal and pathological aging. Biochim Biophys Acta. 2010;1801:934&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">20359547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauch DH, N&#xe4;gler K, Schumacher S, G&#xf6;ritz C, M&#xfc;ller EC, Otto A, Pfrieger FW. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294:1354&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701931</ArticleId></ArticleIdList></Reference><Reference><Citation>Morel L, Chiang MSR, Higashimori H, Shoneye T, Iyer LK, Yelick J, Tai A, Yang Y. Molecular and Functional Properties of Regional Astrocytes in the Adult Brain. J Neurosci. 2017;37:8706&#x2013;8717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5588463</ArticleId><ArticleId IdType="pubmed">28821665</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliva CA, Vargas JY, Inestrosa NC. Wnts in adult brain: from synaptic plasticity to cognitive deficiencies. Front Cell Neurosci. 2013;7:224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3847898</ArticleId><ArticleId IdType="pubmed">24348327</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre M, Kamphuis W, Osborn LM, Melief J, Kooijman L, Huitinga I, Klooster J, Bossers K, Hol EM. Acute isolation and transcriptome characterization of cortical astrocytes and microglia from young and aged mice. Neurobiol Aging. 2014;35:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">23954174</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannese E. Morphological changes in nerve cells during normal aging. Brain Struct Funct. 2011;216:85&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">21431333</ArticleId></ArticleIdList></Reference><Reference><Citation>Peek SL, Mah KM, Weiner JA. Regulation of neural circuit formation by protocadherins. Cell Mol Life Sci. 2017;74:4133&#x2013;4157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5643215</ArticleId><ArticleId IdType="pubmed">28631008</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelvig DP, Pakkenberg H, Stark AK, Pakkenberg B. Neocortical glial cell numbers in human brains. Neurobiol Aging. 2008;29:1754&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pubmed">17544173</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bio-conductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JT, Liu CC, Zhao N, Wang J, Putzke T, Yang L, Shinohara M, Fryer JD, Kanekiyo T, Bu G. Subacute ibuprofen treatment rescues the synaptic and cognitive deficits in advanced-aged mice. Neurobiol Aging. 2017;53:112&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385269</ArticleId><ArticleId IdType="pubmed">28254590</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakers K, Lake AM, Khazanchi R, Ouwenga R, Vasek MJ, Dani A, Dougherty JD. Astrocytes locally translate transcripts in their peripheral processes. Proc Natl Acad Sci USA. 2017;114:E3830&#x2013;E3838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5441704</ArticleId><ArticleId IdType="pubmed">28439016</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson RD, Barnes CA. Impact of aging brain circuits on cognition. Eur J Neurosci. 2013;37:1903&#x2013;1915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694726</ArticleId><ArticleId IdType="pubmed">23773059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz E, Yang L, Su T, Morris DR, McKnight GS, Amieux PS. Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. Proc Natl Acad Sci USA. 2009;106:13939&#x2013;13944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728999</ArticleId><ArticleId IdType="pubmed">19666516</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Ya-masaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74:691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekar S, McDonald J, Cuyugan L, Aldrich J, Kurdoglu A, Adkins J, Serrano G, Beach TG, Craig DW, Valla J, et al. Alzheimer&#x2019;s disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes. Neurobiol Aging. 2015;36:583&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4315763</ArticleId><ArticleId IdType="pubmed">25448601</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, Van Doren V, et al. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530:177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752392</ArticleId><ArticleId IdType="pubmed">26814963</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV. Astrogliosis. Cold Spring Harb Perspect Biol. 2015;7:a020420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4315924</ArticleId><ArticleId IdType="pubmed">25380660</ArticleId></ArticleIdList></Reference><Reference><Citation>Soreq L, Rose J, Soreq E, Hardy J, Trabzuni D, Cookson MR, Smith C, Ryten M, Patani R, Ule J UK Brain Expression Consortium; North American Brain Expression Consortium. Major Shifts in Glial Regional Identity Are a Transcriptional Hallmark of Human Brain Aging. Cell Rep. 2017;18:557&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5263238</ArticleId><ArticleId IdType="pubmed">28076797</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Thelen KM, Falkai P, Bayer TA, L&#xfc;tjohann D. Cholesterol syn- thesis rate in human hippocampus declines with aging. Neurosci Lett. 2006;403:15&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">16701946</ArticleId></ArticleIdList></Reference><Reference><Citation>Theodosis DT, Poulain DA, Oliet SHR. Activity-dependent structural and functional plasticity of astrocyte-neuron interactions. Physiol Rev. 2008;88:983&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">18626065</ArticleId></ArticleIdList></Reference><Reference><Citation>van Deijk AF, Camargo N, Timmerman J, Heistek T, Brouwers JF, Mogavero F, Mansvelder HD, Smit AB, Verheijen MHG. Astrocyte lipid metabolism is critical for synapse development and function in vivo. Glia. 2017;65:670&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">28168742</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Gamo NJ, Yang Y, Jin LE, Wang XJ, Laubach M, Mazer JA, Lee D, Arnsten AFT. Neuronal basis of age-related working memory decline. Nature. 2011;476:210&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193794</ArticleId><ArticleId IdType="pubmed">21796118</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff-Pak DS, Foy MR, Akopian GG, Lee KH, Zach J, Nguyen KPT, Comalli DM, Kennard JA, Agelan A, Thompson RF. Differential effects and rates of normal aging in cerebellum and hippocampus. Proc Natl Acad Sci USA. 2010;107:1624&#x2013;1629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824421</ArticleId><ArticleId IdType="pubmed">20080589</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA. Genomic analysis of reactive astrogliosis. J Neurosci. 2012;32:6391&#x2013;6410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480225</ArticleId><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MS, Li G, et al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron. 2016;89:37&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Kim MS, Jia B, Yan J, Zuniga-Hertz JP, Han C, Cai D. Hypothalamic stem cells control ageing speed partly through exosomal miRNAs. Nature. 2017;548:52&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5999038</ArticleId><ArticleId IdType="pubmed">28746310</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29467003</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Feb</Month><Day>22</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Extracellular &#x3b1;-synuclein levels are regulated by neuronal activity.</ArticleTitle><Pagination><StartPage>9</StartPage><MedlinePgn>9</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-018-0241-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">&#x3b1;-Synuclein is a presynaptic protein abundant in the cytoplasmic compartment of neurons, whereas its presence in the extracellular space has also been observed under physiological conditions. Extracellular &#x3b1;-synuclein has pathological significance, exhibiting cellular toxicity and impairment of synaptic transmission. Notably, misfolded &#x3b1;-synuclein drives the cell-to-cell propagation of pathology via the extracellular space. However, the primary mechanism that regulates the extracellular levels of &#x3b1;-synuclein remains to be determined.</AbstractText><AbstractText Label="METHODS">Using several mechanistically distinct methods to modulate neuronal/synaptic activities in primary neuronal culture and in vivo microdialysis, we examined the involvement of neuronal/synaptic activities on &#x3b1;-synuclein release.</AbstractText><AbstractText Label="RESULTS">We demonstrate here that physiological release of endogenous &#x3b1;-synuclein highly depends on intrinsic neuronal activities. Elevating neuronal activity rapidly increased, while blocking activity decreased, &#x3b1;-synuclein release. In vivo microdialysis experiments in freely moving mice revealed that ~&#x2009;70% of extracellular &#x3b1;-synuclein arises from neuronal activity-dependent pathway. Selective modulation of glutamatergic neurotransmission altered extracellular &#x3b1;-synuclein levels, implicating this specific neuronal network in the mechanism of activity-dependent release of &#x3b1;-synuclein. While neuronal activity tightly regulated &#x3b1;-synuclein release, elevated synaptic vesicle exocytosis per se was capable to elicit &#x3b1;-synuclein release. We also found that extracellular &#x3b1;-synuclein exists as high molecular weight species.</AbstractText><AbstractText Label="CONCLUSIONS">The present study uncovers a novel regulatory pathway associated with &#x3b1;-synuclein release, whose dysregulation might affect various pathological actions of extracellular &#x3b1;-synuclein including its trans-synaptic propagation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-3696-0604</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan. yamadaka@m.u-tokyo.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan. iwatsubo@m.u-tokyo.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>26890009</GrantID><Agency>JSPS KAKENHI, Grant-in-Aid for Research Activity Start-up</Agency><Country>International</Country></Grant><Grant><GrantID>16K20969</GrantID><Agency>JSPS KAKENHI, Grant-in-Aid for Young Scientists (B)</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Neuronal activity</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Propagation</Keyword><Keyword MajorTopicYN="N">&#x3b1;-synuclein</Keyword></KeywordList><CoiStatement>ETHICS APPROVAL: All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of the Graduate School of Medicine at the University of Tokyo. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29467003</ArticleId><ArticleId IdType="pmc">PMC5822605</ArticleId><ArticleId IdType="doi">10.1186/s13024-018-0241-0</ArticleId><ArticleId IdType="pii">10.1186/s13024-018-0241-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840. doi: 10.1038/42166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/42166</ArticleId><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz NH, Bonner D, Mitchell HK, Tatum EL, Beadle GW. Genic control of biochemical reactions in Neurospora. Am Nat. 1945;79:304&#x2013;317. doi: 10.1086/281267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/281267</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Bae EJ, Lee SJ. Extracellular &#x3b1;-synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol. 2014;10:92&#x2013;98. doi: 10.1038/nrneurol.2013.275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.275</ArticleId><ArticleId IdType="pubmed">24468877</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, Luk KC, Lee VM-Y. Addition of exogenous &#x3b1;-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous &#x3b1;-synuclein to Lewy body and Lewy neurite&#x2013;like aggregates. Nat Protoc. 2014;9:2135&#x2013;2146. doi: 10.1038/nprot.2014.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2014.143</ArticleId><ArticleId IdType="pmc">PMC4372899</ArticleId><ArticleId IdType="pubmed">25122523</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg CR, McLean PJ. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012;7:42. doi: 10.1186/1750-1326-7-42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-42</ArticleId><ArticleId IdType="pmc">PMC3483256</ArticleId><ArticleId IdType="pubmed">22920859</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, Glabe C, Hyman BT, McLean PJ. Heat-shock protein 70 modulates toxic extracellular &#x3b1;-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J. 2011;25:326&#x2013;336. doi: 10.1096/fj.10-164624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.10-164624</ArticleId><ArticleId IdType="pmc">PMC3005424</ArticleId><ArticleId IdType="pubmed">20876215</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm V, Carroll J, Zhang B, O&#x2019;Brien P, Trojanowski JQ, Lee VM. Pathological &#x3b1;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949&#x2013;953. doi: 10.1126/science.1227157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1227157</ArticleId><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Di&#xf3;genes MJ, Dias RB, Rombo DM, Miranda HV, Maiolino F, Guerreiro P, N&#xe4;sstr&#xf6;m T, Franquelim HG, Oliveira LMA, Castanho MARB, Lannfelt L, Bergstr&#xf6;m J, Ingelsson M, Quintas A, Sebasti&#xe3;o AM, Lopes LV, Outeiro TF. Extracellular alpha-Synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci. 2012;32:11750&#x2013;11762. doi: 10.1523/JNEUROSCI.0234-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0234-12.2012</ArticleId><ArticleId IdType="pmc">PMC6703775</ArticleId><ArticleId IdType="pubmed">22915117</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrivastava AN, Redeker V, Fritz N, Pieri L, Almeida LG, Spolidoro M, Liebmann T, Bousset L, Renner M, L&#xe9;na C, Aperia A, Melki R, Triller A. &#x3b1;-synuclein assemblies sequester neuronal &#x3b1;3-Na+/K+-ATPase and impair Na+ gradient. EMBO J. 2015;34:2408&#x2013;2423. doi: 10.15252/embj.201591397.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201591397</ArticleId><ArticleId IdType="pmc">PMC4601662</ArticleId><ArticleId IdType="pubmed">26323479</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Ho D-H, Suk J-E, You S, Michael S, Kang J, Joong Lee S, Masliah E, Hwang D, Lee H-J, Lee S-J. Neuron-released oligomeric &#x3b1;-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562. doi: 10.1038/ncomms2534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2534</ArticleId><ArticleId IdType="pmc">PMC4089961</ArticleId><ArticleId IdType="pubmed">23463005</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 2010;30:6838&#x2013;6851. doi: 10.1523/JNEUROSCI.5699-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5699-09.2010</ArticleId><ArticleId IdType="pmc">PMC3842464</ArticleId><ArticleId IdType="pubmed">20484626</ArticleId></ArticleIdList></Reference><Reference><Citation>Melachroinou K, Xilouri M, Emmanouilidou E, Masgrau R, Papazafiri P, Stefanis L, Vekrellis K. Deregulation of calcium homeostasis mediates secreted &#x3b1;-synuclein-induced neurotoxicity. Neurobiol Aging. 2013;34:2853&#x2013;2865. doi: 10.1016/j.neurobiolaging.2013.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.06.006</ArticleId><ArticleId IdType="pubmed">23891486</ArticleId></ArticleIdList></Reference><Reference><Citation>Emanuele M, Esposito A, Camerini S, Antonucci F, Ferrara S, Seghezza S, Catelani T, Crescenzi M, Marotta R, Canale C, Matteoli M, Menna E, Chieregatti E. Exogenous alpha-Synuclein alters pre- and post-synaptic activity by fragmenting lipid rafts. EBioMedicine. 2016;7:191&#x2013;204. doi: 10.1016/j.ebiom.2016.03.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2016.03.038</ArticleId><ArticleId IdType="pmc">PMC4909369</ArticleId><ArticleId IdType="pubmed">27322472</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H-J, Patel S, Lee S-J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci. 2005;25:6016&#x2013;6024. doi: 10.1523/JNEUROSCI.0692-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0692-05.2005</ArticleId><ArticleId IdType="pmc">PMC6724798</ArticleId><ArticleId IdType="pubmed">15976091</ArticleId></ArticleIdList></Reference><Reference><Citation>Paillusson S, Clairembault T, Biraud M, Neunlist M, Derkinderen P. Activity-dependent secretion of alpha-synuclein by enteric neurons. J Neurochem. 2013;125:512&#x2013;517. doi: 10.1111/jnc.12131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12131</ArticleId><ArticleId IdType="pubmed">23278133</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmanouilidou E, Elenis D, Papasilekas T, Stranjalis G, Gerozissis K, Ioannou PC, Vekrellis K. Assessment of &#x3b1;-synuclein secretion in mouse and human brain parenchyma. PLoS One. 2011;6:1&#x2013;9. doi: 10.1371/journal.pone.0022225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0022225</ArticleId><ArticleId IdType="pmc">PMC3136497</ArticleId><ArticleId IdType="pubmed">21779395</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Walig&#xf3;rska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM. Association of cerebrospinal fluid &#x3b2;-amyloid 1-42, t-tau, p-tau &lt;inf&gt;181&lt;/inf&gt;, and &#x3b1;-synuclein levels with clinical features of drug-naive patients with early parkinson disease. JAMA Neurol. 2013;70:1277&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4034348</ArticleId><ArticleId IdType="pubmed">23979011</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-D&#xf6;ring F, Trenkwalder C, Schlossmacher MG. &#x3b1;-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10:230&#x2013;240. doi: 10.1016/S1474-4422(11)70014-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70014-X</ArticleId><ArticleId IdType="pubmed">21317042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n D, Garc&#xed;a-Garc&#xed;a E, G&#xf3;mez-Ramos A, Falc&#xf3;n-P&#xe9;rez JM, D&#xed;az-Hern&#xe1;ndez M, Hern&#xe1;ndez F, Avila J. Tau overexpression results in its secretion via membrane vesicles. Neurodegener Dis. 2012;10:73&#x2013;75. doi: 10.1159/000334915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000334915</ArticleId><ArticleId IdType="pubmed">22269430</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu N, Joshi PR, Cepeda C, Masliah E, Levine MS. Alpha-Synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway. J Neurosci Res. 2010;88:1764&#x2013;1776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707301</ArticleId><ArticleId IdType="pubmed">20029978</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundblad M, Decressac M, Mattsson B, Bj&#xf6;rklund A. Impaired neurotransmission caused by overexpression of &#x3b1;-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A. 2012;109:3213&#x2013;3219. doi: 10.1073/pnas.1200575109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1200575109</ArticleId><ArticleId IdType="pmc">PMC3295273</ArticleId><ArticleId IdType="pubmed">22315428</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi K, Watanabe Y, Tsujimura A, Tatebe H, Miyata S, Tokuda T, Mizuno T, Tanaka M. Differential expression of alpha-synuclein in hippocampal neurons. PLoS One. 2014;9:e89327. doi: 10.1371/journal.pone.0089327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0089327</ArticleId><ArticleId IdType="pmc">PMC3934906</ArticleId><ArticleId IdType="pubmed">24586691</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmanouilidou E, Minakaki G, Keramioti MV, Xylaki M, Balafas E, Chrysanthou-Piterou M, Kloukina I, Vekrellis K. GABA transmission via ATP-dependent K+ channels regulates &#x3b1;-synuclein secretion in mouse striatum. Brain. 2016;139:871&#x2013;890. doi: 10.1093/brain/awv403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv403</ArticleId><ArticleId IdType="pubmed">26912647</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgr&#xe4;fe K, Mandelkow E-M, Holtzman DM. Neuronal activity regulates extracellular tau in vivo. J Exp Med. 2014;211:387&#x2013;393. doi: 10.1084/jem.20131685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20131685</ArticleId><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow E-M, Diamond MI, Lee VM-Y, Holtzman DM. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci. 2011;31:13110&#x2013;13117. doi: 10.1523/JNEUROSCI.2569-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2569-11.2011</ArticleId><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;dhof TC. Alpha-Latrotoxin and its receptors: neurexins and CIRL/latrophilins. Annu Rev Neurosci. 2001;24:933&#x2013;962. doi: 10.1146/annurev.neuro.24.1.933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.24.1.933</ArticleId><ArticleId IdType="pubmed">11520923</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922. doi: 10.1016/j.neuron.2005.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.10.028</ArticleId><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, Lee SJ. Non-classical exocytosis of &#x3b1;-synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem. 2010;113:1263&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">20345754</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronzitti G, Bucci G, Emanuele M, Leo D, Sotnikova TD, Mus LV, Soubrane CH, Dallas ML, Thalhammer A, Cingolani LA, Mochida S, Gainetdinov RR, Stephens GJ, Chieregatti E. Exogenous &#x3b1;-Synuclein decreases raft partitioning of Cav2.2 channels inducing dopamine release. J Neurosci. 2014;34:10603&#x2013;10615. doi: 10.1523/JNEUROSCI.0608-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0608-14.2014</ArticleId><ArticleId IdType="pmc">PMC6802592</ArticleId><ArticleId IdType="pubmed">25100594</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebe H, Watanabe Y, Kasai T, Mizuno T, Nakagawa M, Tanaka M, Tokuda T. Extracellular neurosin degrades &#x3b1;-synuclein in cultured cells. Neurosci Res. 2010;67:341&#x2013;346. doi: 10.1016/j.neures.2010.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2010.04.008</ArticleId><ArticleId IdType="pubmed">20403393</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Patel TK, Hochgr&#xe4;fe K, Mahan TE, Jiang H, Stewart FR, Mandelkow E-M, Holtzman DM. Analysis of in vivo turnover of tau in a mouse model of tauopathy. Mol Neurodegener. 2015;10:55. doi: 10.1186/s13024-015-0052-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0052-5</ArticleId><ArticleId IdType="pmc">PMC4621881</ArticleId><ArticleId IdType="pubmed">26502977</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, Sanders DW, Cook C, Fu H, Boonen RACM, Herman M, Nahmani E, Emrani S, Figueroa YH, Diamond MI, Clelland CL, Wray S, Duff KE. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci. 2016;19:1085&#x2013;1092. doi: 10.1038/nn.4328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4328</ArticleId><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14:389&#x2013;394. doi: 10.1038/embor.2013.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2013.15</ArticleId><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K. In vivo microdialysis of brain interstitial fluid for the determination of extracellular tau levels. Methods Mol Biol. 2017;1523:285&#x2013;296. doi: 10.1007/978-1-4939-6598-4_17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-6598-4_17</ArticleId><ArticleId IdType="pubmed">27975257</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29475810</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2468-2667</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Lancet. Public health</Title><ISOAbbreviation>Lancet Public Health</ISOAbbreviation></Journal><ArticleTitle>Contribution of alcohol use disorders to the burden of dementia in France 2008-13: a nationwide retrospective cohort study.</ArticleTitle><Pagination><StartPage>e124</StartPage><EndPage>e132</EndPage><MedlinePgn>e124-e132</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2468-2667(18)30022-7</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2468-2667(18)30022-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Dementia is a prevalent condition, affecting 5-7% of people aged 60 years and older, and a leading cause of disability in people aged 60 years and older globally. We aimed to examine the association between alcohol use disorders and dementia risk, with an emphasis on early-onset dementia (&lt;65 years).</AbstractText><AbstractText Label="METHODS">We analysed a nationwide retrospective cohort of all adult (&#x2265;20 years) patients admitted to hospital in metropolitan France between 2008 and 2013. The primary exposure was alcohol use disorders and the main outcome was dementia, both defined by International Classification of Diseases, tenth revision discharge diagnosis codes. Characteristics of early-onset dementia were studied among prevalent cases in 2008-13. Associations of alcohol use disorders and other risk factors with dementia onset were analysed in multivariate Cox models among patients admitted to hospital in 2011-13 with no record of dementia in 2008-10.</AbstractText><AbstractText Label="FINDINGS">Of 31&#x2008;624&#x2008;156 adults discharged from French hospitals between 2008 and 2013, 1&#x2008;109&#x2008;343 were diagnosed with dementia and were included in the analyses. Of the 57&#x2008;353 (5&#xb7;2%) cases of early-onset dementia, most were either alcohol-related by definition (22&#x2008;338 [38&#xb7;9%]) or had an additional diagnosis of alcohol use disorders (10&#x2008;115 [17&#xb7;6%]). Alcohol use disorders were the strongest modifiable risk factor for dementia onset, with an adjusted hazard ratio of 3&#xb7;34 (95% CI 3&#xb7;28-3&#xb7;41) for women and 3&#xb7;36 (3&#xb7;31-3&#xb7;41) for men. Alcohol use disorders remained associated with dementia onset for both sexes (adjusted hazard ratios &gt;1&#xb7;7) in sensitivity analyses on dementia case definition (including Alzheimer's disease) or older study populations. Also, alcohol use disorders were significantly associated with all other risk factors for dementia onset (all p&lt;0&#xb7;0001).</AbstractText><AbstractText Label="INTERPRETATION">Alcohol use disorders were a major risk factor for onset of all types of dementia, and especially early-onset dementia. Thus, screening for heavy drinking should be part of regular medical care, with intervention or treatment being offered when necessary. Additionally, other alcohol policies should be considered to reduce heavy drinking in the general population.</AbstractText><AbstractText Label="FUNDING">None.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schwarzinger</LastName><ForeName>Micha&#xeb;l</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Translational Health Economics Network, Paris, France; Infection Antimicrobials Modeling and Evolution, UMR 1137, INSERM-Universit&#xe9; Paris Diderot, Sorbonne Paris Cit&#xe9;, Paris, France. Electronic address: michael.schwarzinger@transhealthecon.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollock</LastName><ForeName>Bruce G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasan</LastName><ForeName>Omer S M</ForeName><Initials>OSM</Initials><AffiliationInfo><Affiliation>Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dufouil</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM, University of Bordeaux, Centre INSERM U1219-Bordeaux Population Health, ISPED-Bordeaux School of Public Health, Bordeaux, France; Bordeaux University Hospital, Public Health Department, Medical Information Service, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rehm</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Institute for Clinical Psychology and Psychotherapy, Technical University Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>QalyDays Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Public Health</MedlineTA><NlmUniqueID>101699003</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Public Health. 2018 Mar;3(3):e103-e104. doi: 10.1016/S2468-2667(18)30031-8.</RefSource><PMID Version="1">29475811</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Public Health. 2018 May;3(5):e216. doi: 10.1016/S2468-2667(18)30070-7.</RefSource><PMID Version="1">29731156</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Public Health. 2018 May;3(5):e217. doi: 10.1016/S2468-2667(18)30074-4.</RefSource><PMID Version="1">29731157</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Baillot</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guibert</LastName><ForeName>Q</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Planchet</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luchini</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29475810</ArticleId><ArticleId IdType="doi">10.1016/S2468-2667(18)30022-7</ArticleId><ArticleId IdType="pii">S2468-2667(18)30022-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29482212</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Proximity to Parental Symptom Onset and Amyloid-&#x3b2; Burden in Sporadic Alzheimer Disease.</ArticleTitle><Pagination><StartPage>608</StartPage><EndPage>619</EndPage><MedlinePgn>608-619</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.5135</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Alzheimer disease (AD) develops during several decades. Presymptomatic individuals might be the best candidates for clinical trials, but their identification is challenging because they have no symptoms.</AbstractText><AbstractText Label="OBJECTIVE">To assess whether a sporadic parental estimated years to symptom onset calculation could be used to identify information about amyloid-&#x3b2; (A&#x3b2;) levels in asymptomatic individuals with a parental history of AD dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cohort study analyzed A&#x3b2;1-42 in cerebrospinal fluid (CSF) specimens from 101 cognitively normal individuals who had a lumbar puncture as part of the Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) cohort from September 1, 2011, through November 30, 2016 (374 participants were enrolled in the cohort during this period). The study estimated each participant's proximity to his/her parent's symptom onset by subtracting the index relative's onset age from his/her current age. The association between proximity to parental symptom onset and A&#x3b2; levels was then assessed using apolipoprotein E &#x3b5;4 (APOE4) status and sex as interactive terms. These analyses were performed again in 2 independent cohorts using CSF and Pittsburgh compound B carbon 11-labeled positron emission tomography (PIB-PET) A&#x3b2; biomarkers: the Adult Children Study (ACS) and the Wisconsin Registry for Alzheimer Prevention (WRAP) cohorts.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The association between proximity to parental symptom onset and A&#x3b2; burden in asymptomatic individuals with a parental history of sporadic AD.</AbstractText><AbstractText Label="RESULTS">The present analysis included a subset of 101 PREVENT-AD individuals (mean [SD] age, 61.8 [5.1] years; 30 [29.7%] male), 128 ACS participants (112 participants underwent CSF measurement: mean [SD] age, 63.4 [5.1] years; 31 [27.7%] male; and 107 underwent PIB-PET: mean [SD] age, 64.6 [5.3] years; 27 [25.2%] male), and 135 WRAP participants (85 participants underwent CSF measurement: mean [SD] age, 59.9 [6.0] years; 27 [31.8%] male; and 135 underwent PIB-PET: mean [SD] age, 59.6 [6.1] years; 43 [31.9%] male). In the PREVENT-AD cohort, individuals approaching their parent's onset age had lower CSF A&#x3b2;1-42 levels (range, 402-1597; B&#x2009;=&#x2009;-9.09, P&#x2009;=&#x2009;.04). This association was stronger in APOE4 carriers (B&#x2009;=&#x2009;-17.9, P&#x2009;=&#x2009;.03) and women (B&#x2009;=&#x2009;-19.8, P&#x2009;=&#x2009;.02). In the ACS cohort, the main association was replicated using PIB-PET data, and the sex interaction was replicated using CSF and PIB-PET data. In the WRAP cohort, the results were not replicated using cross-sectional data, but the main association and the APOE interaction were replicated using PIB-PET longitudinal data.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">These results suggest that proximity to parental symptom onset may help estimate A&#x3b2; biomarker changes in women or APOE4 carrier asymptomatic individuals with a parental history of sporadic AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Villeneuve</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Jacob W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonneaud</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pichet Binette</LastName><ForeName>Alexa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosa-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breitner</LastName><ForeName>John C S</ForeName><Initials>JCS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poirier</LastName><ForeName>Judes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG021155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037639</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 AG054115</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 RR024995</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG045957</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002373</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054047</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007507</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>T32 GM008692</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000427</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="N">Asymptomatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010290" MajorTopicYN="Y">Parents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Villeneuve reported having a Canada research chair and receiving research support from the Canadian Institutes of Health Research (CIHR), the Alzheimer&#x2019;s Association, the Alzheimer&#x2019;s Society of Canada, and the Brain Canada Foundation. Mr Vogel reported receiving a Vanier Canada Graduate Doctoral Scholarship. Dr Gonneaud reported having a postdoctoral scholarship from the PREVENT-AD program. Ms Pichet Binette reported having a PhD scholarship from CIHR. Dr Rosa-Neto reported receiving research support from the CIHR, Canadian Consortium on Neurodegeneration in Aging, the Fonds de recherche du Qu&#xe9;bec&#x2013;Sant&#xe9;, Chercheur Burcier Junior 2, and the Weston Brain Institute; receiving nonfinancial support from Avid Pharmaceuticals, Enigma Radiopharmaceuticals, Merck &amp; Co, and Roche; and serving as a consultant for Merck &amp; Co, Eli Lilly and Company, Pyramal, and Kalgene. Dr Gauthier reported receiving clinical trial support from Eli Lilly and Company, Roche, TauRx, and Lundbeck; serving as a data and safety monitoring board member for the Alzheimer's Disease Cooperative Study, the Alzheimer's Therapeutic Research Institute, the Alzheimer's Prevention Initiative, and Eisai; and serving as a scientific adviser for AbbVie, ADvantage, Alzheon, Axovant, Boehringer Ingelheim, Firalis, Heptares, IntelGen, Kalgene, Eli Lilly and Company, Lundbeck, Novartis, Otsuka, Servier, Sanofi, Schwabe, Takeda, TauRx, TVM Capital, and Roche. Dr Bateman reported receiving research support from the National Institutes of Health, the Alzheimer&#x2019;s Association, Forest Biometrics Research Institute, BrightFocus Foundation, Cure Alzheimer&#x2019;s Fund, Glenn Foundation for Medical Research, the Metropolitan Life Foundation, Biogen, Abbvie, Eli Lilly and Company, and the Dominantly Inherited Alzheimer Network&#x2013;Trial Meeting (DIAN-TU) Pharma Consortium (Biogen Idec, Elan Pharmaceuticals, Eli Lilly and Company, Hoffman&#x2013;La Roche, Genentech, Janssen Alzheimer Immunotherapy, Mithridion, Novartis Pharma AG, Pfizer Biotherapeutics R and D, Sanofi, and Eisai); receiving nonfinancial support from Avid Pharmaceuticals, Cogstate, and Bracket; serving as a consultant for IMI, Sanofi, Global Alzheimer&#x2019;s Platform, Boehringer Ingelheim, and Merck &amp; Co; and serving as an invited speaker for Roche and the Organisation for Economic Co-operation and Development. Dr Fagan reported being on the scientific advisory boards of IBL International and Roche and serving as a consultant for AbbVie, Novartis, and DiamiR. Dr Morris reported currently participating in clinical trials of antidementia drugs from Eli Lilly and Company, Biogen, and Janssen; serving as a consultant for Eli Lilly and Company; receiving research support from Eli Lilly and Company and Avid Radiopharmaceuticals; and receiving funding from grants P01AG003991, P01AG026276, and UF01AG032438 from the National Institutes of Health. Dr Benzinger reported receiving research support from the National Institutes of Health, the Alzheimer&#x2019;s Association, the Barnes-Jewish Hospital Foundation, Avid Radiopharmaceuticals, and the DIAN-TU Pharma Consortium (Biogen Idec, Elan Pharmaceuticals, Eli Lilly and Company, Hoffman&#x2013;La Roche, Genentech, Janssen Alzheimer Immunotherapy, Mithridion, Novartis Pharma AG, Pfizer Biotherapeutics R and D, Sanofi, and Eisai) and nonfinancial support from Avid Pharmaceuticals. Dr Johnson reported receiving research support from the National Institutes of Health. Dr Breitner reported having a Canada research chair. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>2</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29482212</ArticleId><ArticleId IdType="pmc">PMC5885216</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.5135</ArticleId><ArticleId IdType="pii">2673390</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. ; Dominantly Inherited Alzheimer Network . Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367(9):795-804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, et al. . Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168-174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingo TS, Lah JJ, Levey AI, Cutler DJ. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol. 2012;69(1):59-64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3332307</ArticleId><ArticleId IdType="pubmed">21911656</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261(5123):921-923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer&#x2019;s disease. Lancet. 1993;342(8873):697-699.</Citation><ArticleIdList><ArticleId IdType="pubmed">8103819</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann A, Tian L, Henderson VW, Greicius MD; Alzheimer&#x2019;s Disease Neuroimaging Initiative Investigators . Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75(4):563-573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117990</ArticleId><ArticleId IdType="pubmed">24623176</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder HM, Asthana S, Bain L, et al. . Sex biology contributions to vulnerability to Alzheimer&#x2019;s disease: a think tank convened by the Women&#x2019;s Alzheimer&#x2019;s Research Initiative. Alzheimers Dement. 2016;12(11):1186-1196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10341380</ArticleId><ArticleId IdType="pubmed">27692800</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JCS, Poirier J, Etienne PE, Leoutsakos JM. Rationale and structure for a new center forStudies on Prevention of Alzheimer's Disease (StoP-AD). J Prev Alzheimers Dis. 2016;3(4):236-242.</Citation><ArticleIdList><ArticleId IdType="pubmed">29199324</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong C, Roe CM, Buckles V, et al. . Role of family history for Alzheimer biomarker abnormalities in the adult children study. Arch Neurol. 2011;68(10):1313-1319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3327304</ArticleId><ArticleId IdType="pubmed">21987546</ArticleId></ArticleIdList></Reference><Reference><Citation>Coats M, Morris JC. Antecedent biomarkers of Alzheimer&#x2019;s disease: the Adult Children Study. J Geriatr Psychiatry Neurol. 2005;18(4):242-244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16306247</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer&#x2019;s disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer&#x2019;s Prevention. J Geriatr Psychiatry Neurol. 2005;18(4):245-249.</Citation><ArticleIdList><ArticleId IdType="pubmed">16306248</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V, et al. . The Montreal Cognitive Assessment, MOCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendlin BB, Ries ML, Canu E, et al. . White matter is altered with parental family history of Alzheimer&#x2019;s disease. Alzheimers Dement. 2010;6(5):394-403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933285</ArticleId><ArticleId IdType="pubmed">20713315</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluidtau/&#x3b2;-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine AM, Koscik RL, Berman SE, et al. . Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. Brain. 2016;139(pt 8):2261-2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958904</ArticleId><ArticleId IdType="pubmed">27324877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin N, De Beaumont L, Gagnon K, et al. . BDNFVal66Met polymorphism interacts with sleep consolidation to predict ability to create new declarative memories. J Neurosci. 2016;36(32):8390-8398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5811258</ArticleId><ArticleId IdType="pubmed">27511011</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. ; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group . Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Lesnick TG, et al. . Brain &#x3b2;-amyloid load approaches a plateau. Neurology. 2013;80(10):890-896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. ; Amyloid Biomarker Study Group . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Seeley WW, Zhou J, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Gender modulates the APOE &#x3b5;4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci. 2012;32(24):8254-8262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394933</ArticleId><ArticleId IdType="pubmed">22699906</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Aisen PS, De Strooper B, et al. . Autosomal-dominant Alzheimer&#x2019;s disease: a review and proposal for the prevention of Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2011;3(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G. Alzheimer disease: A&#x3b2;-independent processes-rethinking preclinical AD. Nat Rev Neurol. 2013;9(3):123-124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3935395</ArticleId><ArticleId IdType="pubmed">23399647</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Duff K. Linking A&#x3b2; and &#x3c4; in late-onset Alzheimer&#x2019;s disease: a dual pathway hypothesis. Neuron. 2008;60(4):534-542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692134</ArticleId><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Wirth M, La Joie R. Are AD-typical regions the convergence point of multiple pathologies? Front Aging Neurosci. 2015;7:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4373381</ArticleId><ArticleId IdType="pubmed">25859215</ArticleId></ArticleIdList></Reference><Reference><Citation>Craik FI, Bialystok E, Freedman M. Delaying the onset of Alzheimer disease: bilingualism as a form of cognitive reserve. Neurology. 2010;75(19):1726-1729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033609</ArticleId><ArticleId IdType="pubmed">21060095</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Reed BR, Madison CM, et al. . Vascular risk and A&#x3b2; interact to reduce cortical thickness in AD vulnerable brain regions. Neurology. 2014;83(1):40-47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114172</ArticleId><ArticleId IdType="pubmed">24907234</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Villeneuve S, La Joie R, Marks SM, Jagust WJ. Gene-environment interactions: lifetime cognitive activity, APOE genotype, and &#x3b2;-amyloid burden. J Neurosci. 2014;34(25):8612-8617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4061397</ArticleId><ArticleId IdType="pubmed">24948815</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29490706</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>11</StartPage><MedlinePgn>11</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-018-0244-x</ELocationID><Abstract><AbstractText Label="BACKGROUND">Besides the two main classical features of amyloid beta aggregation and tau-containing neurofibrillary tangle deposition, neuroinflammation plays an important yet unclear role in the pathophysiology of Alzheimer's disease (AD). Microglia are believed to be key mediators of neuroinflammation during AD and responsible for the regulation of brain homeostasis by balancing neurotoxicity and neuroprotective events. We have previously reported evidence that neuritic plaques are derived from dead neurons that have accumulated intraneuronal amyloid and further recruit Iba1-positive cells, which play a role in either neuronal demise or neuritic plaque maturation or both.</AbstractText><AbstractText Label="METHODS">To study the impact of microglia on neuritic plaque development, we treated two-month-old 5XFAD mice with a selective colony stimulation factor 1 receptor (CSF1R) inhibitor, PLX3397, for a period of 3 months, resulting in a significant ablation of microglia. Directly after this treatment, we analyzed the amount of intraneuronal amyloid and neuritic plaques and performed behavioral studies including Y-maze, fear conditioning and elevated plus maze.</AbstractText><AbstractText Label="RESULTS">We found that early long-term PLX3397 administration results in a dramatic reduction of both intraneuronal amyloid as well as neuritic plaque deposition. PLX3397 treated young 5XFAD mice also displayed a significant decrease of soluble fibrillar amyloid oligomers in brain lysates, a depletion of soluble pre-fibrillar oligomers in plasma and an improvement in cognitive function measured by fear conditioning tests.</AbstractText><AbstractText Label="CONCLUSIONS">Our findings demonstrate that CSF1R signaling, either directly on neurons or mediated by microglia, is crucial for the accumulation of intraneuronal amyloid and formation of neuritic plaques, suggesting that these two events are serially linked in a causal pathway leading to neurodegeneration and neuritic plaque formation. CSF1R inhibitors represent potential preventative or therapeutic approach that target the very earliest stages of the formation of intraneuronal amyloid and neuritic plaques.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sosna</LastName><ForeName>Justyna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, University of California, Irvine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Philipp</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, University of California, Irvine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albay</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, University of California, Irvine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes-Ruiz</LastName><ForeName>Jorge Mauricio</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, University of California, Irvine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baglietto-Vargas</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders (UCIMIND), University of California, Irvine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders (UCIMIND), University of California, Irvine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glabe</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, University of California, Irvine, USA. cglabe@uci.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry Department, Faculty of Science and Experimental Biochemistry Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, 21589, Saudi Arabia. cglabe@uci.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG056507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027544</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NIRG-15-363477</GrantID><Agency>Alzheimer's Association</Agency><Country>International</Country></Grant><Grant><GrantID>AG056507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG000538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG056507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027544</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG00538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000631">Aminopyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058227">Amyloidogenic Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000604004">Csf1r protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016187">Receptors, Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>6783M2LV5X</RegistryNumber><NameOfSubstance UI="C000600259">pexidartinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000631" MajorTopicYN="N">Aminopyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058227" MajorTopicYN="N">Amyloidogenic Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N">Pyrroles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016187" MajorTopicYN="N">Receptors, Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Amyloid beta</Keyword><Keyword MajorTopicYN="N">Intraneuronal amyloid</Keyword><Keyword MajorTopicYN="N">Microglia</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword><Keyword MajorTopicYN="N">Plaques</Keyword></KeywordList><CoiStatement>ETHICS APPROVAL AND CONSENT TO PARTICIPATE: All mouse experiments were performed according to animal protocols approved by the Institutional Animal Care and Use Committee at the University of California, Irvine. CONSENT FOR PUBLICATION: The authors have no conflict of interest. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29490706</ArticleId><ArticleId IdType="pmc">PMC5831225</ArticleId><ArticleId IdType="doi">10.1186/s13024-018-0244-x</ArticleId><ArticleId IdType="pii">10.1186/s13024-018-0244-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ramirez-Bermudez J. Alzheimer's disease: critical notes on the history of a medical concept. Arch Med Res. 2012;43(8):595&#x2013;599. doi: 10.1016/j.arcmed.2012.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2012.11.008</ArticleId><ArticleId IdType="pubmed">23178566</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer A. &#xdc;ber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatrie Psychisch-gerichtl Med. 1907;64:146&#x2013;148.</Citation></Reference><Reference><Citation>Barage SH, Sonawane KD. Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides. 2015;52:1&#x2013;18. doi: 10.1016/j.npep.2015.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.npep.2015.06.008</ArticleId><ArticleId IdType="pubmed">26149638</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013;369(4):341&#x2013;350. doi: 10.1056/NEJMoa1210951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1210951</ArticleId><ArticleId IdType="pubmed">23883379</ArticleId></ArticleIdList></Reference><Reference><Citation>Pensalfini A, Albay R, 3rd, Rasool S, Wu JW, Hatami A, Arai H, Margol L, Milton S, Poon WW, Corrada MM et al: Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. Neurobiol Dis 2014, 71:53&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4179983</ArticleId><ArticleId IdType="pubmed">25092575</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129&#x2013;10140. doi: 10.1523/JNEUROSCI.1202-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409&#x2013;421. doi: 10.1016/S0896-6273(03)00434-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00434-3</ArticleId><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, Wu J, Albay R, 3rd, Pensalfini A, Yeung S, Head E et al. Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Abeta oligomers. Mol Neurodegener. 2010;5:57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3019145</ArticleId><ArticleId IdType="pubmed">21144050</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MRP, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, Kitazawa M, Matusow B, Nguyen H, West BL, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82(2):380&#x2013;397. doi: 10.1016/j.neuron.2014.02.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.02.040</ArticleId><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg EE, Lee RJ, Najafi AR, Rice RA, Elmore MRP, Blurton-Jones M, West BL, Green KN. Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-beta pathology. Brain. 2016;139:1265&#x2013;1281. doi: 10.1093/brain/aww016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww016</ArticleId><ArticleId IdType="pmc">PMC5006229</ArticleId><ArticleId IdType="pubmed">26921617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruttger J, Karram K, Wortge S, Regen T, Marini F, Hoppmann N, Klein M, Blank T, Yona S, Wolf Y, et al. Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. Immunity. 2015;43(1):92&#x2013;106. doi: 10.1016/j.immuni.2015.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.06.012</ArticleId><ArticleId IdType="pubmed">26163371</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatami A, Albay R, 3rd, Monjazeb S, Milton S, Glabe C. Monoclonal antibodies against Abeta42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain. J Biol Chem. 2014;289(46):32131&#x2013;32143. doi: 10.1074/jbc.M114.594846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.594846</ArticleId><ArticleId IdType="pmc">PMC4231689</ArticleId><ArticleId IdType="pubmed">25281743</ArticleId></ArticleIdList></Reference><Reference><Citation>Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc. 2007;2(2):322&#x2013;328. doi: 10.1038/nprot.2007.44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2007.44</ArticleId><ArticleId IdType="pmc">PMC3623971</ArticleId><ArticleId IdType="pubmed">17406592</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarnyai Z, Sibille EL, Pavlides C, Fenster RJ, McEwen BS, Toth M. Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin(1A) receptors. Proc Natl Acad Sci U S A. 2000;97(26):14731&#x2013;14736. doi: 10.1073/pnas.97.26.14731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.26.14731</ArticleId><ArticleId IdType="pmc">PMC18987</ArticleId><ArticleId IdType="pubmed">11121072</ArticleId></ArticleIdList></Reference><Reference><Citation>McAllister WR, McAllister DE. Behavioral measurements of conditioned fear. In: Brush FR, editor. Aversive conditioning and learning. New York: Academic Press; 1971. pp. 105&#x2013;179.</Citation></Reference><Reference><Citation>Fendt M. Injections of the NMDA receptor antagonist aminophosphonopentanoic acid into the lateral nucleus of the amygdala block the expression of fear-potentiated startle and freezing. J Neurosci. 2001;21(11):4111&#x2013;4115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762710</ArticleId><ArticleId IdType="pubmed">11356899</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones SV, Heldt SA, Davis M, Ressler KJ. Olfactory-mediated fear conditioning in mice: simultaneous measurements of fear-potentiated startle and freezing. Behav Neurosci. 2005;119(1):329&#x2013;335. doi: 10.1037/0735-7044.119.1.329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0735-7044.119.1.329</ArticleId><ArticleId IdType="pmc">PMC2881597</ArticleId><ArticleId IdType="pubmed">15727538</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer WA, Vassar R. Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation. Mol Neurodegener. 2013;8:2. doi: 10.1186/1750-1326-8-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-2</ArticleId><ArticleId IdType="pmc">PMC3552866</ArticleId><ArticleId IdType="pubmed">23316765</ArticleId></ArticleIdList></Reference><Reference><Citation>Szalay G, Martinecz B, Lenart N, Kornyei Z, Orsolits B, Judak L, Csaszar E, Fekete R, West BL, Katona G, et al. Microglia protect against brain injury and their selective elimination dysregulates neuronal network activity after stroke. Nat Commun. 2016;7:11499. doi: 10.1038/ncomms11499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11499</ArticleId><ArticleId IdType="pmc">PMC4857403</ArticleId><ArticleId IdType="pubmed">27139776</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017;23(9):1018&#x2013;1027. doi: 10.1038/nm.4397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4397</ArticleId><ArticleId IdType="pubmed">28886007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarlus H, Heneka MT. Microglia in Alzheimer's disease. J Clin Invest. 2017;127(9):3240&#x2013;3249. doi: 10.1172/JCI90606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90606</ArticleId><ArticleId IdType="pmc">PMC5669553</ArticleId><ArticleId IdType="pubmed">28862638</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J Mol Neurosci. 2001;17(2):137&#x2013;145. doi: 10.1385/JMN:17:2:137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:17:2:137</ArticleId><ArticleId IdType="pubmed">11816787</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich RP, Tepper K, Ronicke R, Soom M, Westermann M, Reymann K, Kaether C, Fandrich M. Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicity. Proc Natl Acad Sci U S A. 2010;107(5):1942&#x2013;1947. doi: 10.1073/pnas.0904532106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0904532106</ArticleId><ArticleId IdType="pmc">PMC2836607</ArticleId><ArticleId IdType="pubmed">20133839</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007;8(7):499&#x2013;509. doi: 10.1038/nrn2168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2168</ArticleId><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Elwood F, Britschgi M, Villeda S, Zhang H, Ding Z, Zhu L, Alabsi H, Getachew R, Narasimhan R, et al. Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. J Exp Med. 2013;210(1):157&#x2013;172. doi: 10.1084/jem.20120412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20120412</ArticleId><ArticleId IdType="pmc">PMC3549715</ArticleId><ArticleId IdType="pubmed">23296467</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer&#x2019;s disease. Ann Transl Med. 2015;3(10):136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486922</ArticleId><ArticleId IdType="pubmed">26207229</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingues C, da Cruz ESOAB, Henriques AG. Impact of cytokines and chemokines on Alzheimer's disease neuropathological hallmarks. Curr Alzheimer Res. 2017;14(8):870&#x2013;882. doi: 10.2174/1567205014666170317113606.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205014666170317113606</ArticleId><ArticleId IdType="pmc">PMC5543563</ArticleId><ArticleId IdType="pubmed">28317487</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia S, Hartkamp LM, Malvar-Fernandez B, van Es IE, Lin H, Wong J, Long L, Zanghi JA, Rankin AL, Masteller EL, et al. Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritis. Arthritis Res Ther. 2016;18:75. doi: 10.1186/s13075-016-0973-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-0973-6</ArticleId><ArticleId IdType="pmc">PMC4818474</ArticleId><ArticleId IdType="pubmed">27036883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300(5618):486&#x2013;489. doi: 10.1126/science.1079469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18. doi: 10.1186/1750-1326-2-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-2-18</ArticleId><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Breydo L, Kurouski D, Rasool S, Milton S, Wu JW, Uversky VN, Lednev IK, Glabe CG. Structural differences between amyloid beta oligomers. Biochem Bioph Res Co. 2016;477(4):700&#x2013;705. doi: 10.1016/j.bbrc.2016.06.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.06.122</ArticleId><ArticleId IdType="pmc">PMC11247950</ArticleId><ArticleId IdType="pubmed">27363332</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight EM, Kim SH, Kottwitz JC, Hatami A, Albay R, Suzuki A, Lublin A, Alberini CM, Klein WL, Szabo P, et al. Effective anti-Alzheimer a beta therapy involves depletion of specific a beta oligomer subtypes. Neurol Neuroimmunol Neuroinflamm. 2016;3:e237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4864617</ArticleId><ArticleId IdType="pubmed">27218118</ArticleId></ArticleIdList></Reference><Reference><Citation>Diociaiuti M, Macchia G, Paradisi S, Frank C, Camerini S, Chistolini P, Gaudiano MC, Petrucci TC, Malchiodi-Albedi F. Native metastable prefibrillar oligomers are the most neurotoxic species among amyloid aggregates. Biochim Biophys Acta. 2014;1842(9):1622&#x2013;1629. doi: 10.1016/j.bbadis.2014.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2014.06.006</ArticleId><ArticleId IdType="pubmed">24932517</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Lee L, Palmeri A, Calabrese G, Arancio O. Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines. Biochem Pharmacol. 2014;88(4):450&#x2013;467. doi: 10.1016/j.bcp.2014.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2014.01.011</ArticleId><ArticleId IdType="pmc">PMC4014001</ArticleId><ArticleId IdType="pubmed">24462904</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulin SP, Dautoff R, Morris JC, Barrett LF, Dickerson BC. Alzheimer's disease neuroimaging I: amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity. Psychiatry Res. 2011;194(1):7&#x2013;13. doi: 10.1016/j.pscychresns.2011.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pscychresns.2011.06.014</ArticleId><ArticleId IdType="pmc">PMC3185127</ArticleId><ArticleId IdType="pubmed">21920712</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29518357</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer's Disease Models.</ArticleTitle><Pagination><StartPage>1032</StartPage><EndPage>1048.e5</EndPage><MedlinePgn>1032-1048.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2018.02.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(18)30101-6</ELocationID><Abstract><AbstractText>Variants of TREM2 are associated with Alzheimer's disease (AD). To study whether increasing TREM2 gene dosage could modify the disease pathogenesis, we developed BAC transgenic mice expressing human TREM2 (BAC-TREM2) in microglia. We found that elevated TREM2 expression reduced amyloid burden in the 5xFAD mouse model. Transcriptomic profiling demonstrated that increasing TREM2 levels conferred a rescuing effect, which includes dampening the expression of multiple disease-associated microglial genes and augmenting downregulated neuronal genes. Interestingly, 5xFAD/BAC-TREM2 mice showed further upregulation of several reactive microglial genes linked to phagocytosis and negative regulation of immune cell activation. Moreover, these mice showed enhanced process ramification and phagocytic marker expression in plaque-associated microglia and reduced neuritic dystrophy. Finally, elevated TREM2 gene dosage led to improved memory performance in AD models. In summary, our study shows that a genomic transgene-driven increase in TREM2 expression reprograms microglia responsivity and ameliorates neuropathological and behavioral deficits in AD mouse models.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>C Y Daniel</ForeName><Initials>CYD</Initials><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, The Jane and Terry Semel Institute for Neuroscience &amp; Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daggett</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, The Jane and Terry Semel Institute for Neuroscience &amp; Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, The Jane and Terry Semel Institute for Neuroscience &amp; Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lu-Lin</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Neuroscience and Aging Research Center, Sanford-Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langfelder</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, The Jane and Terry Semel Institute for Neuroscience &amp; Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoguang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Neuroscience and Aging Research Center, Sanford-Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, The Jane and Terry Semel Institute for Neuroscience &amp; Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yingjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuroscience and Aging Research Center, Sanford-Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Chang Sin</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, The Jane and Terry Semel Institute for Neuroscience &amp; Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Yonatan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, The Jane and Terry Semel Institute for Neuroscience &amp; Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferando</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mody</LastName><ForeName>Istvan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, USA; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, The Jane and Terry Semel Institute for Neuroscience &amp; Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, USA; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuroscience and Aging Research Center, Sanford-Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>X William</ForeName><Initials>XW</Initials><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, The Jane and Terry Semel Institute for Neuroscience &amp; Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: xwyang@mednet.ucla.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS084298</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH106008</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH073526</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038710</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG048519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056114</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS030549</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074312</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG044420</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046673</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056130</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044420</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS062691</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2018 Mar 7;97(5):991-993. doi: 10.1016/j.neuron.2018.02.018.</RefSource><PMID Version="1">29518360</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067470" MajorTopicYN="N">Cellular Reprogramming Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018628" MajorTopicYN="N">Gene Dosage</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">BAC</Keyword><Keyword MajorTopicYN="N">RNA-sequencing</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">amyloid plaque</Keyword><Keyword MajorTopicYN="N">gene dosage</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">mouse</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">reprogramming</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29518357</ArticleId><ArticleId IdType="mid">NIHMS947635</ArticleId><ArticleId IdType="pmc">PMC5927822</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.02.002</ArticleId><ArticleId IdType="pii">S0896-6273(18)30101-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287950</ArticleId><ArticleId IdType="pubmed">25260700</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, et al. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) J Biol Chem. 2015;290:26043&#x2013;26050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CC, DeVaux LB, Farzan M. The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E. J Biol Chem. 2015;290:26033&#x2013;26042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646256</ArticleId><ArticleId IdType="pubmed">26374897</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, Kokiko-Cochran ON, Crish SD, Lasagna-Reeves CA, Ransohoff RM, et al. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener. 2017;12:74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5644120</ArticleId><ArticleId IdType="pubmed">29037207</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GC, Neher JJ. Microglial phagocytosis of live neurons. Nat Rev Neurosci. 2014;15:209&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">24646669</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Caberoy NB, Alvarado G, Bigcas JL, Li W. Galectin-3 is a new MerTK-specific eat-me signal. J Cell Physiol. 2012;227:401&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225605</ArticleId><ArticleId IdType="pubmed">21792939</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Allen M, Burgess JD, Wang X, Strickland SL, Aryal S, Siuda J, Kachadoorian ML, Medway C, Younkin CS, et al. A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer&#x2019;s disease risk and increased TREML1 and TREM2 brain gene expression. Alzheimers Dement. 2017;13:663&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5462884</ArticleId><ArticleId IdType="pubmed">27939925</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma&#x2019;ayan A. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637064</ArticleId><ArticleId IdType="pubmed">23586463</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WS, Welsh CA, Barres BA, Stevens B. Do glia drive synaptic and cognitive impairment in disease? Nat Neurosci. 2015;18:1539&#x2013;1545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739631</ArticleId><ArticleId IdType="pubmed">26505565</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol. 2003;3:445&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">12776204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science. 2012;335:1503&#x2013;1506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651582</ArticleId><ArticleId IdType="pubmed">22323736</ArticleId></ArticleIdList></Reference><Reference><Citation>Curzon P, Rustay NR, Browman KE. Cued and Contextual Fear Conditioning for Rodents. In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. Boca Raton (FL): 2009.</Citation><ArticleIdList><ArticleId IdType="pubmed">21204331</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG, Goate AM. Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol Neurodegener. 2017;12:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferando I, Faas GC, Mody I. Diminished KCC2 confounds synapse specificity of LTP during senescence. Nat Neurosci. 2016;19:1197&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003660</ArticleId><ArticleId IdType="pubmed">27500406</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol. 2009;21:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723941</ArticleId><ArticleId IdType="pubmed">19230638</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatro TF, Holtman IR, Lerario AM, Vainchtein ID, Brouwer N, Sola PR, Veras MM, Pereira TF, Leite REP, M&#xf6;ller T, et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat Neurosci. 2017;20:1162&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">28671693</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S, Heppner FL. Microglia as dynamic and essential components of the amyloid hypothesis. Neuron. 2013;78:575&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494439</ArticleId><ArticleId IdType="pubmed">23719156</ArticleId></ArticleIdList></Reference><Reference><Citation>Gokce O, Stanley GM, Treutlein B, Neff NF, Camp JG, Malenka RC, Rothwell PE, Fuccillo MV, Sudhof TC, Quake SR. Cellular Taxonomy of the Mouse Striatum as Revealed by Single-Cell RNA-Seq. Cell Rep. 2016;16:1126&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5004635</ArticleId><ArticleId IdType="pubmed">27425622</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong JS, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, Yanagisawa K, Michikawa M. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem. 2002a;277:29919&#x2013;29926.</Citation><ArticleIdList><ArticleId IdType="pubmed">12042316</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong S, Yang XW. Modification of bacterial artificial chromosomes (BACs) and preparation of intact BAC DNA for generation of transgenic mice. Curr Protoc Neurosci. 2005;Chapter 5(Unit 5):21.</Citation><ArticleIdList><ArticleId IdType="pubmed">18428623</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong S, Yang XW, Li C, Heintz N. Highly efficient modification of bacterial artificial chromosomes (BACs) using novel shuttle vectors containing the R6Kgamma origin of replication. Genome Res. 2002b;12:1992&#x2013;1998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187570</ArticleId><ArticleId IdType="pubmed">12466304</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, Nowak NJ, Joyner A, Leblanc G, Hatten ME, et al. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature. 2003;425:917&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">14586460</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E, Jaeger BN, O&#x2019;Connor C, Fitzpatrick C, Pasillas MP, et al. An environment-dependent transcriptional network specifies human microglia identity. Science. 2017;356</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Graeber MB. Changing face of microglia. Science. 2010;330:783&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">21051630</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JSK, Younkin S, et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013a;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, Lohmann E, Bras JM, Gibbs JR, Rohrer JD, Gurunlian N, Dursun B, Bilgic B, Hanagasi H, Gurvit H, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013b;70:78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001789</ArticleId><ArticleId IdType="pubmed">23318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38:576&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898526</ArticleId><ArticleId IdType="pubmed">20513432</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath S, Dong J. Geometric interpretation of gene coexpression network analysis. PLoS Comput Biol. 2008;4:e1000117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2446438</ArticleId><ArticleId IdType="pubmed">18704157</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KL, Marcora E, Pimenova AA, Di Narzo AF, Kapoor M, Jin SC, Harari O, Bertelsen S, Fairfax BP, Czajkowski J, et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer&#x2019;s disease. Nat Neurosci. 2017;20:1052&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759334</ArticleId><ArticleId IdType="pubmed">28628103</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT, Landreth GE. Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer&#x2019;s Disease. J Neurosci. 2017;37:637&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J Exp Med. 2015;212:287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan DM, Frangakis SG, Golzio C, Cassa CA, Kurtzberg J, Davis EE, Sunyaev SR, Katsanis N Genomics T.F.f.N. Identification of cis-suppression of human disease mutations by comparative genomics. Nature. 2015;524:225&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4537371</ArticleId><ArticleId IdType="pubmed">26123021</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Cruchaga C, Goate AM. Alzheimer&#x2019;s disease genetics: from the bench to the clinic. Neuron. 2014;83:11&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4120741</ArticleId><ArticleId IdType="pubmed">24991952</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell. 2017;169:1276&#x2013;1290. e1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura R, Ohno M. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol Dis. 2009;33:229&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2741400</ArticleId><ArticleId IdType="pubmed">19026746</ArticleId></ArticleIdList></Reference><Reference><Citation>Knafo S, Venero C, Merino-Serrais P, Fernaud-Espinosa I, Gonzalez-Soriano J, Ferrer I, Santpere G, DeFelipe J. Morphological alterations to neurons of the amygdala and impaired fear conditioning in a transgenic mouse model of Alzheimer&#x2019;s disease. J Pathol. 2009;219:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">19449368</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity. 2017;47:566&#x2013;581. e569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Cantle JP, Chatzopoulou D, Wang N, Gao F, Al-Ramahi I, Lu XH, Ramos EM, El-Zein K, Zhao Y, et al. Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat Neurosci. 2016;19:623&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984042</ArticleId><ArticleId IdType="pubmed">26900923</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. Eigengene networks for studying the relationships between co-expression modules. BMC Syst Biol. 2007;1:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267703</ArticleId><ArticleId IdType="pubmed">18031580</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. Fast R Functions for Robust Correlations and Hierarchical Clustering. J Stat Softw. 2012;46</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465711</ArticleId><ArticleId IdType="pubmed">23050260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY, Tse W, Smith JD, Landreth GE. Apolipoprotein E promotes beta-amyloid trafficking and degradation by modulating microglial cholesterol levels. J Biol Chem. 2012;287:2032&#x2013;2044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265883</ArticleId><ArticleId IdType="pubmed">22130662</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, Holtzman DM. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S A. 2017;114:11524&#x2013;11529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer&#x2019;s disease. J Neurosci. 1996;16:5795&#x2013;5811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578961</ArticleId><ArticleId IdType="pubmed">8795633</ArticleId></ArticleIdList></Reference><Reference><Citation>Matarin M, Salih DA, Yasvoina M, Cummings DM, Guelfi S, Liu W, Nahaboo Solim MA, Moens TG, Paublete RM, Ali SS, et al. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep. 2015;10:633&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">25620700</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazure CM, Swendsen J. Sex differences in Alzheimer&#x2019;s disease and other dementias. Lancet Neurol. 2016;15:451&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4864429</ArticleId><ArticleId IdType="pubmed">26987699</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, Oldham MC, Geschwind DH. A systems level analysis of transcriptional changes in Alzheimer&#x2019;s disease and normal aging. J Neurosci. 2008;28:1410&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902235</ArticleId><ArticleId IdType="pubmed">18256261</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller WL, Bose HS. Early steps in steroidogenesis: intracellular cholesterol trafficking. J Lipid Res. 2011;52:2111&#x2013;2135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3283258</ArticleId><ArticleId IdType="pubmed">21976778</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120:4081&#x2013;4091.</Citation><ArticleIdList><ArticleId IdType="pubmed">18032783</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldham MC, Langfelder P, Horvath S. Network methods for describing sample relationships in genomic datasets: application to Huntington&#x2019;s disease. BMC Syst Biol. 2012;6:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3441531</ArticleId><ArticleId IdType="pubmed">22691535</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71:656&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR, 3rd, Lafaille JJ, Hempstead BL, Littman DR, Gan WB. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell. 2013;155:1596&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S, Colonna M. TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest. 2015;125:2161&#x2013;2170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463196</ArticleId><ArticleId IdType="pubmed">25893602</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832824</ArticleId><ArticleId IdType="pubmed">20110278</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabenstein M, Vay SU, Flitsch LJ, Fink GR, Schroeter M, Rueger MA. Osteopontin directly modulates cytokine expression of primary microglia and increases their survival. J Neuroimmunol. 2016;299:130&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">27725111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotshenker S. The role of Galectin-3/MAC-2 in the activation of the innate-immune function of phagocytosis in microglia in injury and disease. J Mol Neurosci. 2009;39:99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">19253007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadleir KR, Eimer WA, Cole SL, Vassar R. Abeta reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol Neurodegener. 2015;10:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297413</ArticleId><ArticleId IdType="pubmed">25567526</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano H, Hsu DK, Apgar JR, Yu L, Sharma BB, Kuwabara I, Izui S, Liu FT. Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest. 2003;112:389&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166291</ArticleId><ArticleId IdType="pubmed">12897206</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva AJ, Simpson EM, Takahashi JS, Lipp HP, Nakanishi S, Wehner JM, Giese KP, Tully T, Abel T, Chapman PF, et al. Mutant mice and neuroscience: recommendations concerning genetic background. Banbury Conference on genetic background in mice. Neuron. 1997;19:755&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354323</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat Genet. 2017;49:1373&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Skerrett R, Pellegrino MP, Casali BT, Taraboanta L, Landreth GE. Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor Agonist Treatment Reduces Amyloid &#x3b2; Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. J Biol Chem. 2015;290:21591&#x2013;21602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4571883</ArticleId><ArticleId IdType="pubmed">26163517</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan AH, Barres BA, Stevens B. The Complement System: An Unexpected Role in Synaptic Pruning During Development and Disease. Annual Review of Neuroscience. 2012;35:369&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">22715882</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Kleinberger G, Araque Caballero M&#xc1;, Brendel M, Rominger A, Alcolea D, Fortea J, Lle&#xf3; A, Blesa R, Gispert JD, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer&#x2019;s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8:466&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CDP, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005;201:647&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Ulland TK, Colonna M, Holtzman DM. Elucidating the Role of TREM2 in Alzheimer&#x2019;s Disease. Neuron. 2017;94:237&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">28426958</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Gray M, Lu XH, Cantle JP, Holley SM, Greiner E, Gu X, Shirasaki D, Cepeda C, Li Y, et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington&#x2019;s disease. Nat Med. 2014;20:536&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4067603</ArticleId><ArticleId IdType="pubmed">24784230</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213:667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox RR. Introduction to robust estimation and hypothesis testing. 3. Amsterdam ; Boston: Academic Press; 2012.</Citation></Reference><Reference><Citation>Wilson MD, Barbosa-Morais NL, Schmidt D, Conboy CM, Vanes L, Tybulewicz VLJ, Fisher EMC, Tavar&#xe9; S, Odom DT. Species-specific transcription in mice carrying human chromosome 21. Science. 2008;322:434&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3717767</ArticleId><ArticleId IdType="pubmed">18787134</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XW, Model P, Heintz N. Homologous recombination based modification in Escherichia coli and germline transmission in transgenic mice of a bacterial artificial chromosome. Nat Biotechnol. 1997;15:859&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pubmed">9306400</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XW, Wynder C, Doughty ML, Heintz N. BAC-mediated gene-dosage analysis reveals a role for Zipro1 (Ru49/Zfp38) in progenitor cell proliferation in cerebellum and skin. Nat Genet. 1999;22:327&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">10431235</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Hansen DV, Sheng M. TREM2, Microglia, and Neurodegenerative Diseases. Trends Mol Med. 2017;23:512&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">28442216</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron. 2016;91:328&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron. 2016;90:724&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarrei M, MacDonald JR, Merico D, Scherer SW. A copy number variation map of the human genome. Nat Rev Genet. 2015;16:172&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">25645873</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell. 2013;153:707&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015;17:170&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4312504</ArticleId><ArticleId IdType="pubmed">25580734</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>